org_study_id,nct_id,brief_title,official_title,overall_status,start_date,completion_date.text,completion_date..attrs,completion_date_type,lead_sponsor/agency,overall_official.last_name,overall_official.role,overall_official.affiliation,phase,study_type,enrollment.text,enrollment..attrs,primary_condition,primary_outcome,eligibility.gender,eligibility.minimum_age,eligibility.maximum_age,eligibility.healthy_volunteers,sponsors.lead_sponsor.agency,sponsors.lead_sponsor.agency_class,date_disclaimer,completion_date,overall_official.last_name.1,overall_official.role.1,overall_official.affiliation.1,enrollment,primary_outcome.measure,primary_outcome.measure.1,sponsors.collaborator.agency,sponsors.collaborator.agency_class,sponsors.collaborator.agency.1,sponsors.collaborator.agency_class.1,name,primary_outcome.time_frame,primary_outcome.time_frame.1,primary_outcome.measure.2,sponsors.collaborator.agency.2,sponsors.collaborator.agency_class.2,primary_outcome.measure.3,primary_outcome.measure.4,primary_outcome.measure.5,sponsors.collaborator.agency.3,sponsors.collaborator.agency_class.3,sponsors.collaborator.agency.4,sponsors.collaborator.agency_class.4,primary_outcome.description,overall_official.last_name.2,overall_official.role.2,overall_official.affiliation.2,overall_official.last_name.3,overall_official.role.3,overall_official.affiliation.3,primary_outcome.measure.6,primary_outcome.measure.7,measure,eligibility.sampling_method,eligibility.textblock.1,overall_official.last_name.4,overall_official.role.4,overall_official.affiliation.4,primary_outcome.description.1,primary_outcome.time_frame.2,primary_outcome.description.2,primary_outcome.time_frame.3,primary_outcome.description.3,start_date.text,start_date..attrs,primary_outcome.time_frame.4,primary_outcome.description.4,primary_outcome.time_frame.5,primary_outcome.description.5,primary_outcome.time_frame.6,primary_outcome.description.6,primary_outcome.time_frame.7,primary_outcome.description.7,primary_outcome.measure.8,primary_outcome.time_frame.8,primary_outcome.description.8,primary_outcome.measure.9,primary_outcome.time_frame.9,primary_outcome.description.9,primary_outcome.measure.10,primary_outcome.time_frame.10,primary_outcome.description.10,primary_outcome.measure.11,primary_outcome.time_frame.11,primary_outcome.description.11,sponsors.collaborator.agency.5,sponsors.collaborator.agency_class.5,sponsors.collaborator.agency.6,sponsors.collaborator.agency_class.6,overall_official.last_name.5,overall_official.role.5,overall_official.affiliation.5,overall_official.last_name.6,overall_official.role.6,overall_official.affiliation.6,overall_official.last_name.7,overall_official.role.7,overall_official.affiliation.7,overall_official.last_name.8,overall_official.role.8,overall_official.affiliation.8,sponsors.collaborator.agency.7,sponsors.collaborator.agency_class.7,sponsors.collaborator.agency.8,sponsors.collaborator.agency_class.8,sponsors.collaborator.agency.9,sponsors.collaborator.agency_class.9,sponsors.collaborator.agency.10,sponsors.collaborator.agency_class.10,sponsors.collaborator.agency.11,sponsors.collaborator.agency_class.11,address.city,primary_outcome.measure.12,primary_outcome.time_frame.12,eligibility.gender_based,eligibility.gender_description,overall_official.last_name.9,overall_official.role.9,overall_official.affiliation.9
A0661126,NCT00084227,Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America,"A Phase Ii/Iii, Randomized, Double Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Atovaquone-Proguanil For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In South America",Completed,July 2004,July 2005,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 2/Phase 3,Interventional,244,Actual,"Malaria, Falciparum",parasite clearance,All,18 Years,N/A,No,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC940,NCT00118807,"Trial of the Effectiveness of AQ/AS, SP/AQ and SP/CQ for Uncomplicated Malaria in Gambian Children","Randomized Trial of the Effectiveness of Amodiaquine-Artesunate, Amodiaquine-Sulfadoxine-Pyrimethamine, and Chloroquine-Sulfadoxine-Pyrimethamine, for Treatment of Uncomplicated Malaria in Gambian Children",Completed,August 2003,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Sam K Dunyo, PhD",Principal Investigator,Medical Research Council,Phase 3,Interventional,NA,NA,Malaria,NA,All,6 Months,10 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",February 2004,"Paul J Milligan, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,1800,Clinical failure by day 28,Incidence of adverse events,Medical Research Council,Other,"National Malaria Control Programme, The Gambia",Other,Medical Research Council Laboratories,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2001/HD11/524/RQ,NCT00124267,Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria,Efficacy of Intrarectal Versus Intravenous Quinine for the Treatment of Childhood Cerebral Malaria: a Randomized Clinical Trial,Unknown status,September 2003,NA,NA,NA,Makerere University,"Jane Achan, MBChB",Principal Investigator,"Department of Paediatrics and Child Health, Makerere University",Phase 3,Interventional,NA,NA,Cerebral Malaria,Parasite clearance time,All,6 Months,5 Years,No,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",January 2004,NA,NA,NA,108,NA,NA,Sanofi-Synthelabo,Industry,"Ministry of Health, Uganda",Other,Mulago Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
00-021,NCT00133393,Pentoxifylline in Children With Malaria,Dose Finding Study of Pentoxifylline in Children With Cerebral Malaria,Terminated,January 2002,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 2,Interventional,NA,NA,Plasmodium Falciparum Malaria,NA,All,9 Months,96 Months,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",July 2005,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,KEMRI Centre for Geographic Medicine Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PSB-2004-paracetamol,NCT00137566,The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau,The Effect of Paracetamol in the Treatment of Non-severe Malaria in Children in Guinea-Bissau,Unknown status,May 2004,January 2010,Anticipated,Anticipated,Bandim Health Project,"Peter Aaby, Professor",Study Director,Bandim Health Project,Phase 4,Interventional,NA,NA,Malaria; Falciparum,NA,All,N/A,15 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,parasite clearance time,recrudescence rate,NA,NA,NA,NA,Bandim Health Project,35 days,35 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3354,NCT00137657,Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on Antifolate Resistance,"An Evaluation of the Impact of Cotrimoxazole Prophylaxis for HIV-Infected Adults on the Development of Antifolate Resistance Among Plasmodium Falciparum, Streptococcus Pneumoniae, and Escherichia Coli",Completed,February 2002,NA,NA,NA,Centers for Disease Control and Prevention,"Mary J Hamel, M.D.",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,NA,NA,HIV; Malaria; Diarrhea; Pneumonia; Opportunistic Infections,NA,All,15 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",November 2003,NA,NA,NA,1478,Change in Plasmodium falciparum molecular markers of antifolate resistance before and while taking daily CTX,"Change in nasopharyngeal pneumococcal resistance before and while taking daily CTX, and among children living in households where adults are taking daily CTX",Kenya Medical Research Institute,Other,NA,NA,CDC KEMRI Research Institute,NA,NA,Change in commensal E. coli resistance before and while taking daily CTX,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Timika_FP_VP,NCT00157859,"To Evaluate Current Efficacy of Antimalarials Used in Timika, Papua, Indonesia","To Evaluate the Efficacy of Chloroquine and SP for Acute Uncomplicated P. Falciparum and the Efficacy of Chloroquine for Acute Uncomplicated P. Vivax in the Timika Region of Papua, Indonesia.",Completed,April 2004,NA,NA,NA,Menzies School of Health Research,"Emiliana Tjitre, PhD",Principal Investigator,"National Institute of Health Research and Development (NIHRD), Indonesia",N/A,Interventional,NA,NA,Falciparum Malaria; Vivax Malaria,NA,All,12 Months,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",September 2004,NA,NA,NA,150,• 42 day cure rate; corrected for reinfection by PCR genotyping.,• Overall Cure Rate at Day 42,Wellcome Trust,Other,"National Health and Medical Research Council, Australia",Other,SP9 & SP12 Public Health- Malaria control clinics,NA,NA,NA,"National Institute of Health Research and Development (NIHRD), Indonesia",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Timika_AMT,NCT00157885,"A Randomised Trial of Artekin and Artesunate & Amodiaquine for Uncomplicated Malaria in Timika, Papua, Indonesia.","A Randomized Trial to Compare the Efficacy of Artekin and Amodiaquine Plus Artesunate for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua",Completed,July 2005,NA,NA,NA,Menzies School of Health Research,"Ric N Price, MD",Principal Investigator,Menzies School of Health Research,N/A,Interventional,NA,NA,"Malaria, Falciparum; Malaria, Vivax",Overall day 42 cure rate (incorporating early and late treatment failures),All,12 Months,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2005,Emiliana Tjitra,Principal Investigator,"National Institute of Health Research and Development, Jakarta, Indonesia",400,NA,NA,"National Institute of Health Research and Development (NIHRD), Indonesia",Other,Wellcome Trust,Other,SP9 & SP12 Public Health & Malaria Control Clinics,NA,NA,NA,"National Health and Medical Research Council, Australia",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A0661134,NCT00082576,Azithromycin Plus Chloroquine Versus Mefloquine for the Treatment of Uncomplicated Malaria in Africa,"A Phase II/III, Randomized, Double-Blind, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa",Completed,June 2004,May 2006,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 2/Phase 3,Interventional,238,Actual,"Malaria, Falciparum",Parasite clearance,All,18 Years,N/A,No,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A-13399,NCT00197054,"A Study to Evaluate Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.","A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02A, and RTS,S/AS01B, Two Candidate Malaria Vaccines in Malaria-experienced Adults Living in Western Kenya.",Completed,July 2005,September 2006,Actual,Actual,U.S. Army Medical Research and Materiel Command,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,255,Actual,Plasmodium Falciparum,Safety of the vaccine up to 7 days post Dose 3.,All,18 Years,35 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,GlaxoSmithKline,Industry,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,U.S. Army Research Unit-Kenya,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"SEACAT 01 Mono (Am 1,2,3,5,6)",NCT00203801,Combination Antimalarials in Uncomplicated Malaria,"An Open Label In Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT),in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carriage and Prevalence of Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections.",Completed,January 2002,NA,NA,NA,University of Cape Town,"Karen Barnes, MBChB",Principal Investigator,University of Cape Town,N/A,Interventional,NA,NA,Malaria,NA,All,12 Months,N/A,No,University of Cape Town,Other,"ClinicalTrials.gov processed this data on July 26, 2017",July 2005,NA,NA,NA,700,Therapeutic efficacy defined as:,"Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure (ETF), Late Treatment Failure (LTF), defined as Late Clinical Failure (LCF) and Late Parasitological Failure (LPF);",World Health Organization,Other,"Medical Research Council, South Africa",Other,NA,NA,NA,"Sensitive or parasitological failure (RI, early and late, RII, RIII)",Global Fund,Other,Parasitological failures will be classified as recrudescence or re-infection (or indeterminate) using GLURP and MSP I & II markers;,Parasite clearance time;,Fever clearance time.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A0661123,NCT00084240,"Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia","A Phase 2/3, Randomized, Comparative, Double Blind Trial Of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine For The Treatment Of Uncomplicated, Symptomatic Falciparum Malaria In Southeast Asia",Terminated,March 2004,April 2005,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 2/Phase 3,Interventional,32,Actual,"Malaria, Falciparum",parasite clearance,All,18 Years,85 Years,No,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04-068,NCT00123552,Longitudinal Antimalarial Combinations in Uganda,"Longitudinal Comparison of Combination Antimalarial Therapies in Ugandan Children: Evaluation of Safety, Tolerability, and Efficacy",Completed,November 2004,December 2008,Actual,Actual,"University of California, San Francisco",NA,NA,NA,Phase 3,Interventional,690,Actual,Malaria,NA,All,1 Year,10 Years,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Annual incidence of malaria per treatment arm,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,NA,NA,Assessment Center - Mulago Hospital,duration of study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
06/2002/FOS-CLIN/JP006,NCT00217451,Treatment of Malaria in Gabon With Fosmidomycin-Clindamycin,Evaluation of Fosmidomycin in Combination With Clindamycin in Children With Acute Uncomplicated Plasmodium Falciparum Malaria,Completed,June 2002,NA,NA,NA,Albert Schweitzer Hospital,"Steffen Borrmann, MD",Principal Investigator,"Kenya Medical Research Institute, Centre for Geographic Medicine Research, Coast, kilifi, Kenya",Phase 2,Interventional,NA,NA,Malaria,NA,All,12 Months,14 Years,No,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",March 2003,"Peter G. Kremsner, MD, FRCP",Principal Investigator,Albert Schweitzer Hospital,51,Proportion of patients cured by day 14,Incidence of adverse events after the start of treatment,NA,NA,NA,NA,"Medical Research Unit, Lambaréné",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1123,NCT00223990,"Double-blind, Randomized, Controlled Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine","A Dbl-blind,Randomized,Controlled,Phase IIb Field Trial in 12-47 Month-old Children in Western Kenya to Eval the Efficacy,Safety and Immunogenicity of the FMP1/AS02A Malaria Vaccine vs Rabies Vaccine",Completed,March 2005,NA,NA,NA,U.S. Army Medical Research and Materiel Command,"Bernhards Ogutu, M.D.",Principal Investigator,Kenya Medical Research Institute,Phase 2,Interventional,NA,NA,"Malaria, Falciparum",To assess the efficacy of the FMP1/AS02A malaria vaccine on clinical episodes of P. falciparum malaria during the Efficacy Follow-up Period (EFP),All,12 Months,47 Months,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",April 2006,NA,NA,NA,400,NA,NA,The PATH Malaria Vaccine Initiative (MVI),Other,United States Agency for International Development (USAID),U.S. Fed,Walter Reed Project,NA,NA,NA,GlaxoSmithKline,Industry,NA,NA,NA,Kenya Medical Research Institute,Other,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ICA4-CT-2002-10053-REVAC,NCT00126217,Revaccination of Young Children With Bacille Calmette Guerin (BCG) Vaccine,BCG Vaccination and Childhood Morbidity and Mortality: Interventions With Possible Implications for the Immunisation Policy in Developing Countries. Revaccination of Young Children With BCG Vaccine.,Terminated,July 2002,September 2006,Actual,Actual,Bandim Health Project,Peter Aaby,Principal Investigator,Bandim Health Project,Phase 4,Interventional,2871,Actual,Malaria,NA,All,19 Months,24 Months,NA,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Mortality till 5 years of age,Hospitalisations till 5 years of age,International Cooperation with Developing Countries,Other,"Leiden University Medical Centre, DEPT of Parasitology, Leiden Holland",Other,Bandim Health Project,NA,NA,Adverse effects within 12 months after intervention,"Medical Research Council Unit, The Gambia",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3429,NCT00126906,Prevention of Malaria During Pregnancy Using Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine: Malawi,Intermittent Preventive Treatment With Sulfadoxine/Pyrimethamine During Pregnancy Among HIV-Positive and HIV-Negative Women: 2-Dose Versus Monthly – Malawi,Completed,October 2002,NA,NA,NA,Centers for Disease Control and Prevention,"Scott J Filler, MD, DTM&H",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,NA,NA,"Malaria, Falciparum; HIV Infections","Placental malaria parasitemia rates measured at time of delivery, stratified by HIV status",Female,15 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",March 2005,NA,NA,NA,700,NA,NA,"Ministry of Health and Population, Malawi",Other,NA,NA,Machinga District Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AM-P 001-2005,NCT00243737,"Efficacy, Safety and Pharmacokinetic of ArtequinTM P. Falciparum Malaria","Open-label, Stratified Study on the Efficacy, Safety and Pharmacokinetic Characteristics of Two Paediatric Formulations of ArtequinTM in Children With Acute Uncomplicated P. Falciparum Malaria",Completed,October 2005,NA,NA,NA,Albert Schweitzer Hospital,"Maryvonne Kombila, Prof Dr",Principal Investigator,"Département de Parasitologie-Mycologie, Faculté de médecine",Phase 2,Interventional,NA,NA,Malaria,"Efficacy, Proportion of patients cured on day 28",All,N/A,N/A,No,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",April 2006,NA,NA,NA,70,NA,NA,Mepha Ltd.,Industry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UR10_01_2005,NCT00274235,Intermittent Preventive Treatment During Pregnancy in Benin,"Intermittent Preventive Treatment During Pregnancy in Benin: a Randomized, Open, and Equivalent Trial Comparing Sulfadoxine-Pyrimethamine With Mefloquine",Completed,July 2005,April 2008,Actual,Actual,Institut de Recherche pour le Developpement,"Michel Cot, MD",Principal Investigator,Institut de Recherche pour le Developpement,Phase 3,Interventional,1600,Anticipated,Malaria,"proportion of infants with low birthweight (<2,500 grams)",Female,N/A,N/A,No,Institut de Recherche pour le Developpement,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,"National Malaria Control Program, Benin",Other,"Ministry of Foreign Affairs, France",Other,Institut de Recherche pour le Développement,NA,NA,NA,"Institut des Sciences Biomédicales Appliquées, Bénin",Other,NA,NA,NA,"Faculté des Sciences de la Santé, Bénin",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A0661121,NCT00082563,Azithromycin in Combination With Chloroquine Versus Chloroquine in the Eradication of Asymptomatic Plasmodium Falciparum,"A Phase II, Randomized, Comparative Trial Of Azithromycin In Combination With Chloroquine Versus Chloroquine In The Eradication Of Asymptomatic Plasmodium Falciparum Infection In Semi-Immune Adults",Terminated,August 2004,November 2004,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 2,Interventional,14,Actual,"Malaria, Falciparum",Parasite clearance,All,18 Years,60 Years,Accepts Healthy Volunteers,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A0661154,NCT00282919,A Three Day Trial of Azithromycin Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria,"A Phase 2, Open Label, Non-Comparative Trial Of Azithromycin 2000 mg Plus Chloroquine 600 Mg Base Daily For Three Days For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria",Completed,March 2006,February 2008,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 2,Interventional,110,Actual,Falciparum Malaria,NA,All,18 Years,N/A,No,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of Participants With Parasite Clearance at Day 28,NA,NA,NA,NA,NA,NA,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Parasite clearance was defined as the clearance of asexual Plasmodium falciparum (P falciparum) parasitemia (defined as three consecutive 0 parasite counts) within 7 days of initiation of treatment, without subsequent recrudescence up to Day 28. Failure to achieve clearance of asexual P falciparum parasitemia was defined as parasitemia not cleared within 7 days of initiation of treatment, or subsequent recrudescence (confirmed by molecular testing) by Day 28 after achieving clearance. Percentage of participants with clearance is reported. Here ""N"" (Number of participants analyzed) signify participants who were evaluable (parasitological per protocol) at Day 28.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
03-149,NCT00299208,Azithromycin Combination Therapy for Malaria,"Phase II, Open Label, Randomized Study of Azithromycin Combination Therapy for the Treatment of Acute, Uncomplicated Falciparum Malaria",Completed,NA,July 2005,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 2,Interventional,NA,NA,Plasmodium Falciparum Malaria,NA,All,20 Years,65 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,120,NA,NA,NA,NA,NA,NA,Mahidol University Hospital for Tropical Diseases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-4314,NCT00127998,Antimalarial Drug Resistance in Mali,Characterization of Novel Molecular Tools for the Epidemiological Surveillance of Antimalarial Drug Resistance in Mali,Completed,July 2005,NA,NA,NA,Centers for Disease Control and Prevention,"Robert D. Newman, MD, MPH",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,NA,NA,Malaria,NA,All,6 Months,59 Months,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Kassoum Kayentao, MD, MSPH",Principal Investigator,"Malaria Research and Training Center, Bamako, Mali",1011,"Early Treatment Failure (ETF, defined as: Development of danger signs or severe malaria on Day 1, 2, or 3, in the presence of parasitemia",Parasitemia on Day 2 higher than Day 0 count irrespective of axillary temperature,"Malaria Research and Training Center, Bamako, Mali",Other,NA,NA,NA,NA,NA,Parasitemia on Day 3 with axillary temperature ≥37.5°C,NA,NA,Parasitemia on Day 3 ≥ 25% of count on Day 0,"Late Clinical Failure (LCF), defined as: Development of danger signs or severe malaria from Day 4 to Day 28 in the presence of parasitemia, without previously meeting any of the criteria of ETF","Presence of parasitemia and axillary temperature ≥37.5° C on any day from Day 4 to Day 28, without previously meeting any of the criteria of ETF",NA,NA,NA,NA,NA,"John Barnwell, PhD, MPH",Principal Investigator,Centers for Disease Control and Prevention,"Ogobara Doumbo, MD, PhD",Principal Investigator,"Malaria Research and Training Center, Bamako, Mali","Late parasitological failure (LPF), defined as: Presence of parasitemia on Day 14 to Day 28 and axillary temperature <37.5°C without previously meeting any of the criteria of ETF or LCF","Adequate Clinical and Parasitological Response (ACPR), defined as: Absence of parasitemia on Day 28 irrespective of axillary temperature, without previously meeting any of the criteria of ETF, LCF or LPF",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3683,NCT00130065,The Effect of Folic Acid on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya,The Effect of Folic Acid Supplementation on Efficacy of Sulfadoxine-pyrimethamine in Pregnant Women in Western Kenya,Completed,November 2003,February 2006,Actual,Actual,Centers for Disease Control and Prevention,"Annemieke Van Eijk, M.D., Ph.D.",Principal Investigator,"Centers for Disease Control and Prevention, Kenya Medical Research Institiute",Phase 4,Interventional,NA,NA,Malaria,NA,Female,15 Years,45 Years,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Monica Parise, M.D.",Principal Investigator,Centers for Disease Control and Prevention,600,Peripheral parasitemia,Hemoglobin level,Kenya Medical Research Institute,Other,Kenya Ministry of Health,Other,CDC/Kenya Medical Research Institute,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Laurence Slutsker, M.D.",Principal Investigator,"Centers for Disease Control and Prevention, Kenya Medical Research Institute",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3606,NCT00111163,Intermittent Preventive Treatment With Antimalarials in Kenyan Infants,Efficacy and Safety of Pediatric Immunization-linked Preventive Intermittent Treatment With Antimalarials in Decreasing Anemia and Malaria Morbidity in Rural Western Kenya,Completed,March 2004,March 2008,Actual,Actual,Centers for Disease Control and Prevention,"Robert D Newman, MD, MPH",Principal Investigator,U.S. Centers for Disease Control and Prevention,N/A,Interventional,NA,NA,Malaria; Anemia,Clinical malaria in the first year of life,All,5 Weeks,16 Weeks,Accepts Healthy Volunteers,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Laurence Slutsker, MD, MPH",Principal Investigator,U.S. Centers for Disease Control and Prevention,1516,NA,NA,Kenya Medical Research Institute,Other,Bill and Melinda Gates Foundation,Other,"Lwak, Abidha, Ongielo and Saradidi clinics",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HD200211/246,NCT00113854,Mannitol as Adjunct Therapy for Childhood Cerebral Malaria,Effect of Mannitol as Adjunct Therapy on the Clinical Outcome of Childhood Cerebral Malaria in Mulago Hospital: A Randomised Clinical Trial,Unknown status,October 2004,NA,NA,NA,Makerere University,NA,NA,NA,Phase 3,Interventional,NA,NA,Cerebral Malaria,Coma recovery time (that is time from beginning of antimalarial treatment until patient has fully regained consciousness).,All,6 Months,5 Years,No,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",May 2005,NA,NA,NA,156,NA,NA,NA,NA,NA,NA,"Department of Paediatrics and Child Health, Makerere Medical School",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2003/GD/23,NCT00301054,Study on Preventing Anemia in Children in Ghana,Preventing Anemia in Children (6months-30months) in a Malaria Endemic Rural Area in Ghana - A Randomized Double Blind Study,Completed,June 2005,NA,NA,NA,Ghana Health Services,"ANTHONY A OFOSU, MBChB, MPH",Principal Investigator,GHANA HEALTH SERVICE BEREKUM DISTRICT,N/A,Interventional,NA,NA,Anaemia in Children,"Haemoglobin concentration, Blood Film for malaria parasitaemia, weight/height ratio",All,6 Months,30 Months,Accepts Healthy Volunteers,Ghana Health Services,Other,"ClinicalTrials.gov processed this data on July 26, 2017",April 2006,"DONNA M DENNO, MD, PAEDS",Study Director,"UNIVERSITY OF WASHINGTON MEDICAL CENTER, SEATTLE, USA",872,NA,NA,Netherlands Overseas Agency,Other,NA,NA,District Health Directorate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1249,NCT00312702,Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America,"A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS02A Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States",Completed,April 2006,April 2007,Actual,Actual,U.S. Army Medical Research and Materiel Command,"James F Cummings, MD",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 1/Phase 2,Interventional,36,Actual,Malaria; Plasmodium Falciparum Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety - adverse events,Reactogenicity,GlaxoSmithKline,Industry,The PATH Malaria Vaccine Initiative (MVI),Other,Walter Reed Army Institute of Research,7 days post dose,study duration,NA,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PSB-2001-chl-amo,NCT00137514,Chloroquine and Amodiaquine for Treatment of Malaria in Children,Chloroquine and Amodiaquine for Treatment of Symptomatic Children With Plasmodium Malaria in Guinea-Bissau,Completed,March 2001,May 2004,Actual,Actual,Bandim Health Project,Peter Aaby,Study Director,Bandim Health Project,Phase 4,Interventional,NA,NA,"Malaria, Falciparum",NA,All,N/A,15 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,720,Parasite reappearance rate,hospitalization during follow-up,NA,NA,NA,NA,Bandim Health Project,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04-110,NCT00138372,Human Immunity to MSP-1 in Western Kenya,Human Immunity to MSP-1 in Western Kenya,Unknown status,NA,NA,NA,NA,Case Western Reserve University,NA,NA,NA,N/A,Observational,NA,NA,Plasmodium Falciparum Malaria,NA,All,1 Month,N/A,Accepts Healthy Volunteers,Case Western Reserve University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,445,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,NA,NA,Kenya Medical Research Institute,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0074,NCT00314899,Fetal Immunity to Falciparum Malaria,Fetal Immunity to Plasmodium Falciparum Malaria,Unknown status,May 2007,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Plasmodium Falciparum Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",September 2011,NA,NA,NA,1020,NA,NA,NA,NA,NA,NA,KEMRI Centre for Geographic Medicine Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AnKaHeresoRDT,NCT00317590,Effectiveness and Cost-Effectiveness of a Rapid Diagnostic Test for Malaria,"Evaluation de l'utilité et du coût-efficacité du Test Rapide Paracheck® Pour la Prise en Charge Des Cas de Paludisme Dans Les régions Des Hauts Bassins et Des Cascades, au Burkina Faso",Completed,April 2006,October 2006,Actual,Actual,Centro per le Malattie Tropicali,"Zeno Bisoffi, MD, DTM&H",Principal Investigator,"Centro per le Malattie Tropicali, Ospedale S. Cuore, Negrar (Verona), Italy",Phase 4,Interventional,4000,Anticipated,Malaria,Clearance of fever,All,6 Months,N/A,No,Centro per le Malattie Tropicali,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,Districts Médicaux de Banfora et de Bobo 15,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-2577,NCT00140361,Efficacy of Sulphadoxine-pyrimethamine and Artemisinin-containing Combination Therapy for Malaria,Assessing and Monitoring the Efficacy of Sulfadoxine/ Pyrimethamine (SP) and the Combination of SP Plus Artesunate for Uncomplicated Malaria Infections Among Children,Completed,January 2000,January 2008,Actual,Actual,Centers for Disease Control and Prevention,"Peter B Bloland, DVM, MPVM",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,390,Actual,Malaria (Uncomplicated),Clinical and parasitologic failure rate,All,N/A,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Salim Abdulla, MD, PhD",Study Director,Ifakara Health Research and Development Centre,NA,NA,NA,United States Agency for International Development (USAID),U.S. Fed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"John R MacArthur, MD, MPH",Study Director,Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,Clinical and parasitologic failure rate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3537,NCT00144352,In-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Adults,The in-Vivo Response of P. Falciparum to Antimalarial Treatment in HIV-Infected and HIV-Uninfected Individuals-a 28 Day Efficacy Trial Involving HIV+ and HIV- Adults.,Completed,September 2002,NA,NA,NA,Centers for Disease Control and Prevention,"Snehal Shah, MD",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,NA,NA,Malaria; HIV; AIDS,Drug failure,All,18 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",July 2004,NA,NA,NA,540,NA,NA,Kenya Medical Research Institute,Other,NA,NA,CDC KEMRI Research Institute,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Drug failure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0068,NCT00322816,Malaria Prevalence in Children,"Malaria Prevalence, Incidence and Mortality in Children",Unknown status,June 2006,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Plasmodium Falciparum Malaria,NA,All,6 Months,10 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",January 2007,NA,NA,NA,2000,NA,NA,NA,NA,NA,NA,Medical Research Council's Laboratories,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
104297,NCT00323622,Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine,"An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose.",Completed,April 2005,May 2007,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,1737,Actual,Malaria,NA,All,33 Months,69 Months,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Subjects With Serious Adverse Events (SAEs),NA,NA,NA,NA,NA,GSK Investigational Site,"Throughout the entire study period: from Month 21 to Month 45 (Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in the NCT00197041 study).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NIH/DMID 05-0110,NCT00327964,"Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda","Utility of Rapid Diagnostic Tests (RDTs) for Malaria in Kampala, Uganda",Completed,October 2005,May 2006,Actual,Actual,"University of California, San Francisco","Heidi Hopkins, MD",Principal Investigator,"University of California, San Francisco",N/A,Observational,600,Actual,Febrile Illness; Malaria,RDT accuracy,All,1 Year,11 Years,No,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,NA,NA,Mulago Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,RDT accuracy,Probability Sample,"
        Inclusion Criteria: Member of the cohort participating in clinical trial of antimalarial
        drug efficacy in Kampala, which was enrolled based on criteria including the following
        characteristics:

          1. Ages 1-10 (at time of original enrollment)

          2. Parents' or guardians' agreement to bring the child to the study clinic for any fevers
             or other illnesses

          3. Agreement to avoid medications administered outside the study

          4. Intention to remain in Kampala for the full study period

          5. Native Ugandan

        Exclusion Criteria:

          1. Presence of any known serious chronic disease (e.g. AIDS, sickle cell disease,
             malignancy)

          2. Serious side effects to study medications used in cohort clinical trial of
             antimalarial drug efficacy
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04/04/2006,NCT00336375,Treatment of Uncomplicated Childhood Malaria in Tanzania by Artemether+Lumefantrine - Efficacy and Genotyping,"Treatment of Uncomplicated Childhood Malaria by an Artemisinin Derivative in Combination With Lumefantrine. Efficacy, Safety and Genotyping.",Completed,June 2006,July 2006,Actual,Actual,Karolinska University Hospital,"Anders Bjorkman, Professor",Study Director,Karolinska University Hospital,Phase 4,Interventional,50,Actual,Malaria,NA,All,1 Year,10 Years,No,Karolinska University Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of P.falciparum genotypes identified at baseline compared with accumulated number of genotypes in all blood samples,NA,Muhimbili University of Health and Allied Sciences,Other,NA,NA,Fukayosi Primary Health Care Center,72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3807,NCT00164255,Efficacy of Combination Therapy for Prevention of Effects of Malaria During Pregnancy,Efficacy of Intermittent Sulfadoxine-Pyrimethamine and Sulfadoxine-Pyrimethamine + Artesunate Treatment in the Prevention of Malaria in Pregnancy in an Area With Chloroquine-Resistant Plasmodium Falciparum,Completed,January 2003,June 2009,Actual,Actual,Centers for Disease Control and Prevention,"John MacArthur, MD, MPH",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,1614,Actual,Malaria,NA,Female,15 Years,N/A,Accepts Healthy Volunteers,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Salim Abdulla, MD, PhD",Principal Investigator,Ifakara Health Research and Development Centre,NA,placental parasitemia,reported or noted adverse reactions,Ifakara Health Research and Development Centre,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-4539,NCT00164710,Assessing the Efficacy of Four Drug Combinations as the Next First-line Therapy for Uncomplicated Malaria in Malawi,"An Open Randomised Trial of the Efficacy of Sulfadoxine-Pyrimethamine (SP), Amodiaquine + SP (AQ-SP), AQ + Artesunate (AQ-Art), Chlorproguanil-Dapsone + Art (CD-Art), and Lumefantrine-Artemether (LA) for Uncomplicated Malaria in Malawi",Completed,April 2005,September 2005,Actual,Actual,Centers for Disease Control and Prevention,"Rachel N Bronzan, MD, MPH",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,NA,NA,"Malaria, Falciparum",• Rate of Adequate Clinical and Parasitological Response at 14 days (WHO-defined measure of efficacy),All,6 Months,59 Months,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,365,NA,NA,"Ministry of Health and Population, Malawi",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC975,NCT00118794,Lapdap and Coartemether for Uncomplicated Malaria,Randomized Trial of the Safety and Effectiveness of Lapdap and Coartemether for Uncomplicated Malaria in Operational Settings,Completed,September 2004,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Paul J Milligan, BSc MSc PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,NA,NA,Malaria,Clinical failure by day 28,All,6 Months,10 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",June 2005,"Sam K Dunyo, MD PhD",Principal Investigator,Medical Research Council,1200,NA,NA,Medical Research Council,Other,"National Malaria Control Programme, The Gambia",Other,Medical Research Council Laboratories,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-4341,NCT00126971,Chlorproguanil-Dapsone in Pregnant Women,"Pharmacokinetics of Chlorproguanil-Dapsone in Pregnant Women With Plasmodium Falciparum Infection, and Reinfection With P. Falciparum During Pregnancy Following Treatment",Suspended,July 2005,NA,NA,NA,Centers for Disease Control and Prevention,"Robert D Newman, MD, MPH",Principal Investigator,Centers for Disease Control and Prevention,Phase 1,Interventional,NA,NA,Malaria,Pharmacokinetic analyses of pregnant women taking CD,Female,15 Years,49 Years,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Kassoum Kayentao, MD, MSPH",Principal Investigator,Malaria Research and Training Center,132,NA,NA,"Malaria Research and Training Center, Bamako, Mali",Other,Liverpool School of Tropical Medicine,Other,Faladje Missionary Dispensary,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Feiko ter Kuile, MD, PhD",Principal Investigator,Liverpool School of Tropical Medicine,"Ogobara Doumbo, MD, PhD",Principal Investigator,Malaria Research and Training Center,NA,NA,NA,NA,NA,"Monica E Parise, MD",Principal Investigator,Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0146,NCT00358332,Phase I Pediatric FMP2.1/AS02A Trial in Mali,"Randomized, Controlled, Dose Escalation Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of WRAIR's AMA-1 Malaria Vaccine (FMP2.1) Adjuvanted in GSKBio's AS02A Vs. Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali",Completed,November 2006,December 2007,Actual,Actual,U.S. Army Medical Research and Materiel Command,NA,NA,NA,Phase 1,Interventional,100,Actual,Plasmodium Falciparum Malaria,NA,All,1 Year,6 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Occurrence of Solicited Systemic Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0, 30, and 60.","Occurrence of Unsolicited Symptoms During a 30-day Surveillance Period Following Vaccinations at Days 0, 30, and 60.",National Institute of Allergy and Infectious Diseases (NIAID),NIH,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"University of Bamako, Malaria Research and Training Center",7 Days following any vaccination,Day of vaccination and 30 subsequent days.,Number of Subjects Spontaneously Reporting Any Serious Adverse Event.,GlaxoSmithKline,Industry,"Occurrence of Solicited Local Symptoms During a 7-day Surveillance Period (Systematically Collected) Following Vaccinations at Days 0, 30, and 60.",NA,NA,University of Maryland,Other,NA,NA,"The number of participants reporting drowsiness irritability/fussiness, loss of appetite, vomiting, and feverishness. Participants are counted only once but may have experienced symptoms on multiple occasions.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The number of participants spontaneously reporting any symptom (defined as any Adverse Event considered associated with the product) within 30 days of any vaccination. Participants are counted only once but may have experienced events on multiple occasions.,1 year after the last vaccination.,"Any untoward medical occurrence that resulted in death, persistent/significant disability/incapacity, required in-patient hospitalization or prolongation thereof, was life threatening or a congenital anomaly/birth defect in offspring of a study subject; or may have jeopardized the participant or required intervention to prevent one of the outcomes.",7 Days following any vaccination,"The number of participants reporting pain, swelling and erythema. Participants are counted only once but may have experienced symptoms on multiple occasions.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MVDC-2006-004,NCT00367380,Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers,Evaluation of Reproducibility of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers,Completed,December 2006,March 2007,Actual,Actual,Malaria Vaccine and Drug Development Center,"Socrates Herrera, MD",Principal Investigator,Director,Phase 2,Interventional,18,Actual,MALARIA; FEVER; Sweating Fever; Chills; ANEMIA,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Malaria Vaccine and Drug Development Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Infection for P. Vivax,NA,Fundacion Clinica Valle del Lili,Other,NA,NA,Malaria Vaccine and Drug Development Center,Twenty eight days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Thick blood smear was performed to patients daily on days 7 to 23, and every other day until day 29. Any prove of P. vivax infection was considered positive and confirmed later by real time polymerase chain reaction (rPCR).",NA,NA,NA,NA,NA,NA,NA,NA,Infection for P. Vivax,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
28574,NCT00167843,Reducing the Effects of Malaria in Children by Administering Repeated Preventive Doses,"A Longitudinal Study Assessing the Infectious Status and Immunity of Mothers and Their Children in Lambaréné, Including Intermittent Treatment of Children With Sulfadoxine-pyrimethamine for Malaria Control and Its Impact on Long-term Health",Completed,December 2002,NA,NA,NA,Albert Schweitzer Hospital,"Peter G Kremsner, MD",Principal Investigator,Albert Schweitzer Hospital,Phase 4,Interventional,NA,NA,Malaria,NA,All,N/A,5 Months,Accepts Healthy Volunteers,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",March 2007,NA,NA,NA,1189,Efficacy:,The proportion of children with at least one episode of anemia from 3 to 18 months of life,"Medical Research Unit, Lambarene",Other,Bundesministerium fuer Bildung und Forschung (BMBF),Other,Medical Research Unit of the Albert Schweitzer Hospital,NA,NA,The proportion of children with at least one episode of malaria from 3 to 18 months of life,Deutscher Akademischer Austausch Dienst,Other,Safety:,The proportion of children with at least one episode of an adverse event,The proportion of children with at least one episode of a serious adverse event,German Research Foundation,Other,Bill and Melinda Gates Foundation,Other,NA,NA,NA,NA,NA,NA,NA,Rebound:,"The proportion of children with at least one episode of anemia from 18-30 months of life, the proportion of children with at least one episode of malaria from 18-30 months of life",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
01KA0202-T,NCT00168948,Intermittent Antimalaria Treatment With SP in African Children,"Intermittent Treatment With Sulfadoxine-Pyrimethamine for Malaria Control in Children: A Randomised, Double Blind, and Placebo-Controlled Clinical Trial",Unknown status,March 2003,NA,NA,NA,"Charite University, Berlin, Germany","Frank Mockenhaupt, PhD",Study Director,"Charite University-Medicine, Berlin, Germany",Phase 4,Interventional,NA,NA,Malaria; Anemia,NA,All,2 Months,4 Months,Accepts Healthy Volunteers,"Charite University, Berlin, Germany",Other,"ClinicalTrials.gov processed this data on July 26, 2017",August 2005,NA,NA,NA,1200,Efficacy and safety of IPTi with SP,Impact of IPTi on incidence on malaria attacks,Deutscher Akademischer Austausch Dienst,Other,NA,NA,NA,NA,NA,Impact of IPTi on anemia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PSB-2001-Fansidar,NCT00137553,The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children,The Efficacy of Re-treatment With Sulfadoxine-pyrimethamine in Children With Recrudescent Malaria in Guinea-Bissau,Completed,May 2001,NA,NA,NA,Bandim Health Project,"Peter Aaby, Professor",Study Director,Bandim Health Project,Phase 4,Interventional,NA,NA,"Malaria, Falciparum",Re-appearing parasitaemia,All,N/A,15 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",March 2004,NA,NA,NA,60,NA,NA,NA,NA,NA,NA,Bandim Health Project,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Re-appearing parasitaemia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04-027,NCT00138307,Correlates of Protection in Ghana,Immunological Correlates of Protection Against Clinical Malaria in a Cohort of Young Children in the Kassena Nankana District of Ghana,Completed,NA,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Malaria,NA,All,1 Year,5 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",March 2006,NA,NA,NA,300,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P051063,NCT00372684,PALUREA: Severe Imported Malaria in Adults,PALUREA: Severe Falciparum Imported Malaria in Adults: Clinical and Physiopathological Study,Completed,September 2006,March 2010,Actual,Actual,Assistance Publique - Hôpitaux de Paris,"Fabrice Bruneel, MD",Principal Investigator,Assistance Publique - Hôpitaux de Paris,N/A,Observational,302,Actual,Malaria,NA,All,18 Years,N/A,No,Assistance Publique - Hôpitaux de Paris,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,"Institut National de la Santé Et de la Recherche Médicale, France",Other,NA,NA,Ch Versailles,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

        Inclusion Criteria in Severe Malaria Group:

          -  Hospitalization in the ICU and

          -  Presence of asexual forms of Plasmodium falciparum in the blood and

          -  One or more severe manifestations according to the World Health Organization (WHO)
             definition of severe falciparum malaria published in 2000

        Inclusion Criteria in Uncomplicated Malaria Group:

          -  Hospitalization in Medicine unit or ambulatory and

          -  Presence of asexual forms of Plasmodium falciparum in the blood and

          -  Absence of any severe manifestation according to the WHO definition of severe
             falciparum malaria published in 2000 with the exception of the criteria hyper
             parasitaemia (superior4%) when isolated or the criteria jaundice /total bilirubin
             superior 5 micromol/L when isolated

        Exclusion Criteria:

          -  Patient < 18 years-old

          -  Impossible to obtain informed consent

          -  Curative treatment of malaria for more than 72 hours
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC027.1,NCT00374998,Safety and Immunogenicity Study of the Malaria Vaccines FP9 PP and MVA PP,A Phase I Study to Assess the Safety and Immunogenicity of the Polyprotein Malaria Vaccine Candidates FP9 PP and MVA PP in Healthy Adults Using a Prime-Boost Delivery Schedule,Completed,April 2006,NA,NA,NA,European Malaria Vaccine Initiative,"Adrian VS Hill, MA, BM BCh, DPhil, DM",Principal Investigator,University of Oxford,Phase 1,Interventional,NA,NA,"Malaria, Falciparum; Malaria",NA,All,18 Years,50 Years,Accepts Healthy Volunteers,European Malaria Vaccine Initiative,Other,"ClinicalTrials.gov processed this data on July 26, 2017",January 2007,NA,NA,NA,35,Immediate reactogenicity,Adverse events occurring before the end of the trial,University of Oxford,Other,Wellcome Trust,Other,"Centre for Clinical Vaccinology & Tropical Medicine, University of Oxford",NA,NA,Biological safety (haematological and biochemical indices),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
103967,NCT00197028,Examine Safety and Immune Responses of GSK 257049 Vaccine When Administered to Infants Living in a Malaria-endemic Region,"A Phase I/IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine in Infants Living in a Malaria-endemic Region",Completed,"August 23, 2005","December 27, 2007",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,214,Actual,Malaria,NA,All,6 Weeks,12 Weeks,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Subjects With Serious Adverse Events (SAEs).,NA,NA,NA,NA,NA,GSK Investigational Site,From Month 0 to Month 6,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SEACAT 01 Am 4 (RCT),NCT00203736,A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria,"Open Label Drug Study (With Single and Parallel Group Components) to Evaluate Combination Antimalarial Therapy for Efficacy, Gametocyte Carriage and Molecular Markers Associated With SP Resistance in Uncomplicated Plasmodium Falciparum Infections",Completed,January 2003,NA,NA,NA,University of Cape Town,"Karen Barnes, MBChB",Principal Investigator,University of Cape Town,N/A,Interventional,NA,NA,Malaria,NA,All,12 Months,N/A,No,University of Cape Town,Other,"ClinicalTrials.gov processed this data on July 26, 2017",October 2003,NA,NA,NA,240,"Therapeutic efficacy defined as: Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure (ETF), Late Treatment Failure (LTF), defined as Late Clinical Failure (LCF) and Late Parasitological Failure (LPF)","Sensitive or parasitological failure (RI, early and late, RII, RIII)",World Health Organization,Other,"Medical Research Council, South Africa",Other,NA,NA,NA,Parasitological failures will be classified as recrudescence or re-infection (or indeterminate) using GLURP and MSP I & II markers,Global Fund,Other,Parasite clearance time,Fever clearance time,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-4476,NCT00164216,Efficacy and Effectiveness of Combined Therapy for Uncomplicated Malaria Treatment in Peru,"Evaluation of the Efficacy and Effectiveness of Combined Therapy With Mefloquine and Artesunate for Uncomplicated Malaria Treatment in the Loreto Region (Amazon Basin), Peru",Completed,March 2005,March 2008,Actual,Actual,Centers for Disease Control and Prevention,"Alexandre Macedo de Oliveira, MD, MSc",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Observational,208,Actual,Malaria Falciparum,NA,All,1 Year,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Wilmer Marquiño Quezada, MD",Principal Investigator,"National Institute of Health, Peru",NA,NA,NA,"National Institute of Health, Peru",Other,NA,NA,Loreto Healthcare Facility,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-4538,NCT00164359,Amodiaquine Plus Artesunate Versus Lapdap Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi,A Double-blind Randomised Trial to Assess the Tolerability of Amodiaquine Plus Artesunate (AQ-Art) Versus Chlorproguanil Plus Dapsone Plus Artesunate (CDA) in the Treatment of Uncomplicated P. Falciparum Malaria in Malawi,Completed,April 2005,September 2005,Actual,Actual,Centers for Disease Control and Prevention,"Rachel N Bronzan, MD, MPH",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,NA,NA,"Malaria, Falciparum","Incidence of abdominal pain on days 1, 2, and 3 in the two treatment groups",All,5 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,212,NA,NA,"Ministry of Health and Population, Malawi",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
06-0022,NCT00379821,Chloroquine Alone or in Combination for Malaria in Children in Malawi,"A Longitudinal Study of Chloroquine as Monotherapy or in Combination With Artesunate, Azithromycin or Atovaquone-Proguanil to Treat Malaria in Children in Blantyre, Malawi",Completed,February 2007,September 2012,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 3,Interventional,640,Actual,Plasmodium Falciparum Infection,NA,All,6 Months,5 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Clinical Malaria Episodes Per Year of Follow-up,NA,NA,NA,NA,NA,Blantyre Malaria Project - Ndirande Health Centre,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Clinical malaria episode was defined as at least one symptom of malaria and a positive malaria smear. The number of clinical malaria episodes (not including the initial malaria episode) reported by participants during follow up is presented as the number per Person Years at Risk (PYAR).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ARAMF_L_01570,NCT00386503,Bioavailability of the Fixed Combination of Amodiaquine and Artesunate Under Fed & Fasted Conditions,"A Randomized, Open-Label, Cross-Over Study, to Compare the Bioavailability of the Fixed Combination of Amodiaquine and Artesunate (COARSUCAM™) After Single Oral Administration Under Fed and Fasted Conditions in Healthy Subjects",Completed,June 2006,NA,NA,NA,Sanofi,Valerie Lameyre,Study Director,Sanofi,Phase 1,Interventional,NA,NA,Malaria,NA,Male,18 Years,50 Years,Accepts Healthy Volunteers,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,22,"Pharmacokinetics/Time course of the plasma concentrations of AS, AQ & their pharmacologically active metabolites dihydroartemisinin (DHA) & desethylamodiaquine (DSA), used to determine:Tmax, Cmax, t1/2, AUC(0-t) & AUC(0-Inf) for AS, DHA & AQ","Tmax, Cmax, Truncated AUC(0-10d) for DSA",NA,NA,NA,NA,Sanofi-Aventis,During all the study conduct,during the study conduct,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TimNet,NCT00209781,IPTp Plus ITNs for Malaria Control in Pregnant Women,"Effect of Intermittent Preventive Treatment (IPTp) With Sulfadoxine-Pyrimethamine Plus Insecticide Treated Nets, Delivered Through Antenatal Clinics for the Prevention of Malaria in Mozambican Pregnant Women",Unknown status,August 2003,NA,NA,NA,Hospital Clinic of Barcelona,"Clara Menendez, MD, PhD",Principal Investigator,"Centre for International Health, Hospital Clinic de Barcelona",N/A,Interventional,NA,NA,Pregnancy,Evaluate whether two doses of intermittent treatment with SP delivered through antenatal clinics provides additional benefit to the protection afforded by ITNs on low birth weight,Female,N/A,N/A,Accepts Healthy Volunteers,Hospital Clinic of Barcelona,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2006,NA,NA,NA,1028,NA,NA,NA,NA,NA,NA,Centro de Investigaçao em Saude da Manhiça,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
06/2005/FOS-CLIN/SP,NCT00214643,Efficacy of Fosmidomycin-Clindamycin for Treating Malaria in Gabonese Children,A Comparative Assessment of the Efficacy of Fosmidomycin-Clindamycin Versus Sulfadoxine-Pyrimethamine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria,Completed,June 2005,NA,NA,NA,Albert Schweitzer Hospital,"Saadou Issifou, MD",Principal Investigator,Albert Schweitzer Hospital,Phase 3,Interventional,NA,NA,Malaria,Clinical and parasitological cure rate by day 28,All,3 Years,14 Years,No,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",July 2006,NA,NA,NA,160,NA,NA,NA,NA,NA,NA,"Medical Research Unit, Lambaréné",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCOA566A2412,NCT00386750,"Safety of Artemether - Lumefantrine, and Other Malaria Drugs and Their Effect on the Auditory Function","An Open-label, Single-center Study of the Effects of Co-artemether, Atovaquone-proguanil, and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older.",Terminated,June 2005,November 2005,Actual,Actual,Novartis Pharmaceuticals,Novartis Pharmaceuticals,Study Chair,Novartis Pharmaceuticals,Phase 4,Interventional,NA,NA,Malaria; Falciparum,Auditory abnormalities at Day 7 assessed by Auditory Brainstem Response (ABR) wave form latencies (a type of hearing test).,All,12 Years,N/A,No,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,265,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PEV001,NCT00400101,Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Peptides,A Randomized Placebo-Controlled Phase Ia Malaria Vaccine Trial of Two Virosome-Formulated Synthetic Peptides in Healthy Adult Volunteers,Terminated,November 2003,NA,NA,NA,Swiss Tropical & Public Health Institute,"Blaise Genton, MD PhD",Principal Investigator,Swiss Tropical & Public Health Institute,Phase 1,Interventional,NA,NA,Falciparum Malaria,NA,All,18 Years,30 Years,Accepts Healthy Volunteers,Swiss Tropical & Public Health Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",October 2005,NA,NA,NA,46,Incidence of adverse events,Antibody concentration by Elisa,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HS02310105,NCT00215267,"The Effect of Praziquantel Treatment on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria, Uganda",The Effect of One Versus Two Praziquantel Treatments on Schistosoma Mansoni Morbidity and re-Infection Along Lake Victoria in Uganda,Completed,September 2005,October 2007,Actual,Actual,DBL -Institute for Health Research and Development,"Edridah M Tukahebwa, Msc",Principal Investigator,"Ministry of Health, Uganda",N/A,Interventional,540,Anticipated,Schistosomiasis; Malaria,NA,All,8 Years,N/A,Accepts Healthy Volunteers,DBL -Institute for Health Research and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,cure rates,re-infection,"Ministry of Health, Uganda",Other,NA,NA,Musoli village,NA,NA,pathology regression,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AgeMal,NCT00231452,Age of Exposure and Immunity to Malaria in Infants,Age of Exposure and Immunity to Malaria in Infants,Completed,September 2005,March 2009,Actual,Actual,Hospital Clinic of Barcelona,"Pedro Alonso, MD, PhD",Principal Investigator,"Barcelona Center for International Health Research, Hospital Clinic/University of Barcelona",N/A,Interventional,349,Actual,Malaria,NA,All,N/A,1 Week,Accepts Healthy Volunteers,Hospital Clinic of Barcelona,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Carlota Dobaño, PhD",Principal Investigator,"Barcelona Center for International Health Research, Hospital Clinic/University of Barcelona",NA,(Clinical) Time to first or only episode of clinical malaria in the second year of life detected by passive case detection,NA,European Commission,Other,NA,NA,Centro de Investigaçao em Saude da Manhiça,from 12 to 24 months of age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Global comparison between the 3 groups of the time to first or only episode of clinical malaria (according to the primary case definition) in the second year of follow up detected by passive case detection in the According-To-Protocol cohort. In addition, pairwise comparisons of the 3 groups are also presented.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-004-06,NCT00403260,Pyronaridine Artesunate (3:1) Versus Mefloquine Artesunate in P Falciparum Malaria Patients,"A Phase III Comparative, Open-Label, Randomised, Multi-Centre, Clinical Study to Assess the Safety and Efficacy of Fixed Dose Formulation Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Mefloquine (250 mg Tablet) Plus Artesunate (100 mg Tablet) in Children and Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria",Completed,January 2007,December 2008,Actual,Actual,Medicines for Malaria Venture,"Isabelle Borghini-Fuhrer, PhD",Study Director,Medicines for Malaria Venture,Phase 3,Interventional,1269,Actual,Malaria,NA,All,3 Years,60 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR-corrected adequate clinical and parasitological response (ACPR) on Day 28,Treatment success or failures will be classified according to WHO Guidelines 2005,Shin Poong Pharmaceuticals,Industry,NA,NA,NA,Day 28,28 days,"Incidence and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Day 28 and Day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
91199 / 104. DAN.8-864,NCT00406146,Amodiaquine+Artesunate vs. Artemether-Lumefantrine for Uncomplicated Malaria in Ghanaian Children,NA,Unknown status,October 2004,NA,NA,NA,University of Ghana Medical School,"George O. Adjei, MD",Principal Investigator,"Dept. of Child Health, Korle Bu Teaching Hospital, Accra, Ghana",Phase 3,Interventional,NA,NA,Uncomplicated Malaria,NA,All,6 Months,14 Years,NA,University of Ghana Medical School,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2006,"Bamenla Q. Goka, MBchB",Principal Investigator,"Dept of Child Health, Korle Bu Teaching Hospital, Accra, Ghana",NA,NA,NA,University of Copenhagen,Other,NA,NA,Korle Bu Teaching Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Jorgen A.L. Kurtzhals, MD, Ph.D",Principal Investigator,"Dept. of Clinical Microbiology, Copenhagen University Hospital (Rigshospitalet), Copenhagen, Denmark",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C06-015,NCT00408369,Prophylactic Antimalarial Activity of DB289 in Volunteers,Prophylactic Antimalarial Activity of DB289 in Volunteers Challenged With Plasmodium Falciparum,Completed,November 2006,November 2007,Actual,Actual,"Immtech Pharmaceuticals, Inc","Theresa A. Shapiro, MD, PhD",Principal Investigator,Johns Hopkins University,Phase 1/Phase 2,Interventional,19,Anticipated,Prophylactic Activity Against Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,"Immtech Pharmaceuticals, Inc",Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The primary endpoint of this study is the appearance of erythrocytic parasites,"(parasitemia), which indicates a prophylaxis failure. Parasitemia will be sought by",NA,NA,NA,NA,Johns Hopkins University School of Medicine,NA,NA,"multiple means, including blood culture, polymerase chain reaction (PCR), Quantitative",NA,NA,"Buffy Coat (QBC) analysis, and thick and thin blood smears (detailed methods,",Appendix II).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
GMZ2_2_07,NCT00424944,Safety of Recombinant Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine,"A Single Centre, Randomised Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Lactococcus Lactis Hybrid GMZ 2 [GLURP + MSP 3] Blood Stage Malaria Vaccine Versus Rabies Vaccine in Healthy Gabonese Adult Volunteers",Unknown status,June 2007,August 2008,Anticipated,Anticipated,African Malaria Network Trust,"Peter Kremsner, MD, PhD",Study Director,"Medical research Unit, Albert Schweitzer Hospital",Phase 1,Interventional,40,Anticipated,Malaria,NA,Male,18 Years,45 Years,Accepts Healthy Volunteers,African Malaria Network Trust,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Local and systemic reactogenicity,Unsolicited adverse events,NA,NA,NA,NA,"Medical Research Unit, Albert Schweitzer Hospital",28 days following each immunization,1 year,Occurrence of serious adverse events,NA,NA,Biological safety,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,1 year,NA,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SFB544-A8-AQ2005,NCT00261222,Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso,Efficacy of Amodiaquine in the Treatment of Uncomplicated Falciparum Malaria in Young Children of Burkina Faso,Completed,September 2005,NA,NA,NA,Heidelberg University,"Germain Mandi, MD",Principal Investigator,Centre de Recherche en Santé de Nouna,Phase 2,Interventional,NA,NA,Malaria,NA,All,6 Months,59 Months,No,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",November 2005,"Olaf Mueller, MD, PhD",Study Director,"University of Heidelberg, Germany, Institute of Tropical Medecine and Public Health",120,Total clinical failure rate on day 14.,Clinical failure rate on day 14 in rural study area.,"Centre de Recherche en Sante de Nouna, Burkina Faso",Other,NA,NA,Centre de Recherche en Santé de Nouna (CRSN),NA,NA,Clinical failure rate on day 14 in urban study area.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IPTi219,NCT00285662,Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants,Intermittent Preventive Treatment (IPTi) for the Prevention of Malaria and Anaemia in PNG Infants,Completed,June 2006,May 2010,Actual,Actual,Papua New Guinea Institute of Medical Research,"Ivo Mueller, PhD",Principal Investigator,Papua New Guinea Institute of Medical Research,N/A,Interventional,1100,Anticipated,Malaria; Anemia,NA,All,2 Months,4 Months,Accepts Healthy Volunteers,Papua New Guinea Institute of Medical Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"John Reeder, Prof",Principal Investigator,Papua New Guinea Institute of Medical Research,NA,Incidence of symptomatic malaria (due to any Plasmodium species) from 3 - 15 months of age,Incidence of symptomatic P. falciparum malaria from 3 - 15 months of age,University of Melbourne,Other,Case Western Reserve University,Other,Papua New Guinea Institute of Medical Research,15 months,15 months,Incidence of symptomatic P. vivax malaria from 3-15 months of age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,!5 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
257049/034,NCT00197067,"A Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered IM According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.","A Bridging Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Candidate Vaccines RTS,S/AS02D (0.5 mL Dose) and RTS,S/AS02A (0.25 mL Dose) Administered According to a 0, 1, 2 Month Vaccination Schedule in Children Aged 3 to 5 Years Living in a Malaria-endemic Region of Mozambique.",Completed,NA,"April 26, 2005",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,200,Actual,Malaria,Occurrence of solicited and unsolicited symptoms and serious adverse events during the entire study period; to assess antibody levels for relevant immunological indicators at time points when post completion of vaccination schedule.,All,3 Years,5 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,GSK Investigational Site,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"March 15, 2004",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SEACAT 01a ASSP,NCT00203814,A Randomised Efficacy Study of Combination Antimalarials to Treat Uncomplicated Malaria,"Open-Label, Randomised, Parallel Group in Vivo Drug Study to Evaluate Combination Anti-Malarial Therapy (CAT), Artesunate and Sulfadoxine-Pyrimethamine Versus Sulfadoxine-Pyrimethamine Alone, in Terms of Therapeutic Efficacy, Prevalence of Gametocyte Carriage and Prevalence of Molecular Markers Associated With SP Resistance In Uncomplicated Plasmodium Falciparum Infections.",Completed,January 2004,NA,NA,NA,University of Cape Town,"Karen Barnes, MBChB",Principal Investigator,University of Cape Town,N/A,Interventional,NA,NA,Malaria,NA,All,12 Months,N/A,No,University of Cape Town,Other,"ClinicalTrials.gov processed this data on July 26, 2017",March 2005,NA,NA,NA,280,"Therapeutic efficacy defined as:Adequate Clinical and Parasitological Response (ACPR), Early Treatment Failure (ETF), Late Treatment Failure (LTF), defined as Late Clinical Failure (LCF) and Late Parasitological Failure (LPF)","Sensitive or parasitological failure (RI, early and late, RII, RIII)",World Health Organization,Other,"Medical Research Council, South Africa",Other,NA,NA,NA,Parasitological failures will be classified as recrudescence or re-infection (or indeterminate) using GLURP and MSP I & II markers,NA,NA,Parasite clearance time,Fever clearance time,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1168,NCT00298610,Safety and Efficacy Study of IV Artesunate to Treat Malaria,"A Phase II, Open Label, Study of the Safety, Tolerability, Efficacy and Pharmacokinetics of Intravenous Artesunate in Adults With Uncomplicated Malaria",Completed,March 2006,October 2007,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Shon A Remich, MD",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 2,Interventional,30,Actual,Malaria,NA,All,18 Years,65 Years,No,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change in Percentage of Parasites Detected at 48 Hours,NA,Military Infectious Diseases Research Program (MIDRP),Other,NA,NA,New Nyanza Provincial Hospital,48 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Change in Percentage of Parasites Detected at 48 Hours. With positive numbers to represent increases and negative numbers to represent decreases,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
03-246,NCT00299247,SP Resistance and Falciparum Malaria Transmission,SP Resistance Markers and Falciparum Malaria Transmission,Withdrawn,NA,December 2006,Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 3,Interventional,NA,NA,Plasmodium Falciparum Malaria,NA,All,5 Years,N/A,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,150,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PSB-2006-Coartem,NCT00426439,Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau,Chloroquine and Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Guinea Bissau.,Completed,December 2006,November 2008,Actual,Actual,Bandim Health Project,Peter Aaby,Study Director,Bandim Health Project,Phase 4,Interventional,300,Anticipated,"Malaria, Falciparum",NA,All,6 Months,15 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Parasite reappearance rate,",NA,NA,NA,NA,NA,Bandim Health Project,70 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-006-06,NCT00440999,Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria,"A Phase III Multi-Centre, Randomised, Double-Blind, Double-Dummy, Comparative Clinical Study to Assess the Safety and Efficacy of a Fixed-Dose Formulation of Oral Pyronaridine Artesunate (180:60 mg Tablet) Versus Chloroquine (155 mg Tablet), in Children and Adult Patients With Acute Plasmodium Vivax Malaria",Completed,March 2007,September 2008,Actual,Actual,Medicines for Malaria Venture,"Isabelle Borghini Fuhrer, PhD",Study Director,Medicines for Malaria Venture,Phase 3,Interventional,456,Anticipated,Malaria,NA,All,3 Years,60 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cure rate on Day 14.,"Incidence of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities.",Shin Poong Pharmaceuticals,Industry,NA,NA,NA,Day 14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TIM,NCT00209794,IPTi in Mozambican Infants for Malaria Prevention,The Impact of Intermittent Malaria Treatment Administered Through the EPI Scheme on Malaria Morbidity in Mozambican Children,Unknown status,September 2002,NA,NA,NA,Hospital Clinic of Barcelona,"Clara Menendez, MD, PhD",Principal Investigator,"Center for International Health, Hospital Clinic de Barcelona",Phase 1/Phase 2,Interventional,NA,NA,Malaria,Incidence of first or only malaria episodes in each study cohort by 12 months of age.,All,N/A,3 Months,NA,Hospital Clinic of Barcelona,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2005,NA,NA,NA,1498,NA,NA,NA,NA,NA,NA,Centro de Investigaçao em Saude da Manhiça,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
104298,NCT00289185,"Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants","A Phase IIb Randomized, Double-blind, Controlled Study of the Safety, Immunogenicity and Proof-of-concept of RTS,S/AS02D, a Candidate Malaria Vaccine, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes DTPw/Hib in Infants Living in a Malaria-endemic Region.",Completed,"September 27, 2006","January 15, 2009",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,340,Actual,Malaria,NA,All,6 Weeks,10 Weeks,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Concentrations of Antibodies Against Hepatitis B (Anti-HB),Number of Subjects With Serious Adverse Events (SAEs),NA,NA,NA,NA,GSK Investigational Site,"Prior to vaccination at Week 0 (PRE), at Month 2 and at Month 3.",From Week 0 to Month 9.,Concentrations of Antibodies Against Diphtheria (Anti-D),NA,NA,Concentrations of Antibodies Against Tetanus (Anti-T),Concentrations of Anti-polyribosyl Ribitol Phosphate Antibodies (Anti-PRP).,Number of Subjects With Serious Adverse Events (SAEs),NA,NA,NA,NA,Concentrations were expressed as geometric mean concentrations (GMCs) in milli-international unit per milliliter (mIU/mL). The cut-off of the assay was the seroprotection cut-off of 10 mIU/mL. Month 3 results are the specific results for this primary outcome measure.,NA,NA,NA,NA,NA,NA,Concentrations of Anti-Bordetella Pertussis Toxin Antibodies (Anti-BPT).,Number of Subjects With Hepatitis B Antibody (Anti-HB) Concentrations Equal to or Above (>=) the Seroprotection Cut-off Value,NA,NA,NA,NA,NA,NA,"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","Prior to vaccination at Week 0 (PRE), and at Month 3.",Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). Concentrations were expressed as geometric mean concentrations (GMCs) in international unit per milliliter (IU/mL). The cut-off of the assay was the seroprotection cut-off of 0.1 IU/mL. Month 3 results are the specific results for this primary outcome measure.,"Prior to vaccination at Week 0 (PRE), and at Month 3.",Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). Concentrations were expressed as geometric mean concentrations (GMCs) in international unit per milliliter (IU/mL). The cut-off of the assay was the seroprotection cut-off of 0.1 IU/mL. Month 3 results are the specific results for this primary outcome measure.,NA,NA,"Prior to vaccination at Week 0 (PRE), and at Month 3.",Concentrations were expressed as geometric mean concentrations (GMCs) in microgram per milliliter (µg/mL). The cut-off of the assay is the seroprotection cut-off value of 0.15 µg/mL. Month 3 results are the specific results for this primary outcome measure.,From Month 9 to Month 20.,"SAEs assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","Prior to vaccination at Week 0 (PRE), and at Month 3.",Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). Concentrations were expressed as geometric mean concentrations (GMCs) in ELISA unit per milliliter (EL.U/mL). The cut-off of the assay was the seropositivity cut-off of 15 EL.U/mL. Month 3 results are the specific results for this primary outcome measure.,"Prior to vaccination at Week 0 (PRE), at Month 2 and at Month 3.","The seroprotection cut-off value was 10 milli-international units per milliliter (mIU/mL). Blood samples were collected prior to vaccination at Week 0 (PRE), at Month 2 and at Month 3. Month 3 results are the specific results for this primary outcome measure.",Number of Subjects With Anti-diphtheria Antibody (Anti-D) Concentrations Equal to or Above (>=) the Seroprotection Cut-off Value,"Prior to vaccination at Week 0 (PRE), and at Month 3.","Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). The seroprotection cut-off value was 0.1 international unit per milliliter (IU/mL). Blood samples were collected prior to vaccination at Week 0 (PRE), and at Month 3. Month 3 results are the specific results for this primary outcome measure.",Number of Subjects With Anti-tetanus Antibody (Anti-T) Concentrations Equal to or Above (>=) the Seroprotection Cut-off Value,"Prior to vaccination at Week 0 (PRE), and at Month 3.","Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). The seroprotection cut-off value was 0.1 international unit per milliliter (IU/mL). Blood samples were collected prior to vaccination at Week 0 (PRE), and at Month 3. Month 3 results are the specific results for this primary outcome measure.",Number of Subjects With Anti-polyribosyl Ribitol Phosphate Antibody (Anti-PRP) Concentrations Equal to or Above (>=) the Seroprotection Cut-off Value,"Prior to vaccination at Week 0 (PRE), and at Month 3.","Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). The seroprotection cut-off value was 0.15 microgram per milliliter (µg/mL). Blood samples were collected prior to vaccination at Week 0 (PRE), and at Month 3. Month 3 results are the specific results for this primary outcome measure.",Number of Subjects With Anti-Bordetella Pertussis Toxin Antibody (Anti-BPT) Concentrations Equal to or Above (>=) the Seropositivity Cut-off Value,"Prior to vaccination at Week 0 (PRE), and at Month 3.","Antibodies were measured by Enzyme-linked immunosorbent assay (ELISA). The seropositivity cut-off value was 15 ELISA units per milliliter (EL.U/mL). Blood samples were collected prior to vaccination at Week 0 (PRE), and at Month 3. Month 3 results are the specific results for this primary outcome measure.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
RapAct 28-02-2006,NCT00301015,Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers,Rapid Diagnostic Testing and Artemisinin-Based Combination Therapy for Uncomplicated Malaria by Community Health Workers,Completed,March 2006,August 2006,Actual,Actual,Karolinska University Hospital,"Anders Björkman, MD, PhD",Study Director,"Dept of Medicine, Karolinska University Hospital, 171 76 Stockholm, Sweden",Phase 4,Interventional,3005,Actual,Uncomplicated Plasmodium Falciparum Malaria,NA,All,N/A,N/A,No,Karolinska University Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of patients with fever prescribed artemether-lumefantrine for the treatment of malaria in respective study groups,NA,Muhimbili University of Health and Allied Sciences,Other,NA,NA,Villages,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Number of patients with fever prescribed artemether-lumefantrine for the treatment of malaria in respective study groups,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BFT2006/2,NCT00351013,The Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities,A Pilot Study of the Use of Homeopathic-Based Treatment Approaches to Reduce the Prevalence of Malaria in Depressed Communities,Completed,June 2006,June 2007,Actual,Actual,Malamed,"Jacob Minah, MD",Principal Investigator,"Specialist Pediatrician, Homeopath, Germany",Phase 4,Interventional,731,Actual,Malaria,NA,All,18 Years,N/A,Accepts Healthy Volunteers,Malamed,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Florence M. Margai, PhD",Principal Investigator,"Professor, Binghamton University-New York",NA,reduction in the burden and severity of malaria episodes,NA,Blackie Foundation Trust,Other,NA,NA,Malamed,four months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,reduction in the burden and severity of malaria episodes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A0661120,NCT00074841,Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Malaria in India,"A Phase II/III, Randomized, Comparative Trial of Azithromycin Plus Chloroquine Versus Sulfadoxine-Pyrimethamine Plus Chloroquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in India",Completed,September 2003,January 2005,Actual,Actual,Pfizer,NA,NA,NA,Phase 2/Phase 3,Interventional,230,Actual,PLASMODIUM FALCIPARUM MALARIA,NA,All,18 Years,N/A,No,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1032,NCT00075049,"Safety and Efficacy Study of RTS,S AS02A/AS01B Vaccine to Prevent Malaria","Dbl-Blind, Rand Phase 1/2a Human Challenge Study, to Eval Safety, Reactogenicity, Immunogenicity and Preliminary Efficacy After Sporozoite Challenge/Rechallenge of Vaccines Containing RTS,S",Completed,December 2003,January 2006,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Kent Kester, MD",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 1/Phase 2,Interventional,NA,NA,Malaria,To assess the safety and reactogenicity of the candidate vaccine,All,18 Years,45 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,104,NA,NA,GlaxoSmithKline,Industry,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,Walter Reed Army Institute of Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IDCVNHIL01,NCT00442442,Clinical Evaluation of Mosquito Coils to Control Malaria in China,Clinical Evaluation of Mosquito Coils to Control Malaria in China,Unknown status,April 2007,December 2007,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Nigel Hill, PhD",Principal Investigator,LSHTM,Phase 3,Interventional,8000,Anticipated,Malaria,NA,All,6 Years,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Hong Ning Zhou, MSc",Principal Investigator,Yunnan Institute of Parasitic Diseases,NA,Malaria cases,NA,Yunnan Institute,Other,NA,NA,Yunnan Institute of Parasitic Diseases,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1263,NCT00459615,Phase II Dose Ranging Study of Artesunate,"A Phase II, Randomized, Open-Label, Dose-Ranging Study of Intravenous Artesunate Therapy for the Treatment of Acute, Uncomplicated Plasmodium Falciparum Malaria.",Completed,April 2007,January 2008,Actual,Actual,U.S. Army Office of the Surgeon General,"Mark Polhemus, MD",Principal Investigator,USAMRU-K,Phase 2,Interventional,120,Anticipated,Falciparum Malaria; Uncomplicated Malaria,NA,All,12 Years,65 Years,No,U.S. Army Office of the Surgeon General,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Bryan Smith, MD",Principal Investigator,"Armed Forces Research Institute of Medical Sciences, Thailand",NA,The primary endpoint for this pharmacodynamic study is clearance of falciparum parasites from the blood.,Reference microscopic interpretation of Giemsa-stained thick and thin blood smears for malaria will serve as the diagnostic method of parasitemia detection.,Military Infectious Diseases Research Program (MIDRP),Other,U.S. Army Medical Research and Materiel Command,U.S. Fed,NA,NA,NA,Parasite clearance will be quantified using a discrete variable denoting efficacy to clear at least 90% of asexual parasites from the peripheral blood by 48 hours after administration of IV artesunate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IRD/Prevmal/Bol/06,NCT00290420,Prevention of P. Vivax Malaria During Pregnancy in Bolivia,"Prevention of P. Vivax Malaria During Pregnancy: Effects on Mother and Child Health in Santa Cruz, Bolivia. Open, Multicentric, Randomized Clinical Trial, Comparing Prophylaxis Once a Week to Malaria Attack Treatment, Both by Chloroquine.",Withdrawn,March 2006,November 2007,Anticipated,Anticipated,Institut de Recherche pour le Developpement,"Michel Cot, MD-PhD",Study Director,Institut de Recherche pour le Developpement,Phase 4,Interventional,0,Actual,Malaria,NA,Female,N/A,N/A,Accepts Healthy Volunteers,Institut de Recherche pour le Developpement,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Laurent Brutus, MD-MSc",Study Director,"Institut de Recherche pour le Développement, IRD, Bolivia",NA,Incidence of women presenting a malaria attack during pregnancy,NA,Instituto Nacional de Laboratorios de Salud (INLASA),Other,Pan American Health Organization,Other,NA,two years,NA,NA,"Ministry of Health, Bolivia",Other,NA,NA,NA,NA,NA,NA,NA,NA,"Agnès Le Port, MSc",Principal Investigator,"Institut de Recherche pour le Développement, IRD, Bolivia",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVG46,NCT00297882,Artemisinin-Based Combination Therapy: Clinical Trials in Cameroon,Phase III Clinical Trials of Artemisinin-based Combination Therapy in Cameroon,Completed,July 2006,July 2009,Actual,Actual,Gates Malaria Partnership,"Wilfred F Mbacham, ScD",Principal Investigator,University of Yaounde,Phase 3,Interventional,900,Actual,Malaria,NA,All,12 Months,120 Months,No,Gates Malaria Partnership,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cure rate on Day 28,NA,University of Yaounde,Other,Cameroon Baptist Convention Health,Other,NA,"Day 1, 2, 3, 7, 14, 28",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0012,NCT00125489,CQSP in Malawi: Chloroquine and Sulfadoxine-pyrimethamine Efficacy for the Treatment of Malaria in Malawi,"Chloroquine and Sulfadoxine-Pyrimethamine Efficacy for the Treatment of Uncomplicated Falciparum Malaria in Blantyre, Malawi",Completed,May 2005,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 4,Interventional,NA,NA,Malaria; Plasmodium Falciparum Malaria,NA,All,6 Months,12 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",December 2005,NA,NA,NA,210,NA,NA,NA,NA,NA,NA,Blantyre Malaria Project,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SA-179787-1,NCT00131235,Gestational Sulfadoxine-pyrimethamine and Azithromycin Treatment to Prevent Preterm Birth,"Lungwena Antenatal Intervention Study. A Single-centre Intervention Trial in Rural Malawi, Testing Maternal and Infant Health Effects of Presumptive Intermittent Treatment of Pregnant Women With Sulfadoxine-pyrimethamine and Azithromycin",Completed,December 2003,March 2012,Actual,Actual,University of Tampere,"Per Ashorn, MD, PhD",Study Director,"University of Tampere, Medical School",Phase 3,Interventional,1320,Actual,Malaria; Sexually Transmitted Diseases; Preterm Birth; Pregnancy,NA,Female,15 Years,N/A,Accepts Healthy Volunteers,University of Tampere,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Kenneth M Maleta, MBBS, PhD",Principal Investigator,University of Malawi College of Medicine,NA,Proportion of preterm births,Number of serious and any adverse events,Academy of Finland,Other,"Foundation for Paediatric Research, Finland",Other,"College of Medicine, University of Malawi","once, after delivery",Cumulative during pregnancy and neonatal period,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Teija Kulmala, MD, PhD",Principal Investigator,"University of Tampere, School of Public Health",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SFB544-A8-ASMB2006,NCT00354380,Safety and Efficacy of Methylene Blue Combined With Artesunate or Amodiaquine for Malaria Treatment in Children of Burkina Faso: a Pilot Study,NA,Completed,September 2006,NA,NA,NA,Heidelberg University,"Olaf Mueller, MD, MPH",Principal Investigator,Heidelberg University,Phase 2,Interventional,NA,NA,Malaria,Incidence of observed and self-reported non-serious adverse events over the 28 days observation period (definition chapter 11),All,6 Years,10 Years,NA,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",November 2006,"Peter Meissner, MD, MSc Trop Paed",Principal Investigator,Heidelberg University,NA,NA,NA,NA,NA,NA,NA,Nouna District Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SFB544D4,NCT00355225,Community-Effectiveness of the Distribution of Insecticide-Treated Bed Nets Through Social Marketing Antenatal Care Services in Malaria Control in Rural Burkina Faso,NA,Completed,NA,NA,NA,NA,Heidelberg University,"Olaf Mueller, MD, MPH",Principal Investigator,Heidelberg University,N/A,Interventional,NA,NA,Malaria,NA,All,N/A,N/A,NA,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,ITN coverage in households 12 and 24 months after the start of the interventions,ITN use during pregnancy and infancy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC1076,NCT00473837,Chloroquine and Post Malaria Anaemia Study,Chloroquine as a Therapeutic Option for Mild Post Malaria Anaemia,Completed,July 2007,December 2009,Actual,Actual,"Medical Research Council Unit, The Gambia","Chidi V Nweneka, MSc.",Principal Investigator,"Medical Research Council Unit, The Gambia",N/A,Interventional,96,Actual,Malaria Anaemia,NA,All,12 Months,72 Months,Accepts Healthy Volunteers,"Medical Research Council Unit, The Gambia",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Sophie Moore, PhD",Study Director,"Medical Research Council Unit, The Gambia",NA,Changes in Haemoglobin Concentration From Day 3 Post Treatment of Malaria Episode to Day 90 in the Weekly Chloroquine and Placebo Arms,NA,NA,NA,NA,NA,NA,90 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
T26/181/33,NCT00486694,Artesunate Plus Sulfadoxine-Pyrimethamine Versus Chloroquine for Vivax Malaria,A Randomised Non-Inferiority Trial of Sulfadoxine-Pyrimethamine Plus Artesunate Compared to Chloroquine for the Treatment of Vivax Malaria in Eastern Afghanistan.,Completed,March 2004,August 2004,Actual,Actual,London School of Hygiene and Tropical Medicine,"Mark W Rowland, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 2,Interventional,190,Actual,"Malaria, Vivax",Proportion of patients with parasitological cure up to day 28 after treatment (defined as clearance of circulating vivax parasites by day 7 and absence until end of follow-up).,All,2 Years,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
02 52 5 406,NCT00304980,Comparative Evaluation of the Safety and the Efficacy of 2 Antimalarials Depending on HIV Status,Comparative Evaluation of the Safety and the Efficacy of Artemether + Lumefantrine (Coartem™) vs. Sulfadoxine + Pyrimethamine (SP) in Both HIV+ and HIV- Adults With Uncomplicated P. Falciparum Malaria in Zambia,Terminated,March 2003,NA,NA,NA,"Institute of Tropical Medicine, Belgium","Umberto D'Alessandro, MD,MSc, PHD",Principal Investigator,"Institute of Tropical Medicine, Antwerp",N/A,Interventional,NA,NA,Plasmodium Falciparum Malaria,PCR corrected clinical and parasitological outcome at day 45,All,15 Years,45 Years,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",April 2005,NA,NA,NA,3000,NA,NA,NA,NA,NA,NA,Tropical Disease Research Center,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1250,NCT00312663,Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America,"A Phase I/IIa Controlled Study of the Safety, Immunogenicity and Preliminary Efficacy of FMP011/AS01B Candidate Malaria Vaccine in Malaria-naive Adults Living in the United States",Completed,April 2006,April 2007,Actual,Actual,U.S. Army Medical Research and Materiel Command,"James F. Cummings, MD",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 1/Phase 2,Interventional,36,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To assess the safety and reactogenicity of candidate FMP011/ASO1 malaria vaccine (as either a 10ug or 50ug dose antigen),NA,GlaxoSmithKline,Industry,The PATH Malaria Vaccine Initiative (MVI),Other,Walter Reed Army Institute of Research,"at 0, 1 months schedule.",NA,NA,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,NA,NA,NA,NA,"FMP011/ASO1 malaria vaccine (as either a 10ug or 50ug dose antigen) when administered as 2 doses intramuscularly on a 0, 1 months schedule to healthy malaria-naive adults aged 18- 50 years",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
02-004,NCT00138489,Papua New Guinean Duffy Negativity And Vivax Malar,Protocol 3B Susceptibility to Plasmodium Vivax Infection and Malaria During Early Childhood,Suspended,January 2004,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Plasmodium Vivax Malaria,NA,All,N/A,24 Months,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,266,NA,NA,NA,NA,NA,NA,Papua New Guinea Institute of Medical Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
arginine,NCT00147368,Arginine Malaria Trial: Study of Adjunctive Arginine in Falciparum Malaria,Pharmacokinetic-Pharmacodynamic Study of Adjunctive Arginine in Falciparum Malaria,Completed,February 2005,December 2007,Actual,Actual,Menzies School of Health Research,"Nick M Anstey, MBBS",Principal Investigator,MSHR,Phase 1/Phase 2,Interventional,50,Anticipated,"Malaria, Falciparum",NA,All,18 Years,60 Years,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,exhaled and systemic nitric oxide production,endothelial function,Wellcome Trust,Other,"National Health and Medical Research Council, Australia",Other,RSMM Hospital,NA,NA,NA,MSHR,Other,NA,NA,NA,"National Institute of Health Research and Development (NIHRD), Indonesia",Other,Rumah Sakit Mitra Masyarakat Hospital,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,University of Utah,Other,University of Sydney,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PM_L_0164,NCT00316329,ATAQ EASY: Artesunate + Amodiaquine Fixed Dose Combination in the Treatment of Uncomplicated Plasmodium Falciparum Malaria,"Multinational, Randomized, Comparative Study of the Efficacy and Safety of Three Therapeutic Regimens: Coarsucam™ (Artesunate + Amodiaquine Fixed-Dose Combination) Administered in 1 or 2 Intakes Per Day Versus Coartem® (Artemether + Lumefantrine) in the Treatment of Uncomplicated Plasmodium Falciparum Malaria",Completed,March 2006,NA,NA,NA,Sanofi,Valérie Lameyre,Study Director,Sanofi,Phase 3,Interventional,NA,NA,Malaria,"Clinical and parasitological cure (after PCR correction) on D28 in compliance with WHO classification, for the Coarsucam™ & Coartem® groups",All,N/A,N/A,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,1032,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0067,NCT00322738,Time to Infection With Malaria Parasites,Time to Infection With Malaria Parasites in Adults,Unknown status,June 2006,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Plasmodium Falciparum Malaria,NA,All,18 Years,40 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",January 2007,NA,NA,NA,552,NA,NA,NA,NA,NA,NA,Medical Research Council's Laboratories,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
U01AI062677-01,NCT00356824,Relationship Between HIV and Malaria in Ugandan Children,"Prospective Longitudinal Study of Interactions Between HIV and Malaria in Ugandan Children: A UCSF/Makerere University ""Children With HIV and Malaria Project""",Completed,November 2005,May 2010,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Diane V. Havlir, MD",Principal Investigator,"University of California, San Francisco and San Francisco General Hospital",N/A,Observational,300,Anticipated,HIV Infections; Malaria,NA,All,1 Year,10 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Moses R. Kamya, MBChB, MMed, MPH",Principal Investigator,"Department of Medicine, Makerere University, Kampala, Uganda",NA,NA,NA,NA,NA,NA,NA,"Pediatric Infectious Diseases Clinic, Mulago Hospital Complex",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rukyalekere-Adeodadata Kekitiinwa,Principal Investigator,"Department of Pediatrics, Makerere University, Kampala, Uganda",Anne Gasasira,Principal Investigator,"Makerere University Medical School, Makerere University, Kampala, Uganda",NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  HIV infected

          -  Resides within a 20 km (12.4 mi) radius of the study clinic in Kampala, Uganda

          -  Had a minimum of 1 regularly scheduled clinic visit in the 3 months prior to study
             entry

          -  Willing to return to the study clinic if fever or other illness occurs during this
             study

          -  Willing to avoid medications administered outside the Mulago Hospital Complex

          -  Parent or guardian willing to provide informed consent

        Exclusion Criteria:

          -  Intends to move more than 20 km (12.4 mi) from the study clinic during the follow-up
             period

          -  Weigh less than 5 kg (11 lbs)

          -  Participating in another Infectious Disease Clinic (IDC) cohort study

          -  Any current medical problem requiring in-patient evaluation or home care

          -  History of allergy or sensitivity to amodiaquine, artesunate, or quinine

          -  Life-threatening screening laboratory values in the absence of malaria. More
             information on this criterion can be found in the protocol.
      ",Israel Kalyesubula,Principal Investigator,"Department of Pediatrics, Makerere University, Kampala, Uganda",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Grant Dorsey,Principal Investigator,"University of California, San Francisco",Edwin Charlebois,Principal Investigator,"University of California, San Francisco",Philip Rosenthal,Principal Investigator,"University of California, San Francisco",Huyen Cao,Principal Investigator,California Department of Human Services,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05 34 5 520,NCT00372632,IPT of Malaria With SP in Different Zones of Drug Resistance in Rwanda,Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in Different Zones of Drug Resistance in Rwanda,Completed,December 2005,April 2008,Actual,Actual,"Institute of Tropical Medicine, Belgium","Umberto D'Alessandro, MD,MSc, PHD",Study Director,"Institute of Tropical Medicine, Antwerp",Phase 4,Interventional,1717,Actual,Non HIV Infected Pregnant Women,NA,Female,21 Years,50 Years,Accepts Healthy Volunteers,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,malaria infection will be defined as the presence of asexual stage parasites on thick smears made with maternal side placental blood and Maternal peripheral blood,NA,NA,NA,NA,NA,Programme Nationale de Controle de Paludisms,maternal placental blood at delivery; maternal peripheral blood at monthly visits between 16 weeks of gestation and delivery,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3279,NCT00510679,Study of Post-Training Supports for Health Workers in Benin,"A Randomized Controlled Trial of Post-Training Supports for Health Workers Trained in the Use of Integrated Management of Childhood Illness Guidelines in Ouémé Department, Benin",Completed,July 1999,October 2004,Actual,Actual,Centers for Disease Control and Prevention,"Rowe K Alexander, MD, MPH",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,1577,Actual,Malaria; Pneumonia; Diarrhea; Measles; Malnutrition,NA,All,N/A,59 Months,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Proportion of children with potentially life-threatening illnesses who received recommended treatment, according to Integrated Management of Childhood Illness guidelines.","Proportion of children with potentially life-threatening illnesses who received recommended treatment, according to Integrated Management of Childhood Illness guidelines, or adequate treatment.","Ministry of Health, Benin",Other,NA,NA,All eligible health facilities,3 years,3 years,Mean proportion of needed case management tasks that were performed during consultations.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,3 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EDCTP/MMV07-01,NCT00522132,Phase II Artesunate Study in Severe Malaria,"Phase II Randomized, Double-Blind Study of the Efficacy, Safety, Tolerability, and Pharmacokinetics of Intravenous Artesunate in Children With Severe Malaria",Completed,September 2007,December 2008,Actual,Actual,Medicines for Malaria Venture,"Peter Kremsner, MD",Principal Investigator,"University of Tuebingen, Germany",Phase 2,Interventional,200,Anticipated,Malaria,NA,All,6 Months,10 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The proportion of patients with parasite clearance (more than 99% reduction from the baseline asexual parasite count) at 24 hours after initiation of study drug.,NA,European and Developing Countries Clinical Trials Partnership (EDCTP),Other,Severe Malaria in African Children Consortium,Other,NA,24 hours after initiation of study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Mefloquine HIV zambia,NCT00373048,Mefloquine Prophylaxis in HIV-1 Individuals: a Randomized Placebo-controlled Trial,Mefloquine Malaria Prophylaxis in HIV-1 Infected Individuals and Its Influence on the Evolution Towards AIDS: a Randomized Placebo-controlled Trial,Completed,October 2005,May 2011,Actual,Actual,"Institute of Tropical Medicine, Belgium","Umberto D'Alessandro, MD,MSc, PHD",Study Director,"Institute of Tropical Medicine, Antwerp",N/A,Interventional,300,Anticipated,HIV Infections,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Rate of decline of CD4 counts between different time points,"Proportion of patients entering the AIDS stage (WHO stage 3,4)",NA,NA,NA,NA,Tropical Disease Research Center,"months 0, 6, 12 and 18",during 18 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04-070,NCT00377494,"CS DNA MVA Trial in Mampong, Ghana","A Phase I Trial of PFCSP DNA/MVA.CSO Prime/Boost Vaccine in Mampong, Ghana",Withdrawn,NA,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Plasmodium Falciparum Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",July 2008,NA,NA,NA,48,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"Don Krogstad, K 0154 (Phase 1)",NCT00323375,"Phase 1 Studies of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine","Randomized Controlled Trial of AQ-13, a Candidate Aminoquinoline Antimalarial, in Comparison With Chloroquine",Completed,August 1999,NA,NA,NA,Tulane University Health Sciences Center,"Donald J. Krogstad, MD",Principal Investigator,Tulane University Health Sciences Center,Phase 1,Interventional,NA,NA,Malaria,NA,All,21 Years,45 Years,Accepts Healthy Volunteers,Tulane University Health Sciences Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",August 2005,NA,NA,NA,122,Adverse Events (AEs),Pharmacokinetic Profile,National Institutes of Health (NIH),NIH,NA,NA,Tulane-LSU-Charity Hospital General Clinical Research Center,NA,NA,Effects on the QTc Interval,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SGS64,NCT00330902,Randomized Trial of Two Antimalarial Treatments for Clearing Low Density P.Falciparum Parasitaemia in Sudan,Randomized Trial of Sulfadoxine-Pyrimethamine Plus Artesunate (SP+AS) Versus SP+AS Plus Primaquine for Clearance of Low Density P. Falciparum Infection in Eastern Sudan,Completed,January 2004,November 2004,Actual,Actual,London School of Hygiene and Tropical Medicine,"Badria B El Sayed, PhD",Principal Investigator,"TMRI, Khartoum",Phase 3,Interventional,104,Actual,Plasmodium Infections,NA,All,3 Years,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Omer Z Baraka, MD",Study Chair,"Faculty of Medicine, University of Khartoum",NA,"P.falciparum parasitaemia detected by PCR on days 3,7 and 14.",NA,Tropical Medicine Research Institute,Other,World Health Organization,Other,Tropical Medicine Research Institute,14 days from start of treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
5184,NCT00529620,Three Alternative Drug Regimens for Malaria Seasonal Preventive Treatment in Senegal,Randomized Trial of Effectiveness and Acceptability of Three Alternative Regimens for Malaria Seasonal Intermittent Preventive Treatment in Senegal,Completed,September 2007,December 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Badara Cisse, PhD",Principal Investigator,Universite Cheikh Anta Diop,Phase 3,Interventional,1833,Actual,Malaria,NA,All,2 Months,59 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Paul J Milligan, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,Incidence of malaria,NA,"Cheikh Anta Diop University, Senegal",Other,NA,NA,"Departement de Parasitologie et Mycologie, Universite Cheikh Anta Diop",Four months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A10828,NCT00623155,Seasonal Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine in Children in Mali,Evaluation of a Malaria Transmission Target Strategy Based on the Periodic Treatment With Sulfadoxine-Pyrimethamine vs. Early Case Management,Completed,July 2002,January 2004,Actual,Actual,University of Bamako,"Ogobara Doumbo, MD",Study Director,University of Bamako,N/A,Interventional,262,Actual,Malaria,NA,All,6 Months,10 Years,Accepts Healthy Volunteers,University of Bamako,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Alassane Dicko, MD",Principal Investigator,University of Bamako,NA,incidence rate of clinical malaria,in vivo adequate clinical and parasitological response of P. falciparum to SP,World Health Organization,Other,NA,NA,"Malaria Research and Training Center, Faculty of Medicine Pharmacy and Dentistry, University of Bamako",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14617,NCT00338520,Hyperphenylalaninemia in Cerebral Malaria,Hyperphenylalaninemia in Cerebral Malaria,Completed,October 2007,January 2012,Actual,Actual,University of Utah,"Donald L Granger, M.D.",Principal Investigator,"University of Utah, Division of Infectious Diseases",N/A,Observational,285,Actual,Plasmodium Falciparum Malaria,NA,All,6 Months,6 Years,Accepts Healthy Volunteers,University of Utah,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Esther D. Mwaikambo, M.D.",Principal Investigator,Hubert Kairuki Memorial Hospital (HKMU),NA,NA,NA,Hubert Kairuki Memorial University,Other,Duke University,Other,Hubert Kairuki Memorial University,NA,NA,NA,National Institutes of Health (NIH),NIH,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

        Uncomplicated malaria (UM) Inclusion Criteria:

          -  Age between 6 months and 6 years, male and female.

          -  P. falciparum parasitemia (greater than or equal to 10,000 trophozoites/microliter).

          -  Clinical syndrome consistent with malaria associated with documented fever (axillary
             temperature greater than or equal to 38 degrees C) or reported history of fever in the
             last 48 hours with no other cause present.

          -  No other infection identified (ie. Negative blood and/or urine cultures).

          -  Commenced oral quinine less than or equal to 8 hours prior to enrollment.

          -  Parental permission obtained from parent or legal guardian.

        Cerebral Malaria (CM) Inclusion Criteria:

          -  Age between 6 months to 6 years, male and female.

          -  Coma (Blantyre Coma Score less than or equal to 2) which persists for > 30 minutes
             after correction of hypoglycemia and/or seizure.

          -  Other causes of coma excluded by lumbar puncture.

          -  Any degree of P. falciparum parasitemia.

          -  Less than 8 hours since commencement of intravenous quinine (ideally not yet commenced
             or soon after).

          -  Parental permission obtained from parent or legal guardian.

        Non-malaria CNS disease (NMC) Inclusion Criteria:

          -  Age between 6 months and 6 years, male and female.

          -  Non-malaria cause of altered consciousness/coma identified (eg. Meningitis,
             subarachnoid hemorrhage, trauma, metabolic, toxic, post-ictal febrile seizure).

          -  Parental permission obtained from parent or legal guardian.

        Healthy Control (HC) Inclusion Criteria:

          -  Age between 6 months and 6 years, male and female.

          -  No febrile illness within 2 weeks of evaluation.

          -  No active inflammatory condition identified.

          -  Parental permission obtained from parent or legal guardian.

          -  Negative RDT (rapid diagnostic test for malaria).

        Exclusion Criteria:

        Uncomplicated malaria (UM) Exclusion Criteria:

          -  Mixed infection with P. falciparum and any other malaria species (P. malariae, P.
             ovale, P. vivax).

          -  Co-infection with any other organism identified (ie. Positive blood culture).

          -  On quinine or artemesinin derivatives for greater than or equal to 8 hours.

          -  Presence of warning signs suggesting more severe disease, including the following:

               1. Unable to suckle, eat and/or drink

               2. Excessive vomiting

               3. Abnormal respiration/respiratory distress (use of accessory muscles of
                  respiration, tracheal tugging, intercostal retractions)

               4. Recent history of convulsions

               5. Altered mental state

               6. Prostration (unable to sit unaided)

        Cerebral Malaria (CM) Exclusion Criteria

          -  Untreated severe malaria anemia (hemoglobin less than or equal to 6 gm/dl).

          -  Lumbar puncture not performed.

          -  Mixed infection with P. falciparum and any other malaria species (P. malariae, P.
             ovale, P. vivax).

          -  On quinine or artemesinin derivatives for greater than or equal to 8 hours.

        Non-malaria CNS disease (NMC) Exclusion Criteria:

          -  Lumbar puncture not performed.

          -  Untreated severe anemia (hemoglobin less than or equal to 6.0 gm/dl due to any cause).

          -  Any degree of P. falciparum parasitemia.

        Healthy Control (HC) Exclusion Criteria

          -  Fever (Temp > 38.0 degrees C).

          -  History of sickle cell disease or sickle cell trait.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999902248,NCT00341783,"Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Don gu Bougou, Mali","Assessment of Biologic Parameters in Preparation for Future Malaria Vaccine Trials in Doneguebougou, Mali",Terminated,July 2002,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Malaria,NA,All,N/A,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",July 2005,NA,NA,NA,515,NA,NA,NA,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04-075,NCT00344539,AMA1-C1/Alhydrogel + CpG 7909 for Malaria,"Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,May 2005,January 2007,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,75,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cellular immune response to vaccination.,Serum antibody response to vaccination.,NA,NA,NA,NA,University of Rochester,"Anti-AMA1 antibody will be measured by ELISA on Days 0, 14, 28, 42, 56, 70, 84, 140, and 236.",Day 70.,"Safety: frequency of vaccine-associated adverse events, as classified by severity through active and passive surveillance.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Duration of study.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCOA566B2303,NCT00386763,Efficacy and Safety of the Pediatric Formulation of Artemether- Lumefantrine in Children With Uncomplicated P. Falciparum Malaria.,"A Randomized, Investigator-Blinded, Multicenter, Parallel-Group Study to Compare Efficacy, Safety and Tolerability of Arthemeter/ Lumefantrine Dispersible Tablet Formulation vs. Artemether/ Lumefantrine 6-Dose Crushed Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants and Children.",Completed,August 2006,NA,NA,NA,Novartis,Novartis Pharmaceuticals,Study Chair,Novartis Pharmaceuticals,Phase 3,Interventional,NA,NA,Malaria; Falciparum,Proportion of patients free of parasites at day 28.,All,N/A,12 Years,No,Novartis,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",March 2007,NA,NA,NA,890,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
4 ABC,NCT00393679,Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children,Evaluation of 4 Artemisinin-based Combinations for Treating Uncomplicated Malaria in African Children,Completed,July 2007,December 2009,Actual,Actual,"Institute of Tropical Medicine, Belgium","UmbertoC D'Alessandro, MD MsC PhD",Study Director,"Institute of Tropical Medicine, Antwerp",Phase 3,Interventional,4112,Actual,Fever; Malaria,NA,All,6 Months,59 Months,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"PCR unadjusted treatment failure (TF28U): all treatment failures detected during the active follow up, regardless of genotyping.",PCR adjusted treatment failure up to day 28 (TF28A): all early failures before day 14 plus the recurrent parasitaemias detected at day 14 or later and classified by genotyping as recrudescence.,Liverpool School of Tropical Medicine,Other,East African Network for Monitoring Antimalarial Treatment,Other,NA,Day 28,Day 28,NA,Centre Muraz,Other,NA,NA,NA,University of Calabar,Other,"Tropical Diseases Research Centre, Zambia",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,University Hospital Tuebingen,Other,Albert Schweitzer Hospital,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Uganda Malaria Surveillance Project,Other,Mbarara University of Science and Technology,Other,"Ministry of Health, Rwanda",Other,University of Barcelona,Other,Centro de Investigacao em Saude de Manhica,Other,NA,NA,NA,NA,NA,NA,NA,NA
A0661157,NCT00677833,Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated P. Falciparum Malaria In Children In Africa,"Phase 2/3, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Artemether-Lumefantrine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Children In Africa",Completed,June 2008,September 2010,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 2/Phase 3,Interventional,361,Actual,"Malaria, Falciparum",NA,All,6 Months,12 Years,No,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of Participants With Polymerase Chain Reaction (PCR)-Corrected Adequate Clinical and Parasitologic Response (ACPR) at Day 28 in the Modified Intent-to-treat (mITT) Population,Percentage of Participants With PCR-corrected ACPR at Day 28 in Per-Protocol (PP) Population,NA,NA,NA,NA,NA,Day 28,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ACPR (PCR-corrected) was defined as asexual Plasmodium falciparum (P.falciparum) parasitologic clearance at Day 28 irrespective of axillary, oral, rectal, or tympanic temperature, without previously meeting the criteria of Early Treatment Failure (ETF) (see measure description in secondary outcome measures 7 and 8) or PCR-corrected Late Treatment Failure (LTF) (which includes PCR-corrected Late Clinical Failures [LCF] - see measure description in secondary outcome measure 9 and 10, and PCR-corrected Late Parasitologic Failures (LPF)- see measure description in secondary outcome measure 11 and 12). PCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ACPR (PCR-corrected) was defined as asexual P.falciparum parasitologic clearance at Day 28 irrespective of axillary, oral, rectal, or tympanic temperature, without previously meeting the criteria of ETF (see measure description in secondary outcome measures 7 and 8) or PCR-corrected LTF (which includes PCR-corrected LCF - see measure description in secondary outcome measure 9 and 10, and PCR-corrected LPF - see measure description in secondary outcome measure 11 and 12). PCR-corrected refers to the use of molecular testing to differentiate recrudescence from reinfection in the context of an efficacy evaluation.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IUGR Malaria,NCT00680732,Prevention of Intrauterine Growth Retardation in Burkina Faso: the Malaria Component,"Prevention of Intrauterine Growth Retardation in Hounde District, Burkina Faso: the Malaria Component",Completed,June 2003,October 2006,Actual,Actual,"Institute of Tropical Medicine, Belgium","Marie Claire Henry, MD",Principal Investigator,Centre Muraz,Phase 4,Interventional,1370,Actual,Malaria; Malaria in Pregnancy,NA,Female,15 Years,44 Years,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Efficacy of standard antimalarial treatment in preventing clinical malaria in pregnant women under weekly chemoprophylaxis or intermittent treatment.,NA,"Departments of Parasitology and Public Health, ITM, Antwerp, Belgium",Other,Centre Muraz,Other,Centre Muraz,Up to delivery,NA,NA,"Laboratoire National de Santé Publique, Ouagadougou, Burkina Faso",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04-031,NCT00349713,"FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali","Double Blind Randomized, Controlled Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of the WRAIR AMA1 Malaria Antigen (FMP2.1) Adjuvanted in GSK's AS02A Versus Rabies Vaccine in Malaria-experienced Adults in Bandiagara, Mali",Completed,November 2004,December 2006,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Mahamadou A. Thera, M.D.",Principal Investigator,University of Bamako,Phase 1,Interventional,60,Actual,Malaria; Plasmodium Falciparum Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Chris V. Plowe, M.D.",Principal Investigator,University of Maryland,NA,Safety and Reactogenicity (SAEs and AEs),NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"University of Bamako, Malaria Research and Training Center",12 months,NA,NA,GlaxoSmithKline,Industry,NA,NA,NA,University of Maryland,Other,NA,NA,The primary objective was to evaluate the safety and reactogenicity of 2 dose levels of WRAIR's AMA1 malaria antigen (FMP2.1) adjuvanted in GlaxoSmithKline Biologicals' (GSK) AS02A compared to rabies vaccine in malaria-experienced Malian adults aged 18-55 years inclusive. Solicated AEs were recorded for the 7 day surveillance period after each vaccination. Unsolicited AEs were recorded for 30 days after each vaccination.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
106367,NCT00360230,Partially-blind (Observer-blind) Study of Safety and Immunogenicity of Two Malaria Vaccines in Ghanaian Children,A Partially-blind (Observer-blind) Study to Evaluate the Safety and Immunogenicity of 3 Different Vaccination Schedules With 2 GSK Biologicals' Candidate Plasmodium Falciparum Vaccines in Children Aged 5 to 17 Months Living in Ghana,Completed,August 2006,May 2008,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,540,Actual,Plasmodium Falciparum; Malaria,NA,All,5 Months,17 Months,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of SAEs.,NA,NA,NA,NA,NA,NA,From the time of first vaccination until ten months post Dose 1.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EudraCT: 2005-004568-22,NCT00397449,"GMZ2-Aluminum Hydroxide Phase I, Tübingen","Assessment of the Safety and Immunogenicity of the Recombinant Lactococcus Lactis Hybrid GMZ2 [GLURP+MSP3] a Malaria Vaccine in Healthy Adult Volunteers. A Phase I, Double-Blind, Randomised, Dose-Selection, Unicentre Trial",Unknown status,October 2006,December 2007,Anticipated,Anticipated,European Malaria Vaccine Initiative,"Jurgen Knobloch, MD",Principal Investigator,"Insitut of Tropical Medicine, University of Tubingen",Phase 1,Interventional,30,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,European Malaria Vaccine Initiative,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Peter Kremsner, MD, PhD",Study Director,"Insitut of Tropical Medicine, University of Tubingen",NA,Safety,Immunogenicity,NA,NA,NA,NA,"Institut for Tropical Medicine, University of Tubingen",one year,one year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UMCN-AKF 06.02,NCT00421473,Drug Interaction Study Between Atovaquone and Antiretroviral Agents in HIV-1 Infected Patients,Drug Interactions Between ATOvaquone Used in MAlaria Prophylaxis and Antiretroviral Agents in HIV-1 Infected Patients (ATOMA),Completed,March 2007,December 2008,Actual,Actual,Radboud University,"D.M. Burger, Dr.",Principal Investigator,Radboud University Medical Centre Nijmegen,Phase 4,Interventional,79,Actual,HIV Infections; Malaria,"Pharmacokinetic blood samples will be taken just before dosing Malarone, and 12 samples in the time between 0,5 hour and 168 hours after dosing.",All,18 Years,65 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
RBx/MMV05-06,NCT00362050,RBx11160 Phase II Dose Ranging Study RBx/MMV05-06,"A Phase II, Double-Blind, Parallel-Group, Randomized, Dose-Ranging Study Assessing the Antimalarial Activity and Safety of RBx 11160 Administered for 7 Days in Patients With Acute Uncomplicated Plasmodium Falciparum Malaria",Completed,June 2006,January 2007,Actual,Actual,Medicines for Malaria Venture,"Sornchai Looareesuwan, MD",Principal Investigator,"Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand",Phase 2,Interventional,NA,NA,Plasmodium Falciparum Malaria,Median time to 90% parasite clearance (PC90).,All,13 Years,65 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Salim M Abdulla, MD",Principal Investigator,"District Hospital Bagamoyo, Dar es Salaam, Tanzania",255,NA,NA,Ranbaxy Laboratories Limited,Industry,Swiss Tropical & Public Health Institute,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Anders Björkman, MD",Principal Investigator,"Kivunge Public Health Care Center, Zanzibar, Tanzania","Neena Valecha, MD",Principal Investigator,"Malaria Research Center, Rourkela, India",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
01KA22062006,NCT00374205,Randomized Trial on Effectiveness of ACTs in Ghana,A Comparative Assessment of the Effectiveness of Artemether Plus Lumefantrine Versus Artesunate Plus Amodiaquine for the Treatment of Children With Uncomplicated Plasmodium Falciparum Malaria,Terminated,September 2006,October 2007,Actual,Actual,Bernhard Nocht Institute for Tropical Medicine,"Daniel Ansong, MD",Principal Investigator,"School of Medical Science (SMS), Kwame Nkrumah University of Science and Technology (KNUST), Kumasi, Ghana",Phase 4,Interventional,245,Actual,"Malaria, Falciparum",NA,All,6 Months,59 Months,No,Bernhard Nocht Institute for Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Clinical and PCR-controlled parasitological cure rate at day 28,NA,Presbyterian Health Service (PHS),Other,Kumasi Centre for Collaborative Research (KCCR),Other,Agogo Presbyterian Hospital,28 days,NA,NA,School of Medical Sciences Kumasi (SMS/KNUST),Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AL Oct-Dec/06-07,NCT00440752,The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance,The Impact of Artemether-Lumefantrine on Genes Associated With Antimalarial Resistance in an Area of Seasonal Transmission,Completed,October 2006,December 2006,Actual,Actual,Tropical Medicine Research Institute,"Colin Sutherland, PhD.",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Observational,100,Actual,Falciparum Malaria; Antimalarials,NA,All,2 Years,N/A,Accepts Healthy Volunteers,Tropical Medicine Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Badria B El-Sayed, PhD",Study Chair,Tropical Medicine Research Institute,NA,"Levels of expression of pfcrt and pfmdr-1 alleles on day 0, 3, 7, 14, 21, 28 detected by real-time PCR.",NA,London School of Hygiene and Tropical Medicine,Other,World Health Organization,Other,Tropical Medicine Research Institute,2007 to 2009,NA,NA,International Atomic Energy Agency,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PM_L_0163,NCT00445796,Arsucam® (Artesunate + Amiodaquine) Efficacy and TOLerance,"Randomised, Comparative Study of the Efficacy and Safety of Arsucam® Administered as a Single Daily Intake Versus Two Daily Intakes in the Treatment of Plasmodium Falciparum Malaria Attack",Completed,June 2005,NA,NA,NA,Sanofi,Valérie Lameyre,Study Director,Sanofi,Phase 4,Interventional,NA,NA,Malaria,NA,All,N/A,N/A,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,300,clinical and parasitological cure on Day 14,Secondary: incidence and severity of adverse events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BKMAL0701,NCT00682578,A Comparative Study of Artekin With Standard Malarial Treatment Regimes in Afghanistan,Randomized Clinical Trial of the Efficacy and Safety of Dihydroartimisinine+Papiraquine (Artekin) Compared With First Line Drugs for Treatment of Vivax and Uncomplicated Falciparum Malaria in Afghanistan,Unknown status,July 2007,December 2010,Anticipated,Anticipated,University of Oxford,"Sasithon Pukrittayakamee, MD",Principal Investigator,Mahidol University,Phase 3,Interventional,1100,Anticipated,Uncomplicated Falciparum Malaria; Vivax Malaria,NA,All,3 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR corrected adequate clinical and parasitological response (PCR corrected 'adequate clinical and parasitological response' or ACPR),NA,Wellcome Trust,Other,Ministry of public Health Afghanistan,Other,NA,Day 56,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITMP0208,NCT00701961,Pharmacokinetic of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnancy,The Pharmacokinetic of the Fixed-dose Combination of Mefloquine-Artesunate in Plasmodium Falciparum Malaria Infection in Pregnant Women,Completed,October 2008,July 2009,Actual,Actual,"Institute of Tropical Medicine, Belgium","Tinto Halidou, PhD",Principal Investigator,Centre Muraz,Phase 2/Phase 3,Interventional,48,Actual,Plasmodium Falciparum Malaria,NA,Female,18 Years,49 Years,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Umberto D'Alessandro, MD",Study Chair,ITM Belgium,NA,To estimate the pharmacokinetic of MQ-AS for treatment of P. falciparum or mixed infection in pregnant compared to non-pregnant women.,NA,Centre Muraz,Other,Liverpool School of Tropical Medicine,Other,Centre Muraz,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BMGF28580,NCT00152204,The Community Effectiveness of IPTi in Southern Tanzania,Community Effectiveness of Intermittent Preventive Treatment Delivered Through the Expanded Programme of Immunisation for Malaria and Anaemia Control in Tanzanian Infants,Unknown status,March 2005,December 2008,Anticipated,Anticipated,Swiss Tropical & Public Health Institute,"David M Schellenberg, MRCP PhD",Principal Investigator,"London School of Hygiene & Tropical Medicine, London, UK/Ifakara Health Research & Development Centre, Tanzania",Phase 3,Interventional,13000,Anticipated,"Malaria, Falciparum; Anemia",NA,All,N/A,N/A,Accepts Healthy Volunteers,Swiss Tropical & Public Health Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Hassan Mshinda, PhD",Principal Investigator,"Ifakara Health Research & Development Centre, Tanzania",NA,Mortality rate in children aged 2-11 months (estimated by birth history questioning),"Incidence of severe adverse drug reactions following IPTi (as detected by spontaneous, passive reporting system)",Ifakara Health Research and Development Centre,Other,"Ministry of Health, Tanzania",Other,Ifakara Health Research & Development Centre,Up to 12 months of age,"All age groups, particular attention in under 2 year olds",NA,Hospital Clinic of Barcelona,Other,NA,NA,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,NA,"Joanna RM Armstrong Schellenberg, PhD",Principal Investigator,"London School of Hygiene & Tropical Medicine, London, UK/Ifakara Health Research & Development Centre, Tanzania","Pedro L Alonso, MD PhD",Principal Investigator,"Hospital Clinic, Barcelona, Spain",NA,NA,NA,NA,NA,"Marcel Tanner, PhD",Principal Investigator,"Swiss Tropical Institute, Basle, Switzerland",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3602,NCT00153491,Adherence to Lumefantrine-Artemether,Assessment of Adherence to a 6-Dose Regimen of Coartem for Treatment of Uncomplicated Malaria in Children Under 5 Years in Tanzania,Completed,August 2002,NA,NA,NA,Centers for Disease Control and Prevention,"Louise Causer, MBBS, MScPH",Study Director,Centers for Disease Control and Prevention,Phase 4,Observational,NA,NA,"Malaria, Uncomplicated",NA,All,N/A,59 Months,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",August 2006,"Salim Abdulla, MD, PhD",Study Director,Ifakara Health Research and Development Centre,300,NA,NA,Ifakara Health Research and Development Centre,Other,NA,NA,Mkuranga District Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Peter B Bloland, DVM, MPVM",Principal Investigator,Centers for Disease Control and Prevention,"Stephen P Kachur, MD, MPH",Study Director,Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AOR 06066,NCT00451269,Evaluation of Rapid Diagnosis Tests in Imported Malaria,Multicentric Evaluation of Rapid Diagnosis Tests for the Diagnosis of Imported Malaria.,Completed,April 2007,January 2010,Actual,Actual,Assistance Publique - Hôpitaux de Paris,"Sophie MATHERON, MD",Principal Investigator,Assistance Publique - Hôpitaux de Paris,N/A,Observational,1297,Actual,Malaria,NA,All,N/A,N/A,No,Assistance Publique - Hôpitaux de Paris,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Hopital BICHAT CLAUDE BERNARD,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  No refusal by patient

          -  Sample for malaria diagnosis

        Exclusion criteria:

          -  Patient who do not want to participated to the study
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
K0154-2,NCT00455494,"Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial","Food-Effect Bioavailability Study of AQ-13, a Candidate Antimalarial",Unknown status,March 2007,NA,NA,NA,Tulane University Health Sciences Center,"Donald J Krogstad, MD",Principal Investigator,Tulane University Health Sciences Center,Phase 1,Interventional,NA,NA,Malaria,NA,All,21 Years,45 Years,Accepts Healthy Volunteers,Tulane University Health Sciences Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,14,Area under the time-concentration curve,Maximal blood concentration,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,Tulane-LSU General Clinical Research Center,NA,NA,Adverse events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC027.2,NCT00375128,Sporozoite Challenge of Polyprotein Vaccinees,"Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Polyprotein Malaria Vaccines 'FP9−PP, MVA−PP' and Control Non−Vaccinated Volunteers",Completed,September 2006,April 2007,Actual,Actual,European Malaria Vaccine Initiative,"Adrian VS Hill, MA, BM BCh, DPhil, DM",Principal Investigator,University of Oxford,Phase 1/Phase 2,Interventional,NA,NA,"Malaria, Falciparum; Malaria",Efficacy (time in hours to parasitaemia),All,18 Years,50 Years,Accepts Healthy Volunteers,European Malaria Vaccine Initiative,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,26,NA,NA,University of Oxford,Other,Wellcome Trust,Other,NA,NA,NA,NA,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A00096/990954,NCT00378625,"Efficacy, Effect on Gametocytes and Tolerability of the Addition of Artesunate to Amodiaquine in Colombia","Randomised, Double Blind Clinical Trial of the Efficacy, Effect on Gametocytes and Tolerability of Amodiaquine Vs Amodiaquine Plus Artesunate in the Treatment of Uncomplicated P. Falciparum Malaria in Quibdo, Colombia",Completed,April 2000,NA,NA,NA,Centro Internacional de Entrenamiento e Investigaciones Médicas,"Lyda Osorio, MD PhD",Principal Investigator,Centro Internacional de Entrenamiento e Investigaciones Médicas,Phase 3,Interventional,NA,NA,"Malaria,Falciparum; Malaria; Antimalarials",NA,All,1 Year,65 Years,No,Centro Internacional de Entrenamiento e Investigaciones Médicas,Other,"ClinicalTrials.gov processed this data on July 26, 2017",March 2006,NA,NA,NA,360,treatment failures,adverse events,World Health Organization,Other,Instituto Colombiano para el Desarrollo de la Ciencia y la Tecnología (COLCIENCIAS),Other,Hospital Ismael Roldan and Centro de Salud San Vicente,NA,NA,gametocyte carriage,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
GMZ2_3_08,NCT00703066,Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years,"A Phase I, Randomized, Controlled, Double-Blind, Single Centre Trial to Evaluate the Safety and Immunogenicity of 30 and 100 µg of GMZ2 in Gabonese Children Aged 1-5 Years",Unknown status,June 2008,August 2009,Anticipated,Anticipated,African Malaria Network Trust,"Peter Kremsner, MD, PhD",Study Director,"Medical research Unit, Albert Schweitzer Hospital",Phase 1,Interventional,30,Anticipated,Malaria,NA,All,1 Year,5 Years,Accepts Healthy Volunteers,African Malaria Network Trust,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Immediate reactogenicity.,Local and systemic reactogenicity,NA,NA,NA,NA,"Medical Research Unit, Albert Schweitzer Hospital",within 30 minutes after each injection,14 days following each immunization,unsolicited Adverse events,NA,NA,Occurrence of serious adverse events,Biological safety,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,up to 1 month after the 3rd vaccination,NA,1 year,NA,NA,NA,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PSP01,NCT00712374,Evaluation of the Public Health Impact of Seasonal Intermittent Preventive Treatment (IPT) in Children in Senegal,Evaluation of the Public Health Impact and Cost Effectiveness of Seasonal Intermittent Preventive Treatment in Children in Senegal,Unknown status,September 2008,July 2012,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Oumar Gaye, PhD",Study Director,Universite CHeikh Anta Diop,Phase 4,Interventional,100000,Anticipated,Malaria,NA,All,3 Months,119 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Badara Cisse, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,All-causes mortality,NA,Senegal: Ministere de la Sante,Other,Institut de Recherche pour le Developpement,Other,NA,2008-2010,NA,NA,"Cheikh Anta Diop University, Senegal",Other,NA,NA,NA,NA,NA,NA,NA,NA,"Cheikh Sokhna, PhD",Principal Investigator,"IRD, Dakar","Oumar Faye, MD",Principal Investigator,Ministere de la Sante et de la Prevention,NA,NA,NA,NA,NA,"Paul Milligan, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PED-MTV-2004,NCT00465777,Improved Management and in-Hospital Mortality,Reduced in-Hospital Mortality After Improved Management of Patients Hospitalised With Malaria. A Randomised Trial,Completed,December 2004,February 2006,Actual,Actual,Bandim Health Project,"Peter Aaby, DMSc",Study Chair,Bandim Health Project,N/A,Interventional,NA,NA,Mortality; Malaria,In-hospital case-fatality,All,3 Months,5 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,950,NA,NA,Statens Serum Institut,Other,World Health Organization,Other,Bandim Health Project,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2005/57/01,NCT00484900,Multi-Centre Trial Comparing Three Artemisinin-Based Combination Treatments on P. Falciparum Malaria,"Open Randomized Multi-Centre Trial, Comparing Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 3 Days, Artesunate-Sulfamethoxypyrazine-Pyrimethamine FDC Over 48 Hours and Artemether-Lumefantrine FDC Over 3 Days on P. Falciparum Malaria",Completed,May 2006,May 2007,Actual,Actual,Dafra Pharma,"Issaka Sagara, Dr",Principal Investigator,"University of Bamako, Mali",Phase 3,Interventional,1390,Actual,Plasmodium Falciparum Malaria,NA,All,6 Months,N/A,No,Dafra Pharma,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Wilfred F Mbacham, Dr",Principal Investigator,"University Yaoundé, Cameroon",NA,PCR corrected Adequate Clinical and Parasitological Response,Early treatment failure,NA,NA,NA,NA,NA,on day 28 (follow-up period),between day 0 and day 3,Late clinical failure,NA,NA,Late parasitological failure,NA,NA,NA,NA,NA,NA,NA,"Ishag A Adam, Dr",Principal Investigator,"University of Khartoum, Sudan","Stephen Rulisa, Dr",Principal Investigator,"Kigali Central University Hospital, Rwanda",NA,NA,NA,NA,NA,NA,NA,NA,NA,between day 4 and day 28,NA,between day 7 and day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0119,NCT00384267,Congenital and Neonatal Malaria in Mali,Congenital and Neonatal Malaria in Mali,Completed,October 2006,April 2009,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,44,Actual,Malaria,NA,All,N/A,N/A,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,# of neonates with malaria infection,NA,NA,NA,NA,NA,Hopital Gabriel Toure,Immediately upon entry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria: Neonates: 1) Preterm born before 37 weeks of pregnancy admitted for
        inpatient care at HGT or Neonates aged between 0 - 28 days admitted for inpatient care at
        HGT 2) Admission weight more than 2000 grams 3) Parental informed consent obtained and
        signed for infant participation Criteria for Mothers: - Consenting mother of an enrolled
        infant Exclusion Criteria: Neonates: 1) Outpatient infant 2) Infant weighing less than
        2000g 3) Infants presenting the following symptoms of critical condition: bradycardy, gasp,
        severely altered general condition 4) Presence of severe anemia 5) Infants who are judged
        by the study physicians to be unfit for enrollment for any reason 6) Informed consent
        denied Criteria for Mothers: 1) Mothers with severe malaria (2) 2) Mothers with an acute
        severe disease 3) Mothers who are judged by the study physician to be unfit for enrollment
        for any reason 4) Informed consent denied
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2004/HD11/1353U,NCT00399074,Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prevention in Children With Sickle Cell Anemia,Presumptive Treatment With Sulfadoxine- Pyrimethamine Versus Weekly Chloroquine for Malaria Prophylaxis in Children With Sickle Cell Anemia,Completed,October 2006,February 2007,Actual,Actual,Makerere University,"Victoria Nakibuuka, MBChB",Principal Investigator,"Department of Paediatrics and Child Health , Makerere University",Phase 3,Interventional,220,Anticipated,Sickle Cell Anemia; Malaria,NA,All,6 Months,12 Years,No,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Grace Ndeezi, M.Med",Principal Investigator,"Department of Paediatrics and Child Health, Makerere University",NA,Malaria episodes,NA,NA,NA,NA,NA,Mulago Hospital,4 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Deborah Nakiboneka, M.Med",Principal Investigator,"Department of Paediatrics and Child Health, Makerere University","Christopher Ndugwa, PhD",Principal Investigator,"Department of paediatrics and Child Health, Makerere University",NA,NA,NA,NA,NA,"James Tumwine, PhD",Principal Investigator,"Department of Paediatrics and Child Health, Makerere University",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TIMIKA_FC,NCT00157833,"A Randomized Trial of Coartemether and Artekin for the Treatment of Uncomplicated Malaria in Papua, Indonesia.","A Randomized Trial to Determine the Efficacy and Safety of Coartemether and Artekin for the Treatment of Acute Falciparum and Vivax Malaria in Timika, Papua",Completed,July 2004,NA,NA,NA,Menzies School of Health Research,Ric N Price,Principal Investigator,Menzies School of Health Research,N/A,Interventional,NA,NA,Falciparum Malaria; Vivax Malaria,Overall Cure Rate at Day 42,All,12 Months,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",August 2005,Emiliana Tjitra,Principal Investigator,National Institute of Health Research and Development,750,NA,NA,"National Institute of Health Research and Development (NIHRD), Indonesia",Other,"National Health and Medical Research Council, Australia",Other,SP9 and SP12 Malaria-Public Health Clinics,NA,NA,NA,Wellcome Trust,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04/2003/IBU,NCT00167713,Treatment of Fever Due to Malaria With Ibuprofen,"Randomised, Double-Blind, Placebo Controlled Study of the Antipyretic Effect of Ibuprofen in Children With Uncomplicated Malaria",Completed,April 2003,NA,NA,NA,Albert Schweitzer Hospital,"Michel A. Missinou, PhD",Principal Investigator,Albert Schweitzer Hospital,Phase 4,Interventional,NA,NA,Fever,NA,All,2 Years,7 Years,No,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",January 2004,NA,NA,NA,50,Fever clearance time,Fever time,NA,NA,NA,NA,"Medical research Unit, Lambaréné",NA,NA,Area under the fever curve,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A60487,NCT00720811,Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs,Assessment of Use of Rapid Diagnostic Testing in the Context of Home Management With ACTs,Completed,October 2009,January 2012,Actual,Actual,Mbarara University of Science and Technology,"Francis Bajunirwe, MBChB PhD",Study Director,Mbarara University of Science and Technology,N/A,Interventional,6456,Actual,Malaria; Pneumonia,NA,All,4 Months,59 Months,No,Mbarara University of Science and Technology,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"George Pariyo, MB ChB, PhD",Study Director,Makerere University,NA,Recovery rate from fever at Day 3,NA,Makerere University,Other,"Ministry of Health, Uganda",Other,NA,Day 3,NA,NA,"Navrongo Health Research Centre, Ghana",Other,NA,NA,NA,"National Malaria Research and Training Centre, Burkina Faso",Other,NA,NA,NA,"James Tibenderana, MB ChB, PhD",Principal Investigator,Malaria Consortium,"Alfred Tiono, PhD",Principal Investigator,"National Malaria Research and Training Center, Burkina Faso",NA,NA,NA,NA,NA,"Thomas Anyorigiya, MSc",Principal Investigator,"Navrongo Health Research Centre, Ghana",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1396,NCT00722150,Artemisinin Resistance in Cambodia II,Artemisinin Resistance in Cambodia II,Completed,July 2008,August 2009,Actual,Actual,"Armed Forces Research Institute of Medical Sciences, Thailand","Delia Bethell, BM BCh",Principal Investigator,Armed Forces Research Institute of Medical Sciences (AFRIMS),N/A,Interventional,143,Actual,Falciparum Malaria,NA,All,18 Years,65 Years,No,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Socheat Duong, M.D.",Principal Investigator,"National Center for Parasitology, Entomology and Malaria Control",NA,Primary clinical outcome is cure (Adequate Clinical and Parasitological Response - ACPR as defined by WHO criteria) on Day 28 and 42,Safety and tolerability of oral artesunate,World Health Organization,Other,Bill and Melinda Gates Foundation,Other,Tasanh Health Center,Day 28 and 42,Up to 42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Se Youry, M.D., M.P.H.M.",Principal Investigator,Armed Forces Research Institute of Medical Sciences (AFRIMS),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04/2003/Q/SP,NCT00167739,Treatment of Malaria With Quinine Plus Sulfadoxine-Pyrimethamine,Short Course of Quinine Plus a Single Dose of Sulphadoxine-Pyrimethamine for Plasmodium Falciparum Malaria,Completed,April 2003,NA,NA,NA,Albert Schweitzer Hospital,"Michel A. Missinou, PhD",Principal Investigator,Albert Schweitzer Hospital,Phase 4,Interventional,NA,NA,Malaria,Proportion of cured patients by day 28,All,2 Years,7 Years,No,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",February 2004,NA,NA,NA,50,NA,NA,NA,NA,NA,NA,"Medical Research Unit, Lambaréné",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04 025,NCT00190281,"Contrast-Enhanced US of Spleen, Liver and Kidney","Contrast-Enhanced US of Spleen, Liver and Kidney in Patients With Acute Infection (Malaria and Other Infectious Diseases: a Functional Study",Unknown status,August 2005,NA,NA,NA,Assistance Publique - Hôpitaux de Paris,"Jean-Michel Correas, MD PhD",Principal Investigator,Necker University Hospital,Phase 3,Observational,NA,NA,Malaria; Pyelonephritis; Bacterial Infections,NA,All,18 Years,N/A,No,Assistance Publique - Hôpitaux de Paris,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Pierre Buffet, MD PhD",Study Director,Centre Médical – Institut Pasteur,53,NA,NA,NA,NA,NA,NA,"Department of Adult Radiology, Necker University Hospital",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Olivier Lortholary, MD PhD",Study Director,Necker University Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IronMal,NCT00497471,RCT Iron Supplementation and Malaria Chemoprophylaxis for Prevention of Severe Anemia and Malaria in Tanzanian Infants,The Prevention of Anaemia and Malaria in Infants in an Area of Intense and Perennial Malaria Transmission,Terminated,February 1995,July 1999,Actual,Actual,Hospital Clinic of Barcelona,"Clara Menendez, MD, PhD",Principal Investigator,"Centre for International Health, Hospital Clinic / Universitat Barcelona",N/A,Interventional,832,Actual,Malaria; Anemia,NA,All,N/A,1 Day,Accepts Healthy Volunteers,Hospital Clinic of Barcelona,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Clinical Malaria,Severe Anemia (PCV < 25%),Agencia Española de Cooperación Internacional,Other,World Health Organization,Other,Ifakara Centre,During first year of life,During first year of life,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC- PEPFAR CoAg#U62P024421,NCT00527800,Interactions Between HIV and Malaria in African Children,Interactions Between HIV and Malaria in African Children,Completed,August 2007,March 2013,Actual,Actual,"University of California, San Francisco","Grant Dorsey, MD, PhD",Principal Investigator,"University of California, San Francisco",Phase 3,Interventional,351,Actual,Malaria; HIV Infections,NA,All,6 Weeks,9 Months,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of clinical episodes of malaria,Risk of treatment failure at Day 28 defined as any early treatment failure or late clinical/parasitological failure adjusted and unadjusted by genotyping to distinguish recrudescence (treatment failure due to drug resistance) and new infections,Centers for Disease Control and Prevention,U.S. Fed,Makerere University,Other,Tororo District Hospital,over entire course of follow-up,28 days following each malaria treatment,NA,The AIDS Support Organization,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SEACAT 2.4.1,NCT00790881,Artemether/Lumefantrine and Nevirapine Interaction Study in HIV-infected Adults,Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Nevirapine in HIV-infected Adults,Completed,October 2008,December 2009,Actual,Actual,University of Cape Town,"Karen Barnes, MD",Principal Investigator,University of Cape Town,Phase 4,Interventional,36,Anticipated,Malaria; HIV,NA,All,18 Years,N/A,No,University of Cape Town,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Tamara Kredo, MD",Study Director,University of Cape Town,NA,Lumefantrine plasma concentration,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,"Groote Schuur Hospital, Research ward",day 7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SSC1464,NCT00791531,Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers,Phase 1 Assessment of Safety and Pharmacokinetics of a Low Dose of Methotrexate in Healthy Adult Male Kenyan Volunteers,Completed,March 2009,August 2009,Actual,Actual,KEMRI-Wellcome Trust Collaborative Research Program,"Alexis Nzila, Msc",Principal Investigator,KEMRI-Wellcome Trust Collaborative Research Program,Phase 1,Interventional,25,Actual,Malaria,NA,Male,18 Years,55 Years,Accepts Healthy Volunteers,KEMRI-Wellcome Trust Collaborative Research Program,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Clinical safety parameters:oral ulcers, GI tract disturbance,hematology, renal hepatic & other unsolicited safety AEs",NA,University of Oxford,Other,NA,NA,"Kenya Medical Research Institute, Center for Clinical Research",42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
01KA0202-K7.3,NCT00206739,Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infants,"Intermittent Treatment With Sulfadoxine-pyrimethamine for Malaria Control in Infant: a Randomized, Double-blind, and Placebo-controlled Clinical Trial",Completed,January 2003,September 2005,Actual,Actual,Bernhard Nocht Institute for Tropical Medicine,"Ohene Adjei, Prof. Dr.",Principal Investigator,Kumasi Centre for Collaborative Research in Tropical Medicine,Phase 4,Interventional,1070,Actual,Malaria; Anemia,NA,All,2 Months,4 Months,Accepts Healthy Volunteers,Bernhard Nocht Institute for Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Jürgen May, PD Dr.",Study Director,"Bernhard Nocht Institute for Tropical Medicine Hamburg, Infection Epidemiology",NA,• Efficacy of an extended intermittent treatment with sulfadoxine-pyrimethamine for the control of clinical malaria and anemia (proportion and rates of children with one or more episodes of malaria or anemia in the age of 3 to 21 months of life),• Determination of the rate of clinical malaria and anemia after suspending an extended intermittent treatment for analysis of possible rebound effects,German Federal Ministry of Education and Research,Other,Deutscher Akademischer Austausch Dienst,Other,Kumasi Centre for Collaborative Research in Tropical Medicine,NA,NA,• Evaluation of safety and adverse effects of the administration of single doses of sulfadoxine-pyrimethamine in infants and children,The Volkswagen Foundation,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SFB 544 D4(1),NCT00225368,Effects of Insecticide Treated Bednets on Child Morbidity and Mortality,Long Term Effects of Insecticide Treated Bednets on the Morbidity and Mortality Caused by Malaria and on the Overall Mortality in Young Children of a Rural Population in Burkina Faso,Completed,NA,NA,NA,NA,Heidelberg University,"Olaf Mueller, MD, PhD",Principal Investigator,Heidelberg University,N/A,Interventional,NA,NA,Malaria; All-cause Mortality,NA,All,N/A,15 Days,NA,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Nouna Health Research Centre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
GN02- PK/PD of artesunate,NCT00538382,Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo,Phase I Study of Pharmacokinetics and Pharmacodynamics of Artesunate in Pregnant Women in the Democratic Republic of Congo,Completed,May 2007,December 2008,Actual,Actual,NICHD Global Network for Women's and Children's Health,"Carl Bose, M.D.",Principal Investigator,University of North Carolina,Phase 1,Interventional,51,Actual,Malaria,NA,Female,18 Years,40 Years,Accepts Healthy Volunteers,NICHD Global Network for Women's and Children's Health,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Antoinette Tshefu, M.D., M.P.H.",Principal Investigator,Kinshasa School of Public Health,NA,"Levels of the unbound active major metabolite, dihydroartemisinin (DHA), will be similar for parasitemic pregnant women during their 2nd and 3rd trimesters vs. the same women 3 months postpartum",NA,Global Network for Women's and Children's Health Research,Other,Bill and Melinda Gates Foundation,Other,Kingasani Maternity Clinic,48 hours,NA,NA,John E. Fogarty International Center (FIC),NIH,NA,NA,NA,National Center for Complementary and Integrative Health (NCCIH),NIH,National Institute of Dental and Craniofacial Research (NIDCR),NIH,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,National Cancer Institute (NCI),NIH,RTI International,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,University of North Carolina,Other,Kinshasa School of Public Health,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ARAMF_L_02873,NCT00540410,Cohort Study in Senegal Comparing Artesunate + Amiodaquine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks,A Randomized Study to Compare Artesunate + Amiodaquine Versus Artemether + Lumefantrine in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During 2 Years in a Cohort in Senegal,Completed,September 2007,February 2009,Actual,Actual,Sanofi,Valerie Lemeyre,Study Director,Sanofi,Phase 4,Interventional,366,Actual,Malaria,NA,All,N/A,N/A,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR corrected and uncorrected clinical and parasitological cure rate,NA,NA,NA,NA,NA,Sanofi-Aventis Administrative Office,at D28 and for the first attack,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-3913,NCT00229775,Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines,Efficacy of Chloroquine + Sulfadoxine Pyrimethamine Versus Artemether + Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Philippines,Completed,July 2003,July 2008,Actual,Actual,Centers for Disease Control and Prevention,"Dorin Bustos, MD, PhD",Study Director,"RITM, DOH, Philippines",N/A,Interventional,560,Actual,Malaria,Clinical cure,All,N/A,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,"Department of Health, Philippines",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCOA566A2401,NCT00233337,"Efficacy, Safety and Tolerability of Co-artemether in Non-immune Travelers","Open-label, Multi-center, Non-comparative Efficacy, Safety, and Tolerability Study of Co-artemether in the Treatment of Acute Uncomplicated Malaria in Non-immune Patients",Completed,May 2001,August 2005,Actual,Actual,Novartis Pharmaceuticals,Novartis Pharmaceuticals,Study Chair,Novartis Pharmaceuticals,Phase 4,Interventional,NA,NA,Acute Uncomplicated P. Falciparum Malaria,Proportion of patients free of parasites in the blood after 28 days.,All,18 Years,N/A,NA,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KHRC1,NCT00832754,Restricting the Use of Artesunate Plus Amodiaquine Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial,Effects of Restricting the Use of AS-AQ Combination Therapy to Malaria Cases Confirmed by a Dipstick Test: A Cluster Randomised Control Trial,Completed,March 2009,December 2012,Actual,Actual,"Kintampo Health Research Centre, Ghana",Frank E Baiden,Principal Investigator,Kintampo Health Research Center,Phase 4,Interventional,3063,Actual,Malaria,NA,All,N/A,48 Months,No,"Kintampo Health Research Centre, Ghana",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,Jayne Webster,Principal Investigator,London School of Hygiene and Tropical Medicine,NA,"Incidence of malaria (fever + any level of parasite density) in < 48 month-old children (Stage 2, Component A)",NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,Kintampo Health Research Center,Three years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Christopher Whitty,Principal Investigator,London School of Hygiene and Tropical Medicine,Seth Owusu-Agyei,Principal Investigator,Kintampo Health Research Center,NA,NA,NA,NA,NA,Daniel Chandramohan,Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Jane Bruce,Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H40380-31179-01,NCT00845533,Pharmacokinetics of Dihydroartemisinin-Piperaquine in the Treatment of Uncomplicated Malaria in Children in Burkina Faso,NA,Completed,August 2007,January 2009,Actual,Actual,"University of California, San Francisco","Sunil Parikh, M.D., M.P.H.",Principal Investigator,"University of California, San Francisco",Phase 4,Interventional,NA,NA,Uncomplicated Malaria,NA,All,6 Months,10 Years,NA,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Philip J Rosenthal, M.D.",Principal Investigator,"University of California, San Francsico",NA,NA,NA,"Holley-Cotec Pharmaceuticals Co., LTD.",Other,Mahidol University,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Jean-Bosco Ouedraogo, M.D., PhD",Principal Investigator,Institut de Receherche en Sciences de la Sante Bobo-Dioulasso,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC030,NCT00408668,Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen,Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Virosomal Vaccine PEV3A and FP9-MVA ME-TRAP. A Phase I / IIa Controlled Challenge Trial,Completed,August 2005,NA,NA,NA,University of Oxford,"Adrian VS Hill, MA, BM BCh, DPhil, DM",Principal Investigator,University of Oxford,Phase 1/Phase 2,Interventional,NA,NA,"Malaria; Malaria, Falciparum",Vaccine efficacy: The primary outcome is protection against malaria infection in a P. falciparum sporozoite challenge model.,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",February 2006,NA,NA,NA,30,NA,NA,Medical Research Council,Other,Pevion Biotech Ltd,Industry,Centre for Clinical Vaccinology and Tropical Medicine,NA,NA,NA,Swiss Tropical & Public Health Institute,Other,NA,NA,NA,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-005-06,NCT00422084,Pyronaridine Artesunate (3:1) Versus Coartem® in P Falciparum Malaria Patients,"A Phase III Comparative, (Double-Blind, Double-Dummy), Randomised, Multi-Centre, Clinical Study to Assess the Safety and Efficacy of Fixed Dose Formulation of Oral Pyronaridine Artesunate Tablet (180:60 mg) Versus Coartem® (Artemether Lumefantrine) in Children and Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria",Completed,January 2007,May 2008,Actual,Actual,Medicines for Malaria Venture,"Claude Oeuvray, PhD",Study Director,Medicines for Malaria Venture,Phase 3,Interventional,1269,Anticipated,Malaria,NA,All,3 Years,60 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR-corrected adequate clinical and parasitological response (ACPR) rate on Day 28,Treatment success or failures will be classified according to WHO Guidelines 2005,Shin Poong Pharmaceuticals,Industry,NA,NA,NA,Day 28,Day 28,"Incidence and severity of adverse events and of clinically significant laboratory results, ECG, vital signs or physical examination abnormalities",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Day 28 and Day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
arginineSM1,NCT00616304,Safety and Preliminary Efficacy of L-arginine in Severe Falciparum Malaria,"Safety and Preliminary Efficacy, Pharmacokinetics, Pharmacodynamics of L-arginine in Severe Falciparum Malaria",Suspended,February 2008,NA,NA,NA,Menzies School of Health Research,"Nicholas M Anstey, MBBS",Principal Investigator,Menzies School of Health Research,Phase 2,Interventional,8,Actual,Severe Falciparum Malaria,NA,All,18 Years,60 Years,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Emiliana Tjitra, MD",Principal Investigator,National Institute of Health Research and Development,NA,Improvement in endothelial function and lactate clearance.,NA,Wellcome Trust,Other,"National Health and Medical Research Council, Australia",Other,Mitra Masyarakat Hospital,Endothelial function: end of 8 hour infusion. Lactate clearance: area under the curve until lactate returns to the upper limit of normal,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MIENKO2,NCT00628459,Effect of Iron Versus Multiple Micronutrient Supplementation on Anemia in Preschool Children of Malaria-Endemic Area,NA,Completed,August 2006,February 2008,Actual,Actual,Centre National de la Recherche Scientifique et Technologique,"Philippe Donnen, PhD",Study Director,"Université Libre de Bruxelles, Belgium",N/A,Interventional,297,Actual,Anemia; Undernutrition,NA,All,6 Months,23 Months,No,Centre National de la Recherche Scientifique et Technologique,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Anemia,NA,"Universite Libre de Bruxelles, Belgium",Other,"Fonds pour la recherche scientifique médicale (FRSM), Belgium",Other,District Sanitaire de Kongoussi,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LLIH,NCT00853281,A Cluster Randomized Trial to Evaluate Long Lasting Insecticidal Hammocks to Prevent Forest Malaria in Vietnam,A Cluster Randomized Trial to Evaluate the Effectiveness of Long Lasting Insecticidal Hammocks for Controlling Forest Malaria in Central Vietnam,Completed,March 2004,June 2007,Actual,Actual,"Institute of Tropical Medicine, Belgium","Annette Erhart, MD",Study Director,Institute of Tropical Medicine,N/A,Interventional,18646,Actual,Malaria,NA,All,N/A,N/A,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Reduction of malaria prevalence and incidence,NA,"National Institute of Malariology, Parasitology and Entomology, Vietnam",Other,London School of Hygiene and Tropical Medicine,Other,Ninh Thuan Provincial Malaria Station,24 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
5482,NCT00878397,Impact of School-based Delivery of Long Lasting Insecticide Nets,Evaluating the Impact of Delivering Long Lasting Insecticide Nets Through Schools on Household Access and the Health of School Children in North Eastern Kenya,Completed,May 2009,November 2010,Actual,Actual,London School of Hygiene and Tropical Medicine,"Simon Brooker, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine / KEMRI-Wellcome Trust Programme,N/A,Interventional,5113,Actual,Malaria,NA,All,5 Years,18 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Anaemia,NA,Wellcome Trust,Other,NA,NA,KEMRI-Wellcome Trust Programme,2 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-009-07,NCT00682630,Bioequivalence of Pyronaridine Artesunate to-be-Marketed Tablet to the Clinical Trial Reference Tablet,Bioequivalence Trial of Pyronaridine:Artesunate to-be-Marketed Tablet to the Clinical Trial Reference Tablet,Completed,September 2007,September 2008,Actual,Actual,Medicines for Malaria Venture,NA,NA,NA,Phase 1,Interventional,42,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To determine the bioequivalence of the combination of pyronaridine and artesunate (180:60mg) to-be-marketed tablet to the clinical trial reference tablet administered as a single total dose of 720:240 mg in healthy adults.,NA,Shin Poong Pharmaceuticals,Industry,NA,NA,"Cross Research S.A., Phase I Unit",85 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2516114389,NCT00697164,Randomized Trial of Erythropoietin During Cerebral Malaria,Randomized Trial of Erythropoietin to Prevent Death From Cerebral Impairment During Severe Malaria,Unknown status,October 2007,March 2009,Anticipated,Anticipated,Claude Bernard University,"Stephane PICOT, MD PhD",Principal Investigator,"Claude Bernard University, Malaria Research Unit",Phase 2/Phase 3,Interventional,120,Anticipated,Cerebral Malaria,NA,All,6 Months,15 Years,No,Claude Bernard University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Survival,NA,NA,NA,NA,NA,Gabriel Toure Hospital,day 5 post-inclusion,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Survival,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EARS-Handeni,NCT00439595,A Trial of 2 'Point of Care' Diagnostic Methods to Improve Detection and Treatment of Anaemia in African Children,A Cluster Randomised Trial of Different Methods of Haemoglobin Measurement to Improve Recognition and Treatment of Childhood and Pregnancy-related Anaemia in a Malaria Endemic Area of North East Tanzania.,Completed,February 2007,May 2008,Actual,Actual,London School of Hygiene and Tropical Medicine,"Hugh Reyburn, MD",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,450,Anticipated,Anaemia,NA,All,N/A,5 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The proportion of clinic attenders under the age of 5 years who are diagnosed with anaemia (adjusted for anaemia in the community),NA,"National Institute for Medical Research, Tanzania",Other,NA,NA,Handeni District Health Facilities,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FSP 97008500,NCT00442403,Safety and Efficacy of Chloroquine Associated With Dehydroepiandrosterone Sulphate to Treat Uncomplicated Falciparum Malaria,Etude de l’Activite (Efficacite et Tolerance) de l’Association de la Chloroquine Avec la Dehydroepiandrosterone-Sulfate (Dheas) Dans le Traitement de l’Acces Palustre Simple A Plasmodium Falciparum,Suspended,April 2002,NA,NA,NA,Université Victor Segalen Bordeaux 2,"Michel LE BRAS, Professor",Study Director,"Université Victor Segalen Bordeaux 2, Centre René Labusquière (Santé et Développement)",Phase 3,Interventional,NA,NA,Malaria,NA,All,15 Years,N/A,No,Université Victor Segalen Bordeaux 2,Other,"ClinicalTrials.gov processed this data on July 26, 2017",September 2002,"Pascal MILLET, Doctor",Principal Investigator,"Université Victor Segalen Bordeaux 2, Pôle des Maladies Tropicale, CHU de Bordeaux",200,Development of any adverse event;,Rate of clinical and/or parasitological failure during the 14 days of follow up.,NA,NA,NA,NA,"Institute of Medical Research and study of Medicinal Plants, Medical Research Center",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B0731004,NCT00894660,A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects,A Bioequivalence Study Comparing Amodiaquine Tablet (Pfizer) To Amodiaquine Tablets (Arsuamoon-Guilin China) In Healthy Subjects,Completed,June 2009,July 2009,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 1,Interventional,38,Actual,Falciparum Malaria,NA,All,21 Years,55 Years,Accepts Healthy Volunteers,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,AUC and Cmax of amodiaquine,NA,NA,NA,NA,NA,Pfizer Investigational Site,1 month,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IMEA5982FAU90,NCT00913146,Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria?,"Can Treatment of Malaria be Restricted to Parasitologically Confirmed Malaria? A School-Based Prospective, Exposed/Non Exposed to Fever, Study in Benin.",Completed,February 2008,March 2009,Actual,Actual,Institut de Recherche pour le Developpement,"Jean-François Faucher, MD, PhD",Principal Investigator,IRD,N/A,Observational,484,Actual,Malaria,NA,All,5 Years,15 Years,No,Institut de Recherche pour le Developpement,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,malaria incidence in the 2 groups (index and control),NA,Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba,Other,NA,NA,Centre de Santé de Commune,after 14 days of follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria in the index group:

          -  School children aged 5 to 15 years.

          -  Tympanic temperature at 37.8°C or above, or if a history of fever in the preceding 24
             hours was reported.

          -  A negative malaria (Paracheck® Plasmodium falciparum) RDT.

          -  Informed consent.

          -  Asymptomatic children were screened for the Control Group on gender, age, week of
             inclusion. The first child with a negative RDT and for whom an informed consent was
             obtained, was included in the CG.

        Exclusion Criteria:

          -  Adequate malaria treatment within a month prior screening.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EM-036,NCT00716599,Training in Fever Case Management With Rapid Diagnostic Tests (RDTs) for Malaria in Uganda,Effectiveness and Safety of Training in Fever Case Management Incorporating Rapid Diagnostic Tests (RDTs) for Malaria at Peripheral Health Centers in Uganda,Completed,January 2008,July 2008,Actual,Actual,"University of California, San Francisco","Heidi Hopkins, MD",Principal Investigator,"University of California, San Francisco",N/A,Interventional,14000,Actual,Malaria; Fever,NA,All,N/A,N/A,No,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To compare changes in the proportion of patients prescribed any antimalarial therapy between health centers with and without an RDT training intervention.,NA,Exxon Mobil,Industry,Makerere University,Other,Uganda Malaria Surveillance Project,point of care,NA,NA,Uganda Malaria Surveillance Project,Other,NA,NA,NA,National Institutes of Health (NIH),NIH,Doris Duke Charitable Foundation,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0053,NCT00744133,Malaria Challenge With NF54 Strain,An Interventional Plasmodium Falciparum Malaria Challenge Model Utilizing the NF54 Strain of Parasite Transmitted by Aseptic A. Stephensi Mosquitoes to Healthy Malaria-Naïve Adult Volunteers,Completed,March 2009,November 2011,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,37,Actual,Plasmodium Falciparum Infection,NA,All,18 Years,40 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of a positive malaria smear after the malaria challenge.,Occurrence of serious adverse events.,NA,NA,NA,NA,University of Maryland School of Medicine - Center for Vaccine Development - Baltimore,"During a 56-day surveillance period (day of challenge and days 5-28, 35, 42, 49, and 56 after challenge).","After malaria challenge during a 56-day surveillance period (day of challenge and days 5-28, 35, 42, 49, and 56 after challenge) and 10 month follow-up period",Occurrence and severity of solicited symptoms.,NA,NA,Occurrence and severity of unsolicited adverse events.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7 days after the malaria challenge and for the duration of follow-up after a malaria event (treatment days x 3 and smear-negative x 2 plus weekly follow-up x 4).,NA,After malaria challenge during a 56-day surveillance period (day of challenge and 55 subsequent days. Volunteers will be questioned at Visits 2-29).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AITM0107,NCT00451139,Ototoxicity of Artemether / Lumefantrine (Coartem) and Other Antimalarials,NA,Completed,NA,NA,NA,NA,Jimma University,"Nebreed Fesseaha, MD, Dean",Study Chair,Facuty of Medical Sciences Jimma University,Phase 4,Interventional,NA,NA,Malaria,NA,All,5 Years,N/A,NA,Jimma University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,Ludwig-Maximilians - University of Munich,Other,NA,NA,Jimma University Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ARTEN_L_00848,NCT00452907,ACT MALI: Treatment of Malaria Based on Combination Therapies,Assessment of the Public Health Benefit of Artemisinine Based Combination Therapies for Uncomplicated Malaria Treatment in Mali,Completed,July 2005,June 2007,Actual,Actual,Sanofi,Valérie Lameyre,Study Director,Sanofi,Phase 4,Interventional,780,Actual,Malaria,NA,All,6 Months,N/A,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Clinical and parasitological cure rate,Clinical and biological tolerability,NA,NA,NA,NA,Sanofi-Aventis Administrative Office,at day 28,During the study period,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-237/2007,NCT00917202,Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8 Project of the SFB 544,Efficacy of Methylene Blue for Malaria Treatment in Adults of Burkina Faso: Proof of Principle Study in Semi-Immune Adults of Burkina Faso in the Frame of the A8,Completed,NA,NA,NA,NA,Heidelberg University,NA,NA,NA,Phase 2,Interventional,NA,NA,Malaria,Adequate clinical and parasitolgical response (ACPR) until D 28,Male,17 Years,55 Years,NA,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Nouna Health District,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACT Consortium,NCT00935688,Examination of ACT Implementation in a Vivax / Falciparum Co-endemic Area,An Examination of ACT Strategy in South-central Asia on Falciparum Malaria in a Context Where Vivax is the Major Species,Completed,May 2009,October 2010,Actual,Actual,London School of Hygiene and Tropical Medicine,"Toby Leslie, PhD",Principal Investigator,LSHTM,Phase 4,Interventional,4200,Actual,Malaria; Fever,NA,All,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of patients correctly treated,NA,Health Protection and Research Organisation,Other,HealthNet TPO,Other,NA,2009-2010,NA,NA,Medical Emergency Relief International (Merlin),Other,NA,NA,NA,NA,NA,NA,NA,"Composite measure defined as patients with Pf malaria receiving ACT Drugs; Pv malaria receiving CQ; patients with no malaria receiving no antimalarial drugs.
NOTE: Previously reported here as ""Proportion of patients incorrectly treated"" being 1 minus the Proportion correctly treated. No change in how the outcome was measured.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1490,NCT00761020,Merozoite Surface Protein 1 Antibody Response in Asymptomatic Human Malaria Infection,Analysis of Anti-Plasmodium Falciparum Merozoite Surface Protein 1 Antigen Specific Antibodies in a Human Malaria Challenge Using Mefloquine Prophylaxis to Confirm Assay Sensitivity and Establish Key Antibody Kinetic Parameters,Completed,September 2008,December 2009,Actual,Actual,Walter Reed Army Institute of Research (WRAIR),"James Moon, MD",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 1,Interventional,31,Anticipated,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The number of subjects in each group who develop at least a four-fold increase in Anti-Plasmodium falciparum MSP-1 IgG antibody titer at any time point from baseline divided by the number infected,NA,NA,NA,NA,NA,Walter Reed Army Institute of Research,one year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IP.07.31080.002,NCT00811421,Evaluation of Alternative Antimalarial Drugs for Malaria in Pregnancy,Evaluation of the Safety and Efficacy of Mefloquine as Intermittent Preventive Treatment of Malaria in Pregnancy,Completed,September 2009,December 2013,Actual,Actual,Hospital Clinic of Barcelona,"Clara Menendez, MD, PhD",Principal Investigator,Barcelona Centre for International Health Research,N/A,Interventional,5820,Actual,Pregnancy; Malaria; HIV Infections,NA,Female,N/A,N/A,Accepts Healthy Volunteers,Hospital Clinic of Barcelona,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Trial 1 (IPTp MQ vs IPTp SP): Low birth weight.,Trial 2 (CTX+IPTp MQ vs. CTX+IPTp placebo): Peripheral parasitaemia.,Barcelona Centre for International Health Research,Other,"Institute of Tropical Medicine, University of Tuebingen",Other,NA,"day 0, birth","day 0, delivery",NA,Institut de Recherche pour le Developpement,Other,NA,NA,NA,Université d'Abomey-Calavi,Other,Albert Schweitzer Hospital,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Kenya Medical Research Institute,Other,Ifakara Health Institute,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Centro de Investigacao em Saude de Manhica,Other,"Vienna School of Clinical Research (VSCR), Austria.",Other,Centers for Disease Control and Prevention,U.S. Fed,Malaria in Pregnancy Consortium,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NP05-M4,NCT00238017,Efficacy and Safety of Amodiaquine and Amodiaquine-Artesunate,"A Randomized, Double Blind Trial on the Efficacy and Safety of Amodiaquine-Artesunate and Amodiaquine Alone in the Treatment of Children With Uncomplicated Falciparum Malaria",Unknown status,October 2005,NA,NA,NA,"Charite University, Berlin, Germany","Rowland N Otchwemah, PhD",Principal Investigator,University for Development Studies,Phase 4,Interventional,NA,NA,Malaria,NA,All,6 Months,59 Months,No,"Charite University, Berlin, Germany",Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2005,"Frank P Mockenhaupt, MD",Principal Investigator,"Malaria Unit, Institute of Tropical Medicine, Charite University, Berlin, Germany",400,Parasitological and clinical cure rates by days 14 and 28,Parasite and fever clearance times,"University for Development Studies, Tamale, Ghana",Other,"Kintampo Health Research Centre, Ghana",Other,University for Development Studies,NA,NA,"Carrier rates of sexual parasite stages at days 7, 14 and 28",NA,NA,Incidence rates of adverse events,NA,NA,NA,NA,NA,NA,NA,"Seth Owusu-Agyei, PhD",Principal Investigator,"Kintampo Health Research Centre, Ghana",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ghana5.2.malaria,NCT00258024,Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment,Control of Pregnancy Associated Malaria With Intermittent Preventive Treatment Through Community Involvement in Rural Ghana,Completed,November 2005,October 2007,Actual,Actual,DBL -Institute for Health Research and Development,"Victoria Bam, reg. nurse",Principal Investigator,"Dept. Community Health, School of Health Sciences, Kumasi University",N/A,Interventional,420,Anticipated,Anaemia; Malaria,NA,Female,14 Years,45 Years,No,DBL -Institute for Health Research and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Birth weight,anaemia,NA,NA,NA,NA,Afiya Sekyere district,NA,NA,parasitaemia,NA,NA,fever episodes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Malariallada,NCT00460369,Treatment of Uncomplicated Malaria in Benin,Sulfadoxine-Pyrimethamine Versus Artemether-Lumefantrine Versus Amodiaquine-Artesunate Coformulation in Uncomplicated Plasmodium Falciparum Malaria : an Open Randomized Study,Completed,April 2007,November 2007,Actual,Actual,Institut de Recherche pour le Developpement,"Jean-François Faucher, MD PhD",Principal Investigator,Institut de recherche pour le développement UR010,N/A,Interventional,240,Actual,Uncomplicated Malaria,NA,All,6 Months,119 Months,No,Institut de Recherche pour le Developpement,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Philippe Deloron, MD PhD",Study Director,Institut de Recherche pour le Développement UR010,NA,efficacy,NA,NA,NA,NA,NA,Centre de santé,day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDA/RWD/2006,NCT00461578,Tolerability and Efficacy of CD+A Compared to AQ+SP for the Treatment of P.Falciparum Malaria in Rwandan Children,Open Study on the Tolerability and Efficacy of the Combination Chlorproguanil-Dapsone+Artesunate Compared to Amodiaquine+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria in Rwandan Children,Completed,April 2005,October 2006,Actual,Actual,London School of Hygiene and Tropical Medicine,"Umberto d'Alessandro, MD",Study Director,ITM,N/A,Interventional,NA,NA,Malaria,Incidence of microscopically and genotypically confirmed recrudescent infections in the different treatment groups by day 28,All,12 Months,59 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,800,NA,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,Programme Nationale Integre de Lutte contre le Paludisme,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1000013476,NCT01001871,Treatment of Iron Deficiency Anemia in Malaria Endemic Ghana,Seasonal Impact of Iron Fortification on Malaria Incidence in Ghanaian Children,Unknown status,November 2009,May 2011,Anticipated,Anticipated,The Hospital for Sick Children,"Stanley H Zlotkin, PhD",Principal Investigator,"The Hospital for Sick Children, Toronto, Canada",N/A,Interventional,3880,Anticipated,Anemia,NA,All,6 Months,24 Months,Accepts Healthy Volunteers,The Hospital for Sick Children,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,incidence of clinical malaria (if fever recorded a blood sample will be taken to determine parasite species and count),NA,NA,NA,NA,NA,Kintampo Health Research Centre,5 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITGBVG01,NCT01024426,Impact of Enhanced Health Facility Care in Uganda,"Evaluating the Impact of Enhanced Health Facility-based Care for Malaria and Febrile Illnesses in Children in Tororo, Uganda",Completed,December 2010,July 2013,Actual,Actual,Uganda Malaria Surveillance Project,"Sarah G Staedke, MD, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 4,Interventional,25000,Actual,Malaria,NA,All,N/A,15 Years,Accepts Healthy Volunteers,Uganda Malaria Surveillance Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Prevalence of anemia in children under five in the cross-sectional surveys,NA,London School of Hygiene and Tropical Medicine,Other,"University of California, San Francisco",Other,Infectious Diseases Research Collaboration,annually,NA,NA,"Infectious Diseases Research Collaboration, Uganda",Other,NA,NA,NA,NA,NA,NA,NA,"Proportion of hemoglobin measurements < 11.0 g/dL as measured in cross sectional surveys. Anemia will be classified according to severity: mild (Hb 8.0 - 10.9), moderate (Hb 5.0 - 7.9), severe (Hb < 5.0).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B0731001,NCT00859807,A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects,A Bioequivalence Study Comparing Camoquin® Suspension (Pfizer) To Flavoquine® Tablets (Sanofi Aventis) In Healthy Subjects,Completed,May 2009,June 2009,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 4,Interventional,38,Actual,Falciparum Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Cmax, AUCtlast and AUCinf for amodiaquine.",NA,NA,NA,NA,NA,Pfizer Investigational Site,end of study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TRANSACT09,NCT00868465,Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy (TRANSACT),NA,Completed,April 2009,May 2010,Actual,Actual,Radboud University,NA,NA,NA,N/A,Interventional,600,Anticipated,Uncomplicated Malaria,NA,All,6 Months,10 Years,No,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To determine the clinical efficacy of artemether-lumefantrine (AL) and dihydroartemisinin-piperaquine (DP) in the treatment of uncomplicated falciparum malaria in children living in north-western Tanzania and in western Kenya.,NA,"Kilimanjaro Christian Medical Centre, Tanzania",Other,European Union,Other,NA,during 42 day follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MSP3_TN_0303,NCT00469651,Phase Ib Trial of MSP3 LSP in Children in Tanzania,"A Double Blind, Randomized, Controlled Phase Ib Field Trial in 12 to 24 Month Old Children in Tanzania to Evaluate the Safety and Immunogenicity of Candidate Malaria Vaccine MSP 3 Versus Hepatitis B Vaccine",Unknown status,October 2007,August 2008,Anticipated,Anticipated,African Malaria Network Trust,"Martha M Lemnge, MS, PhD",Study Director,National Institute For Medical Research in Tanzania,Phase 1,Interventional,45,Anticipated,Malaria,NA,All,12 Months,24 Months,Accepts Healthy Volunteers,African Malaria Network Trust,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"John P Lusingu, MD, PhD",Principal Investigator,National Institute for Medical Research in Tanzania,NA,Safety of MSP3 by assessing the reactogenicity,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,Kwashemshi village,"Solicited and unsolicited adverse events (immediate reactogenicity within 60 minutes of each vaccination; 7-day assessment, and 28 days",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Mba/06/MIP,NCT00495508,Quinine vs. Artemether/Lumefantrine in Uncomplicated Malaria During Pregnancy,"A Randomised, Open-label Non-inferiority Trial of Artemether-lumefantrine Versus Quinine for the Treatment of Uncomplicated Falciparum Malaria During Pregnancy, Mbarara, Uganda (2006-2007)",Completed,October 2006,June 2009,Actual,Actual,Epicentre,"Patrice Piola, MD, MPH",Principal Investigator,Epicentre,Phase 4,Interventional,300,Anticipated,Malaria,NA,Female,N/A,N/A,No,Epicentre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Philippe J Guerin, MD, MPH, PhD",Study Chair,Epicentre,NA,PCR-corrected adequate clinical and parasitological response (ACPR) on Day 42 or at delivery.,NA,"Medecins Sans Frontieres, Netherlands",Other,University of Cape Town,Other,Epicentre,3 years,NA,NA,Sholklo Malaria Research Unit,Other,NA,NA,NA,NA,NA,NA,NA,NA,"Elizabeth Ashley, MB BS",Study Chair,Epicentre,"Rose McGready, MD, PhD",Study Chair,Shoklo Malaria Research Unit (SMRU),NA,NA,NA,NA,NA,"François Nosten, MD, PhD",Study Chair,SMRU,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WR 1584,NCT01024686,Phase 1/2a Trial of Pf GAP p52-/p36- Sporozoite Malaria Vaccine,"Phase 1/2a Trial to Assess the Safety, Immunogenicity and Efficacy of Genetically-attenuated Plasmodium Falciparum Parasites p52-/p36- (GAP) Vaccine, Administered by Bite of Infected Anopheles Mosquito to Malaria-naïve Adults Living in the United States.",Terminated,March 2010,June 2011,Actual,Actual,Seattle Biomedical Research Institute,"Michele Spring, M.D.",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 1/Phase 2,Interventional,6,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Seattle Biomedical Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of solicited adverse events (AE),Occurrence of unsolicited AEs,NA,NA,NA,NA,Walter Reed Army Institute of Research,From administration of study vaccine through 7 days (± 1 days) post dosing,From administration of study vaccine through 28 days (± 4 days) post dosing,Occurrence of laboratory adverse events (AE),NA,NA,Detection of breakthrough peripheral parasitemia by thick blood film,Occurrence of serious adverse events (SAE),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,From administration of study vaccine through 7 days (± 1 days) post dosing,NA,From 7 days after administration of vaccine through 28 days (+ 4 days) post-dosing,NA,NA,NA,From administration of study vaccine through the duration of the trial,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCZVED-5628,NCT01052584,Ethiopia Malaria Therapeutic Efficacy Study,Ethiopia In-vivo Efficacy Study 2009: Evaluating the Efficacy of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Infection and Either Artemether-lumefantrine or Chloroquine for P. Vivax Infection,Completed,October 2009,January 2010,Actual,Actual,Centers for Disease Control and Prevention,"Jimee Hwang, MD",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,354,Actual,Malaria,NA,All,6 Months,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Determine Early Treatment Failures, Late Clinical Failures, Late Parasitological Failures, or Adequate Clinical and Parasitological Response during 28 days of follow-up for P. falciparum. Measure the treatment failure of AL and CQ for P. vivax",NA,United States Agency for International Development (USAID),U.S. Fed,Columbia University,Other,NA,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC033,NCT00890019,A Study of AdCh63 ME−TRAP Alone and With MVA ME−TRAP,"A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidate AdCh63 ME-TRAP, Alone and With MVA ME-TRAP, Using a Prime-boost Delivery Schedule",Completed,July 2007,September 2011,Actual,Actual,University of Oxford,"Adrian VS Hill, Professor",Principal Investigator,University of Oxford,Phase 1,Interventional,54,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"To assess the safety of a new malaria vaccine, AdCh63 ME-TRAP, when administered individually and sequentially with MVA ME-TRAP in a prime-boost regime to healthy volunteers",NA,NA,NA,NA,NA,NA,24 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
YNG0901,NCT00902811,Effectiveness of Artemisinin Combination Regimens in Falciparum Malaria,Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria,Unknown status,December 2008,December 2009,Anticipated,Anticipated,"Medecins Sans Frontieres, Netherlands","Frank Smithuis, MD",Principal Investigator,"Medecins Sans Frontieres, Netherlands",Phase 4,Interventional,600,Anticipated,Uncomplicated Falciparum Malaria,NA,All,6 Years,N/A,No,"Medecins Sans Frontieres, Netherlands",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cure rate,NA,Mahidol University,Other,University of Oxford,Other,NA,63 days,NA,NA,"Disease Control, Department of Health, Myanmar",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
APRIORI1/01,NCT00509015,Mass-Drug Administration to Reduce Malaria Transmission,"Mass-Drug Administration With a Gametocytocidal Drug Combination, a Model for a Transmission Blocking Vaccine",Completed,February 2008,August 2008,Actual,Actual,Radboud University,"Seif Shekalaghe, MPH MD",Principal Investigator,Kilimanjaro Christian Medical Centre,N/A,Interventional,6000,Anticipated,"Malaria, Falciparum",NA,All,1 Year,N/A,No,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Robert Sauerwein, Prof MD PhD",Study Chair,Radboud University,NA,malaria morbidity by active and passive case detection.,"asexual parasite prevalence and density by microscopy, rapid diagnostic test and molecular QT-NASBA","Kilimanjaro Christian Medical Centre, Tanzania",Other,London School of Hygiene and Tropical Medicine,Other,Kilimanjaro Christian Medical Centre,during the entire study period,monthly during the entire study period,gametocyte prevalence and density by QT-NASBA and microscopy,NA,NA,transmission intensity quantified by entomologic inoculation rate,human infectious reservoir,NA,NA,NA,NA,NA,NA,"Frank Mosha, PhD",Study Director,Kilimanjaro Christian Medical Centre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,monthly during the entire study period,NA,continuously during the study period,NA,NA,NA,prior to the intervention and several months after the intervention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LSA3_01_06,NCT00509158,Safety and Efficacy Study of Plasmodium Falciparum LSA-3 Malaria Vaccine,"Phase I and IIa Trial for Assessment of Safety, Immunogenicity and Efficacy Against Sporozoite Challenge of the Candidate Malaria Vaccine PfLSA-3-rec",Completed,October 2007,October 2008,Actual,Actual,Radboud University,"Robert Sauerwein, Prof MD",Principal Investigator,Radboud University,Phase 1/Phase 2,Interventional,36,Anticipated,Healthy,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Phase I: proportion and severity of adverse events in both intervention groups.,Phase IIa: proportion of volunteers reaching day 21 post-infection without or with a delayed onset of parasitemiae compared to control group (parasetimiae defined as ≥2 parasites per 200 fields in a thick blood film).,Institut Pasteur,Industry,NA,NA,Radboud University Nijmegen Medical Centre,1 year from first immunization,6 weeks from sporozoite challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITMP0409,NCT01053325,Establishing Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy,A Clinical Trial to Establish The Effectiveness of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria in Pregnancy,Completed,September 2010,February 2013,Actual,Actual,"Institute of Tropical Medicine, Belgium","Christine Manyando, MD",Principal Investigator,"Tropical Diseases Research Centre, Zambia",Phase 3,Interventional,848,Actual,Malaria in Pregnancy; HIV Infections,NA,Female,N/A,N/A,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Umberto D'Alessandro, MD, PhD",Study Director,"Insitute of Tropical Medicine, Antwerp, Belgium",NA,To establish that in HIV negative pregnant women co-trimoxazole prophylaxis is non inferior to SP IPT with respect to birth weight at delivery (or within 24 hours). Non inferiority is defined as a difference in mean birth weights of no more than 100g.,NA,"Tropical Diseases Research Centre, Zambia",Other,NA,NA,Kabuta Health Centre,Up to the end of pregancy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP09C08,NCT01055002,A Pilot Study to Test Activity of Antimalarial Drugs Against an Induced Malaria Infection in Healthy Volunteers,A Pilot Phase II Study of the Efficacy of Antimalarial Drugs Against Plasmodium Falciparum by Experimental Challenge With a Low Dose of Blood Stage Parasites in Healthy Male Volunteers,Completed,January 2010,August 2010,Actual,Actual,Medicines for Malaria Venture,"James McCarthy, MD FRACP",Principal Investigator,Queensland Institute of Medical Research,Phase 1/Phase 2,Interventional,16,Anticipated,Healthy; Non-smokers,NA,Male,18 Years,45 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite clearance rates by PCR,NA,Queensland Institute of Medical Research,Other,Q-Pharm Pty Limited,Industry,"Q-Pharm Clinics, Royal Brisbane and Women's Hospital",1-7 days after drug treatment,NA,NA,Trident Clinical Research Pty Ltd,Industry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NHLAO1,NCT00938379,Clinical Evaluation of Insect Repellent and Insecticide Treated Nets in Lao PDR,"Clinical Evaluation of Insect Repellent and Insecticide Treated Nets Against Malaria, JE & Dengue in Rural Communities in Lao PDR",Unknown status,July 2009,June 2011,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Nigel Hill, PhD",Principal Investigator,LSHTM,Phase 3,Interventional,5000,Anticipated,Malaria; Dengue; Japanese Encephalitis,NA,All,5 Years,70 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,reduction in malaria incidence,NA,Population Services International,Other,NA,NA,"Rural villages in Attepu and Sekong Provinces, Laos PDR",monthly over 7 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
01-2009,NCT00964691,A Randomized Controlled Trial for Intermittent Preventive Treatment in Pregnancy With Fansidar in Solomon Islands,Intermittent Preventive Treatment With Sulfadoxine-Pyrimethamine Versus Weekly Chloroquine Prophylaxis During Pregnancy in Solomon Islands: a Randomized Controlled Trial,Terminated,August 2009,August 2010,Anticipated,Anticipated,"Ministry of Health and Medical Services, Solomon Islands","Anna Maria van Eijk, MD PhD",Study Chair,NA,Phase 4,Interventional,2504,Anticipated,Malaria; Malaria in Pregnancy,NA,Female,15 Years,49 Years,Accepts Healthy Volunteers,"Ministry of Health and Medical Services, Solomon Islands",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Placental malaria among primigravidae at time of delivery,NA,World Health Organization,Other,NA,NA,Honiara City Council,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AAKE99,NCT00266058,Drug Interaction Study Between Antimalarial and Anti-HIV Medications,"Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combination, Artemether/Lumefantrine",Completed,December 2005,November 2010,Actual,Actual,"University of California, San Francisco","Francesca Aweeka, Pharm.D.",Principal Investigator,"University of California, San Francisco",Phase 1,Interventional,33,Actual,HIV Infections; Malaria,NA,All,21 Years,60 Years,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Pharmacokinetic assessment of potential drug-drug interactions of antimalarials and antiretroviral agents.,NA,NA,NA,NA,NA,San Francisco General Hospital,Intensive serial PK sampling of antimalarials conducted on study day 4 (without antiretrovirals) and study day 31 (in the context of antiretrovirals,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pharmacokinetic assessment of potential drug-drug interactions of antimalarials and antiretroviral agents.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S1954-21/22-2,NCT00270530,Intermittent Preventive Treatment of Malaria in HIV-Seropositive Pregnant Women in Zambia,Intermittent Preventive Treatment of Malaria With Sulfadoxine-Pyrimethamine in HIV-Seropositive and HIV-Seronegative Pregnant Women in Zambia,Completed,November 2002,NA,NA,NA,Center for International Health and Development,"Davidson H Hamer, MD",Principal Investigator,"Center for International Health and Development, Boston University",Phase 4,Interventional,NA,NA,Placental Malaria Infection; HIV Infections; Stillbirth; Prematurity; Neonatal Deaths,NA,Female,18 Years,50 Years,No,Center for International Health and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",October 2004,NA,NA,NA,454,• Prevalence of placental malaria infection,• Prevalence of maternal peripheral parasitemia,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,Tropical Diseases Research Centre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QALE07,NCT00540202,Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children,Effectiveness of Oral Quinine and Artemether-Lumefantrine in the Treatment of Uncomplicated Malaria in Ugandan Children,Unknown status,September 2007,April 2008,Anticipated,Anticipated,Makerere University,"Ambrose O Talisuna, PhD",Principal Investigator,"Ministry of Health, Uganda",Phase 4,Interventional,302,Anticipated,Uncomplicated Malaria,NA,All,6 Months,5 Years,No,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,1. PCR adjusted parasitological cure rate on day 28. 2. Clinical cure rates on day 28.,NA,"Ministry of Health, Uganda",Other,Uganda Malaria Surveillance Project,Other,Mulago National Referral Hospital,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MB-2007b,NCT00545935,Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso,Safety and Efficacy of Methylene Blue Combined With Amodiaquine or Artesunate for Malaria Treatment in Children of Burkina Faso: RCT in the Frame of the A8 Project of SFB 544,Completed,July 2007,NA,NA,NA,Heidelberg University,"Olaf Mueller, Prof.",Principal Investigator,Heidelberg University,Phase 2,Interventional,NA,NA,Malaria,NA,All,6 Months,59 Months,NA,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",October 2007,NA,NA,NA,186,Incidence of observed and self-reported non-serious adverse events over the 28 days observation period,NA,NA,NA,NA,NA,Centre de Recherche en Sante de Nouna,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PAACT PK,NCT01082718,Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection,Pharmacokinetics of Mefloquine-Artesunate in Pregnant Women With Uncomplicated Plasmodium Falciparum Infection,Withdrawn,March 2010,October 2010,Anticipated,Anticipated,Centers for Disease Control and Prevention,"Meghna Desai, MPH PhD",Principal Investigator,Centers for Disease Control and Prevention,Phase 2/Phase 3,Interventional,0,Actual,Malaria; Pregnancy,NA,Female,18 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Area under the curve of Mefloquine - artesunate in pregnant versus matched non-pregnant women with P. falciparum malaria,NA,NA,NA,NA,NA,NA,Multiple measures up to 63 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A0661158,NCT01103063,Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa,"A Phase 3, Open Label, Randomized, Comparative Study To Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa",Terminated,October 2010,November 2013,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 3,Interventional,2891,Actual,Intermittent Preventive Treatment In Pregnancy (IPTp),NA,Female,16 Years,35 Years,Accepts Healthy Volunteers,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage Participants With Sub-optimal Pregnancy Outcome in Intent-to-Treat (IIT) Population,NA,London School of Hygiene and Tropical Medicine,Other,Medicines for Malaria Venture,Other,NA,Approximately 40 weeks of gestational age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Adverse pregnancy outcomes were defined as live-borne neonate (singleton) with low birth weight (LBW) (<2,500 g), premature births (<37 weeks as confirmed by the Ballard score), abortion (≤28 weeks), still birth (>28 weeks), lost to follow-up prior to termination of pregnancy or delivery, or missing birth weight of the neonates.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ART-P 001-2007,NCT00978172,Safety and Efficacy Study of Artesunate and Mefloquin in Children With Uncomplicated Malaria,A Phase IV Study on the Safety and Effectiveness of a Fixed-dose Combination of Artesunate and Mefloquine (Artequin[TM] Paediatric) Administered for 3 Days in Children With Uncomplicated Plasmodium Falciparum Malaria in Africa,Completed,December 2007,March 2009,Actual,Actual,Mepha Ltd.,"Felix Tietche, Prof",Principal Investigator,Faculty of Medicine and Biomedical Sciences University of Yaounde (Cameroon),Phase 4,Interventional,220,Actual,Malaria,NA,All,N/A,N/A,No,Mepha Ltd.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To assess the neuropsychiatric and neurological safety of a fixed-dose combination of artesunate and mefloquine (Artequin Paediatric) in the treatment of children (>=10kg to <=20kg body weight) with uncomplicated P. falciparum malaria,NA,Centre Mère et Enfant de la Fondation Chantal Biya,Other,NA,NA,"Centre Mère et Enfant, Fondation Chantal Biya","Baseline (day1), day 7, day 28, day 63",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
08-0009,NCT01026246,EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults,"Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly in Semi-immune Adults",Completed,June 2010,March 2012,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,60,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,40 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of subjects experiencing severe (Grade 3) solicited injection site reactions.,Number of subjects experiencing severe solicited systemic reactions (Grade 3).,NA,NA,NA,NA,Noguchi Memorial Institute for Medical Research - Immunology,Within 14 days following vaccination.,Within 14 days following vaccination.,Number of subjects experiencing severe (Grade 3) clinical laboratory values.,NA,NA,Number of subjects spontaneously reporting adverse events considered associated with the vaccination that are severe (Grade 3).,Serious adverse events considered associated with the vaccination.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Within 14 days following vaccination.,NA,Duration of study.,NA,NA,NA,Duration of study.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ZRDT 2005,NCT00549003,Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar,Efficacy and Cost Effectiveness of Malaria Diagnosis Procedures and the Rational Use of ACT in Zanzibar,Completed,February 2005,August 2005,Actual,Actual,Karolinska University Hospital,"Anders Björkman, MD,PhD",Study Director,Karolinska UH,Phase 4,Interventional,9346,Actual,Malaria,NA,All,N/A,N/A,No,Karolinska University Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Mwinyi I Msellem, HLSO",Principal Investigator,Karolinska UH,NA,NA,NA,NA,NA,NA,NA,"Muyuni, Uzini, Kinyasini and Mzambarauni Primary Health Care Units",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2006/HD20/4758U,NCT00565071,Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness,Parasite-based Diagnosis for Malaria in Uganda: Feasibility and Cost-Effectiveness,Unknown status,October 2006,December 2012,Anticipated,Anticipated,Makerere University,"Fred Nuwaha, MD, PhD",Study Chair,"Department of Disease Control and Environmental Health, Makerere Universtiy School of Public Health",N/A,Interventional,102087,Anticipated,Fever; Malaria,NA,All,3 Months,N/A,No,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,diagnostic test validity; unit cost per malaria case diagnosed and treated with Artemether-Lumefantrine; total savings associated with treatment of confirmed malaria cases; compliance with directives for use of rapid test or microscopy,NA,"Department for International Development, United Kingdom",Other,NA,NA,Bushenyi and Iganga districts - Government Health Cetres level III,18 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ST3073-ST3074-DM-09-006,NCT01103830,Safety Study on the Effect of Eurartesim™ on QT/QTc Interval Compared to Riamet in Healthy Volunteers,"Phase I, Randomized, Parallel Group Study to Evaluate the Effect of Multiple Oral Doses of Eurartesim on the QT/QTc Interval Compared to Riamet, Placebo and Moxifloxacin in Healthy Male and Female Volunteers",Completed,February 2010,December 2010,Actual,Actual,sigma-tau i.f.r. S.p.A.,"Lionel Hovsepian, MD",Principal Investigator,SGS Aster S.A.S.,Phase 1,Interventional,287,Actual,"Malaria, Falciparum",NA,All,18 Years,50 Years,Accepts Healthy Volunteers,sigma-tau i.f.r. S.p.A.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,QTcF interval (Fridericia's correction QT interval),NA,Medicines for Malaria Venture,Other,NA,NA,SGS aster s.a.s,"before study drugs administration, during the 24 hrs post first and third dose and during follow-up",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Group 1,4 and 5 (Day -1: pre-dose, each hour till 13h post-dose. Day 1: pre-dose, 1, 2, 3, 4, 5, and 6 h post-dose. Day 3: pre-dose, each hour till 13h post-dose and then 24h).
Group 2 (Day -2: pre-dose, each hour till 13h post-dose and then 24h. Day 3: pre-dose, each hour till 13h post-dose and then 24h).
Group 3 and 6 (Day -1: pre-dose, each hour till 13h post-dose. Day 1: pre-dose, 1, 2, 3, 4, 6, 8, 12 and 24h post-dose. Day 3: pre-dose, pre-dose, each hour till 13h post-dose. Day 4: pre-dose, 1, 2, 3, 4, 6, 8, 12 and 24h post-dose).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CPR 07,NCT01122134,Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate for Severe Malaria Treatment,Pharmacokinetics and Pharmacodynamics of Intravenous Artesunate in Treatment of Severe Malaria in Ugandan Patients,Unknown status,May 2010,September 2010,Anticipated,Anticipated,Makerere University,"Pauline Byakika-Kibwika, MSc, MMed",Principal Investigator,Makerere University,N/A,Observational,20,Anticipated,Severe Malaria,NA,All,18 Years,65 Years,No,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Pharmacokinetic parameters; total area under the plasma concentration vs. time curve (AUC) of artesunate and DHA, maximum plasma concentration (Cmax), time to attain maximum concentration, elimination half life",NA,NA,NA,NA,NA,Mulago National Referral hospital,6 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pharmacokinetic parameters for artesunate and dihydroartemisinin,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          1. Patients aged 18 years and above

          2. With severe malaria according to the following ciriteria:

          3. A positive blood smear for malaria with P. falciparum mono-infection with parasitemia
             > 500 parasites/ul of blood

          4. Who according to the attending physician require parenteral treatment and admission
             for malaria

          5. Willing to participate in the study

          6. Who are or whose first degree parents/caretakers are able to provide written informed
             consent

        Exclusion Criteria:

          1. Patients with history of prior antimalarial use within the last 72 hours

          2. Pregnant women

          3. Patients with contraindications to taking the study drugs

          4. Patients taking known inhibitors or inducers of cytochrome P450 -
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
09/04,NCT01031524,Trial to Assess the Efficacy of Malaria Vaccine PfCS 102,Randomized Double-blind Controlled Phase I/IIa Trial to Assess the Efficacy of Malaria Vaccine PfCS 102 (282-383) to Protect Against Artificial Challenge With P. Falciparum,Completed,March 2004,November 2004,Actual,Actual,Swiss Tropical & Public Health Institute,"Blaise Genton, MD PhD",Principal Investigator,University Hospital,Phase 1/Phase 2,Interventional,16,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Swiss Tropical & Public Health Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Length of time between artificial challenge and development of blood stage parasitaemia detected by microscopy,NA,Centre Hospitalier Universitaire Vaudois,Other,Radboud University,Other,Department of Ambulatory Care and Community Medicine; University Hospital,1month,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
09.07,NCT01038063,Safety and Effectiveness of Artemisinin-based Combination Therapies (ACTs) With Repeated Treatments for Uncomplicated Falciparum Malaria Over a Three-year Period,Programmatic Implementation of ACTs in Malawi: Safety and Effectiveness of Combination Therapies With Repeated Treatments for Uncomplicated P. Falciparum Malaria Over a Three-year Period,Unknown status,October 2010,September 2013,Anticipated,Anticipated,Liverpool School of Tropical Medicine,"David Lalloo, MD",Principal Investigator,Liverpool School of Tropical Medicine,Phase 4,Interventional,1200,Anticipated,Malaria,NA,All,4 Months,48 Months,No,Liverpool School of Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Prevalence of ototoxicity at 18 months and 36 months of enrolment.,NA,Malawi-Liverpool-Wellcome Trust Clinical Research Programme,Other,"National Malaria Control Programme, Malawi",Other,"Malawi-Liverpool-Wellcome Trust Research Programme, College of Medicine",At 18 mo and 36 month of follow up,NA,NA,Research for Equity and Community Health Trust,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
07-0010,NCT00593398,Malarial Immunity in Pregnant Cameroonian Women,Malarial Immunity in Pregnant Cameroonian Women,Unknown status,September 2008,September 2013,Anticipated,Anticipated,University of Hawaii,"Diane W Taylor, PhD",Principal Investigator,University of Hawaii,N/A,Observational,1376,Anticipated,Plasmodium Falciparum Malaria,NA,Female,N/A,50 Years,Accepts Healthy Volunteers,University of Hawaii,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,NA,NA,University of Yaounde 1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

        Pregnant women who will be followed longitudinally during pregnancy:

          -  Greater than or equal to 15 years of age.

          -  Willingness to provide informed consent.

          -  Confirmed pregnancy.

          -  All gestational ages. Women less than 16 weeks of pregnancy will be enrolled, but they
             will not receive intermittent preventive therapy using sulfadoxine plus pyrimethamine
             (IPT-SP) until the 16th week of pregnancy or thereafter.

          -  Long-term residence in Yaounde, Ngali II or Ntouessong.

          -  Willingness of a women residing in Yaounde to release HIV testing results, obtained
             through a service provided by the MOH, to Dr. Leke, Cam-PI.

          -  Women residing in Ngalii II and Ntouessong will be encouraged to be HIV tested and
             asked to provide data on their HIV status to the project. However, HIV testing and
             providing the results will be optional.

        Pregnant women enrolled near term:

          -  Same as above.

          -  Women who have a health booklet with entries entered by a physician/midwife/pharmacist
             about antimalarial treatment they have received during pregnancy

        Inclusion criteria for infants living in Ngali II and Ntouessong:

          -  Resident of Ngali II or Ntouessong.

          -  Willingness of the mother/caregivers to give informed consent for their babies.

          -  Agree to bring the baby to the clinic whenever s/he becomes ill. Alternatively, inform
             the designated staff member or village health care worker that the baby is ill.

          -  Willingness to bring the baby for all recommended routine child-hood immunizations.

          -  Agree to provide a stool sample from the baby when s/he is 6 and 12 months of age.

          -  Twins will be included in the study.

        Exclusion Criteria:

        Pregnant Cameroonian women following longitudinally during pregnancy:

          -  Women who report a history of allergic reactions to sulfamides

          -  Women who report reactions to previously unknown antimalarial drugs

          -  Women with serious liver attacks (e.g., chronic hepatitis) or kidney failure or
             neurological conditions (e.g., seizures).

          -  Women with history of skin allergies

          -  Other conditions that in the opinion of the Director of Clinical Studies (DCS) or
             clinical staff (CS) would jeopardize the safety and rights of a participant in the
             trial or would render the participant unable to comply with the protocol.

        Pregnant women enrolled near term:

        Infants living in Ngali II and Ntouessong:

          -  Vague or incomplete information on maternal use of anti-malarials during pregnancy.

          -  Failure to inform the project staff that they are about to, or have delivered their
             babies, thereby preventing access to baseline information and specimens at birth that
             are critical for conduct of the study.

          -  Other conditions that in the opinion of the DCS, CS, or Cam-PI would jeopardize the
             safety and rights of a participant in the trial or would render the participant unable
             to comply with the protocol.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MUW # 83/2008,NCT00639873,Artemisinin Resistance in Bangladesh,Artemisinin Resistance in Bangladesh,Completed,June 2008,November 2009,Actual,Actual,Medical University of Vienna,"Harald Noedl, MD, PhD",Principal Investigator,Medical University of Vienna,N/A,Interventional,126,Actual,Malaria,NA,All,8 Years,65 Years,No,Medical University of Vienna,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cure,NA,"International Centre for Diarrhoeal Disease Research, Bangladesh",Other,World Health Organization,Other,Bandarban Sadar Hospital,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Cure is defined as adequate clinical and parasitological response (ACPR) as opposed to early treatment failure / late treatment failure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PHGBVG04,NCT01130155,IMPACT2: Monitoring Interventions to Improve Artemisinin-based Combination Therapy (ACT) Access and Targeting,IMPACT2: Monitoring Interventions to Improve ACT Access and Targeting,Unknown status,May 2010,December 2012,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Catherine Goodman, PhD",Principal Investigator,LSHTM,N/A,Observational,33900,Anticipated,Malaria; Anaemia,NA,All,3 Months,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Patrick Kachur, MD",Principal Investigator,Centers for Disease Control and Prevention,NA,Percent of population reporting fever in last two weeks that received ACT within 24hrs/48hrs,Percent of population reporting fever in last two weeks that got a finger/heel stick for a malaria diagnostic test within 24hrs/48hrs,Ifakara Health Institute,Other,Centers for Disease Control and Prevention,U.S. Fed,Ifakara Health Institute,NA,NA,Proportion of patients presenting to public health facilities with fever who receive a diagnostic test for malaria,Bill and Melinda Gates Foundation,Other,Proportion of patients presenting to public health facilities with fever who receive rapid diagnostic test (RDT) for malaria and are appropriately treated according to RDT results,NA,NA,NA,NA,NA,NA,NA,"Salim Abdulla, PhD",Principal Investigator,Ifakara Health Institute,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  Household survey - All consenting and assenting residents available in selected
             households

          -  Health facility survey - patients presenting to selected health facilities with fever
             or history of fever in the prior 24 hours; Age >= 3 months, or Weight ≥ 5 kg; First
             visit to this health facility for this illness episode

        Exclusion Criteria:

          -  Household survey - Children less than 3 months of age will be excluded from providing
             a blood sample

          -  Health facility survey - Signs of severe illness
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
70270,NCT01136850,Intermittent Preventive Treatment With Azithromycin-containing Regimens in Pregnant Women in Papua New Guinea,Intermittent Preventive Treatment With Azithromycin-containing Regimens for the Prevention of Malarial Infections and Anaemia and the Control of Sexually Transmitted Infections in Pregnant Women in Papua New Guinea,Completed,November 2009,January 2013,Actual,Actual,University of Melbourne,"Stephen J Rogerson, FRACP PhD",Principal Investigator,University of Melbourne,Phase 3,Interventional,2793,Actual,Malaria in Pregnancy; Sexually Transmitted Infections; Anaemia,NA,Female,16 Years,49 Years,Accepts Healthy Volunteers,University of Melbourne,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Proportion of women delivering low birth weight babies, <2500 g",NA,Papua New Guinea Institute of Medical Research,Other,The University of Western Australia,Other,Papua New Guinea Institute of Medical Research,At delivery,NA,NA,Walter and Eliza Hall Institute of Medical Research,Other,NA,NA,NA,University of Barcelona,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCZVED-5794,NCT01043796,Evaluation of Insecticide Treated Nets and Wall Liners for the Prevention of Malaria,"Malaria Transmission Consortium: The Added Effects of Insecticide Treated Materials, Artemisinin-containing Combination Treatments, and Larviciding on Malaria Transmission and Illness",Completed,May 2010,December 2014,Actual,Actual,Centers for Disease Control and Prevention,"John E Gimnig, Ph.D.",Principal Investigator,Centers for Disease Control and Prevention,Phase 3,Interventional,1730,Actual,Malaria,NA,All,6 Months,11 Years,Accepts Healthy Volunteers,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of new malaria infections,NA,Kenya Medical Research Institute,Other,Bill and Melinda Gates Foundation,Other,Kenya Medical Research Institute,Monthly,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Incidence of new malaria infections,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACTUGA2,NCT01048801,Role and Effectiveness of Rapid Diagnostic Tests in Home-based Management of Malaria,Role and Effectiveness of Rapid Diagnostic Tests in Home-based Management of Malaria: Comparative Trials in Two Areas of High and Low Transmission in Uganda,Completed,March 2010,July 2012,Actual,Actual,DBL -Institute for Health Research and Development,"Richard Ndyomugyenyi, MD",Principal Investigator,"Ministry of Health, Uganda",N/A,Interventional,2000,Actual,Fever; Malaria,NA,All,5 Months,59 Months,No,DBL -Institute for Health Research and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of patients given prompt effective treatment by CDDs: % of <5-year-old children diagnosed with malaria who receive appropriate ACT treatment within 24 hours of onset of malaria.,NA,"Ministry of Health, Uganda",Other,London School of Hygiene and Tropical Medicine,Other,Rukungiri District,36 months,NA,NA,Artemisinin-based Combination Therapy,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
03-EPID-153,NCT00287300,Efficacy and Safety of Azithromycin and Artesunate in Pregnant Women,A Pilot Randomized Controlled Trial of Azithromycin or Artesunate Added to Sulphadoxine Pyrimethamine as Therapy for Malaria in Pregnancy,Completed,September 2003,NA,NA,NA,University of North Carolina,"Steve R Meshnick, M.D., Ph.D.",Principal Investigator,"2. Department of Epidemiology, School of Public Health, University of North Carolina, Chapel Hill NC USA",N/A,Interventional,NA,NA,Malaria,NA,Female,15 Years,49 Years,No,University of North Carolina,Other,"ClinicalTrials.gov processed this data on July 26, 2017",August 2005,"Stephen J Rogerson, MB BS, Ph.D.",Principal Investigator,"3. Department of Medicine, University of Melbourne, Royal Melbourne Hospital, Parkville Victoria Australia",141,Parasitological failure rates,Parasite clearance time,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,Mpemba and Madziabango Health Centers,NA,NA,Fever clearance times,NA,NA,Incidence rate of adverse events,NA,NA,NA,NA,NA,NA,NA,"Marjorie Chaponda, MB BS, MPH",Principal Investigator,"1. UNC Malaria Project, Department of Community Health, College of Medicine, University of Malawi",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC867,NCT00289250,Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum,Effect of Antimalarial Treatment on Gametocyte Carriage in Asymptomatic P. Falciparum: A Randomized Controlled Trial,Completed,May 2001,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Margaret Pinder, PhD",Study Director,"Medical Research Council Unit, The Gambia",Phase 3,Interventional,NA,NA,Asymptomatic P.Falciparum Malaria,Presence of gametocytes 7 days after treatment,All,6 Months,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2001,"Paul J Milligan, PhD",Study Chair,London School of Hygiene and Tropical Medicine,360,NA,NA,"Medical Research Council Unit, The Gambia",Other,NA,NA,Medical Reseearch Council Laboratories The Gambia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sam K Dunyo, PhD",Principal Investigator,"Medical Research Council Unit, The Gambia",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC039,NCT01142765,"Study to Assess Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP","A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of New Malaria Vaccine Candidates AdCh63 AMA1, MVA AMA1, AdCh63 MSP1, MVA MSP1, AdCh63 ME-TRAP & MVA ME-TRAP",Completed,June 2010,March 2011,Actual,Actual,University of Oxford,"Adrian VS Hill, D.Phil, FRCP",Principal Investigator,University of Oxford,Phase 1/Phase 2,Interventional,52,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety and efficacy of vaccine,NA,NA,NA,NA,NA,NA,Up to 18 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To assess if volunteers who receive the novel vaccine candidates; AdCh63 MSP1, MVA MSP1, AdCh63 AMA1, MVA AMA1, AdCh63 ME-TRAP and MVA ME-TRAP in heterologous prime boost regimens are protected wholly or partially against malaria infection in a sporozoite challenge model. This will be determined by noting the number of subjects who develop malaria infection and the time in hours between exposure and parasitaemia as detected by thick-film blood smear compared with controls.
To assess the safety of the immunisation regimens alone and during co-administration.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MSF-nutcon02,NCT01154803,Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection,"Effectiveness of Nutritional Supplementation (RUTF and Multi Micronutrient) in Preventing Malnutrition in Children 6-59 Months With Infection (Malaria, Pneumonia, Diarrhoea), a Randomized Controlled Trial in Nigeria",Completed,February 2012,February 2013,Actual,Actual,"Medecins Sans Frontieres, Netherlands","Saskia Kam van der, Ir",Principal Investigator,Medecins Sans Frontieres Amsterdam,N/A,Interventional,2213,Actual,Malnutrition; Malaria; Lower Respiratory Tract Infection; Diarrhoea,NA,All,6 Months,59 Months,No,"Medecins Sans Frontieres, Netherlands",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"""negative nutritional outcome"" of a child",NA,NA,NA,NA,NA,Goronyo health clinic outpatient department,6 months follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The incidence of a negative nutritional outcome will be defined in two different ways according to the baseline nutritional status.
i) for children with no malnourishment at time of entry into study, ""negative nutritional outcome"" is defined as progression to moderate or severe malnourishment ii) for children with moderate malnourishment at time of entry into study, ""negative nutritional outcome"" is defined as loss of ³10% of baseline weight or progression to severe malnourishment, whichever is reached first.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MC-001,NCT01058226,Reproducibility of Malaria Challenge in Healthy Volunteers,Reproducibility of Malaria Challenge in Healthy Volunteers,Completed,February 2010,September 2010,Actual,Actual,Seattle Biomedical Research Institute,"Angela Talley, M.D.",Principal Investigator,Seattle Biomedical Research Institute,Phase 1,Interventional,6,Anticipated,Healthy,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Seattle Biomedical Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Development of malaria parasitemia and time to parasitemia demonstrated on peripheral blood smear,NA,The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,Seattle Biomedical Research Institue's Malaria Clinical Trial Center,Day 5 through Day 28 post challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Epicentre/Mba/2010/MalPrev,NCT01062386,"Malaria Survey in Mbarara District, Uganda 2010","The Epidemiology of Malaria Among Children Under Five in Mbarara District, Uganda - A Cross-sectional Population-based Survey 2010",Completed,January 2010,July 2010,Actual,Actual,Epicentre,Carolyn Nabasumba,Principal Investigator,Epicentre,N/A,Observational,2320,Actual,Malaria,NA,All,1 Month,59 Months,Accepts Healthy Volunteers,Epicentre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of malaria infections in children under 5 years of age,NA,"Medecins Sans Frontieres, Netherlands",Other,NA,NA,Greater Mbarara district,January-February 2010,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  Males and females

          -  Ages 1 month to 59 months

        Exclusion Criteria:
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CIR 212,NCT00320658,Safety of and Immune Response to a Malaria Vaccine (MSP1 42-C1) With or Without CPG 7909 Adjuvant,"Phase 1 Study of the Safety and Immunogenicity of MSP1 42-C1/Alhydrogel With and Without CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,March 2006,July 2007,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Anna Durbin, MD",Principal Investigator,Johns Hopkins Bloomberg School of Public Health,Phase 1,Interventional,60,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Frequency of vaccine-related adverse events, as classified by both intensity and severity through active and passive surveillance",Anti-MSP1 42 antibody concentration as measured by ELISA,Johns Hopkins Bloomberg School of Public Health,Other,NA,NA,"Center for Immunization Research, Johns Hopkins University, Bloomberg School of Public Health",Throughout study,At Day 70,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Fatol 1,NCT00322907,Cotrifazid Safety and Efficacy Against Malaria,A Randomised Safety and Efficacy Trial of Rifampicin/Cotrimoxazole/Isoniazid Versus Mefloquine or Quinine+SP Against Resistant Malaria in Papua New Guinea,Terminated,April 2000,NA,NA,NA,Policlinique Médicale Universitaire,"Blaise Genton, MD, PhD",Principal Investigator,Swiss Tropical & Public Health Institute,Phase 2,Interventional,NA,NA,Clinical Malaria,NA,All,6 Months,N/A,No,Policlinique Médicale Universitaire,Other,"ClinicalTrials.gov processed this data on July 26, 2017",January 2003,NA,NA,NA,330,Clinical treatment failure rate on day 14.,Incidence of adverse events.,Papua New Guinea Institute of Medical Research,Other,Swiss Tropical & Public Health Institute,Other,Health centers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AAAF0995,NCT01156896,Malaria and the Safety of Iron Supplements and Iron Fortification,Malaria and Iron Intervention Safety: Absorption and NTBI,Completed,July 2010,July 2014,Actual,Actual,Columbia University,"Gary M. Brittenham, M.D.",Principal Investigator,Columbia University,N/A,Interventional,23,Actual,Iron Deficiency,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Columbia University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Plasma non-transferrin-bound iron (NTBI),NA,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,"Hospital for Tropical Diseases, Mahidol University","0, 2, 4, 8, 12 and 24 hours",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"After administration of an iron intervention, plasma non-transferrin-bound iron pharmacokinetics will be determined.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EK-2009-N-19,NCT01163877,"Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma","Iron Absorption and Utilization in Adolescents Infected With Malaria Parasites, Hookworms or Schistosoma.",Completed,April 2010,September 2013,Actual,Actual,Swiss Federal Institute of Technology,"Rita Wegmüller, Dr.",Principal Investigator,Swiss Federal Institute of Technology (ETH) Zurich,N/A,Interventional,43,Actual,"Malaria, Falciparum; Hookworm Infections; Schistosoma Haematobium",NA,All,12 Years,16 Years,No,Swiss Federal Institute of Technology,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Isotope absorption into blood stream,Isotope absorption into blood stream,NA,NA,NA,NA,Taabo Cité Hospital,Day 15,Day 43,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU0908,NCT01074905,Study on the Treatment of Vivax Malaria,"A Randomised Open Label Study Comparing the Efficacy of Chloroquine/Primaquine, Chloroquine and Artesunate in the Treatment of Vivax Malaria Along the Thai-Burmese Border",Completed,May 2010,October 2012,Actual,Actual,University of Oxford,"Francois Nosten, MD",Principal Investigator,Shoklo Malaria Research Unit,Phase 3,Interventional,655,Actual,Vivax Malaria,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The first recurrence of Plasmodium vivax malaria,NA,Mahidol University,Other,NA,NA,Shoklo Malaria Research Unit,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The first recurrence of Plasmodium vivax malaria within 28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DP v AL01,NCT01075945,Dihydroartemisinin- Piperaquine Versus Artemether- Lumefantrine in the Treatment Uncomplicated Plasmodium Falciparum Malaria in Sudan,NA,Unknown status,February 2010,April 2010,Anticipated,Anticipated,University of Khartoum,NA,NA,NA,Phase 4,Interventional,140,Anticipated,Malaria,NA,All,5 Years,95 Years,No,University of Khartoum,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,comparing the cure rate between the two drugs,NA,"Southeast University, China",Other,NA,NA,Sinnar,3 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,PCR cure rate Parasite clearance time Fever clearance time,NA,NA,NA,NA,NA,NA,NA,NA,comparing the cure rate between the two drugs,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-CGH-5756,NCT01120145,Assessment of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi,Assessment of the Efficacy and Effectiveness of Sulphadoxine-pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Malawi,Completed,March 2010,January 2011,Actual,Actual,Centers for Disease Control and Prevention,"Jacek Skarbinski, MD",Principal Investigator,"Malaria Branch, Centers for Disease Control and Prevention",N/A,Observational,1410,Actual,Malaria in Pregnancy,NA,All,N/A,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Don Mathanga, MD, PhD",Principal Investigator,University of Malawi College of Medicine,NA,Therapeutic efficacy study: Development of fever or symptoms of severe malaria (defined by WHO) and parasitemia at any time after the first dose of SP during the 42 day follow up period,Birth outcomes study: Evidence of malaria infection based on placental histology at the time of delivery,University of Malawi College of Medicine,Other,NA,NA,Machinga District Hospital,42 days,At time of birth,Characterizing molecular markers of SP resistance: Prevalence of molecular markers of sulphadoxine-pyrimethamine resistance at the time of health facility visit,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Therapeutic efficacy study

        Inclusion Criteria:

          -  16-26 weeks gestation based on last menstrual period (LMP) or quickening

          -  Axillary temperature <37.5 degrees Celsius

          -  Informed consent

        Exclusion Criteria:

          -  History of hypersensitivity reaction to SP or components of SP

          -  Axillary temperature ≥37.5 degrees C

          -  History of receipt of antimalarials in the past month

          -  Known HIV infection

        Birth outcomes study:

        Inclusion Criteria:

          -  Singleton pregnancy

          -  SP IPTp history available

          -  Informed consent

        Exclusion Criteria:

          -  Blood transfusion after the 16th gestational week

          -  Receipt of antimalarials other than SP for IPTp after 16th gestational week

          -  Known HIV infection

        Characterizing molecular markers of SP resistance:

        Inclusion Criteria:

          -  Outpatient attending selected health facility

          -  Informed consent

        Exclusion Criteria:
      ",NA,NA,NA,NA,Day 1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACTUGA3,NCT01194557,Introducing Rapid Diagnostic Tests Into the Private Health Sector,Introducing Rapid Diagnostic Tests Into the Private Health Sector in Uganda: a Randomised Trial Among Registered Drug Shops to Evaluate Impact on Antimalarial Drug Use,Completed,September 2010,July 2012,Actual,Actual,DBL -Institute for Health Research and Development,"Anthony K Mbonye, PhD",Principal Investigator,"Ministry of Health, Uganda",N/A,Interventional,2600,Actual,Fever; Malaria; Diagnosis; Referral,NA,All,1 Month,N/A,No,DBL -Institute for Health Research and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Appropriateness of treatment,NA,"Ministry of Health, Uganda",Other,London School of Hygiene and Tropical Medicine,Other,Mukono District,36 months,NA,NA,Artemisinin-based Combination Therapy,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
42657-EG,NCT01190540,Integrated Infectious Disease Capacity-Building Evaluation,"Cost Effectiveness of Building Capacity of Mid-level Practitioners in Sub-Saharan Africa for the Care and Prevention of HIV, Tuberculosis, Malaria and Related Infectious Diseases",Completed,November 2008,August 2012,Actual,Actual,University of Washington,"Marcia Weaver, PhD",Principal Investigator,University of Washington,N/A,Interventional,72,Actual,Capacity Building; Support for Midlevel Health Professionals; Diagnostic Training,NA,All,N/A,N/A,Accepts Healthy Volunteers,University of Washington,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Sarah Naikoba, BMBCh, MPH",Principal Investigator,"Infectious Disease Institute, Makarere University",NA,Model of Integrated Capacity Building Program,Competence of individual clinicians,Makerere University,Other,Accordia Global Health Foundation,Other,"Infectious Disease Institute, Makerere University",monthly over 3 years,3 observations at pre/post IMID and final,Practice of individual clinicians,NA,NA,Clinical performance indicators,NA,NA,NA,NA,NA,NA,The principal output of this evaluation will be a proven model of an integrated capacity-building package for the care and prevention of infectious disease in Africa. The package will include a single curriculum for MLP and a portfolio of on-site support services founded on Accordia Global Health Foundation's considerable experience in training clinicians in North America and Africa.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Competence of individual clinicians will be measured by scores on 12 written case scenarios or vignettes. Three blocks of 4 scenarios each covered different aspects of HIV/AIDS, tuberculosis, malaria, and other infectious diseases and included cases involving children, adults, and pregnant women. Each case scenario addressed 6 principal domains: emergency or danger signs, history and physical examination, laboratory testing, diagnosis or classification of patients' medical problems; initial treatment or referral plan, and evolution of the case over time.",Baseline and Endline (9 months),"Clinical assessments will be conducted by mobile team faculty who will observe individual clinicians during five outpatient visits with children under five years and five HIV clinic visits. Clinical practice will be assessed on history, physical examination, review of medical records (HIV clinic only), laboratory investigations ordered, diagnosis, treatment prescribed and patient education.",Monthly beginning 5 months before OSS,"54 clinical performance indicators used by the Ministry of Health, the Uganda Malaria Surveillance Program or recommended by international organizations will be used to measure performance in general areas: 1) HIV prevention, 2) HIV care, 3) Antiretroviral therapy, 4) TB/HIV care, 5) Case management of respiratory infections, 6) Case Management of Fever, and 7) Emergency Triage and Treatment.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PIC/INSSA/UPB-01,NCT01255605,Impact of IPT With Sulfadoxin Pyrimetamin on Pregnant Women and Their Babies Outcomes in Peri-urban Areas of Bobo-Dioulasso(Burkina Faso),"Impact of Intermittent Preventive Treatment (IPT) With Sulfadoxine-pyrimethamine (SP) on the Morbidities Associated With Malaria in Pregnant Women and Newborns in Peri-urban Areas of Bobo-Dioulasso, 5 Years After Its Adoption by the National Program for Fight Against Malaria in Burkina Faso.",Completed,September 2010,June 2011,Actual,Actual,Université Polytechnique de Bobo-Dioulasso,"Mamoudou Cisse, MD",Principal Investigator,Centre MURAZ Research Institute,N/A,Observational,772,Actual,"Malaria, Pregnancy",NA,Female,N/A,N/A,No,Université Polytechnique de Bobo-Dioulasso,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Peripheral and placental malaria,NA,NA,NA,NA,NA,Institut Supérieur des Sciences de la Santé/Université Polytechnique de Bobo-Dioulasso,Peripheral malaria : at antenatal clinics and at delivery. Placental malaria: at delivery,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The investigators will check if pregnant women have any malaria parasites by making a finger prick thick respectively at antenatal clinics and at delivery. A placental thin smear will be made at delivery.,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  Residing in the health area of Lafiabougou or secteur 24

          -  Having agreed to give free and informed consent

        Exclusion Criteria:

          -  Bleeding from during the pregnancy

          -  eclampsia
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SUD 6/025,NCT00646126,Antimalarial Treatments for Clearing Low Density P. Falciparum and Its Impact on Malaria Transmission,Validation of the Use of Istope-Based Molecular Techniques for Malaria Control,Completed,August 2005,NA,NA,NA,Tropical Medicine Research Institute,"Badria B El Sayed, PhD,MSc,BSc",Principal Investigator,Tropical Medicine Research Institute,Phase 3,Interventional,NA,NA,Plasmodium Falciparum; Asymptomatic Parataemia; Sub Patent Parasitaemia,NA,All,1 Year,N/A,Accepts Healthy Volunteers,Tropical Medicine Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parsitaemia detected during the transmission season among dry season PCR negative persons in the intervention and control villages,NA,London School of Hygiene and Tropical Medicine,Other,International Atomic Energy Agency,Other,Tropical Medicine Research Institute,October to December 2006,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HF2003,NCT00687895,Improved Clinical and Microscopy Diagnosis at Primary Health Care in Tanzania,Quality Malaria Case Management In Under- Fives In Primary Health Care (Phc) Institutions In Bagamoyo And Kibaha Districts Of Coastal Tanzania:a Multicomponent Controlled Intervention Study,Completed,July 2003,March 2004,Actual,Actual,Muhimbili University of Health and Allied Sciences,"Anders Bjorkman, MD",Study Director,Karolinska Institutet,Phase 4,Interventional,3131,Actual,Malaria,NA,All,6 Months,59 Months,No,Muhimbili University of Health and Allied Sciences,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,the proportion of study children receiving prescriptions of antimalarial drugs in the respective arms,NA,Karolinska Institutet,Other,NA,NA,dispensaries/health centers in Kibaha and Bagamoyo,Day 0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Epicentre/Nig/2010/PaluMadaua,NCT01204411,"Efficacy of Artesunate-amodiaquine (AS-AQ) in Children With Malaria and Severe Acute Malnutrition, Madaoua, Niger 2010","Efficacy of the Artesunate-amodiaquine Combination for Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Between 6 and 59 Months of Age With Severe Acute Malnutrition in Madaoua, Tahoua Region, Niger",Withdrawn,NA,NA,NA,NA,Epicentre,"Francesco Grandesso, MSc",Principal Investigator,Epicentre,Phase 4,Interventional,0,Actual,"Malaria, Falciparum; Malnutrition; Child",NA,All,6 Months,59 Months,No,Epicentre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To measure the PCR adjusted clinical and parasitological efficacy of the artesunate-amodiaquine combination in children 6-59 months of age with severe malnutrition and uncomplicated P. falciparum malaria over a period of 42 days.,NA,"Medecins Sans Frontieres, Spain",Other,NA,NA,Integrated health centre (CSI),42 day follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FIGHTMAL,NCT01214876,Correlating Protection Against Malaria With Serum Profiles Against Plasmodium Falciparum Antigen Repertoires,NA,Completed,August 2010,March 2011,Actual,Actual,Radboud University,NA,NA,NA,N/A,Observational,500,Anticipated,Malaria; Schistosomiasis; Hiv Infection,NA,All,1 Year,N/A,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Immune correlates of protection against clinical malaria episodes with plasmodium falciparum,NA,London School of Hygiene and Tropical Medicine,Other,Medical Biotech Laboratories,Other,Medical Biotech Laboratories,NA,NA,NA,University Of Perugia,Other,NA,NA,NA,Imperial College London,Other,Microtest Matrices Ltd,Other,"IMMUNE RESPONSES: protein array.
CLINICAL MALARIA EPISODES: (reported) fever with i) P. falciparum parasites; ii) ... at a density >=5,000 parasites/ul; iii) ... at a density >=10,000 parasites/ul IMMUNOLOGICALLY PROTECTED INDIVIDUALS: parasitaemic during follow-up without reporting to the health facility with indicators of a clinical malaria episode",NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  age 1-5 years, 6-10 years or 25 yearsand above

          -  written informed consent must be given

          -  the individual must have been resident of the area since birth or for a minimum period
             of two years

          -  the individual must be willing to submit required information and to participate in
             repeated sampling (total blood volume ~2.5 mL over a period of 12 months)

          -  Absence of danger signs (as defined by WHO) or clinical features of AIDS. An HIV-test
             will be offered to all participants at enrolment and completion of the study.

        Exclusion Criteria:

          -  unwillingness to sign consent form

          -  unwillingness to reside in the study area during the follow-up period
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR # 1737,NCT01280162,Malaria Active Epidemiology and Treatment Study,An Active Malaria Epidemiology Cohort Study With Evaluation of a 2 Day Versus 3 Day Treatment Regimen of DHA-Piperaquine for Patients With Uncomplicated Malaria,Completed,September 2010,December 2012,Actual,Actual,"Armed Forces Research Institute of Medical Sciences, Thailand","David Saunders, MD, MPH",Principal Investigator,USAMC-AFRIMS,N/A,Interventional,222,Actual,Malaria,NA,All,18 Years,65 Years,Accepts Healthy Volunteers,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Comparative efficacy.,NA,United States Army Medical Materiel Development Activity,U.S. Fed,NA,NA,Oddar Meancheay,4-5 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Comparative rates of malaria recurrence between the 2 and 3 day DP regimens at 42 days after treatment of malaria infection, diagnosed by positive PCR-corrected malaria microscopy.",NA,NA,NA,NA,NA,NA,NA,NA,Comparative efficacy.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC044,NCT01351948,"Safety and Immunogenicity of Malaria Vaccines AdCh63 AMA1, MVA AMA1 and AMA1-C1/Alhydrogel®+/- CPG 7909","A Phase Ia Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines; AdCh63 AMA1, MVA AMA1 & AMA1-C1/Alhydrogel® +/- CPG 7909",Completed,June 2011,March 2013,Actual,Actual,University of Oxford,"Adrian VS Hill, D.Phil, FRCP",Principal Investigator,"The Jenner Institute, University of Oxford",Phase 1,Interventional,35,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety of vaccination,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,NA,NA,"Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Old Road, Headington",Expected average of 12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To assess the safety of vaccination of healthy adults with AdCh63 AMA1, MVA AMA1 & AMA1-C1/Alhydrogel® +/- CPG 7909 administered in various schedules using actively and passively collected data on adverse events",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ARAMF_L_02661,NCT00699920,Cohort Study in Uganda Comparing Artesunate + Amiodaquine (Coarsucam) Versus Artemether + Lumenfantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks,"A Randomised Study to Compare a Fixed Dose Combination of Artesunate Plus Amiodaquine (Coarsucam) Versus a Fixed Dose Combination of Artemether Plus Lumefantrine (Coartem) in the Treatment of Repeated Uncomplicated Plasmodium Falciparum Malaria Attacks Occurring During the 2 Years of Follow-up, in Children in Uganda.",Completed,June 2008,June 2010,Actual,Actual,Sanofi,Valerie Lemeyre,Study Director,Sanofi,Phase 4,Interventional,413,Actual,Malaria,NA,All,6 Months,59 Months,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR corrected and uncorrected clinical and parasitological cure rate,NA,NA,NA,NA,NA,Sanofi-aventis administrative office,At Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
07-0548-AE,NCT00707200,The Cytoadherence in Pediatric Malaria (CPM) Study,Clinical Outcomes in Pediatric Plasmodium Falciparum Malaria According to Host Cytoadherence Factors,Completed,October 2007,November 2009,Actual,Actual,"University Health Network, Toronto","Nicolette Nabukeera-Barungi, MBChB, MMEd",Study Director,Mulago Hospital/Makerere University (lead local investigator),N/A,Observational,2000,Anticipated,Plasmodium Falciparum Malaria,NA,All,6 Months,12 Years,No,"University Health Network, Toronto",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Combined severe morbidity & mortality,NA,University of Toronto,Other,NA,NA,Mulago Hospital Acute Care Unit & Makerere University Department of Paediatrics & Child Health,Discharge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Clinical diagnosis of Plasmodium falciparum malaria infection

        Exclusion Criteria:

          -  HIV or significant malnutrition
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ST3073/ST3074-DM09-007,NCT01222949,A Pharmacokinetic (PK) Trial in Healthy Asian and Caucasian Volunteers Investigating the PK Profile of Eurartesim™,"A Phase I, Pharmacokinetic Trial, in Healthy Asian and Caucasian Volunteers for Investigating the Pharmacokinetic Profiles of Eurartesim™ (40 mg Dihydroartemisinin (DHA)/320 mg Piperaquine (PQ) Phosphate.",Completed,February 2010,August 2010,Actual,Actual,sigma-tau i.f.r. S.p.A.,NA,NA,NA,Phase 1,Interventional,80,Actual,"Malaria, Falciparum",NA,All,18 Years,50 Years,Accepts Healthy Volunteers,sigma-tau i.f.r. S.p.A.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"PK: tmax, Cmax, AUC0-12(DHA), AUC0-24(PQ), AUC0-inf, λz, t1/2",NA,"CPR Pharma Services Pty Ltd, Australia",Industry,NA,NA,NA,During the first and last day of drug administration (day 0 and 2) and followed up till Day 90,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"DHA evaluation: At pre-dose on day Day 0 and Day 2 and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose.
PQ evaluation: At pre-dose Day 0 and then at 1, 2, 3, 4, 5, 6, 8, 12, and 16 hours post-dose; then at pre-dose Day 1 and Day 2 and finally at 1, 2, 3, 4, 5, 6, 8, 12, and 16 hours post-dose on day 2; on Day 3, 4, 5, 7, 14, 21, 28, 42, 56 and 90.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ST3073/ST3074-DM09-008,NCT01222962,Food Interaction Study on the Pharmacokinetics of Eurartesim™ (DHA and PQP)in Healthy Male Adult Volunteers,Study of the Effect of Food on the Pharmacokinetics of DHA and PQP After Single Oral Administration of Eurartesim™ in Healthy Male Adult Volunteers,Completed,March 2010,June 2010,Actual,Actual,sigma-tau i.f.r. S.p.A.,NA,NA,NA,Phase 1,Interventional,37,Actual,"Malaria, Falciparum",NA,Male,18 Years,50 Years,Accepts Healthy Volunteers,sigma-tau i.f.r. S.p.A.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"tmax, Cmax, AUC0-last, AUC0-24 [PQ], and AUC0-inf, λz, t1/2, Cl/F, Vz/F [DHA].",NA,"CPR Pharma Services Pty Ltd, Australia",Industry,NA,NA,"CMAX, a division of IDT Australia Limited","from the day of study drug administration, till Day 7 follow-up",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Blood samples for determination of plasma DHA were collected at the following times: At pre-dose Day 0 and then at 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, and 12 hours post-dose.
Blood samples for determination of plasma PQ were collected at the following times: At pre-dose Day 0 and then at 1, 2, 3, 4, 5, 6, 8, and 12 hours post-dose; on Day 1, 2, 3, 4, 5 and 7.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MAL-V-A001,NCT01397227,"A Study to Assess the Immunogenicity, Tolerability and Safety of a Malaria Vaccine and Also Its Protective Efficacy in a Malaria Challenge Model","A Phase I/IIa, Double-blind, Randomized, Placebo-controlled, Dose-escalation Clinical Study Evaluating Safety, Tolerability and Immunogenicity of Two Dose Levels of Recombinant Adenoviral Serotype Ad35 and Serotype Ad26 Vectors Expressing the Malaria Plasmodium Falciparum Circumsporozoite Antigen Administered as Heterologous Prime-boost Regimen, and Assessing Protective Efficacy of the Higher Dose in a Malaria Challenge Model in Unblinded Conditions",Completed,June 2011,May 2012,Actual,Actual,Crucell Holland BV,"Angela Talley, MD",Principal Investigator,Seattle Biomedical Research Institute,Phase 1/Phase 2,Interventional,36,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Crucell Holland BV,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Solicited local and systemic adverse events (AEs),Unsolicited AEs,The PATH Malaria Vaccine Initiative (MVI),Other,Seattle Biomedical Research Institute,Other,Malaria Clinical Trials Center at Seattle Biomedical Research Institute,For 7 days after each vaccination and at each visit during the challenge period,At each visit during the vaccination period,Vital signs,NA,NA,Changes in laboratory parameters from baseline to end of vaccination phase,NA,NA,NA,NA,NA,NA,Type and frequency of solicited local and systemic AEs to be recorded. Solicited AEs in the challenge period are collected via a reactogenicity checklist during study visits. Solicited AEs in the vaccination period are collected via a Subject Diary.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Type and frequency of unsolicited AEs to be recorded,"Before and after each vaccination during the vaccination period, before and after malaria challenge and at each visit during the challenge period","Temperature (oral), pulse, respiratory rate, blood pressure and pulse oximetry will be measured","Screening/baseline, 7 days after each vaccination, and Days 101 and 115 of the challenge period","Assessment made on the changes in each laboratory parameter from baseline to the end of the vaccination phase at each time point. Parameters measured:
Biochemistry: glucose, potassium, creatinine, γ-glutamyl transferase, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, total bilirubin, C-reactive protein and erythrocyte sedimentation rate.
Hematology: hemoglobin, hematocrit, white blood cell count, white blood cell differential, red blood cell count and platelet count.
Urinalysis: leucocytes, blood, protein, ketones and glucose (by dipstick).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
5911,NCT01403350,Cluster Randomised Trial of Malaria RDTs Used by CHWs in Afghanistan,Effectiveness of Community Level Deployment of Rapid Diagnostic Tests for Malaria in Afghanistan: Cluster Randomised Trial,Completed,February 2012,August 2012,Actual,Actual,London School of Hygiene and Tropical Medicine,"Toby Leslie, PhD",Principal Investigator,LSHTM,Phase 4,Interventional,2421,Actual,Malaria; Fever; Acute Febrile Illness; Pneumonia,NA,All,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of cases correctly treated,NA,Health Protection and Research Organisation,Other,HealthNet TPO,Other,NA,Outcomes measured during consultation - approximately 30-40 minutes,NA,NA,Medical Emergency Relief International,Other,NA,NA,NA,NA,NA,NA,NA,"Correctly treated defined as:
Those with PCR positive blood sample given an appropriate antimalarial; Those with PCR negative blood sample not given any antimalarial",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCOA566A2403,NCT00709969,Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets in African Infants and Children With Uncomplicated P. Falciparum Malaria,"Open Label, Multicenter Study for Evaluation of Safety and Efficacy of Artemether-Lumefantrine Tablets (6-Dose Regimen) in African Infants and Children in the Treatment of Acute Uncomplicated Falciparum Malaria",Completed,July 2002,February 2003,Actual,Actual,Novartis,Novartis,Study Chair,Novartis Pharmaceuticals,Phase 3,Interventional,310,Actual,Plasmodium Falciparum Malaria,NA,All,N/A,N/A,NA,Novartis,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Adverse events, SAEs; hematology and biochemistry parameters; electrocardiogram; urine values; vital signs; physical neurological examinations; and neurological examinations",NA,World Health Organization,Other,Avenue Appia 20,Other,NA,28 days,NA,NA,CH - 1211 Geneva 27,Other,NA,NA,NA,Switzerland,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AMA-1_1_03,NCT00730782,Assessment of Three Formulations of the Candidate Vaccine AMA 1 in Healthy Dutch Adult Volunteers,"Assessment of the Safety and Immunogenicity of Three Formulations of the Recombinant Pichia Pastoris Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]), Blood-Stage Malaria Vaccine in Healthy Dutch Adult Volunteers : a Phase 1, Single- Blind, Randomised, Dose-Escalating, Unicentre Trial",Completed,November 2005,August 2008,Actual,Actual,European Malaria Vaccine Initiative,"Robert Sauerwein, Prof. MD",Principal Investigator,Radboud University,Phase 1,Interventional,56,Actual,Plasmodium Falciparum Malaria,NA,Male,18 Years,45 Years,Accepts Healthy Volunteers,European Malaria Vaccine Initiative,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Local and systemic reactogenicity,NA,Radboud University,Other,Biomedical Primate Research Centre,Other,NA,Day 0-14 after each vaccination,NA,NA,GlaxoSmithKline,Industry,NA,NA,NA,"SEPPIC, Paris",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
iNO RCT,NCT01255215,Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial,Inhaled Nitric Oxide for the Adjunctive Therapy of Severe Malaria: a Randomized Controlled Trial,Completed,July 2011,January 2014,Actual,Actual,"University Health Network, Toronto","Michael Hawkes, MD",Study Director,University of Toronto,Phase 1/Phase 2,Interventional,180,Actual,Severe Malaria,NA,All,1 Year,10 Years,No,"University Health Network, Toronto",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change in serum angiopoietin-2 level,NA,Makerere University,Other,University of Toronto,Other,Jinja Regional Referral Hospital,Admission through 72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Daily Ang-2 measurements over the first 72 hours of hospital admission will be the primary efficacy outcome. Elevated Ang-2 levels are associated with poor clinical outcome in severe malaria and Ang-2 has been used to follow disease progression and recovery in previous studies of malaria. Thus, Ang-2 is an objective, quantitative surrogate marker of disease severity, validated for longitudinal follow-up of patients with malaria.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ART004,NCT01258049,Superiority of ArTiMist Versus Quinine in Children With Severe Malaria,"A Phase III, Randomised, Open Labelled, Active Controlled, Multi Centre, Superiority Trial of ArTiMist™ Versus Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications.",Completed,December 2010,September 2012,Actual,Actual,Proto Pharma Ltd,"Daryl Bendel, MBChB MFPM",Study Chair,Xidea Solutions Limited,Phase 3,Interventional,151,Actual,Plasmodium Falciparum Malaria,NA,All,N/A,N/A,No,Proto Pharma Ltd,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasitological Success (MITT),Parasitological Success (PP),NA,NA,NA,NA,NA,24 hours after start of treatment,24 hours after start of treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Parasitological success defined as a reduction in parasite count of ≥ 90% of baseline at 24 hours after the first dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2006/177,NCT00329134,Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria,Investigation of the Efficacy of Quinine Sulphate Administered Via Taste-Masked Pellets to Children With Falciparum Malaria,Completed,July 2006,May 2007,Actual,Actual,University Ghent,"Luc Van Bortel, MD, PhD",Principal Investigator,"University Hospital, Ghent",Phase 2,Interventional,56,Anticipated,Malaria,NA,All,6 Months,59 Months,No,University Ghent,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Clocktime when child has had no fever for minimal 48h (< 37,5°C)",Parasitemy,NA,NA,NA,NA,Centre Hospitalier De Butare,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-003-05,NCT00331136,Pyronaridine and Artesunate (3:1) in Children With Acute Uncomplicated Plasmodium Falciparum Malaria,"An Open-Label, Phase II, Dose-Escalation Clinical Study to Assess the Pharmacokinetics, Safety, Tolerability and Pharmacodynamics of Fixed Dose Combination of Pyronaridine and Artesunate (3:1) In Children With Acute Uncomplicated Plasmodium Falciparum Malaria",Completed,June 2006,December 2006,Actual,Actual,Medicines for Malaria Venture,"Michael Ramharter, MD",Principal Investigator,"Albert Schweitzer Hospital, Lambaréné, Gabon",Phase 2,Interventional,45,Actual,Uncomplicated Plasmodium Falciparum Malaria,NA,All,2 Years,14 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To determine the PK of once daily dosing for 3 days of 3 dose levels of pyronaridine artesunate in children weighing between 10 and 40 kg,To determine the safety and tolerability of 3 dose levels of the fixed tablet formulation of pyronaridine:artesunate (3:1).,Shin Poong Pharmaceuticals,Industry,"Institute of Tropical Medicine, University of Tuebingen",Other,"Medical Research Unit, Albert Schweitzer Hospital",Day 42,42 Days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACT10004,NCT00739206,Study of SAR97276A in the Treatment of Uncomplicated and Severe Malaria in Adults and Children.,"A Multicenter, Open Label, Efficacy and Safety Study of Parenteral SAR97276A in the Treatment of Symptomatic Uncomplicated and Severe Malaria in Adults and Children",Terminated,August 2008,June 2009,Actual,Actual,Sanofi,ICD CSD,Study Director,Sanofi,Phase 2,Interventional,113,Actual,Malaria,NA,All,6 Months,65 Years,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Combination of fever clearance, general condition improvement at 48h parasite reduction at 72h and no need for rescue therapy at 72h",NA,NA,NA,NA,NA,NA,3 initial days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A0661186,NCT00844207,A Phase 1 Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine,"A Phase 1, Open Label, Randomized, Single Dose, Parallel Group Study To Estimate The Relative Bioavailability Of Fixed Combination Tablets Of Azithromycin And Chloroquine Compared To Co-Administered Individual Tablets Of Azithromycin And Chloroquine In Healthy Adult Subjects",Completed,February 2009,April 2009,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 1,Interventional,40,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,AUClast and Cmax of azithromycin and chloroquine for each treatment.,NA,NA,NA,NA,NA,Pfizer Investigational Site,up to 96 hours post dose on Day 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC042,NCT01450293,AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Children in a Malaria Endemic Area,Safety and Immunogenicity of Heterologous Prime-boost Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Infants in a Malaria- Endemic Area,Completed,October 2011,March 2013,Actual,Actual,University of Oxford,Kalifa Bojang,Principal Investigator,"Medical Research Council PO Box 273, Banjul The Gambia",Phase 1,Interventional,72,Actual,Malaria,NA,All,10 Weeks,12 Months,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety of heterologous prime-boost vaccination with AdCh63 ME-TRAP followed eight weeks later by MVA ME-TRAP,NA,European and Developing Countries Clinical Trials Partnership (EDCTP),Other,NA,NA,Medical Research Council Laboratories,"Participants will be followed for the duration of the study, an expected average of 16 months",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,To assess the safety of heterologous prime-boost vaccination of healthy infants in a malaria-endemic area with AdCh63 ME-TRAP followed eight weeks later by MVA ME-TRAP by recording local and systemic solicited and unsolicited adverse events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WT-Clarke-Sen2011,NCT01454752,"Intermittent Parasite Clearance (IPC) in Schools: Impact on Malaria, Anaemia and Cognition","Intermittent Parasite Clearance (IPC) in Schools: a Randomised Double-blind Placebo-controlled Trial of the Impact of IPC on Malaria, Anaemia and Cognition Amongst School Children in Kedougou, Senegal",Completed,November 2011,February 2012,Actual,Actual,London School of Hygiene and Tropical Medicine,"Sian E Clarke, PhD",Principal Investigator,"London School of Hygiene and Tropical Medicine, UK",N/A,Interventional,860,Actual,Malaria; Anaemia,NA,All,7 Years,14 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Prevalence of malaria parasitaemia,Prevalence of anaemia (Haemoglobin<11 g/dL),"Division Controle Medicale Scolaire, Ministry of Education, Senegal",Other,"Ministry of Health, Senegal",Other,Institut de Recherche pour le Developpement,8 weeks after treatment (February 2012),8 weeks after treatment (February 2012),NA,"Institut National d'Etude et d'Action pour le Developpement de l'Education, Senegal",Other,NA,NA,NA,"Cheikh Anta Diop University, Senegal",Other,"Institut de Recherche pour le Developpement, Senegal",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Harvard University,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACTc TACT,NCT01292707,A Cluster-randomised Trial of Interventions to Improve Antimalarial Prescribing With Malaria Tests,A Cluster-randomised Trial of Health Worker and Community Interventions to Improve Adherence to National Guidelines for the Use of ACTs in Tanzania,Completed,February 2011,April 2012,Actual,Actual,London School of Hygiene and Tropical Medicine,"Hugh Reyburn, MD",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,1152,Actual,Malaria,NA,All,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The proportion of patients with a non-severe non-malarial illness prescribed a recommended antimalarial drug in a new consultation.,NA,"Kilimanjaro Christian Medical Centre, Tanzania",Other,"Ministry of Health, Tanzania",Other,Joint Malaria Programme,1year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The proportion of patients with a non-severe non-malarial illness prescribed a recommended antimalarial drug in a new consultation.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
113681,NCT01345240,Study to Evaluate Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049),Immunogenicity of the Hepatitis B Antigen of the GSK Biologicals' Candidate Malaria Vaccine (257049),Completed,November 2011,February 2017,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,705,Actual,Malaria,NA,All,8 Weeks,12 Weeks,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Anti-Hepatitis B (HBs) Antibody Concentrations,Anti-Hepatitis B (HBs) Antibody Concentrations.,NA,NA,NA,NA,NA,"At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B™","At Month 3, aka at one month post Dose 3 of RTS,S vaccine or Engerix-B™",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL). The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 10 mIU/mL. A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis, with study groups pooled by primary vaccine administered (RTS,S vs Engerix-B™).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Concentrations, by enzyme-linked immunosorbent assay (ELISA), were presented as geometric mean concentrations (GMCs), and expressed in milli-international units per milliliter (mIU/mL). The assay cut-off was the seropositivity cut-off value of greater than or equal to (>=) 10 mIU/mL. A decrease in the specificity of the anti-HBs ELISA assay had been observed in some studies for low levels of antibody (10-100 mIU/mL). The table shows updated results following partial or complete retesting/reanalysis, with study groups pooled by RTS,S or Engerix-B™ vaccination regimen received.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-4701,NCT00336388,Use of Rapid Diagnostic Tests for Malaria Case Management in Kenya,"Introduction of Malaria Rapid Diagnostic Tests, Artemisinin-based Combination Therapy, and Malaria Case Management Guidelines at Health Facilities in Kenya: A Cluster Randomized Trial to Evaluate Adherence and Acceptance by Health Care Workers, Impact on Antimalarial Prescription Practices, and Patient Perceptions",Completed,July 2006,September 2006,Actual,Actual,Centers for Disease Control and Prevention,"Mary Hamel, MD",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,NA,NA,Malaria,Sensitivity and specificity of malaria diagnosis 6 weeks after the introduction of malaria rapid diagnostic tests,All,5 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Alexandre Macedo De Oliveira, MD",Principal Investigator,Centers for Disease Control and Prevention,3600,NA,NA,Kenya Medical Research Institute,Other,Kenya Division of Malaria Control,Other,Bondo and Kericho District Health Facilities,NA,NA,NA,KEMRI-Wellcome Trust Collaborative Research Program,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TAN.5.2.SAF,NCT00347113,"Schistosome and Intestinal Worm Infections and Malaria Morbidity Among School and Pre-school Children in, Tanzania","The Effect of Schistosome and Soil-transmitted Helminth Infections on Malaria,Infection, Morbidity and Antibody Response Among School and Pre-school Children in Mwanza, Tanzania",Completed,July 2006,January 2011,Actual,Actual,DBL -Institute for Health Research and Development,"Safari M Kinung'hi, Msc",Principal Investigator,"National Insitute for Medical Research, Mwanza, Tanzania",N/A,Interventional,620,Anticipated,Anaemia; Malaria; Hepatosplenomegaly,NA,All,5 Years,15 Years,No,DBL -Institute for Health Research and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,incidence of malaria cases,Spleen and liver size,NA,NA,NA,NA,Mwanza Medical Research Centre,NA,NA,Hæmoglobin,NA,NA,P. falciparum specific antibodies (IgG3),Prevalence and intensity of schistosome anfd intestinal helminth infections,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SEACAT 2_4_2,NCT00869700,Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults,Pharmacokinetic Interaction Between the Antimalarial Combination Artemether/Lumefantrine and Combination Antiretroviral Therapy Including Lopinavir/Ritonavir in HIV-infected Adults,Completed,June 2009,February 2010,Actual,Actual,University of Cape Town,"Karen I Barnes, MBChB MMed(clin pharm)",Principal Investigator,University of Cape Town,Phase 4,Interventional,18,Actual,HIV Infections; Malaria,NA,All,18 Years,N/A,Accepts Healthy Volunteers,University of Cape Town,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Lumefantrine concentration,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,"Groote Schuur Hospital, Ward J51, Old Main Building",day 7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Lumefantrine concentration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2004/GD/70,NCT00873938,Compliance to Artesunate-Amodiaquine Therapy for Uncomplicated Malaria in Rural Ghana,NA,Completed,October 2005,September 2006,Actual,Actual,"Kintampo Health Research Centre, Ghana","Seth Owusu-Agyei, PhD",Principal Investigator,"Kintampo Health Research Centre, Ghana",N/A,Observational,411,Actual,Malaria,NA,All,10 Years,N/A,No,"Kintampo Health Research Centre, Ghana",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Kwaku P Asante, MD, MPH",Principal Investigator,"Kintampo Health Research Centre, Ghana",NA,The main outcome is compliance to artesunate-amodiaquine combination therapy,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,Kintampo Health Research Centre,Within first three days after diagnosis of malaria,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion criteria:

          -  Male and female patients aged above ten years reporting at the Kintampo district
             hospital.

          -  Diagnosed as having Plasmodium falciparum uncomplicated malaria.

          -  Axillary temperature ≥37.5oC but less than 40 oC or history of fever in preceding 24
             hr.

          -  Ability to tolerate oral therapy.

          -  Patient who live and can be located in the Kintampo District.

          -  Consent of patient and/or care giver (in the case of children)

        Exclusion criteria:

          -  Pregnant women.

          -  Children ten years and below (to be catered for in the child antimalarial efficacy
             studies mentioned above).
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
JP012,NCT01464138,Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated P.Falciparum Malaria in Children,Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children,Completed,September 2010,September 2011,Actual,Actual,Jomaa Pharma GmbH,"Quique Bassat, PhD",Principal Investigator,"CRESIB, Barcelona",Phase 2,Interventional,52,Actual,Malaria,NA,All,6 Months,3 Years,No,Jomaa Pharma GmbH,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Day 28 cure rate >95%,NA,Fundacio Clinic,Other,Hospital Clinic of Barcelona,Other,Centro de Investigacao em Saude da Manhica,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CKAE609X2201,NCT01524341,"Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection","A Proof-of-concept, Open Label, 3-day Repeated Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection",Completed,January 2012,June 2012,Actual,Actual,Novartis Pharmaceuticals,Novartis Pharmaceuticals,Study Director,Novartis Pharmaceuticals,Phase 2,Interventional,27,Actual,Malaria,NA,All,20 Years,60 Years,No,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite clearance time,NA,NA,NA,NA,NA,NA,From baseline to the time point when the blood parasite count is zero(up to a maximum of 5 days),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Calculated based on parasite count in blood. In thin film, use actual WBCs/µl, of blood to calculate parasite density by using the following formula: parasites/µl= #parasites× actual WBC/#WBCs counted. In thick film, assume that there are 250 RBCs per HPF, RBC count from 8 HPF equal 2000 RBC, Use actual RBCs/µl blood to calculate parasite density by using the following formula: parasites/µl= # of parasites in 8HPF/2000)× actual RBC.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC043,NCT01364883,Safety and Immunogenicity of Novel Vaccination Schedules With Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP,A Phase I Study to Assess the Safety and Immunogenicity of Novel Schedules for Vaccination With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP,Completed,July 2011,July 2013,Actual,Actual,University of Oxford,Adrian VS Hill,Principal Investigator,University of Oxford,Phase 1,Interventional,39,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Vaccine Safety,NA,NA,NA,NA,NA,"Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford","Participants will be followed for the duration of the study, an expected average of 21 months",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,To assess the safety of vaccination of healthy adults with AdCh63 ME-TRAP and MVA ME-TRAP according to vaccination schedules 1 to 7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC041,NCT01373879,AdCh63 ME-TRAP and MVA ME-TRAP Malaria Vaccines Evaluation in Healthy Adults and Children in a Malaria Endemic Area,Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults and Children in a Malaria Endemic Area,Completed,June 2010,December 2011,Actual,Actual,University of Oxford,Kalifa Bojang,Principal Investigator,"Medical Research Council PO Box 273, Banjul The Gambia",Phase 1,Interventional,52,Actual,Malaria,NA,Male,2 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP,NA,European and Developing Countries Clinical Trials Partnership (EDCTP),Other,NA,NA,Dr Kalifa Bojang,"Participants will be followed for the duration of the study, an expected average of 12 months",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,To assess the safety of a heterologous prime-boost vaccine strategy with AdCh63 ME-TRAP and MVA ME-TRAP in healthy adults and children in The Gambia by recording local and systemic solicited and unsolicited adverse events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BSPZC1,NCT01540903,Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites in Tanzanian Adults,Controlled Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites (PfSPZ Challenge)in Tanzanian Adults,Completed,February 2012,August 2013,Actual,Actual,Sanaria Inc.,"Salim Abdulla, MD, PhD",Principal Investigator,"Ifakara Health Institute (IHI), Tanzania",Phase 1,Interventional,30,Actual,Malaria,NA,Male,20 Years,35 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of volunteers positive in each group through day 28 of follow up.,NA,Ifakara Health Research and Development Centre,Other,Swiss Tropical & Public Health Institute,Other,"Bagamoyo Research and Training Center, Ifakara Health Institute",5 to 28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Thick smears will be performed according to a standard operating procedure. In short, 15 μL of whole blood will be distributed on standardized 3-well slides, providing an equal slide thickness for all smears. Slides are dried and stained with Giemsa. 200 fields per slide will be read at 1000X. Slides are considered positive if they contain 2 or more parasites per 200 fields.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CIV - 08 - 102010,NCT01585077,Exposure of Naive and Pre-immune Subjects to P. Vivax Challenge,Comparison of the Susceptibility of Naive and Pre-immune Volunteers to Infectious Challenge With Viable Plasmodium Vivax Sporozoites.,Completed,October 2012,November 2013,Actual,Actual,Socrates Herrera Valencia,"Sócrates Herrera, MD",Principal Investigator,Malaria Vaccine and Drug Development Center,Phase 1/Phase 2,Interventional,16,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Socrates Herrera Valencia,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Pre-patent period onset,NA,NA,NA,NA,NA,Malaria Vaccine and Drug development Center (MVDC),Two months after the challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"begining at day 7 after mosquito bites exposure, both groups of volunteers will be evaluated with dayly Thick blood smear to compare the malaria onset between the pre-immune and naive groups.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NIMR/HQ/R.8a/Vol.IX/794,NCT00885287,Interactions Between Artemether-lumefantrine and Antiretrovirals in HIV-patients With Uncomplicated Malaria in Tanzania,"Study of Therapeutic Efficacy, Safety and Pharmacokinetic Interactions Between Artemether-lumefantrine and Nevirapine-based Antiretrovirals in HIV-infected Patients With Uncomplicated Falciparum-malaria in Muheza, Northeastern Tanzania",Completed,July 2009,January 2013,Actual,Actual,University of Copenhagen,"Lasse Vestergaard, MD, PhD",Principal Investigator,University of Copenhagen,Phase 4,Interventional,830,Actual,"Malaria, Falciparum; HIV Infections",NA,All,15 Years,60 Years,No,University of Copenhagen,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Martha Lemnge, PhD",Principal Investigator,"National Institute for Medical Research, Tanzania",NA,Clinical and parasitological efficacy of artemether-lumefantrine; incidence and severity of treatment-related clinical and paraclinical adverse events; changes in pharmacokinetic profiles of artemether-lumefantrine.,NA,"National Institute for Medical Research, Tanzania",Other,London School of Hygiene and Tropical Medicine,Other,Muheza Designated District Hospital,42 days of post-treatment follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MAL 034,NCT00890760,A Study to Assess the Effectiveness of a New Malaria Vaccine Candidate by Infecting Vaccinated Volunteers With Malaria Parasites,Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With AdCh63 ME-TRAP and MVA ME-TRAP,Completed,March 2009,February 2011,Actual,Actual,University of Oxford,"Adrian VS Hill, D.Phil, FRCP",Principal Investigator,University of Oxford,Phase 1/Phase 2,Interventional,55,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Vaccine prevention (partial or complete) of malaria infection by sporozoite challenge,NA,NA,NA,NA,NA,"Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford",Approxiamately 5-16 months following last intervention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ARAMF_C_05370,NCT01378286,Efficacy and Tolerability of Artesunate Amodiaquine Versus Chloroquine in the Treatment of Uncomplicated Plasmodium Vivax Malaria,A Randomised Comparative Study to Assess the Efficacy and Tolerability of Blood Schizonticidal Treatments With Artesunate Amodiaquine Winthrop® / Coarsucam (ASAQ) Versus Chloroquine (CQ) for Uncomplicated Plasmodium Vivax Monoinfection Malaria,Completed,January 2012,June 2013,Actual,Actual,Sanofi,Clinical Sciences & Operations,Study Director,Sanofi,Phase 3,Interventional,380,Actual,Malaria,NA,All,6 Months,N/A,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Assessment of clinical and parasitological efficacy based on temperature and parasitemia after Polymerase chain reaction (PCR) correction,NA,NA,NA,NA,NA,Administrative office,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_11_001,NCT01383096,Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers,A Phase I Study To Investigate The Relative Bioavailability of OZ439 Formulations In Healthy Volunteers,Completed,April 2012,August 2012,Actual,Actual,Medicines for Malaria Venture,"Peter Peter Hodsman, MD",Principal Investigator,"AMREP Centre for Clinical Studies, Nucleus Network, 89 Commercial Road, Melbourne, VIC 3004 Australia",Phase 1,Interventional,52,Actual,Healthy Volunteers,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 Cmax,OZ439 AUC0-∞,Nucleus Network Ltd,Other,INC Research,Other,AMREP Centre for Clinical Studies,"1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing","1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing",OZ439 t1/2,NA,NA,NA,NA,NA,NA,NA,NA,NA,The maximum observed plasma drug concentrations (Cmax),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Area under the plasma concentration-time curve from zero to infinity (AUC0-∞),"1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 and 168 hours post dosing",Apparent terminal half life (t1/2),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-002-05,NCT01594931,Phase II Dose-ranging Study of Pyronaridine/Artesunate in Adults Patients With Plasmodium Falciparum Malaria,"A Randomised, Multi-Centre, Phase II, Dose-Ranging Clinical Study to Assess the Safety and Efficacy of Fixed Dose, Orally Administered Pyronaridine and Artesunate (3:1) in Adult Patients With Acute Uncomplicated Plasmodium Falciparum Malaria",Completed,July 2005,April 2006,Actual,Actual,Medicines for Malaria Venture,"Sornchai Looareesuwan, MD",Principal Investigator,"Hospital of Tropical Diseases, Mahidol University, Bangkok, Thailand",Phase 2,Interventional,477,Actual,Plasmodium Falciparum Malaria,NA,All,15 Years,60 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Duong Socheat, MD",Principal Investigator,"National Centre for Parasitology,Entomology and Malaria Control, Phnom Penh,Cambodia",NA,Cure rate on Day 28,Safety,Shin Poong Pharmaceutical Co. Ltd.,Industry,NA,NA,NA,28 days,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The primary efficacy endpoint will be the cure rate on Day 28 defined as the proportion of patients with PCR-corrected Adequate Clinical and Parasitological Response (ACPR). PCR-corrected ACPR is defined as patients with clearance of asexual parasitaemia within 7 days of initiation of study treatment and without recrudescence within 28 days of initiation of study treatment.,"Emiliana Tjitra, PhD",Principal Investigator,"Bethesda Hospital, Tomohon, North Sulawasi, Indonesia","Kalifa Bojang, MD",Principal Investigator,"MRC Laboratories, Faraffeni, The Gambia",NA,NA,NA,NA,NA,"Patrice Piola, MD",Principal Investigator,"Epicentre, Mbarara, Uganda",Incidence of any adverse event or clinically significant abnormal laboratory parameters,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Oumar Gaye, MD",Principal Investigator,"Centre de santé Roi Baudouin, Guediawaye, Senegal",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TIP4,NCT01660854,Re-exposure of Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites,Re-exposure of Previously Immunized and Challenged Human Volunteers to a Heterologous Strain of P. Falciparum Sporozoites,Completed,July 2012,January 2013,Actual,Actual,Radboud University,"RW Sauerwein, PhD",Study Director,Radboud University,N/A,Interventional,21,Actual,"Malaria, Falciparum",NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Duration of prepatent period after challenge infection as measured by microscopy,NA,Leiden University Medical Center,Other,NA,NA,Leiden University Medical Centre,21 days after challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_09_001,NCT00928083,"A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects","A Phase I Study To Investigate The Safety, Tolerability And Pharmacokinetic Profile Of OZ439 In Healthy Male and Female Subjects",Completed,April 2009,December 2009,Actual,Actual,Medicines for Malaria Venture,"Joerg Moehrle, PhD",Study Director,Medicines for Malaria Venture,Phase 1,Interventional,63,Actual,Malaria Falciparum; Malaria Vivax; Healthy Volunteers,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Maria Gutierrez, MD",Principal Investigator,"Comprehensive Phase One Miramar, 3400 Enterprise Way, Miramar, FL 33025",NA,Adverse Events,NA,NA,NA,NA,NA,Comprehensive Phase One Miramar; 3400 Enterprise Way,From screening and at 10 (+/-2) days after last dose of study medication,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Safety/Tolerability evaluation took into account the recorded AE profile, clinical laboratory safety tests, vital signs, 12 lead and continuous (Parts A and C) ECG monitoring, audiometry/Brainstem Auditory Evoked Potentials (BAEP) parameters (Parts A and C) including any additional tests required to evaluate any safety concerns.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL0901,NCT00936767,Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia,Artemisone for the Treatment of Uncomplicated Falciparum Malaria in Western,Withdrawn,October 2010,October 2010,Anticipated,Anticipated,University of Oxford,"Duong Socheat, MD",Principal Investigator,Cambodia National Malaria Control Programme,Phase 2/Phase 3,Interventional,75,Anticipated,Uncomplicated Falciparum Malaria,NA,All,16 Years,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Presence of light microscopic assessed peripheral blood parasitaemia at 72 hours after start of antimalarial treatment.,NA,Mahidol University,Other,Medicines for Malaria Venture,Other,Pailin Hospital,72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-012-11,NCT01383109,Human Mass Balance Study of Pyronaridine,A Human Mass Balance Study of Pyronaridine Using Accelerator Mass Spectrometry,Completed,June 2011,December 2011,Actual,Actual,Medicines for Malaria Venture,"Isabelle Borghini Fuhrer, PhD",Study Director,Medicines for Malaria Venture,Phase 1,Interventional,6,Actual,Malaria,NA,Male,40 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Total radioactivity on blood, urine and faeces",Number of participants with adverse events as a measure of safety and tolerability,Shin Poong Pharmaceuticals,Industry,NA,NA,Covance Clinical Research Unit AG,87 days,87 days,Blood concentrations of Pyronaridine and its metabolites,NA,NA,"Metabolite profililing and identification of metabolites in blood, urine and faeces",NA,NA,NA,NA,NA,NA,"Total radioactivity in blood to determine Cmax, Tmax, Half-life, AUC0-t, AUC0-∞ Total radioactivity in urine and faeces at each time interval and cumulative radioactivity (mass balance)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Adverse events; Laboratory parameters; Vital signs, clinical signs and symptoms and physical examination, including changes from baseline; ECG evaluation",87 days,"Blood concentrations of Pyronaridine and its metabolites to determine Cmax, Tmax, Half-life, AUC0-t, AUC0-∞",87 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
11-I-N237,NCT01434381,Initial Study of Malaria Vaccine Pfs25-EPA/Alhydrogel(Registered Trademark),"Open Label Phase 1 Study in Malaria Naive Adults of the Safety and Immunogenicity of Pfs25-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum",Completed,August 2011,August 2013,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Patrick Duffy, MD",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,30,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of local and systemic adverse events,NA,NA,NA,NA,NA,Johns Hopkins University,All adverse events will be recorded though Day 28 after each vaccination. The frequency of systemic and local AEs will be summarized.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Subjects will be monitored for 30 minutes following each immunization. Subjects will return to the clinic on Days 3,7,14 and 28 following each vaccination for clinical assessments, and periodically thereafter until completion",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FTM1202,NCT01662700,Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand,An Open Label Randomized Comparison of Two Antimalarial Drugs Regimens in Patient With Plasmodium Vivax Malaria in Thailand,Unknown status,October 2012,December 2014,Anticipated,Anticipated,Mahidol University,NA,NA,NA,Phase 4,Interventional,120,Anticipated,Acute Uncomplicated Malaria With P.Vivax Infection,NA,All,18 Years,65 Years,No,Mahidol University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite Clearance Rate,Relapse rate of P. vivax,NA,NA,NA,NA,NA,7 days,3 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Parasite clearance rate as defined by the slope of the linear portion of the natural logarithm parasite clearance curve,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Incidence of relapse in P.vivax infection,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Eurartesim-2012,NCT01704508,Improving Anti-malarial Treatment Options in Guinea-Bissau - Part A,Efficacy and Safety of Artemether + Lumefantrine and Dihydroartemisinin + Piperaquine for the Treatment of Uncomplicated Malaria in Guinea-Bissau.,Unknown status,November 2012,January 2015,Anticipated,Anticipated,Bandim Health Project,NA,NA,NA,Phase 4,Interventional,346,Anticipated,Malaria,NA,All,6 Months,12 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adequate clinical and parasitological response rate,NA,Karolinska Institutet,Other,NA,NA,Bandim Health Project,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The data will be analysed using survival estimates of per protocol treatment failure rates but also intention to treat treatment failure rates.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1R01HD064416-01A1,NCT01743417,Computerized Cognitive Rehabilitation in Children After Severe Malaria,Computerized Cognitive Rehabilitation in Children After Severe Malaria,Completed,NA,"August 23, 2016",Actual,Actual,Makerere University,"Michael J Boivin, PhD",Principal Investigator,Michigan State University,N/A,Interventional,300,Actual,Malaria,NA,All,5 Years,12 Years,Accepts Healthy Volunteers,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Noeline Nakasujja, PhD",Principal Investigator,Makerere University,NA,Executive attention,NA,Michigan State University,Other,University of Michigan,Other,Makerere University,Measured at 12 months post-intervention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Executive attention will be measured by the Test of Variables of Attention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,April 2011,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NIMPE - ITM,NCT01775592,Plasmodium Falciparum Artemisinin Resistance Vietnam,"Monitoring the Efficacy of Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Traleng Commune, Central Vietnam",Completed,September 2012,January 2013,Actual,Actual,"National Institute of Malariology, Parasitology and Entomology, Vietnam","Annette Erhart, MD, PhD",Principal Investigator,ITM,Phase 4,Interventional,95,Actual,Plasmodium Falciparum,NA,All,2 Months,N/A,No,"National Institute of Malariology, Parasitology and Entomology, Vietnam",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite clearance time,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,Health Centre Tra Leng,Day 2-5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NHRCIRB098,NCT01459146,"Artemisinin-based Combination Therapy-Intermittent Preventive Treatment (ACT-IPT) Trial Among Schoolchildren in Kassena-Nankana, Ghana","The Impact of Intermittent Preventive Malaria Treatment With Artemisinin Combination Therapy (ACT) on Hemoglobin, Malaria, Schistosomiasis, and School Attention Among Primary Schoolchildren in the Kassena-Nankana Districts, Ghana",Unknown status,December 2010,November 2012,Anticipated,Anticipated,"Navrongo Health Research Centre, Ghana","Ernest C Opoku, MD, MPH",Principal Investigator,"Navrongo Health Research Centre, Ghana",Phase 4,Interventional,345,Anticipated,Malaria; Schistosomiasis; Helminthiasis; Anemia; Change in Sustained Attention,NA,All,6 Years,12 Years,No,"Navrongo Health Research Centre, Ghana",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Pascal Magnussen, MD",Principal Investigator,University of Copenhagen,NA,"Prevalence and density of malaria parasites, determined by microscopy, as a measure of efficacy",NA,DBL -Institute for Health Research and Development,Other,NA,NA,NHRC,Day 28 post intervention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Change from baseline of prevalence and density of malaria parasitemia 28 days post interventions,"Abraham V Hodgson, MD, MPH, PhD",Study Director,"Navrongo Health Research Centre, Ghana","Edmund L Browne, MD, MPH, PhD",Principal Investigator,University of Development Studies,NA,NA,NA,NA,NA,"Annette Olsen, PhD",Principal Investigator,University of Copenhagen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC049,NCT01465048,Optimisation of Controlled Human Malaria Infection Using Sporozoites Administered by Needle and Syringe,A Pilot Study to Optimise Controlled Human Malaria Infections Using Plasmodium Falciparum Sporozoites Administered by Needle and Syringe,Completed,October 2011,February 2013,Actual,Actual,University of Oxford,"Adrian VS Hill, DPhil FRCP",Principal Investigator,University of Oxford,N/A,Interventional,18,Actual,Malaria; Plasmodium Falciparum,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Participants Infected,NA,Sanaria Inc.,Industry,NA,NA,"Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford, Churchill Hospital",21 days post administration of PfSPZ Challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,To determine the infectivity rates of PfSPZ Challenge administered in various regimens by thick film microscopy and highly sensitive PCR for Plasmodium falciparum DNA.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV,NCT01783340,Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis,Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine or Chloroquine/Azithromycin Prophylaxis,Withdrawn,April 2013,April 2014,Anticipated,Anticipated,Radboud University,"RW Sauerwein, MD PhD",Study Director,Radboud University,Phase 1/Phase 2,Interventional,0,Actual,"Malaria, Falciparum",NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"LG Visser, MD PhD",Principal Investigator,Leiden University Medical Centre,NA,Volunteers falciparum positive by thick smear,NA,Leiden University Medical Center,Other,Medicines for Malaria Venture,Other,Leiden University Medical Centre,One year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Percentage of P. falciparum thick smear negative volunteers on day 21 (protection against challenge infection),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BCAPES,NCT01784315,Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria,PARASITIC CLEARANCE AND RECURRENCE RATES AMONG PATIENTS WITH VIVAX MALARIA ON CHLOROQUINE AND PRIMAQUINE THERAPY,Unknown status,March 2013,December 2014,Anticipated,Anticipated,"Ministry of Health, Bhutan",Dr.Yeshey Dorjey,Principal Investigator,"Ministry of Health, Bhutan",N/A,Observational [Patient Registry],50,Anticipated,Parasitemia,NA,All,1 Year,N/A,Accepts Healthy Volunteers,"Ministry of Health, Bhutan",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To measure recurrence rates among patients with vivax malarial infection put on standard dose of Chloroquine and Primaquine,NA,Asia Pacific Malaria Elimination Network,Other,Menzies School of Health Research,Other,NA,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Patients with P.vivax mono-infection will be recruited for the study with a follow up for a period of 12 months. These patients will be put on standard dose of Chloroquine(10mg/Kg on day 0 and 5mg/kg on day 1, and 2) and Primaquine(0.25mg/kg)and any recurrence rates will be measured.",NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  age above 12months

          -  infection with P.vivax

          -  presence of axillary temperature >37.5 or history of fever during the past 24h

          -  ability to swallow oral medication

          -  ability and willingness to comply with the study protocol for the duration of the
             study ie 12 months follow up

          -  informed consent from the patient/parent/guardian in the case of children

        Exclusion Criteria:

          -  signs and symptoms of severe or complicated malaria requiring parenteral treatment
             according to WHO criteria

          -  severe malnutrition

          -  febrile conditions caused by disease other than malaria or other known underlying
             chronic or severe diseases

          -  regular medication which interferes with antimalarial pharmacokinetics

          -  history of hypersensitivity reactions or contraindications to the medicine tested

          -  positive pregnancy test or breastfeeding

          -  unable to or unwilling to take contraceptives
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EPLS08-JBS,NCT01545115,Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal,Study of the Environmental Factors Modulating Children Immune Response in Northern Senegal,Completed,October 2008,February 2010,Actual,Actual,Biomedical Research Center EPLS,"Franck Remoué, PhD",Study Chair,Biomedical Research Center EPLS,N/A,Observational,410,Actual,Whooping Cough; Malaria; Malnutrition,NA,All,1 Year,10 Years,Accepts Healthy Volunteers,Biomedical Research Center EPLS,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Emmanuel Hermann, PhD A. Pr.",Study Director,Biomedical Research Center,NA,NA,NA,Institut Pasteur de Lille,Other,"Institut de Recherche pour le Developpement, Senegal",Other,Biomedical Research Center EPLS,NA,NA,NA,Institut de Recherche pour le Developpement,Other,NA,NA,NA,University of Lille Nord de France,Other,"Région Nord-Pas de Calais, France",Other,NA,"Jean Biram Sarr, PhD",Principal Investigator,Biomedical Research Center EPLS,"Lobna Gaayeb, VetMed",Principal Investigator,Biomedical Research Center EPLS,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Age: between 1 and 10 years

        Exclusion Criteria:

          -  Fever (body temperature superior to 38.5 °C)
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Centre d'Infection et d'Immunité de Lille,Other,"Centre National de la Recherche Scientifique, France",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Institut National de la Santé Et de la Recherche Médicale, France",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
11-0027,NCT01546389,Sanaria™ PfSPZ Challenge Vaccine,"A Phase I, Randomized Malaria Challenge Study of Intradermally-Administered Infectious (Replication-intact), Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) in Malaria-Naïve Adults",Completed,April 2012,April 2013,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,30,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of a positive malaria smear after the malaria challenge during a 56-day surveillance period and stratified by group.,The number of serious adverse events throughout the duration of the study.,NA,NA,NA,NA,University of Maryland School of Medicine - Center for Vaccine Development - Baltimore,"Days 0, 5-18, 20, 22, 24, 26, 28, 35, 42, and 56 .",Day 0 to1 year.,The number and severity of solicited systemic symptoms for 14 days following ID administration of PfSPZ.,NA,NA,The number and severity of injection site reactions within 14 days following ID administration of PfSPZ.,The number and severity of unsolicited adverse events after the malaria challenge during a 56-day surveillance period (day of challenge and 55 subsequent days) but not related to malaria event symptoms.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Within 14 days after PfSPZ administration.,NA,Within 14 days after PfSPZ administration.,NA,NA,NA,Days 0-56.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
04-059,NCT00347555,Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly,"Phase I, Double-Blinded, Placebo-Controlled Dosage-Escalation Study of the Safety and Immunogenicity of EBA-175 RII-NG Malaria Vaccine Administered Intramuscularly",Completed,May 2006,April 2008,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,80,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,40 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Frequency and severity of injection site and systemic adverse events (AEs).,NA,NA,NA,NA,NA,Baylor College of Medicine - Molecular Virology and Microbiology,Duration of study.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ICDDRB #2006-024,NCT00356005,Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh,Azithromycin Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Bangladesh: An Open Label Randomized Controlled Trial,Completed,August 2006,NA,NA,NA,Medical University of Vienna,"Rashidul Haque, MBBS,PhD",Principal Investigator,"International Centre for Diarrhoeal Disease Research, Bangladesh",Phase 2,Interventional,228,Actual,Uncomplicated Falciparum Malaria,NA,All,8 Years,65 Years,No,Medical University of Vienna,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Harald Noedl, MD, MCTM,PhD",Principal Investigator,Medical University of Vienna,NA,Primary clinical outcome is cure (ACPR as defined by WHO criteria) on Day 42.,NA,"International Centre for Diarrhoeal Disease Research, Bangladesh",Other,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,Sadar Hospital,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Epicentre-MSF-OCBA,NCT01567423,Efficacy Study of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Malaria,"Efficacy of Amodiaquine-Artesunate and Artemether-Lumefantrine for the Treatment of Uncomplicated Childhood Plasmodium Falciparum Malaria in Pweto, Democratic Republic of Congo, 2008",Completed,April 2008,April 2009,Actual,Actual,Epicentre,"Emmanuelle Espié, PhD",Principal Investigator,Epicentre,N/A,Interventional,301,Actual,"Malaria, Falciparum",NA,All,6 Months,59 Months,No,Epicentre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR-adjusted clinical and parasitological cure rate up to day 42 of the follow-up period determined in the per-protocol population,NA,"Medecins Sans Frontieres, Spain",Other,NA,NA,General reference hospital of Chamfubu,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Outcomes were classified according to 2009 WHO guidelines as adequate clinical and parasitological response, early treatment failure, late clinical failure, late parasitological failure or follow-up interrupted.
The per protocol population comprised only the patients who were followed throughout the protocol, defined follow-up period and in whom a clear treatment outcome can be determined.
The risk of failure for each treatment group was calculated as the proportion of patients classified as failure divided by the number of patients in the evaluable population.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACTIVE,NCT01603251,Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission,A Double Blind Randomized Controlled Trial of Artemether-Lumefantrine Alone and in Combination With Ivermectin to Reduce Post-Treatment Malaria Transmission,Completed,January 2013,April 2013,Actual,Actual,London School of Hygiene and Tropical Medicine,Teun Bousema,Principal Investigator,LSHTM,Phase 1/Phase 2,Interventional,120,Actual,Malaria,NA,All,15 Years,25 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety,NA,Radboud University,Other,"Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso",Other,Centre National de Recherche et de Formation sur le Paludisme,8 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The number of adverse events; number of participants with abnormal haemoglobin, biochemistry or full blood count values",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
﻿﻿OPP1002407,NCT01972321,ICCM of Common Childhood Diseases: Mozambique and Uganda,Integrated Community Case Management of Common Childhood Diseases: Mozambique and Uganda,Completed,April 2013,December 2015,Actual,Actual,Malaria Consortium,"Sylvia Meek, PhD",Study Director,Malaria Consortium,N/A,Interventional,2289,Actual,Malaria; Pneumonia; Diarrhoea,NA,All,N/A,N/A,Accepts Healthy Volunteers,Malaria Consortium,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Appropriate treatment of malaria, pneumonia and diarrhoea in children under five years of age",NA,London School of Hygiene and Tropical Medicine,Other,"University College, London",Other,NA,1 year,NA,NA,Karolinska Institutet,Other,NA,NA,NA,Makerere University,Other,NA,NA,"Proportion of children under five years of age with symptoms of malaria, pneumonia and diarrhoea who received appropriate treatment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCIRD-6393,NCT01810731,Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya,"A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity, and Efficacy of Standard Dose Quadrivalent Inactivated Influenza Vaccine, and Double Dose Quadrivalent Inactivated Influenza Vaccine in HIV-Infected and HIV-Uninfected Pregnant Women in a Malaria-Endemic Area of Rural Western Kenya",Withdrawn,April 2014,April 2014,Actual,Actual,Centers for Disease Control and Prevention,"Meredith L McMorrow, MD, MPH",Study Director,Centers for Disease Control and Prevention,Phase 2/Phase 3,Interventional,0,Actual,"Influenza, Human; HIV; Malaria; Tetanus; Polio",NA,Female,13 Years,49 Years,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Joshua A Mott, PhD",Principal Investigator,Centers for Disease Control and Prevention Kenya Country Office,NA,Proportion of women with an appropriate rise in Hemagglutination Inhibition (HI) titers,Proportion of infants born to standard dose (15 µg) QIV and double dose (30 µg) QIV recipients with HI titers greater than or equal to 40 in cord blood compared to same in controls.,NA,NA,NA,NA,Siaya District Hospital,Enrollment (Day 0) vs. Day 28 for each study arm,At delivery,Number of solicited and unsolicited adverse events post-vaccination by study arm,NA,NA,NA,NA,NA,NA,NA,NA,NA,The proportion of standard dose (15 µg) QIV and double dose (30 µg) QIV recipients with a fourfold rise in HI titers or HI titers ≥40 if baseline HI titer <10 compared to the same proportion in controls,"Nancy Otieno, MS",Principal Investigator,Kenya Medical Research Institute,"Marc-Alain Widdowson, VetMB, MSc",Study Director,Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,NA,NA,NA,"During follow-up period, approx. 9 months",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EC5550,NCT00941785,Dihydroartemisinin (DHA)-Piperaquine for IPT to Prevent Malaria in Children in Burkina Faso,"Randomized Trial of the Efficacy, Safety, Tolerability and Pharmacokinetics of Dihydroartemisinin-piperaquine for Seasonal IPT to Prevent Malaria in Children Under 5 Years",Completed,July 2009,December 2009,Actual,Actual,London School of Hygiene and Tropical Medicine,"Jean-Bosco Ouédraogo, MD",Study Director,"IRSS, Direction Régionale,BP 545 Bobo-Dioulasso (Burkina Faso)",Phase 2/Phase 3,Interventional,1500,Actual,Malaria,NA,All,3 Months,59 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Paul JM Milligan, PhD",Study Chair,London School of Hygiene and Tropical Medicine,NA,Efficacy against clinical malaria,Incidence of adverse events,BEIJING HOLLEY-COTEC PHARMACEUTICALS CO. LTD.,Other,NA,NA,IRSS,August to December 2009,Within 7 days of each treatment round and within 1 month of treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Issaka Zongo, MD",Principal Investigator,"IRSS, Burkina Faso and LSHTM, UK",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
T26/181/33 A00017,NCT00959517,Trial of Artesunate Combination Therapy in Pakistan,"Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan",Completed,July 2001,August 2006,Actual,Actual,London School of Hygiene and Tropical Medicine,"Mark W Rowland, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 2,Interventional,588,Actual,Uncomplicated Falciparum Malaria,NA,All,2 Years,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasitological outcome after 28 days follow-up,NA,HealthNet TPO,Other,NA,NA,HealthNet International,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
vivax,NCT01625871,Artemether/Lumefantrine and Vivax Malaria,Artemether/Lumefantrine in the Treatment of Plasmodium Vivax Malaria in Eastern Sudan,Completed,September 2011,September 2012,Actual,Actual,University of Khartoum,NA,NA,NA,Phase 3,Interventional,38,Actual,Vivax Malaria,NA,All,5 Years,80 Years,No,University of Khartoum,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The cure rate,NA,"University of Kassala, Sudan",Other,NA,NA,Kassala,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The proportion of the cure patients,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
OPP1032354,NCT01663831,Repellents as Added Control Measure to Long Lasting Insecticidal Nets,Repellents as Added Control Measure to Long Lasting Insecticidal Nets to Target the Residual Transmission in Southeast Asia: a Step Forwards to Malaria Elimination,Completed,May 2012,December 2013,Actual,Actual,"Institute of Tropical Medicine, Belgium","Marc Coosemans, Professor",Principal Investigator,Institute of Tropical Medicine Antwerp,N/A,Interventional,40000,Actual,Malaria,NA,All,2 Years,N/A,Accepts Healthy Volunteers,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change from baseline in malaria prevalence at 6 months,NA,NCHADS - Ministry of Health of Cambodia,Other,Institut Pasteur,Industry,NA,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria prevalence (PCR detection) will be measured in both study arms at the start and end of the malaria season for 2 consecutive years.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Banlung,NA,NA,NA,NA,NA,NA,NA
A0661155,NCT00367653,Azithromycin Plus Chloroquine Versus Mefloquine In the Treatment of Uncomplicated P. Falciparum Malaria.,"A Phase 3, Randomized, Open-Label, Comparative Trial Of Azithromycin Plus Chloroquine Versus Mefloquine For The Treatment Of Uncomplicated Plasmodium Falciparum Malaria In Africa",Completed,November 2006,September 2007,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 3,Interventional,397,Actual,Malaria,NA,All,18 Years,N/A,No,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"The primary objective is to confirm the hypothesis that azithromycin plus chloroquine is noninferior to mefloquine for the treatment of symptomatic, uncomplicated malaria due to P. falciparum in Africa.","The primary endpoint of the study will be the asexual P. falciparum Parasite Clearance Rates (adjusted for molecular testing determining recrudescence, true failures, from reinfection, true cures) at Day 28 in the Parasitologic Per Protocol population.",NA,NA,NA,NA,NA,duration of trial,duration of trial,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0050,NCT00371189,Adenovirus Vaccine for Malaria,"A Phase I Randomized, Controlled, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Healthy Adults 18 to 45 Years of Age",Completed,January 2007,June 2014,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,75,Actual,Plasmodium Falciparum Infection,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Frequency and severity of local, systemic, and safety laboratory adverse events.",NA,NA,NA,NA,NA,NA,Enrollment through to Day 208,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2013-CQ,NCT01814423,Pharmacokinetic Study of Multi-dose Chloroquine,Pharmacokinetic Study of Multi-dose Chloroquine,Completed,April 2013,March 2014,Actual,Actual,Bandim Health Project,"Poul-Erik Kofoed, Ph.d",Principal Investigator,Bandim Health Project,Phase 4,Interventional,30,Actual,Malaria,NA,All,2 Years,9 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Chloroquine serum concentration,NA,NA,NA,NA,NA,Projecto de Saúde de Bandim,"Twice daily during treatment, on day 1 an additional 8 measurements.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Filterpaper blood samples will be collected in the morning and evening on the days of treatment. On day 1 hourly during daytime.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
RDT-ClearTZ1,NCT01843764,Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Malaria Infections,Efficacy of Plasmodium Falciparum Specific Rapid Diagnostic Tests for Assessment of Initial Clearance and Detection of Recurrent Infections After Antimalarial Treatment,Completed,June 2009,June 2012,Actual,Actual,Anders Björkman,"Anders Björkman, Professor",Study Director,Karolinska Institutet,N/A,Observational,53,Actual,Plasmodium Falciparum Malaria,NA,All,6 Months,59 Months,No,Anders Björkman,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Clearance time with five diagnostic tests,Detection of recurrent infection with HRP2 and LDH-based Rapid diagnostic tests during follow up,Muhimbili University of Health and Allied Sciences,Other,NA,NA,NA,2009 June to 2012 May (up to day 42),2009 June to 2012 May (up to day 42),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Children were followed up on 9 occasions until day 42. Mean and median time until clearance after initiation of arthemeter-lumefantrine treatment was measured for HRP2 based Rapid diagnostic tests, LDH-based Rapid diagnostic tests, Giemsa and Acridine Orange stained microscopy and real-time PCR.",NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  children between 6-59 months

          -  fever (≤37.5 C) or history of fever during the preceding 24 hours

          -  confirmed P.falciparum monoinfection

          -  uncomplicated malaria

          -  parasite density between 2000-250.000/µL

          -  willing/able to comply with the 42 day follow up

          -  informed concent from patient/guardian

        Exclusion Criteria:

          -  children with history of antimalaria drug intake within the last two weeks

          -  symptoms / signs of severe disease
      ",NA,NA,NA,Ability to detect recurrent malaria infection with the HRP2 and LDH-Rapid diagnostic tests during the 42 days of follow up was studied through comparing them with three other diagnostic tests.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IRD-Sidaction-01,NCT00970879,Prevention of Pregnancy-associated Malaria in HIV-infected Women: Cotrimoxazole Prophylaxis Versus Mefloquine,Prevention of Pregnancy-associated Malaria in HIV-infected Women : Randomised Controlled Trial Testing Cotrimoxazole Prophylaxis Versus Intermittent Preventive Treatment With Mefloquine,Completed,December 2009,December 2012,Actual,Actual,Institut de Recherche pour le Developpement,"Marcel D Zannou, Professor",Principal Investigator,"Cotonou University Hospital & Faculté des Sciences de la Santé, Benin",Phase 3,Interventional,430,Actual,Malaria in Pregnancy; HIV Infections,NA,Female,18 Years,N/A,No,Institut de Recherche pour le Developpement,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Pierre-Marie Girard, Professor",Study Chair,"Saint Antoine Hospital, Assistance Publique-Hôpitaux se Paris",NA,proportion of placental malaria (presence of parasites in the placental blood smear at delivery),NA,Sidaction,Other,Saint Antoine University Hospital,Other,NA,delivery,NA,NA,"National University Hospital, Cotonou",Other,NA,NA,NA,Université d'Abomey-Calavi,Other,"Ministry of Health, Benin",Other,NA,"Michel Cot, MD, PHD",Study Director,Institut de Recherche pour le Developpement,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1583,NCT00984256,Weekly Dosing of Malarone ® for Prevention of Malaria,Pilot Evaluation of Weekly Dosing of Atovaquone/Proguanil (Malarone ®) for Malaria Chemoprophylaxis,Completed,September 2009,April 2010,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Gregory Deye, MD",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 2,Interventional,35,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Prophylactic Efficacy of 3 Different Doses of Atovaquone/Proguanil (Malarone@) Given 1 Week Before Infectious Sporozoite Challenge Using the P. Falciparum Human Challenge Model.,NA,NA,NA,NA,NA,Walter Reed Army Institute of Research,Days 6-20,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Number of participants with prophylactic efficacy was determined by the absence of cases of malaria parasitemia, defined as microscopically detectable parasitemia by Giemsa-stained thick smears, in those receiving any dose of Malarone as compared to the control (no treatment) group",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC046,NCT01666925,Efficacy of Malaria Vaccines in Kenyan Adults,Efficacy Study of ChAd63MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection.,Completed,March 2012,August 2012,Actual,Actual,University of Oxford,NA,NA,NA,Phase 2,Interventional,120,Actual,Malaria,NA,Male,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Vaccine Efficacy,NA,European and Developing Countries Clinical Trials Partnership (EDCTP),Other,NA,NA,"KEMRI/Wellcome Trust Programme, Centre for Geographic Medicine Research - Coast",18 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The first episode of P.falciparum infection positive by PCR, for P.falciparum.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC048,NCT01669512,Adjuvanting Viral Vectored Malaria Vaccines With Matrix M,Safety and Immunogenicity of ChAd63 ME-TRAP / MVA ME-TRAP Heterologous Prime Boost Malaria Vaccination Adjuvanted With Matrix M™,Completed,August 2012,December 2014,Actual,Actual,University of Oxford,"Adrian Hill, MD",Principal Investigator,University of Oxford,Phase 1,Interventional,23,Actual,Malaria; Matrix M,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To assess the safety of ChAd63 ME-TRAP / MVA ME-TRAP heterologous prime boost vaccination adjuvanted with Matrix M™,NA,NA,NA,NA,NA,Centre for Clinical Vaccinology and Tropical Medicine,24 weeks from first vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Analysis of all solicited and unsolicited local and general vaccine-linked adverse events (AEs) occurring in Low Dose Matrix M™ and Standard Dose Matrix M™ Group volunteers.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ARTEKINPERU,NCT00373607,Efficacy and Safety of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Malaria in Peru,"Phase 3a: Efficacy, Safety, and Tolerability of Dihydroartemisinin/Piperaquine (Artekin®) for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Peruvian Amazon Region",Completed,July 2003,July 2005,Actual,Actual,"Institute of Tropical Medicine, Belgium","Umberto D'Alessandro, MD,MSc, PHD",Study Director,"Institute of Tropical Medicine, Antwerp",Phase 3,Interventional,522,Actual,Malaria,NA,All,5 Years,60 Years,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adequate Clinical and parasitological response,NA,NA,NA,NA,NA,NA,Day 63,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
05-0124,NCT00393757,Malaria Transmission and Immunity in Highland Kenya,Malaria Transmission and Immunity in Highland Kenya,Unknown status,October 2006,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Plasmodium Falciparum Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",January 2010,NA,NA,NA,6400,NA,NA,NA,NA,NA,NA,Kenya Medical Research Institute,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
117014,NCT01857869,"Efficacy, Safety and Immunogenicity Study of GlaxoSmithKline(GSK) Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults","Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine 257049 in the Sporozoite Challenge Model in Healthy Malaria-naïve Adults",Completed,May 2013,December 2014,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,64,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of Plasmodium falciparum parasitemia in the delayed fractional dose group,"Occurrence of P. falciparum parasitemia in the 0, 1, 2-month group",Walter Reed Army Institute of Research (WRAIR),U.S. Fed,The PATH Malaria Vaccine Initiative (MVI),Other,GSK Investigational Site,28 days post-challenge (Study Day 245),28 days post-challenge (Study Day 245),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-017-12,NCT01868438,"Relative Bioavailability of Pyronaridine-artesunate in Tablet and Granule Formulations, in Healthy Volunteers","Phase 1, Open-label, Cross-over Study to Investigate the Relative Bioavailability of Pyramax (Pyronaridine-artesunate) in Tablet and Granule Formulations, in Healthy Volunteers",Completed,May 2013,January 2014,Actual,Actual,Medicines for Malaria Venture,NA,NA,NA,Phase 1,Interventional,60,Actual,Malaria,NA,All,20 Years,45 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Area Under the concentration-time Curve from hour 0 to the last sampling point (AUC 0-t) for pyronaridine and dihydroartemisinin (DHA),NA,Shin Poong Pharmaceutical Co. Ltd.,Industry,NA,NA,"Dept. of Clinical Pharmacology and Therapeutics, Asan Medical Center, Univ. of Ulsan",Pyronaridine PK to Day 43; DHA PK to 24 hours post dose.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Area Under the concentration-time Curve from hour 0 to the last sampling point (AUC 0-t) for pyronaridine and dihydroartemisinin (DHA),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DRI10382,NCT00988507,Dose Ranging Study of Ferroquine With Artesunate in African Adults and Children With Uncomplicated Plasmodium Falciparum Malaria,"Parallel Group, Double-blind, Randomized Study Assessing the Efficacy, Safety and Pharmacokinetic Profiles of Ferroquine Associated With Artesunate and a Single-blind Dose Level of Ferroquine Alone in a 3-day Treatment of Uncomplicated Malaria Due to Plasmodium Falciparum in an Immune Symptomatic African Adult and Pediatric Population.",Terminated,October 2009,November 2010,Actual,Actual,Sanofi,Clinical Sciences & Operations,Study Director,Sanofi,Phase 2,Interventional,440,Anticipated,Plasmodium Falciparum Infection,NA,All,N/A,N/A,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Recrudescent infections at D28 in the groups with ferroquine associated with artesunate. Recrudescence is defined as the recurrence of the same original strain of Plasmodium falciparum regardless of clinical symptoms,NA,NA,NA,NA,NA,NA,4 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Sanaria.2008.001,NCT01001650,Clinical Trial of the PfSPZ Vaccine,A Phase 1/2a Trial of the PfSPZ Vaccine Administered Subcutaneously or Intradermally to Malaria-Naïve Adult Volunteers,Completed,April 2009,September 2010,Actual,Actual,Sanaria Inc.,"Judith E Epstein, M.D.",Principal Investigator,Naval Medical Research Center,Phase 1,Interventional,80,Actual,Plasmodium Falciparum,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"To determine the safety and tolerability of a non-replicating, metabolically active Plasmodium falciparum sporozoite (PfSPZ) vaccine in malaria-naïve healthy volunteers following multiple-dose subcutaneous (SC) or intradermal (ID) administration.",NA,The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,NA,October 2010,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SRP-KY-DK-06,NCT00414479,Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment,Assessment of Anaemia Attributable to Schistosomiasis in School Children in Kenya: Mechanisms and Effect of Treatment,Completed,July 2006,January 2010,Actual,Actual,DBL -Institute for Health Research and Development,"Diana Karanja, DR",Principal Investigator,Kenya Medical Research Institute,N/A,Observational,1500,Actual,Anaemia; Schistosomiasis Infection; Malaria; Iron Deficiency,hemoglobin level,All,9 Years,12 Years,No,DBL -Institute for Health Research and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Kenya Medical Research Institute,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  school children between 9 to 12 year
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCID-5022,NCT00425763,Efficacy of Amodiaquine-artesunate in Children Aged 6-59 Months With Uncomplicated P. Falciparum Malaria,"Efficacy of Amodiaquine-artesunate in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children at an IPTi Site in Rural Western Kenya",Completed,May 2007,August 2007,Actual,Actual,Centers for Disease Control and Prevention,"Meghna Desai, PhD",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,110,Actual,Malaria,"28 Day Adequate Clinical and Parasitological Response, Early Treatment Failure, Late Clinical Failure, Late Parasitological",All,6 Months,59 Months,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Mary Hamel, MD",Principal Investigator,Centers for Disease Control and Prevention,NA,NA,NA,London School of Hygiene and Tropical Medicine,Other,Kenya Medical Research Institute,Other,Bondo District Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Patrick Kachur, MD, MPH",Study Chair,Centers for Disease Control and Prevention,"Robert Newman, MD, MPH",Study Chair,Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,"Larry Slutsker, MD, MPH",Study Chair,Centers for Disease Control and Prevention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Julie Thwing, MD",Study Director,Centers for Disease Control and Prevention,Christopher O Odero,Study Director,CDC/KEMRI,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVP54,NCT01697852,The Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) for Malaria Prevention,"Cluster Randomised Trial to Compare Effectiveness of the Combined Use of Indoor Residual Spraying (IRS) and Long-lasting Insecticidal Nets (LLINs) to LLINs Alone for Malaria Prevention in Muleba District, Kagera Region, Tanzania",Unknown status,January 2011,December 2012,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Mark Rowland, PHD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 4,Interventional,22300,Anticipated,Malaria,NA,All,6 Months,14 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Immo Kleinschmidt, PHD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,Prevalence of malarial infection in children 6 months to 10 years,NA,"National Institute for Medical Research, Tanzania",Other,"Kilimanjaro Christian Medical Centre, Tanzania",Other,PAMVERC office,9 months post randomisation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SPK,NCT01707199,SPK Study in Afghanistan,Efficacy and Safety of Artesunate+Sulphadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Center Asadabad in Kunar Province of Afghanistan,Unknown status,October 2012,December 2013,Anticipated,Anticipated,University of Oxford,"Ghulam Rahim Awab, MD",Principal Investigator,Research Dept. Ministry of Public Health (MoPH) Afghanistan,N/A,Interventional,100,Anticipated,Uncomplicated P. Falciparum Malaria,NA,All,4 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adequate clinical and parasitological response (ACPR),NA,World Health Organization,Other,NA,NA,"Narang, Asadabad, Watapoor district health centres",42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,WHO defined ACPR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MTC Belu,NCT01878357,Surveillance and Treatment With Dihydroartemisinin-piperaquine Plus Primaquine,"Impact of Mass Screening and Selective Treatment With Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in High Endemic Area, Belu Regency, Nusa Tenggara Timur Province, Indonesia: a Randomized Cluster Trial",Completed,June 2013,November 2013,Actual,Actual,Indonesia University,NA,NA,NA,Phase 4,Interventional,1488,Actual,Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,Indonesia University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria incidence,NA,Walter and Eliza Hall Institute of Medical Research,Other,NA,NA,Kecamatan Wewiku,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria incidence in children at the elementary schools (all arms),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KEMRI_CT_2013/0017,NCT01899820,Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya,Evaluation of the Efficacy of Artemisinin Combination Therapy in Kenya,Unknown status,April 2013,July 2015,Anticipated,Anticipated,Sabah Ahmed Omar,"Sabah A Omar, PhD",Principal Investigator,KEMRI CGMR-C,Phase 3,Interventional,2100,Anticipated,Malaria,NA,All,6 Months,10 Years,No,Sabah Ahmed Omar,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The primary endpoint will be the PCR-corrected and parasitological response (PCR corrected ACPR) at days 28 and 42. Change in this outcome measure will be assessed.,NA,World Bank,Other,Kenya Medical Research Institute,Other,NA,Day 28 and day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ACPR is defined as the absence of parasitaemia on day 42 irrespective of the temperature without previously meeting any of the criteria of early treatment failure or late clinical or parasitological failure.
Patients with late asexual parasite reappearance will be considered ACPR if the CR analyses shows a new infection rather than a recrudescence (through PCR genotyping).
The total treatment failure is defined according to the WHO criteria as the sum of early and late treatment failures.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACT2010,NCT01002066,Effectiveness Of Rapid Diagnostic Tests in the New Context of Low Malaria Endemicity in Zanzibar,Rapid Malaria Diagnostic Tests in Fever Patients Attending Primary Health Care Facilities in Zanzibar - Effectiveness as Diagnostic and Surveillance Tool in the New Context of Low Malaria Endemicity,Completed,May 2010,February 2011,Actual,Actual,Karolinska University Hospital,"Anders Björkman, Professor",Principal Investigator,Karolinska University Hopsital,N/A,Observational,3890,Actual,Fever; Malaria,NA,All,2 Months,N/A,No,Karolinska University Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Andreas Mårtensson, Ph.D, M.D.",Principal Investigator,Karolinska University Hospital,NA,Adherence to Rapid diagnostic tests (RDT) result,NA,Zanzibar Malaria Control Programme,Other,World Health Organization,Other,Primary health care centers (PHCC)s and Primary health care units (PHCUs),Five months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Kristina Elfving, M.D.",Principal Investigator,Karolinska University Hospital,"Mwinyi Msellem, MSc",Principal Investigator,Zanzibar Malaria Control Programme,NA,NA,Adherence to Rapid diagnostic tests (RDT) result,Non-Probability Sample,"
        Inclusion Criteria:

          -  All patients >2 months of age with confirmed fever, with a measured axillary
             temperature of ≥37.5˚C, or history of fever within the preceding 24 hours

          -  Presenting to the health facility from 8.00 to 16.00 Monday to Friday.

          -  Informed consent

        Exclusion Criteria:

          -  Previous enrolment in the study within the last 28 days.

          -  Severe disease that requires immediate referral as defined by the clinician
      ","Delér Shakely, M.D.",Principal Investigator,Karolinska University Hopsital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
JP015,NCT01002183,Fosmidomycin With Clindamycin or With Clindamycin Plus Artesunate,Evaluation of Fosmidomycin and Clindamycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria,Withdrawn,NA,NA,NA,NA,Jomaa Pharma GmbH,NA,NA,NA,Phase 2,Interventional,40,Anticipated,Malaria,NA,All,15 Years,55 Years,No,Jomaa Pharma GmbH,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Efficacy of fosmidomycin and clindamycin/artesunate when co-administered to adults with acute uncomplicated P.f. malaria.,NA,Mahidol University,Other,Thammasat University,Other,Mahidol University,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WHO_IR_SUDAN,NCT01713517,Impact of Insecticide Resistance on Vector Control,Impact of Insecticide Resistance in Anopheles Arabiensis on the Effectiveness of Malaria Vector Control in Sudan,Unknown status,April 2011,October 2014,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Immo Kleinschmidt, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 4,Interventional,28000,Anticipated,"Malaria, Falciparum",NA,All,6 Months,10 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Martin J Donnelly, PhD",Principal Investigator,Liverpool School of Tropical Medicine,NA,Malaria Incidence,NA,"Federal Ministry of Health, Sudan",Other,World Health Organization,Other,NA,3 years,NA,NA,Liverpool School of Tropical Medicine,Other,NA,NA,NA,NA,NA,NA,NA,Infection with malarial parasites determined by rapid diagnostic tests/microscopy in cohort members who report or have fever (>37.5C),"Khalid A Elmardi, MD",Study Director,"Federal Ministry of Health, Sudan","Hmooda T Kafy, MSc",Principal Investigator,"Federal Ministry of Health, Sudan",NA,NA,NA,NA,NA,"Bashir A Ismail, MSc",Principal Investigator,"Federal Ministry of Health, Sudan",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Mohamed Ahmed A Mohamed, MSc",Principal Investigator,"Federal Ministry of Health, Sudan",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC052,NCT01739036,"A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1","A Phase I/IIa Sporozoite Challenge Study to Assess the Efficacy of Candidate Combination Malaria Vaccine Approaches Using the ChAd63 and MVA Vectors Encoding the Antigens ME-TRAP, CS and AMA1",Completed,January 2013,October 2013,Actual,Actual,University of Oxford,"Adrian V S Hill, MD",Principal Investigator,University of Oxford,Phase 1/Phase 2,Interventional,48,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The effectiveness of ChAd63-MVA ME-TRAP combined with ChAd63-CS and ChAd63-MVA AMA1 at preventing malaria infection.,NA,NA,NA,NA,NA,NA,Up to 30 days post challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To assess the efficacy of each of two combinations of heterologous prime-boost immunisation strategies:
ChAd63-MVA ME-TRAP combined with ChAd63-MVA CS
ChAd63-MVA ME-TRAP combined with ChAd63-MVA CS and ChAd63-MVA AMA1 Kaplan-Meier analysis of time to blood stage infection in vaccinees compared to unvaccinated control volunteers.
Comparison of the number of individuals who develop malaria infection between vaccinees and unvaccinated control volunteers.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
200187,NCT01954264,Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa,Epidemiology Study of Malariometric Determinants in Selected Post-Approval Programme Study Sites in Sub-Saharan Western Africa,Completed,October 2013,November 2013,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,N/A,Interventional,1680,Actual,Malaria,NA,All,6 Months,9 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of P. falciparum parasitaemia,Occurrence of malaria control interventions,NA,NA,NA,NA,NA,At Epoch 1 (Survey visit) (approximately 35 days),At Epoch 1 (Survey visit) (approximately 35 days),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NMRR-13-18375,NCT02001012,P. Knowlesi Trial of Artemether-lumefantrine vs Chloroquine,"Artemether-lumefantrine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi Malaria: a Randomized Open Label Trial in Sabah, Malaysia (CAN KNOW Trial)",Completed,January 2014,March 2015,Actual,Actual,Menzies School of Health Research,"Jayaram Menon, MBBS",Study Director,Sabah Ministry of Health,Phase 3,Interventional,123,Actual,Uncomplicated Knowlesi Malaria,NA,All,1 Year,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Matthew Grigg, MBBS",Study Director,Menzies School of Health Research,NA,Parasite clearance,NA,"Ministry of Health, Malaysia",Other,NA,NA,NA,24 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The primary endpoint is the therapeutic efficacy of artemether-lumefantrine versus chloroquine, as defined by the assessment of microscopic P. knowlesi parasite clearance 24 hours after initiation of treatment.","Prabakaran Dhanaraj, MBBS",Study Director,Sabah Ministry of Health,"Tsin Yeo, MBBS",Study Director,Menzies School of Health Research,NA,NA,NA,NA,NA,"Bridget Barber, MBBS",Study Director,Menzies School of Health Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Nicholas Anstey, MBBS",Study Director,Menzies School of Health Research,"Ric Price, MBBS",Study Director,Menzies School of Health Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TIP1,NCT01002833,Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection,Comparison of Three Plasmodium Falciparum Isolates in an Experimental Human Malaria Infection,Completed,April 2010,November 2010,Actual,Actual,Radboud University,NA,NA,NA,N/A,Interventional,15,Anticipated,Plasmodium Falciparum; Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"A significant difference in kinetics of parasitemia between groups A, B and C",NA,Leiden University Medical Center,Other,NA,NA,Leiden University Medical Center,35 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NH-HNI01,NCT01019408,Extended-dose Chloroquine (ECQ) for Resistant Falciparum Malaria Among Afghan Refugees in Pakistan,Clinical Trial of Extended-dose Chloroquine Versus Standard Chloroquine Treatment for Resistant Falciparum Malaria Among Afghan Refugees in NWFP Pakistan,Completed,November 1993,January 1995,Actual,Actual,London School of Hygiene and Tropical Medicine,"Mark Rowland, PhD",Principal Investigator,LSHTM,Phase 4,Interventional,163,Actual,"Malaria, Falciparum",NA,All,6 Months,60 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,therapeutic and parasitological cure with no recrudescence,NA,European Union,Other,United Nations High Commissioner for Refugees,Other,NA,60 days,NA,NA,World Health Organization,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC054,NCT02044198,"A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria","A Phase I/IIa Study of the Safety, Immunogenicity and Efficacy of FMP2.1/AS01B, an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria",Completed,March 2014,December 2014,Actual,Actual,University of Oxford,Simon J Draper,Principal Investigator,University of Oxford,Phase 1/Phase 2,Interventional,30,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,Saul N Faust,Principal Investigator,University of Southampton,NA,PCR-derived parasite multiplication rate (PMR),NA,The PATH Malaria Vaccine Initiative (MVI),Other,"National Institute for Health Research, United Kingdom",Other,NA,From the day before CHMI until 23 days after the challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PCR-derived parasite multiplication rate (PMR) will be the primary study endpoint, and comparison of the endpoint between the two study groups will constitute the primary analysis for efficacy.",Graham S Cooke,Principal Investigator,Imperial College London,NA,NA,NA,NA,NA,PCR-derived parasite multiplication rate (PMR),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
07200734,NCT02143934,Effect of Liver and Blood-stage Treatment on Subsequent Plasmodium Reinfection and Morbidity,"Host and Parasites Factors Contributing to Risk of Plasmodium Re-infection and Morbidity in Elementary School Children in Maprik, East Sepik Province",Completed,August 2009,May 2014,Actual,Actual,Papua New Guinea Institute of Medical Research,"Ivo Mueller, PhD",Principal Investigator,Walter and Eliza Hall Institute of Medical Research; Centre de Recerca en Salut Internacional de Barcelona (CRESIB),Phase 4,Interventional,524,Actual,Plasmodium Vivax Infection; Plasmodium Vivax Clinical Episode; Plasmodium Falciparum Infection; Plasmodium Falciparum Clinical Episode,NA,All,5 Years,10 Years,Accepts Healthy Volunteers,Papua New Guinea Institute of Medical Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Inoni Betuela, MD PhD",Principal Investigator,PNG Institute of Medical Research,NA,Time to first or only Plasmodium vivax infection by light microscopy and PCR,Time to first or only clinical P. vivax episode,Walter and Eliza Hall Institute of Medical Research,Other,Swiss Tropical & Public Health Institute,Other,PNG Institute of Medical Research,8 months post-baseline,8 months post-baseline,NA,Barcelona Centre for International Health Research,Other,NA,NA,NA,NA,NA,NA,NA,NA,"Louis Schofield, PhD",Principal Investigator,Walter and Eliza Hall Institute of Medical Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MEG001,NCT01743820,Phase2a Primaquine Dose Escalation Study,"Phase 2a Dose Escalation Study of the Efficacy, Safety, and Pharmacokinetics of Low Dose Primaquine for Gametocytocidal Activity Against P. Falciparum in Sub-Saharan Africa and South East Asia",Completed,September 2013,December 2014,Actual,Actual,"University of California, San Francisco","Roland Gosling, MD, PhD",Principal Investigator,"University of California, San Francisco",Phase 2,Interventional,81,Actual,Malaria,NA,Male,18 Years,50 Years,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Alassane Dicko, MD",Principal Investigator,Malaria Research and Training Centre,NA,mosquito infectivity assessed through membrane feeding,NA,"Malaria Research and Training Center, Bamako, Mali",Other,"Shoklo Malaria Research, Tak, Thailand",Other,Malaria Research and Training Centre,7 days,NA,NA,Mahidol Oxford Tropical Medicine Research Unit,Other,NA,NA,NA,Bill and Melinda Gates Foundation,Other,Wellcome Trust,Other,"Baseline, Days 1, 2, 7","François Nosten, MD",Principal Investigator,Shoklo Malaria Research Unit,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2012-03,NCT01746199,Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum,Comparative Study of Efficacy of Two Antifolates Prophylactic Strategies Against Malaria in HIV Positive Pregnant Women (MACOMBA Study),Unknown status,December 2013,NA,NA,NA,Institut Pasteur,Muriel Vray,Study Director,"Unité d'épidémiologie des maladies émergentes, Institut Pasteur Paris, France",Phase 3,Interventional,300,Anticipated,Malaria in Pregnancy; HIV Infection,NA,Female,18 Years,N/A,No,Institut Pasteur,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Alexandre Manirakiza, MD",Principal Investigator,"Unité d'Epidémiologie, Institut Pasteur de Bangui, Central African Republic",NA,placental parasitaemia,NA,Institut Pasteur de Bangui,Other,NA,NA,NA,at parturition,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,microscopic observation and confirmation by Polymerase Chain Reaction (PCR),Mirdad Kazanji,Study Chair,"Director of the Institut Pasteur de Bangui, Central African Republic",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
artesunate and malaria,NCT01805232,Intravenous Artesunate and Malaria,"Intravenous Artesunate Versus Quinine in Severe Malaria at Kassla, Sudan",Unknown status,March 2013,July 2013,Anticipated,Anticipated,University of Khartoum,NA,NA,NA,Phase 4,Interventional,80,Anticipated,Malaria,NA,All,1 Year,80 Years,No,University of Khartoum,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,clearance of the parasite and fever,NA,"University of Kassala, Sudan",Other,Kassala,Other,Kassala,3 days,NA,NA,Sudan,Other,NA,NA,NA,NA,NA,NA,NA,To compare the parasite clearance time and fever clearance time between the two groups,NA,NA,NA,NA,NA,NA,NA,NA,clearance of the parasite and fever,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Swiss TPH P 001-01-12,NCT01828333,Malaria Treatment With Injectable ArteSunate,Treatment of Severe Malaria - An Operational Comparative Study Between Quinine and Artesunate for the Treatment of Severe Malaria in Hospitals and Health Centers of Kinshasa and Lower Congo,Completed,April 2013,June 2013,Actual,Actual,Swiss Tropical & Public Health Institute,"Christian Burri, PhD",Principal Investigator,Swiss Tropical & Public Health Institute,N/A,Observational,350,Actual,Severe Malaria,NA,All,2 Months,N/A,No,Swiss Tropical & Public Health Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Antoinette Tshefu, MD",Principal Investigator,Kinshasa School of Public Health,NA,Duration of hospitalization (from registration to discharge),NA,Medicines for Malaria Venture,Other,NA,NA,NA,3-7 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

        Patients (= 2 months old) admitted to one of the study sites and treated for severe malaria
        with IV quinine in the first part of the study and patients treated with IV/IM artesunate
        in the second part of the study will be included. Patients need to fulfill the WHO criteria
        for severe malaria and must be unable to take oral treatment (WHO, 2010, WHO, 2011). In
        addition all participants need to give their informed consent

        Conditions: Positive rapid diagnostic test (RDT) for Plasmodium falciparum HRP2 or lactate
        dehydrogenase and/or a positive blood slide (thick smear). Patient will be considered to be
        positive if one of the two tests is positive. In case of negative result of both tests, the
        patient will not be enrolled in the study and will receive care according to the usual
        routine practice in the hospital/health center in question.

        Definition of severe malaria according to WHO (WHO, 2010): In a patient with P. falciparum
        asexual parasitaemia and no other obvious cause for the symptoms, the presence of one or
        more of the following clinical or laboratory features classifies the patient as suffering
        from severe malaria:

        Clinical features (hospitals and health centers):

          -  impaired consciousness or unrousable coma

          -  prostration, i.e. generalized weakness so that the patient is unable walk or sit up
             without assistance

          -  failure to feed

          -  multiple convulsions - more than two episodes in 24 h

          -  deep breathing, respiratory distress (acidotic breathing)

          -  circulatory collapse or shock, systolic blood pressure < 70 mm Hg in adults and < 50
             mm Hg in children

          -  clinical jaundice plus evidence of other vital organ dysfunction

        Complementary Laboratory findings (hospitals only)

          -  severe anaemia (Hb < 5g/dl, packed cell volume < 15%)

          -  hypoglycemia (blood glucose < 2.2 mmol/l or < 40 mg/dl)

          -  metabolic acidosis (plasma bicarbonate < 15 mmol/l)

          -  serum creatinine > 265 ìmol/l suggesting renal impairment

        Exclusion Criteria:

        Patients with known serious adverse reactions to quinine and artemisinin derivatives or
        patients who have received adequate antimalarial treatment 24 hours before admission will
        not be included in the study.

        Women with known or suspected pregnancy in all trimesters will not be included in the study
        and will be treated with quinine infusions according to the new national DRC guidelines
        (Programme Nationale de Lutte contre le Paludisme, 2012). According to current routine
        procedures determination of pregnancy will be done by medical anamnesis and/ or by a
        positive pregnancy test.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_12_001,NCT01615822,"Safety, Tolerability & Pharmacokinetics (PK) of Co-administered Single Doses of OZ439 and Mefloquine (MQ) in Healthy Volunteers","A Phase I Healthy Volunteer Study Investigating the Safety, Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 and Mefloquine",Terminated,August 2012,April 2013,Actual,Actual,Medicines for Malaria Venture,Karen I Barnes,Principal Investigator,University of Cape Town,Phase 1,Interventional,25,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 AUC0-t,NA,University of Cape Town,Other,NA,NA,"Division of Clinical Pharmacology, University of Cape Town",Up to 42 days post-dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Area under the plasma concentration versus time curve (AUC) of OZ439,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
033-2004,NCT00149383,Safety and Efficacy Study of Adjunctive Rosiglitazone in the Treatment of Uncomplicated Falciparum Malaria,"A Randomized, Double-blind, Placebo-controlled Trial of Rosiglitazone as Adjunctive Therapy for P.Falciparum Infection",Completed,December 2004,January 2006,Actual,Actual,Mahidol University,"Kevin C Kain, MD, FRCPC",Principal Investigator,"Faculty of Medicine, University of Toronto; McLaughlin-Rotman Center for Global Health, Toronto",Phase 1/Phase 2,Interventional,140,Actual,Falciparum Malaria,NA,All,18 Years,N/A,No,Mahidol University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Time to clearance (in hours) of parasitemia from blood is recorded,NA,"McLaughlin-Rotman Center for Global Health, University of Toronto",Other,NA,NA,"Faculty of Tropical Medicine, Mahidol University",5 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AMA1_02_07,NCT00431808,Safety and Immunogenicity of Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]),"Randomized Controlled Trial to Evaluate the Safety and Immunogenicity of Recombinant Pichia Pastoris-Expressed P. Falciparum Apical Membrane Antigen 1 (PfAMA-1-FVO[25-545]) Versus Tetanus Toxoid, in Healthy Malian Adult in Bandiagara",Unknown status,May 2007,June 2008,Anticipated,Anticipated,African Malaria Network Trust,"Mahamadou A Thera, MD MPH",Principal Investigator,Malaria Research and Training Center,Phase 1,Interventional,40,Anticipated,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,African Malaria Network Trust,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,*Safety evaluation through:,Solicited adverse events measured from day 0 to day 7 after each dose;,NA,NA,NA,NA,Malaria Research and Training Center,1 year,7 days,Unsolicited adverse events measured up to one month after each dose;,NA,NA,Serious Adverse Events measured during the 12 months of study duration.,"Biological safety: two and four weeks after each vaccination, and thereafter every 12 weeks, in reference with the baseline before the first dose, by measuring the following :","RBC, hemoglobin, hematocrit, MCV, MCH, MCHC, platelets, WBC with differential counts, potassium, sodium, ASAT, ALAT, total bilirubin, alkaline phosphatase, γGT, creatinin",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,84 days,NA,1 year,NA,NA,NA,1 year,NA,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EHMI-8,NCT00442377,Study to Investigate the Induction of an Protective Immune Response to Malaria,Exposure of Human Volunteers to Live Malaria Sporozoites Under Chloroquine Prophylaxis,Completed,January 2007,July 2007,Actual,Actual,Radboud University,"Robert Sauerwein, Prof",Principal Investigator,Radboud University,N/A,Interventional,15,Anticipated,Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,A significant difference in time of thick smear positivity between exposed and control groups,A significant difference in parasitemia as measured by 18S Pf NASBA between exposed and control group,NA,NA,NA,NA,Radboud University Nijmegen Medical Centre,NA,NA,A significant difference in kinetics of parasitemia between exposed and control groups as measured by 18S Pf NASBA.,NA,NA,A difference in occurrence or height of fever between exposed and control groups.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ALN5P,NCT01916954,Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Malaria in Pregnancy,Comparison of Two Regimens of Artemether-lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Pregnant Women in the Democratic Republic of Congo,Completed,July 2013,NA,NA,NA,University of Oxford,"Nicholas P Day, MD PhD",Principal Investigator,University of Oxford,Phase 3,Interventional,96,Actual,Malaria,NA,Female,18 Years,45 Years,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Pharmacokinetics measures,NA,University of Kinshasa,Other,NA,NA,"University of Kinshasa, Democratic Republic of Congo",1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Drug plasma concentration profiles for lumefantrine, artemether and dihydroartemisinin will be characterized for each patient. Ten samples per patient will be taken at fixed and random times.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL 1302,NCT01936766,Optimal Fluid Management in Adult Severe Malaria,Optimal Fluid Management in Adult Severe Malaria - Development of Renal Impairment and Pulmonary Edema in Complicated Malaria Under Conventional Fluid Strategy,Unknown status,June 2013,December 2015,Anticipated,Anticipated,University of Oxford,"Arjen Dondorp, MD",Principal Investigator,"Mahidol-Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University",N/A,Observational [Patient Registry],120,Anticipated,Malaria; Sepsis,NA,All,16 Years,65 Years,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Association between the mean Global End-Diastolic Volume Index and serum creatine level and extravascular lung water index,NA,NA,NA,NA,NA,Chittagong Medical College Hosiptal,24 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The association between the mean Global End-Diastolic Volume Index (GEDVI) over the first 24 hours and (1) serum creatinine level, and (2) Extravascular Lung Water Index (EVLWI)",NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

        A. Severe Malaria

          1. Any level of asexual form of P. falciparum parasitemia on blood smear

          2. Severe malaria with one or more of the following:

             i. Cerebral malaria (GCS < 11). ii. Renal impairment (Creatinine > 2mg/dL or Anuria)
             iii. Hypoglycaemia (Glucose < 40mg/dL) iv. Systolic blood pressure < 80mmHg with cool
             extremities v. Pulmonary edema vi. Venous bicarbonate < 15mmol/L vii. Venous lactate >
             4mmol/L

          3. Age 16-65 years

          4. Written informed consent obtained from patient or attending relative.

        B. Severe Sepsis

          1. Negative blood smear for any Plasmodium species

          2. Clinical signs of infection with two of following:

             i. Heart rate > 90/min ii. Respiratory rate > 20/min iii. Body temperature >38°C or
             <36°C iv. White blood cell count of > 12000/μL or < 4000/μL

          3. Severe sepsis with one or more of the following due to infection:

             i. Systolic blood pressure < 90mmHg despite fluid resuscitation ii. Lactate > 4mmol/L
             iii. Urine output < 0.5mL/kg/hour for > 2 hours despite fluid resuscitation iv. Acute
             lung injury with PaO2/FiO2 < 250 in the absence of pneumonia v. Acute lung injury with
             PaO2/FiO2 < 200 in the presence of pneumonia vi. Creatinine > 2mg/dL vii. Bilirubin >
             2mg/dL viii. Platelet count < 100000/μL

          4. Age 16-65 years

          5. Written informed consent obtained from patient or attending relative

        Exclusion Criteria:

        A. Severe Malaria

          1. Patient or relative unable or unwilling to give informed consent

          2. Serious pre-existing disease The following exclusion criteria described below are
             applied to patient for whom invasive hemodynamic monitoring will be performed.

          3. Spontaneous bleeding or platelet count < 30000/μL on enrollment

          4. Pregnancy.

          5. Contraindication or unsuitable condition for thermodilution technique

        B. Severe Sepsis

          1. Patient or relative unable or unwilling to give informed consent

          2. Serious pre-existing disease The following exclusion criteria described below are
             applied to patient for whom invasive hemodynamic monitoring will be performed.

          3. Spontaneous bleeding or platelet count < 30000/μL on enrollment

          4. Pregnancy.

          5. Contraindication or unsuitable condition for thermodilution technique
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LSHTM-2542,NCT02073149,Safe and Efficacious Iron for Children in Kenya,Comparison of Home Fortification With Two Iron Formulations in Kenyan Children Protected Against Malaria by Artemisinin-based Combination Therapy: a Placebo-controlled Non-inferiority Trial,Completed,June 2014,December 2014,Actual,Actual,London School of Hygiene and Tropical Medicine,"Hans Verhoef, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 2/Phase 3,Interventional,338,Actual,Anaemia,NA,All,12 Months,36 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Hemoglobin concentration,NA,"Maseno University, Maseno, Kenya",Other,NA,NA,Maseno University,End of the 30-day fortification period,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PR-14053,NCT02389374,A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh,A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of Glucose-6-dehydrogenase Status in South-east Bangladesh,Completed,August 2014,March 2015,Actual,Actual,Menzies School of Health Research,NA,NA,NA,Phase 4,Interventional,181,Actual,Malaria,NA,All,12 Months,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The proportion of adverse and serious adverse events following unsupervised primaquine treatment,NA,"International Centre for Diarrhoeal Disease Research, Bangladesh",Other,NA,NA,NA,during follow up (day 28),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCOA566A2417,NCT00444106,Evaluation of Potential Effect of Artemether - Lumefantrine and Malaria Drugs on Auditory Function,"An Open-label, Randomized, Single-center, Parallel Group Study of the Effects of Artemether-lumefantrine (Coartem®) Atovaquone-proguanil (Malarone®) and Artesunate-mefloquine on Auditory Function Following the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Patients 12 Years of Age or Older",Completed,May 2007,November 2008,Actual,Actual,Novartis,Novartis,Study Director,Novartis,Phase 4,Interventional,265,Actual,Malaria; Falciparum,NA,All,12 Years,N/A,NA,Novartis,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of Participants With Auditory Abnormalities at Day 7 Assessed by Auditory Brainstem Response (ABR) Wave III Latency Changes on Day 7(a Type of Hearing Test),NA,NA,NA,NA,NA,Novartis Investigational Site,7 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To demonstrate the safety of artemether-lumefantrine after 3 days of treatment in patients with acute, uncomplicated falciparum malaria by testing the null hypothesis that the rate of auditory abnormalities is ≥ 15% in the population treated with artemether-lumefantrine as assessed by ABR at Day 7 following initiation of treatment compared with their baseline values. An ""auditory nerve abnormality"" is here defined as a greater than 0.30 ms change in Wave III latency from baseline to Day 7. Exact Pearson-Clopper two-sided 95% confidence limits were constructed for all three treatment groups.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MSP3_BF_0302,NCT00452088,A Phase Ib Trial of MSP 3 LSP in 1-2 Year Old Children in Burkina Faso,"Randomized, Controlled, Dose Escalation Phase Ib Trial of MSP 3 LSP Adjuvanted in Aluminium Hydroxide Versus Hepatitis Bin 12 to 24 Month Old Children in Burkina Faso.",Unknown status,April 2007,May 2008,Anticipated,Anticipated,African Malaria Network Trust,"Issa Nebie, PhD",Study Director,Projet de Développement de Vaccins Anti-Paludique- Centre National de Recherche et de Formation sur le Paludisme,Phase 1,Interventional,45,Anticipated,Malaria,NA,All,1 Year,2 Years,Accepts Healthy Volunteers,African Malaria Network Trust,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Immediate reactogenicity (within 1 hour, with emphasis on allergic reactions)",Local and systemic reactogenicity during the 7 days following the vaccine,London School of Hygiene and Tropical Medicine,Other,NA,NA,Projet de Développement de Vaccins Anti-Paludique- Centre National de Recherche et de Formation sur le Paludisme,7 days,7 days,Unsolicited adverse events occurring within 28 days following each vaccination,NA,NA,Serious adverse events (SAE) throughout the study period,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28 Days,NA,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-CCID-5597,NCT01043744,Non-malarial Febrile Illness in Children in Areas of Perennial Malaria Transmission,Treatment Outcomes for Non-malarial Febrile Illness in Children Aged 6-59 Months in Areas of Perennial Malaria Transmission,Completed,January 2010,December 2011,Actual,Actual,Centers for Disease Control and Prevention,"Meredith L McMorrow, MD, MPH",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,1000,Actual,Malaria; Non-malarial Febrile Illness,NA,All,6 Months,59 Months,Accepts Healthy Volunteers,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"S. Patrick Kachur, MD, MPH",Study Chair,Centers for Disease Control and Prevention,NA,Hematological recovery (Hb return to normal),Mean time to next infection,NA,NA,NA,NA,NA,"28, 63, 91 days",Weekly,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Larry Slutsker, MD",Study Chair,Centers for Disease Control and Prevention,"Saumu Ahmed, MD",Study Director,Ifakara Health Institute,NA,NA,NA,NA,NA,"Salim MK Abdulla, MD, PhD",Study Chair,Ifakara Health Institute,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ART003,NCT01047436,Efficacy of ArTiMist™ in Children,"An Open Label Randomised Comparative Trial to Establish the Efficacy of 3 mg/kg ArTiMist™ When Compared to Intravenous Quinine in Children With Severe or Complicated Falciparum Malaria, or Uncomplicated Falciparum Malaria With Gastrointestinal Complications",Completed,December 2009,January 2010,Actual,Actual,Proto Pharma Ltd,"Daryl Bendel, MBChB MBA Dip Pharm Med MFPM",Study Director,Xidea Solutions Limited,Phase 2,Interventional,31,Actual,Falciparum Malaria,NA,All,N/A,N/A,No,Proto Pharma Ltd,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasitological Success Defined as a Reduction in Parasite Count of ≥ 90% of Baseline at 24 Hours After the First Dose,Time for Parasite Count to Fall by 90% PCT(90),Xidea Solutions Limited,Other,NA,NA,NA,24 hours after first dose,"3h (hours), 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h",Time for Parasite Count to Fall by 50% PCT(50),NA,NA,NA,NA,NA,NA,NA,NA,NA,The time taken for the parasite count to fall 90% from baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The time taken for the parasite count to fall 50% from baseline,"3 h (hours) , 6h, 12h, 18h, 24h, 30h, 36h, 48h, 54h, 60h",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HS 567,NCT01944189,Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics and Population Pharmacokinetics,Artemether/ Lumefantrine: A Study of the Effect of Local Food on Pharmacokinetics of Lumefantrine and Population Pharmacokinetics of Lumefantrine Among Ugandan Children,Unknown status,September 2013,March 2015,Anticipated,Anticipated,Makerere University,"Norah Mwebaza, MBChB M Sc",Principal Investigator,"• Department of Pharmacology and Therapeutics, Makerere University College of Health Sciences (MakCHS), Uganda",Phase 4,Interventional,70,Anticipated,"Malaria, Falciparum",NA,All,6 Months,5 Years,No,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Urban Hellgren, MD PhD",Study Chair,"Div Infectious Diseases, Karolinska Institutet (KI) , Sweden",NA,Pharmacokinetic (PK) exposure parameters of lumefantrine,NA,Karolinska Institutet,Other,Swedish International Development Cooperation Agency (SIDA),Other,"Department of Pharmacology & Therapeutics, MakCHS, Mulago Hospital Complex",28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sparse pharmacokinetic data will be pooled for evaluation of both individual and population PK parameter estimates of lumefantrine using Non linear mixed effect model. Pharmacokinetic exposure will be depicted principally by area under the concentration-time curves following the last dose through to 28 days of follow up (AUC0-28). Other PK parameters portraying exposure will also be assessed alongside. These include half life (t1/2), peak concentrations (Cmax) and time to reach Cmax (Tmax), apparent clearance and volumes of distribution.","Lars L Gustaffson, MD PhD",Study Chair,"Dep Lab Medicine, Div Clinical Pharmacology, KI","Paul Waako, PhD",Study Chair,"Department of Pharmacology and Therapeutics, MakCHS, Kampala, Uganda",NA,NA,NA,NA,NA,"Celestino Obua, PhD",Study Chair,"Department of Pharmacology and Therapeutics, MakCHS, Kampala, Uganda",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HMMP001,NCT02151578,Home Management of Malaria and Pneumonia,Home and Community Management of Fevers/Malaria and Pneumonia in Children Under-five: a Cluster Randomised Controlled Trial of an Integrated Approach in a Rural District of Burkina Faso,Completed,January 2009,September 2012,Actual,Actual,World Health Organization,"Sodiomon Bienvenu SIRIMA, MD, PhD",Principal Investigator,"Groupe de Recherche Action en santé (GRAS), 06 BP 10248 Ouagadougou 06, Burkina Faso",Phase 4,Interventional,11500,Actual,Malaria; Pneumonia,NA,All,6 Months,59 Months,No,World Health Organization,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of death in children aged 6 to 59 months,NA,NA,NA,NA,NA,Groupe de Recherche Action en Sante (GRAS sarl),12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,annual crude mortality rate in children aged 0 to 6 months in the different study arms,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TQ study 058,NCT01290601,Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults,"A Randomized, Active-control, Double-blind, Double-dummy Study to Evaluate the Efficacy and Safety of Tafenoquine for the Treatment of Plasmodium Vivax in Adults",Completed,September 2003,January 2005,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Sornchai Looareesuwan, MD",Principal Investigator,Mahidol University,Phase 2,Interventional,70,Actual,Malaria; Plasmodium Vivax,NA,All,20 Years,60 Years,No,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adequate Clinical Response (ACR).,NA,GlaxoSmithKline,Industry,NA,NA,Bangkok Hospital for Tropical Diseases/Mahidol University,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Day 28 cure rate. A subject will be considered a success (cure) if they have an Adequate Clinical Response (ACR).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Cambodia1,NCT02389439,Efficacy and Safety of Pyronaridine-artesunate for the Treatment in Uncomplicated Falciparum Malaria,"Monitoring and Evaluation of the Therapeutic Efficacy and Safety of Pyronaridine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Western Cambodia, an Area of Artemisinin-resistant Falciparum Malaria",Unknown status,March 2015,June 2016,Anticipated,Anticipated,University of Oxford,NA,NA,NA,Phase 2,Interventional,145,Anticipated,"Malaria, Falciparum",NA,All,7 Years,N/A,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,result of PCR,NA,NCHADS - Ministry of Health of Cambodia,Other,NA,NA,NA,42 day,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU0909,NCT01076868,Incidence of Vivax Along the Thai Burma Border,Determining the Incidence of New Plasmodium Vivax Infections After Radical Treatment Following Vivax Malaria Along the Thai Burma Border,Unknown status,February 2010,December 2014,Anticipated,Anticipated,University of Oxford,"Francois Nosten, MD",Principal Investigator,Shoklo Malaria Research Unit,N/A,Interventional,200,Anticipated,Vivax Malaria,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence,NA,Mahidol University,Other,NA,NA,Shoklo Malaria Research Unit,Up to 3 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Incidence of primary infections with vivax malaria,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MVDC 2003-002,NCT01081847,Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants,Malaria Vaccine Phase IB Clinical Trial: Safety and Immunogenicity Study of Plasmodium Vivax CS Derived Synthetic Peptides Formulated in Two Adjuvants,Completed,July 2005,April 2006,Actual,Actual,Malaria Vaccine and Drug Development Center,"Myriam Arevalo-Herrera, PhD",Study Director,MVDC,Phase 1,Interventional,40,Actual,"Malaria, Vivax",NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Malaria Vaccine and Drug Development Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety and Immunogenicity of Plasmodium vivax CS Derived Long Synthetic Peptides Adjuvanted with Montanide ISA 720 or Montanide ISA 51,NA,Centro médico Imbanaco,Other,Asoclinic Inmunología Ltda.,Industry,NA,9 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
134/CNBS/11,NCT02168569,In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate in Mozambican Children,"In Vivo Efficacy of Artemether-lumefantrine and Amodiaquine-artesunate for the Treatment of Uncomplicated Falciparum Malaria in Children: A Multisite, Open-label, Two-cohort Clinical Trial in Mozambique.",Completed,June 2011,January 2013,Actual,Actual,Centro de Investigacao em Saude de Manhica,NA,NA,NA,Phase 4,Interventional,700,Actual,Malaria,NA,All,6 Months,59 Months,No,Centro de Investigacao em Saude de Manhica,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"To measure the Day 28, PCR corrected cure rates of artemether-lumefantrine (Coartem) and Amodiaquine-artesunate (Coarsucam).",NA,FHI 360,Other,NA,NA,NA,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"This cure rate is defined as the proportion of patients with adequate clinical and parasitological response (ACPR) at Day 28, once PCR correction to differentiate recrudescences friom new infections have been applied (and hence only considering as treatment failures those parasite recurrences confirmed as recrudescences).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
INESS 02/2012,NCT02199951,"Introduction of Eurartesim® in Burkina Faso, Mozambique, Ghana and Tanzania",Observational Study to Evaluate the Clinical Safety After Introduction of the Fixed Dose Artemisinin-based Combination Therapy Eurartesim® (Dihydroartemisinin/Piperaquine [Dha/Pqp]) in Public Health Districts in Sub-Saharan Africa.,Unknown status,September 2013,December 2014,Anticipated,Anticipated,INDEPTH Network,"Fred N Binka, MD, PhD",Principal Investigator,INDEPTH Network,Phase 4,Observational,10000,Anticipated,Malaria,NA,All,6 Months,N/A,No,INDEPTH Network,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adverse events,NA,"Ministry of Health, Ghana",Other,Ifakara Health Research and Development Centre,Other,NA,28 Days,NA,NA,"Ministry of Health, Burkina Faso",Other,NA,NA,NA,Centro de Investigacao em Saude de Manhica,Other,NA,NA,"• Clinical safety will be determined by analysis of the number of adverse events (frequency, intensity, action taken, outcome) captured during their follow up contacts on Day 5 (±2 days) after starting the treatment with Eurartesim® as well as those identified in the referring hospitals or through adverse events spontaneously reported by the patient detected at the health facility within 28 days after the first medication intake.",NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Uncomplicated malaria (Plasmodia of any species) diagnosed as per national policies
             and in line with WHO recommendations (a history of fever in the previous 24 h and/or
             the presence of anaemia, for which pallor of the palms appears to be the most reliable
             sign in young children). Confirmation of malaria by a parasitological diagnosis with
             RDT is encouraged but its absence does not prevent patients from being enrolled.

               -  Age ≥ 6 months and weight ≥ 5 kg.

               -  Capability of taking an oral medication.

               -  Ability and willingness to participate based on signed informed consent (a parent
                  or a guardian has to sign for children below 18 years old), or on verbal consent
                  given in front of a witness signing the informed consent, and access to health
                  facility. The patient is to comply with all scheduled follow-up visits.

        Exclusion Criteria:

          -  • Known allergy to artemisinin or to piperaquine.

               -  Known pregnancy.

               -  Lactating women should be excluded if other anti-malarial treatments are
                  available

               -  Complicated malaria.

               -  Taking medicinal products that are known to prolong the QTc interval. These
                  include (but are not limited to):

               -  Antiarrhythmics (e.g. amiodarone, disopyramide, dofetilide, ibutilide,
                  procainamide, quinidine, hydroquinidine, sotalol).

               -  Neuroleptics (e.g. phenothiazines, sertindole, sultopride, chlorpromazine,
                  haloperidol, mesoridazine, pimozide, or thioridazine), antidepressive agents.

               -  Certain antimicrobial agents, including agents of the following classes:

          -  macrolides (e.g. erythromycin, clarithromycin),

          -  fluoroquinolones (e.g. moxifloxacin, sparfloxacin),

          -  imidazole and triazole antifungal agents,

          -  and also pentamidine and saquinavir.

               -  Certain non-sedating antihistamines (e.g. terfenadine, astemizole, mizolastine).

               -  Cisapride, droperidol, domperidone, bepridil, diphemanil, probucol, levomethadyl,
                  methadone, vinca alkaloids, arsenic trioxide.

               -  Have taken a DHA/PQP dose in the previous four weeks.

               -  Family history of sudden unexplained death, or personal or family history of
                  predisposing cardiac conditions for arrhythmia/QT prolongation (including
                  congenital long QT syndrome, arrhythmia, QTc interval greater than 450
                  milliseconds with either Bazett or Fridericia correction).
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A-14620.a,NCT00666380,A Study to Determine the Effects of an Investigational Malaria Vaccine Given to Adults Living in the United States and Thereafter to Adults Living in Kenya,"Phase 1a Open-label Dose Escalation Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B in Healthy Malaria-Naïve Adults",Completed,April 2008,June 2009,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Michele D Spring, MD, M.S.P.H.",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 1,Interventional,26,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Nekoye N. Otsyula, M.B. Ch. B.",Principal Investigator,Kenya Medical Research Institute,NA,Number of solicited adverse events,Number of unsolicited adverse events,GlaxoSmithKline,Industry,United States Agency for International Development (USAID),U.S. Fed,NA,7 days,30 days,Number of serious adverse events,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,Kenya Medical Research Institute,Other,NA,NA,Occurrence and intensity of solicited symptoms on day of vaccination and Days 1-7 after each vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Occurrence and intensity of unsolicited symptoms over a 30-day follow-up period (day of vaccination and 29 subsequent days) after each vaccination,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCOA566B2306,NCT01619878,"Efficacy, Safety and Pharmacokinetics of Artemether-lumefantrine Dispersible Tablet in the Treatment of Malaria in Infants < 5 kg","An Open-label, Single-arm Study to Evaluate the Efficacy, Safety and PK of Artemether-lumefantrine Dispersible Tablet in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Infants <5 kg Body Weight",Completed,October 2012,July 2014,Actual,Actual,Novartis Pharmaceuticals,Novartis Pharmaceuticals,Study Director,Novartis Pharmaceuticals,Phase 2/Phase 3,Interventional,20,Actual,Acute Uncomplicated Falciparum Malaria,NA,All,N/A,N/A,No,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Polymerase Chain Reaction (PCR) Corrected 28 Day Parasitological Cure Rate,NA,Medicines for Malaria Venture,Other,NA,NA,NA,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Number of participants with clearance of asexual parasites by day 7 after initiating study treatment without recrudescence at day 28, corrected for re-infection by Polymerase Chain Reaction (PCR) assay.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IMPACT TZ IV2010,NCT01082705,Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children,Impact Tanzania in Vivo Efficacy 2010: Assessing the Efficacy of Artemisinin Combination Therapies for Treatment of Uncomplicated Malaria Infection in Children Aged 6-59 Months,Completed,April 2010,June 2011,Actual,Actual,Centers for Disease Control and Prevention,"Julie R Gutman, MD MSc",Study Director,Centers for Disease Control and Prevention,Phase 3,Interventional,323,Actual,P. Falciparum Malaria,NA,All,6 Months,59 Months,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"S. Patrick Kachur, MD MPH",Principal Investigator,Centers for Disease Control and Prevention,NA,42-day polymerase chain reaction (PCR)-adjusted parasitological cure of P. falciparum parasitemia,NA,NA,NA,NA,NA,Miono Health Center,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PAACT-PF,NCT01082731,Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Falciparum in Pregnancy in Brazil,"A Multi-center, Open-label, Randomized, Phase 4, Trial of Artemether-Lumefantrine and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Falciparum Malaria Parasitemia in Pregnant Women in Brazil",Terminated,November 2010,January 2012,Actual,Actual,Centers for Disease Control and Prevention,"Meghna Desai, PhD MPH",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,6,Actual,Malaria,NA,Female,15 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,63-day PCR-adjusted parasitological cure of P. falciparum,NA,NA,NA,NA,NA,NA,63 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,63-day PCR-adjusted parasitological cure of P. falciparum,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MR/K007319/1,NCT02211729,A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children,A Trial of Seasonal Malaria Chemoprevention Plus Azithromycin in African Children,Unknown status,August 2014,June 2017,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,NA,NA,NA,Phase 3,Interventional,19200,Anticipated,Malaria; Respiratory Infections,NA,All,3 Months,59 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,severe morbidity and mortality,NA,"Malaria Research and Training Center, Bamako, Mali",Other,"Institut de Recherche en Sciences de la Sante, Burkina Faso",Other,NA,from the time of enrolment upto the end of malara transmission in year3 ( the person time at risk will be restricted to three malaria transmission seasons),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Incidence of the combination of death or hospital admission for at least 24 hours, not due to trauma or elective surgery during the intervention period.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CKAF156X2201,NCT01753323,"Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection","A Proof-of-concept, Open Label Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAF156 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-infection",Completed,March 2013,August 2014,Actual,Actual,Novartis Pharmaceuticals,Novartis Pharmaceuticals,Study Director,Novartis Pharmaceuticals,Phase 2,Interventional,43,Actual,Malaria,NA,All,20 Years,60 Years,No,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Time to Parasite Clearance,28-day Cure Rate - Part 2,NA,NA,NA,NA,NA,Day 5,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and blood density assessments.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
JP017,NCT02198807,Evaluation of Fosmidomycin and Piperaquine in the Treatment of Acute Falciparum Malaria,"A Phase IIa Proof of Concept Study to Explore the Efficacy, Tolerability and Safety of Fosmidomycin Sodium When Administered With Piperaquine Tetraphosphate to Adults and Older Children With Acute Uncomplicated Plasmodium Falciparum Malaria",Unknown status,March 2014,December 2015,Anticipated,Anticipated,Jomaa Pharma GmbH,NA,NA,NA,Phase 2,Interventional,100,Actual,Oral Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria,NA,All,1 Year,60 Years,No,Jomaa Pharma GmbH,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Per protocol, PCR-corrected cure rate on Day 28",NA,Centre de Recherche Médicale de Lambaréné,Other,NA,NA,NA,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Six-hourly asexual counts until negative on three successive occasions.
Weekly smears on days 7, 14, 21 and 28",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MSF-nutcon03,NCT01497236,"Effectiveness of Nutritional Supplementation in Preventing Malnutrition in Children With Infection in Karamoja, Uganda","Effectiveness of Nutritional Supplementation (RUTF and Multi Micronutrient) in Preventing Malnutrition in Children 6-59 Months With Infection (Malaria, Pneumonia, Diarrhoea), a Randomized Controlled Trial in Kaabong, Karamoja, Uganda",Completed,March 2011,October 2012,Actual,Actual,"Medecins Sans Frontieres, Spain",Nuria Salse,Principal Investigator,MSF Spain,N/A,Interventional,2202,Actual,Child Malnutrition; Infant Morbidity,NA,All,6 Months,59 Months,Accepts Healthy Volunteers,"Medecins Sans Frontieres, Spain",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"""negative nutritional outcome"" of a child",NA,NA,NA,NA,NA,Kaabong Hospital,6 months follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The incidence of a negative nutritional outcome will be defined in two different ways according to the baseline nutritional status.
i) for children with no malnourishment at time of entry into study, ""negative nutritional outcome"" is defined as progression to moderate or severe malnourishment ii) for children with moderate malnourishment at time of entry into study, ""negative nutritional outcome"" is defined as loss of ³10% of baseline weight or progression to severe malnourishment, whichever is reached first",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC036,NCT01095055,A Study of AdCh63 AMA1 Alone and With MVA AMA1,A Phase I Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 AMA1 Alone and With MVA AMA1,Completed,March 2010,October 2010,Actual,Actual,University of Oxford,Adrian VS Hill,Principal Investigator,"Oxford Vaccine Group, Centre for Clinical Vaccinology and Tropical Medicine (CCVTM), Churchill Hospital",Phase 1,Interventional,16,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Safety of AdCh63 administered alone, and combinedwith MVA AMA1",NA,NA,NA,NA,NA,NA,Up to 6 months following the last vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To assess the safety in healthy volunteers of two candidate malaria vaccines, AdCh63 AMA1 with MVA AMA1 in a prime-boost regimen. The safety of AdCh63 administered alone, and combined with MVA AMA1 will be assessed. The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A0661195,NCT01100060,A Phase 1 Study To Estimate The Relative Bioavailability Of Co-Administered Formulations Of Azithromycin Microsphere And Chloroquine Test Formulation Compared With Co-Administered Immediate Release Individual Azithromycin And Chloroquine Tablets In Healthy Adult Subjects,"A Phase 1, Open-Label, Randomized, Single Dose, Parallel Design Study To Estimate The Relative Bioavailability Of Co Administered Formulations Of Azithromycin Microsphere (AZ) And Chloroquine Test Formulation (CQ) Compared With Co Administered Immediate Release Individual AZ And CQ Tablets In Healthy Adult Subjects",Completed,April 2010,June 2010,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 1,Interventional,40,Actual,Malaria Prophylaxis,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,AUClast of azithromycin and chloroquine,NA,NA,NA,NA,NA,Pfizer Investigational Site,Through Day 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
6619,NCT02371395,Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil,Validation of RealAmp Method for the Diagnosis of Malaria in Endemic Areas of Brazil,Unknown status,February 2015,March 2016,Anticipated,Anticipated,Centers for Disease Control and Prevention,"Alexandre Macedo de Oliveira, MD",Principal Investigator,Centers for Disease Control and Prevention,N/A,Observational,1000,Anticipated,Malaria Diagnosis,NA,All,7 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria Diagnosis,NA,Evandro Chagas Institute of Clinical Research,Other,NA,NA,Hospital do Jurua,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Information not to be used for clinical management,NA,NA,NA,NA,NA,NA,NA,NA,Malaria Diagnosis,Non-Probability Sample,"
        Inclusion Criteria:

          -  Age 7 years

          -  Signed informed consent for patients 18 years and older

          -  Signed parental/guardian consent form and assent from the patient (for those less than
             18 years)

          -  Documented fever (auxiliary temperature greater than 37.5C) or self-reported fever in
             previous 24 hours in the absence of another obvious cause of fever

          -  First visit for current illness at the diagnostic post

        Exclusion Criteria:

          -  Absence of fever or no history of fever

          -  Follow-up visit for the current illness

          -  No consent/assent to participate

          -  Antimalarial treatment use in previous 30 days
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pro00035154,NCT01809873,Sustainable Financial Incentives To Improve Prescription Practices For Malaria,Sustainable Financial Incentives To Improve Prescription Practices For Malaria,Completed,September 2012,March 2014,Actual,Actual,Duke University,NA,NA,NA,N/A,Interventional,14862,Actual,Malaria,NA,All,N/A,N/A,No,Duke University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of children under 5 years of age who are treated with antimalarials following a negative malaria test,NA,Moi University,Other,NA,NA,Moi University,At one year post-intervention,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The study is designed to detect a reduction in the proportion of children under 5 years of age who are prescribed antimalarials following a negative malaria diagnostic test between the intervention and comparison arms.,NA,NA,NA,NA,NA,NA,NA,NA,Proportion of children under 5 years of age who are treated with antimalarials following a negative malaria test,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IPTi-DRWG- SP Lambaréné,NCT00453856,Efficacy of Sulfadoxine-Pyrimethamine for Treating Malaria in Gabonese Children,"Efficacy of Sulfadoxine-Pyrimethamine in the Treatment of Symptomatic, Uncomplicated Plasmodium Falciparum Malaria Among 6-59 Month Old Children in Lambaréné",Terminated,March 2007,NA,NA,NA,Albert Schweitzer Hospital,"Martin P Grobusch, MD",Study Director,"Medical Research Unit, Albert Schweitzer Hospital Lambaréné",Phase 4,Interventional,139,Anticipated,Malaria,"Measure the clinical and parasitological efficacy of SP among patients aged between 6-59 months suffering from uncomplicated P falciparum malaria,",All,6 Months,59 Months,No,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Saadou Issifou, MD MSc",Principal Investigator,Albert Schweitzer Hospital,NA,NA,NA,Bill and Melinda Gates Foundation,Other,NA,NA,Medical Research Unit of the Albert Schweitzer Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCC-2007,NCT00454961,Effectiveness of Artemether-Lumefantrine for Malaria Treatment of Children at Community Level in Tanzania,Effectiveness of Artemether-Lumefantrine Treatment Provided by Community Health Worker Against Uncomplicated Malaria in Children Under 5 Years of Age in Tanzania,Completed,April 2007,NA,NA,NA,Karolinska University Hospital,"Anders Björkman, Professor",Study Director,Karolinska University Hospital,Phase 4,Interventional,200,Anticipated,Malaria,NA,All,N/A,5 Years,No,Karolinska University Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Effectiveness (PCR adjusted parasitological cure rate) of artemether-lumefantrine,during 42 days follow-up.,NA,NA,NA,NA,Kibaha District,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Fe_Malaria_Benin,NCT01108939,Study of Iron Absorption and Utilization in Asymptomatic Malaria,The Effect of Asymptomatic Malaria on Iron Absorption and Utilization From a Sorghum-based Meal in Adult Women in Benin,Completed,February 2009,April 2010,Actual,Actual,Swiss Federal Institute of Technology,"Michael Zimmermann, Prof., MD",Principal Investigator,"Human Nutrition Laboratory, Swiss Federal Institute of Technology",Early Phase 1,Interventional,23,Actual,"Malaria, Falciparum",NA,Female,16 Years,35 Years,No,Swiss Federal Institute of Technology,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,European Union,Other,NA,NA,Hopital de zone de Natitingou,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1002,NCT01115439,Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Falciparum Malaria,"Efficacy and Safety of Artesunate+Sulfadoxine-Pyrimethamine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malaria Control Centers in Nangarhar, Kunar, Thakhar and Faryab Provinces of Afghanistan",Completed,March 2010,July 2011,Actual,Actual,University of Oxford,"Ghulam Rahim Awab, MD",Principal Investigator,Mahidol Oxford Research Unit,N/A,Observational,100,Actual,Falciparum Malaria,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of patients experiencing therapeutic failure,NA,"National Malaria and Leishmaniasis Control Program, Afghanistan",Other,World Health Organization,Other,NA,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Proportion of patients experiencing therapeutic failure,NA,NA,NA,NA,NA,NA,NA,NA,Proportion of patients experiencing therapeutic failure,Non-Probability Sample,"
        Inclusion:

          -  Age over six months.

          -  Mono-infection with P. falciparum detected by microscopy at a level of 500-150,000/µL
             asexual forms

          -  Presence of axillary or tympanic temperature ≥ 37.5 °C or oral or rectal temperature
             of ≥ 38 °C or history of fever during the past 24 h;

          -  ability to swallow oral medication;

          -  ability and willingness to comply with the study protocol for the duration of the
             study and to comply with the study visit schedule; and

          -  Informed consent from the patient or from a parent or guardian in the case of children
             under 18 years of age.

        Exclusion criteria:

          -  Presence of general danger signs in children aged under 5 years or signs of severe
             falciparum malaria according to the definitions of the World Health Organization (WHO)

          -  Mixed or mono-infection with another Plasmodium species detected by microscopy

          -  Presence of severe malnutrition (defined as a child whose growth standard is below -3
             z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm
             circumference < 110 mm)

          -  Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute
             lower respiratory tract infection, severe diarrhoea with dehydration) or other known
             underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases,
             HIV/AIDS);

          -  Regular medication, which may interfere with antimalarial pharmacokinetics;

          -  History of hypersensitivity reactions or contraindications to any of the study
             medications;

          -  Female over 12 years of age
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Malactres-BF,NCT00808951,In Vivo and in Vitro Efficacy of Antimalarial Treatments in Children in Burkina Faso,In Vivo and in Vitro Efficacy of the Recommended First Line Antimalarial Treatments (Artemether-Lumefantrine and Amodiaquine-Artesunate) in Children With Uncomplicated Malaria in Burkina Faso,Completed,December 2008,February 2011,Actual,Actual,Centre Muraz,"Halidou Tinto, PhD",Principal Investigator,Centre Muraz,Phase 4,Interventional,440,Actual,Malaria,NA,All,6 Months,15 Years,No,Centre Muraz,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR unadjusted treatment failure (regardless of genotyping).,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,Tinto Halidou,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
RPC390,NCT01555255,Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria,Malaria Rapid Diagnostic Tests (RDTs) in Pregnancy: Detection of Placental Malaria,Unknown status,November 2010,December 2012,Anticipated,Anticipated,"Foundation for Innovative New Diagnostics, Switzerland","Heidi A Hopkins, MD",Principal Investigator,"Foundation for Innovative New Diagnostics, Kampala, Uganda",N/A,Observational,1205,Anticipated,Malaria; Placental Malaria; Malaria in Pregnancy,NA,Female,16 Years,44 Years,No,"Foundation for Innovative New Diagnostics, Switzerland",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Jean-Bosco Ouedraogo, MD, PhD",Principal Investigator,"IRSS, Direction Regionale de l'Ouest, Bobo-Dioulasso, Burkina Faso",NA,accuracy of diagnostic tests during gestation,accuracy of diagnostic tests during gestation,UNICEF,Other,United Nations Development Programme,Other,NA,2nd trimester of pregnancy,3rd trimester of pregnancy,NA,World Bank,Other,NA,NA,NA,World Health Organization,Other,NA,NA,"accuracy of malaria RDTs, blood smears and PCR performed on maternal peripheral blood to diagnose or predict placental malaria during gestation","David Bell, MBBS, PhD",Study Director,"Foundation for Innovative New Diagnostics, Geneva, Switzerland","Jane Cunningham, MD",Study Director,"UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases (TDR), Geneva, Switzerland",NA,NA,NA,Non-Probability Sample,"
        Specific participant selection criteria include:

          1. Presenting for care after quickening and before onset of labor (i.e. in the second or
             third trimester of pregnancy)

          2. Age between 16 years and 44 years, inclusive

          3. Willingness and ability to follow up with study visits and activities through the
             duration of pregnancy and at delivery

          4. Absence of history of serious adverse reaction to sulfa drugs

          5. Absence of history of serious adverse reaction to artemisinin-based drugs (depending
             on national policy on treatment of malaria in pregnancy)

          6. Absence of HIV infection (both because guidelines for malaria prevention in pregnancy
             for HIV-infected women differ from those for HIV-negative women, and in order to avoid
             confounding of pregnancy outcomes by HIV-related complications or treatments in this
             early evaluation)

          7. Absence of history of or current obstetrical complications (e.g. pre-eclampsia,
             eclampsia, hypertension during pregnancy, post-partum hemorrhage, evidence of multiple
             gestation)

          8. Absence of chronic disease (e.g. diabetes mellitus, sickle cell disease)

          9. Absence of evidence of severe acute disease requiring inpatient management or referral

         10. Provision of written informed consent

         11. Enrollment Hb ≥7 g/dL
      ","Miriam Nakalembe, MBChB",Principal Investigator,"Makerere University Faculty of Medicine, Kampala, Uganda","accuracy of malaria RDTs, blood smears and PCR performed on maternal peripheral blood to diagnose or predict placental malaria during gestation",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
001/ASMQ/JURUA/2009,NCT01144702,Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Malaria by Plasmodium Falciparum,"Effectiveness of the Association Artesunate and Mefloquine in the Treatment of Uncomplicated Malaria by Plasmodium Falciparum, Juruá Valley, State of Acre, Brazil, 2009.",Completed,November 2010,July 2014,Actual,Actual,Oswaldo Cruz Foundation,"Simone L Andrade, PhD",Study Director,"Oswaldo Cruz Institute, Oswaldo Cruz Foundation",Phase 2/Phase 3,Interventional,163,Actual,Falciparum Malaria,NA,All,6 Months,70 Years,No,Oswaldo Cruz Foundation,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,treatment failure,NA,Pan American Health Organization,Other,"Ministry of Health, Brazil",Other,NA,42 days,NA,NA,University of Sao Paulo,Other,NA,NA,NA,NA,NA,NA,NA,"The efficacy of the treatment will be based on clinical and parasitological evaluation of the participants, conducted in all follow-up visits during the 48 days. All individuals will be classified in: a) Early treatment failure b) Late Clinical Failure, Late Parasitological Failure and adequate clinical and parasitological response. As the parasitological cure is the endpoint of treatment of malaria, all individuals classified as treatment failure should be treated with the alternative scheme (quinine + doxycycline).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WHO/TDR - A70283,NCT01232530,Pharmacovigilance for ACTs in Africa,Pharmacovigilance for Artemisinin-based Combination Treatments in Africa,Completed,June 2010,December 2013,Actual,Actual,Centre Muraz,"Halidou Tinto, PharmD, PhD",Principal Investigator,Centre Muraz,N/A,Observational,3176,Actual,Malaria,NA,All,N/A,N/A,No,Centre Muraz,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,World Health Organization,Other,NA,NA,Clinical Research Unit of Nanoro (CRUN) / Centre Muraz,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  Males and Females living in Nanoro DSS catchment area;

          -  Signed (or thumb-printed whenever patients are illiterate) informed consent.

          -  Patients' willingness and ability to comply with the study protocol for the duration
             of the study.

        Exclusion Criteria:

          -  Severe malaria.

          -  Danger signs: not able to drink or breast-feed, vomiting (> twice in 24hours), recent
             history of convulsions (>1 in 24h), unconscious state, unable to sit or stand.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BMGF1,NCT02080026,Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis,Identification of Pre-erythrocytic Target Antigens Induced by Plasmodium Falciparum Sporozoite Immunization Under Chemoprophylaxis,Completed,June 2014,July 2015,Actual,Actual,Radboud University,"Robert W Sauerwein, Prof.",Principal Investigator,Radboud University,N/A,Interventional,15,Actual,Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Generation of B-cells for delineation of antibody responses against Plasmodium falciparum pre-erythrocytic stages in CPS-immunized, protected volunteers.",NA,Bill and Melinda Gates Foundation,Other,NA,NA,Radboud university medical center,On day 232-238 of the study (6-11 days after challenge malaria infection),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,After immunization and Controlled Human Malaria Infection (CHMI) blood will be drawn to isolate plasmablast for further delineation of the antibody responses following CPS-immunization.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LiberiaDL,NCT02448745,Liberia Insecticide Treated Durable Wall Linings Study: Protocol for a Cluster Randomised Trial (DL),NA,Unknown status,January 2014,April 2017,Anticipated,Anticipated,The Mentor Initiative,"David J Giesbrecht, MSc",Principal Investigator,Study Coordinator,N/A,Interventional,1900,Anticipated,"Malaria, Falciparum; Anemia",NA,All,2 Months,59 Months,Accepts Healthy Volunteers,The Mentor Initiative,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria Prevalence,NA,"Ministry of Health, Liberia",Other,NA,NA,Bomi County Health Team,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Tested by mRDT and PCR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP12C10,NCT02453581,Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Volunteers,An Experimental Study To Characterize the Effectiveness of OZ439 Against Early Plasmodium Falciparum Blood Stage Infection In Healthy Volunteers,Completed,September 2012,March 2013,Actual,Actual,Medicines for Malaria Venture,"James McCarthy, Pr",Principal Investigator,Q-Pharm Pty Limited,Phase 1,Interventional,24,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Individual Parasite Reduction Ratio (PRR),500mg Cohort Mean Parasite Reduction Ratio (PRR),Queensland Institute of Medical Research,Other,NA,NA,Q-Pharm,48 hours,48 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PRR estimates the efficacy of an anti-malarial treatment and is the ratio of the parasite density between admission and 48 hours post-treatment.
Individual subject PRR and corresponding 95% CI were calculated using the slope and corresponding standard error of mean (SE) of the optimal regression model.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 500mg individual subject PRR and corresponding 95% CI were used to calculate the OZ439 500mg cohort specific PRR and the corresponding 95% CI: the weighted average slope estimate and corresponding SE were calculated by the inverse-variance method.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
003,NCT02517879,Community Point Distribution of Insecticide Treated Bed Nets,Measuring Attendance of Community Point Distribution of Insecticide-treated Bed Nets and the Impact of Community Health Worker Hang-up in Rural Zambia: A Randomized Controlled Trial and Cost Analysis,Completed,November 2013,May 2014,Actual,Actual,IDinsight,"Paul Wang, MPAID/MBA",Principal Investigator,IDinsight,N/A,Interventional,560,Actual,Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,IDinsight,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Community point distribution attendance,Self-installation of ITNs,"National Malaria Control Centre, Zambia",Other,"Ministry of Health, Zambia",Other,NA,At time 0,"Each group is randomized to receive a community health worker visit after a different duration, an average of 7 days after the point distribution",Household ITN retention,Clinton Health Access Initiative Inc.,Other,Household ITN retention,Household percentage of ITNs hung,Household percentage of ITNs hung,NA,NA,NA,NA,"The percentage of pre-registered households that collected ITNs at the community point distributions on November 14, 19, and 21, 2013.",NA,NA,NA,NA,NA,NA,Household percentage of sleeping spaces covered,Household percentage of sleeping spaces covered,NA,NA,NA,NA,NA,NA,The percentage of ITNs distributed to a household that the CHW found hanging at his/her visit.,An average of 9 weeks after community point distribution,The percentage of ITNs distributed to a household that were found still in the household at the 7-11 week follow-up.,An average of 5.5 months after community point distribution,The percentage of ITNs distributed to a household that were found still in the household at the 5-6 month follow-up.,NA,NA,An average of 9 weeks after community point distribution,The percentage of ITNs distributed to a household that were found hanging during the 7-11 week follow-up.,An average of 5.5 months after community point distribution,The percentage of ITNs distributed to a household that were found hanging during the 5-6 month follow-up.,An average of 9 weeks after community point distribution,The percentage of sleeping spaces in the household that were covered by an ITN distributed during the community point distribution at the 7-11 week follow-up.,An average of 5.5 months after community point distribution,The percentage of sleeping spaces in the household that were covered by an ITN distributed during the community point distribution at the 5-6 month follow-up.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CKAE609X2202,NCT01860989,"A Study to Assess Efficacy, Safety of KAE609 in Adult Patients With Acute Malaria Mono-infection","An Open Label, Single Dose Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of KAE609 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum Malaria Mono-infection",Completed,July 2013,August 2014,Actual,Actual,Novartis Pharmaceuticals,Novartis Pharmaceuticals,Study Director,Novartis Pharmaceuticals,Phase 2,Interventional,11,Actual,Cure Rate,NA,All,20 Years,60 Years,No,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,28-day Cure Rate,NA,NA,NA,NA,NA,NA,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"28-day cure rate was measured by the endpoint of complete cure without recrudescence before Day 29. The primary variable of 28-day cure rate was defined as the proportion of patients with clearance of asexual parasitemia (by blood film) by day 6 of the study, and without subsequent recrudescence (by blood film).",NA,NA,NA,NA,NA,NA,NA,NA,28-day Cure Rate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AC-071-102,NCT02223871,Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects,A Proof-of-concept Study to Assess the Effect of ACT-451840 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Subjects,Completed,June 2014,July 2014,Actual,Actual,Actelion,Michelle Lee,Study Director,Actelion,Phase 1,Interventional,8,Actual,Healthy Subjects,NA,Male,18 Years,50 Years,Accepts Healthy Volunteers,Actelion,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Drug-specific Parasite Reduction Ratio (PRR48) of ACT-451840 Over 48 Hours Using a Standardized Approach,NA,NA,NA,NA,NA,Q-Pharm Clinics,48 hours after study drug administration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"After the blood stage Plasmodium falciparum challenge (BSPC), malaria parasitemia was measured by polymerase chain reaction (PCR) in regularly collected blood samples.
The subject-specific and drug-specific parasite reduction rates over a 48 h period (PRR48) were calculated using an objective standardized approach (observed data over 48 h)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR#1877,NCT01849640,Antimalarial Drug Resistance With Assessment of Transmission Blocking Activity,Active Surveillance for P. Falciparum Drug Resistance With Assessment of Transmission Blocking Activity of Single Dose Primaquine in Cambodia,Suspended,December 2012,June 2016,Anticipated,Anticipated,David Saunders,"David Saunders, MD, MPH",Principal Investigator,"Dept. of Immunology and Medicine, Armed Forces Research Institute of Medical Sciences (AFRIMS)",N/A,Interventional,150,Anticipated,Uncomplicated Plasmodium Falciparum Malaria,NA,All,18 Years,65 Years,No,David Saunders,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Clinical efficacy of DP,NA,"National Centre for Parasitology, Entomology and Malaria Control, Cambodia",Other,Royal Cambodian Armed Forces,Other,Anlong Veng Referral Hospital,3 years,NA,NA,US Department of Defense Armed Forces Health Surveillance Center,Other,NA,NA,NA,NA,NA,NA,NA,Efficacy rates at 42 days (with 95% confidence intervals) for DP with and without single dose primaquine for uncomplicated P. falciparum diagnosed by positive PCR-corrected malaria microscopy.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CKNT_1,NCT00550160,The Synergistic Effects of Home-management and Intermittent Preventive Treatment of Malaria in Children,The Clinical Impact of Seasonal Intermittent Preventive Treatment (IPT) and Home Management of Malaria (HMM) Using AQ+AS in Ghanaian Children Under 5 Years of Age - a Cluster Randomised Placebo Controlled Trial.,Completed,April 2007,October 2008,Actual,Actual,Kwame Nkrumah University of Science and Technology,"Harry Tagbor, DrPH",Principal Investigator,"Department of Community Health, School of Medical Science, Kwame Nkrumah University of Science & Technology",Phase 4,Interventional,1490,Actual,Malaria,NA,All,3 Months,59 Months,Accepts Healthy Volunteers,Kwame Nkrumah University of Science and Technology,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Edmund Browne, PhD",Principal Investigator,"Department of Community Health, School of Medical Sciences, Kwame Nkrumah University of Science & Technology",NA,Incidence rate of clinical episodes of malaria per child per year,NA,"Department for International Development, United Kingdom",Other,"Malaria Consortium, UK",Other,District Health Administration,One year,NA,NA,Center for International Health and Development,Other,NA,NA,NA,NA,NA,NA,NA,NA,"Helen Counihan, PhD",Principal Investigator,"Malaria Consortium, UK","Sylvia Meek, PhD",Principal Investigator,"Malaria Consortium, UK",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
114001,NCT01190202,Epidemiology Study of Malaria Transmission Intensity in Africa,Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa,Completed,March 2011,December 2013,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,N/A,Observational,13380,Actual,Malaria,NA,All,6 Months,N/A,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of Plasmodium falciparum parasitemia during the first year,Occurrence of P. falciparum parasitemia during the second year,The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,NA,At year 1,At year 2,Occurrence of P. falciparum parasitemia during the third year,NA,NA,Occurrence of P. falciparum parasitemia during the fourth year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  Subjects who the investigator believes that they and/or their parent(s)/Legally
             Acceptable Representative(s) can and will comply with the requirements of the
             protocol.

          -  A male or female 6 months or older at the time of survey.

          -  Written informed consent obtained from the subject/from the parent(s)/ Legally
             Acceptable Representative(s) of the subject.

        Exclusion Criteria:

          -  Child in care.

          -  Previous or current participation in any malaria vaccine trial.
      ",NA,NA,NA,NA,At year 3,NA,At year 4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AL-eff 2010-2,NCT01133314,Artemether-Lumefantrine Effectiveness in Guinea-Bissau 2,The Routine Use of Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum in Bissau - 2,Unknown status,May 2010,March 2014,Anticipated,Anticipated,Bandim Health Project,"Poul-Erik Kofoed, MD, Ph.d.",Principal Investigator,Bandim Health Project,N/A,Observational,600,Anticipated,Malaria,NA,All,N/A,15 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of children treated for malaria with a parasitological confirmed malaria.,NA,NA,NA,NA,NA,Bandim Health Project,6 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The blood samples will be analysed for parasites at the end of the study. The results do not have any impact on the treatment of the children.,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Children seeking a health centre and by the health staff given the diagnosis: malaria
             and/or being treated with an antimalarial.

        Exclusion Criteria:

          -  Children where the parents do not accept to participate in the study.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ULagosclinicaltrials,NCT01152931,Antioxidant Micronutrients in Malaria,Antioxidant Micronutrients in Malaria:a Randomised Clinical Trial,Completed,August 2010,December 2010,Actual,Actual,"University of Lagos, Nigeria","Osede Ignis Iribhogbe, MB.BS, M.Sc",Principal Investigator,"Department of Pharmacology and Therapeutics, College of Medicine, Ambrose Alli University, Ekpoma",Phase 3,Interventional,10,Actual,Malaria,NA,All,6 Months,5 Years,No,"University of Lagos, Nigeria",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Ibrahim Oreagba, B.Pharm, M.Sc, Ph.D",Study Director,"Deparment of Pharmacology, College of Medicine, University of Lagos, Nigeria",NA,7-day cure rate,NA,NA,NA,NA,NA,NA,4 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,7-day Cure rate will be defined as initial and sustained parasite and symptom clearance with no increase in asexual parasitemia 48 h after the initiation of treatment and the absence of microscopically detected asexual parasitemia within 120 h of the commencement of treatment until day 7,"Elizabeth O. Agbaje, B.Sc, M.Sc, MPhil, Ph.D",Study Chair,"Department of Pharmacology, College of Medicine University of Lagos, Nigeria","Prof. Onyebiguwa Patrick NMORSI, PhD, MD",Study Director,"Dean, Faculty of Natural Sciences Ambrose Alli University Ekpoma",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
07-0003,NCT00460525,Phase II AMA-1 Malaria Vaccine FMP2.1/AS02A Trial in Mali,"Randomized, Controlled Phase II Clinical Trial to Evaluate the Safety, Immunogenicity and Efficacy of the AMA-1 Malaria Vaccine FMP2.1/AS02A Versus Rabies Vaccine in 1-6 Year Old Children in Bandiagara, Mali",Completed,May 2007,July 2009,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Mahamadou A Thera, MD, MPH",Principal Investigator,University of Bamako,Phase 2,Interventional,400,Actual,Plasmodium Falciparum Malaria,NA,All,1 Year,6 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the First Vaccination,Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Second Vaccination.,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"University of Bamako, Malaria Research and Training Center",0-7 days after first vaccination,0-7 days after the second vaccination,Number of Subjects Reporting Solicited Adverse Events During the 7-day Surveillance Period After the Third Vaccination.,GlaxoSmithKline,Industry,Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the First Vaccination,Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Second Vaccination,Number of Unsolicited Non-serious Adverse Events Reported During the 30-day Surveillance Period After the Third Vaccination,"University of Maryland, Baltimore County",Other,NA,NA,"Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after each vaccination. ""Reported Limitation of Arm Motion"" refers to the parents' report of the symptom while ""Limitation of Arm Motion"" refers to the clinicians' assessment of the symptom, collected separately.",NA,NA,NA,NA,NA,NA,Time to First Clinical Malaria Episode With Significant Parasitemia (2500/mm^3) and Temperature of Greater Than or Equal to 37.5 Degrees C.,Number of Subjects Reporting Serious Adverse Events,NA,NA,NA,NA,NA,NA,"Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after vaccination. ""Reported Limitation of Arm Motion"" refers to the parents' report of the symptom while ""Limitation of Arm Motion"" refers to the clinicians' assessment of the symptom, collected separately.",0-7 days after the third vaccination,"Solicited symptoms were recorded by study staff at clinic visits on Days 0, 1, 2 and 7 after vaccination. ""Reported Limitation of Arm Motion"" refers to the parents' report of the symptom while ""Limitation of Arm Motion"" refers to the clinicians' assessment of the symptom, collected separately.",Day 0-29 after first vaccination,"Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.",NA,NA,Day 0-29 after second vaccination,"Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.",Day 0-29 after third vaccination,"Unsolicited non-serious adverse events reported are those occurring within 30 days after vaccination. The categories are the MedDRA System Organ Classes for which at least one adverse event was reported. All non-serious adverse events are included, regardless of severity or relationship to vaccination.",Occurring between randomization and 6 months after the assigned date of the 3rd immunization.,"Time to first clinical malaria episode is displayed in a life table format to display the number of subjects at risk, the number with first clinical episode and the number censored at each time point.",24 months after initial vaccination,"A serious adverse event was defined as any untoward medical occurrence that results in death, is life threatening, results in persistent or significant disability/incapacity, requires in-patient hospitalization or prolongation of existing hospitalization or is a congenital anomaly/birth defect in the offspring of a study subject. In addition, important medical events that may jeopardize the participant or may require intervention to prevent one of the other outcomes listed above was considered serious.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACOIII,NCT00465257,Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction in Zanzibar,Efficacy of Artesunate + Amodiaquine Four Years After Its Introduction as New Treatment Policy for Uncomplicated Plasmodium Falciparum Malaria in Zanzibar,Suspended,May 2007,NA,NA,NA,Karolinska University Hospital,"Anders Björkman, Professor",Study Director,Karolinska UH,Phase 4,Interventional,110,Anticipated,Malaria,PCR adjusted parasitological cure rate by day 42.,All,6 Months,59 Months,No,Karolinska University Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Guida Rotlland, MD, MPH",Principal Investigator,Karolinska UH,NA,NA,NA,NA,NA,NA,NA,Kivunge Cottage Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,PCR adjusted parasitological cure rate by day 42.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A-7540,NCT02491606,Evaluation of Weekly Tafenoquine,Evaluation of Weekly Tafenoquine (SB 252263 / WR 238605) Compared to Placebo for Chemosuppression of Plasmodium Falciparum in Western Kenya,Completed,May 1997,September 1998,Actual,Actual,U.S. Army Medical Research and Materiel Command,A.J Oloo,Principal Investigator,Kenya Medical Research Institute,Phase 2,Interventional,249,Actual,Malaria,NA,All,18 Years,55 Years,No,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Prophylactic outcome.,NA,SmithKline Beecham,Industry,NA,NA,NA,13 Weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Thick blood films were stained with Giemsa stain and malaria parasite counts determined by counting the number of asexual parasites per 200 white blood cells.
A blood slide was not considered negative until an examination of 200 oil immersion fields showed no parasites.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
06-0084,NCT00466557,Plasmodium Resistance in A. Gambiae,Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae,Unknown status,June 2007,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Malaria; Plasmodium Falciparum Malaria,NA,All,5 Years,10 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,Centre National de Recherche et de Formation sur le Paludisme,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR #1296,NCT00479206,Artemisinin Resistance in Cambodia,Artemisinin Resistance in Cambodia,Completed,October 2006,February 2007,Actual,Actual,Medical University of Vienna,"Harald Noedl, MD, MCTM, PhD",Study Director,USAMC-AFRIMS,N/A,Interventional,NA,NA,"Malaria, Falciparum",Primary clinical outcome is cure (Adequate Clinical and Parasitological Response - ACPR as defined by WHO criteria) on Day 28.,All,18 Years,65 Years,No,Medical University of Vienna,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,Global Emerging Infections Surveillance and Response System,U.S. Fed,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,Tasanh Health Center,NA,NA,NA,"National Center for Parasitology, Entomology and Malaria Control",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QA620,NCT02325180,"Artemisinin-based Combination Therapy for Treatment of Plasmodium Falciparum Malaria in North Sumatera, Indonesia","Clinical Efficacy of Artemisinin-based Combination Therapy for Treatment of Uncomplicated Plasmodium Falciparum Malaria in North Sumatera, Indonesia and the Association of Molecular Markers With Treatment Outcomes",Completed,January 2015,June 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,"Colin J Sutherland, BSc PhD MPH",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 4,Interventional,338,Actual,"Malaria, Falciparum",NA,All,6 Months,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Efficacy of dihydroartemisinin-piperaquine and artemether-lumefantrine,NA,University of Sumatera Utara,Other,NA,NA,NA,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Early treatment failure, late treatment failure, adequate clinical and parasitological response Proportion of participants with Adequate Clinical and Parasitological Response",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UYaounde1,NCT02563704,A Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon,A Randomized Trial of the Efficacy of Artesunate and Three Quinine Regimens in the Treatment of Severe Malaria in Children at the Ebolowa Regional Hospital - Cameroon,Completed,September 2013,March 2014,Actual,Actual,University of Yaounde 1,Elie MBONDA,Study Director,"Faculty of Medicine and Biomedical Sciences, University of Yaounde I",Phase 3,Interventional,238,Actual,Malaria,NA,All,3 Months,15 Years,No,University of Yaounde 1,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Fever clearance time,Coma recovery time,NA,NA,NA,NA,NA,Time (in hours) from the onset of treatment till rectal temperature went down to 37.5°C for at least 24 hour,Time (in hours) from the onset of treatment till the participant was fully conscious with a BCS of 5 or GCS of 15 for an average of 24 hours,Time to sit unsupported,NA,NA,Time to eat and drink,Parasite clearance time,Parasite reduction rate 24 hours after onset of treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Time (in hours) from the onset of treatment till when the participant could sit unsupported for an average of 24 hours if the participant was unable to do so on admission,NA,Time (in hours) from the onset of treatment till when the participant could eat and drink for an average of 24 hours if the participant was unable to do so on admission,NA,NA,NA,"Time (in hours) from the onset of treatment to the time of the first of two successive negative blood smear through hospital discharge, an average of one week",NA,24 hours from onset of treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP14C12,NCT02389348,A Phase Ib Induced Malaria Infection Study With the Combination of OZ439 and DSM265,A Proof-of-concept Study to Assess the Effect of a Range of Doses of Combined Therapy With OZ439 and DSM265 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants,Completed,February 2015,June 2015,Actual,Actual,Medicines for Malaria Venture,"James McCarthy, Prof",Principal Investigator,Q-Pharm Pty Limited,Phase 1/Phase 2,Interventional,13,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PK/PD relationship on clearance of P falciparum parasites from the blood,NA,Q-Pharm Pty Limited,Industry,QIMR Berghofer Medical Research Institute,Other,Q-Pharm Clinics,"From treatment administration to clearance of parasites or administration of Standard of Care therapy, whichever comes first, and up to 42 days following inoculum",NA,NA,Clinical Network Services (CNS) Pty Ltd,Industry,NA,NA,NA,NA,NA,NA,NA,The Parasite Reduction Ratio (PRR) is estimated using the slope of the optimal fit of the log-linear relationship of the parasitemia decay.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CTS-5031,NCT02118428,Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria,AIMS Study: African Investigation of Mirasol System for Whole Blood. Clinical and Biological Efficacy of Mirasol-treated Fresh Whole Blood for the Prevention of Transfusion-transmitted Malaria,Completed,March 2014,December 2014,Actual,Actual,Terumo BCTbio,"Shirley Owusu-Ofori, MD",Principal Investigator,Komfo Anokye Teaching Hospital,N/A,Interventional,226,Actual,Malaria,NA,All,18 Years,N/A,No,Terumo BCTbio,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Transfusion-transmitted Malaria,NA,NA,NA,NA,NA,Komfo Anokye Teaching Hospital,Within 28 days post-transfusion,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
USARIEM C07-04,NCT01166815,Zinc Supplementation to Reduce Diarrhea Rates in Adults in Western Kenya.,"A Randomized, Double Blind, Controlled Study to Determine the Efficacy of Zinc Supplementation on Diarrhea Incidence in an Adult Population in Western Kenya.",Completed,July 2007,January 2008,Actual,Actual,United States Army Research Institute of Environmental Medicine,"Maria E Bovill, Dr.PH",Principal Investigator,"U.S. Army Medical Research Unit - Kenya (USAMRU-K), Kisumu, Kenya",Phase 2/Phase 3,Interventional,500,Actual,Diarrhea; Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,United States Army Research Institute of Environmental Medicine,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Mark E Polhemus, MD",Principal Investigator,"U.S. Army Medical Research Unit - Kenya (USAMRU-K), Kisumu, Kenya",NA,Determine the incidence of diarrhea in zinc vs. placebo-supplemented adults,NA,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,"Daily, for 104 days",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Diarrhea is defined as 3 or more loose motions within a period of 24 hours. Field workers will visit each subject to record diarrhea morbidity data, daily for 104 days.","Lucas Otieno, MB.ChB",Principal Investigator,"Kenya Medical Research Institute (KEMRI)/Walter Reed Project (WRP), Kisumu, Kenya","Stella K Apollo, BSN",Study Director,"Walter Reed Project (WRP), Kisumu, Kenya",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
10.55,NCT01210040,Long-term Iron Supplements and Malaria Risk in Early Pregnancy: a Randomized Controlled Trial,Malaria Risk Prior to and During Early Pregnancy in Nulliparous Women Receiving Long-term Weekly Iron and Folic Acid Supplementation (WIFS): a Non-inferiority Randomized Controlled Trial,Completed,April 2011,January 2014,Actual,Actual,Liverpool School of Tropical Medicine,"Bernard J BRABIN, Professor",Study Director,Liverpool School of Tropical Medicine,N/A,Interventional,1959,Actual,Malaria,NA,Female,15 Years,24 Years,Accepts Healthy Volunteers,Liverpool School of Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Sabine GIES, MD, MTropMed, PhD",Principal Investigator,Clinical Research Unit Nanoro (CRUN),NA,Prevalence of peripheral parasitaemia at first antenatal clinic visit (13-16 weeks gestation),NA,"Institute of Tropical Medicine, Belgium",Other,University of Manchester,Other,"Institute de Recherche en Sciences de la Sante, Direction Regionale de l'Ouest (IRSS-DRO) - / Centre Muraz",Nov 2013,NA,NA,Institut de Recherche en Sciences de la Sante-Direction Regionale de l'Ouest,Other,NA,NA,NA,Centre Muraz,Other,National Institutes of Health (NIH),NIH,Completed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_10_002,NCT01213966,"Efficacy, Tolerability, PK of OZ439 in Adults With Acute, Uncomplicated P.Falciparum or Vivax Malaria Mono-infection","Phase IIa Exploratory, Open Label, Single/Multiple Dose Testing Clinical Study to Assess the Preliminary Efficacy, Tolerability and PK of OZ439 in Adult Patients With Acute, Uncomplicated P. Falciparum or Vivax Malaria Mono-infection",Completed,October 2010,May 2012,Actual,Actual,Medicines for Malaria Venture,"Sasithon Pukrittayakamee, MD",Principal Investigator,Mahidol University,Phase 2,Interventional,82,Actual,"Malaria, Falciparum; Malaria, Vivax",NA,All,18 Years,60 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Derived Parasite Reduction Rate at 24 Hours (PPR24),NA,Mahidol University,Other,NA,NA,NA,24 hours after study drug administration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PRR24 is the log10 change in parasitemia over 24 hours estimated from a regression model fit separately for each patient. The relationship between parasite counts and time was analyzed by fitting a variable lag phase, then a linear decline to the natural log of parasite count versus time relationship. The slope of this log linear relationship is the primary end-point.
The time points chosen for the regression are those that yield the highest degree of significance when assessing the regression when the number of time points are greater than or equal to 3. No extrapolation was performed.",NA,NA,NA,NA,NA,NA,NA,NA,Derived Parasite Reduction Rate at 24 Hours (PPR24),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ZonMw1,NCT01218893,Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis,Immunization With Different Doses of Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis,Completed,April 2011,March 2012,Actual,Actual,Radboud University,"Leo G Visser, MD, PhD",Principal Investigator,Leiden University Medical Centre,N/A,Interventional,30,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Period to thick smear positivity after challenge in groups 1, 2, 3 and 4","Parasitemia and kinetics of parasitemia as measured by PCR in groups 1, 2, 3 and 4",NA,NA,NA,NA,Leiden University Medical Centre,21 days after challenge (day 218 of study),21 days after challenge (day 218 of study),"Frequency of signs or symptoms in groups 1, 2, 3 and 4",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Day 21 after challenge (day 218 of study),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
GN 02 - Pilot,NCT00489619,Safe Pregnancy by Infectious Disease Control,Safe Pregnancy by Infectious Disease Control in the Democratic Republic of Congo - Pilot Study,Completed,April 2004,March 2005,Actual,Actual,NICHD Global Network for Women's and Children's Health,"Robin Ryder, M.D.",Principal Investigator,University of North Carolina,N/A,Observational,2008,Actual,Pregnancy; Malaria,NA,Female,15 Years,N/A,Accepts Healthy Volunteers,NICHD Global Network for Women's and Children's Health,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,Global Network for Women's and Children's Health Research,Other,Bill and Melinda Gates Foundation,Other,NA,NA,NA,NA,John E. Fogarty International Center (FIC),NIH,NA,NA,NA,National Center for Complementary and Integrative Health (NCCIH),NIH,National Institute of Dental and Craniofacial Research (NIDCR),NIH,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,National Cancer Institute (NCI),NIH,RTI International,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,University of North Carolina,Other,Kinshasa School of Public Health,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1-Dondorp,NCT00493363,Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia,Clinical Investigation of In-vivo Susceptibility of P.Falciparum to Artesunate in Western Cambodia,Completed,June 2007,December 2009,Actual,Actual,University of Oxford,"Nicholas J White, DSc,FRCP,FRS",Principal Investigator,Oxford University/ Mahidol University,N/A,Interventional,40,Anticipated,Falciparum Malaria,NA,All,6 Years,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Duong Socheat, MD",Study Chair,National Malaria Control Programme Cambodia,NA,parasite clearance times in relation to artesunate/DHA plasma concentrations (PK-PD),NA,World Health Organization,Other,NCHADS - Ministry of Health of Cambodia,Other,Pailin Referal Hospital,June 2008,NA,NA,Mahidol University,Other,NA,NA,NA,Institut Pasteur,Industry,FHI 360,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Li Ka Shing Foundation,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PROMOTE-BC2,NCT02282293,Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE-BC2),Reducing the Burden of Malaria in HIV-Infected Pregnant Women and Their HIV-Exposed Children (PROMOTE Birth Cohort 2),"Active, not recruiting",December 2014,August 2018,Anticipated,Anticipated,"University of California, San Francisco","Diane V Havlir, MD",Principal Investigator,"University of California, San Francisco",Phase 3,Interventional,200,Actual,Malaria; Human Immunodeficiency Virus,NA,Female,16 Years,N/A,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Grant Dorsey, MD, PhD",Principal Investigator,"University of California, San Francisco",NA,Prevalence of placental malaria,"Incidence of malaria, pregnant women",Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,IDRC Research Clinic - Tororo District Hospital,at delivery estimated to be within 10 to 30 weeks of study entry,"Time at risk will begin at birth and will end when study participants reaches 24 months of age, when the intervention will be stopped, or early study termination (if prior to 24 months of age).","Incidence of malaria, infants during the first 24 months of life",NA,NA,Virologic suppression in pregnant women,"Incidence of malaria, infants during 24 - 36 months of life",NA,NA,NA,NA,NA,The primary outcome will be the prevalence of placental malaria based on placental histopathology and dichotomized into any evidence of placental infection (parasites or pigment) vs. no evidence of placental infection.,"Moses R Kamya, MBChB, MMed, PhD",Principal Investigator,Makerere University; Infectious Disease Research Collaboration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The primary outcome will be the incidence of malaria, defined as the number of incident episodes per time at risk. Incident cases will include all treatments for malaria not proceeded by another treatment in the previous 14 days.",Time at risk will begin at birth and will end at 24 months of life,Infants born to mothers randomized to receive IPTp with daily TS + monthly DP are anticipated to have a lower incidence of malaria during the first 24 months of life compared to infants born to mothers who were randomized to receive IPTp with daily TS + monthly DP placebo,at delivery estimated to be within 10 to 30 weeks of study entry,The primary outcome is virologic suppression defined as HIV-1 RNA viral load less than 400 copies/ml.,NA,NA,24 - 36 months of life,Infants randomized to receive daily TS + monthly DP between 2-24 months of age will have a lower incidence of malaria between 24-36 months of age after the intervention is stopped compared to infants randomized to daily TS + monthly DP placebo between 2-24 months of age.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-CGH-2015-204,NCT02600767,Artemeter-lumefantrine for Treatment of P. Falciparum Malaria in Brazil,"Evaluating the Efficacy of Artemether-lumefantrine for Treatment of Plasmodium Falciparum Malaria in Cruzeiro do Sul, Acre, Brazil",Not yet recruiting,December 2015,June 2017,Anticipated,Anticipated,Centers for Disease Control and Prevention,"Alexandre Macedo de Oliveira, MD",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,81,Anticipated,Malaria,NA,All,5 Years,N/A,Accepts Healthy Volunteers,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Absence of malaria parasites in blood.,Absence of malaria parasites in blood.,Secretaria Estadual de Saúde do Acre,Other,"Ministry of Health, Brazil",Other,Hospital do Jurua,28 days,28 days,NA,Evandro Chagas National Institute of Infectious Disease,Other,NA,NA,NA,NA,NA,NA,NA,Investigators will evaluate the percentage of patients who remain free of malaria parasites in the blood during the 28-day follow-up period.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Investigators will evaluate the percentage of patients who remain free of malaria symptoms in the blood during the 28-day follow-up period.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
GHS-A-00-00020-00-5,NCT00513500,Zambia Integrated Management of Malaria and Pneumonia Study,Zambia Integrated Management of Malaria and Pneumonia Study,Completed,June 2007,September 2009,Actual,Actual,Boston University,"Kojo Yeboah-Antwi, MD, MPH",Principal Investigator,Center for International Health and Development,N/A,Interventional,3125,Actual,Pneumonia; Malaria,NA,All,6 Months,5 Years,No,Boston University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Children Who Received Early and Appropriate Treatment for Pneumonia.,Number of Children With Fever Who Received Coartem (Artemether-lumefantrine),Center for International Health and Development,Other,United States Agency for International Development (USAID),U.S. Fed,Chikankata Health Services,one year,one year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Early and appropriate is defined as receiving 13-15 doses of amoxicillin over 5 days and receiving the first dose within 24-48 hours of onset of first symptom,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PMAL03,NCT00513669,"Phase Ib Trial of Two Virosome Formulated Malaria Vaccine Components (PEV 301, PEV 302) in Tanzania",A Phase Ib Double-blind Randomized Placebo Controlled Age-deescalating Trial of Two Virosome Formulated Anti-malaria Vaccine Components (PEV 301 and PEV 302) Administered in Combination to Healthy Semi-immune Tanzanian Volunteers,Completed,January 2008,March 2009,Actual,Actual,Swiss Tropical & Public Health Institute,"Blaise Genton, MD PhD",Principal Investigator,"Swiss tropical institute, Ifakara Health Research and Development Center",Phase 1,Interventional,50,Actual,Falciparum Malaria,NA,All,5 Years,45 Years,Accepts Healthy Volunteers,Swiss Tropical & Public Health Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety (incidence of local and systemic adverse events) Humoral immunity,NA,Mymetics Corporation,Industry,Pevion Biotech Ltd,Industry,Bagamoyo Research and Training Unit,30 days post-injection,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MC-004,NCT02313376,"Safety, Attenuation and Immunogenicity of GAP3KO Administered Via A Stephensi Mosquitoes","Trial to Assess the Safety, Attenuation and Immunogenicity of Genetically-attenuated p52-/p36-/sap1- Plasmodium Falciparum Parasites (GAP3KO) Administered Via Infected Anopheles Stephensi Mosquitoes to Malaria-Naïve Adults",Completed,December 2014,August 2015,Actual,Actual,Seattle Biomedical Research Institute,NA,NA,NA,Phase 1,Interventional,10,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Seattle Biomedical Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Safety assessed by frequency of AEs, SAEs, and patent parasitemia via peripheral blood smear",NA,NA,NA,NA,NA,Seattle Biomedical Research Institute Malaria Clinical Trial Center,28 Days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC058,NCT02083887,A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants,A Phase I Study to Assess the Safety and Immunogenicity of ChAd63 ME-TRAP - MVA ME-TRAP Heterologous Prime-boost Vaccination Co-administered With EPI Vaccines in Gambian Infants,Completed,February 2014,November 2015,Actual,Actual,University of Oxford,Muhammed Afolabi,Principal Investigator,"Medical Research Council Unit, The Gambia Unit",Phase 1,Interventional,65,Actual,Malaria,NA,All,N/A,16 Weeks,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety of ChAd63 ME-TRAP / MVA ME-TRAP prime boost immunisation co-administered with EPI vaccines,NA,Malaria Vectored Vaccines Consortium,Other,NA,NA,"Medical Research Council Unit, Fajara","Participants will be followed for the duration of the study, an expected average of 36 weeks",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Recording of all solicited and unsolicited local and systemic adverse events (including laboratory abnormalities considered adverse events) and the assessment of their causal relationships to the investigative medicinal products (IMPs).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NIMPE - ITM- P.f,NCT02604966,P. Falciparum Resistance to Artemisinin in Vietnam,Efficacy of Artesunate Monotherapy and Dihydroartemisinin - Piperaquine in Patients With Uncomplicated Falciparum Malaria in Central Vietnam,Recruiting,April 2015,December 2016,Anticipated,Anticipated,"National Institute of Malariology, Parasitology and Entomology, Vietnam","Duong Tran, MD, PhD",Principal Investigator,"National Institute of Malariology, Parasitology and Entomology, Hanoi, Vietnam",Phase 4,Interventional,120,Anticipated,Drug Resistant Malaria Due to Plasmodium Falciparum,NA,All,1 Year,N/A,No,"National Institute of Malariology, Parasitology and Entomology, Vietnam",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Anna Rosanas-Urgell, MD, PhD",Principal Investigator,"Institute of Tropical Medicine, Antwerp, Belgium",NA,Median parasite clearance time after treatment with Artesunate or with DHA - PIP,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,Chu R Cam commune,From time of first treatment dose (day0 hh-mm) until day and time of parasite clearance (=two consecutive blood samples are found negative for parasites) assessed up day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Median parasite clearance time (total hours) in both arms (by light microscopy (LM) and quantitative real time PCR (qPCR)) will be computed using the 12-hourly parasite density measurements from day0 till parasite clearance. Parasite clearance time (in hours) will be computed using the Parasite Clearance Estimator tool available online (http://www.wwarn.org/toolkit/data-management/parasite-clearance-estimator).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Malawi TES 2014,NCT02637128,In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated P. Falciparum Malaria,"In Vivo Efficacy of Artemether-Lumefantrine and Artesunate-Amodiaquine for Uncomplicated Plasmodium Falciparum Malaria in Malawi, 2014",Completed,March 2014,July 2014,Actual,Actual,Centers for Disease Control and Prevention,"Don P Mathanga, MBBS, PhD",Principal Investigator,"1. Malaria Alert Centre (MAC), University of Malawi College of Medicine, Blantyre, Malawi",Phase 4,Interventional,452,Actual,"MALARIA, FALCIPARUM",NA,All,6 Months,59 Months,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adequate clinical and parasitological response (ACPR),NA,University of Malawi College of Medicine,Other,NA,NA,"Malaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi",28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Absence of parasitaemia on day 28, assessed by microscopy, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure",NA,NA,NA,NA,NA,NA,NA,NA,Adequate clinical and parasitological response (ACPR),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WB-Malaria- Tanzania.,NCT02590627,In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure,In-vivo Efficacy and Safety of Artemether/Lumefantrine Vs Dihydroartemisinin-piperaquine for Treatment of Uncomplicated Malaria and Assessment of Parasite Genetic Factors Associated With Parasite Clearance or Treatment Failure,"Active, not recruiting",May 2014,December 2015,Anticipated,Anticipated,"National Institute for Medical Research, Tanzania","Deus Ishengoma, PHD",Principal Investigator,National Institute for Medical Research,Phase 4,Interventional,600,Anticipated,Malaria,NA,All,6 Months,10 Years,No,"National Institute for Medical Research, Tanzania",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Celine Mandara, MD, Msc",Study Director,National Institute for Medical Research,NA,parasitological cure on day 28 for ALu and 42 for DHA-PQ,NA,"Ministry of Health and Social Welfare, Tanzania",Other,World Health Organization,Other,NA,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,non-adjusted and adjusted by PCR to account for new infections.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LiHMS,NCT01785979,Prednisone Plus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly,Prednisone Plus Chloroquine Versus Chloroquine for the Treatment of Hyper-reactive Malarial Splenomegaly in Papua New Guinea: a Randomized Open-label Trial,Withdrawn,January 2016,February 2017,Anticipated,Anticipated,Lihir Medical Centre,"Oriol Mitja, PhD",Principal Investigator,Lihir Medical Centre,Phase 3,Interventional,0,Actual,Hyper-reactive Malarial Splenomegaly; Malaria; Anaemia,NA,All,18 Years,N/A,No,Lihir Medical Centre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,composite clinical & immunological endpoint,NA,NA,NA,NA,NA,Lihir medical Centre,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Clinical cure, defined as a sustained reduction in spleen size of at least 40% at the 12 month follow up examination, compared with the spleen size at the baseline examination. Immunological cure, defined as a two-fold decrease of total immunoglobulin M levels is also needed.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
﻿﻿OPP1002407,NCT01972321,ICCM of Common Childhood Diseases: Mozambique and Uganda,Integrated Community Case Management of Common Childhood Diseases: Mozambique and Uganda,Completed,April 2013,December 2015,Actual,Actual,Malaria Consortium,"Sylvia Meek, PhD",Study Director,Malaria Consortium,N/A,Interventional,2289,Actual,Malaria; Pneumonia; Diarrhoea,NA,All,N/A,N/A,Accepts Healthy Volunteers,Malaria Consortium,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Appropriate treatment of malaria, pneumonia and diarrhoea in children under five years of age",NA,London School of Hygiene and Tropical Medicine,Other,"University College, London",Other,NA,1 year,NA,NA,Karolinska Institutet,Other,NA,NA,NA,Makerere University,Other,NA,NA,"Proportion of children under five years of age with symptoms of malaria, pneumonia and diarrhoea who received appropriate treatment",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
6550,NCT02645513,"Text Message Reminders to Health Workers on Malaria, Pneumonia, and Diarrhea Case Management in Malawi",The Effect of Mobile Phone Text Message Reminders on Health Workers' Adherence to Malaria and Other Disease Case Management Guidelines in Malawi,"Active, not recruiting",January 2015,August 2016,Anticipated,Anticipated,Centers for Disease Control and Prevention,"Don Mathanga, MD, PhD",Principal Investigator,Malaria Alert Centre,N/A,Interventional,182,Actual,Malaria; Pneumonia; Diarrhea,NA,All,N/A,N/A,Accepts Healthy Volunteers,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Questionnaire measurement of diagnosis and treatment of malaria among outpatients,NA,Malaria Alert Centre,Other,NA,NA,NA,12 months after end of text messages,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Patient exit interviews will be used to assess: 1) whether all suspect malaria patients are tested with a malaria diagnostic test; 2) whether patients with a positive test are prescribed the first- or second-line antimalarial; and 3) whether dosing of antimalarials are correct.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EHMI9,NCT01236612,Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis,Experimental Human Malaria Infection After Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis,Completed,April 2011,June 2012,Actual,Actual,Radboud University,"Robert W Sauerwein, MD, PhD",Principal Investigator,Radboud University,N/A,Interventional,25,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Duration of prepatent period as measured by microscopy,Parasitemia and kinetics of parasitemia as measured by PCR,NA,NA,NA,NA,Radboud University Nijmegen Medical Centre,21 days after challenge,21 days after challenge,Frequency of signs or symptoms in study groups,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21 days after challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1102,NCT01288820,Study of ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria,"Comparison of the Efficacy and Safety of Two ACTs Plus Primaquine for Uncomplicated Plasmodium Vivax Malaria in North Sumatera, Indonesia: 1 Year Followup",Completed,January 2011,April 2012,Actual,Actual,University of Oxford,"Ayodhia Pitaloka Pasaribu, MD",Principal Investigator,"Department of Pediatric, Sumatera Utara University",Phase 3,Interventional,331,Actual,Vivax Malaria,NA,All,1 Year,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Assessment of cure rate of both arms AS-AQ + PQ and DHP+PQ,NA,Mahidol University,Other,"Ministry of Health, Indonesia",Other,Labuhan Batu Utara Regency Tanjung leidong village,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Evaluate the relative efficacy of the study drugs in providing parasite clearance over the observation period of 42 days.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_13_003,NCT02083380,Phase II Efficacy Study of Artefenomel & Piperaquine in Adults & Children With P. Falciparum Malaria.,"Randomised Phase IIb Study of Efficacy, Safety, Tolerability & Pharmacokinetics of a Single Dose Regimen of Artefenomel (OZ439) in Loose Combination With Piperaquine in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria.",Completed,July 2014,November 2015,Actual,Actual,Medicines for Malaria Venture,"Fiona Macintyre, PhD",Study Director,Medicines for Malaria Venture (MMV),Phase 2/Phase 3,Interventional,448,Actual,Uncomplicated Plasmodium Falciparum Malaria,NA,All,6 Months,70 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Michael Ramharter, MD",Principal Investigator,CERMEL (Centre de Recherches Médicale de Lambaréné),NA,PCR-adjusted ACPR at Day 28 in the PP Population (All Patients),PCR-adjusted ACPR at Day 28 in the PP Population: Asia (All Ages),NA,NA,NA,NA,NA,Day 28,Day 28,PCR-adjusted ACPR at Day 28 in the PP Population: Africa (All Ages),NA,NA,PCR-adjusted ACPR at Day 28 in the PP Population: Africa (> Than 5 Years),PCR-adjusted ACPR at Day 28 in the PP Population: Africa (< = 5 Years),PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>2 to <= 5 Years),NA,NA,NA,NA,"Polymerase chain reaction (PCR)-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification. Per protocol population (PP).
95% Clopper-Pearson 2-sided Confidence Interval (CI) constructed around the single binomial proportion per treatment arm and total.",NA,NA,NA,NA,NA,NA,PCR-adjusted ACPR at Day 28 in the PP Population: Africa (>= 0.5 to <= 2 Years),NA,NA,NA,NA,NA,NA,NA,"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.",Day 28,"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.",Day 28,"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.",NA,NA,Day 28,"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.",Day 28,"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.",Day 28,"PCR-adjusted adequate clinical and parasitological response (ACPR) at Day 28: defined as: absence of parasitaemia on Day 28, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure (ETF), late clinical failure (LCF) or late parasitological failure (LPF). Definition of ETF, LCF and LPF according to a modified standard WHO classification.
95% Clopper-Pearson 2-sided CI constructed around the single binomial proportion per treatment arm and total.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Epicentre/Mba/2011/TTBN-RDTmal,NCT01325974,Time to Become Negative of Three Rapid Diagnostic Tests for Malaria,"Time to Become Negative of Three Rapid Diagnostic Tests for Malaria in Children Under 5 Years of Age. Evaluation in Two Different Malaria Epidemiological Settings in Greater Mbarara District, South Western Uganda",Completed,September 2011,May 2013,Actual,Actual,Epicentre,"Francesco Grandesso, MSc",Principal Investigator,Epicentre,N/A,Observational,424,Actual,"Malaria, Falciparum",NA,All,N/A,5 Years,No,Epicentre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Carolyn Nabasumba, MD",Study Chair,Epicentre,NA,"To estimate the proportion of positive tests in patients successfully treated for malaria (smear negative) at different time points after treatment, for three rapid diagnostic tests: two HRP2 test and one pLDH test.",NA,"Medecins Sans Frontieres, Netherlands",Other,NA,NA,NA,"day 2, 3, 5, 7, 14, 21, 28, 35 and 42 after the start of antimalarial treatment intake",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Yap Boom, MSc, PhD",Study Chair,Epicentre,"Anne-Laure Page, PhD",Study Chair,Epicentre,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria (sensitivity/specificity analysis):

          -  Age under 5 years

          -  Clinical malaria defined as fever (axillary temperature ≥ 37.5°C) or history of fever
             in the previous 48 hours

          -  Weight ≥ 5 kg

          -  Informed consent given by the parent or a tutor

        Additional inclusion criteria (time to become negative analysis):

          -  Positive blood smear with a Plasmodium falciparum monoinfection at the day of
             inclusion

          -  At least one RDT positive at the day of inclusion

          -  High probability of coming to all follow-up visits

        Exclusion Criteria (time to become negative analysis):

          -  General signs of danger or of severe malaria according to the WHO criteria

          -  Treatment course of antimalarials in the previous 2 weeks
      ","Mathieu Bastard, MSc",Study Chair,Epicentre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Jean-François Etard, MD, PhD",Study Director,Epicentre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
5108,NCT01829815,"Impact of a Parenting Program in Liberia to Improve Parenting, Education, and Health Outcomes for Children in Liberia","Impact Evaluation of a Parenting Program to Improve Parenting, Education, and Health Outcomes for Young Children in Liberia",Completed,August 2012,March 2013,Actual,Actual,International Rescue Committee,"Eve Puffer, PhD",Principal Investigator,Duke University,N/A,Interventional,270,Actual,Parenting Behavior; Pre-academic and Developmental Skills; Malaria Prevention,NA,All,18 Years,N/A,Accepts Healthy Volunteers,International Rescue Committee,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Rhea Chase, PhD",Principal Investigator,Duke University,NA,Parenting Behavior Assessment (adapted from multiple scales for this context),Parenting Self-Efficacy and Beliefs Assessment (adapted from other scales for this context; includes unique items developed for this context),Duke University,Other,NA,NA,International Rescue Committee,1 month,1 month,Child Behavior Assessment (items adapted from the Strengths and Difficulties Questionnaire),NA,NA,Parent-Child Interaction Observation,Child Cognitive / Pre-Academic Abilities and Emotional Well-being,NA,NA,NA,NA,NA,"This is a caregiver-report survey measures including items on various parenting practices, including: caregiver-child communication; discipline and behavior management practices; caregiver-child affection and shared activities; caregiver involvement in child's school and educational activities. These items will yield several subscores for these different domains. Some items may also be analyzed as single items, as they measure specific and important outcomes (e.g., use of a harsh discipline strategy)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"These items assess parents' confidence in their parenting abilities and their beliefs about caregiving practices. This measure will yield separate scores for self-efficacy and beliefs about caregiving practices. Some items may also be analyzed as single items, as they measure specific and important outcomes (e.g., parents' belief about an aspect of harsh discipline)",1 month,"This tool assess children's behaviors and emotional well-being in the domains of hyperactivity, anger, aggression, mood, and peer relationships. They will be analyzed as an overall score, and single items may be analyzed for certain behaviors or indicators of emotional well-being.",1 month,"Caregivers and children in the study will be asked to engage in a play interaction for five minutes, and their verbal interactions will be audio-recorded. Recordings will be coded for specific behaviors. The coding system is adapted from the Dyadic Parent Child Interaction Coding System.",NA,NA,1 month,"Children will be administered activity-based items to assess a range of cognitive and learning skills, including verbal and language skills (as measured by several activities), numeracy, and pattern recognition. Items will be combined into composite scores but may also be analyzed separately to measure outcomes on specific abilities (e.g., counting). Children will also be asked five questions related to their emotional well-being adapted from the Strengths and Difficulties Questionnaire. These items will be analyzed as a sum score, and individual items may be analyzed for specific indicators of emotional well-being.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR2017,NCT02052323,Harmonized AS/MQ Efficacy Study - Thailand,Study to Determine the Efficacy of Artesunate-mefloquine Combination Therapy for the Treatment of Uncomplicated P. Falciparum Malaria in Thailand,Completed,October 2013,October 2015,Actual,Actual,"Armed Forces Research Institute of Medical Sciences, Thailand","Krisada Jongsakul, MD",Principal Investigator,"Armed Forces Research Institute of Medical Sciences, Thailand",Phase 4,Interventional,48,Actual,Malaria,NA,All,5 Years,65 Years,No,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite clearance rate,NA,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,Global Emerging Infections Surveillance and Response System,U.S. Fed,Kwai River Christian Hospital in Sangklaburi,one year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Parasite clearance rate as defined by the slope of the linear portion of the logarithm parasite clearance curve using microscopy to determine parasitemia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
5856,NCT01319448,Intermittent Preventive Treatment for Malaria in Patient With Sickle Cell Disease,Safety and Tolerability of Bi-monthly Intermittent Preventive Treatment With Mefloquine-Artesunate or Sulfadoxine-Pyrimethamine Plus Amodiaquine for Prevention of Malaria and Related Complications in Patients With Sickle Cell Anaemia.,Completed,September 2011,April 2013,Actual,Actual,London School of Hygiene and Tropical Medicine,"Paul J Milligan, PhD",Study Chair,LSHTM,Phase 1/Phase 2,Interventional,270,Actual,Malaria; Sickle Cell Crisis,NA,All,6 Months,45 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Kalifa Bojang, PhD",Study Director,MRC Laboratories,NA,Incidence of adverse events,Adherence to the recommended regimen,"Medical Research Council Unit, The Gambia",Other,Wellcome Trust,Other,"Department of Paediatrics and Child Health, University of Ilorin Teaching Hospital",12 months,12 months,NA,University of Ilorin Teaching Hospital,Other,NA,NA,NA,NA,NA,NA,NA,NA,"Rasaq Olaosebikan, MD",Principal Investigator,University of Ilorin,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PQPF912,NCT01365598,Evaluation of the Gametocytocidal Efficacy and Safety of Primaquine in Uncomplicated Falciparum Malaria in Uganda,Evaluation of the Efficacy and Safety of Primaquine for Clearance of Gametocytes in Uncomplicated Falciparum Malaria in Uganda,Completed,December 2011,May 2013,Actual,Actual,London School of Hygiene and Tropical Medicine,"Alice C Eziefula, MBBS MCRP MRCPath",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,468,Actual,Falciparum Malaria,NA,All,1 Year,10 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Mean number of days to gametocyte clearance (gametocyte clearance time, GCT)",Mean (+/- SD) maximal fall in Hb (g/dL) from enrollment to day 28 of follow-up,Wellcome Trust,Other,NA,NA,Walukuba Health Centre IV,14 days,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Mean number of days per treatment arm for gametocytes to become undetectable using sub-microscopic molecular testing methods (real-time nucleic acid sequence-based amplification, QT-NASBA)and interpolated from measured data points.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Mean maximal greatest negative difference in Hb (measured by Hemocue®) from enrollment value per treatment arm over 28 days follow up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SSC protocol No. 1210,NCT00529867,Randomised Efficacy Study of Two Artemether-Lumefantrine Oral Formulations for the Treatment of Uncomplicated P. Falciparum Malaria,A Randomized Open-Label Trial of the Efficacy of Artemether-Lumefantrine Suspension Compared With Artemether-Lumefantrine Tablets for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Less Than Five Years in Western Kenya,Completed,May 2007,December 2007,Actual,Actual,Dafra Pharma,"Elizabeth A Juma, Dr.",Principal Investigator,Kenya Medical Research Institute,Phase 4,Interventional,267,Actual,"Malaria, Falciparum",NA,All,6 Months,59 Months,No,Dafra Pharma,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To compare PCR corrected cure-rates on day 14 and 28,NA,Kenya Medical Research Institute,Other,NA,NA,Chulaimbo Health Centre,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-007-07,NCT00541385,Pyronaridine Artesunate 3:1 Granule Formulation vs. Coartem© Crushed Tablets in P. Falciparum Malaria Pediatric Patients,"Phase III Comparative, Open-Labelled, Randomised, Clinical Study to Assess a Fixed Dose of Oral Pyronaridine Artesunate Granule Formulation vs. Coartem® Crushed Tablets in Infants With Acute Uncomplicated Plasmodium Falciparum Malaria",Completed,October 2007,November 2008,Actual,Actual,Medicines for Malaria Venture,"Claude Oeuvray, PhD",Study Director,Medicines for Malaria Venture,Phase 3,Interventional,534,Anticipated,Malaria,NA,All,N/A,12 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR corrected ACPR on Day 28,NA,Shin Poong Pharmaceuticals,Industry,NA,NA,NA,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pro00052602,NCT02199977,Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector,Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector,Completed,June 2014,July 2015,Actual,Actual,Duke University,"Wendy O'Meara, PhD",Principal Investigator,Duke University,N/A,Interventional,444,Actual,Fever; Malaria,NA,All,1 Year,N/A,No,Duke University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Effect of conditional drug subsidy on proportion of participants who choose to receive a free malaria diagnostic test,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Moi University,Other,Moi University,Within two days of group assignment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The primary outcome of interest is to compare the proportion of participants who choose to receive a free malaria diagnostic test when they can receive a subsidy for a discounted drug conditional on a positive test compared to those without the offer of a conditional subsidy.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WR2115,NCT02297477,The ASAP Study - Therapeutic Efficacy of Atovaquone-proguanil vs. Artesunate-atovaquone-proguanil in Cambodia,Therapeutic Efficacy of Atovaquone-proguanil and Artesunate-atovaquone-proguanil for the Treatment of Uncomplicated P. Falciparum Malaria in Areas of Multidrug Resistance in Cambodia.,Completed,December 2014,NA,NA,NA,"Armed Forces Research Institute of Medical Sciences, Thailand","Lek Dysoley, MD",Principal Investigator,"National Center for Parasitology, Entomology and Malaria Control",Phase 4,Interventional,205,Actual,Malaria,NA,All,18 Years,65 Years,No,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Mariusz Wojnarski, MD",Principal Investigator,Armed Forces Research Institute of Medical Sciences (AFRIMS),NA,Efficacy at 42 days (with 95% confidence intervals) for AP with and without artesunate for uncomplicated P. falciparum diagnosed by positive PCR-corrected malaria microscopy.,NA,"National Centre for Parasitology, Entomology and Malaria Control, Cambodia",Other,"Naval Medical Research Center, Asia (NMRC-A)",Other,Anlong Veng Referral Hospital,6 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SAFEPRIM,NCT02174900,Safety of Primaquine + Artemether-lumefantrine in G6PD Deficient Males With an Asymptomatic Malaria Infection (SAFEPRIM),Evaluation of the Safety of Primaquine in Combination With Artemether-lumefantrine in Glucose-6-phosphate Dehydrogynase Deficient Males With an Asymptomatic Malaria Infection in Burkina Faso (SAFEPRIM),Completed,October 2014,December 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,"Teun Bousema, PhD",Principal Investigator,LSHTM,Phase 2/Phase 3,Interventional,70,Actual,Malaria,NA,Male,18 Years,45 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Haemoglobin concentration relative to baseline value,NA,"Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso",Other,University Medical Center Nijmegen,Other,Centre National de Recherche et de Formation sur le Paludisme,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Haemoglobin concentration relative to baseline value,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WP2-01-NEU,NCT01589289,Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases in Neurological Disorders in DRC,"Rapid Diagnostic Tests in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases in Patients With Neurological Disorders in Rural Hospitals of Bandundu,Democratic Republic of Congo",Completed,September 2012,May 2015,Actual,Actual,"Institute of Tropical Medicine, Belgium","Emmanuel Bottieau, MD",Study Director,ITM,Phase 3,Interventional,352,Actual,Neurological Disorders; Cerebral Malaria; Bacterial Meningitis; Central Nervous System Tuberculosis; Neurosyphilis; Cryptococcal Meningitis,NA,All,5 Years,N/A,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Marleen Boelaert, MD, PhD",Study Chair,ITM,NA,Prevalence of HAT and other NTDs/IDs,Identification of reliable diagnostic tests,"Institut National de Recherche Biomédicale. Kinshasa, République Démocratique du Congo",Other,"University Hospital, Geneva",Other,Reference Hospital Mosango,18 months,18 months,Predictive values of RDTs,NA,NA,Identification of clinical and laboratory diagnostic indicators,NA,NA,NA,NA,NA,NA,"Number of patients diagnosed with HAT and other NTDs/IDs among those presenting with neurological disorders in rural hospitals of Bandundu, DRC (pre-test probability)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Assessment of the sensitivity, likelihood ratios and performances (diagnostic accuracy) of the novel study RDTs for the respective target conditions, and identification of those that should be included in future diagnostic protocols",18 months,"Predictive values (post-test probabilities) of novel and existing RDTs, alone and in combination, for the respective target conditions within this multi-disease approach",18 months,"Assessment of the specificity of the different clinical and first-line laboratory features for the diagnosis of HAT and other priority NTDs/IDs in the setting, for determining those that should be included in future diagnostic protocols",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DAPPI-1,NCT02259426,Dihydroartemisinin-piperaquine With Low Dose Primaquine to Reduce Malaria Transmission,A Double Blind Randomized Controlled Trial of Dihydroartemisinin-piperaquine Alone and in Combination With Single Dose Primaquine to Reduce Post-treatment Malaria Transmission.,Completed,October 2014,December 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,"Teun Bousema, PhD",Principal Investigator,"Radboud university medical center, London School of hygiene and tropical medicine",Phase 3,Interventional,120,Actual,Malaria; Asymptomatic Malaria; Plasmodium Falciparum,NA,All,5 Years,15 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Patrick Sawa, MD",Principal Investigator,ICIPE,NA,Gametocyte prevalence on day 7 after initiation of treatment,NA,Radboud University,Other,International centre for Insect Physiology and Ecology (ICIPE),Other,ICIPE,day 7 of follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Gametocyte prevalence on day 7 after initiation of treatment is measured by molecular methods.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Epicentre/MBA/2011/NO,NCT01388842,Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide as Adjunctive Treatment for Cerebral Malaria in Children,Evaluation of the Efficacy and Safety of Inhaled Nitric Oxide (iNO) as Adjunctive Treatment for Cerebral Malaria in Children: A Randomized Open Label Phase II Clinical Trial,Completed,September 2011,February 2014,Actual,Actual,Epicentre,"Juliet Mwanga-Amumpaire, Dr",Principal Investigator,Epicentre,Phase 2,Interventional,92,Actual,"Malaria, Cerebral",NA,All,2 Months,12 Years,No,Epicentre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Angiopoietin 1 (Ang-1),NA,Mbarara University of Science and Technology,Other,Massachusetts General Hospital,Other,Mbarara Regional Referral Hospital,48 hours,NA,NA,Harvard Medical School,Other,NA,NA,NA,"Medecins Sans Frontieres, Netherlands",Other,NA,NA,Increase in Ang-1 between inclusion and 48 hours of combined therapy (iNO or placebo plus antimalarial chemotherapy),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1201,NCT01641289,Paracetamol Effect on Oxidative Stress and Renal Function in Severe Malaria,Paracetamol Effect on Oxidative Stress and Renal Function in Severe Falciparum Malaria With Intravascular Haemolysis: A Randomised Controlled Clinical Trial,"Active, not recruiting",July 2012,December 2017,Anticipated,Anticipated,University of Oxford,"Katherine Plewes, MD",Principal Investigator,University of Oxford,N/A,Interventional,62,Actual,Malaria,NA,All,12 Years,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Effect of paracetamol concentrations,NA,NA,NA,NA,NA,NA,72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Compare the effect of therapeutic paracetamol concentrations compared with absent or low paracetamol concentration on renal function, peak creatinine levels or trough creatinine clearance, defined as the change at 72 hours compared to baseline, in patients with severe and moderately severe falciparum malaria stratified by the level of intravascular haemolysis (cell-free haemoglobin).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EGSPZV1,NCT02418962,Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated PfSPZ Vaccine in Equatoguinean Adults,"Phase 1, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety and Immunogenicity of Direct Venous Inoculation of a Radiation-attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults",Completed,March 2015,February 2016,Actual,Actual,Sanaria Inc.,"Salim Abdulla, MD, PhD",Principal Investigator,Ifakara Health Institute,Phase 1,Interventional,33,Actual,Malaria; Plasmodium Falciparum,NA,Male,18 Years,35 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of adverse events as a measure of safety and tolerability,Number of serious adverse events,Ifakara Health Institute,Other,Swiss Tropical & Public Health Institute,Other,La Paz Medical Center,Until 28 days after each vaccination,From first vaccination upto 50 weeks,Number of Pf infections,Government of Equatorial Guinea,Other,NA,NA,NA,Hospital Universitario La Paz,Other,Marathon Oil Corporation,Industry,"Occurrence of solicited adverse events during a 7-day surveillance period after vaccination (day of vaccination and study days 1, 2, 3, 4, 5 and 6). Occurrence of unsolicited adverse events during a 28-day surveillance period after each vaccination.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Occurrence of serious adverse events during the study period.,From first vaccination upto 50 weeks,Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Noble Oil Services,Industry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KMRL_01_2016,NCT02708199,Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases and Malaria Antibody Kinetic,Molecular Assessment of Drug Resistance Markers in Asymptomatic Malaria Cases in Myanmar Artemisinin Resistance Containment Zones and Malaria Antibody Kinetic Analysis,Completed,January 2015,December 2015,Actual,Actual,"Department of Medical Research, Lower Myanmar",NA,NA,NA,N/A,Observational,1179,Actual,Increased Drug Resistance; Asymptomatic Infection; Malaria,NA,All,6 Years,N/A,Accepts Healthy Volunteers,"Department of Medical Research, Lower Myanmar",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of the Asymptomatic malaria infection,NA,Kangwon National University,Other,NA,NA,NA,2016 March,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Number of the asymptomatic malaria infection by molecular method in the sample collected from apparently healthy individuals. It have been done by nested PCR based method. Number of the asymptomatic infection will be finished in March 2016. (up to up to 5 months after last samples collection),NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Local resident in stud sites

          -  Who give informed consent

          -  No known tentative plan to move/ migrant elsewhere within one year

        Exclusion Criteria:

          -  Migrant or mobile population

          -  Less than 6 year
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WR2211,NCT02653898,Malaria Elimination Pilot Study in Military Forces in Cambodia,"Defining Effective, Appropriate, Implementable Strategies for Malaria Elimination in Military Forces in Cambodia as a Model for Mobile Populations",Recruiting,January 2016,August 2016,Anticipated,Anticipated,"Armed Forces Research Institute of Medical Sciences, Thailand","Chanthap Lon, MD",Principal Investigator,"Armed Forces Research Institute of Medical Sciences, Thailand",Phase 4,Interventional,1200,Anticipated,Malaria; Parasitic Diseases,NA,All,2 Years,65 Years,Accepts Healthy Volunteers,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The absolute risk reduction based on the proportion of subjects remaining malaria-free at the end of 6 months between the study arms as diagnosed by PCR-corrected malaria microscopy,NA,"National Center for Parasitology, Entomology, and Malaria Control (CNM)",Other,"Ministry of National Defense, Royal Cambodian Armed Forces Department of Health",Other,RCAF treatment facilities,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC050,NCT01635647,A Phase 1/2b Study of an Investigational Malaria Vaccination Strategy in 5-17 Month Old Infants and Children in Burkina Faso,"A Phase 1/2b Double Blind Randomised Controlled Trial of the Efficacy, Safety and Immunogenicity of Heterologous Prime-boost Immunisation With the Candidate Malaria Vaccines ChAd63 ME-TRAP and MVA ME-TRAP in 5-17 Month Old Burkinabe Infants and Children",Completed,November 2012,September 2014,Actual,Actual,University of Oxford,NA,NA,NA,Phase 1/Phase 2,Interventional,730,Actual,Malaria,NA,All,5 Months,17 Months,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Time to first episode of malaria meeting the primary case definition of clinical malaria episode,NA,European and Developing Countries Clinical Trials Partnership (EDCTP),Other,NA,NA,Centre for Clinical Vaccinology and 1. Centre National de Recherche et de Formation sur le Paludisme (CNRFP)/ Unité de Recherche Clinique de Banfora (URC-B),6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PR-11019,NCT01374126,Azithromycin Combination Therapy for the Treatment of Severe Malaria,Azithromycin Combination Therapy for the Treatment of Severe Malaria - A Pilot Safety and Efficacy Study in Uncomplicated Falciparum Malaria in Bangladesh,Completed,July 2011,November 2012,Actual,Actual,Medical University of Vienna,NA,NA,NA,Phase 2,Interventional,75,Actual,Falciparum Malaria,NA,All,8 Years,65 Years,No,Medical University of Vienna,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety and Tolerability (Number of Participants with Adverse Events),Adequate Clinical and Parasitological Response (ACPR) on Days 28 and 42,"International Centre for Diarrhoeal Disease Research, Bangladesh",Other,NA,NA,MARIB,42 days,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UA-IHU-2010-01 version 1,NCT01374581,Impact of Artemisinin-based Combination Therapy and Quinine on Treatment Failure and Resistance in Uncomplicated Malaria,A Randomized Clinical Trial to Measure the Impact of Retreatment With an Artemisinin-based Combination on Malaria Incidence and Its Potential Selection of Resistant Strains,Completed,May 2012,June 2014,Actual,Actual,Universiteit Antwerpen,"Hypolite M. Mavoko, MD MPH",Principal Investigator,"Kinshasa University, RDCongo",Phase 3,Interventional,2117,Actual,Malaria,NA,All,12 Months,59 Months,No,Universiteit Antwerpen,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Carolyn Nabasumba, M.B.Ch.B",Principal Investigator,Kazo health centre IV Uganda,NA,Late Parasitological Failure,NA,European and Developing Countries Clinical Trials Partnership (EDCTP),Other,"Fund for Scientific Research, Flanders, Belgium",Other,NA,Day4-Day28,NA,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,NA,University of Kinshasa,Other,Centre Muraz,Other,Parasitaemia after day 3 in the absence of fever (axillary temperature <37.5°C),"Jean-Pierre Van geertruyden, MD MPH PhD",Study Director,International Health Unit Antwerp university,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Other,Makerere University,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MSansFrontieres,NCT02741024,"Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for Uncomplicated Malaria in South Kivu, DR Congo","In Vivo Efficacy of Artesunate-amodiaquine and Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria: an Open-randomised, Non-inferiority Clinical Trial in South Kivu, DR Congo",Completed,October 2013,December 2014,Actual,Actual,"Medecins Sans Frontieres, Netherlands","Marit de Wit, MD, MIH",Principal Investigator,"Medecins sans Frontieres, Operational Centre Amsterdam",Phase 4,Interventional,288,Actual,Malaria,NA,All,6 Months,59 Months,No,"Medecins Sans Frontieres, Netherlands",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of children with adequate parasitological clearance after treatment of artesunate-amodiaquine (ASAQ) and artemether-lumefantrine (AL),NA,NA,NA,NA,NA,NA,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"In a Kaplan Meyer survival curve it will be shown what the parasitological free period is for children treated with ASAQ or AL, uncorrected for PCR (reinfection and recrudescence) and PCR corrected (recrudescence only).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP14C11,NCT02281344,MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants,A Proof-of-concept Study to Assess the Effect of MMV390048 Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants.,Completed,October 2014,December 2014,Actual,Actual,Medicines for Malaria Venture,"James McCarthy, Dr.",Principal Investigator,Q-Pharm Pty Limited,Phase 1,Interventional,6,Actual,"Malaria, Falciparum",NA,Male,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite reduction rate (PRR) following MMV390048 treatment,NA,Q-Pharm Pty Limited,Industry,NA,NA,"Q-Pharm Clinics, Royal Brisbane and Women's Hospital",up to Day 21 Post-dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The clearance of malaria parasitemia by Polymerase Chain Reaction (PCR) measurement,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WT099875_Malaria in Early Life,NCT02001428,Malaria in Early Life Study,"Intermittent Screening and Treatment for the Control of Malaria in the First Year of Life in Papua, Indonesia: A Cluster Randomized Controlled Trial",Recruiting,May 2014,April 2017,Anticipated,Anticipated,Gadjah Mada University,"Jeanne R Poespoprodjo, MD, MSc, PhD",Principal Investigator,University of Gadjah Madah,N/A,Interventional,756,Anticipated,Plasmodium Falciparum Malaria; Plasmodium Vivax Malaria,NA,All,N/A,1 Year,No,Gadjah Mada University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The incidence of clinical malaria in the first year of life,NA,"Timika Research Facility, Indonesia",Other,"Eijkman Institute, Jakarta, Indonesia",Other,Timika Research Facility,Total number of new clinical cases per child during the first year of life,NA,NA,Menzies School of Health Research,Other,NA,NA,NA,NA,NA,NA,NA,The total number of new clinical malaria cases from birth to one year old will be measured at one year of age.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
404067/2012-3,NCT02691910,Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine for Plasmodium Vivax Infection,Efficacy of Chloroquine (CQ) Alone Compared to Concomitant CQ and Primaquine (PQ) for the Treatment of Uncomplicated Plasmodium Vivax Infection,Completed,August 2014,September 2015,Actual,Actual,Oswaldo Cruz Foundation,"MARCELO U FERREIRA, MD-PHD",Study Director,Biomedical Sciences Institute of São Paulo University,Phase 2/Phase 3,Interventional,204,Actual,"Malaria, Vivax",NA,All,5 Years,N/A,No,Oswaldo Cruz Foundation,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"SIMONE L ANDRADE, MD-PHD",Principal Investigator,Oswaldo Cruz Institute,NA,Early treatment failure,NA,University of Sao Paulo,Other,NA,NA,NA,within the first 3 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"danger signs or severe malaria on day 1, 2 or 3 in the presence of parasitaemia OR parasitaemia on day 2 higher than on day 0 OR parasitaemia on day 3 with axillary temperature ≥ 37.5 ºC OR parasitaemia on day 3 ≥ 25% of count on day 0",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC040,NCT01379430,Safety and Immunogenicity of AdCh63 ME-TRAP and MVA ME-TRAP Vaccines in Malaria Endemic Areas,Safety and Immunogenicity of Heterologous Prime-boost With the Candidate Malaria Vaccines AdCh63 ME-TRAP and MVA ME-TRAP in Healthy Adults in a Malaria Endemic Area,Completed,June 2010,May 2011,Actual,Actual,University of Oxford,NA,NA,NA,Phase 1,Interventional,30,Actual,Malaria,NA,Male,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety and reactogenicity of AdCh63 ME-TRAP followed by MVA ME-TRAP in adults in Kenya.,NA,Kenya Medical Research Institute,Other,European and Developing Countries Clinical Trials Partnership (EDCTP),Other,"KEMRI/Wellcome Trust Programme, Centre for Geographic Medicine Research - Coast","Participants will be followed for the duration of the study, an expected average of 12 months",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,To assess safety and reactogenicity of AdCh63 ME-TRAP followed by MVA ME-TRAP in adults in Kenya by recording local and systemic solicited and unsolicited adverse events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
45114,NCT01392014,Dihydroartemisinin-piperaquine and Primaquine for Uncomplicated Plasmodium Falciparum Cases,Effectiveness of Dihydroartemisinin-piperaquine With or Without Primaquine on Gametocytes Plasmodium Falciparum in Mesoendemic Area of Indonesia,Completed,December 2008,October 2010,Actual,Actual,Indonesia University,"Inge Sutanto, MD",Principal Investigator,Univesity of Indonesia,Phase 4,Interventional,374,Actual,Malaria,NA,All,4 Years,N/A,No,Indonesia University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Development of sexual stages of P.falciparum,NA,NA,NA,NA,NA,Hanura Primary Health Center,42 days post treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Finger prick blood samples are collected for malaria blood smear. Thick and thin blood smears were stained with 3% Giemsa solution for 40 minutes and were read under binocular microscope with 1,000X magnification.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ELIPI,NCT02793336,Early Life Cohort in Papua Indonesia (ELIPI Study),NA,Recruiting,NA,July 2020,Anticipated,Anticipated,Menzies School of Health Research,NA,NA,NA,N/A,Observational,500,Anticipated,Malaria,NA,All,1 Year,5 Years,Accepts Healthy Volunteers,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,P. vivax parasitaemia (PCR or microscopy),NA,"Timika Research Facility Kompleks RSMM, Timika-Papua, Indonesia",Other,NA,NA,Timika Research Facility,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The incidence rate of any P. vivax parasitaemia (PCR or microscopy) over 1 year in all infants,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Patient enrolled in the Baby-Cohort study

        Exclusion Criteria:

          -  Patients not enrolled in the Baby-Cohort study
      ",NA,NA,NA,NA,NA,NA,NA,NA,"August 3, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_DSM265_13_02,NCT02123290,DSM265 Phase IIa Investigation Treating Plasmodium Falciparum or Vivax,"A Proof-of-Concept, Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Single Doses of DSM265 in Adult Patients With Acute, Uncomplicated Plasmodium Falciparum or Vivax Malaria Mono-Infection Over a 35-Day-Extended Observation Period",Completed,January 2016,January 2016,Actual,Actual,Medicines for Malaria Venture,"Alejandro Llanos, Professor",Principal Investigator,Clínica de la Asociación Civil Selva Amazónica,Phase 2,Interventional,45,Actual,Plasmodium Falciparum Malaria; Plasmodium Vivax Malaria,NA,All,18 Years,60 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adequate Clinical and Parasitological Response rate at Day 14,Pharmacokinetic parameter for exposure up to 168 hours,Asociacion Civil Selva Amazonica,Other,NA,NA,Clínica de la Asociación Civil Selva Amazónica,Day 14,Day 0 to 168 hours post-dose,Pharmacokinetic parameter for exposure AUC (0-t),NA,NA,Area under the plasma concentration vs time curve from time zero to infinity,Maximum plasma concentration (Cmax),Time to reach maximum plasma concentration (tmax),NA,NA,NA,NA,Day 14 clinical and parasitological response rate for Plasmodium falciparum and Plasmodium vivax cohorts,NA,NA,NA,NA,NA,NA,Terminal half-life (t½),The plasma concentration at 168hours post-dose (C168h),NA,NA,NA,NA,NA,NA,Area under the plasma concentration vs time curve from time zero up to and including Day 7 (AUC 0-168),Day 0 to Day 28,Area under the plasma concentration vs time curve from time zero to the time of the last measurable concentration post-dose,To Day 28,"Area under the plasma concentration vs time curve from time zero to the infinity. Participants will be followed for 28 days, data will be extrapolated.",NA,NA,Day 0 to Day 28,Pharmacokinetic parameter maximum plasma concentration,Day 0 to Day 28,Pharmacokinetic parameter: Time to reach maximum plasma concentration (tmax),Day 0 to Day 28,Pharmacokinetic parameter: Terminal half-life,Day 7,Pharmacokinetic parameter C168 hours,The terminal elimination rate constant,Day 0 to 28,Pharmacokinetic parameter: The terminal elimination rate constant (Lambda z),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1506994146,NCT02557425,Prophylaxis Against Malaria to Enhance Child Development (PROTECT Study),Prophylaxis Against Malaria to Enhance Child Development,"Active, not recruiting",October 2015,December 2021,Anticipated,Anticipated,Indiana University,"Chandy C John, MD",Principal Investigator,Indiana University,N/A,Observational,272,Actual,Neurobehavioral Manifestations,NA,All,10 Months,38 Months,No,Indiana University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Z-scores for Overall cognitive ability,Z-scores for Overall cognitive ability,Makerere University,Other,NA,NA,Tororo District Hospital,12 months of age,24 months of age,Z-scores for Overall cognitive ability,NA,NA,Z scores for Elicited Imitation,Z scores for Elicited Imitation,Z scores for Elicited Imitation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          1. Enrolled in Makerere University-UCSF PROMOTE II study

          2. HIV-uninfected

          3. 12 months of age at the time of enrollment

          4. Within 30 km of the clinic

        Exclusion Criteria:

          1. Serious adverse event to the study drugs requiring cessation of study drug

          2. Active illness at enrollment (child can be enrolled once active illness has been
             treated and they are back to baseline health)

          3. Previous history of head trauma or coma in the child

          4. Cerebral palsy or other severe neurologic disease

          5. Known chronic illness requiring medical care

          6. Major medical abnormalities on screening history of past health

          7. Known developmental delay
      ",NA,NA,NA,NA,36 months of age,NA,12 months of age,NA,NA,NA,24 months of age,NA,36 months of age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MT-1,NCT02473796,"Home Based Child Care to Reduce Mortality and Malnutrition in Tribal Children of Melghat, India: CRCT","Effect of Home Based Child Care on Child Mortality and Malnutrition in a Tribal Population of Melghat, India: Cluster Randomised Control Field Trial",Completed,January 2004,April 2010,Actual,Actual,MAHAN Trust,"Ashish R Satav, MBBS., MD.",Principal Investigator,MAHAN,N/A,Interventional,7594,Actual,Acute Respiratory Tract Infections; Diarrhea; Malaria; Neonatal Sepsis; Birth Asphyxia,NA,All,N/A,5 Years,No,MAHAN Trust,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Under-5 mortality rate,NA,"Stitching Geron and Cordaid, The Netherlands.",Other,"Caring Friends, Mumbai",Other,"MAHAN Trust, Melghat (Dharni)",Four years.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCZVED-3620,NCT00544024,Mefloquine Bioequivalence Among 3 Commercially Available Tablets.,Mefloquine Bioequivalence Among Three Commercial Tablet Formulations in Peruvian Subjects With Uncomplicated Plasmodium Falciparum Malaria,Completed,March 2004,March 2007,Actual,Actual,Centers for Disease Control and Prevention,"Michael D Green, PhD",Principal Investigator,Centers for Disease Control and Prevention,N/A,Observational,39,Actual,Malaria,NA,All,N/A,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Wilmer Marquino, MD",Principal Investigator,"Instituto Nacional de Salud, Lima, Peru",NA,Measure concentrations of mefloquine in blood to determine pharmacokinetic parameters and assess bioequivalence.,NA,Naval Medical Research Center,U.S. Fed,Universidad Peruana Cayetano Heredia,Other,Apoyo Hospital,56 days,NA,NA,"Ministry of Health, Lima Peru",Other,NA,NA,NA,NA,NA,NA,NA,NA,"David Bacon, PhD",Principal Investigator,Naval Medical Research Center Detachment,NA,NA,NA,NA,NA,Measure concentrations of mefloquine in blood to determine pharmacokinetic parameters and assess bioequivalence.,Probability Sample,"
        Inclusion Criteria:

          -  The inclusion criteria for enrolling patients included; male or non-pregnant female ≥
             18 years of age, infection with P. falciparum alone, with a parasite density between
             250 and 50,000 asexual parasites/mm3 as determined by microscopic examination of a
             thick blood smear, informed consent from patient, and a willingness to be hospitalized
             for the first 24 hours after therapy is initiated and to return for follow-up visits
             through day 56.

        Exclusion Criteria:

          -  Patients exhibiting evidence of severe malaria or with a history of an underlying
             chronic disease or illness that could interfere with the absorption of MQ, a history
             of hypersensitivity to MQ, or a history of neuropsychiatric illness or cardiac
             conduction problems were excluded.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACT10420,NCT00563914,A Comparative Safety and Activity Study With Ferroquine Associated With Artesunate Versus Amodiaquine Associated With Artesunate in African Adult Patients With Uncomplicated Malaria,"An Open Label, 4 Escalating Dose, Randomized Multicentre Study Evaluating the Safety and Activity of Ferroquine Associated With Artesunate Versus a Positive Calibrator (Amodiaquine Associated With Artesunate) in African Adult Patients With Uncomplicated Malaria",Completed,October 2007,November 2008,Actual,Actual,Sanofi,"Christian Supan, MD",Principal Investigator,"URM (Unité de Recherches Médicales), Hôpital Albert Schweitzer, BP 118 Lambaréné, Gabon",Phase 1/Phase 2,Interventional,72,Actual,Malaria,NA,Male,18 Years,65 Years,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Hepatic safety :ALT, AST, Alkaline Phosphatase, Total Bilirubin",NA,NA,NA,NA,NA,NA,"Sreening , baseline, days D3,D5,D6,D7,D9,D14,D21 and D28",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SFB544A8,NCT01407887,Efficacy and Safety of Artesunate-amodiaquine-methylene for Malaria Treatment in Children,Efficacy and Safety of Artesunate-amodiaquine Combined With Methylene Blue for Falciparum Malaria Treatment in African Children,Completed,August 2011,December 2011,Actual,Actual,Heidelberg University,"Olaf Müller, Prof Dr",Principal Investigator,"Institut of Public health, University of heidelberg",Phase 2,Interventional,180,Actual,Uncomplicated Falciparum Malaria,NA,All,6 Months,59 Months,No,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,P. falciparum gametocyte prevalence,NA,NA,NA,NA,NA,Nouna Health District,day 14 of follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,P. falciparum gametocyte prevalence on day 14 of follow-up (PCR determination),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ZonMw2,NCT01422954,Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis,Immunization With Plasmodium Falciparum Sporozoites Under Chloroquine Versus Mefloquine Prophylaxis,Completed,January 2012,April 2013,Actual,Actual,Radboud University,"Leo G Visser, MD, PhD",Principal Investigator,Leiden University Medical Centre,N/A,Interventional,20,Actual,Malaria; Plasmodium Falciparum,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Duration of prepatent period after challenge infection as measured by microscopy,NA,ZonMw: The Netherlands Organisation for Health Research and Development,Other,NA,NA,Leiden University Medical Centre,21 days after challenge (day 239 of the study),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
09-0559,NCT01027663,Impact of Host Iron Status and Iron Supplement Use on Erythrocytic Stage of Plasmodium Falciparum,Impact of Host Iron Status and Iron Supplement Use on Growth and Viability of the Erythrocytic Stage of Plasmodium Falciparum,Completed,November 2009,January 2015,Actual,Actual,"University of North Carolina, Chapel Hill","Raj Kasthuri, MD",Principal Investigator,"University of North Carolina, Chapel Hill",N/A,Interventional,45,Actual,Iron Deficiency Anemia; Malaria,NA,All,18 Years,70 Years,Accepts Healthy Volunteers,"University of North Carolina, Chapel Hill",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,University of North Carolina at Chapel Hill,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
01-416,NCT00587249,ICC-1132 - Candidate Vaccine Against P Falciparum Malaria,"Phase I Trial of ICC-1132, a Candidate Vaccine Against Plasmodium Falciparum Malaria Based on a Viral-like Particle Comprising Recombinant Hepatitis B Core Antigen and Circumsporozoite Epitopes, to Assess Vaccine Safety and Immunogenicity in Healthy Adult Volunteers",Completed,July 2002,July 2005,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,75,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Provide a preliminary assessment of the safety of ICC-1132 plus alhydrogel in healthy adults and to determine if there are any probable or definitive SAEs.,NA,NA,NA,NA,NA,University of Maryland Baltimore,Duration of study.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACTComMada,NCT00612547,ACT for the Home Management in Malagasy Children,Assessment of the Use of Fixed Doses of Artesunate Plus Amodiaquine Combination for the Home Management of Presumed Malaria in Malagasy Children,Completed,February 2008,February 2009,Actual,Actual,"National Malaria Control Programme, Madagascar","Benjamin Ramarosandratana, MD",Study Chair,National Malaria Control Programme,N/A,Observational,1200,Actual,Fever; Suspected Malaria,NA,All,2 Months,5 Years,No,"National Malaria Control Programme, Madagascar",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Assessment of the councils delivered by the community-based service provider to the parents or guardians of children and assessment of the observance of the treatment given by the parents or guardians.,NA,Population Services International,Other,Reggio Terzo Mondo,Other,Institut Pasteur,one year,NA,NA,Santé Net,Other,NA,NA,NA,"Inter Aide Santé,",Other,Adventist Development and Relief Agency,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  All children under the age of five years (2 months to 5 years) having fever and
             consulting the community-based service provider, residing in the zone covered by the
             community-based service provider throughout the entire follow-up period, having signed
             an informed consent

        Exclusion Criteria:

          -  Children with no informed consent
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,SAF FJKM,Other,Sanofi,Industry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Institut Pasteur de Madagascar,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PDY11737,NCT01445938,Anti-parasitic Activity and Safety Assessment of SAR97276A in Children With Uncomplicated Malaria,"An Open-label, Randomized Multicenter Study to Investigate the Anti-parasitic Activity, Pharmacokinetic and Safety of IM SAR97276A With Oral ACTs as Positive Control in Children Presenting With Symptomatic Plasmodium Falciparum Uncomplicated Malaria",Terminated,October 2011,January 2012,Actual,Actual,Sanofi,Clinical Sciences & Operations,Study Director,Sanofi,Phase 2,Interventional,20,Actual,Malaria,NA,All,2 Years,17 Years,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite Reduction Ratio (PRR),NA,NA,NA,NA,NA,NA,at 72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC038,NCT01450280,Safety and Immunogenicity of New Malaria Vaccine Candidate ChAd63 CS Administered Alone and With MVA CS,A Phase Ia Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 CS Administered Alone and With MVA CS,Completed,December 2011,October 2012,Actual,Actual,University of Oxford,Sam McConkey,Principal Investigator,Clinical Research Centre Royal College of Surgeons in Ireland (RCSI),Phase 1,Interventional,24,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety assessment of new candidate malaria vaccines ChAd63 CS,NA,NA,NA,NA,NA,"Clinical Research Centre Royal College of Surgeons in Ireland (RCSI), Beaumont Hospital","Participants will be followed for the duration of the study, an expected average of 12 months",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,To assess the safety of new candidate malaria vaccines ChAd63 CS administered alone and with MVA CS in a prime-boost regime to healthy volunteers by recording local and systemic solicited and unsolicited adverse events.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
JP011,NCT01464125,Fosmidomycin and Azithromycin for Acute Uncomplicated Plasmodium Falciparum Malaria (P. Malaria) in Adults,Evaluation of Fosmidomycin and Azithromycin When Administered Concurrently to Adult Subjects With Acute Uncomplicated Plasmodium Falciparum Malaria,Unknown status,November 2008,December 2011,Anticipated,Anticipated,Jomaa Pharma GmbH,"Srivicha Krudsood, Prof",Principal Investigator,Mahidol University,Phase 2,Interventional,43,Actual,Malaria,NA,All,15 Years,55 Years,No,Jomaa Pharma GmbH,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,day 28 cure rate of >95%,Safety and Tolerance,Mahidol University,Other,Thammasat University,Other,Mahidol University,12 months,12 months,Day 7 cure rate of 100%,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Efficacy of fosmidomycin and azithromycin when co-administered to adults with acute uncomplicated P.falciparum malaria.
Day 7 cure rate and Day 28 cure rates will be calculated from the following ratio: Number of subjects with clearance of asexual parasitaemia within seven days of commencement of treatment, without subsequent recrudescence within 28 days divided by total number of evaluable subjects.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To determine the safety and tolerance of fosmidomycin and azothromycin when co-administered orally over three days. Safety and tolerability will be evaluated by the incidence, intensity, seriousness and relationship of new adverse event(s), and clinically relevant laboratory changes. The drug will be considered as safe if there are no serious adverse events attributable to the study drug.",12 months,"Efficacy of fosmidomycin and azithromycin when co-administered to adults with acute uncomplicated P.falciparum malaria.
Day 7 cure rate and Day 28 cure rates will be calculated from the following ratio: Number of subjects with clearance of asexual parasitaemia within seven days of commencement of treatment, without subsequent recrudescence within 28 days divided by total number of evaluable subjects.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-014-11,NCT01523002,Drug Interaction Study of Pyronaridine-artesunate and Metoprolol and Pyronaridine-artesunate Re-dosing Study in Healthy Volunteers,"Open-label, Drug Interaction Study of Pyramax (Pyronaridine:Artesunate) and Metoprolol in Healthy Volunteers and Pyramax Re-dosing Study in Healthy Volunteers",Completed,January 2012,October 2012,Actual,Actual,Medicines for Malaria Venture,"Rolf Pokorny, MD, MSc",Principal Investigator,Covance Research Unit AG,Phase 1,Interventional,56,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Profile of Pharmacokinetics,Safety of re-treatment,Shin Poong Pharmaceuticals,Industry,NA,NA,Covance Clinical Research Unit AG,140 days,140 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Area Under Curve (AUC)0-t, AUC0-∞, Cmax, Tmax, and halflife.
Plasma samples for determination of metoprolol and alphahydroxymetoprolol: pre-dose and 0.25, 0.5, 0.75, 1, 1.5, 2, 3, 4,6, 8, 10, 12, and 24 h post-dose.
Plasma samples for determination of artesunate and dihydroartemisinin: pre-dose and 1, 3, and 6 h post-dose.
Blood samples for determination of pyronaridine:pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h and 2, 3, 5, 12, 19, 26, 33, and 40 days.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Pyramax Re-dosing sub-study (Arm A and Arm B):Peak ALT and peak AST values following the first and the second three day Pyramax administration.
Safety assessments include monitoring of:
Adverse events, Laboratory parameters, Vital signs, clinical signs and symptoms and physical examination, including changes from baseline, ECG evaluation.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
C14-60,NCT02658253,Trial to Evaluate the Safety and Immunogenicity of a Placental Malaria Vaccine Candidate (PRIMVAC ) in Healthy Adults,"Phase Ia/Ib, Randomized, Double Blinded, Dose Escalation Trial to Evaluate the Safety and Immunogenicity in Healthy European and Burkinabe Adults of a Placental Malaria Vaccine Candidate (PRIMVAC) Formulated With Alhydrogel ® or GLA-SE",Recruiting,January 2016,April 2018,Anticipated,Anticipated,"Institut National de la Santé Et de la Recherche Médicale, France","Odile Launay, Professor",Study Chair,"Institut National de la Santé Et de la Recherche Médicale, France",Phase 1,Interventional,68,Anticipated,Malaria,NA,Female,18 Years,35 Years,Accepts Healthy Volunteers,"Institut National de la Santé Et de la Recherche Médicale, France",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Benoit GAMAIN, Dr",Study Director,"Institut National de la Santé Et de la Recherche Médicale, France",NA,Proportion of volunteers with treatment-related adverse events as assessed by FDA scale and the INYVAX EC FP7 Brighton Collaboration Foundation,NA,EVI,Other,CIC COCHIN,Other,NA,35 days,NA,NA,CNRFP,Other,NA,NA,NA,EUCLID,Other,NA,NA,Grade 3 or higher clinical or laboratory ARI and persisting at Grade 3 for > 48 hours between D0 and D35.,"Sodiomon SIRIMA, Dr",Study Chair,CNRFP,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999913209,NCT01955382,Evaluation of Oral Activated Charcoal on the Ability of an Antimalarial Drug to Kill Parasites in Malian Children With Mild Malaria,Effect of Oral Activated Charcoal on Parasite Clearance Rates in Response to Intravenous Artesunate in Malian Children With Uncomplicated Plasmodium Falciparum Malaria,Completed,September 2013,July 2015,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Rick M Fairhurst, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 2,Interventional,70,Anticipated,Malaria; Severe Malaria,NA,All,2 Years,10 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Serum cytokine levels at 0, 24, and 48 h",To compare parasite clearance half-life in patients treated with oAC + IV AS or IV AS,NA,NA,NA,NA,"Universite des Sciencies, Techniques et Technologies de Bamako",Post patient recruitment,Post patient recruitment,To assess the safety of adjunct treatment with oAC,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,During patient recruitment and treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-14-02,NCT02174978,Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) to Evaluate the Safety and Efficacy of the Plasmodium Falciparum Vaccine Candidate FMP012 Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults,"Phase 1 Clinical Trial With Controlled Human Malaria Infection (CHMI) Open-label Dose Safety, Reactogenicity, Immunogenicity, and Efficacy of the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), Administered Intramuscularly With AS01B Adjuvant System in Healthy Malaria-Naïve Adults","Active, not recruiting",August 2014,September 2019,Anticipated,Anticipated,U.S. Army Medical Research and Materiel Command,"Jason W Bennett, LTC, MC",Principal Investigator,"Malaria Vaccine Branch, Military Malaria Research Program, WRAIR",Phase 1,Interventional,36,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of solicited adverse events (AE),Number of unsolicited AEs,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,United States Agency for International Development (USAID),U.S. Fed,"Clinical Trials Center, WRAIR",7 days after each vaccination,28 days after each vaccination,Occurrence of serious adverse events (SAE) at any time during the study period (enrollment to final follow-up visit),Military Infectious Diseases Research Program (MIDRP),Other,NA,NA,NA,GlaxoSmithKline,Industry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12 months after vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A-17085,NCT01540474,"Trial of a Falciparum Malaria Protein (FMP012), E. Coli-expressed PfCelTOS, in Healthy Malaria-Naive Adults","Phase 1 Study With the Vaccine Candidate Plasmodium Falciparum Malaria Protein (FMP012), an E.Coli-expressed Cell-Traversal Protein, Administered Intramuscularly in Healthy Malaria-Naive Adults",Completed,February 2012,December 2012,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Jessica J. Cowden, MD",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 1,Interventional,30,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety,NA,United States Agency for International Development (USAID),U.S. Fed,IDRI,Other,"Clinical Trials Center, WRAIR",Participants will be followed up to 1 year after vaccination (up to study day 450),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Occurrence of solicited adverse events over a 7-day follow-up period after each vaccination (the day of the vaccination and Days 1, 2, 3, and 6)
Occurrence of unsolicited adverse events over a 28-day follow-up period after each vaccination (the day of the vaccination and 27 subsequent days)
Occurrence of serious adverse events at any time during the study period (enrollment to final follow-up visit) . Occurrence of adverse events of special interest over a 12-month phone follow-up period after the final vaccination (phone follow-up at 6 months and 12 months)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR #849,NCT01556945,"Safety and Preliminary Efficacy of the Malaria Vaccine Candidates Falciparum Merozoite Protein-1 (FMP1) and SmithKlineBeecham (SKBB) Candidate Malaria Vaccine RTS,S","Phase I/IIa Safety, Immunogenicity, and Preliminary Efficacy of an Administration Schedule of FMP1 and SmithKlineBeecham Biologicals' Candidate Malaria Vaccine RTS,S Each Adjuvanted With SBAS2, Given Concomitantly in Separate Injections",Completed,April 2001,NA,NA,NA,U.S. Army Medical Research and Materiel Command,NA,NA,NA,Phase 1/Phase 2,Interventional,72,Actual,"Malaria, Falciparum",NA,All,18 Years,45 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety,NA,GlaxoSmithKline,Industry,NA,NA,WRAIR Clinical Trials Center,two years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Measured through adverse event collection and immunogenicity results,NA,NA,NA,NA,NA,NA,NA,NA,Safety,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MVDC-2008-005,NCT01082341,Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites,Phase 1 and Phase 2a Clinical Trial:Immunization of Human Volunteers With P. Vivax Irradiated Sporozoites,"Active, not recruiting",June 2012,September 2017,Anticipated,Anticipated,Malaria Vaccine and Drug Development Center,"Socrates Herrera, MD",Principal Investigator,Malaria Vaccine Develepment Center,Phase 1/Phase 2,Interventional,27,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Malaria Vaccine and Drug Development Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Three groups are considered to be intervened. Experimental, Control and Fy(-) groups. Comparison will be done between E and C groups for protective efficacy. For immune response tests E vs Fy(-),E vs Fy(-), and Fy(-) vs C, pairs will be compared.",NA,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,Asoclinic Inmunología Ltda.,Industry,Malaria Vaccine of Develepmente Center,2 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1601,NCT02876549,G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria,G6PD Assessment Before Primaquine for Radical Treatment of Vivax Malaria,Not yet recruiting,August 2016,NA,NA,NA,University of Oxford,NA,NA,NA,Phase 4,Interventional,1000,Anticipated,Vivax Malaria,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Sensitivity of CareStart™ G6PD rapid test compared to a genotyping result as gold-standard,Specificity of CareStart™ G6PD rapid test compared to a genotyping result as gold-standard,Mahidol Oxford Tropical Medicine Research Unit,Other,"Nangarhar University, Afghanistan",Other,Dr. Ghulam Rahim Awab MD,3 years,3 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
REACT,NCT01350752,Research on the Economics of Artemisinin Combination Therapy (ACTs) for the Treatment of Malaria,A Cost-effectiveness Analysis of Alternative Strategies for the Deployment of ACTs at the Community Level in Cameroon and Nigeria,Completed,May 2011,January 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,Virginia Wiseman,Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,6513,Actual,Malaria,NA,All,6 Months,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,Wilfred Mbacham,Principal Investigator,University of Yaounde I,NA,Proportion of febrile patients receiving treatment as recommended in clinical guidelines for uncomplicated malaria,NA,University of Yaounde,Other,"University of Nigeria, Enugu Campus",Other,NA,As patients exit the health facility,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Recommended treatment is defined as
Febrile patients should be tested for malaria, either using microscopy or using a RDT
Artemisinin-based Combination Therapy (ACT) should be provided if the patient has a positive malaria test result
No antimalarial should be provided if patient has a negative test result.",Obinna Onwujekwe,Principal Investigator,University of Nigeria,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
REDHOT_OPP1024438,NCT01575613,Reducing the Burden of Malaria by Targeting Hotspots of Malaria Transmission,Reducing the Burden of Malaria by Targeting Hotspots of Transmission and Improving Malaria Control Measures in the Highlands of Western Kenya: Simultaneous Rollout of Four Malaria Control Interventions and Evaluation by Cross-sectional Surveys,Completed,April 2012,November 2012,Actual,Actual,Radboud University,"Teun Bousema, PhD",Principal Investigator,Radboud University,N/A,Interventional,17506,Actual,Malaria,NA,All,6 Months,N/A,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Jon Cox, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,Parasite prevalence in the evaluation zone surrounding malaria hotspots,NA,"London School of Hygiene & Tropical Medicine, London, UK",Other,"Kenya Medical Research Institute, Kisumu, Kenya",Other,NA,"3 cross-sectional surveys in up to 210 days, the timing being: at enrolment; 45-75 days post enrolment (coinciding with the peak malaria transmission season) and 150-210 days post enrolment (coinciding with the end of the malaria transmission season)",NA,NA,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,NA,"International Centre of Insect Physiology and Ecology, Mbita, Kenya",Other,"Division of Malaria Control, Ministry of Health, Nairobi, Kenya",Other,"Parasite prevalence, determined by PCR, in the evaluation zone surrounding hotspots in intervention and control clusters","Jennifer Stevenson, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Rachuonyo District,NA,NA,NA,NA,NA,NA,NA
Pf PEBS-Ia-IIa,NCT01605786,"Trial for Malaria Vaccine Candidate, PfPEBS (P. Falciparum Pre-Erythrocytic and Blood Stage)","Phase I and IIa Trial for Assessment of Safety, Immunogenicity (Phase Ia) and Efficacy (Phase IIa) Against Sporozoite Challenge of P. Falciparum Pre-Erythrocytic and Blood Stage (PfPEBS-LSP) Malaria Vaccine Candidate",Unknown status,May 2012,August 2013,Anticipated,Anticipated,Vac4All,"Pierre L Druilhe, MD",Study Director,Vac4All,Phase 1/Phase 2,Interventional,36,Anticipated,Malaria,NA,All,18 Years,44 Years,Accepts Healthy Volunteers,Vac4All,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Francois Spertini, MD",Principal Investigator,Centre Hospitalier Universitaire Vaudois (CHUV),NA,Adverse events following vaccination,Change from baseline of antibodies active in the ADCI assay,Centre Hospitalier Universitaire Vaudois,Other,Radboud University,Other,Centre Hospitalier Universitaire Vaudois (CHUV),Up to one year following first vaccination,Within one year following first vaccination,Parasitemia following mosquito challenge,European Commission,Other,NA,NA,NA,NA,NA,NA,NA,The safety and reactogenicity of the vaccine will be assessed by comparing the proportion and severity of expected and unexpected adverse events as well as serious adverse events (SAE) between groups.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The vaccine antigen should induce adequate antibodies that are active in the ADCI assay, which measures parasite killing of erythrocytic stages of the malaria parasite by antibodies in Monocyte-dependant manner and is hypothesized to be able to provide protection against clinical malaria disease.",From Day 4 up to Day 21 post challenge,"Subjects will be monitored for emergence of malaria parasites in the blood, using the gold standard of thick film slide microscopy, and rapid diagnostic testing, RT-PCR and LAMP. Treatment will be initiated as soon as subjects are parasitemic, defined as >1 parasites per 400 fields in a thick blood film, OR a positive RDT OR two positive RT-PCR OR one positive result with RT-PCR AND one positive result with LAMP OR two positive results with two different methods.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WAO 93-442,NCT00623857,Micronutrients and Child Health Study,Effects of Supplementation With Zinc and Other Micronutrients on the Health and Development of African Children,Completed,March 2008,March 2009,Actual,Actual,Wageningen University,"Hans Verhoef, PhD",Principal Investigator,"Wageningen University, Cell Biology and Immunology Group",Phase 3,Interventional,612,Actual,Malaria,NA,All,6 Months,60 Months,Accepts Healthy Volunteers,Wageningen University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Raimos M Olomi, MD MMed MPH",Study Chair,Kilimanjaro Christian Medical Centre,NA,Febrile malaria episodes,NA,"Kilimanjaro Christian Medical Centre, Tanzania",Other,NA,NA,Kilimanjaro Christian Medical Centre,60 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Huub FJ Savelkoul, PhD",Study Director,"Wageningen University, Cell Biology and Immunology Group","John F. Shao, MD",Study Director,Kilimanjaro Christian Medical Centre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MSP3_ML_0304,NCT00652275,"Immunogenicity, Efficacy and Safety Study of an MSP3-LSP (Long Synthetic Peptide) Malaria Vaccine","Phase IIb Immunogenicity, Efficacy and Safety Study of P. Falciparum Vaccine Candidate, MSP3-LSP Adjuvanted in Aluminium Hydroxide Versus Verorab Control in Healthy Children Aged 12-48 Months in Mali.",Unknown status,May 2008,December 2010,Anticipated,Anticipated,African Malaria Network Trust,"Mahamadou S Sissoko, MD, MSPH",Principal Investigator,"Malaria Research and Training Center (MRTC), Bamako Mali",Phase 2,Interventional,378,Anticipated,Malaria,NA,All,12 Months,48 Months,Accepts Healthy Volunteers,African Malaria Network Trust,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Roma Chilengi, MBChB, MSc",Study Director,African Malaria Network Trust,NA,Number of clinical malaria episodes occurring during the consecutive malaria transmission season after the third vaccination,NA,NA,NA,NA,NA,Malaria Research Training Center,27 Months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CKAE609A2109,NCT02543086,Effectiveness of KAE609 in Reducing Asexual & Sexual Blood-stage P.Falciparum Infection & Infectivity to Mosquitos,A Phase1 Interventional Sequential Single Site Study to Characterize the Effectiveness of Oral KAE609 in Reducing Asexual & Sexual Blood-stage P. Falciparum Following Inoculation in Healthy-volunteers & Subsequent Infectivity to Mosquitoes,Terminated,July 2015,September 2015,Actual,Actual,Novartis Pharmaceuticals,"James McCarthy, MD FRACP",Principal Investigator,Q-Pharm Pty Limited,Phase 1,Interventional,8,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasitic count in blood by Polymerase Chain Reaction,NA,Medicine for Malaria Venture,Other,NA,NA,Novartis Investigative Site,36 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Clearance of Plasmodium falciparum asexual and sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B16-963,NCT02750384,Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects,An Assessment of the Bioavailability and Effect of Food on DSM265 Granules in Healthy Adult Subjects,Terminated,May 2016,July 2016,Actual,Actual,Medicines for Malaria Venture,"David , Carter, MD",Principal Investigator,AbbVie,Phase 1,Interventional,11,Actual,Healthy Volunteers; Bioavailability,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,DSM265 maximum observed plasma concentration (Cmax),DSM265 time to Cmax (Tmax),AbbVie,Industry,NA,NA,AbbVie Clinical Pharmacology Research Unit (ACPRU),"Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours","Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours",DSM265 observed concentration at 168 hours after dosing (C168),NA,NA,DSM265 apparent terminal phase elimination rate constant (β),DSM265 terminal elimination half-life (t1/2),DSM265 area under the plasma concentration-time curve from time 0 to the time of the last measurable concentration (AUCt),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,DSM265 area under the plasma concentration-time curve from time 0 to infinity (AUC∞),NA,NA,NA,NA,NA,NA,NA,NA,"Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours",NA,"Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours",NA,NA,NA,"Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours",NA,"Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours",NA,"Pre-dose and post-dose at 0.5, 1, 2, 4, 6, 8, 12, 24, 72, 120, 168, 216, 312 and 480 hours",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU 1303,NCT01902797,Malaria Survey in the Tak Province Refugee Camps,Malaria Survey in the Tak Province Refugee Camps,Completed,July 2013,December 2013,Actual,Actual,University of Oxford,"Stephane Proux, PhD",Principal Investigator,Shoklo Malaria Research Unit,N/A,Interventional,908,Actual,Malaria,NA,All,12 Months,N/A,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria prevalence,NA,NA,NA,NA,NA,Refugee Camps,1 day,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Comparison of malaria prevalence by conventional microscopy and RT-PCR to determine the malaria epidemiology in the population,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MRTC_Arge01,NCT01645254,Phase 1b Malaria Clinical Trial Using Argemone Mexicana in Healthy Adults in Mali,Phase 1b Clinical Trial Using Argemone Mexicana in Healthy Adults Infected or Not Infected With Plasmodium Falciparum in Mali: Pharmacokinetics and Observational Study,Unknown status,September 2012,November 2012,Anticipated,Anticipated,University of Bamako,"Issaka Sagara, MD,MSPH",Principal Investigator,University of Bamako,Phase 1,Interventional,24,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Bamako,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Adverse Events,NA,"University of Geneva, Switzerland",Other,NA,NA,"Malaria Research and Training Center, USTTB",6 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,health volunteers will be assessed daily for 3 days and then on Day 7 and then weekly up to 6 weeks.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
19371-106,NCT01652365,Feasibility and Impact of Malaria Rapid Diagnostic Tests in the African Retail Sector,Evaluation of the Feasibility and Impact of Introducing Malaria Rapid Diagnostic Tests in the Retail Sector: A Randomized Controlled Trial in Eastern Uganda,Completed,March 2011,June 2012,Actual,Actual,Harvard School of Public Health,"Jessica Cohen, PhD",Principal Investigator,Harvard School of Public Health,N/A,Interventional,2800,Actual,Malaria,NA,All,18 Years,N/A,Accepts Healthy Volunteers,Harvard School of Public Health,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Gunther Fink, PhD",Principal Investigator,Harvard School of Public Health,NA,Fraction of Illnesses Diagnosed for Malaria,NA,"Clinton Health Access Initiative, Nigeria",Other,Innovations for Poverty Action-Uganda,Other,NA,Up To One Year,NA,NA,Uganda Health Marketing Group,Other,NA,NA,NA,NA,NA,NA,NA,"Comparison of the rate of malaria diagnosis in treatment vs. control. Comparison will be at the village level and at the shop level. Denominator will be: all illnesses, febrile illnesses only or suspected malaria episodes only.","William Dickens, PhD",Principal Investigator,Northeastern University,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FMPOS 2014-70,NCT02894294,Evaluation of Seasonal Malaria Chemoprevention in Kita,"Measuring the Impact of Seasonal Malaria Chemoprevention as Part of Routine Malaria Control in Kita, Mali",Completed,July 2014,June 2015,Actual,Actual,University of Bamako,NA,NA,NA,N/A,Observational [Patient Registry],1162,Actual,Malaria; Anemia,NA,All,3 Months,59 Months,Accepts Healthy Volunteers,University of Bamako,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Coverage of SMC,Change in malaria infection from baseline,United States Agency for International Development (USAID),U.S. Fed,Centers for Disease Control and Prevention,U.S. Fed,NA,Four months (August to November in 2014),December 2014 (one month post last round of SMC),Change in prevalence of malaria illness from baseline,NA,NA,Adherence to SMC,NA,NA,NA,NA,NA,NA,Proportion of the children aged 3-59 months at the time of SMC who received the three days' treatment of SMC during that specific round,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  Children age 3-59 months

          -  Residence in the study areas

          -  Provision of inform consent

        Exclusion Criteria:

          -  Age < 3 months or >= 60 months

          -  Not resident in the study areas

          -  No provision of inform consent
      ",NA,NA,NA,Malaria infection was defined as presence of malaria parasitemia by blood smear,December 2014 (one month post last round of SMC),axillary temperature >= 37.5o C and blood smear positive for asexual forms of malaria parasites,1-3 days post post first SMC dose,proportion of children who received the second and third dose of AQ at home,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
07MA,NCT01887821,Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam,A Randomised Controlled Trial to Assess the Antimalarial Drug Susceptibility and Molecular Characterization of Plasmodium Vivax Isolates in Vietnam,Completed,February 2013,June 2015,Actual,Actual,"Oxford University Clinical Research Unit, Vietnam",NA,NA,NA,Phase 4,Interventional,330,Actual,Plasmodium Vivax Malaria,NA,All,3 Years,N/A,No,"Oxford University Clinical Research Unit, Vietnam",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of patients with adequate response to treatment,NA,"Institute of Malaria, Parasitology and Entomology, Ho Chi Minh City, Viet Nam",Other,"Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam",Other,Bu Gia Map Health Station,Day 63,NA,NA,"Agency for Science, Technology and Research",Other,NA,NA,NA,Wellcome Trust,Other,NA,NA,"Adequate response = adequate clinical and parasitological response. Absence of parasitaemia on day 63, irrespective of temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Transmal study version 2.0,NCT02769013,Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity,Assessing the Effect of Neglected Tropical Diseases on Plasmodium Falciparum Transmission in an Area of Co-endemicity,Recruiting,April 2016,September 2018,Anticipated,Anticipated,University Hospital Tuebingen,"Ulysse ATEBA NGOA, Dr.",Principal Investigator,"CERMEL, Lambarene, GABON",N/A,Observational,395,Anticipated,Malaria Transmission,NA,All,6 Years,30 Years,Accepts Healthy Volunteers,University Hospital Tuebingen,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Oumou MAIGA, PhD",Principal Investigator,"KCCR, Kumasi, Ghana",NA,Number of participants with Plasmodium falciparum gametocytes and/or asexual blood stages,NA,NA,NA,NA,NA,NA,15 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Presence of Plasmodium falciparum gametocytes and/or asexual blood stages will be assessed by a quantitative real-time PCR assay in the blood obtained from participants. Unit of measurements for both parameters is numbers/µl.,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  Subjects aged from 6 to 30 years

          -  Without severe or moderate disease

          -  Agreement to be enrolled in the study (written informed consent or consent by the
             legal representative and assent)

          -  Living in the study area for at least 1 year

        Exclusion Criteria:

          -  Anaemia with haemoglobin less than 8g/dl

          -  Know sickle cell disease

          -  Macroscopic haematuria

          -  Any other know severe disease
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TRIPI,NCT02787070,"A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)","A Randomized Controlled Trial on Malaria Primaquine Treatment in Timika, Indonesia (TRIPI)",Recruiting,NA,July 2018,Anticipated,Anticipated,Menzies School of Health Research,NA,NA,NA,Phase 4,Interventional,420,Anticipated,Uncomplicated Malaria,NA,All,1 Year,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The incidence risk of symptomatic P. vivax malaria over 6 months in patients enrolled with any malaria infection,NA,"Timika Research Facility Kompleks RSMM, Timika-Papua, Indonesia",Other,NA,NA,Timika Research Facility,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"September 14, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR-1327,NCT01659281,"Efficacy of Artesunate-Mefloquine Combination Therapy in Trat Province, Thailand","Efficacy of Artesunate-Mefloquine Combination Therapy for the Treatment of Uncomplicated Falciparum Malaria in Trat Province, Thailand",Completed,September 2007,May 2012,Actual,Actual,"Armed Forces Research Institute of Medical Sciences, Thailand","Wichai - Satimai, M.D., D.T.M. & H.",Principal Investigator,"Bureau of Vector-Borne Disease, Department of Disease Control, Ministry of Public Health",N/A,Interventional,13,Actual,Plasmodium Falciparum Malaria,NA,All,5 Years,70 Years,No,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Mark M. Fukuda, M.D.",Principal Investigator,"Dept. of Immunology and Medicine, AFRIMS",NA,Determination of parasitological cure rate of directly observed antimalarial therapy,NA,NA,NA,NA,NA,"Vector Borne Diseases Control Units (VBDC, malaria clinics)",63 days from initiation of treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
19850-101,NCT01722734,Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment,Preserving ACTs - Text Reminders to Increase Adherence to ACT Treatment,Completed,June 2011,January 2013,Actual,Actual,Harvard School of Public Health,"Gunther Fink, PhD",Principal Investigator,Harvard School of Public Health,N/A,Interventional,1140,Actual,Malaria,NA,All,18 Years,N/A,Accepts Healthy Volunteers,Harvard School of Public Health,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Self-reported Adherence to Artemisinin-combination Therapy (ACT) Treatment,NA,NA,NA,NA,NA,Study site,70 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Percentage of participants completing full ACT treatment regimen 70 hours after treatment initiation. Subjects were visited at home, and asked to report when each of the prescribed six doses were taken. Adherence was defined as the (self-reported) completion of all six doses.",NA,NA,NA,NA,NA,NA,NA,NA,Self-reported Adherence to Artemisinin-combination Therapy (ACT) Treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IMPAACT P1079,NCT01728961,Pharmacology of Antimalarial Therapy With or Without Antiretroviral Therapy,Pharmacology of Artemisinin-Based Antimalarial Therapy Within the Context of Antiretroviral Therapy,Terminated,February 2012,March 2014,Actual,Actual,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,"Francesca Aweeka, Pharm.D.",Principal Investigator,IMPAACT/UCSF,Phase 4,Interventional,19,Anticipated,HIV Infection; Malaria,NA,All,3 Years,12 Years,No,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Area under the curve from time zero to last quantifiable concentration (AUC),Toxicity,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,"NVP PK: At study entry and study day 3, AL PK: At study days 3, 4, 8, and 14",At study entry and study days 28 and 42,Maximum observed plasma concentration (Cmax),NA,NA,Minimum observed plasma concentration (Cmin),Toxicity,NA,NA,NA,NA,NA,Area under the plasma concentration versus time curve from time zero to time of last quantifiable concentration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Number of subjects with adverse events of Grade 3 or higher will be recorded,"NVP PK: At study entry and study day 3, AL PK: At study days 3, 4, 8, and 14",Maximum observed plasma concentration computed for each individual and then summarized for the strata,"NVP PK: At study entry and study day 3, AL PK: At study days 3, 4, 8, and 14",Minimum observed plasma concentration computed for each individual and then summarized for the strata,NA,NA,At study days 28 and 42,Percentage of subjects with adverse events of Grade 3 or higher will be recorded Safety Issue: Yes,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VanSI_2013,NCT01837992,Safety and Efficacy of Primaquine for P. Vivax,Evaluation of Safety and Efficacy of Two Primaquine Dosing Regimens for the Radical Treatment of Plasmodium Vivax Malaria in Vanuatu and Solomon Islands,Unknown status,May 2013,May 2015,Anticipated,Anticipated,Menzies School of Health Research,NA,NA,NA,N/A,Interventional,180,Anticipated,Malaria,NA,All,12 Months,60 Years,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Efficacy: Numbers of Plasmodium vivax relapses per person-years of follow-,NA,Walter and Eliza Hall Institute of Medical Research,Other,"Ministry of Health, Vanuatu",Other,NA,12 months,NA,NA,"Ministry of Health, Solomon Islands",Other,NA,NA,NA,World Health Organization,Other,NA,NA,"Total number of microscopically diagnosed (including both symptomatic and asymptomatic infections), PCR-confirmed relapses with Plasmodium vivax in participants in each treatment arm over the 3-month follow-up period, expressed as number of relapses per person-years of follow-up.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VHT_041406,NCT02374580,Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams,Partnership and Dignity: a Mixed-methods Survey on Supporting and Retaining Uganda's Village Health Teams,Completed,February 2015,May 2015,Actual,Actual,George Washington University,"William S Schroth, MD MPH",Principal Investigator,George Washington University School of Medicine and Health Sciences,N/A,Observational,143,Actual,Malaria; Diarrhea; Pneumonia,NA,All,18 Years,N/A,Accepts Healthy Volunteers,George Washington University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Predicted longevity related to support sufficiency,NA,Makerere University,Other,NA,NA,The George Washington University School of Medicine and Health Sciences,Up to 5 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,This outcome will be measured by asking VHTs to rate aspects of their current support. We will follow up those questions by asking how long they expect to be able to continue in their position as VHTs. The two results will be evaluated for possible trends connecting sufficiency of existing support with predicted longevity.,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

        VHT subjects must have been actively working as a VHT member for at least 6 months.
        Stakeholders, that is, program managers, health administrators and policy makers, must be
        involved in managing, administrating, or guiding policy for VHT programs as part of their
        official job description. These persons must also have been acting in those roles for at
        least 6 months. All study subjects will be 18 years of age or older. All study subjects
        will be literate and able to be informed to give or withhold consent of participation.

        Exclusion Criteria:

        There will be no exclusion or inclusion based on gender, race, tribal or ethnic
        affiliation, religion, or health status.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
STUDY00002592,NCT02414399,Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children,Azithromycin to Prevent Post-discharge Morbidity and Mortality in Kenyan Children,Recruiting,June 2016,December 2020,Anticipated,Anticipated,University of Washington,"Judd L Walson, MD, MPH",Principal Investigator,University of Washington Department of Global Health,Phase 4,Interventional,1400,Anticipated,Pneumonia; Diarrhea; Malaria; Co-infection; Death; Malnutrition,NA,All,1 Month,59 Months,Accepts Healthy Volunteers,University of Washington,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Patricia B Pavlinac, PhD, MS",Study Director,University of Washington Department of Global Health,NA,Composite outcome of mortality and hospital readmission,NA,Kenya Medical Research Institute,Other,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Kisii Teaching and Referral Hospital & Homa Bay District Hospital,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2006/HD11/4748U,NCT00658450,Rehabilitation Program for Cognitive Deficits in Ugandan Children After Cerebral Malaria,A Randomised Trial to Investigate the Effect of a Rehabilitation Program for Cognitive Deficits in Ugandan Children After Cerebral Malaria.,Completed,February 2008,October 2010,Actual,Actual,Makerere University,"Charles Ibingira, MMED",Study Chair,"Chairman, Makerere University Faculty of Medicine Research and Ethics Committee",N/A,Interventional,123,Actual,"Malaria, Cerebral",NA,All,5 Years,15 Years,Accepts Healthy Volunteers,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Improvement in attention scores,NA,Karolinska Institutet,Other,NA,NA,Mulago hospital Acute Care Unit and the Cerebral Malaria Project,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ISO105774,NCT00675064,"Single-Blind, Placebo-Controlled, Randomized Study Testing Single Ascending Doses Of GSK369796 In Healthy Subjects","Single-blind, Placebo-controlled, Randomized Study Testing Single Ascending Doses of GSK369796 in Healthy Subjects",Completed,May 2008,October 2008,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,41,Actual,Healthy Subjects; Malaria,NA,All,18 Years,40 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety and tolerability,NA,Medicines for Malaria Venture,Other,NA,NA,GSK Investigational Site,From Day 1 to follow-up visit,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PV001,NCT02817919,Cohort Event Monitoring in Sub Saharan Africa,"Modified Cohort Event Monitoring Of Injectable Artesunate, Artemether And Quinine In Ethiopia, Ghana, Malawi And Uganda",Recruiting,May 2016,December 2016,Anticipated,Anticipated,African Collaborating Centre for Pharmacovigilance,"Kwaku P. Asante, MD, PhD",Principal Investigator,"Kintampo Health Research Centre, Ghana",N/A,Observational,3000,Anticipated,Malaria,NA,All,N/A,N/A,No,African Collaborating Centre for Pharmacovigilance,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Alexander NO Dodoo, PhD",Principal Investigator,WHO Collaborating Centre for Advocacy and Training in Pharmacovigilance,NA,The proportion of adverse events following administration of Injectable artesunate.,NA,"Kintampo Health Research Centre, Ghana",Other,University of Health and Allied Sciences,Other,NA,28 days after administration of injectable artesunate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion criteria

          -  Severe Malaria (Plasmodia of any species) diagnosed as per national policies and
             health facility practice/protocol

          -  Ability and willingness to participate by giving signed informed consent. In the case
             of some adults and all children, signed informed consent would be obtained from the
             patient or a carer/guardian.

          -  Participants who agree to for follow-up visits and can be contacted by phone.

        Exclusion criteria

          -  Patients (or carers/guardians) unwilling or unable to provide signed informed consent

          -  Patients with any illness that the investigator feels would be harmful to them to
             participate in the study

          -  Has not received Inj AS, AR, or Q.

          -  Existence of serious concurrent illness
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC 1430,NCT02672228,Feasibility of the Vapor Nanobubble Technology for Malaria Diagnostics (MalariaSense),Feasibility of the Vapor Nanobubble Technology (MalariSense) for Malaria Diagnostics,Completed,October 2015,December 2015,Actual,Actual,"Medical Research Council Unit, The Gambia","Umberto D'alessandro, PhD, MD",Principal Investigator,"Medical Research Council Unit, The Gambia",N/A,Interventional,208,Actual,Malaria,NA,All,1 Year,N/A,No,"Medical Research Council Unit, The Gambia",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"""Hemozoin-generated vapour nanobubble (H-VNB) amplitude thresholds among malaria infected and uninfected individuals""",NA,Precision Acoustics ltd UK,Other,"Standa, UAB Lithuania",Other,Basse Health Centre,Day 1,NA,NA,"X Instruments LLC, CA, USA",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BKMAL0804,NCT00692627,"Evaluation of Volume Status, Haemodynamics and Microcirculatory Flow in Adult Patients With Severe Falciparum Malaria","Evaluation of Volume Status, Haemodynamics and Microcirculatory Flow in Adult Patients With Severe Falciparum Malaria",Completed,July 2008,December 2008,Actual,Actual,University of Oxford,"Arjen Dondorp, MD",Study Director,Mahidol Oxford Research Unit,N/A,Observational,80,Anticipated,Severe Falciparum Malaria,NA,All,16 Years,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Metabolic Acidosis,NA,NA,NA,NA,NA,Chittagong Medical College Hospital,48 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria

          1. Severe malaria, defined by the modified criteria of Hien et al and the presence of
             asexual forms of P. falciparum in the peripheral blood smear.

          2. The patients or their attending relative able and willing to give fully informed
             written consent.

          3. Age ≥ 16 years

        Exclusion Criteria

        1. Patients or relatives unable or unwilling to give informed consent.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H6930-27654,NCT00697892,Pharmacokinetic Interactions Between Antiretroviral Agents and Antimalarial Drug Combinations,"Pharmacokinetic Interactions Between Antiretroviral Agents, Lopinavir/Ritonavir and Efavirenz and Antimalarial Drug Combinations, Artesunate/Amodiaquine and Artemether/Lumefantrine.",Completed,July 2005,December 2010,Actual,Actual,Fran Aweeka,"Francesca T Aweeka, PharmD",Principal Investigator,"University of California, San Francisco",Phase 1,Interventional,38,Actual,HIV Infections; Malaria,NA,All,21 Years,60 Years,Accepts Healthy Volunteers,Fran Aweeka,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,AUC (zero to infinity) of the antimalarial agent,NA,NA,NA,NA,NA,San Francisco General Hospital,Each 3-day antimalarial treatment course throughout study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,AUC (zero to infinity) of the antimalarial agent,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KEMRI/SERU/CGHR/017/3129,NCT02687373,"Safety, Tolerability and Efficacy of PfSPZ Vaccine in Healthy Children and Infants 5 Months - 9 Years Living in Kenya","Safety, Tolerability and Efficacy of PfSPZ Vaccine Administered by Direct Venous Inoculation (DVI) to Healthy Children and Infants 5 Months Through 9 Years of Age Living in an Area of High Malaria Transmission in Western Kenya: Age De-escalation and Dose Escalation and a Double Blind, Randomized Placebo-Controlled Trial for Safety and Efficacy",Recruiting,July 2016,November 2018,Anticipated,Anticipated,Sanaria Inc.,"Martina Oneko, MD",Principal Investigator,"Kenya Medical Research Institute, Centre for Global Health Research, Kisumu, Kenya",Phase 1/Phase 2,Interventional,572,Anticipated,Malaria,NA,All,5 Months,9 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Part 1 - Incidence and type of adverse events (AE),Part 1 - Incidence and type of possibly/probably or definitely related serious adverse events (SAEs),Kenya Medical Research Institute,Other,Centers for Disease Control and Prevention,U.S. Fed,"Center for Global Health Research, KEMRI",Collected from day of each vaccination until day 28 post vaccination,"Collected from day of first vaccination until close out visit (28 days for 3 lower doses, 84 days for 2 higher doses)",Part 1 - Assessment of Pf-specific antibodies in the different age categories and to the different vaccine doses,National Institutes of Health (NIH),NIH,Part 2 - Incidence and type of adverse events in infants 5-12 months of age following administration of PfSPZ Vaccine,Part 2 - Incidence and type of possibly/probably or definitely related serious adverse events (SAEs) following administration of PfSPZ Vaccine,Part 2 - Assessment of Pf-specific antibodies in infants of 5-12 months to three vaccinations of PfSPZ Vaccine,University of Maryland,Other,NA,NA,"Incidence and type of solicited and unsolicited adverse events including breakthrough malaria infections and clinical laboratory assessments (hematological, liver and renal function) will be collected within 28 days after each vaccination. Proportions of participants with AEs and frequencies of individual AEs will be calculated and compared against participants in the same age category and dose group receiving placebo.",NA,NA,NA,NA,NA,NA,Part 2 - Ratio of Pf positive blood smear (+BS) in experimental arm to Pf +BS in placebo arm to determine efficacy of PfSPZ Vaccine during 6 months after last dose,NA,NA,NA,NA,NA,NA,NA,"Incidence of all hospitalizations, deaths, disabilities caused by at least possibly related SAEs during study participation",Collected 1 week after each vaccination,Collection of blood samples for antibodies on day 8 after each vaccination. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA) respectively.,Collected from day of each vaccination until day 28 post vaccination,"Incidence and type of solicited and unsolicited adverse events including breakthrough malaria infections and clinical laboratory assessments (hematological, liver and renal function) will be collected during 28 days after each vaccination.",NA,NA,Collected from day of first vaccination through the 12-month follow-up period.,"Incidence of all hospitalizations, deaths, disabilities caused by at least possibly related to the study product during the 12-month follow-up period.",Collected 1 week after the first and second vaccination and 2 weeks after the third vaccination.,Collection of blood samples for antibodies on day 8 after vaccination 1 and 2 and day 15 after the third PfSPZ vaccination. Following vaccination serum will be taken and an assessment of Plasmodium falciparum (Pf)f-specific antibodies against specific malaria proteins such as the circumsporozoite protein (CSP) PfCSP and whole Pf sporozoites (SPZ) will be determined by enzyme-linked immunosorbent assay (ELISA) and automated immunofluorescence assay (aIFA) respectively.,2 weeks to 6 months after the last vaccine dose,"Efficacy against malaria infection of PfSPZ Vaccine administered to infants 5-12 months of age in 3 doses by passive and active surveillance for naturally acquired Pf infection, measured by blood smear microscopy, during 6 months following the last vaccine dose.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SR-M-TZ,NCT02294214,Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania,Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Tanzania,Withdrawn,February 2016,April 2016,Actual,Actual,University of Notre Dame,"Neil Lobo, PhD",Principal Investigator,University of Notre Dame,N/A,Interventional,0,Actual,Malaria,NA,All,6 Months,59 Months,Accepts Healthy Volunteers,University of Notre Dame,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Nicole Achee, PhD",Principal Investigator,University of Notre Dame,NA,Malaria Incidence,NA,Ifakara Health Institute,Other,NA,NA,Ifakara Health Institute,104 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Incidence of malaria infections among human cohorts during the follow-up period as detected by PCR,NA,NA,NA,NA,NA,NA,NA,NA,Malaria Incidence,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC063,NCT02927145,"A Challenge Study to Assess the Safety, Immunogenicity and Efficacy of a Malaria Vaccine Candidate","A Phase I/IIa Clinical Trial to Assess the Safety, Immunogenicity and Efficacy of the Blood-stage Plasmodium Falciparum Malaria Vaccine Candidate RH5.1/AS01",Recruiting,NA,November 2018,Anticipated,Anticipated,University of Oxford,NA,NA,NA,Phase 1/Phase 2,Interventional,78,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,efficacy of the RH5.1/AS01 vaccine by demonstrating a reduced PMR in vaccinated subjects compared to infectivity controls against 3D7 clone parasites in a CHMI model.,the safety of RH5.1/AS01 in healthy malaria-naïve adults in the UK.,NA,NA,NA,NA,NA,8 months,8 months,the in vitro growth inhibition activity (GIA) against 3D7 clone P. falciparum parasites of IgG purified from the serum of vaccinees.,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PCR-derived parasite multiplication rate (PMR) will be the primary efficacy endpoint for the Phase IIa stage of the trial, and comparison of the endpoint between the Groups 5 and 6 will constitute the primary analysis for efficacy.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.,8 months,The specific endpoints for GIA in vitro will be assessed from a titration of the purified IgG in the assay.,NA,NA,"October 17, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
4980/A0/04/001/010,NCT02866097,"Integrated Community Case Management Study in Eastern Province, Zambia","Strengthening the Delivery of Integrated Community Case Management (iCCM) in Two Districts of Eastern Province, Zambia",Recruiting,March 2016,September 2016,Anticipated,Anticipated,Zambia Center for Applied Health Research and Development,"Godfrey Biemba, MBChB, M.Sc",Principal Investigator,ZCAHRD and Boston University,N/A,Interventional,3840,Anticipated,Malaria; Diarrhea; Pneumonia,NA,All,1 Month,5 Years,No,Zambia Center for Applied Health Research and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"David Hamer, MD",Principal Investigator,Boston University,NA,"Composite percentage of children appropriately treated for malaria, diarrhea, and pneumonia.",NA,UNICEF,Other,Bill and Melinda Gates Foundation,Other,Chadiza and Chipata Districts,"Through study completion, up to six months",NA,NA,Boston University,Other,NA,NA,NA,"Ministry of Health, Zambia",Other,"Ministry of Community Development, Mother and Child Health",Other,"Defined as percentage of sick children under five years of age presenting with an i-CCM condition to an i-CCM trained health worker (CHW or a CHA) who received appropriate treatment for an iCCM condition (composite indicator):
Appropriate treatment for malaria: received artemisinin-based combination therapy (ACT) for malaria for at least three days or Appropriate treatment for pneumonia: received amoxicillin for pneumonia for at least five days or Appropriate treatment for diarrhea: received zinc in addition to fluid from ORS packet or oral rehydration solution (ORS) liquid or homemade fluid for diarrhea","Boniface M Chiluba, B.Sc, M.Sc",Study Director,Zambia Center for Applied Health Research and Development,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IDC-08-01,NCT00725777,Treatment of Non-falciparum Malaria,"Efficacy and Safety of Artemether Lumefantrine Combination Therapy for the Treatment of Malaria Due to Plasmodium Ovale, Plasmodium Malariae, and Mixed Plasmodium Infections in Gabon",Completed,July 2008,February 2012,Actual,Actual,Albert Schweitzer Hospital,"Sabine Bélard, MD",Principal Investigator,Medical Research Unit of the Albert Schweitzer Hospital in Lambaréné,N/A,Interventional,40,Actual,Acute Non-falciparum Malaria,NA,All,6 Months,60 Years,No,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasitological cure rate on day 28,NA,NA,NA,NA,NA,Medical Research Unit of the Albert Schweitzer Hospital,D28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DELIMAL,NCT00730366,New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa,New Approaches to Improve Coverage and Compliance of Antimalarial Treatment for Pregnant Women in Rural Africa.,Completed,March 2004,December 2006,Actual,Actual,"Institute of Tropical Medicine, Belgium","Sheick Coulibaly Oumar Coulibaly, MD PhD",Study Director,Directeur de la Biologie Médicale du Laboratoire National de Santé Publique,Phase 3,Interventional,2766,Actual,Malaria in Pregnancy,NA,Female,N/A,N/A,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Umberto D'Alessandro, MD",Study Chair,Institute of Tropical Medicine,NA,Birth weight,NA,"University of Ouagadougou, Burkina Faso",Other,"National Laboratory of Public Health,Burkina Faso",Other,District Sanitaire,At delivery,NA,NA,Liverpool School of Tropical Medicine,Other,NA,NA,NA,Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA),Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVG50,NCT00694694,Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria.,A Randomized Trial of Azithromycin + Artesunate v Artemether-lumefantrine in Uncomplicated Malaria in Tanzanian Children.,Completed,June 2008,February 2009,Actual,Actual,London School of Hygiene and Tropical Medicine,Christopher Whitty,Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,261,Actual,Malaria,NA,All,6 Months,5 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasitological failure by day 28,NA,"National Institute for Medical Research, Tanzania",Other,NA,NA,Teule Hospital,Within 28 days of treatment.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BIT014 PR001 V01,NCT02938975,Field Efficacy Of Insecticide Treated Uniforms And Skin Repellents for Malaria Prevention,Field Efficacy Of Insecticide Treated Uniforms And Skin Repellents To Reduce Malaria Incidence In Military Personnel On Active Duty In Regions Of Hyperendemicity,Not yet recruiting,NA,June 2019,Anticipated,Anticipated,Ifakara Health Institute,"Sarah J Moore, PhD",Principal Investigator,Ifakara Health Institute,Phase 3,Interventional,1500,Anticipated,Malaria,NA,All,18 Years,40 Years,Accepts Healthy Volunteers,Ifakara Health Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of Plasmodium falciparum malaria through monthly measurement of malaria positivity by direct polymerase chain reaction (PCR) to detect parasite DNA,NA,Swiss Tropical & Public Health Institute,Other,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,Ifakara Health Institute,Monthly active case detection for 12 months,NA,NA,U.S. Army Medical Research and Materiel Command,U.S. Fed,NA,NA,NA,NA,NA,NA,NA,Blood spots will be collected on Whatman 3 filter paper and processed for PCR detection of parasites,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,November 2017,Anticipated,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1030,NCT00317473,Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children,"Double-blind,Randomized,Controlled,Dose Escalation Phase 1 Trial in 12-47 Month Old Children in Western Kenya to Evaluate the Safety and Immunogenicity of WRAIR's MSP-1(FMP1) Malaria Vaccine Adjuvanted in GSK's AS02A Versus Rabies Vaccine.",Completed,June 2003,July 2005,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Mark R. Withers, M.D., MPH",Principal Investigator,USAMRU-K,Phase 1,Interventional,NA,NA,Plasmodium Falciparum Malaria,NA,All,12 Months,47 Months,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,135,"Occurrence of solicited symptoms during a 7 day follow-up period after each vaccination (5 visits: day of vaccination and days 1, 2, 3, and 7)",Occurrence of unsolicited symptoms during a 30 day follow-up period after each vaccination (day of vaccination and the 29 subsequent days),Kenya Medical Research Institute,Other,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,Walter Reed Project Kombewa Clinic,NA,NA,Occurrence of serious adverse events during an 8 month follow-up period following the first dose of study vaccine,The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,NA,United States Agency for International Development (USAID),U.S. Fed,GlaxoSmithKline,Industry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
015NECHR,NCT02434952,Safety and Tolerability of Low Dose Primaquine,The Tolerability and Safety of Low Dose Primaquine for Transmission Blocking in Symptomatic Falciparum Infected Cambodians,Completed,October 2014,NA,NA,NA,Malaria Consortium,"Dysoley Lek, MD",Principal Investigator,"National Centre for Parasitology, Entomology and Malaria Control, Cambodia",Phase 4,Interventional,109,Actual,"Malaria, Falciparum; G6PD Deficiency",NA,All,1 Year,N/A,No,Malaria Consortium,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Haemoglobin concentration,NA,"National Centre for Parasitology, Entomology and Malaria Control, Cambodia",Other,"Institute Pasteur, Cambodia",Other,Ratanakiri Provincial Hospital,Day 7,NA,NA,World Health Organization,Other,NA,NA,NA,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,"Compare haemoglobin concentrations in g/dL between the G6PD deficient arm given DHA PP plus primaquine, and the G6PD normal arm receiving the same regimen",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IPTCVP17,NCT00738946,A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children,A Trial of the Combined Impact of Intermittent Preventive Treatment and Insecticide Treated Bednets in Reducing Morbidity From Malaria in African Children,Completed,August 2008,December 2009,Actual,Actual,London School of Hygiene and Tropical Medicine,"Brian M Greenwood, MD, FRCP",Study Director,London School of Hygiene and Tropical Medicine,N/A,Interventional,6000,Anticipated,Malaria,NA,All,3 Months,59 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of clinical malaria,NA,"Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso",Other,"Malaria Research and Training Centre, Mali",Other,NA,2008-2009,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EHMI-8B,NCT00757887,Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites,Re-exposure of EHMI-8 Human Volunteers to Live Malaria Sporozoites,Completed,October 2009,August 2010,Actual,Actual,Radboud University,"Robert Sauerwein, Prof. Dr.",Principal Investigator,Radboud University,N/A,Interventional,15,Anticipated,P. Falciparum Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,A significant difference in time of thick smear positivity between EHMI-8 and control volunteers,A significant quantitative difference in parasitemia as measured by PCR between EHMI-8 and control volunteers,NA,NA,NA,NA,UMC St. Radboud,21 days,21 days,A significant difference in kinetics of parasitemia between EHMI-8 and control volunteers as measured by PCR.,NA,NA,A difference in occurrence of signs or symptoms between EHMI-8 and control volunteers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,21 days,NA,21 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_13_002,NCT01853475,Healthy Volunteer Study of the Pharmacokinetics of Oral Piperaquine With OZ439 + TPGS Formulation in the Fasted State,"Open Label, Parallel Group Study to Investigate the Pharmacokinetics (PK) Following Oral Co-administration of Piperaquine Phosphate (PQP) Tablets With a Prototype OZ439 + TPGS Formulation in the Fasted State in Healthy Volunteers",Completed,April 2013,July 2013,Actual,Actual,Medicines for Malaria Venture,"Ulrike Lorch, MD FRCA FFPM",Principal Investigator,Richmond Pharmacology Limited,Phase 1,Interventional,24,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 Cmax,OZ439 AUC0-inf,Richmond Pharmacology Limited,Industry,NA,NA,Richmond Pharmacology Limited,"Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43","Day 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours(Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5),168 (Day 8), Day 11, Day 15, Day 29 and Day 43",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 maximum concentration observed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Area under the OZ439 plasma concentration time curve from time zero to time infinity using observed values.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVT68,NCT01907672,The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level,The Role of Rapid Diagnostic Tests for Malaria for Targeting of ACTs at Community Level: a Cluster Randomized Trial,Completed,August 2011,April 2013,Actual,Actual,Ghana Health Services,"Evelyn K Ansah, MD,MPH,PhD",Principal Investigator,Ghana Health Services,Phase 4,Interventional,4748,Actual,Malaria,NA,All,6 Months,N/A,No,Ghana Health Services,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Christopher C Whitty, BSc,MSc,PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,The proportion of clients negative for malaria by double read research blood slide who received an anti-malarial in both arms,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,"Dodowa Health Research Centre, Ghana Health Service",Until the estimated sample size is obtained or up to 2 yrs whichever comes first,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Out of all clients who test negative when their blood slides are read by two independent expert microscopists, how many received an antimalarial treatment from the Licensed Chemical Seller","Margaret Gyapong, BSc,MSc,PhD",Principal Investigator,Ghana Health Services,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CASTEP,NCT02974348,Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa,Assessment of Antimalaria Drugs Susceptibility Testing for an Effective Management of Infected Patients in Sub-Sahara Africa,Completed,January 2013,October 2014,Actual,Actual,University of Bamenda,"Xiaonong Zhou, PhD",Study Director,National Institute for Parasitic Disease,Phase 3,Interventional,300,Actual,Drug Resistant Malaria Due to Plasmodium Falciparum,NA,All,6 Months,59 Months,No,University of Bamenda,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,efficacy and safety assessment,NA,Ministry of Science and Technology of the People´s Republic of China,Other,"National Institute for Parasitic Disease, Chinese Center for Disease Control and Prevention",Other,CDC Hospital,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The primary endpoint was the 28-day and 42-day cure rates and was defined as proportion of patients with adequate clinical and parasitological response (ACPR) after 28 and 42 days of follow-up. Absence of parasitemia until day 28 and day 42 irrespective of axillary temperature was categorized as an adequate clinical and parasitologic response (ACPR). Secondary endpoints were early treatment failure (ETF), late clinical failure (LCF), late parasitological failure (LPF), adverse events (clinical and laboratory abnormalities), anaemia (Hematocrit < 30%), clearance rate of fever and parasitaemia, and gametocyte",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PATH-WIRB-1155095,NCT02654912,Community-led Responses for Elimination: Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration,Community-led Responses for Elimination (CoRE): A Cluster Randomized Controlled Trial of Reactive Case Detection Versus Reactive Drug Administration in Malaria Elimination Areas in Southern Province Zambia,Recruiting,February 2016,December 2018,Anticipated,Anticipated,PATH,"Daniel Bridges, PhD",Principal Investigator,Akros,Phase 4,Interventional,4800,Anticipated,Malaria,NA,All,3 Months,N/A,Accepts Healthy Volunteers,PATH,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria seropositivity in children under five,NA,"Ministry of Health, Zambia",Other,AKROS Global Health,Other,Southern province medical office,24 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria seropositivity in children under five after two-year intervention within health center catchment areas,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HA.577/Vol. II/126,NCT02482116,A Comparison of Diagnostic Approaches for Malaria and Pneumonia,"Malaria and Pneumonia in Children Under the Age of Five Years Old Presenting to Primary Healthcare Centres in Benin City, Nigeria: a Comparison of Early Diagnostic Approaches","Active, not recruiting",August 2015,July 2017,Anticipated,Anticipated,University of Nottingham,"Kelly O Elimian, MSc",Principal Investigator,University of Nottingham & University of Benin,N/A,Observational,1000,Actual,Malaria; Pneumonia,NA,All,2 Months,4 Years,No,University of Nottingham,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Puja R Myles, PhD",Study Director,University of Nottingham,NA,Malaria confirmed by microscopy (yes/no),Pneumonia confirmed by chest x-ray (yes/no),University of Benin,Other,NA,NA,"Health Services Department, University of Benin",Participants will be assessed within an average period of 24 hours of presenting to study primary healthcare centres,Participants will be assessed within an average period of 48 hours of presenting to study primary healthcare centres,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,This is the gold standard diagnosis for malaria and will be used to assess the accuracy of other diagnostic approaches,"Catherine Pritchard, PhD",Study Director,University of Nottingham,"Ayebo Sadoh, PhD",Study Director,University of Benin,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Suspected malaria (symptoms reported by caregiver that are consistent with malaria:
             high temperature, chills and no other probable diagnosis)

          -  Suspected pneumonia (fever, cough, shortness of breath/difficulty in breathing, with
             or without chills and no other probable diagnosis)

          -  Willingness of caregiver to provide written or verbal consent in the presence of a
             witness.

        Exclusion Criteria:
      ",NA,NA,NA,This is the gold standard test for pneumonia and will be used to assess the accuracy of other diagnostic approaches,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SAFEPRIM-II,NCT02654730,Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia,Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia,Terminated,December 2015,December 2016,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,NA,NA,NA,Phase 2/Phase 3,Interventional,61,Actual,Malaria,NA,Male,10 Years,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Haemoglobin concentration relative to baseline value as measured by HemoCue,NA,"Medical Research Council Unit, The Gambia",Other,NA,NA,Medical Research Council Laboratories,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
06-55,NCT00766662,Intermittent Preventive Treatment in Infant in Mali,NA,Completed,October 2006,December 2007,Actual,Actual,University of Bamako,"Alassane Dicko, MD",Principal Investigator,"Faculty of Medicine, Pharmacy and Dentistry; University of Bamako",N/A,Interventional,NA,NA,Malaria,NA,All,N/A,23 Months,Accepts Healthy Volunteers,University of Bamako,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Ogobara K Doumbo, MD",Study Director,"Faculty of Medicine, Pharmacy and Dentistry; University of Bamako",NA,EPI vaccines and other health interventions coverage,Molecular makers of resistance of P. falciparum to Sulfaxodine- pyrimethamine,UNICEF,Other,NA,NA,"Malaria Research & Training Center; Faculty of Medicine, Pharmacy and Dentistry, University of Bamako",1 year,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1477,NCT00811096,Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax,Pilot Human Study of Tinidazole Efficacy For Radical Cure Of Plasmodium Vivax,Completed,November 2008,April 2009,Actual,Actual,Walter Reed Army Institute of Research (WRAIR),"Francois Nosten, MD",Principal Investigator,"Malaria Research Unit, Thailand",Phase 2,Interventional,20,Actual,"Malaria, Vivax",NA,All,18 Years,65 Years,No,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cure is defined as absence of malaria infection on thick/thin malaria smears up to and on day 63 after initial clearance of parasitemia. Subjects will be followed to day 90 to rule out delayed presentation of malaria (as opposed to cure).,NA,NA,NA,NA,NA,"Malaria Research Unit, 68/30 Ban Toong Road, P.O. Box 46",63 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EGSPZV2,NCT02859350,"Safety, Tolerability and Immunogenicity of PfSPZ Vaccine in an Age De-escalation Trial in Equatorial Guinea.","Age Escalation / De-escalation Study to Evaluate the Safety, Tolerability and Immunogenicity of a Radiation-attenuated Plasmodium Falciparum (Pf) Sporozoite Vaccine (PfSPZ Vaccine) in Equatoguinean Adults, Children and Infants, and Comparison With Non-attenuated Pf Sporozoites (PfSPZ Challenge) Administered Under Chloroquine Prophylaxis (PfSPZ-CVac Approach) for Efficacy Against Controlled Human Malaria Infection.",Recruiting,November 2016,August 2017,Anticipated,Anticipated,Sanaria Inc.,"Salim Abdulla, MD, PHD",Study Director,Ifakara Health Institute (IHI),Phase 1,Interventional,135,Anticipated,Malaria,NA,All,6 Months,65 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence and type of Adverse Events,NA,Ifakara Health Institute,Other,Swiss Tropical & Public Health Institute,Other,La Paz Medical Center,Day of first immunization until one year,NA,NA,Government of Equatorial Guinea,Other,NA,NA,NA,Marathon Oil Corporation,Industry,Noble Oil Services,Industry,"Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings post first immunization onwards.
Occurrence of solicited symptoms during a 7-day surveillance period after vaccination (day of vaccination (Vx) and +7 days post vaccination)
Occurrence of unsolicited symptoms during a 28-day surveillance period after each vaccination.
Occurrence of serious adverse events during the study period.
Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"La Paz Medical Center, Malabo, Equatorial Guinea",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU1504,NCT02800109,Child Follow-up Until 2 Years,"Impact of Malaria Infection in Pregnancy on Fetal and Newborn Growth - Child Follow-up Until 2 Years of Age, in Relation to the Fetal Growth",Recruiting,NA,March 2018,Anticipated,Anticipated,University of Oxford,NA,NA,NA,N/A,Observational,1680,Anticipated,Malaria; Pregnancy,NA,All,N/A,2 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The proportion of children with sub-optimal growth by 2 years of age among children born to mother exposed to malaria and those born to mother non-exposed to malaria,NA,NA,NA,NA,NA,Shoklo Malaria Research Unit,up to 2 years of age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Participant's parent or legal guardian is willing and able to give informed consent
             for participation in the study

          -  Able (in the Investigators opinion) to comply with study requirements

        Exclusion Criteria:

        The participant may not enter the study if ANY of the following apply:

          -  Medical or congenital complications which would (in the investigator's opinion) make
             it difficult to comply with study requirements

          -  Aged older than 2 years
      ",NA,NA,NA,NA,NA,NA,NA,NA,May 2016,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TRANSACT 2,NCT01939886,Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2),Treatment Efficacy and Malaria TRANSmission After Artemisinin Combination Therapy 2 (TRANSACT2),Completed,April 2013,November 2013,Actual,Actual,London School of Hygiene and Tropical Medicine,"Patrick Sawa, MB.Ch.B, MSc.",Principal Investigator,KCMC/ICIPE,Phase 3,Interventional,219,Actual,Malaria,NA,All,6 Months,10 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Jaffu Chilongola, PhD",Principal Investigator,KCMC,NA,the number of participants with clinical and parasitological treatment failure after treatment artemether-lumefantrine (AL) and mefloquine-artesunate MQ-AS,NA,"Kilimanjaro Christian Medical Centre, Tanzania",Other,Radboud University,Other,"St. Jude's Clinic, ICIPE Thomas Odhiambo Campus",42 day follow-up,NA,NA,European Union,Other,NA,NA,NA,NA,NA,NA,NA,Parasite prevalence will be determined by microscopy and molecular methods on days 3-42 after intitiation of treatment. Clinical (fever+parasitological failure) and parasitological efficacy will be determined in relation to treatment arm and parasite clearance dynamics,"Colin Sutherland, PhD",Study Director,LSHTM,"Henk Schallig, PhD",Study Chair,"KIT, Amsterdam",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_13_004,NCT01958619,Open Label Pharmacokinetic Study of OZ439 and Piperaquine on Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in Healthy Volunteers,Open Label Pharmacokinetic Study of OZ439 and Piperaquine Following Administration of OZ439+TPGS Granules for Oral Suspension Alone or With Either Piperaquine Phosphate Tablets or Granules for Oral Solution in the Fasted State in Healthy Volunteers,Completed,October 2013,January 2014,Actual,Actual,Medicines for Malaria Venture,"Ulrike Lorch, MD FRCA FFPM",Principal Investigator,Richmond Pharmacology Limited,Phase 1,Interventional,55,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 Cmax,OZ439 AUC0-∞,Richmond Pharmacology Limited,Industry,NA,NA,Richmond Pharmacology Ltd.,"Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.","Days 1 pre-dose and post-dose at 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16 and 24 hours (Day 2), and, 48 (Day 3), 72 (Day 4), 96 (Day 5) and 168 (Day 8) hours post-dose. Sampling will also be done on Day 11, 15, 29 and 43.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 observed maximum drug plasma concentration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 Area under plasma concentration time curve from time zero extrapolated to infinity.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PROMOTE-BC3,NCT02793622,Prevention of Malaria in HIV-uninfected Pregnant Women and Infants,Prevention of Malaria in HIV-uninfected Pregnant Women and Infants,Recruiting,September 2016,June 2018,Anticipated,Anticipated,"University of California, San Francisco","Grant Dorsey, MD PhD",Principal Investigator,"University of California, San Francisco",Phase 3,Interventional,782,Anticipated,Malaria,NA,Female,16 Years,N/A,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Diane V Havlir, MD",Principal Investigator,"University of California, San Francisco",NA,Proportion of women who deliver with a composite adverse birth outcome,Incidence of malaria in infants,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,Bill and Melinda Gates Foundation,Other,IDRC - Tororo Research Clinic,Delivery,Time at risk will begin at birth and end when study participants reaches 12 months of age or early study termination,Comparison of estimates of gestational age at birth using two methods,NA,NA,NA,NA,NA,NA,NA,NA,NA,Composite adverse birth outcome defined as any one of the following: 1) Low birth weight (< 2500 gm); 2) Preterm delivery (< 37 weeks gestational age); 3) Small for gestational age (< 10th percentile relative to an external growth reference),"Moses Kamya, MBChB MMed PhD",Principal Investigator,Makarere Univeritys ; Infectious Disease Research Collaboration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Gestational age in weeks determined by two methods: 1) ultrasound dating (gold standard); 2) by metabolic profiling outcome,At the time of delivery,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
104297,NCT00323622,Long-Term Follow-up of Children for a 2-Year Period to Confirm the Safety and Immunogenicity of GSK 257049 Vaccine,"An Open Study for a 2-year Period to Confirm the Safety and Immunogenicity of the Candidate Malaria Vaccine RTS,S/AS02A in Mozambican Children Aged 1 to 4 Years at the Time of First Vaccine Dose.",Completed,April 2005,May 2007,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,1737,Actual,Malaria,NA,All,33 Months,69 Months,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Subjects With Serious Adverse Events (SAEs),NA,NA,NA,NA,NA,GSK Investigational Site,"Throughout the entire study period: from Month 21 to Month 45 (Month 0 = administration of Dose 1 of RTS,S/AS02A or comparator vaccine in the NCT00197041 study).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVG37,NCT00121823,Malaria Infection Diagnosed by Polymerase Chain Reaction (PCR) as a Means of Evaluating Pre-erythrocytic Candidate Malaria Vaccines,Malaria Infection Diagnosed by PCR as a Means of Evaluating Pre-erythrocytic Candidate Malaria Vaccines,Completed,June 2004,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Adrian VS Hill, Phd",Study Chair,University of Oxford,Phase 1/Phase 2,Interventional,NA,NA,Malaria,Suitability and acceptability of study method,Male,15 Years,45 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2004,"Brian M Greenwood, MD",Study Director,Gates Malaria Partnership,120,NA,NA,"Medical Research Council Unit, The Gambia",Other,University of Oxford,Other,Medical Research Council Laboratories,NA,NA,NA,Wellcome Trust,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
9751,NCT02909712,Cardio‑Safety of Dihydroartemisinin‑Piperaquine and Pharmacokinetics of Piperaquine Amongst Pregnant Women in Tanzania,Cardio‑Safety of Dihydroartemisinin‑Piperaquine and Pharmacokinetics of Piperaquine Amongst Pregnant Women in Tanzania,Recruiting,September 2016,September 2017,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,R Matthew Chico,Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 2,Interventional,200,Anticipated,Malaria; Pregnancy; Cardiotoxicity; Parasitemia,NA,Female,18 Years,34 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,Daniel Chandramohan,Principal Investigator,London School of Hygiene and Tropical Medicine,NA,Proportion of participants in Groups 3-4 with an absolute QTc of > 500 milliseconds,NA,"Kilimanjaro Christian Medical Centre, Tanzania",Other,"National Institute for Medical Research, Tanzania",Other,Handeni District Hospital,Measured on day 7 post-dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Brian Greenwood,Principal Investigator,London School of Hygiene and Tropical Medicine,Frank Mosha,Principal Investigator,Kilimanjaro Christian Medical College,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
201/CNBS/15,NCT02914145,"Mass Drug Administrations of DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique","Mass Drug Administration of Monthly DHA-PQP to Accelerate Towards Malaria Elimination in Magude District, Southern Mozambique","Active, not recruiting",November 2015,December 2017,Anticipated,Anticipated,Centro de Investigacao em Saude de Manhica,"Pedro Aide, MD, MSc, PhD",Study Director,pedro.aide@manhica.net,N/A,Interventional,50000,Anticipated,Malaria,NA,All,6 Months,N/A,Accepts Healthy Volunteers,Centro de Investigacao em Saude de Manhica,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Decrease in Parasite prevalence according to RDT,Decrease in Parasite prevalence according to PCR,Barcelona Institute for Global Health,Other,NA,NA,NA,6 months,6 months,Total and confirmed outpatient (OPD) malaria case incidence and inpatient (IPD) malaria case incidence among all ages,NA,NA,NA,NA,NA,NA,NA,NA,NA,the proportion of individuals (according to age group) with P. falciparum infection (detected by RDT) out of all tested individuals (in that age group),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,as the proportion of individuals (according to age group) with P. falciparum infection (detected by PCR) out of all tested individuals (in that age group),12 months,"the number of OPD and IPD malaria parasitologically confirmed cases per person per year, as ascertained from the routine passive case detection system utilizing facility catchment population size estimates as denominator.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCR 5094,NCT00132561,A Trial of Intermittent Treatment in the Prevention of Malaria in Senegalese Children,"A Double-blind, Randomised, Placebo-controlled Trial to Measure the Potential of Intermittent Treatment With Artesunate Plus Sulphadoxine/Pyrimethamine (SP) to Reduce the Malaria Burden in Sub-Saharan Africa",Completed,June 2002,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Badara Cisse, MD",Principal Investigator,"Institut de Recherche pour le Developpement, Senegal",Phase 2/Phase 3,Interventional,NA,NA,Malaria,Clinical episodes of malaria,All,6 Weeks,59 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2003,NA,NA,NA,1200,NA,NA,"Institut de Recherche pour le Developpement, Senegal",Other,Institut de Recherche pour le Developpement,Other,Institut de recherche pour le developpement,NA,NA,NA,"Cheikh Anta Diop University, Senegal",Other,NA,NA,NA,"Ministry of Health, Senegal",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVG34,NCT00146718,Anti-Malarial Drug Resistance in Cameroon,Anti-malarial Drug Resistance in Cameroon: Therapeutic Efficacy and Biological Markers of Resistance,Completed,August 2003,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Wilfred Mbacham, ScD",Principal Investigator,"Laboratory for Public Health Biotechnology, University of Yaounde I",Phase 2/Phase 3,Interventional,NA,NA,Malaria,Adequate clinical and parasitological response(ACPR) on Day 28,All,6 Months,59 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",May 2005,NA,NA,NA,755,NA,NA,University of Yaounde,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MSF-nutcon01,NCT00819858,Effect of Ready to Use Therapeutic Food (RUTF) Supplement After an Episode of Malaria Falciparum on Weight,The Effectiveness of Ready to Use Therapeutic Food (RUTF) in Catch up Growth in Children After an Episode of P. Falciparum Malaria,Completed,January 2009,March 2009,Actual,Actual,"Medecins Sans Frontieres, Netherlands","Saskia van der Kam, Ir",Principal Investigator,nutrition expert MSF,N/A,Interventional,180,Actual,Weight Loss; Weight Gain; Convalescence; Malaria,NA,All,6 Months,59 Months,No,"Medecins Sans Frontieres, Netherlands",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,weight gain,NA,NA,NA,NA,NA,Central Hospital,14 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
5503,NCT00878007,Impact of Malaria Prevention on Health and Education in Kenyan Schoolchildren,Impact of Malaria Prevention on Health and Education in Kenyan Schoolchildren,Completed,January 2010,April 2012,Actual,Actual,London School of Hygiene and Tropical Medicine,"Simon Brooker, DPhil",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,5177,Actual,Anaemia; Malaria,NA,All,5 Years,18 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Anaemia,"Education achievement assessed by a battery of tests of reading, writing and arithmetic",World Bank,Other,NA,NA,KEMRI-Wellcome Trust Programme,2 years,2 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCR5096,NCT00146783,Navrongo Drug Options for IPT in Pregnancy Trial,Efficacy of Sulphadoxine-pyrimethamine and Amodiaquine Alone or in Combination as Intermittent Preventive Treatment in Pregnancy in the Kassena-Nankana District of Ghana: a Randomized Controlled Trial,Completed,June 2004,February 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Christine Clerk, MBChB, MSc",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 2/Phase 3,Interventional,3642,Actual,Malaria,NA,Female,15 Years,45 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Daniel Chandramohan, MBBS, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,HB at delivery,NA,"Ministry of Health, Ghana",Other,NA,NA,Navrongo District Hosptial,with inseven 7days of delivery,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Brian Greenwood, FRCP, FRS",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVC98,NCT00158548,"ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan","Studies on Adding Artesunate to Existing Antimalarial Therapies With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan",Completed,June 2001,December 2004,Actual,Actual,London School of Hygiene and Tropical Medicine,"Kate Graham, MSc",Principal Investigator,"HealthNet International, Peshawar, Pakistan",Phase 3,Interventional,650,Actual,Malaria; Falciparum Malaria; Vivax Malaria,NA,All,5 Years,70 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Day 7 slide clearance rate (complete clearance of trophozoites) assessed by microscopists who are blind to treatment allocation.,Day 28 slide clearance rate without subsequent recrudescence.,World Health Organization,Other,HealthNet TPO,Other,HealthNet International,NA,NA,Day 7 gametocyte prevalence.,United Nations High Commissioner for Refugees,Other,NA,NA,NA,Pakistan Directorate of Malaria Control,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B0551003,NCT00894374,Bioequivalence Study Comparing Artesunate Tablet To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects,A Single-Dose Bioequivalence Study Comparing Artesunate Tablet (Pfizer) To Arsuamoon® Tablets (Guilin-China) In Healthy Subjects,Completed,June 2009,August 2009,Actual,Actual,Pfizer,Pfizer CT.gov Call Center,Study Director,Pfizer,Phase 1,Interventional,40,Actual,Falciparum Malaria,NA,All,21 Years,55 Years,Accepts Healthy Volunteers,Pfizer,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,AUC and Cmax of active metabolite of artesunate,NA,NA,NA,NA,NA,Pfizer Investigational Site,30-Aug-2009,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1518,NCT00935623,Clinical Trial for the Development of a Safe Malaria Challenge Model That Can be Reproduced in Humans,Development of a Safe and Reproducible Human Sporozoite Challenge Model for Plasmodium Vivax in Healthy Adults in the United States,Completed,April 2009,September 2011,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Ilin Chuang, MD, MPH",Principal Investigator,"US Military Malaria Vaccine Program, Naval Medical Research Center",Phase 1,Interventional,12,Actual,Plasmodium Vivax Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Detection of erythrocytic stage P. vivax parasites by blood smear in volunteers during the 28 day period post challenge via the bites of five P. vivax-infected mosquitoes; Occurrence and intensity of solicited and unsolicited symptoms post challenge,NA,United States Department of Defense,U.S. Fed,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,WRAIR Clinical Trials Center,28 days post challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2.0.2011,NCT01998295,Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine,Parasite Clearance Time and Time to Recurrent Infection Following Treatment With Artemether/Lumefantrine Among Children With Uncomplicated P. Falciparum Malaria Five Years After Wide Scale Use of the Drug in Tanzania,Completed,May 2012,July 2012,Actual,Actual,Muhimbili University of Health and Allied Sciences,"Andreas Martensson, PhD",Study Director,Karolinska Institutet,Phase 4,Interventional,45,Actual,Instantaneous Clearance,NA,All,6 Months,120 Months,No,Muhimbili University of Health and Allied Sciences,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Time to parasite clearance,NA,Karolinska Institutet,Other,NA,NA,Muhimbili University of Health and Allied Sciences,72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Time to parasite clearance was assessed by taking blood samples and examining it by light microscopy prior (0 hour) and during treatment at 4, 8, 12 hours and then 6 hourly until two consecutive negative blood slides.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-CGH-6371,NCT02043652,"Plasmodium Vivax Efficacy Trial in Cruzeiro do Sul, Acre, Brazil","Efficacy of Chloroquine and Primaquine for the Treatment of Plasmodium Vivax Malaria in Cruzeiro do Sul, Acre, Brazil",Completed,February 2014,December 2014,Actual,Actual,Centers for Disease Control and Prevention,"Alexandre Macedo de Oliveira, MD, PhD",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,117,Actual,Malaria,NA,All,5 Years,70 Years,Accepts Healthy Volunteers,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of patients with adequate clearance of parasites and symptoms,NA,NA,NA,NA,NA,Hospital do Jurua,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Investigators, according to WHO guidelines, will evaluate patients at regular intervals to evaluate symptom and parasitemia clearance.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVF01,NCT00158574,Kilimanjaro IPTi Drug Options Trial,Drug Options for Intermittent Preventive Treatment for Malaria in Infants in an Area With High Resistance to Sulfadoxine/Pyrimethamine: an Evaluation of Short and Long-acting Antimalarial Drugs,Completed,January 2005,June 2008,Actual,Actual,London School of Hygiene and Tropical Medicine,"Roly Gosling, MBChB, MRCP",Study Director,London School of Hygiene and Tropical Medicine,Phase 2/Phase 3,Interventional,2419,Actual,Malaria,NA,All,2 Months,24 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Daniel Chandramohan, MBBS,PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,1. Incidence of clinical malaria: [(history of fever during previous 2 days or axillary temperature >37.5ºC) + parasitaemia of any density + absence of any other obvious causes of fever] during the period of 3-11 months of age,NA,University of Copenhagen,Other,"National Institute for Medical Research, Tanzania",Other,"Ministry of Health, Korogwe and Same District MCH clinics",3-11 months of age,NA,NA,"Kilimanjaro Christian Medical Centre, Tanzania",Other,NA,NA,NA,NA,NA,NA,NA,NA,"Brian Greenwood, FRCP, FRS",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DIF8,NCT00169117,A Stitch in Time May Save Lives: Turning Poor Bednets Into Good Ones,A Stitch in Time May Save Lives: Turning Poor Bednets Into Good Ones,Completed,June 2002,December 2002,Actual,Actual,London School of Hygiene and Tropical Medicine,"Steven W Lindsay, PhD",Principal Investigator,University of Durham,N/A,Interventional,772,Actual,Malaria,NA,All,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Sian E Clarke, PhD",Principal Investigator,"London School of Hygiene and Tropical Medicine, University of London, UK",NA,Number of bednets repaired (pre- vs post intervention),Mean proportion of holes repaired/net (pre- vs post intervention),University of Durham,Other,"Medical Research Council Unit, The Gambia",Other,Medical Research Council Laboratories,November 2003,November 2003,Reduction in mosquitoes with a good net compared with a poor one (pre-intervention survey).,NA,NA,Reduction in mosquitoes with a good net compared with a repaired net (post-intervention survey),NA,NA,NA,NA,NA,NA,NA,"Catherine Panter-Brick, PhD",Principal Investigator,University of Durham,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,November 2003,NA,November 2003,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_MMV390048_16_01,NCT02783820,"Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048, Part A","A Single Centre, Two-part, Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects",Completed,May 2016,December 2016,Actual,Actual,Medicines for Malaria Venture,"James McCarthy, Prof",Principal Investigator,Q-Pharm Pty Ltd and QIMR Berghofer Medical Research Institute,Phase 1,Interventional,24,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,observed and self-reported adverse events,NA,Clinical Network Services (CNS) Pty Ltd,Industry,Q-Pharm Pty Limited,Industry,Q Pharm Clinics,28 days,NA,NA,QIMR Berghofer Medical Research Institute,Other,NA,NA,NA,NA,NA,NA,NA,"The incidence, severity and relationship to the investigational product of observed and self-reported adverse events during 28 days post administration of a single oral dose of MMV390048 to healthy volunteers",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
201807,NCT02658435,Assessment of Any Potential Retinal Effects of Tafenoquine (TQ),"A Phase 1, Multi-center, Single-masked, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Ophthalmologic Safety and Pharmacodynamics of 300mg Single Doses of Tafenoquine (SB 252263) in Adult Healthy Volunteers","Active, not recruiting",February 2016,November 2017,Anticipated,Anticipated,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,384,Actual,"Malaria, Vivax",NA,All,18 Years,45 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of participants in the TQ group having retinal changes from Baseline in Central subfield thickness and Central retinal lesion thickness,Proportion of participants in the TQ group having retinal changes from Baseline in Total macular volume,Medicines for Malaria Venture,Other,NA,NA,NA,Baseline and Day 90(follow-up),Baseline and Day 90(follow-up),Proportion of participants in the TQ group having retinal changes from Baseline in Ellipsoid zone disruption,NA,NA,Proportion of participants in the TQ group having retinal changes from Baseline in abnormal auto-fluorescence patterns,NA,NA,NA,NA,NA,NA,"The change from baseline will be assessed as a binomial output as, Yes or No. Spectral domain OCT (SD-OCT) images/scan will be obtained. For Central subfield thickness and Central retinal lesion thickness, change from baseline of at least 40 microns (µ) will be consider 'Yes'. Central Retinal Lesion Thickness is defined as the distance between the inner limiting membrane of the retina and the inner border of the choriocapillaris measured in the central 1millimeter (mm) of the centre scan",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The change from baseline will be assessed as a binomial output as, Yes or No. SD-OCT images/scan will be obtained. Total Macular Volume, change from baseline of 10% will be considered 'Yes'",Baseline and Day 90(follow-up),"The change from baseline will be assessed as a binomial output as, Yes or No. SD-OCT images/scan will be obtained. Ellipsoid zone disruption will be assessed by manual reading",Baseline and Day 90(follow-up),"The change from baseline will be assessed as a binomial output as, Yes or No. SD-OCT images/scan will be obtained. Abnormal auto-fluorescence will be assessed by FAF by manual reading",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PK13,NCT02242799,Dolutegravir Interactions With Artemisinin-based Combination Therapies,Evaluation of Dolutegravir Interactions With Artemether-Lumefantrine and Amodiaquine-Artesunate,Completed,June 2015,September 2016,Actual,Actual,University of Liverpool,"Mohammed Lamorde, PhD, MBChB",Study Director,Infectious Diseases Institute,Phase 1,Interventional,46,Actual,Malaria; HIV,NA,All,18 Years,N/A,Accepts Healthy Volunteers,University of Liverpool,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Saye H Khoo, FRCP, PhD",Principal Investigator,University of Liverpool,NA,Change in area under time-concentration curve [AUC] of DTG and antimalarial drugs,Change in maximum concentration [Cmax] of DTG and antimalarials,ViiV Healthcare,Industry,Makerere University,Other,Infectious Diseases Institute,At steady state (after 3 days dosing for antimalarials and 7 days for DTG),At steady state (3 days for antimalarials and 7 days for DTG),Change in time to maximum concentration [Tmax] for antimalarials and DTG,NA,NA,Change in clearance [Cl/F] for antimalarials and DTG,Change in trough concentration [Ctrough]) for antimalarial drugs and DTG,NA,NA,NA,NA,NA,"When subjects are at steady state (of single drug or combination, as detailed in the study design section) intensive PK sampling will be performed",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,PK sampling will be done when each drug is at presumed 'steady state',At steady state (3 days for antimalarials and 7 days for DTG),Medications will be dosed up to steady state before PK sampling is undertaken,Steady state - 3 days for antimalarials and 7 days for dolutegravir,Medications will be dosed up to steady state prior to PK sampling,NA,NA,Steady state - 3 days for antimalarials and 7 days for DTG,PK sampling will be performed at steady state,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14.034,NCT02671175,Post-discharge Malaria Chemoprevention(PMC) Study,Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-piperaquine for the Post-discharge Management of Severe Anaemia in Children Aged Less Than 5 Years in Uganda and Kenya: A Two-arm Randomised Placebo Controlled Trial,Recruiting,May 2016,March 2019,Anticipated,Anticipated,Liverpool School of Tropical Medicine,"Dr Titus K Kwambai, MSc",Principal Investigator,Liverpool School of Tropical Medicine,Phase 3,Interventional,2212,Anticipated,Malaria; Severe Anemia,NA,All,N/A,60 Months,No,Liverpool School of Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Dr Simon K Kariuki, PhD",Principal Investigator,Kenya Medical Research Institute,NA,All-cause deaths or all-cause re-admissions by 26 weeks from randomization (composite primary outcome).,NA,The Research Council of Norway,Other,Kenya Medical Research Institute,Other,NA,6 months,NA,NA,Makerere University,Other,NA,NA,NA,NA,NA,NA,NA,NA,"Dr Richard IDRO, PhD",Principal Investigator,Makerere University,"Dr Robert Opoka, M.Med",Principal Investigator,Makerere University,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
050118,NCT00295581,PpPfs25/ISA51 and ScPvs25/ISA51 Vaccines for Malaria,Phase 1 Study of the Safety and Immunogenicity of PpPfs25/ISA51 and ScPvs25/ISA51: Transmission Blocking Vaccines for Plasmodium Falciparum and Plasmodium Vivax Malaria,Completed,"March 7, 2005",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Plasmodium Falciparum; Plasmodium Vivax Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","June 17, 2008",NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HMTV,NCT00673166,Evaluation of Local Mechanisms for Staff Motivation to Reduce Hospital Mortality,Evaluation of Local Mechanisms for Staff Motivation to Improve Treatment and Reduce Mortality Due to Malaria at the Paediatric Ward,Completed,January 2008,December 2008,Actual,Actual,London School of Hygiene and Tropical Medicine,"Amabelia Rodrigues, PhD",Principal Investigator,Bandim Health Project & Gates Malaria Partnership,N/A,Interventional,900,Actual,Hospital Mortality; Malaria,NA,All,N/A,59 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Overall hospital and malaria mortality,NA,Statens Serum Institut,Other,NA,NA,Paediatric department at the national hospital,One year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999908194,NCT00740090,Malaria Vaccine for Children in Mali,"Phase 1, Randomized, Double-Blind, Dose-Escalating Study of the Safety, Reactogenicity, and Immunogenicity of the AMA1-C1/Alhydrogel+CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Children in Mali",Completed,"August 11, 2008",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Malaria; Malaria Infection,The incidence and severity of systemic and local adverse events.,All,1 Year,3 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,200,NA,NA,NA,NA,NA,NA,Malaria Research and Training Center,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVG49,NCT00852371,Intermittent Preventive Treatment of Malaria in Schoolchildren,"IPT in Schoolchildren: Comparison of the Efficacy, Safety, and Tolerability of Antimalarial Regimens in Uganda",Completed,February 2008,June 2008,Actual,Actual,London School of Hygiene and Tropical Medicine,"Sarah G Staedke, MD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,760,Anticipated,Malaria; Intermittent Preventive Treatment,NA,All,8 Years,13 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Risk of parasitaemia (unadjusted by genotyping),NA,Uganda Malaria Surveillance Project,Other,"Ministry of Health, Uganda",Other,NA,after 42 days of follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P.02/15/1679,NCT02721420,Delivery of Malaria Chemoprevention in the Post-discharge Management of Children With Severe Anaemia in Malawi,Malaria Chemoprevention With Monthly Treatment With Dihydroartemisinin-Piperaquine for the Post-discharge Management of Severe Anaemia in Children Less Than 5 Years in Malawi,Recruiting,March 2016,December 2019,Anticipated,Anticipated,University of Malawi College of Medicine,"Kamija Phiri, PhD",Principal Investigator,University of Malawi,Phase 3,Interventional,375,Anticipated,Malaria; Severe Anemia,NA,All,4 Months,59 Months,No,University of Malawi College of Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of those with 100 % uptake of PMC drugs during the 15 weeks of the study period.,NA,University of Bergen,Other,The Research Council of Norway,Other,"College Of Medicine,Training and Research Unit Of Excellence,Zomba Central Hospital",15 weeks,NA,NA,Makerere University,Other,NA,NA,NA,Liverpool School of Tropical Medicine,Other,Kenya Medical Research Institute,Other,100 % uptake is defined as administration of all study drugs and compliance to study visits during the course of 15 weeks.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Universiteit van Amsterdam,Other,Imperial College London,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,London School of Hygiene and Tropical Medicine,Other,"University of Minnesota, MN",Other,"Ministry of Health and Population, Malawi",Other,"Ministry of Health, Malawi",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HQGMP1611887,NCT02878031,Community Case Management of Chest Indrawing Pneumonia,"Community Case Management of Chest Indrawing Pneumonia With Oral Amoxicillin in Children Aged 2-59 Months Old by Community Oriented Resources Persons (CORPs) in Niger State, Nigeria",Recruiting,October 2016,July 2017,Anticipated,Anticipated,Malaria Consortium,"Karin Kallander, MSc, PhD",Principal Investigator,Malaria Consortium,Phase 4,Interventional,308,Anticipated,Pneumonia,NA,All,2 Months,59 Months,No,Malaria Consortium,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Ebenezer Baba, MD, MPH",Principal Investigator,Malaria Consortium,NA,Number of participants with clinical treatment failure,Number of CHWs appropriately managing chest indrawing pneumonia,World Health Organization,Other,NA,NA,Piakoro & Lapai Local Government Areas,By day 3 to 6,At day of enrolment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The proportion of children enrolled with any of the following signs by day 6:
Appearance of a danger sign (unable to drink or breastfeed, convulsions, vomiting after ingestion of food or drink, and abnormally sleepy or difficult to wake)
Hypoxemia (Oxygen saturation ≤90%)
Temperature ≥37.5°C and chest indrawing on day 3
Temperature ≥37.5°C or chest indrawing alone on day 6
Change of antibiotic
Death",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Proportion of children with RA verified chest indrawing pneumonia with no referral sign (unable to drink or breastfeed, convulsions, vomiting after ingestion of food or drink, and abnormally sleepy or difficult to wake, malnutrition) who received the correct age-specific amoxicillin dose for 5 days Proportion of children with RA verified chest indrawing pneumonia with suspected referral sign (unable to drink or breastfeed, convulsions, vomiting after ingestion of food or drink, and abnormally sleepy or difficult to wake, malnutrition) who were given pre-referral amoxicillin treatment and were referred to a health facility.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
222218,NCT00944359,Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children,Community-based Intervention Trial to Compare the Impact of Preventive and Therapeutic Zinc Supplementation Programs Among Young Children in Burkina Faso,Completed,December 2010,February 2012,Actual,Actual,"University of California, Davis","Kenneth H Brown, MD",Principal Investigator,"University of California, Davis",Phase 4,Interventional,7680,Actual,Zinc Deficiency; Diarrhea; Malaria,NA,All,6 Months,27 Months,Accepts Healthy Volunteers,"University of California, Davis",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change in length and length-for-age Z-score,Change in weight and weight-for-age,Université Polytechnique de Bobo-Dioulasso,Other,Helen Keller International,Other,Institut de Recherche en Science de la Sante,12 months,12 months,Incidence of diarrhea and laboratory-confirmed malaria,Thrasher Research Fund,Other,Change in plasma zinc concentration,NA,NA,Canadian International Development Agency,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,12 months,NA,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H9926-33953,NCT00948896,Chemopreventive Therapy for Malaria in Ugandan Children,A Randomized Controlled Trial of Monthly Dihydroartemisinin-piperaquine Versus Monthly Sulfadoxine-pyrimethamine Versus Daily Trimethoprim-sulfamethoxazole Versus No Therapy for the Prevention of Malaria,Completed,June 2010,April 2014,Actual,Actual,"University of California, San Francisco","Diane V. Havlir, MD",Study Director,"University of California, San Francisco",Phase 3,Interventional,600,Actual,Malaria,NA,All,4 Months,5 Months,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"M. Grant Dorsey, MD, PhD",Principal Investigator,"University of California, San Francisco",NA,Incident Malaria Cases Per Person Year at Risk in HIV-unexposed Participants,Incident Malaria Cases Per Person Year at Risk in HIV-exposed Participants,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,IDRC Research Clinic -Tororo District Hospital,6 to 24 months of age,Randomization to 24 months of age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given (6-24 mo of age). Treatments within 14d of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 d after each treatment for malaria.","Moses R Kamya MBChB, MMed, MPH",Principal Investigator,Makerere University; IDRC,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The primary outcome was the incidence of malaria, defined as the number of incident episodes per time at risk, during the period the intervention was given. Treatments within 14 days of a prior episode were not considered incident events. Time at risk was from the day following the initiation of study drugs to the last day of observation, minus 14 days after each treatment for malaria.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC 1124,NCT00944840,Intermittent Preventive Treatment (IPTc) and Home Based Management of Malaria (HMM)in The Gambia,A Trial of Intermittent Preventive Treatment and Home Based Management of Malaria in a Rural Area of The Gambia,Completed,September 2008,August 2009,Actual,Actual,London School of Hygiene and Tropical Medicine,"Kalifa Bojang, MD, PhD",Principal Investigator,MRC Laboratories,Phase 3,Interventional,1312,Actual,Malaria,NA,All,3 Months,59 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria incidence (the number of study subjects seen at the OPD clinic with clinical malaria during the surveillance period).,NA,NA,NA,NA,NA,"Farafenni Field Station, MRC Laboratories",During the surveillance period (September to December 2008),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Rep001,NCT02528279,Relapses in Plasmodium Ovale and Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria,Prospective Assessment of Relapse Characteristics of Plasmodium Ovale and Antimalarial Treatment Efficacy of Artemether-lumefantrine for Mixed Species and Non-falciparum Malaria in Gabon,Completed,October 2014,October 2016,Actual,Actual,Albert Schweitzer Hospital,"Michael Ramharter, Prof.",Principal Investigator,Centre de Recherches Médicales de Lambaréné,N/A,Interventional,50,Anticipated,Malaria,NA,All,1 Year,N/A,No,Albert Schweitzer Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adequate clinical and parasitological response (WHO criteria for antimalarial drug trials),NA,Medical University of Vienna,Other,NA,NA,NA,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Adequate clinical and parasitological response on Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR #719,NCT00951106,Therapeutic Efficacy Study of Pyrimethamine/Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon,Therapeutic Efficacy Study of Pyrimethamine / Sulfdoxine (Fansidar®) for the Treatment of Uncomplicated Falciparum Malaria in the Peruvian Amazon,Completed,January 1998,August 2009,Actual,Actual,Walter Reed Army Institute of Research (WRAIR),"Alan Magill, MD",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),N/A,Interventional,NA,NA,"Malaria, Vivax; Malaria, Falciparum",NA,All,6 Months,N/A,No,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Determine the efficacy of pyrimethamine/sulfdoxine (Fansidar) for the treatment of uncomplicated falciparum malaria in the Peruvian Amazon.,NA,NA,NA,NA,NA,Naval Medical Research Center Detachment,28 days after dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Determine the efficacy of pyrimethamine/sulfdoxine (Fansidar) for the treatment of uncomplicated falciparum malaria in the Peruvian Amazon.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H5747-34097,NCT00978068,HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children,A Randomized Open Label Trial of HIV Protease Inhibitors for the Prevention of Malaria in HIV-Infected Children,Completed,September 2009,January 2013,Actual,Actual,"University of California, San Francisco","Diane V Havlir, MD",Study Director,"University of California, San Francisco",Phase 3,Interventional,186,Actual,Malaria; HIV Infections,NA,All,2 Months,10 Years,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Moses R Kamya MBChB, MMed, MPH",Principal Investigator,Makerere University,NA,Incidence-density of malaria defined as the number of incident episodes of malaria per time at risk.,NA,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,IDRC - Tororo Research Clinic,Time from randomization to at least 24 months of follow up or until end of the study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Grant Dorsey, MD, PhD",Principal Investigator,"University of California, San Francisco","Ted Ruel, MD",Principal Investigator,"University of California, San Francisco",NA,NA,NA,NA,NA,"Jane Achan, MBChB, MPed",Principal Investigator,Makerere University,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ARAMF_L_04314,NCT01023399,Artesunate Plus Amodiaquine in Malaria in Cote d'Ivoire,A Nested Open Labeled Study to Compare the Effectiveness and Safety of a Fixed-dose Combination of Artesunate Plus Amodiaquine (ASAQ Winthrop®) in the Unsupervised Treatment of Uncomplicated Plasmodium Falciparum Malaria Attacks in Two Patient Groups Enrolled at Two Year-intervals in a Pilot District of Côte d'Ivoire,Completed,November 2009,October 2013,Actual,Actual,Sanofi,Clinical Sciences & Operations,Study Director,Sanofi,Phase 4,Interventional,580,Actual,Malaria,NA,All,N/A,N/A,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Polymerase chain reaction (PCR)-corrected and uncorrected clinical and parasitological cure rate (ACPR),NA,Medicines for Malaria Venture,Other,NA,NA,Investigational Site Number 1,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
114582,NCT01928914,Tafenoquine Thorough QTc Study in Healthy Subjects,"A Randomized, Placebo-Controlled Study to Evaluate the Effect of Tafenoquine (SB252263) on the Electrocardiogram (ECG) With Focus on Cardiac Repolarization (QTc Duration) in Healthy Subjects",Completed,NA,"June 4, 2012",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,260,Actual,"Malaria, Vivax",NA,All,18 Years,65 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change from baseline in QTcF for 1200 mg dose of tafenoquine compared to baseline,NA,NA,NA,NA,NA,NA,"Day 1, Day 2, day 3, Day 4, Day 5 and Day 6",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Contineous QTcF will be electronically recorded using holtor monitors. The primary comparison of interest is the mean time-matched change from baseline in QTcF for the difference tafenoquine-placebo for 1200mg dose of tafenoquine at each timepoint.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"July 26, 2011",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Indonesia DHP 2013,NCT02353494,Efficacy and Safety of Dihydroartemisinin-piperaquine (DHP) for the Treatment of Uncomplicated Malaria,"Efficacy and Safety of Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum and Plasmodium Vivax Malaria in Timika, Indonesia",Completed,March 2015,May 2016,Actual,Actual,Menzies School of Health Research,"Jeanne R Poespoprodjo, MD, PhD",Principal Investigator,"Timika Research Facility Kompleks RSMM, Timika-Papua, Indonesia",N/A,Observational,130,Actual,Plasmodium Falciparum Infection; Plasmodium Vivax Infection,NA,All,12 Months,65 Years,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The proportion of adverse and serious adverse observed during the follow up period,"The cumulative incidence of success and failure rates at day 42, PCR-uncorrected and PCR-corrected","Eijkman Institute for Molecular Biology, Jakarta, Indonesia",Other,World Health Organization,Other,Timika District Hospital,6 months,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion criteria:

          -  age between one year (weight more than 5 kgs) to 65 years old;

          -  mono-infection with Plasmodium falciparum or Plasmodium vivax detected by microscopy;

          -  parasitaemia of more than 1000/μl asexual parasites for P. falciparum and more than
             250/μl asexual parasites for P. vivax

          -  presence of axillary temperature ≥ 37.5 °C or history of fever during the past 24 h;

          -  ability to swallow oral medication;

          -  ability and willingness to comply with the study protocol for the duration of the
             study and to comply with the study visit schedule; and

          -  informed consent from the patient or from a parent or guardian in the case of
             children.

        Exclusion criteria:

          -  presence of general danger signs in children aged under 5 years or signs of severe
             falciparum malaria according to the definitions of WHO

          -  mixed or mono-infection with another Plasmodium species detected by microscopy;

          -  presence of severe malnutrition (defined as a child whose growth standard is below -3
             z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm
             circumference < 110 mm);

          -  presence of febrile conditions due to diseases other than malaria (e.g. measles, acute
             lower respiratory tract infection, severe diarrhoea with dehydration) or other known
             underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases,
             HIV/AIDS);

          -  regular medication, which may interfere with antimalarial pharmacokinetics;

          -  history of hypersensitivity reactions or contraindications to
             dihydroartemisinin-piperaquine

          -  a positive pregnancy test or breastfeeding
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_13_007,NCT02083406,Bioavailability Study of Oral OZ439 Prototype Formulations Administered With Piperaquine Phosphate (PQP),Open Label Study to Investigate the Pharmacokinetics of Prototype Formulations of OZ439 Administered With Piperaquine Phosphate in the Fasted State to Healthy Subjects,Completed,July 2014,July 2014,Actual,Actual,Medicines for Malaria Venture,"Jo Collier, MBChB FFPM",Principal Investigator,Quotient Clinical,Phase 1,Interventional,22,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 AUC(0-168h),OZ439 Cmax,Quotient Clinical,Other,NA,NA,Quotient Clinical,Up to 168 hours post-dose,Up to 168 hours post-dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 Area under the plasma concentration (AUC) versus time curve,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 Maximum observed concentration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2242,NCT01658774,Impact of Repeated Anthelmintic Treatment on the Risk of Malaria in Kenyan School Children,"Impact of Repeated Anthelminthic Treatment on Malaria in School Children: an Individual Randomized, Double-blind, Placebo-controlled Trial in Western Kenya",Completed,January 2013,January 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,"Simon J Brooker, DPhil",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,2377,Actual,Intestinal Helminthiasis; Ascariasis; Hookworm; Malaria,NA,All,5 Years,18 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of clinical malaria,NA,European Union,Other,Wellcome Trust,Other,KEMRI-Wellcome Trust Programme,18 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Incidence of clinical malaria, defined as fever (axillary temperature > 37.5 °C) or a reported history of fever within the preceding 24 hours in conjunction with a slide positive for Plasmodium spp. parasites at any density during 18 months of follow-up.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
GMP_REG04,NCT00432367,Intermittent Preventive Treatment (IPTp) Versus Rapid Diagnostic Testing (RDT) and Treatment of Malaria in Pregnancy,"The Effectiveness, Cost and Cost Effectiveness of Intermittent Preventive Treatment or Screening and Treatment of Malaria in Pregnancy Among Women Using Long Lasting Insecticide Treated Bed Net: a Randomised Controlled Trial.",Completed,February 2007,September 2009,Actual,Actual,London School of Hygiene and Tropical Medicine,"Harry Tagbor, DrPH",Principal Investigator,"School of Medical Sciences, KNUST, Kumasi, Ghana",Phase 3,Interventional,3333,Actual,Malaria; Anaemia; Pregnancy,NA,Female,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Brian Greenwood, MD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,Prevalence of severe maternal anaemia (Hb < 8g/dl) at 34 to 36 weeks of gestation.,NA,Kwame Nkrumah University of Science and Technology,Other,NA,NA,Juaben Government Hospital,At 34 to 36 weeks of gestation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Daniel Chandramohan, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,"Jane Bruce, MSc",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,"Edmund Browne, PhD",Principal Investigator,"School of Medical Sciences, KNUST, Kumasi, Ghana",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14-14495,NCT02535767,Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali,Determining a Tolerable Dose of Primaquine in G6PD-deficient Persons Without Malaria in Mali,Completed,August 2015,January 2016,Actual,Actual,"University of California, San Francisco","Roland Gosling, PhD, MS",Principal Investigator,"University of California, San Francisco",Phase 1/Phase 2,Interventional,28,Actual,Malaria,NA,Male,18 Years,50 Years,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Primary outcome: the change in hemoglobin concentration from baseline levels following a single low-dose of primaquine not to exceed 0.75 mg/kg.,NA,"Malaria Research and Training Center, Bamako, Mali",Other,Radboud University,Other,Malaria Research and Training Centre,Between day 0 and day 10.,NA,NA,University of Mississippi Medical Center,Other,NA,NA,NA,Bill and Melinda Gates Foundation,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MenziesSHR,NCT02592408,A Study to Assess Current Standard Malaria Treatment Guidelines in the Republic of the Sudan,A Study to Assess Current Standard Malaria Treatment Guidelines and Evaluate Recently Developed G6PD Diagnostic Tools in the Republic of the Sudan,Completed,November 2015,May 2016,Actual,Actual,Menzies School of Health Research,"Muzamil Mahdi, PhD",Principal Investigator,University of Khartoum,Phase 4,Interventional,320,Actual,Malaria,NA,All,12 Months,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The recurrence of parasitaemia within 42 days of follow in P. falciparum infections,The recurrence of parasitaemia within 42 days of follow in P. vivax infections,University of Khartoum,Other,NA,NA,NA,In the first 42 days,In the first 42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Outcome measure is presented unadjusted and adjusted for PCR and compared between P. falciparum intervention and control arm,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Outcome measure is presented unadjusted and adjusted for PCR and compared between P. vivax intervention and control arm,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VOCE,NCT02793414,Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia,NA,Withdrawn,September 2016,NA,NA,NA,Menzies School of Health Research,NA,NA,NA,N/A,Observational,0,Actual,Malaria,NA,All,5 Years,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Performance of the VOC breathalyser,NA,NA,NA,NA,NA,NA,7 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sensitivity and specificity of the VOC breathalyser compared to microscopy, rapid diagnostic tests (RDTs) and PCR for the diagnosis of clinical malaria.",NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Malaria cohort

          -  Age ≥5 years of age

          -  Malaria microscopy and / or Malaria RDT confirmed malaria infection

          -  Fever (axillary temperature ≥37.5⁰C) or history of fever in preceding 48 hours

          -  Written informed consent Febrile controls

          -  Age ≥5 years of age

          -  Fever (axillary temperature ≥37.5⁰C) or history of fever in preceding 48 hours

          -  Absence of a malaria episode confirmed by malaria microscopy

          -  Written informed consent
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IVMPBPK,NCT02963324,Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers,"Physiologically-based Pharmacokinetic Modeling of Ivermectin in Healthy Human Volunteers - a Single-center, Open-label Pharmacokinetics Study",Completed,November 2016,January 2017,Actual,Actual,"University Hospital, Basel, Switzerland","Stephan Krähenbühl, MD PhD",Principal Investigator,"University Hospital, Basel, Switzerland",Phase 1,Interventional,12,Actual,Malaria,NA,All,18 Years,65 Years,Accepts Healthy Volunteers,"University Hospital, Basel, Switzerland",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Maximum concentration (Cmax) of ivermectin in whole blood, plasma, and capillary blood","Time to maximum concentration (Tmax) of ivermectin in whole blood, plasma, and capillary blood",NA,NA,NA,NA,University Hospital Basel,Intermittent sampling for 72 hours after dosing,Intermittent sampling for 72 hours after dosing,"Area under the curve (AUC) of ivermectin in whole blood, plasma, and capillary blood",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Intermittent sampling for 72 hours after dosing,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
"MMV_MMV390048_16_01, Part B",NCT02783833,"MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects, Part B","A Single Centre, Two-part, Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile of Ascending Oral Doses of MMV390048 and Its Antimalarial Activity Against Plasmodium Falciparum in Healthy Adult Subjects",Completed,NA,"January 16, 2017",Actual,Actual,Medicines for Malaria Venture,"James McCarthy, Prof",Principal Investigator,Q-Pharm Pty Ltd and QIMR Berghofer Medical Research Institute,Phase 1/Phase 2,Interventional,15,Actual,Malaria,NA,All,18 Years,18 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Effect on parasites,NA,Clinical Network Services (CNS) Pty Ltd,Industry,Q-Pharm Pty Limited,Industry,Q-Pharm Clinics,28 days,NA,NA,QIMR Berghofer Medical Research Institute,Other,NA,NA,NA,NA,NA,NA,NA,"The effect of a single oral dose of MMV390048 on P. falciparum blood stage parasites in healthy volunteers with induced blood stage malaria as observed over a period of 28 days post dosing, through:
qPCR analysis of parasite clearance, and
calculation of the parasite reduction ratio (PRR)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,May 2016,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
H5741-34342,NCT00993031,Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women,Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women,Completed,December 2009,July 2013,Actual,Actual,"University of California, San Francisco","Diane Havlir, MD",Principal Investigator,"University of California, San Francisco",Phase 3,Interventional,391,Actual,Malaria; HIV Infections,NA,Female,16 Years,N/A,No,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Deborah Cohan, MD, MPH",Study Chair,"University of California, San Francisco",NA,Prevalence of malaria defined as positive placental blood smear or positive placental blood PCR,NA,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,Tororo District Hospital,Delivery,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Moses R Kamya, MBChB, MMed, PhD",Principal Investigator,Makerere University,"Pius Okong, MMed, PhD",Study Chair,Ugandan Ministry of Health,NA,NA,NA,NA,NA,"Grant Dorsey, MD, PhD",Principal Investigator,"University of California, San Francisco",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC037,NCT01003314,A Study of the Safety and Effectiveness of Two New Malaria Vaccines,A Phase I/IIa Study to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates AdCh63 MSP1 Alone and With MVA MSP1,Completed,November 2009,September 2010,Actual,Actual,University of Oxford,"Adrian VS Hill, D.Phil, FRCP",Principal Investigator,Univeristy of Oxford,Phase 1/Phase 2,Interventional,16,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Safety of new candidate malaria vaccines AdCh63 MSP1 administered alone, and with MVA MSP1 in a prime-boost regime, to healthy volunteers. and safety of the prime-boost vaccine strategy following malaria sporozoite challenge.",NA,NA,NA,NA,NA,"Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford",Up to 6 months post enrollment into the study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SEACAT2.1,NCT00331708,"Artesunate Plus Sulfadoxine-pyrimethamine Pharmacokinetics, Efficacy, Gametocytes Carriage and Birth Outcomes in Pregnant Women With Malaria","An Open-label in Vivo Drug Study to Evaluate Artesunate Plus Sulfadoxine-pyrimethamine (ASSP) Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes in Pregnant Women With Uncomplicated Falciparum Malaria",Terminated,April 2006,July 2007,Actual,Actual,Professor Karen I Barnes,"Karen I Barnes, MBChB",Principal Investigator,University of Cape Town,N/A,Interventional,3,Actual,Malaria,NA,Female,18 Years,N/A,No,Professor Karen I Barnes,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Pharmacokinetic parameters by measurement of whole blood levels of sulfadoxine and pyrimethamine and plasma levels of artesunate and its active metabolite dihydroartemisinin to determine Cmax, Tmax, AUC, half life, volume of distribution and clearance",Correlation of treatment outcome with pharmacokinetic parameters and pregnancy status.,Global Fund,Other,"Medical Research Council, South Africa",Other,Ndlavela Health Centre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SEACAT2.2,NCT00380146,"Pharmacokinetics, Efficacy, Gametocyte Carriage, Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment in Pregnant Women","An Open-label in Vivo Drug Study to Evaluate the Pharmacokinetics, Therapeutic Efficacy, Gametocyte Carriage and Birth Outcomes Following Sulfadoxine-pyrimethamine Intermittent Presumptive Treatment (SP IPT) in Pregnant Women",Completed,September 2006,March 2008,Actual,Actual,Professor Karen I Barnes,"Karen I Barnes, MBChB",Principal Investigator,University of Cape Town,N/A,Interventional,31,Actual,Malaria,NA,Female,18 Years,N/A,No,Professor Karen I Barnes,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Pharmacokinetic parameters by measurement of whole blood levels of sulfadoxine and pyrimethamine and plasma levels of artesunate to determine Cmax, Tmax, AUC, half life, volume of distribution and clearance",NA,Global Fund,Other,"Medical Research Council, South Africa",Other,Ndlavela Health Centre,"0 hours (pre treatment) and repeated on day 0 or 1 at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 and 24 hours, and days 2, 3, 7, 14, 21, 28 and 42",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
08-0037,NCT01018459,Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkina Faso,"A Phase I Randomized, Controlled, Double-Blinded, Dosage-Escalation Trial to Evaluate the Immunogenicity, Safety, and Reactogenicity of an Adenovirus Type 35 Based Circumsporozoite Malaria Vaccine in Burkinabè, Semi-Immune, Healthy Adults 18 to 45 Years of Age",Completed,April 2010,December 2011,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,48,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The number of subjects experiencing severe (Grade 3) solicited injection site reactions.,The number of subjects spontaneously reporting severe (Grade 3) adverse events considered associated with the vaccination.,NA,NA,NA,NA,Centre National de Recherche et de Formation sur le Paludisme - Research and Training,Within 14 days following vaccination.,At any point during the study period.,The number of subjects experiencing severe (Grade 3) solicited systemic reactions,NA,NA,Serious adverse events considered associated with the vaccination reported.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Within 14 days following vaccination.,NA,At any point during the study period.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
COMDIS -Blisterpack,NCT01065116,Artemether-Lumefantrine (AL) Unit Dose Pre-packs Versus Blister Packs,Effectiveness and Treatment Adherence to Artemether/Lumefantrine Pre-packs Versus Blister Packs in the Treatment of Uncomplicated Malaria in Uganda,Completed,March 2010,November 2010,Actual,Actual,"Malaria Consortium, Uganda","Joaniter I Nankabirwa, MSc CEB",Principal Investigator,Makerere University Kampala,Phase 3,Interventional,920,Actual,Malaria,NA,All,4 Months,7 Years,No,"Malaria Consortium, Uganda",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adherence to Blister-packs versus unit dose pre-packs as measured by pill count and self report.,NA,"Ministry of Health, Uganda",Other,Makerere University,Other,Mulanda Health centre IV,Day 3,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WanMal002,NCT00284973,A Study of Safety and Immunogenicity of a Malaria Vaccine Candidate,Ph-1 Double-Blind Randomized Control Study-Evaluate Safety & Immunogenicity of Wanxing Bio-Pharmaceuticals AMA-1/MSP-1 Recombinant Malaria Vaccine (PfCP-2.9) Adj. w/ Montanide ISA 720 Compared to Montanide ISA 720 Alone in Adult Volunteers,Completed,January 2006,NA,NA,NA,Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.,"Jinhong Hu, Dr.",Principal Investigator,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Phase 1,Interventional,NA,NA,Prophylaxis Against Plasmodium Falciparum Malaria,To assess the safety and reactogenicity of the PfCP-2.9 /Montanide ISA 720 vaccine in healthy adult volunteers.,All,18 Years,45 Years,Accepts Healthy Volunteers,Shanghai Wanxing Bio-Pharmaceutical Co. Ltd.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,70,NA,NA,"Xinhua Hospital, Shanghai Jiao Tong University School of Medicine",Other,Second Military Medical University,Other,Shanghai Changhai Hospital,NA,NA,NA,World Health Organization,Other,NA,NA,NA,PATH,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HD57941-01A2,NCT01115478,Malaria in Pregnancy: Nutrition and Immunologic Effects,Malaria in Pregnancy: Nutrition and Immunologic Effects,Completed,July 2010,June 2014,Actual,Actual,Harvard School of Public Health,"Wafaie W Fawzi, MD, DrPH",Principal Investigator,Harvard School of Public Health,N/A,Interventional,2500,Actual,Malaria; Low Birth Weight; Anemia; Perinatal Mortality,NA,Female,18 Years,N/A,Accepts Healthy Volunteers,Harvard School of Public Health,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Ferdinand Mugusi, MD, MMed",Principal Investigator,Muhimbili University of Health and Allied Sciences,NA,Incidence of placental malaria,Low birth weight,Muhimbili University of Health and Allied Sciences,Other,NA,NA,Muhimbili University of Health And Allied Sciences,Delivery,Delivery,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Placental infection status will be categorized as infected if there are asexual parasites in the placenta blood; not infected if the placental blood smear is negative; or status unknown if no placental smear is available.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Low birth weight will be defined as birth weight less than 2500 grams.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
106464,NCT00380393,"Efficacy of RTS,S/AS01 Vaccine Against Episodes of Malaria Due to P. Falciparum Infection in Children.","A Study of the Efficacy Against Episodes of Clinical Malaria Due to P. Falciparum Infection of GSK Biologicals Candidate Vaccine RTS,S/AS01, Administered According to a 0,1,2-months Schedule in Children Aged 5 to 17 Months Living in Tanzania & Kenya",Completed,"January 3, 2007","November 11, 2008",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,855,Actual,Malaria,NA,All,5 Months,17 Months,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,First case of malaria meeting the primary case definition,NA,NA,NA,NA,NA,NA,Over a period starting 14 days after Dose 3 and extending for 4 months.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
112745,NCT01148459,Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children,Safety and Immunogenicity Study of GSK Biologicals' Plasmodium Falciparum Malaria Vaccine 257049 Administered to HIV Infected Infants and Children,Completed,"July 30, 2010","May 24, 2013",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,200,Actual,Malaria,NA,All,6 Weeks,17 Months,No,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of subjects with serious adverse events (SAEs),NA,NA,NA,NA,NA,NA,During the entire study period (from 30 days before Dose 1 up to Month 14),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
111319,NCT00811356,A First Time in Human Study in Healthy Volunteers to Investigate a New Medicine to Treat Malaria,"A Single-Blind, Placebo-Controlled, Randomized First Time in Human Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Dose Escalation of GSK932121 in Healthy Adult Subjects",Terminated,December 2008,March 2009,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,12,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Evidence of safety as determined by assessing adverse events, vital signs, spirometry, ECGs, telemetry, renal biomarkers, safety labs, and physical examination",NA,NA,NA,NA,NA,GSK Investigational Site,Part A: 3-4 months; Part B: ~1 month,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
10-04798,NCT01717885,Antimalarial Pharmacology in Children and Pregnant Women in Uganda,Antimalarial Pharmacology in HIV Infected and Uninfected Children and Pregnant Women in Uganda,Completed,August 2012,September 2016,Actual,Actual,"University of California, San Francisco","Francesca T Aweeka, Pharm.D.",Study Director,"University of California, San Francisco",N/A,Observational,473,Actual,Malaria; HIV,NA,All,6 Months,N/A,No,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Sunil Parikh, MD MPH",Principal Investigator,Yale University,NA,Primary outcome measurement is the area under the plasma concentration versus time curve for all drug analytes.,NA,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,IDRC- Tororo Research Clinic and Tororo District Hospital,At time of the last dose of a 6 dose regimen and up to 42 days of F/U,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pharmacokinetic exposure for the antimalarial medication is estimated through sparse or intensive blood sampling around the last dose and for several days following the last dose.,"Norah Mwebaza, MBChB, MSc",Principal Investigator,Makerere University,"Myaing Nyunt, MD PhD",Principal Investigator,Johns Hopkins University,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

        ALL PARTICIPANTS

          1. Residency within 60 km of the study clinic

          2. Agreement to come to clinic for all follow-up clinical and PK evaluations

          3. Provision of informed consent

        HIV-INFECTED PARTICIPANTS

        Children:

        1) Enrollment in Promote I or meets enrollment criteria and recruited from TDH/TASO or
        other referral site

          1. 6 months to 8 years of age

          2. Weight ≥6 kg

          3. Confirmed HIV infection (positive rapid HIV test to be confirmed by Western Blot or
             HIV RNA after enrollment)

          4. On a stable ART regimen for at least 10 days prior to enrollment

          5. If co-enrolled from PROMOTE, willingness to undergo intensive PK sampling during a
             single episode of uncomplicated malaria, and/or population PK/parasite clearance time
             studies during multiple episodes of uncomplicated malaria.

          6. If enrolled from TDH, willingness to undergo intensive PK sampling during a single
             episode of malaria or population PK/parasite clearance time studies during episodes of
             uncomplicated malaria.

        Pregnant women

          1. Enrollment in Promote Project 2 or meets enrollment criteria and recruited from
             TDH/TASO or other referral site

          2. On a stable ART regimen for at least 10 days prior to enrollment

          3. Presentation with uncomplicated malaria at the time of enrollment

          4. Confirmed pregnancy (apparent pregnancy, positive pregnancy test or pregnancy by
             ultrasound)

          5. Confirmed HIV infection (positive rapid HIV test to be confirmed by Western Blot or
             HIV RNA after enrollment)

          6. 16 years of age or older

          7. Estimated gestational age between 12 and 38 weeks by last menstrual period and report
             of quickening

          8. Willingness to undergo intensive PK sampling during episodes of uncomplicated malaria
             during pregnancy.

        HIV UNINFECTED PARTICIPANTS

        Children:

          1. Enrollment from TDH or other referral site

          2. 6 months to 8 years of age

          3. Weight ≥6 kg

          4. Confirmed HIV negative test (negative rapid HIV test to be confirmed by Western Blot
             or HIV RNA after enrollment)

          5. Presentation with uncomplicated falciparum malaria as indicated by positive smear for
             malaria parasites along with clinical evidence of infection (fever or history of fever
             in the past 24 hours) with planned treatment with AL.

        7) Willingness to undergo intensive PK sampling during a single episode of malaria or
        population PK/parasite clearance time studies during episodes of uncomplicated malaria.

        Non-pregnant adults:

          1. Age ≥ 16 years

          2. Confirmed HIV negative test (negative rapid HIV test to be confirmed by Western Blot
             or HIV RNA after enrollment).

          3. Presentation with uncomplicated falciparum malaria as indicated by positive smear for
             malaria parasites along with clinical evidence of infection (fever or history of fever
             in the past 24 hours) with planned treatment with AL.

          4. Negative pregnancy test

          5. Willingness to undergo intensive PK sampling during treatment for a single episode of
             uncomplicated malaria

        Pregnant women:

          1. Age ≥ 16 years

          2. Confirmed HIV negative test (negative rapid HIV test to be confirmed by Western Blot
             or HIV RNA after enrollment)

          3. Confirmed pregnancy (apparent pregnancy, positive pregnancy test or pregnancy by
             ultrasound)

          4. Estimated gestational age between 12 and 38 weeks by last menstrual period and report
             of quickening

          5. Presentation with uncomplicated malaria as indicated by positive smear for malaria
             parasites along with clinical evidence of infection (fever or history of fever in the
             past 24 hours) with planned treatment with AL.

          6. No evidence of imminent delivery or threatened abortion at the time of presentation
             with malaria.

          7. Willingness to undergo intensive PK sampling during episodes of uncomplicated malaria
             during pregnancy.

        Exclusion Criteria:

          1. History of significant comorbidities such as malignancy, active tuberculosis or other
             WHO stage 4 disease

          2. Current infection with non-falciparum species

          3. Receipt of any medications known to affect cytochrome p450 (CYP450) metabolism (except
             ART) within 14 days of study enrollment (see 4.2.2)

          4. Hemoglobin < 7.0 g/dL

          5. Prior treatment for malaria within 14 days of study enrollment (intensive PK study
             participants only)

          6. Signs or evidence of complicated malaria, defined as unarousable coma OR ANY TWO OF
             THE FOLLOWING SYMPTOMS: Recent febrile convulsions, altered consciousness, lethargy,
             unable to drink, unable to stand/sit due to weakness, severe anemia (Hb < 5.0 gm/dL),
             respiratory distress, jaundice
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HD061232,NCT01119612,Prenatal Iron Supplements: Safety and Efficacy in Tanzania,Prenatal Iron Supplements: Safety and Efficacy in Tanzania,Completed,September 2010,May 2013,Actual,Actual,Harvard School of Public Health,"Wafaie W Fawzi, MD, DrPH",Principal Investigator,Harvard School of Public Health,N/A,Interventional,1500,Actual,Malaria; Anemia,NA,Female,18 Years,N/A,Accepts Healthy Volunteers,Harvard School of Public Health,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Zul Premji, MD, MSC, PhD",Principal Investigator,Muhimbili University of Health and Allied Sciences,NA,Incidence of placental malaria,Placental malaria parasite density,Muhimbili University of Health and Allied Sciences,Other,NA,NA,Muhimbili University of Health And Allied Sciences,Delivery,Delivery,Infant birth weight,NA,NA,Maternal hemoglobin,NA,NA,NA,NA,NA,NA,Placental infection status will be categorized as infected if there are asexual parasites in the placenta blood; not infected if the placental blood smear is negative; or status unknown if no placental smear is available.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Placental malaria parasite density will be defined as number of parasites per μL of blood or 200 white blood cells; the latter will be converted to a count per μL of blood assuming a count of 8000 WBC/μL.,Delivery,Continuous measurement,Delivery,Continuous measurement,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NMRC.2012.0006,NCT01843491,A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents,A Phase I Clinical Trial Immunizing Healthy Adults With the NMRC-M3V-Ad-PfCA Vaccine to Generate Biologic Reagents for Refining Immunologic Assays Supporting the Development of the Protective Malaria Vaccine NMRC-M3V-D/Ad-PfCA (AdBa),Withdrawn,June 2013,June 2014,Anticipated,Anticipated,U.S. Army Medical Research and Materiel Command,"Judith Epstein, MD",Principal Investigator,Naval Medical Research Center,Phase 1,Interventional,0,Actual,Healthy; Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Collection,"ELISpot assay, flow cytometry assay and HLA typing",The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,Naval Medical Research Center Clinical Trials Center,26 weeks,26 weeks,Repository,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Collection of sufficient PBMCs for the laboratory investigators to determine the accuracy, precision, cell usage, throughput, and cost of each of the developed, expanded, or refined immunological assays",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Collection of sufficient PBMCs to meet the minimum required response for positive controls (250 spot forming cells (sfc)/ million PBMCs), with each positive sample characterized using frozen ELISpot assay, flow cytometry assay and HLA typing",26 weeks,Collection of a sufficient bank of characterized PBMCs that vials can be used as global reference reagents for the standardization of malaria vaccine development-specific cellular immunologic assays worldwide,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WP2-01-FEV,NCT01766830,"Rapid Diagnostic Tests and Clinical/Laboratory Predictors of Tropical Diseases In Patients With Persistent Fever in Cambodia, Nepal, Democratic Republic of the Congo and Sudan (NIDIAG-Fever)","Evaluation of Rapid Diagnostic Tests (RDT) in Association With Clinical and Laboratory Predictors for the Diagnosis of Neglected Tropical Diseases (NTD) in Patients Presenting With Persistent Fever (≥1 Week) in Cambodia, Nepal, Democratic Republic of the Congo and Sudan",Completed,January 2013,July 2016,Actual,Actual,"University Hospital, Geneva","François Chappuis, MD, PhD",Study Director,"University Hospitals, Geneva",N/A,Interventional,1927,Actual,Visceral Leishmaniasis; Human African Trypanosomiasis; Enteric Fever; Melioidosis; Brucellosis; Leptospirosis; Relapsing Fever; Rickettsial Diseases; HIV; Tuberculosis; Malaria; Amoebic Liver Abscess,NA,All,5 Years,N/A,No,"University Hospital, Geneva",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Prevalence of Visceral Leishmaniasis (VL), Human African Trypanosomiasis (HAT) and other Neglected Tropical Diseases (NTDs)",Identification of clinical and laboratory diagnostic indicators,"Institute of Tropical Medicine, Belgium",Other,B.P. Koirala Institute of Health Sciences,Other,NA,18 months,18 months,Identification of reliable Rapid Diagnostic Tests (RDTs),"Institut National de Recherche Biomédicale, Kinshasa, DRC",Other,Predictive values of RDTs,NA,NA,University of Khartoum,Other,Sihanouk Hospital Center of HOPE,Other,"Number of patients diagnosed with VL, HAT and other NTDs among those presenting with persistent(≥ 1 week) fever in one of the study sites",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Sensitivity, specificity, crude and adjusted likelihoods ratios (LR), and predictive values (post-test probabilities) of clinical and first-line laboratory predictors for the diagnosis of VL, HAT and other NTDs",18 months,"Assessment of sensitivity, likelihood ratios and performances (diagnostic accuracy) of the novel study RDTs for VL, HAT, enteric fever and",18 months,"Predictive values (post-test probabilities) of RDTs, alone and in combination, for the respective target conditions within the multi-disease approach",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PAMVAC1_15,NCT02647489,Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Variously Adjuvanted,"Safety and Immunogenicity of the Placental Malaria Vaccine Candidate PAMVAC Adjuvanted With Alhydrogel, GLA-SE or GLA-LSQ in Healthy Malaria-Naïve Adults and Healthy, Lifelong Malaria-Exposed, Nulligravid Adult Women",Recruiting,May 2016,December 2017,Anticipated,Anticipated,University Hospital Tuebingen,"Benjamin G Mordmüller, MD",Principal Investigator,University Hospital Tübingen,Phase 1,Interventional,66,Anticipated,"Malaria, Antepartum",NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University Hospital Tuebingen,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Saadou Issifou, MD",Principal Investigator,Université d'Abomey-Calavi,NA,"Number and grade of adverse events (Grade 1-3 and serious adverse events) possibly, likely and definitely related to vaccination",NA,University of Copenhagen,Other,Université d'Abomey-Calavi,Other,Institut de Recherche Clinique du Benin (IRCB),"From the first administration of the interventions through study completion, an average of 1 and a half years",NA,NA,European Malaria Vaccine Initiative,Other,NA,NA,NA,Institut de Recherche pour le Developpement,Other,Expres2ion Biotechnologies APS,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999906147,NCT00346346,"Analysis of the Immune Response to the Malaria Parasite in Mali, West Africa",Longitudinal Analysis of the B-Cell Immune Response to Plasmodium Falciparum in Mali,Completed,"April 17, 2006",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Peter D Crompton, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,237,Anticipated,Malaria,NA,All,2 Years,25 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","January 23, 2013",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria Research and Training Center,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999907217,NCT00527163,Role of Nitric Oxide in Malaria,Role of Nitric Oxide Scavenging by Plasma Hemoglobin and Identification of Hemolysis-Associated Pulmonary Hypertension in Malaria,Completed,"September 4, 2007",NA,NA,NA,"National Heart, Lung, and Blood Institute (NHLBI)","Henry Masur, M.D.",Principal Investigator,National Institutes of Health Clinical Center (CC),N/A,Observational,650,Anticipated,Malaria; Pulmonary Hypertension,NA,All,1 Year,5 Years,No,"National Heart, Lung, and Blood Institute (NHLBI)",NIH,"ClinicalTrials.gov processed this data on July 26, 2017","March 30, 2015",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Hospital Gabriel Toure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999908094,NCT00663546,Malaria Studies in Cambodia,Studies of P. Vivax and P. Falciparum Malaria in Cambodia,Completed,"March 24, 2008",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Rick M Fairhurst, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,2765,Anticipated,Malaria,NA,All,N/A,100 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","December 5, 2013",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999908120,NCT00669084,Innate and Acquired Resistance to Plasmodium Falciparum Malaria in Mali,Studies of Innate and Acquired Resistance to P. Falciparum Malaria in Mali,Completed,"April 21, 2008",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Rick M Fairhurst, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,2100,Anticipated,Malaria,NA,All,6 Months,65 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","November 19, 2013",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ST3073-ST3074-DM-12-002,NCT01992900,A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria,"A Phase II, Open-label, Multicentre, Pharmacokinetic, Pharmacodynamics and Safety Study of a New Paediatric Eurartesim Dispersible Formulation and Crushed Film Coated Eurartesim Tablet, in Infant Patients With P. Falciparum Malaria",Completed,November 2013,January 2016,Actual,Actual,sigma-tau i.f.r. S.p.A.,"Enrique O Bassat, MD",Study Chair,"Manica's health Research Centre, centre de investigacao Saude-Manica (CISM)",Phase 2,Interventional,300,Actual,"Malaria,Falciparum",NA,All,6 Months,12 Months,No,sigma-tau i.f.r. S.p.A.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Comparison of peak plasma concentration of Dihydroartemisinin in the two studied formulations,Comparison of area under the plasma concentration versus time curve of Dihydroartemisinin in the two studied formulations.,NA,NA,NA,NA,NA,"DHA plasma samples will be collected on the first day of study drug administration at 20, 30, 40, 60, 100, 200 and 300 minutes post-dose","DHA plasma samples will be collected on the first day of study drug administration at 20, 30, 40, 60, 100, 200 and 300 minutes post-dose",Comparison of peak plasma concentration of Piperaquine in the two studied formulations,NA,NA,Comparison of area under the plasma concentration versus time curve of Piperaquine in the two studied formulations.,NA,NA,NA,NA,NA,NA,"In order to minimize the blood sampling in infants, patients will be divided into 10 blood sampling groups for both the treatments (water dispersible and crushed film coated tablet) and only 2 blood draws per group will be taken within the prespecified timepoints.
Optimal sampling design was performed by using the appropriate software. The D-optimal design option was used to determine the optimal sampling design.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"In order to minimize the blood sampling in infants, patients will be divided into 10 blood sampling groups for both the treatments (water dispersible and crushed film coated tablet) and only 2 blood draws per group will be taken within the pre-specified timepoints.
Optimal sampling design was performed by using the appropriate software. The D-optimal design option was used to determine the optimal sampling design.","PQP plasma samples will be collected on day 0 of treatment at 40, 80, 280, 720 minutes, then on day 1 at 24 hours and on day 2 at 40, 80, 280, 720 minutes after the last drug administration and then 24, 120, 288 and 456 hours","In order to minimize the blood sampling in infants, patients will be divided into 10 blood sampling groups for both the treatments (water dispersible and crushed film coated tablet) and only 2 blood draws per group will be taken within the pre-specified timepoints.
Optimal sampling design was performed by using the appropriate software. The D-optimal design option was used to determine the optimal sampling design.","PQP plasma samples will be collected on day 0 of treatment at 40, 80, 280, 720 minutes, then on day 1 at 24 hours and on day 2 at 40, 80, 280, 720 minutes after the last drug administration and then 24, 120, 288 and 456 hours","In order to minimize the blood sampling in infants, patients will be divided into 10 blood sampling groups for both the treatments (water dispersible and crushed film coated tablet) and only 2 blood draws per group will be taken within the pre-specified timepoints.
Optimal sampling design was performed by using the appropriate software. The D-optimal design option was used to determine the optimal sampling design.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MVDC-2003-003,NCT01083095,Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers,Establishment of a Sporozoite Challenge Model for Plasmodium Vivax in Human Volunteers,Completed,January 2005,December 2006,Actual,Actual,Malaria Vaccine and Drug Development Center,"Socrates Herrera, MD",Principal Investigator,MVDC,Early Phase 1,Interventional,18,Actual,"Malaria, Vivax",NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Malaria Vaccine and Drug Development Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of infected naïve human volunteers after different number of infected mosquito biting,NA,"Ministerio de la Protección Social, Colombia.",Other,NA,NA,Malaria Vaccine and Drug Testing Center,30 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MiPcMA05,NCT01084213,Intermittent Preventive Treatment Versus Scheduled Screening and Treatment of Malaria in Pregnancy,A Trial of Intermittent Preventive Treatment With Sulfadoxine-pyrimethamine Versus Intermittent Screening and Treatment of Malaria in Pregnancy,Completed,June 2010,October 2012,Actual,Actual,London School of Hygiene and Tropical Medicine,"Brian Greenwood, MD",Principal Investigator,"London School of Hygiene & Tropical Medicine, UK.",Phase 4,Interventional,5354,Actual,Malaria; Pregnancy; Anaemia,NA,Female,16 Years,45 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Daniel Chandramohan, PhD",Principal Investigator,"London School of Hygiene & Tropical Medicine, UK.",NA,Prevalence of low birth weight,Prevalence of third trimester anaemia,"Medical Research and Training Centre, Mali",Other,"University of Ouagadougou, Burkina Faso",Other,NA,6 - 18 months,3 - 12 months,Prevalence of placenta malaria,"Medical Research Council Unit, The Gambia",Other,NA,NA,NA,"Navrongo Health Research Centre, Ghana",Other,Liverpool School of Tropical Medicine,Other,NA,"Paul Milligan, PhD",Principal Investigator,"London School of Hygiene & Tropical Medicine, UK.","Feiko T Kuile, PhD",Principal Investigator,"Liverpool School of Tropical Medicine, UK",NA,NA,NA,NA,NA,"Harry Tagbor, DrPH",Principal Investigator,"Kwame Nkrumah University of Science & Technology, School of Medical Sciences, Ghana",NA,6 - 18 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999910155,NCT01160562,"Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity","Pilot Study to Estimate the Burden and Distribution of Plasmodium Falciparum Malaria in Kalifabougou, Mali in Preparation for a Prospective Cohort Study of Naturally-Acquired Malaria Immunity",Completed,"June 23, 2010",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Peter D Crompton, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,4000,Anticipated,"Malaria, Falciparum; Plasmodium Falciparum",NA,All,N/A,25 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","January 23, 2013",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria Research and Training Center,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999911017,NCT01240603,Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia,Plasmodium Falciparum Clearance Rates in Response to Artesunate in Eastern Cambodia,Completed,"October 24, 2010",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Rick M Fairhurst, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,415,Anticipated,Malaria,NA,All,1 Year,N/A,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","September 11, 2013",NA,NA,NA,NA,NA,NA,"National Centre for Parasitology, Entomology and Malaria Control, Cambodia",Other,NA,NA,"National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PAACT-PV,NCT01107145,Efficacy of Artemisinin Combination Therapies for the Treatment of Uncomplicated P. Vivax in Pregnancy in Brazil (PAACT-PV),"A Multi-center, Open-label, Randomized Trial of Chloroquine, Artemether-Lumefantrine, and Mefloquine-Artesunate for the Treatment of Uncomplicated P. Vivax Malaria in Pregnant Women in Brazil",Terminated,February 2011,January 2012,Actual,Actual,Centers for Disease Control and Prevention,"Meghna Desai, MPH PhD",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,16,Actual,Plasmodium Vivax Malaria,NA,Female,15 Years,N/A,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,63-day PCR-adjusted parasitological cure of P. vivax,NA,NA,NA,NA,NA,NA,63 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,63-day PCR-adjusted parasitological cure of P. vivax,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SP-C-010-10,NCT01156389,Pyronaridine/Artesunate -Ritonavir Drug Drug Interaction Study,"Open-label, Randomised, Drug Interaction Study of Pyramax (Pyronaridine Artesunate) and the Protease Inhibitor Ritonavir in Healthy Volunteers",Completed,July 2010,September 2010,Actual,Actual,Medicines for Malaria Venture,"Isabelle Borghini Fuhrer, PhD",Study Director,Medicines for Malaria Venture,Phase 1,Interventional,34,Anticipated,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Pharmacokinetics,NA,Shin Poong Pharmaceuticals,Industry,NA,NA,Covance Clinical Research Unit AG,Until Day 50 for Arm A and until Day 43 for Arm B,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Pharmacokinetic parameters for pyronaridine, artesunate, DHA and ritonavir will be analysed.
Cmax, C trough, Tmax, AUC0-tau AUC0-t, AUC0-infinity and half-life will be calculated.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999911143,NCT01360112,Preventing the Spread of Malaria in Mali,Malaria Transmission Blocking Assay Development and Gametocyte Carriage in a Vaccine Testing Site in Mali,Completed,"April 16, 2011",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,1000,Anticipated,Malaria,NA,All,3 Months,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"a) Mosquito infectivity by DF, DMFA (a, b, and c), and SMFA (d and e), as measured by infection rate (number of infected vs. un- nfected mosquitoes), and oocyst counts in infected mosquitoes, both determined using microscopy.","b) The period prevalence and density of gametocytes throughout the study period, as detected by thick smear and nucleic acid based techniques",NA,NA,NA,NA,"University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology",24 months,24 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
140121,NCT02153996,Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States,Longitudinal Analysis of Plasmodium Falciparum-Specific Immunity in Travelers and Immigrants From Malaria Endemic Areas to the United States,Terminated,"May 15, 2014","March 15, 2016",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Eugene W Liu, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,3,Actual,Malaria,NA,All,18 Years,65 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Estimate the quality and longevity of P. falciparum-specific humoral and cellular immune responses in the absence of ongoing P. falciparum exposure.,NA,NA,NA,NA,NA,"National Institutes of Health Clinical Center, 9000 Rockville Pike",Five years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC1488,NCT02878200,"RHOST-cRCT, Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission",Reactive Household-based Self-administered Treatment Against Residual Malaria Transmission: a Cluster Randomized Trial,Recruiting,November 2016,December 2018,Anticipated,Anticipated,"Medical Research Council Unit, The Gambia","Umberto D'Alessandro, MD",Principal Investigator,"Medical Research Council Unit, The Gambia",N/A,Interventional,8000,Anticipated,Malaria,NA,All,6 Months,N/A,Accepts Healthy Volunteers,"Medical Research Council Unit, The Gambia",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,prevalence of malaria infection,NA,"Institute of Tropical Medicine, Belgium",Other,London School of Hygiene and Tropical Medicine,Other,Health Centres in NBR,24 months,NA,NA,University of Sheffield,Other,NA,NA,NA,NA,NA,NA,NA,the prevalence of malaria infection (determined by molecular methods) in all age groups at the end of the second intervention year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1407,NCT02451904,Severe and Cerebral Malaria Investigated Through Host Metabolomics,Microvascular and Metabolic Dysregulation in the Pathogenesis of Severe and Cerebral Malaria Investigated Through Host Metabolomics,Not yet recruiting,June 2015,September 2018,Anticipated,Anticipated,University of Oxford,"Prof. Arjen M. Dondorp, MD",Principal Investigator,Mahidol Oxford Tropical Medicine Research Unit,N/A,Observational,840,Anticipated,Severe Malaria,NA,All,12 Years,N/A,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Characterisation of patterns of metabolic dysregulation in severe malaria,NA,Chittagong Medical College and Hospital,Other,NA,NA,NA,4-6 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Interrelationship between disturbances in metabolic pathways associated with acidosis and cerebral malaria,NA,NA,NA,NA,NA,NA,NA,NA,Characterisation of patterns of metabolic dysregulation in severe malaria,Non-Probability Sample,"
        Severe/Cerebral Malaria:

          -  Any P. falciparum parasitaemia detected by asexual stages on a peripheral blood-slide
             or a positive rapid diagnostic test in combination with one or more Modified WHO
             Criteria for Severe Malaria (Hien et al, 1996)

          -  < 24 hours after treatment commencement with either parenteral artemisinin or quinine

          -  Age > 12 years

          -  Full informed written consent obtained

        Uncomplicated malaria:

          -  Any level of Plasmodium parasitaemia, detected by asexual stages on a peripheral
             blood-slide or a positive rapid diagnostic test without any of the complications of
             severe malaria stated above.

          -  Age > 12 years

          -  Full informed written consent obtained

        Sepsis:

          -  Clinical signs of infection in combination with any two of the following signs:

               1. Heart rate > 90 beats per minute;

               2. Respiratory rate > 20 breaths per minute, a PaCO2 of < 32 mmHg, or the use of
                  mechanical ventilation for an acute respiratory process;

               3. Tympanic temperature > 38°C or < 36 °C;

               4. White-cell count of > 12x109/L or < 4x109/L, or a differential count showing 10%
                  immature neutrophils ;

          -  Negative peripheral blood slide for any stages of malaria parasites or a negative
             rapid diagnostic test for falciparum and vivax malaria

          -  [As bacterial culture is not routinely available at the study site, positivity of
             cultures is not required]

          -  Age > 12 years

          -  Full informed written consent obtained

        Acidosis:

          -  Clinical suspicion of metabolic acidosis in combination with any of the following:

               1. Peripheral venous bicarbonate < 15 mmol/L

               2. Peripheral venous base excess < -3 mmol/L

          -  Negative peripheral blood slide for any stages of malaria parasites or a negative
             rapid diagnostic test for falciparum and vivax malaria; and not meeting any of the
             inclusion criteria for sepsis as stated above.

          -  Age > 12 years

          -  Full informed written consent obtained

        Encephalitis:

          -  GCS < 11/15

          -  Documented fever > 38°C

          -  Onset of symptoms < 2 weeks, with an indication a lumbar puncture as part of the
             diagnostic work up

          -  Negative peripheral blood slide for any stages of malaria parasites or a negative
             rapid diagnostic test for falciparum and vivax malaria

          -  Age > 12 years

          -  Full informed written consent obtained

        Healthy volunteers:

          -  No chronic or acute disease

          -  No fever in the past 2 weeks

          -  Age > 16 years

          -  Full informed written consent obtained

        Exclusion Criteria:

          -  Known pre-existing chronic medical conditions including advanced hepatic disease.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC035,NCT00984763,"A Study to Assess Safety, Immunogenicity and Parasite Growth Inhibition of an Asexual Blood Stage Vaccine for P. Falciparum Malaria","A Phase I/IIa Study of the Safety, Immunogenicity and Parasite Growth Inhibitory Activity of AMA1-C1/Alhydrogel® + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,January 2010,September 2010,Actual,Actual,University of Oxford,"Adrian VS Hill, D.Phil, FRCP",Principal Investigator,University of Oxford,Phase 1/Phase 2,Interventional,8,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To demonstrate a correlation between in vitro growth inhibition assay and parasite multiplication rate in vivo,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,NA,NA,"Centre for Clinical Vaccinology and Tropical Medicine, University of Oxford",Up to 16 days following blood stage parasite challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AL-eff 2010,NCT01157689,Artemether-Lumefantrine Effectiveness in Guinea-Bissau,The Routine Use of Coartem for Treatment of Symptomatic Children With Plasmodium Falciparum at the Bandim Health Centre,Unknown status,March 2010,June 2014,Anticipated,Anticipated,Bandim Health Project,NA,NA,NA,N/A,Observational,500,Anticipated,Malaria,NA,All,N/A,15 Years,No,Bandim Health Project,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,ACPR day 42,NA,NA,NA,NA,NA,Bandim Health Project,day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria slides will be examined weekly during follow-up until day 42. The adequate clinical and parasitological cure rate will to calculated for day 42.,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Prescribed an anti-malarial at the Bandim Health Centre

          -  Having P. falciparum parasites in a thick film and/or a positive RDT

          -  The Bandim address is known (to enable follow up).

        Exclusion Criteria:

          -  Children where the parents do not accept to participate in the study.

          -  Signs of severe malaria such as convulsion or severe anemia
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1692,NCT01157897,Study of VMP001 and AS01B in Healthy Malaria-Naïve Adults,"Phase 1/2a Open-label Dose Safety, Reactogenicity, Immunogenicity and Efficacy of the Candidate Plasmodium Vivax Malaria Protein 001 (VMP001) Administered Intramuscularly With GSK Biologicals' Adjuvant System AS01B in Healthy Malaria-Naïve Adults",Completed,July 2010,December 2011,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Jason Bennett, MD",Principal Investigator,"Division of Malaria Vaccine Development (DMVD), Walter Reed Army Institute of Research (WRAIR)",Phase 1/Phase 2,Interventional,48,Actual,Malaria; Plasmodium Vivax,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of solicited adverse events over a 7 day follow-up period after each immunization (the day of the immunization and 6 subsequent days),Occurrence of unsolicited adverse events over a 28 day follow-up period after each immunization (the day of the immunization and 27 subsequent days),The PATH Malaria Vaccine Initiative (MVI),Other,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"Clinical Trials Center, Walter Reed Army Institute of Reserach",7 days after immunization,28 days following immunization,Occurrence of serious adverse events at any time during the study period (enrollment to final follow up visit),United States Department of Defense,U.S. Fed,NA,NA,NA,GlaxoSmithKline,Industry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,study duration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999916004,NCT02627456,"Safety, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali","Dose Escalating and Randomized, Placebo-Controlled, Double-Blind Study to Assess Safaty, Immunogenicity, and Protective Efficacy of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults in Mali","Active, not recruiting","October 8, 2015","July 31, 2017",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,500,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety: Measure the incidence and severity of local and systemic adverse events occurring within 7 days after each vaccine administration and SAE related to vaccination.,NA,NA,NA,NA,NA,University of Bamako,Approximately 7 days after each vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
160039,NCT02639299,"Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge","Screening of Healthy Volunteers for Investigational Antimalarial Drugs, Malaria Vaccines, and Controlled Human Malaria Challenge",Recruiting,"December 17, 2015","March 31, 2026",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,1500,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"To screen healthy volunteers for eligibility to enroll in studies to evaluate investigational antimalarial drugs, malaria vaccines, and/orundergo CHMI.",NA,NA,NA,NA,NA,"National Institutes of Health Clinical Center, 9000 Rockville Pike",One Year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To screen healthy volunteers for eligibility to enroll in studies to evaluate investigational antimalarial drugs, malaria vaccines, and/orundergo CHMI.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PATH-WIRB-20140824,NCT02329301,Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia,Assessing the Effectiveness of Mass Drug Administration (MDA) With Dihydroartemisinin + Piperaquine for Reducing Malaria Parasite Infection Prevalence and Incidence in Southern Province Zambia,"Active, not recruiting",September 2014,July 2017,Anticipated,Anticipated,PATH,"John M Miller, PhD",Principal Investigator,PATH,N/A,Interventional,2430,Actual,"Malaria; Malaria, Falciparum",NA,All,3 Months,N/A,Accepts Healthy Volunteers,PATH,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite prevalence during the high transmission season among children <6 years old (excluding neonates <1 month),P.falciparum infection incidence rate among individuals ≥3 months,"Ministry of Health, Zambia",Other,"Minister of Community Development, Mother and Child Health, Zambia",Other,Southern province medical office,For up to 12 months,For up to 12 months,NA,Tulane University,Other,NA,NA,NA,NA,NA,NA,NA,Parasite prevalence during the high transmission season among children <6 years old (excluding neonates <1 month),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,P.falciparum infection incidence rate among individuals ≥3 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WageningenU,NCT02996513,Assessing Model Parameters for Applying the Retinol Isotope Dilution (RID) Method,Assessing Model Parameters for Applying the Retinol Isotope Dilution (RID) Method in Preschool Nigerian Children Living in an Area With a High Malaria Burden,Recruiting,October 2016,June 2017,Anticipated,Anticipated,Wageningen University,"Alida Melse-Boonstra, PhD",Principal Investigator,Wageningen University,N/A,Interventional,60,Anticipated,Vitamin A Deficiency; Malaria; Inflammation,NA,All,36 Months,59 Months,Accepts Healthy Volunteers,Wageningen University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Vitamin A status,NA,University of Ibadan,Other,Newcastle University,Other,University of Ibadan,28 days,NA,NA,"University of California, Davis",Other,NA,NA,NA,Penn State University,Other,HarvestPlus,Other,Body retinol pool,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
0909M72852,NCT01093989,"Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition","Acute vs. Delayed Iron Therapy: Effect on Iron Status, Anemia and Cognition",Completed,June 2010,December 2014,Actual,Actual,University of Minnesota - Clinical and Translational Science Institute,"Chandy C John, M.D.",Principal Investigator,University of Minnesota - Clinical and Translational Science Institute,N/A,Interventional,239,Actual,Anemia; Inflammation; Malaria Morbidity; Cognitive Development,NA,All,18 Months,5 Years,Accepts Healthy Volunteers,University of Minnesota - Clinical and Translational Science Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Hemoglobin change, anemia prevalence, and socioemotional behavior in the immediate iron vs. delayed iron groups",NA,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,Mulago Hospital,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Hemoglobin change, anemia prevalence, and socioemotional behavior in the immediate iron vs. delayed iron groups",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1101,NCT01350856,Tracking Resistance to Artemisinin (TRAC),"A Multicentre, Randomised Trial to Detect in Vivo Resistance of Plasmodium Falciparum to Artesunate in Patients With Uncomplicated Malaria.",Completed,May 2011,December 2014,Actual,Actual,University of Oxford,"Nicholas J White, DSc MD",Principal Investigator,Mahidol Oxford Research Unit,Phase 4,Interventional,1700,Actual,Falciparum Malaria,NA,All,6 Months,65 Years,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite clearance rate,NA,Mahidol University,Other,Worldwide Antimalarial Resistance Network,Other,NA,Day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Defined by the slope of the linear portion of the natural logarithm parasite clearance curve.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
0001,NCT01160809,Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Ethiopia,Effect of a Combined Use of Mosquito Repellent and Insecticide Treated Net on Malaria in Southern Ethiopia: a Cluster-randomized Controlled Trial,Completed,September 2008,January 2009,Actual,Actual,"Malaria Consortium, Ethiopia",NA,NA,NA,Phase 4,Interventional,6082,Actual,Malaria; Mosquito Repellent; Long Lasting Insecticidal Nets,NA,All,N/A,N/A,Accepts Healthy Volunteers,"Malaria Consortium, Ethiopia",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria parasite (P. falciparum and/or P. vivax)through microscopic detection,NA,Addis Ababa University,Other,Columbia University,Other,"SNNPR, Ethiopia",NA,NA,NA,Coalition Against Malaria in Ethiopia,Other,NA,NA,NA,NA,NA,NA,NA,The objective of the study is to investigate the impact of a combined use of mosquito repellent and LLINs in reducing malaria. The primary outcome of the study is detection of malaria parasites (P. falciparum and/or P. vivax) through examination of microscopic blood slides collected from finger-pricks.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
02MA,NCT01165372,"Study of Malaria Treatment at Phuoc Long Hospital, Binh Phuoc Province, Vietnam","Clinical Investigation of In-vivo Susceptibility of P. Falciparum to Artesunate in Phuoc Long Hospital, Binh Phuoc Province, Vietnam",Completed,August 2010,May 2011,Actual,Actual,"Oxford University Clinical Research Unit, Vietnam","Hien T Tran, MD, PhD",Principal Investigator,"Oxford University Clinical Research Unit, Vietnam",Phase 2,Interventional,166,Actual,Malaria,NA,All,10 Years,N/A,No,"Oxford University Clinical Research Unit, Vietnam",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Slope of the decline in the log parasitemia-time curve relative to historical data,NA,World Health Organization,Other,NA,NA,Phuoc Long Hospital,03 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999916051,NCT02659566,"Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Doneguebougou, Mali","Impact of Antimalarial Treatment on Measures of T Cell Suppression/Regulation in Healthy Adults From Ouelessebougou, Mali",Not yet recruiting,"January 12, 2016","February 28, 2018",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Michal Fried, Ph.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,700,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To measure the percentage of T cells expressing PD-1 during scheduled visits by comparing markers of T cell suppression/regulation in adults (specifically PD-1) who receive or do not receive antimalarial treatment at the beginning of dry season ...,NA,NA,NA,NA,NA,Ouelessebougou Clinical Research Center,Twelve months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,To measure the percentage of T cells expressing PD-1 during scheduled visits by comparing markers of T cell suppression/regulation in adults (specifically PD-1) who receive or do not receive antimalarial treatment at the beginning of dry season ...,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MRT15003.2,NCT02700269,Vanderbilt-Zambia Innovations in Global Health Technologies,Vanderbilt-Zambia Innovations in Global Health Technologies,Recruiting,April 2016,July 2017,Anticipated,Anticipated,"Macha Research Trust, Zambia",NA,NA,NA,N/A,Observational,200,Anticipated,Malaria Diagnosis,NA,All,6 Months,85 Years,Accepts Healthy Volunteers,"Macha Research Trust, Zambia",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Enhancement of malaria RDT to detect low levels of P falciparum parasites,NA,Vanderbilt University,Other,National Institutes of Health (NIH),NIH,Macha Research Trust,5 years,NA,NA,John E. Fogarty International Center (FIC),NIH,NA,NA,NA,NA,NA,NA,NA,The expected outcome of this research project is to enhance the ability of standard malaria RDTs to detect low levels of Plasmodium falciparum malaria in human capillary blood.,NA,NA,NA,NA,NA,NA,NA,NA,Enhancement of malaria RDT to detect low levels of P falciparum parasites,Non-Probability Sample,"
        Inclusion Criteria:

          -  Individuals giving written informed consent for themselves

          -  Children under the age of 18 for whom a parent or guardian can give consent

          -  Individuals seeking care or treatment of suspected or possible malaria

          -  Individuals being screened as a contact of someone with recent malaria

          -  Other individuals willing to have their blood tested for malaria

        Exclusion Criteria:

          -  Anyone over 18 unwilling or unable to provide informed consent

          -  Anyone under 18 who does not have a parent or guardian to give consent

          -  Anyone between the age of 12 and 18 who does not give assent
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MAC-P.02/16/1872,NCT03009526,Efficacy and Safety of IPTp-DP Versus IPTp-SP in Malawi,A Prospective Randomized Open-Label Study on the Efficacy and Safety of Intermittent Preventive Treatment in Pregnancy (IPTp) With Dihydroartemisinin-Piperaquine (DP) Versus IPTp With Sulfadoxine-Pyrimethamine (SP) in Malawi,Recruiting,NA,"December 31, 2018",Anticipated,Anticipated,University of Malawi College of Medicine,"Don P Mathanga, MBBS PhD",Principal Investigator,Malawi College of Medicine,Phase 3,Interventional,602,Anticipated,Malaria; Pregnancy,NA,Female,16 Years,N/A,Accepts Healthy Volunteers,University of Malawi College of Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Julie Gutman, MD MSc",Principal Investigator,Centers for Disease Control and Prevention,NA,Malaria infection at the time of delivery,Fetal morbidity,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,"Malaria Alert Center, University of Malawi College of Medicine",delivery,Delivery,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The composite of peripheral and placental parasitemia, detected by placental histology, positive peripheral blood smear at the time of delivery, or positive rapid diagnostic test at the time of delivery",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Composite endpoint of fetal morbidity, defined as any of the following: Preterm birth (birth before 37 weeks gestation), Low-birth-weight (birth weight under 2,500 grams), Small for gestational age (SGA)",NA,NA,NA,NA,"January 16, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVG30,NCT00144716,Evaluation of Combined Use of ITN's and Insect Repellents Against Malaria,Clinical Evaluation of Combined Use of ITN's and Plant-based Insect Repellent Against Malaria in the Amazon,Completed,June 2003,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Nigel Hill, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,NA,NA,Malaria,Reduction in cases of malaria,All,10 Years,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",October 2003,NA,NA,NA,4250,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KIMORU005,NCT02092766,Parenteral Artesunate Compared to Quinine as a Cause of Late Anaemia in African Children With Malaria,Parenteral Artesunate Compared to Quinine as a Cause of Late Post-treatment Anaemia in African Children With Hyperparasitaemic P. Falciparum Malaria,Completed,June 2014,April 2015,Actual,Actual,University of Oxford,NA,NA,NA,Phase 4,Interventional,217,Actual,Anaemia,NA,All,6 Months,14 Years,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Late onset anaemia,NA,Kinshasa School of Public Health,Other,NA,NA,Kinshasa School of Public Health,Patients are hospitalized for 4 days or longer if still unwell. After discharge the follow-up consists of 6 weekly visits (time frame 42 days). Late anaemia is measured between 7 and 42 days following the start of antimalarial treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Late onset anaemia in this study is defined as a ≥10% drop in haemoglobin on any previous measurement anytime between day 7 and 42,NA,NA,NA,NA,NA,NA,NA,NA,Late onset anaemia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A-14620.b,NCT02458092,"Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B","Phase 1b Controlled Double Blind Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of the Candidate Plasmodium Falciparum Malaria Protein 010 (FMP010) Administered Intramuscularly With GSK Biologicals' Adjuvant AS01B",Completed,April 2008,June 2009,Actual,Actual,U.S. Army Medical Research and Materiel Command,Nekoye Otsyula,Principal Investigator,US Army Medical Research Unit - Kenya,Phase 1,Interventional,30,Actual,Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of solicited adverse events,Number of unsolicited adverse events,GlaxoSmithKline,Industry,United States Agency for International Development (USAID),U.S. Fed,NA,7 days,30 days,Number of serious adverse events,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,Kenya Medical Research Institute,Other,NA,NA,Occurrence and intensity of solicited symptoms on day of vaccination and Days 1-7 after each vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Occurrence and intensity of unsolicited symptoms over a 30-day follow-up period (day of vaccination and 29 subsequent days) after each vaccination,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCR5095,NCT00146692,A Trial of Improved Financial Access to Healthcare in Ghana,Impact of Improved Financial Access to Health Care on Morbidity Due to Severe Malaria and Healthcare Utilization Among Children 6 Months to Five Years of Age in a Hyper Endemic Area in Ghana: a Randomized Controlled Trial,Completed,April 2004,February 2005,Actual,Actual,London School of Hygiene and Tropical Medicine,"Evelyn Ansah, MD",Study Director,Dangme West / LSHTM,Phase 4,Interventional,NA,NA,Malaria,Prevalence of severe anaemia among children under five years of age after peak malaria transmission season.,All,6 Months,5 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Christopher Whitty, FRCP",Study Chair,LSHTM,2000,NA,NA,"Dangme West Health District, Ghana",Other,NA,NA,Dangme West District,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
REG-8,NCT00493922,Trial of Rapid Diagnostic Tests in Rural Ghana,An Individually Randomised Trial of Rapid Diagnostic Tests in Rural Ghana,Completed,July 2007,June 2009,Actual,Actual,London School of Hygiene and Tropical Medicine,"Evelyn K Ansah, MD MPH PhD",Principal Investigator,Ghana Health Services,Phase 4,Interventional,7263,Actual,Malaria; Bacterial Infections,NA,All,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The proportion of RDT test-negative patients who are prescribed an antimalarial in two settings: where there is microscopy and where diagnosis is on clinical basis,NA,Ghana Health Services,Other,NA,NA,Dangme West District,Two years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1280,NCT00385047,"A Study to Determine Whether 2 Investigational Malaria Vaccines Are Safe, Protective Against Malaria in Adults","Phase I/IIa Study of the Safety, Immunogenicity and Preliminary Efficacy After Sporozoite Challenge of FMP2.1/AS01B and FMP2.1/AS02A Candidate Malaria Vaccines Administered Intramuscularly at Months 0, 1, and 2 in Malaria-naive Adults Living in the United States",Completed,September 2006,September 2007,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Michele D. Spring, MD, M.S.P.H.",Principal Investigator,Walter Reed Army Institute of Research (WRAIR),Phase 1/Phase 2,Interventional,41,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of adverse events,NA,The PATH Malaria Vaccine Initiative (MVI),Other,GlaxoSmithKline,Industry,"Clinical Trials Center, Walter Reed Army Institute of Research",Up to 1 year,NA,NA,United States Agency for International Development (USAID),U.S. Fed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
09-0112,NCT01443130,Chloroquine for Malaria in Pregnancy,"A Randomized, Controlled Clinical Trial of Chloroquine as Chemoprophylaxis Versus Intermittent Preventive Therapy to Prevent Malaria in Pregnancy in Malawi",Completed,February 2012,January 2015,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 3,Interventional,900,Actual,Malaria,NA,Female,N/A,99 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of Placental Malaria Infection Based on Histology,NA,NA,NA,NA,NA,Blantyre Malaria Project - Queen Elizabeth Central Hospital,At delivery: Approximately 12-36 weeks after enrollment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The placenta was collected at the time of delivery for examination by histology to determine malaria infection. Malaria infection was concluded if histology identified parasites or malaria pigment in the placental tissue.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
200599,NCT02207816,"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","Extension to Study MALARIA-055 PRI (NCT00866619) for Evaluation of Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in Infants and Children in Africa",Completed,NA,"January 31, 2017",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,3084,Actual,Malaria,NA,All,42 Months,9 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of severe malaria meeting the primary case definition.,NA,NA,NA,NA,NA,NA,Starting January 2014 until the end of the 3-year follow-up period (Year 3).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"September 18, 2014",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
08-0008,NCT01169077,EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria,"A Phase I, Randomized, Controlled Dosage-Escalation Study of the Safety and Reactogenicity of the EP1300 Polyepitope DNA Vaccine Against Plasmodium Falciparum Malaria Administered Via Electroporation to Healthy Adults",Completed,August 2010,July 2012,Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,39,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,40 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The number of serious adverse events considered associated with the vaccine.,The number of subjects reporting solicited systemic adverse events of severity (grade 3) or higher.,NA,NA,NA,NA,Emory Children's Center - Pediatric Infectious Diseases,Reported at any point during follow-up.,Within 14 days after receiving any dose of vaccine.,The number of subjects experiencing spontaneous adverse events of severity (grade 3) or higher and considered associated with the vaccine.,NA,NA,The number of subjects reporting local reactogenicity of severity (grade 3) or higher.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Reported at any point during follow-up.,NA,Within 14 days after receiving any dose of vaccine.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL0903,NCT01178021,Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan,Estimating the Risk of Plasmodium Vivax Relapses in Afghanistan,Unknown status,January 2010,December 2014,Anticipated,Anticipated,University of Oxford,"Ghulam Rahim Awab, MD",Principal Investigator,Mahidol Oxford Research Unit,Phase 4,Interventional,600,Anticipated,Vivax Malaria,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Secondary vivax attack,NA,"National Malaria and Leishmaniasis Control Program, Afghanistan",Other,Mahidol University,Other,NA,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Completion of the 1-year (± 1 month) follow-up period without secondary vivax attack,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
201780,NCT02751294,A Study to Assess the Effects of Dissolution Profile on the Pharmacokinetics of Single Oral Doses of Tafenoquine Tablets and Tafenoquine Stable Isotope Labelled Solution,"A Randomized, Open-label, Single-period, Parallel-group Study in Healthy Subjects to Determine the Effects of Dissolution Profile on the Pharmacokinetics (Via Both Venous and Peripheral Micro-samples) of Single Oral 300 mg Doses of Tafenoquine (SB-252263) Tablets + 30 mg Tafenoquine Stable Isotope Labelled (SIL) Solution",Completed,May 2016,August 2016,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,14,Actual,"Malaria, Vivax",NA,Male,18 Years,55 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Ratio of the geometric means for the area under plasma concentration-time curve (AUC) for Tafenoquine X,NA,Medicines for Malaria Venture,Other,Parexel,Industry,GSK Investigational Site,"Samples will be collected at Pre-dose and 1, 2, 6, 9, 12, 15, 20, 24, 36, 48, 60, and 72 hours post dose on Day 1 and single sample on Day 7, 14, 21, 28, and 56",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Blood samples for PK analysis of TQ will be collected for evaluation of ratio of the geometric means (90% Confidence Interval [CI]) for the area under plasma concentration-time curve from 0 to time t (AUC [0-t]) and area under the concentration-time curve from 0 to infinity (AUC[0-inf]) for the treatment group dissolution profile X compared to Control.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EPI1601,NCT02991963,"Epidemiology of Malaria in Ubon Ratchathani, Thailand","Epidemiology of Malaria in Ubon Ratchathani, Thailand: a Case-control Study",Recruiting,NA,December 2018,Anticipated,Anticipated,University of Oxford,NA,NA,NA,N/A,Observational,660,Anticipated,Epidemiology,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Risk factors for Malaria infection,NA,Mahidol Oxford Tropical Medicine Research Unit,Other,NA,NA,Buntharik Hospital,2 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Risk factors for malaria infection in Ubon Ratchathani Province, Thailand",NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

        - Case (Malaria patient defined by positive RDT or blood smear):

          -  Patients of ≥ 6 months of age testing positive for malaria of any species as
             determined by a positive rapid diagnostic test (RDT) or asexual stage parasites on a
             smear of peripheral blood including individuals with more than one species of
             Plasmodium.

               -  Control (Non-malaria patient defined by negative RDT or blood smear):

          -  Patients > 6 months of age requiring a diagnostic test for malaria but testing
             negative for malaria by rapid diagnostic test (RDT) or asexual stage parasites on a
             smear of peripheral blood. Controls will be age and gender matched to individual cases
             at each study site (details below).

        Exclusion Criteria:

        Not willing to provide written informed consent.
      ",NA,NA,NA,NA,NA,NA,NA,NA,December 2016,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999909134,NCT00889616,"Phase I Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and Mali","Phase 1 Study of the Safety and Immunogenicity of BSAM-2/Alhydrogel +CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria in Adults in the US and in Bancoumana, Mali",Completed,"April 23, 2009","July 18, 2012",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Ruth D Ellis, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,400,Anticipated,Malaria,To assess safety and reactogenicity of BSAM-2/Alhydrogel + CPG 7909 in malaria-naive US adults and semi-immune Malian adults.,All,18 Years,50 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KMUH-IRB-980096,NCT01080989,The Sero-Prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands,The Sero-prevalence and Genetic Study for the Infectious Diseases and Metabolic Syndrome in Solomon Islands,Completed,March 2009,December 2011,Actual,Actual,Kaohsiung Medical University Chung-Ho Memorial Hospital,"Sheng-Hsiung Sheu, Dr",Study Chair,Kaohsiung Medical University Chung-Ho Memorial Hospital,N/A,Interventional,1477,Actual,Flavivirus Infection; Alphavirus Infections; Malaria; Parasitic Disease; Leptospirosis; Hypertension; Metabolic Syndromes,NA,All,N/A,N/A,Accepts Healthy Volunteers,Kaohsiung Medical University Chung-Ho Memorial Hospital,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,health screening for the community,NA,NA,NA,NA,NA,Kaoshing Medical University Chung-Ho Memorial Hospital,one per year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Survey the prevalence of intestinal parasitic diseases, flaviviral(Dengue and Japanese encephalitis), Alpha-viral(Chikungunya virus, Ross river virus), leptospiral and malarial infections, and metabolic syndromes(hypertension, diabetes mellitus, hyperlipidemia and gout).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
110027,NCT01205178,G6PD (Glucose-6-phosphate Dehydrogenase) Study to Evaluate Hemolysis Potential of TFQ (Tafenoquine),A Phase I Study to Investigate the Hemolytic Potential of Tafenoquine in Healthy Subjects With Glucose-6-phosphate Dehydrogenase Deficiency and the Safety and Tolerability of Tafenoquine in Acute Plasmodium Vivax Malaria Patients With Glucose-6-phosphate Dehydrogenase Deficiency,Completed,NA,"April 1, 2013",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,192,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"To evaluate the safety, tolerability, and hemolytic potential of TQ in G6PD-deficient female healthy volunteers compared with G6PD-normal female healthy volunteers. This will be done by measuring maximum absolute decline in Haemoglobin from baseline",NA,Medicines for Malaria Venture,Other,NA,NA,NA,2 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"July 2, 2009",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FTM1001,NCT01218932,Pharmacokinetic Study of Primaquine and Chloroquine in Healthy Subjects,"Phase 1, Open-Label Study to Evaluate Potential Pharmacokinetic Interaction of Orally Administered Primaquine and Chloroquine in Healthy Thai Adult Subjects",Completed,October 2010,March 2012,Actual,Actual,University of Oxford,"Podjanee Jittamala, MD",Principal Investigator,Mahidol Oxford Research Unit,Phase 1,Interventional,16,Actual,Vivax Malaria,NA,All,18 Years,60 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,AUC,NA,Mahidol University,Other,NA,NA,Hospital For Tropical Diseases,36 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Area under the plasma concentration time AUC 0-∞curve for primaquine and metabolites (mPQ) when given alone and together with chloroquine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999906135,NCT00341666,Immune Response Regulation in People Infected Concurrently With Malarial and Filarial Parasites,Regulation of Innate and Adaptive Immune Responses in Individuals Infected Concurrently With Malarial and Filarial Parasites,Completed,"April 3, 2006",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,360,Anticipated,Malaria; Filarial Infection,NA,All,1 Year,65 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","July 15, 2011",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999907148,NCT00471666,Medical Implications of Coinfection With Malaria and Filariasis Parasites,"Coinfection With Plasmodium Falciparum and Wuchereria Bancrofti: Clinical, Epidemiologic and Immunologic Implications",Completed,"May 7, 2007",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,1039,Anticipated,Malaria; Filariasis,NA,All,1 Year,20 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","January 31, 2012",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Faculty of Medicine, Pharmacy and Odonto-Stomatology (FMPOS)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999907198,NCT00508417,"Malaria Incidence in Infants in Bancoumana, Mali","Malaria Incidence in Infants in Bancoumana, Mali",Completed,"July 24, 2007",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,600,Anticipated,Malaria Infection; Malaria Incidence; Anemia,NA,All,6 Weeks,6 Months,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","February 11, 2011",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"National Institute of Allergy and Infectious Diseases (NIAID), 9000 Rockville Pi",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999910133,NCT01196520,Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM),Epidemiology of Burkitt Lymphoma in East Africa Children or Minors (EMBLEM),Recruiting,"May 24, 2010",NA,NA,NA,National Cancer Institute (NCI),"Sam M Mbulaiteye, M.D.",Principal Investigator,National Cancer Institute (NCI),N/A,Observational,6750,Anticipated,"Lymphoma, Non-Hodgkin; Malaria; Herpesvirus 4, Human",NA,All,N/A,15 Years,Accepts Healthy Volunteers,National Cancer Institute (NCI),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Burkitts Lymphoma,Malaria,NA,NA,NA,NA,NA,At enrollment,At enrollment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC051,NCT01816113,Phase Ia Study of ChAd63/MVA PvDBP,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Vivax Malaria Vaccine Candidates ChAd63 PvDBP Alone and With MVA PvDBP,Completed,April 2013,July 2014,Actual,Actual,University of Oxford,"Adrian V S Hill, MD",Principal Investigator,University of Oxford,Phase 1,Interventional,24,Actual,Malaria; Plasmodium Vivax,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"The safety in healthy volunteers of two new candidate malaria vaccines, ChAd63 PvDBP administered alone, and with MVA PvDBP, in a prime-boost regime.",NA,NA,NA,NA,NA,Centre for Clinical Vaccinology and Tropical Medicine,Up to 20 weeks post first vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To assess the safety of ChAd63 PvDBP when administered alone and in heterologous prime-boost with MVA PvDBP. Safety will be assessed by the frequency, incidence and nature of adverse events and serious adverse events arising during the study as well as abnormalities in Hematology and Biochemistry lab tests.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999909004,NCT00772642,Immune Parameters in the Cord Blood of Newborns Exposed to Malaria in the Womb,Profiling Immunological Parameters in the Cord Blood of Neonates Exposed to Plasmodium Falciparum in Utero,Completed,"October 8, 2008",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,120,Anticipated,Malaria,NA,Female,18 Years,99 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","September 10, 2010",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria Research and Training Center,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CBEHPP,NCT01836731,Impact Evaluation of Community-Based Health Programs in Rwanda,"Health Impact Evaluation of the ""Community-Based Environmental Health Promotion Programme"" in Rwanda",Completed,April 2013,"June 30, 2017",Actual,Actual,Georgetown University,"James P Habyarimana, PhD",Principal Investigator,Georgetown University,N/A,Interventional,8718,Actual,Diarrhea; Malaria,NA,All,N/A,5 Years,No,Georgetown University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of Diarrhea,NA,"National University, Rwanda",Other,New York University,Other,NA,2 weeks,NA,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,NA,Innovations for Poverty Action,Other,Bill and Melinda Gates Foundation,Other,The main outcome of the health impact evaluation trial will be 14 day recall self-reported diarrhoea in children under 5 years.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Emory University,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MCDC-SBMC,NCT01231880,School Based Malaria Control in Ugandan Schoolchildren,School-based Malaria Control: Impact of Intermittent Preventive Treatment on Malaria Morbidity and Cognitive Function in Ugandan School Children,Completed,February 2011,September 2012,Actual,Actual,Makerere University,"Joaniter I Nankabirwa, MSc CEB",Principal Investigator,Makerere University Kampala,Phase 3,Interventional,740,Actual,Malaria,NA,All,6 Years,14 Years,Accepts Healthy Volunteers,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Risk of Clinical Malaria,Cognitive function tests,Bill and Melinda Gates Foundation,Other,NA,NA,Mulanda Sub-district,1 year,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Fever(temperature greater or equal to 37.5 degrees centigrade or history of fever in past 24 hours) in presence of parasitemia.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Mean score in the cognitive function tests (Raven's Matrices test and Code transmission test),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCOA566B2401,NCT01256658,A Community Setting Study of Malaria After Systematic Treatment of Symptomatic Carriers of P. Falciparum With COA566 (Coartem®),"A Cluster Randomized, Single-centre, Controlled, Parallel,12-month Prospective Study and Additional 12-month Follow-up in Africa of Malaria Incidence in a Community Setting Following Systematic Treatment of P. Falciparum Asymptomatic Carriers With Artemether-lumefantrine (Coartem® / Coartem® Dispersible)",Completed,November 2010,July 2012,Actual,Actual,Novartis,Novartis Pharmaceuticals,Study Director,Novartis Pharmaceuticals,Phase 4,Interventional,14075,Actual,Malaria,NA,All,N/A,N/A,No,Novartis,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Number of Symptomatic Malaria Episode, RDT-confirmed, With Parasitemia ≥5000/μL (SMRC5000s) Per Person-year in Infants and Children (<5 Years) in Post Community Screening Campaign (CSC) at Month 12 (Per Cluster)",Change in Hemoglobin Level (g/dL) in Asymptomatic Carriers >6 Months of Age (Per Cluster),NA,NA,NA,NA,NA,Month 12 of period 1,Day 1 and day 28 of period 1,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Data is presented ""per cluster"". Number of Symptomatic malaria episode, RDT-confirmed, with parasitemia ≥5000/μL (SMRC5000s) per person-year in infants and children (<5 years) in post Community Screening Campaign (CSC) at month 12 was detected by Rapid Diagnostic Test (RDT) (using a blood sample from each participant) and later confirmed to have a parasite density ≥5000/uL by microscopy.
Number of SMRC5000: sum of all SMRC5000 for all infants and children (<5 years) in post CSC.
Person-year observed: sum of duration (in days) for all infants and children (<5 years) in post CSC present in study /365.25.
Number of SMRC5000 per person-year = number of SMRC5000/person-year observed.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Data is presented ""per cluster"". Change in hemoglobin levels from day 1 to day 28 was measured using the HemoCue® rapid test. This test was performed using a drop of blood collected from the fingertip of each asymptomatic carrier from Community Screening Campaign 1 (CSC1), > 6 months of age, at day 1 and at day 28.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR1935,NCT01976780,In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy,"In Vivo and In Vitro Efficacy of Artemisinin Combination Therapy in Kisumu County, Western Kenya",Completed,June 2013,December 2014,Actual,Actual,Global Emerging Infections Surveillance and Response System,"James F Cummings, MD",Study Chair,GEIS,Phase 4,Interventional,118,Actual,Malaria,NA,All,6 Months,65 Years,No,Global Emerging Infections Surveillance and Response System,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Ben Andagalu, MD",Principal Investigator,Kenya Medical Research Institute/Walter Reed Project,NA,Parasitological clearance rates by microscopy,NA,United States Army Medical Unit - Kenya,U.S. Fed,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"Walter Reed Project, Kombewa Clinic",72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Clearance rates for the first 72 hour period after first ACT dose in patients with uncomplicated P. falciparum malaria,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
140035,NCT02015091,Study of Controlled Human Malaria Infections to Evaluate Protection After Intravenous or Intramuscular Administration of PfSPZ Vaccine in Malaria-Naive Adults,"VRC 314: A Phase 1, Open-Label, Clinical Trial With Experimental Controlled Human Malaria Infections (CHMI) to Evaluate Safety and Durability of Protection Following Intravenous and Intramuscular Administration of PFSPZ Vaccine in Malaria-Naive Adults",Completed,"December 12, 2013","September 8, 2016",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Julie E Ledgerwood, D.O.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,40,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"To evaluate the safety and tolerability of the metabolicallyactive,non-replicating, Plasmodium falciparum sporozoite (PfSPZ) vaccine (PfSPZ Vaccine) in malaria-naive healthy adults following multiple-dose IV administration.","To evaluate the safety and tolerability of the metabolicallyactive,non-replicating, Plasmodium falciparum sporozoite(PfSPZ) vaccine (PfSPZ Vaccine) in malaria-naive healthyadults following multiple-dose IM administration.",NA,NA,NA,NA,NA,The period of follow-up for each vaccinated subject is through at least 24 weeks after the last vaccination.,The period of follow-up for each vaccinated subject is through at least 24 weeks after the last vaccination.,To determine if there is PfSPZ Vaccine-mediated protectionagainst infectious P. falciparum CHMI when the vaccine isadministered at 2.7 x 105 PfSPZ per injection by the IV routeusing a multi-dose schedule and the CHMI is administered at@...,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,At 4 weeks after CHMI.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
P27A_1_13,NCT01949909,Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A : Phase Ia/Ib,"Safety And Immunogenicity Of Novel Candidate Blood-Stage Malaria Vaccine P27A With Alhydrogel® Or GLA-SE As Adjuvant: A Staggered, Antigen And Adjuvant Dose-Finding, Randomized, Multi-Centre Phase Ia/Ib Trial",Completed,March 2014,July 2015,Actual,Actual,Centre Hospitalier Universitaire Vaudois,"François Spertini, MD",Principal Investigator,Centre Hospitalier Universitaire Vaudois (CHUV),Phase 1,Interventional,56,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Centre Hospitalier Universitaire Vaudois,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Salim Abdulla, MD",Principal Investigator,Bagamoyo Research and Training Center,NA,"To evaluate the safety of P27A with Alhydrogel or GLA-SE as adjuvant, in healthy European adults not previously exposed to the parasite Plasmodium falciparum and in healthy African adults previously exposed to the parasite",NA,"European Vaccine Initiative (EVI), Heidelberg, Germany",Other,European & Developing Countries Clinical Trials Partnership (EDCTP),Other,NA,15 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The safety profile will be assessed on the basis of immediate local and systemic reactogenicity measured from Day 0 to Day 28 after each vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NMRR91391379918375 ￼,NCT02348788,Artemether-lumefantrine vs Chloroquine for Uncomplicated P. Vivax Malaria in Malaysia,"Artemether-lumefantrine vs Chloroquine in Patients With Acute Non-severe P. Vivax Malaria in Sabah, Malaysia",Recruiting,January 2015,December 2017,Anticipated,Anticipated,Menzies School of Health Research,"Timothy William, MBBS, FRCP",Principal Investigator,"Ministry of Health, Malaysia",Phase 3,Interventional,98,Anticipated,Plasmodium Vivax Malaria Without Complication,NA,All,1 Year,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite clearance at 48 hours,NA,"Ministry of Health, Malaysia",Other,NA,NA,NA,48 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The difference in proportion of patients with negative microscopy for P. vivax asexual parasites at 48 hours after treatment with A-L compared to CQ.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVG47,NCT00376155,Comparison of Two Strategies for the Delivery of IPTc,Comparison of Two Strategies for the Delivery of Intermittent Preventive Treatment in Children (IPTc) in an Area of Seasonal Malaria Transmission,Completed,May 2006,February 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Kalifa Bojang, MD",Principal Investigator,"MRC Laboratories, The Gambia",Phase 4,Interventional,14000,Actual,Malaria,NA,All,3 Months,5 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria incidence (the number of OPD attendances with clinical malaria that meet the case definitions as indicated below during the surveillance period ) and the number of hospital admissions with malaria during the surveillance period.,Cost-effectiveness of the delivery system.,Medical Research Council,Other,NA,NA,MRC Laboratories,during malaria transmission period,during the study period,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
204853,NCT02737007,A Microdose Study in Healthy Subjects to Describe Intravenous Pharmacokinetics of GSK3191607,A Microdose Study to Describe the Intravenous Pharmacokinetics of GSK3191607 in Healthy Male Subjects Following Administration of [14C]-GSK3191607,Completed,NA,"May 12, 2016",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,6,Actual,"Malaria, Falciparum",NA,Male,18 Years,55 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Maximum observed concentration (Cmax) of GSK3191607 in plasma following a single intravenous (IV) microdose,Terminal phase half life (t1/2) of GSK3191607 following a single IV microdose,Hammersmith Medicines Research,Other,NA,NA,GSK Investigational Site,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion","Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",Time of occurrence of Cmax (tmax) of GSK3191607 following a single IV microdose,NA,NA,AUC(0-t) of GSK3191607 following a single IV microdose,AUC(0-infinity) of GSK3191607 following a single IV microdose,Systemic clearance (CL) of GSK3191607 following a single IV microdose,NA,NA,NA,NA,AUC(0-t) is the area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration.,NA,NA,NA,NA,NA,NA,GSK3191607 volume of distribution at steady state (Vss),Cmax of radioactive drug-related material (RDM) in plasma following a single IV microdose of [14C]-GSK3191607,NA,NA,NA,NA,NA,NA,AUC(0-infinity) is the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time.,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",RDM is a measure of total radioactivity. Cmax of RDM will be compared with that of the parent drug (GSK3191607).,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",T1/2 of RDM will be compared with that of the parent drug.,"April 18, 2016",Actual,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",Tmax of RDM will be compared with that of the parent drug.,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",AUC(0-t) of RDM will be compared with that of the parent drug.,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",AUC(0-infinity) of RDM will be compared with that of the parent drug.,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",Subjects will be asked to void their bladders before study treatment administration. A blank urine sample will be collected pre-dose.,T1/2 of RDM following a single IV microdose of [14C]-GSK3191607,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",NA,Tmax of RDM following a single IV microdose of [14C]-GSK3191607,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",NA,AUC(0-t) of RDM following a single IV microdose of [14C]-GSK3191607,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",NA,AUC(0-infinity) of RDM following a single IV microdose of [14C]-GSK3191607,"Pre-dose; and 0.25, 0.75, 1.5, 3, 6, 8, 12, 16, 24, 48, 72, 96, 120, 168, 216, 264, 312, and 336 hours following start of infusion",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Amount of RDM excreted in urine (Ae) following a single IV microdose of [14C]-GSK3191607,Pre-dose; and 0-24 hours and 24-48 hours after the start of infusion,NA,NA,NA,NA,NA
PQ Study 1,NCT02898779,"Metabolism and Pharmacokinetics of Primaquine Enantiomers in Human Volunteers, Study 1","Development of Safer Drugs for Malaria in U.S. Troops, Civilian Personnel, and Travelers: Clinical Evaluation of Primaquine Enantiomer",Recruiting,NA,September 2017,Anticipated,Anticipated,"University of Mississippi, Oxford","Babu L Tekwani, Ph.D",Principal Investigator,University of Mississippi Medical Center,Phase 1,Interventional,36,Anticipated,Malaria,NA,All,18 Years,60 Years,Accepts Healthy Volunteers,"University of Mississippi, Oxford",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Primary outcome: Plasma concentration of parent primaquine and carboyprimaquine following a single dose treatment with primaquine (racemate or enantiomers) not to exceed 45 mg,NA,NA,NA,NA,NA,University of Mississippi,between 0-24 Hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,This study would provide information on differential pharmacokinetics and metabolism of enantiomers of primaquine in normal human volunteers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"May 1, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_15_001,NCT02387580,Bioavailability Study of Oral OZ439 Prototype Granule Formulations Administered With Piperaquine Phosphate (PQP) Tablets,"A Phase I Bioavailability Study of Selected Oral Prototype Granule Formulations of OZ439 in Healthy Subjects, to Evaluate the Pharmacokinetics of OZ439 When Co-Administered With Piperaquine Phosphate Tablets in the Fasted State",Completed,April 2015,June 2015,Actual,Actual,Medicines for Malaria Venture,"Fiona Macintyre, PhD",Study Director,Medicines for Malaria Ventire,Phase 1,Interventional,48,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 Cmax,OZ439 AUC(0-168 h),Quotient Clinical,Other,NA,NA,Quotient Clinical,"Pre-dose, 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours post-dose","pre-dose, 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours post-dose",Piperaquine Cmax,NA,NA,Piperaquine AUC(0-168 h),NA,NA,NA,NA,NA,NA,OZ439 Maximum observed concentration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 Area under the plasma concentration (AUC) versus time curve,"Pre-dose, 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours and Day36 post-dose",Piperaquine Maximum observed concentration,"Pre-dose, 0, 0.5, 1, 2, 3, 4, 5, 6, 8, 12, 16, 24, 48, 72, 96 and 168 hours and Day36 post-dose",PQP Area under the plasma concentration versus time curve,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HREC 2016-2620,NCT02793388,A Trial on Supervised Primaquine Use in Ethiopia,A Randomized Controlled Trial on Supervised Primaquine Use in Ethiopia,Withdrawn,September 2016,September 2017,Anticipated,Anticipated,Menzies School of Health Research,NA,NA,NA,Phase 4,Interventional,0,Actual,Malaria,NA,All,6 Years,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The incidence risk of symptomatic P. vivax malaria over 4 months in patients enrolled with P. vivax or P. falciparum malaria.,NA,"Armauer Hansen Research Institute, Ethiopia",Other,NA,NA,NA,4 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-NCEZID-5039,NCT01088958,Effectiveness of Selling Micronutrient Sprinkles in Rural Kenya,"Diarrhea, Malaria, Anemia, and Helminthiasis Prevention Through Household-based Interventions in Rural Western Kenya: the Nyando Integrated Child Health and Education (NICHE) Project",Completed,January 2007,September 2014,Actual,Actual,Centers for Disease Control and Prevention,"Parminder S Suchdev, MD MPH",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,7200,Actual,"Anemia, Iron-deficiency",NA,All,6 Months,3 Years,Accepts Healthy Volunteers,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Product sales and use (coverage),NA,Safe Water and AIDS Project,Other,Kenya Medical Research Institute,Other,CDC/Kenya Medical Research Institute,Every 2 weeks,NA,NA,Global Alliance for Improved Nutrition,Other,NA,NA,NA,NA,NA,NA,NA,Biweekly household visits of selected cohort take place to assess purchases and use of health products and self reported morbidity outcomes. Household visits started at enrollment and continued throughout 2-year study period.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
016-2010,NCT01213433,Amodiaquine+Artesunate for Uncomplicated Malaria Treatment,"Amodiaquine+Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso",Completed,October 2010,April 2011,Actual,Actual,Centre Muraz,NA,NA,NA,Phase 4,Interventional,150,Actual,Uncomplicated Malaria,NA,All,6 Months,N/A,No,Centre Muraz,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Treatment failure at day 28,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,CRUN,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Treatment failure at day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
946238-1 (EOM),NCT02910934,Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique,Cost-effectiveness Evaluation of Vector Control Strategies in Mozambique,Recruiting,NA,"March 10, 2019",Anticipated,Anticipated,PATH,"Francisco Saute, Md, MSc, PhD",Principal Investigator,Centro de Investigacoes de Manhica,N/A,Interventional,4636,Anticipated,Malaria,NA,All,6 Months,N/A,Accepts Healthy Volunteers,PATH,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Molly Robertson, MA, MPH",Principal Investigator,PATH,NA,Cost per case averted in children five years of age and under at health facility level by adding Actellic-IRS,NA,United States Agency for International Development (USAID),U.S. Fed,Abt Associates,Industry,NA,24 months,NA,NA,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,NA,Mozambique: Ministry of Health (MISAU),Other,Manhica Health Research Foundation,Other,Incidence at health facility level by passive case detection (with enhanced surveillance and quality control) along with implementation costing data using an ingredients approach,"Carlos Chaccour, MD, MSc, PhD",Principal Investigator,ISGlobal,"Rose Zulliger, PhD",Principal Investigator,"US Presidents Malaria Initiative, Centers for Disease Control and Prevention",NA,NA,NA,NA,NA,"Abuchama Saifodine, PhD",Principal Investigator,"US Presidents Malaria Initiative, USAID",NA,NA,NA,NA,NA,"January 10, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999917006,NCT02942277,"Safety and Immunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum, at Full and Fractional Dosing in Adults in Mali","Phase 1 Dose Escalating, Double-Blind, Randomized Comparator Controlled Trial of the Safety andImmunogenicity of Pfs25M-EPA/AS01 and Pfs230D1M-EPA/AS01 Vaccines, Transmission Blocking Vaccines Against Plasmodium Falciparum at Full and Fractional Dosing in Adults in Mali",Recruiting,"October 6, 2016","April 30, 2018",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,900,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Incidence of local and systemic adverse events and SAEs (Bamako Arms 1a, 2a, 3a and Bamako Arms 1b, 2b, 3b, 4a, 4b)","Incidence of local and systemic adverse events and SAEs. (Field Arms 3c, 3d, 4c)",NA,NA,NA,NA,NA,"Assessment on Study days 0,1,3,7,14,28,29,31,35,42,56,84,112, 140,168,169,171,175,182,196,224, 252,280,308,336","Assessment of Study days - 7, 0, 1, 3, 7, 14, 28, 29, 31, 35, 42, 56, 84, 112, 140, 168, 169, 171, 175, 178, 182, 185, 189, 192, 196, 199, 203, 206, 210, 213, 217, 224, 252, 280, 308, 336",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Bamako Arms 1a, 2a, 3a: Assessment on Study days 0, 1, 3, 7, 14, 28, 29, 31, 35, 42, 56, 84, 112, 140, 168, 169, 171, 175, 182, 196, 224, 252, 280, 308, 336Bamako Arms 1b, 2b, 3b, 4a, 4b: Assessment on Study days 0, 1, 3, 7, 14, 28, 29, 31, 35, 42, 56, 84, 112, 140, 168, 169, 171, 175, 182, 196, 224, 252, 280, 308, 336",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
STOPMiP-KENYA,NCT01669941,"Efficacy of Intermittent Screening and Treatment or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya","Intermittent Screening and Treatment (IST) or Intermittent Preventive Treatment (IPT) With Dihydroartemisinin-Piperaquine, Versus IPT With Sulfadoxine-Pyrimethamine for the Control of Malaria in Pregnancy in Kenya: a Randomized Controlled Trial",Completed,August 2012,December 2015,Actual,Actual,Kenya Medical Research Institute,"Meghna Desai, PhD MPH",Principal Investigator,Centers for Disease Control and Prevention,Phase 4,Interventional,1546,Actual,Pregnancy; Malaria,NA,Female,N/A,N/A,No,Kenya Medical Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Abraham Katana, MD",Principal Investigator,Kenya Medical Research Institute,NA,Maternal malaria at delivery,NA,Centers for Disease Control and Prevention,U.S. Fed,Liverpool School of Tropical Medicine,Other,NA,Delivery,NA,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,NA,NA,NA,NA,NA,"Active or recent infection at delivery measured as the composite of peripheral and placental malaria, detected by: positive peripheral blood smear or RDT or positive placental smear, RDT, or histopathology",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DRI12805,NCT02497612,To Evaluate the Efficacy of a Single Dose Regimen of Ferroquine and Artefenomel in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria,"A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) With Artefenomel (OZ439) in Adults and Children With Uncomplicated Plasmodium Falciparum Malaria",Recruiting,NA,"February 1, 2019",Anticipated,Anticipated,Sanofi,Clinical Sciences & Operations,Study Director,Sanofi,Phase 2,Interventional,662,Anticipated,Plasmodium Falciparum Infection,NA,All,6 Months,70 Years,No,Sanofi,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of patients with Polymerase Reaction Chain (PCR)-adjusted Adequate Clinical and Parasitological Response (ACPR),NA,NA,NA,NA,NA,NA,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"July 25, 2015",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC064,NCT03084289,A Study to Assess the Safety and Immunogenicity of a Candidate Malaria Vaccine Using Novel Routes of Administration,A Phase I Study to Assess the Safety and Immunogenicity of Novel Routes of Administration of Plasmodium Falciparum Malaria Vaccine Candidate ChAd63 Encoding ME-TRAP.,Recruiting,NA,September 2017,Anticipated,Anticipated,University of Oxford,NA,NA,NA,Phase 1,Interventional,15,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of occurrence of emergent adverse events related to subcutaneous and intravenous administration of ChAd63 ME-TRAP in healthy malaria-naïve volunteers,NA,NA,NA,NA,NA,"Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital",3 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events (including solicited local or systemic reactogenicity signs and symptoms for 7 days following the vaccination; occurrence of unsolicited adverse events for 28 days following vaccination, and the occurrence of serious adverse events throughout the 3 month study duration).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"March 28, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ZimWorm,NCT01283165,Worm Infestation and Child Health in Zimbabwe,"Analysis on the Burden of Helminths-plasmodium Polyparasitism, Impact on Anaemia and Effects of Integrated School Based Parasite Control and Health Education in Zimbabwe",Completed,April 2003,December 2006,Actual,Actual,University of Zimbabwe,"Takafira Mduluza, PhD",Principal Investigator,University of Zimbabwe,N/A,Observational,1303,Actual,Integrated Control of Malaria and Polyparasitism,NA,All,5 Years,17 Years,Accepts Healthy Volunteers,University of Zimbabwe,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,This study was conducted to determine the prevalence of polyparasitism among primary school children living in rural and commercial farming areas in Zimbabwe.,NA,"National Institute of Health Research, Zimbabwe",Other,NA,NA,Biochemistry Department University of Zimbabwe,3 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"This study was conducted to determine the prevalence of polyparasitism, the impact of polyparasitism on anaemia, the effect of combined school based treatment for STHs, schistosomiasis, health education and prompt malaria treatment on anaemia and prevalence of polyparasitism in primary school children.",NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  all school children at the primary schools

        Exclusion Criteria:

          -  Very sick with known TB or HIV infection
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LSHTM-5664,NCT01308112,Prenatal Iron and Malaria Study,A Randomised Trial to Assess the Safety and Efficacy or Iron Supplementation in Kenyan Pregnant Women,Completed,October 2011,May 2013,Actual,Actual,London School of Hygiene and Tropical Medicine,"Hans Verhoef, PhD",Principal Investigator,"London School of Hygiene and Tropical Medicine, UK",Phase 4,Interventional,470,Actual,Malaria,NA,Female,15 Years,45 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Maternal Plasmodium infection,NA,University of Nairobi,Other,Wageningen University,Other,University of Nairobi,Parturition,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Assessed by LDH- and HRP2-based dipstick test and PCR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LOPRIM-1,NCT01935882,Low Dose Primaquine for Clearance of Gametocytes,A Double Blind Randomized Controlled Trial to Assess the Efficacy and Safety of Low Dose Primaquine for Clearance of Gametocytes in Asymptomatic Individuals Infected With P. Falciparum in Burkina Faso,Completed,September 2013,July 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,"Alfred Tiono, PhD, MD",Principal Investigator,Centre National de Recherche et de Formation sur le Paludisme,Phase 2/Phase 3,Interventional,360,Actual,Malaria; Asymptomatic Malaria; Plasmodium Falciparum,NA,All,2 Years,15 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Gametocyte carriage,NA,Radboud University,Other,"Centre National de Recherche et de Formation sur le Paludisme, Burkina Faso",Other,Centre National de Recherche et de Formation sur le Paludisme,14 days during follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Gametocyte prevalence at enrolment and on days 2, 3, 7, 10, 14 during follow-up.
The duration of gametocyte carriage in days will be estimated.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QA389,NCT01651416,Seasonal Malaria Chemoprevention Versus Home Management of Malaria in Children Under 5 Years in Ghana,An Individually Randomised Trial of Seasonal Malaria Chemoprevention Versus a Long-acting Artemisinin Combination Therapy for the Prevention of Malaria and Anaemia in Children Living in an Area of Extended Seasonal Transmission in Ghana.,Completed,July 2012,July 2013,Actual,Actual,"Centre for Global Health Research, Ghana","Harry Tagbor, DrPH",Principal Investigator,Kwame Nkrumah University of Science and Technology,Phase 4,Interventional,2400,Actual,Malaria; Anaemia,NA,All,3 Months,59 Months,No,"Centre for Global Health Research, Ghana",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of malaria cases,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,Ejisu-Juaben Municipality,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Incidence of malaria cases recorded by the community health workers (CHWs) and at the study health centres. Malaria will be defined as fever or history of fever combined with parasitologically confirmed P. falciparum infection by blood slide. Management of suspected malaria cases reporting to CHWs and health centres will be according to rapid diagnostic test (RDT).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HuLow-201605,NCT02614404,Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria,Imatinib's Effect on the Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria,Recruiting,November 2015,February 2018,Anticipated,Anticipated,HuLow,"Huynh D Chien, MD, PhD",Principal Investigator,Hue University,Phase 1/Phase 2,Interventional,20,Anticipated,Plasmodium Falciparum Malaria,NA,All,18 Years,50 Years,No,HuLow,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Francesco M Turrini, MD, PhD",Principal Investigator,"University of Turin, Italy",NA,Time to Parasite Clearance,28-day Cure Rate,Purdue University,Other,"University of Turin, Italy",Other,A Tuc,From baseline to the time point when the blood parasite count is zero (up to a maximum of 5 days),Day 28,NA,Università degli Studi di Sassari,Other,NA,NA,NA,Hue University,Other,NA,NA,"Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and qPCR analysis","Philip S Low, PhD",Principal Investigator,Purdue University,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment and no evidence of recurrent infection with the same parasite genotype after reduction of the asexual parasitemia. Follow up after treatment will only be performed in the case of complete clearance of parasites at D5 due to Imatinib treatment.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
43207799,NCT03067558,Acute Respiratory Infection Diagnostic Aids (ARIDA) Controlled Accuracy Evaluation Protocol,Acute Respiratory Infection Diagnostic Aids (ARIDA) for Children Under Five Years When Used in a Controlled Setting in Ethiopia: Study Protocol for Controlled Accuracy Evaluation,Not yet recruiting,NA,June 2017,Anticipated,Anticipated,Malaria Consortium,"Karin Kallander, PhD",Principal Investigator,Malaria Consortium,N/A,Observational,290,Anticipated,Pneumonia Childhood,NA,All,N/A,5 Years,Accepts Healthy Volunteers,Malaria Consortium,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Accuracy of ARIDA test device in children under 5 years with cough or difficulty breathing in a controlled setting.,Consistency of ARIDA test device in children under 5 years with cough or difficulty breathing in a controlled setting.,UNICEF,Other,"Federal Ministry of Health, Ethiopia",Other,NA,60-120 seconds,60-120 seconds,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Mean difference with standard deviation (precision) between ARIDA test device and simultaneous reference standard RR results.,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion criteria for child in accuracy and consistency evaluations for ARIDA test device
        and expert clinician:

        A child (2 to 59 months) who fulfils ALL of the following eligibility criteria will be
        included in the accuracy and consistency evaluations:

          1. Age 2 to 59 months

          2. Cough or difficulty breathing

          3. Parent or Guardian consent

        A young infant (0 to <2 months) who fulfils ALL of the following eligibility criteria will
        be included in the accuracy evaluation:

          1. Age 0 to <2 months

          2. Parent or Guardian consent

        Inclusion criteria for child in RR fluctuation evaluations:

        A child who fulfils ALL of the following eligibility criteria will be included in the
        respiratory rate fluctuation evaluation:

          1. Age 2 to 59 months

          2. Parent or Guardian consent

          3. Normal breathing

        Exclusion criteria for child/young infant in all elements of the study:

        A child/young infant with the following criteria will be excluded from all elements of this
        study:

          1. Presenting illness of greater than two weeks' duration.

          2. General danger signs:

               1. Newborns (<28 days): not feeding well, active convulsions/fits, chest indrawing,
                  fever (37.5 degrees or more), low body temperature (less than 35.5 degrees) or
                  movement only when stimulated/no movement at all.

               2. All other age groups: active convulsions/fits, unconscious/lethargic, not
                  breastfeeding/not drinking or vomiting everything.

          3. Signs of severe pneumonia:

               1. Chest indrawing or

               2. Stridor in a calm child

          4. IMNCI pink referral signs for severe disease including stridor, severe dehydration,
             severe persistent diarrhoea, very severe febrile disease, severe complicated measles,
             mastoiditis, complicated severe malnutrition, and severe anaemia.

          5. Parent or Guardian's age less than 16 years.

          6. No Parent or Guardian consent.

        In addition, a child with the following criteria will be excluded from the respiratory rate
        fluctuation evaluation:

          1. Cough or difficult breathing

          2. Fast breathing (see table 2)

        Additional exclusion criteria for child/young infant in an in-patient facility:

          1. Child/young infant being managed by barrier nursing (such as severe burns, child with
             neutropenia, severe infectious diseases).

          2. Child/young infant not eligible for research procedures as advised by the supervising
             clinician.
      ",NA,NA,NA,Mean difference with standard deviation of respiratory rate readings obtained by two simultaneous ARIDA test devices.,NA,NA,NA,NA,April 2017,Anticipated,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC-CGH-6029,NCT01326754,"Efficacy of Artemether-lumefantrine, Artesunate-amodiaquine and Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Malawi","Efficacy and Safety of the Dispersible Formulation of Artemether-lumefantrine, Co-formulated Artesunate-amodiaquine and Co-formulated Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Machinga District, Malawi",Completed,August 2011,June 2012,Actual,Actual,Centers for Disease Control and Prevention,"Jacek Skarbinski, MD",Principal Investigator,Centers for Disease Control and Prevention,N/A,Interventional,498,Actual,"Malaria, Falciparum",NA,All,6 Months,59 Months,No,Centers for Disease Control and Prevention,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Don Mathanga, MBBS PhD",Principal Investigator,University of Malawi College of Medicine,NA,Adequate clinical and parasitological response (ACPR),NA,University of Malawi College of Medicine,Other,NA,NA,Machinga District Hospital,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Absence of parasitaemia on day 42, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure.",NA,NA,NA,NA,NA,NA,NA,NA,Adequate clinical and parasitological response (ACPR),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IZ5856,NCT01328990,Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine for Intermittent Preventive Treatment in Children (IPTc),Pharmacokinetics of Sulfadoxine-pyrimethamine Plus Amodiaquine When Used for Malaria Intermittent Preventive Treatment in Children,Completed,April 2011,July 2011,Actual,Actual,London School of Hygiene and Tropical Medicine,"Badara Cisse, PhD",Study Chair,Universite Chiekh Anta Diop,Phase 1/Phase 2,Interventional,150,Actual,Malaria,NA,All,3 Months,59 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Paul Milligan, PhD",Study Director,London School of Hygiene and Tropical Medicine,NA,"Concentration of sulfadoxine, pyrimethamine, and desethylamodiaquine",NA,"Cheikh Anta Diop University, Senegal",Other,NA,NA,Universite Chiekh Anta Diop,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Concentration of the drugs will be measured at four time points.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRAA6910,NCT02009215,School-Based Treatment With ACT to Reduce Transmission,'SCHOOL-BASED TREATMENT WITH ACT TO REDUCE TRANSMISSION' (START-IPT): Evaluation of the Community Impact of Intermittent Preventive Treatment for Malaria in Ugandan Children: a Cluster Randomised Trial,Completed,February 2014,April 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,"Sarah G Staedke, MD, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 4,Interventional,10746,Actual,Malaria,NA,All,5 Years,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite prevalence measured by microscopy in final community survey,NA,"Infectious Diseases Research Collaboration, Uganda",Other,"University of California, San Francisco",Other,Infectious Diseases Research Collaboration,Approximately 1-4 months after completion of the intervention,NA,NA,University of Durham,Other,NA,NA,NA,NA,NA,NA,NA,"Proportion of thick blood smears that are positive for asexual parasites, as measured by microscopy.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1501,NCT02461186,Arterolane-PQP Versus DHA-PQP in Uncomplicated Falciparum Malaria in Eastern Myanmar,"An Open-label Randomized Trial to Assess the Therapeutic Efficacy of Arterolane-piperaquine Versus Dihydroartemisinin-piperaquine for the Treatment of Uncomplicated Falciparum Malaria in Eastern Myanmar, an Area of Emerging Artemisinin-resistant Falciparum Malaria",Withdrawn,June 2015,June 2017,Anticipated,Anticipated,University of Oxford,"Arjen M Dondorp, MD",Principal Investigator,Mahidol Oxfrod Tropical Medicine Research Unit,Phase 2/Phase 3,Interventional,0,Actual,Uncomplicated Falciparum Malaria; Artemisinin-resistant,NA,All,18 Years,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Peripheral blood parasite half-life,NA,Mahidol Oxford Tropical Medicine Research Unit,Other,"Department of Medical Research, Lower Myanmar",Other,NA,2 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Peripheral blood parasite half-life of the linear portion of the natural logarithm parasite clearance curve in patients with parasitaemia at inclusion >10,000 parasites/µL",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FosClinChildren,NCT01361269,Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria,Multicentre Evaluation of Fosmidomycin and Clindamycin in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in African Children,Unknown status,June 2011,December 2011,Anticipated,Anticipated,Zentopharm GmbH,"Saadou Issifou, MD PhD",Principal Investigator,"Medical Research Unit, Albert Schweitzer Hospital",Phase 2,Interventional,100,Anticipated,Malaria,NA,All,3 Years,10 Years,No,Zentopharm GmbH,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cure rate,NA,Albert Schweitzer Hospital,Other,Centro de Investigacao em Saude de Manhica,Other,"Medical Research Unit, Albert Schweitzer Hospital",Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Cure rate at day 28 will be determined by PCR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
45114-2,NCT01389557,"Impact of Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lampung Province, Sumatra","Evaluation of Impact Dihydroartemisinin-piperaquine Plus Primaquine on Malaria Transmission in Lempasing Village, Lampung Province, Southern Sumatra",Completed,February 2011,December 2011,Actual,Actual,Indonesia University,"Inge Sutanto, Md PhD",Principal Investigator,Univesity of Indonesia,Phase 4,Interventional,77,Actual,Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,Indonesia University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Presence of malaria (P. falciparum and P. vivax) parasites in blood spot,NA,NA,NA,NA,NA,"Inge Sutanto, Hanura Primary Health Center",6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Finger prick blood samples are collected for malaria blood smear. Thick and thin blood smears were stained with 3% Giemsa solution for 40 minutes and were read under binocular microscope with 1,000X magnification.",NA,NA,NA,NA,NA,NA,NA,NA,Presence of malaria (P. falciparum and P. vivax) parasites in blood spot,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PATH Outgrowers,NCT01397851,Stimulating Private Sector Malaria Control,Stimulating Private Sector Malaria Control: The Outgrower Opportunity,Completed,December 2010,December 2013,Actual,Actual,PATH,NA,NA,NA,N/A,Interventional,81597,Actual,Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,PATH,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cotton Yields,NA,NA,NA,NA,NA,National Malaria Control Centre,2010-2011 season (up to 1 year),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Farmer's cotton yields (kg delivered per household), as defined in the routine data collection system of the participating cotton outgrowing agribusiness",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
40461-B,NCT01425073,Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya,Discontinuation of Trimethoprim-sulfamethoxazole Prophylaxis in Adults on Antiretroviral Therapy in Kenya: a Randomized Trial,Completed,February 2012,October 2013,Actual,Actual,University of Washington,"Christina Polyak, MD, MPH",Principal Investigator,"Kenya Medical Research Institute/ Department of Medicine, University of Washington",N/A,Interventional,500,Actual,HIV Infections; Acquired Immunodeficiency Syndrome; Disease Progression; Immune System Diseases; Malaria; Parasitic Diseases; Pneumonia; Diarrhea; Infectious Disorder of Immune System,NA,All,18 Years,N/A,No,University of Washington,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Incidence of severe infectious morbidity (malaria, pneumonia, diarrhea)",NA,Kenya Medical Research Institute,Other,NA,NA,NA,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"A combined outcome of malaria, pneumonia or severe diarrhea.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1203M11234,NCT01754701,Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria,Acute vs. Delayed Iron: Effect on Red Cell Iron Incorporation in Severe Malaria,Completed,June 2013,May 2015,Actual,Actual,University of Minnesota - Clinical and Translational Science Institute,"Sarah Cusick, Ph.D.",Principal Investigator,University of Minnesota - Clinical and Translational Science Institute,N/A,Interventional,100,Actual,Iron Deficiency; Malaria; Nutrition; Global Health,NA,All,6 Months,59 Months,No,University of Minnesota - Clinical and Translational Science Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percent red blood cell iron incorporation on Day 0 in children in the immediate group vs. percent red blood cell iron incorporation on Day 28 in children in the delayed group,NA,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,NA,Mulago Hospital,56 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,All children will receive iron stable isotope 57Fe on Day 0 and iron stable isotope 58Fe on Day 28. Children in the immediate group will begin 27 days of daily iron syrup at home on Day 1. Children in the delayed group will begin 27 days of daily iron syrup at home on Day 29. All children will be assessed at the hospital at Day 28 and Day 56.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCZC58,NCT02288637,Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product,"Evaluation of a Novel Long Lasting Insecticidal Net and Indoor Residual Spray Product, Separately and Together, Against Malaria Transmitted by Pyrethroid Resistant Mosquitoes.",Recruiting,September 2014,April 2018,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Mark Rowland, Phd",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,3840,Anticipated,Malaria; Anaemia,NA,All,6 Months,14 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Franklin W Mosha, Phd",Principal Investigator,Kilimanjaro Christian Medical College,NA,Difference in prevalence of malaria infection in children 0.5-14 years between intervention arms,Difference in Entomological Inoculation Rate,NA,NA,NA,NA,District Muleba,up to 15 months,up to 15 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria infection tested using Pf/Pan specific Malaria Rapid Diagnostic Test,"William Kisinza, Phd",Principal Investigator,National Institute of Medical Research,"Immo Kleinshmidt, Phd",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,"Natacha Protopopoff, Phd",Principal Investigator,London School of Hygiene and Tropical Medicine,Malaria transmission measured by the Entomological Inoculation Rate (EIR) for each mosquito vector species.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
InstitutRD,NCT03074435,Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire,Insecticide Resistance Management in Burkina Faso and Côte d'Ivoire: Research on Vector Control Strategies,Enrolling by invitation,April 2016,April 2019,Anticipated,Anticipated,Institut de Recherche pour le Developpement,"Cédric Pennetier, PhD",Principal Investigator,Institut de Rehcerche pour le Développement,Phase 3,Interventional,18000,Anticipated,Malaria,NA,All,6 Months,20 Years,Accepts Healthy Volunteers,Institut de Recherche pour le Developpement,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria incidence,NA,"Institut de Recherche en Sciences de la Sante, Burkina Faso",Other,Institut Pierre Richet,Other,NA,continuous monitoring during 2 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria cases reported in local health system,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
REACH,NCT02492178,Bio-availability of Rectal Artesunate in Children With Severe Falciparum Malaria,NA,Completed,July 2015,October 2015,Actual,Actual,University of Oxford,NA,NA,NA,Phase 2,Interventional,82,Actual,Malaria,NA,All,N/A,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Pharmacokinetics profile of rectal artesunate,NA,Kinshasa School of Public Health,Other,NA,NA,Kinshasa School of Public Health,24 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The pharmacokinetics profile of rectal artesunate (the study drug), consisting of: area under the concentration-time curve; terminal elimination half-life; elimination clearance; apparent volume of distribution will be measured and compared to the pharmacokinetic profile of intravenous artesunate (the comparator).",NA,NA,NA,NA,NA,NA,NA,NA,Pharmacokinetics profile of rectal artesunate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2012139,NCT01976416,Novel Use Of Hydroxyurea in an African Region With Malaria,Novel Use Of Hydroxyurea in an African Region With Malaria,"Active, not recruiting",September 2014,October 2017,Anticipated,Anticipated,Indiana University,"Chandy C. John, M.D.",Principal Investigator,Indiana University,Phase 3,Interventional,200,Anticipated,Sickle Cell Anemia; Sickle Cell Disease; Malaria,NA,All,12 Months,47 Months,No,Indiana University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria incidence,NA,Doris Duke Charitable Foundation,Other,Makerere University,Other,Mulago Hospital Sickle Cell Clinic,12 months,NA,NA,"Mulago Hospital, Uganda",Other,NA,NA,NA,"Children's Hospital Medical Center, Cincinnati",Other,NA,NA,"Malaria is defined as the presence of P. falciparum or P. malariae on the peripheral smear of any child brought in for medical evaluation of fever. P. vivax, P. ovale and P. knowlesi are not known to be present in this region, but if a child is seen with suspected infection with any of these malaria parasites, this will also be recorded as a case of malaria.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP15C11,NCT02573857,A Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection,A Phase Ib Study to Characterise the Antimalarial and Transmission Blocking Activity of a Single Dose of DSM265 or OZ439 in Healthy Subjects With Induced Blood Stage Plasmodium Falciparum or Plasmodium Vivax Infection,Terminated,October 2015,May 2016,Actual,Actual,Medicines for Malaria Venture,"James McCarthy, Prof",Principal Investigator,Q-Pharm Pty Limited,Phase 1/Phase 2,Interventional,16,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Efficacy (PRR) of DSM265 or OZ439,Efficacy of OZ439 on P. vivax,Clinical Network Services (CNS) Pty Ltd,Industry,Q-Pharm Pty Limited,Industry,Q-Pharm Clinics,From Drug administration up to day 28 (+/-3 days) following inoculum,From Drug administration up to day 28 (+/-3 days) following inoculum,"Safety of DSM265 or OZ439 - AE, laboratory assessment, ECG, vital signs",Queensland Institute of Medical Research,Other,NA,NA,NA,NA,NA,NA,NA,Efficacy of a single 400 mg dose of DSM265 or a 200mg dose of OZ439. The primary efficacy variable is parasite reduction ratio (PRR) of asexual parasites based on qPCR analysis of blood level parasitemia pre-dose and following administration of study drug.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,To establish the minimum effective OZ439 dose required to achieve P. vivax parasite clearance from the blood of healthy participants.,From challenge inoculum (day 0) up to day 28 (+/-3 days),"Assessement of Adverse Events (AE) (unexpected toxicities, adverse events encountered during or after investigational drug administration), safety laboratory parameters, ECGs and vital signs throughout the study.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BMGF2b,NCT02098590,Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection,Chemoprophylaxis and Plasmodium Falciparum NF54 Sporozoite Immunization Challenged by Heterologous Infection,Completed,October 2014,November 2015,Actual,Actual,Radboud University,"Robert W Sauerwein, Prof",Principal Investigator,Radboud University,N/A,Interventional,40,Actual,Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasitemia,NA,Bill and Melinda Gates Foundation,Other,NA,NA,Radboud university medical center,day 1 - 28 after malaria challenge infection,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The effectiveness of CPS-immunization with NF54 sporozoites to protect against malaria challenge infection with heterologous NF135.C10 or NF166.C8 sporozoites will be determined by the time to parasitemia in immunized versus non-immunized volunteers after the challenge infection.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FY15-G04-6990,NCT02926625,Universal Versus Conditional Three-day Follow-up Visit for Children With Unclassified Fever,Universal Versus Conditional Three-day Follow-up Visit for Children With Unclassified Fever at the Community Level: A Study to be Conducted in Ethiopia,Enrolling by invitation,November 2015,April 2017,Anticipated,Anticipated,Malaria Consortium,"Karin Kallander, MSc, PhD",Principal Investigator,Malaria Consortium,Phase 4,Interventional,4284,Anticipated,Fever,NA,All,2 Months,59 Months,No,Malaria Consortium,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Treatment failure,NA,Karolinska Institutet,Other,Centers for Disease Control and Prevention,U.S. Fed,Ethiopia,Day 7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Proportion of children with non-severe febrile illness who, after initial evaluation by a HEW using iCCM algorithm, are not treated for malaria, pneumonia, or diarrhea and who subsequently decline clinically (defined as death, hospitalization, or the development of one or more danger signs).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Sevuparin/DF02_TSM02,NCT01442168,Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria,"A Phase I/II, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study of Sevuparin/DF02, as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria",Terminated,September 2011,January 2014,Actual,Actual,Modus Therapeutics AB,"Anna Leitgeb, PhD",Study Director,Modus Therapeutics AB,Phase 1/Phase 2,Interventional,53,Actual,"Malaria, Falciparum",NA,All,18 Years,65 Years,No,Modus Therapeutics AB,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Dose limiting toxicities according to specified criteria,Area under the curve of late stage peripheral blood parasitemia over time (Part 2).,University of Oxford,Other,NA,NA,NA,During treatment and 14 days post treatment follow-up.,72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SEN11.16,NCT01449045,Trial of Malaria Seasonal IPTc Combined With Community Case Management,"Cluster Randomized Trial of Malaria Seasonal IPTc Combined With Community Case Management in Saraya District, SE Senegal",Completed,July 2011,February 2012,Actual,Actual,"Cheikh Anta Diop University, Senegal","Oumar Gaye, PhD",Study Director,"Cheikh Anta Diop University, Senegal",Phase 3,Interventional,4554,Actual,Malaria,NA,All,3 Months,10 Years,Accepts Healthy Volunteers,"Cheikh Anta Diop University, Senegal",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Paul Milligan, PhD",Study Chair,London School of Hygiene and Tropical Medicine,NA,Number of children under 10 years of age with clinical malaria,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,University Cheikh Anta Diop,up to 24 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,children under 10 years age presenting symptoms of malaria with fever (or history of fever in the previous 48 hours) with a positive Rapid Diagnostic Test or positive blood slides,"Badara Cisse, PhD",Study Chair,"Cheikh Anta Diop University, Senegal",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITMP0308,NCT00852423,Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria,Safe and Efficacious Artemisinin-based Combination Treatments for African Pregnant Women With Malaria,Completed,June 2010,April 2015,Actual,Actual,"Institute of Tropical Medicine, Belgium","Umberto D'Alessandro, MD",Study Chair,Institute Tropical Medicine Belgium and MRC Unit in The Gambia,Phase 3,Interventional,3428,Actual,Malaria in Pregnancy,NA,Female,15 Years,N/A,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Tinto Halidou, PharmD",Principal Investigator,Centre Muraz,NA,Treatment Failure (PCR adjusted),Safety profiles including significant changes in relevant laboratory values,"National Institute for Medical Research, Tanzania",Other,Kwame Nkrumah University of Science and Technology,Other,NA,Day 63,Until delivery,NA,Centre Muraz,Other,NA,NA,NA,University of Malawi College of Medicine,Other,"Tropical Diseases Research Centre, Zambia",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Institute of Tropical Medicine(KIT), Amsterdam",Other,Liverpool School of Tropical Medicine,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BACHMI-01,NCT01771848,Optimization of Controlled Human Malarial Infection by Injection of P. Falciparum Sporozoites in Non-Immune Adults,A Study to Optimize Controlled Human Malarial Infection by Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults,Completed,December 2012,July 2013,Actual,Actual,Sanaria Inc.,"Pedro L Alonso, MD, Ph.D.",Principal Investigator,"Barcelona Centre for International Health Research (CRESIB), Hospital Clínic-Universitat de Barcelona",Phase 1,Interventional,36,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Infectivity of the administration regimens,NA,Barcelona Centre for International Health Research,Other,NA,NA,NA,Study day 6 to day 90 post challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,For each trial stage (A and B) the infectivity of the three administration regimens will be assessed by thick film microscopy and q-PCR for P. falciparum DNA. The time from parasite inoculation to first detection of blood stage parasitemia will be assessed by thick blood film microscopy.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
115055,NCT02374450,"A Surveillance Study of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Children in Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine","A Prospective Study to Estimate the Incidence of Diseases Specified as Adverse Events of Special Interest, of Other Adverse Events Leading to Hospitalisation or Death, and of Meningitis in Infants and Young Children in Sub-Saharan Africa Prior to Implementation of the RTS,S/AS01E Candidate Vaccine",Recruiting,NA,"May 30, 2022",Anticipated,Anticipated,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,N/A,Interventional,47074,Anticipated,Malaria,NA,All,N/A,5 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of AESI,Occurrence of other AE leading to hospitalisation or death,AMP (Agency Preventive Medicine),Other,"Quintiles, Inc.",Industry,NA,Enrolled children will be followed up through home visits for a total period of 44 months.,Day 0 to Month 44,Occurrence of aetiology confirmed meningitis,RAFT (Francophone Africa Network for Telemedicine),Other,NA,NA,NA,The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,"Acute Disseminated Encephalomyelitis (ADEM), encephalitis, Guillain Barré Syndrome, hypotonic-hyporesponsive episode, generalised convulsive seizure. Intussusception, hepatic insufficiency, renal insufficiency. Intussusception, hepatic insufficiency, renal insufficiency. Juvenile chronic arthritis, Stephen-Johnson syndrome/toxic epidermal necrolysis, Henoch-Schonlein purpura, Kawasaki disease. Diabetes mellitus type I, thrombocytopenia, anaphylaxis.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"AEs were assessed in children <5 years old, included in active or enhanced hospitalisation surveillance, prior to implementation of RTS,S/AS01E.",Day 0 to Month 44,"Aetiology confirmed meningitis was assessed in children <5 years old, included in active or enhanced hospitalisation surveillance, prior to implementation of RTS,S/AS01E.",NA,NA,"October 5, 2015",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TPS_210_202_01033/01034/01035,NCT01456858,Insecticide Treated Polyethylene Sheeting for Prevention of Malaria in Emergencies,Insecticide Treated Polyethylene Sheeting for Prevention of Malaria in Emergencies: an Observational Cohort Study in a Refugee Setting in Sierra Leone,Completed,December 2003,July 2004,Actual,Actual,The Mentor Initiative,"Matthew R Burns, BSc MSc PhD viva pending",Principal Investigator,Wageningen University,Phase 3,Interventional,222,Actual,Malaria,NA,All,4 Months,36 Months,Accepts Healthy Volunteers,The Mentor Initiative,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria Incidence,NA,ECHO,Other,UNHCR Country Office Freetown,Other,The Mentor Initiative,8 months,NA,NA,World Health Organization,Other,NA,NA,NA,Wageningen University,Other,London School of Hygiene and Tropical Medicine,Other,"The primary outcome was the malaria incidence rate between children in each study arm (ITPS V's UPS) in each refugee camp. Between Dec 2003 and July 2004, daily monitoring of children in both camps was conducted from health screening points. Any child presenting with fever or reported fever in the last 24 hours was administered a clinical questionnaire based on the Integrated Management of Childhood Illness (IMCI), after which a RDT was taken to confirm malaria positivity. Malaria incidence rate was estimated as the total number of malaria episodes per person year over the course of the trial.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,National Malaria Control Programme Sierra Leone,Other,Institut de Recherche pour le Developpement,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MC-003,NCT01500980,Malaria Challenge in Healthy Volunteers,Infection-Treatment-Vaccination for Plasmodium Falciparum,Completed,December 2011,November 2012,Actual,Actual,Seattle Biomedical Research Institute,"Sara Healy, M.D. MPH",Principal Investigator,Seattle Biomedical Research Institution,Phase 1,Interventional,36,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Seattle Biomedical Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Microscopic evaluation of peripheral blood smears,qRT-PCR,NA,NA,NA,NA,Seattle Biomedical Research Institute's Malaria Clinical Trials Center,Up to 182 days,Up to 182 days,Number of subjects with adverse events,NA,NA,NA,NA,NA,NA,NA,NA,NA,Detection for evidence of patent parasitemia and time to parasitemia following challenge with homologous P. falciparum sporozoites in subjects with confirmed exposure to P. falciparum sporozoites and early liver stage parasites only,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,qRT-PCR evaluation for detection of subpatent parasitemia following a single episode of ITV,up to 182 days,Occurrence of solicited and unsolicited adverse events (AEs) and serious adverse events (SAEs) during the study period,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LihirMC,NCT02605720,Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns,Electrocardiographic Safety Evaluation of Monthly Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns to Block Malaria Transmission,Completed,September 2015,February 2016,Actual,Actual,Lihir Medical Centre,NA,NA,NA,Phase 3,Interventional,78,Actual,Malaria,NA,All,3 Years,49 Years,Accepts Healthy Volunteers,Lihir Medical Centre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change in QTcF interval (Fridericia's correction QT interval) after study drugs administration compared to baseline,Plasma piperaquine concentrations after study drugs,Walter and Eliza Hall Institute of Medical Research,Other,Papua New Guinea Institute of Medical Research,Other,Lihir medical Centre,Day 58,Day 58,NA,Barcelona Institute for Global Health,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UniHD007,NCT02696928,Methylene Blue Against Vivax Malaria in Ethiopia,Feasibility of Methylene Blue-based Combination Therapy in the Radical Treatment of Adult Patients With Plasmodium Vivax Malaria in Ethiopia: a Randomised Controlled Pilot Trial,Not yet recruiting,April 2016,January 2018,Anticipated,Anticipated,Heidelberg University,"Olaf Müller, Prof. Dr.",Principal Investigator,Heidelberg University,Phase 2,Interventional,99,Anticipated,Vivax Malaria,NA,All,18 Years,N/A,No,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Study feasibility,NA,Ludwig-Maximilians - University of Munich,Other,Jimma University,Other,NA,180 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Patient recruitment rates,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CCOA566A2424,NCT01228344,Surveillance of Effectiveness/Safety of Artemether-lumefantrine in Patients With Malaria,Surveillance for the Effectiveness and Safety of Artemether-lumefantrine in Pediatric and Adult Patients With Malaria,Completed,NA,"September 30, 2015",Actual,Actual,Novartis Pharmaceuticals,Novartis Pharmaceuticals,Study Director,Novartis Pharmaceuticals,N/A,Observational,324,Actual,Malaria,NA,All,N/A,N/A,No,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Effectiveness: Resolution of clinical signs and symptoms after artemether-lumefantrine treatment start,NA,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,"Centers for Disease Control and Prevention,GA",4 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Any male or female infant, child or adult patient diagnosed with malaria who received
             artemether-lumefantrine and was reported to the CDC. Malaria may be clinically
             suspected or confirmed (microscopically, and/or by polymerase chain reaction [PCR],
             and/or rapid diagnostic test [RDT]).

        Exclusion Criteria:
      ",NA,NA,NA,NA,NA,NA,NA,NA,"May 1, 2010",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1605,NCT02992119,Malaria Vaccine Safety and Immunogenicity Study in Healthy Adults,"Safety and Immunogenicity Evaluation of the Malaria Vaccine, RTS,S/AS01, in Healthy Thai Adults",Recruiting,NA,March 2018,Anticipated,Anticipated,University of Oxford,"Lorenz von Seidlein, MD",Principal Investigator,Mahidol-Oxford Tropical Medicine Research Unit (MORU),Phase 2,Interventional,190,Anticipated,Malaria Vaccine,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of serious adverse events,Occurrence of serious adverse events,NA,NA,NA,NA,"Hospital of Tropical Diseases, Faculty of Tropical Medicine, Mahidol University",29 days after last vaccination,6 months,The change of concentration of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody) one month after the first dose,NA,NA,The change of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody) one month after the second dose,The change of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody) one month after the third dose,The change of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody) at month six after first dose,NA,NA,NA,NA,"Occurrence of serious adverse events (SAEs) from the date of the first vaccination to 29 days after the last vaccination, according to the MedRA classification.",NA,NA,NA,NA,NA,NA,The change of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody) at month two after first dose,NA,NA,NA,NA,NA,NA,NA,"Occurrence of SAEs during the whole study period, i.e. during a 6 month follow up period from the receipt of first vaccination, according to the MedRA classification.",1 months,"For groups 1 to 7, the concentration of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody), one month after the first dose (at Study month 1).",2 months,"For groups 1 to 6, the concentration of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody), one month after the second dose (at Study month 2)","June 4, 2017",Actual,3 months,"For groups 1 to 7, the concentration of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody), one month after the third dose (at Study Month 3)",6 months,"For groups 1 to 7, the concentration of antibodies against Plasmodium falciparum circumsporozoite (anti-CS antibody), at six months after the first dose (at Study Month 6).",2 months,For group 7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BSPZV1,NCT02132299,"Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults","Phase 1, Dose Escalation, Randomized Controlled Trial to Evaluate the Safety, Immunogenicity and Efficacy of Intravenously Administered Attenuated Plasmodium Falciparum Sporozoite Vaccine (PfSPZ Vaccine) in Tanzanian Adults",Completed,April 2014,August 2015,Actual,Actual,Sanaria Inc.,"Salim Abdulla, MD, PhD",Principal Investigator,Ifakara Health Institute,Phase 1,Interventional,67,Actual,Malaria; Plasmodium Falciparum Malaria,NA,Male,18 Years,35 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety and tolerability endpoints,Protective Efficacy after CHMI with PfSPZ Challenge (NF54) - CHMI Endpoints,Ifakara Health Institute,Other,Swiss Tropical & Public Health Institute,Other,"Bagamoyo Research and Training Center, Ifakara Health Institute, Kingani Estate, PO Box 74",Vaccination to CHMI (or 28 days after last vaccination); CHMI to 28 days after CHMI,CHMI to 28 days after CHMI,NA,Tanzania Commission for Science and Technology,Other,NA,NA,NA,NA,NA,NA,NA,"Solicited local (IV site) and systemic AEs (AEs) observed in the 7 days after each vaccination and each CHMI.
Unsolicited AEs observed after the first vaccination until day 28 after the last vaccination for volunteers who do not undergo CHMI#1 (e.g. Group 1, those who do not complete the CHMI portion in Groups 2 and 3, and volunteers in Group 4).
Unsolicited AEs observed after the first vaccination until day 28 after the CHMI#1 for volunteers who undergo CHMI#1 3 weeks after the last vaccination (e.g. Groups 2 and 3).
Unsolicited AEs observed from day CHMI#2 (which occurs 24 weeks after the last vaccination) until day 28 after CHMI#2 (e.g. Groups 2-5).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Number of volunteers that remain parasite negative in each group through day 28 of follow up after CHMI with PfSPZ Challenge (NF54) IV inoculation.
Three weeks after their last immunization, volunteers in Groups 2 and 3 will under go their first CHMI with 3.2 x 10^3 PfSPZ Challenge (NF54) administered IV. Twenty-four weeks after the last immunization, volunteers from Groups 2 and 3 who underwent the first CHMI and did not become infected will have a second CHMI by IV injection of 3.2x10^3 PfSPZ Challenge (NF54). Volunteers in Groups 4 and 5 will only participate in the second CHMI assessment.
After CHMI, volunteers will be followed for evidence of infection with blood smears for 28 days.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Bhutan_APMEN_CQ PQ_2013,NCT01716260,Safety and Efficacy of Chloroquine and Primaquine for Vivax Malaria in Bhutan,Parasitic Clearance and Recurrence Rates Among Patients With Vivax Malaria on Chloroquine and Primaquine Therapy,Completed,January 2013,October 2015,Actual,Actual,Menzies School of Health Research,NA,NA,NA,N/A,Observational,24,Actual,Vivax Malaria,NA,All,1 Year,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Chloroquine efficacy for P.vivax infections in Bhutan.,NA,"Ministry of Health, Bhutan",Other,NA,NA,Vector Diseases Control Program,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The purpose is to study the efficacy of Chloroquine alone by recording recrudescent rates and parasitic clearance in P.vivax patients who are given a standard dose of Chloroquine treatment.,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  >12 months of age

          -  infection with P.vivax parasitaemia monoinfection

          -  presence of axillary temperature >37.5 degrees or history of fever during the past 24
             hours

          -  ability to swallow oral medication

          -  ability and willingness to comply with the study protocol for the duration of the
             study, including 12 months follow up

          -  informed consent from the patient/parent/guardian in the case of children

        Exclusion Criteria:

          -  Presence of general danger signs in children aged under 5 years or signs of severe
             malaria according to the definitions of WHO

          -  Presence of severe malnutrition (defined as a child whose growth standard is below -3
             z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm
             circumference < 110 mm);

          -  History of haemolysis or severe anaemia

          -  Acute anaemia <7 mg/dL

          -  Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute
             lower respiratory tract infection, severe diarrhoea with dehydration) or other known
             underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases,
             HIV/AIDS);

          -  Regular medication, which may interfere with antimalarial pharmacokinetics

          -  History of hypersensitivity reactions or contraindications to any of the medicine(s)
             being tested or used as alternative treatment(s)

          -  a positive pregnancy test or lactating
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
OXTREC 2-16,NCT02739763,Controlled Human Malaria Infection in Semi-Immune Kenyan Adults. (CHMI-SIKA),Controlled Human Malaria Infection (CHMI) to Assess Human Immunity to P. Falciparum Using Sporozoites Administered by Direct Venous Inoculation,Recruiting,May 2016,November 2020,Anticipated,Anticipated,University of Oxford,"Philip Bejon, MD,PhD",Principal Investigator,KEMRI Wellcome Trust Research Programme and University of Oxford,Phase 1,Interventional,200,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Infectivity of PfSPZ (malaria infection) as determined by quantitative PCR,NA,KEMRI-Wellcome Trust Collaborative Research Program,Other,Sanaria Inc.,Industry,NA,day 7 to day 21,NA,NA,KEMRI Centre for Clinical Research,Other,NA,NA,NA,Pwani University,Other,University of Cambridge,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Wellcome Trust Sanger Institute,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TIP3,NCT01627951,Comparison of Three Plasmodium Falciparum Isolates in a Controlled Human Malaria Infection,"Comparison of NF54, NF135 and NF166 Strains of Plasmodium Falciparum in a Controlled Human Malaria Infection (TIP3)",Completed,August 2012,November 2012,Actual,Actual,Radboud University,"Perry van Genderen, MD PhD",Principal Investigator,"Havenziekenhuis, Rotterdam",N/A,Interventional,15,Actual,Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Difference in kinetics of infection between groups infected with NF54, NF133 and NF166, as defined by a mathematical model that takes into account multiple measurements of parasitaemia",NA,"Havenziekenhuis, Rotterdam",Other,NA,NA,NA,between day 5 and day 21,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Parasitaemia will be measured retrospectively by QRT-PCR in twice daily drawn venous whole blood, from day 5 post-infection until day of thick smear positivity, or else until day 21 post-infection if volunteers have not yet developed a positive thick smear before then. All these data points will be fed into a mathematical model that amalgamates them to calculate an outcome variable with one single value for burden of (liver-stage) infection and one for (blood-stage) multiplication factor.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IZ70Z0_123900/1,NCT01634945,Efficacy of Iron Fortified Complementary Food and IPT of Malaria in Young Children in Côte d'Ivoire,"Aetiology, Prevention and Control of Anaemia in Sub-Saharan Africa - Work Package 2: Efficacy Study: Efficacy of 2 Iron Fortified Porridges and IPT for the Prevention of Anemia in Young Children in Côte d'Ivoire.",Completed,April 2012,May 2013,Actual,Actual,Swiss Federal Institute of Technology,"Rita Wegmüller, Doctor",Principal Investigator,Swiss Federal Institute of Technology,N/A,Interventional,629,Actual,Anemia,NA,All,12 Months,36 Months,No,Swiss Federal Institute of Technology,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Hemoglobin,NA,Swiss Tropical & Public Health Institute,Other,Swiss National Science Foundation,Other,Hopital General de Taabo Cite,9 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The study population will consist of 12 to 36-month-old infants in villages covered by the Taabo DSS site. Assuming a mean Hb of 97.3±19.6 g/l and that an increase of 8 g/l in Hb would be clinically relevant, and allowing for a dropout rate of 20%, we calculated that 125 infants per group were initially needed to achieve a power level of 90% at a 5% level of significance.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DBS-ALU,NCT02742285,Lumefantrine in Venous Plasma Versus Dried Capillary Blood Spot,Comparison of Lumefantrine Concentrations Measured in Venous Plasma Versus in Dried Capillary Blood Spot Samples in Healthy Volunteers.,Recruiting,May 2016,June 2016,Anticipated,Anticipated,Thierry Buclin,"Thierry Buclin, Professor",Principal Investigator,"Division of Clinical Pharmacology, University Hospital, Lausanne, Switzerland",Phase 4,Interventional,16,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Thierry Buclin,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Concordance of concentrations of lumefantrine measured in dried capillary blood spot samples (DBS) and in plasma, at different time-points after the administration of a single oral adult dose of artemether-lumefantrine.",NA,NA,NA,NA,NA,Division of Clinical Pharmacology,Within the first two weeks after drug intake,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Mini Donor Bank,NCT02810613,Leiden University Medical Center Mini Donor Bank,NA,Not yet recruiting,July 2016,NA,NA,NA,Leiden University Medical Center,NA,NA,NA,N/A,Observational,1000,Anticipated,Malaria; Schistosoma Mansoni; Schistosoma Haematobium; Diabetes; Asthma,NA,All,18 Years,65 Years,Accepts Healthy Volunteers,Leiden University Medical Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"A collection of samples for the purpose of (bio)medical laboratory assays including immunological, metabolic, transcriptional or biological analyses.",NA,NA,NA,NA,NA,NA,10 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"collection of samples for the purpose of biomedical assays, e.g. biobanking of samples for different assays, each one of which has a separate objective",NA,NA,NA,NA,NA,NA,NA,NA,"A collection of samples for the purpose of (bio)medical laboratory assays including immunological, metabolic, transcriptional or biological analyses.",Non-Probability Sample,"
        Inclusion Criteria:

          1. Subject is aged ≥ 18 and ≤ 65 years and in good health.

          2. Subject has adequate understanding of the procedures of the study.

          3. Subject is able to communicate well with the investigator.

          4. Subject has signed informed consent.

          5. Subject refrains from donation to the Sanquin blood bank.

        Exclusion Criteria:

          1. Previous vasovagal collapse during venepuncture.

          2. For female participants: pregnancy or lactation.

          3. Presence of any chronic systemic condition, which could compromise the health of the
             volunteer when performing venepuncture or interfere with the interpretation of
             immunological or metabolic test results.

          4. Chronic use of immunosuppressive drugs.

          5. Total blood volume donated exceeding >500 mL in the past 4 months.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ROSI_v03_22072015,NCT02694874,Rosiglitazone Adjunctive Therapy for Severe Malaria in Children,Rosiglitazone Adjunctive Therapy for Severe Malaria in Children,Recruiting,February 2016,August 2018,Anticipated,Anticipated,Centro de Investigacao em Saude de Manhica,"Eusebio Macete, PhD",Study Director,Fundaçao Manhiça,N/A,Interventional,210,Anticipated,Malaria,NA,All,12 Months,12 Years,No,Centro de Investigacao em Saude de Manhica,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change in serum Ang-2 levels in the first 96 hours of hospital admission.,NA,"University Health Network, Toronto",Other,Barcelona Institute for Global Health,Other,Centro de Investigação em Saude da Manhiça,first 96 hours of hospital admission.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,We will assess the effect of the intervention (vs. placebo) on Ang-2 levels as a biomarker of severe disease in severe malaria,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR # 1849,NCT01624337,Malaria Prevention Cambodia,"A Randomized, Double Blind, Placebo-controlled Clinical Trial of Monthly DHA-piperaquine for Malaria Prevention in Cambodia.",Terminated,May 2012,June 2015,Actual,Actual,"Armed Forces Research Institute of Medical Sciences, Thailand","DAVID SAUNDERS, MD, MPH",Principal Investigator,"Armed Forces Research Institute of Medical Sciences, Thailand",N/A,Interventional,231,Anticipated,Malaria,NA,All,18 Years,65 Years,Accepts Healthy Volunteers,"Armed Forces Research Institute of Medical Sciences, Thailand",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Chanthap Lon, MD",Principal Investigator,"Armed Forces Research Institute of Medical Sciences, Thailand",NA,Protective efficacy,NA,"National Centre for Parasitology, Entomology and Malaria Control, Cambodia",Other,Royal Cambodian Armed Forces,Other,Anlong Veng Referral Hospital,4 months,NA,NA,United States Army Medical Materiel Development Activity,U.S. Fed,NA,NA,NA,NA,NA,NA,NA,"To quantify protective efficacy for the prevention of malaria infection in a setting of mixed multidrug resistant P. falciparum and P. vivax malaria, particularly in non-immune volunteers, in two treatment groups - monthly DHA-piperaquine vs. placebo.
Protective efficacy will be defined by reduction in the incidence of malaria between treatment and placebo groups.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CHMI-trans1,NCT02836002,Controlled Human Malaria Infection Model for Evaluation of Transmission‐Blocking Interventions - Study 1,'Controlled Human Malaria Infection Study to Assess Gametocytaemia and Mosquito Transmissibility in Participants Challenged With Plasmodium Falciparum by Sporozoite Challenge to Establish a Model for the Evaluation of Transmission-blocking Interventions',Recruiting,June 2016,January 2017,Anticipated,Anticipated,Radboud University,NA,NA,NA,Phase 1/Phase 2,Interventional,32,Anticipated,Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Frequency and magnitude of adverse events in the CHMI-trans model in study groups,gametocyte prevalence,The PATH Malaria Vaccine Initiative (MVI),Other,QIMR Berghofer Medical Research Institute,Other,Radboud university medical center,up to day 42 after challenge infection,up to day 42 after challenge infection,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Frequency and magnitude of adverse events in the CHMI-trans model in study groups.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Prevalence of gametocytes in the CHMI-trans model in study groups.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999910156,NCT01168271,"Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali","Host and Parasite Factors That Influence Susceptibility to Malaria Infection and Disease During Pregnancy and Early Childhood in Ouelessebougou and Bamako, Mali",Recruiting,"June 23, 2010",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Patrick E Duffy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,15000,Anticipated,Malaria,NA,All,N/A,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To assess the relationship between malaria exposure during pregnancy and maternal and fetal outcomes,"Identify factors (in the mother, placenta, fetus, offspring or parasite) associated with susceptibility or resistance to malaria infection and disease in children and pregnant women",NA,NA,NA,NA,NA,Pregnant women will be followed 4 wks sp/delivery. Newborns will be followed for 5 yrs. Ages 0-3 yrs will be followed until they reach age 5 yrs. Hospitalized children will be followed 4 wks after admission.,Pregnant women will be followed 4 wks sp/delivery. Newborns will be followed for 5 yrs. Ages 0-3 yrs will be followed until they reach age 5 yrs. Hospitalized children will be followed 4 wks after admission.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999911050,NCT01265407,"Malaria Surveillance in Rakai, Uganda","Malaria Surveillance in Rakai, Uganda",Completed,"December 5, 2010",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Steven J Reynolds, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,1700,Anticipated,Malaria,NA,All,6 Months,N/A,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Episodes of uncomplicated and severe clinical malaria per year in children and adults.,NA,NA,NA,NA,NA,Rakai Health Sciences Program,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SuNMaP-OR1,NCT01636895,Evaluation of SP Resistance and Effectiveness of IPTp in Nigeria,An Evaluation of Sulfadoxine-pyrimethamine Resistance and Effectiveness of IPTp in Nigeria,Unknown status,January 2011,February 2013,Anticipated,Anticipated,"Malaria Consortium, UK","Daniel Chandramohan, PHD",Study Chair,London School of hygeine and tropical medicine,Phase 4,Interventional,600,Anticipated,Pregnancy Complications Parasitic,NA,Female,16 Years,45 Years,Accepts Healthy Volunteers,"Malaria Consortium, UK",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Elvis N Shu, PHD",Principal Investigator,"College of Medicine, University of Nigeria , Enugu Campus",NA,To determine the efficacy of SP-IPTp for clearing peripheral malaria parasiteamia in asymptomatic primi and secondi gravid women,NA,"Department for International Development, United Kingdom",Other,London School of Hygiene and Tropical Medicine,Other,Damboa Hospital Borno state and Park Lane hospital Enugu state,15 months,NA,NA,"University of Nigeria, Enugu Campus",Other,NA,NA,NA,NA,NA,NA,NA,PCR corrected Adequate parasitological clearance by day 42,"Ebenezer S Baba, MBBS, MPH",Study Director,Malaria Consortium,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU1201,NCT01640587,Compare the Effectiveness Between Existing Treatment and New Treatment,Randomized Open-label Trial of Comparison Between DHA-Piperaquine and Mefloquine Artesunate Combinations 3 Day-regimens for the Treatment of Uncomplicated Plasmodium Falciparum Malaria on the Thai-Myanmar Border (RDM),Completed,NA,"March 30, 2017",Actual,Actual,University of Oxford,"Francois Nosten, MD",Principal Investigator,University of Oxford,N/A,Interventional,76,Actual,P. Falciparum Malaria,NA,All,5 Years,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR adjusted adequate clinical and parasitological response,NA,NA,NA,NA,NA,Shoklo Malaria Research Unit,Day 63,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Day 63 PCR adjusted adequate clinical and parasitological response (ACPR) in both DP3 arm and MAS3 arm,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,November 2013,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999911126,NCT01322581,A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali,A Longitudinal Systems Biological Analysis of Naturally Acquired Malaria Immunity in Mali,"Active, not recruiting","March 20, 2011",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Peter D Crompton, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,1200,Anticipated,Plasmodium Falciparum,NA,All,3 Months,40 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Identify genome-wide expression profiles induced by Pf infection thatare associated with malaria immunity.,NA,NA,NA,NA,NA,"University of Bamako, Faculty of Medicine, Pharmacy and Odontostomatology",Blood will be collected by venipuncture at the time of the first research-defined malaria episode. Blood collection by venipuncture will be repeated 7 days after the first research-defined malaria episode.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Identify genome-wide expression profiles induced by Pf infection thatare associated with malaria immunity.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999912048,NCT01511601,Apheresis to Obtain Plasma and White Blood Cells in Malies,Apheresis to Obtain Plasma and Leukocytes in Mali for In Vitro Studies,Withdrawn,"December 20, 2011",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Peter D Crompton, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,0,Actual,Malaria,NA,All,18 Years,55 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","July 28, 2016",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC047,NCT01658696,Efficacy of Candidate Malaria Vaccines in Senegalese Adults,Efficacy Study of ChAd63-MVA ME-TRAP Prime-boost Vaccination Against Plasmodium Falciparum Infection,Completed,August 2012,February 2013,Actual,Actual,University of Oxford,NA,NA,NA,Phase 2,Interventional,120,Actual,Malaria,NA,Male,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Vaccine Efficacy,NA,European and Developing Countries Clinical Trials Partnership (EDCTP),Other,NA,NA,University Cheikh Anta Diop (UCAD),18 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"We will compare active and control vaccination for time to first episode of P.falciparum infection, defined as 2 or more consecutive blood samples confirmed positive by PCR, for P.falciparum.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_12_002,NCT01660022,Safety Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 & Piperaquine to Healthy Subjects,"A Phase I Study to Investigate the Safety, Tolerability & Pharmacokinetics of Co-administered Single Doses of OZ439 and Piperaquine to Healthy Subjects",Completed,September 2012,May 2013,Actual,Actual,Medicines for Malaria Venture,"Milko M Radicioni, MD PhD",Principal Investigator,Cross Research S.A.,Phase 1,Interventional,59,Actual,Healthy,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 Cmax,Piperaquine Cmax,Cross Research S.A.,Industry,NA,NA,Cross Research S.A.,Up to 168 hours post-dose,Up to 1008 hours post-dose (Day 43),OZ439 AUC(0-168),NA,NA,OZ439 t1/2,Piperaquine AUC(0-168),Piperaquine t1/2,NA,NA,NA,NA,OZ439 Maximum concentration level,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Piperaquine Maximum concentration level,Up to 168 hours post-dose,Area under the plasma concentration versus time curve to 168 hours post-dose.,Up to 168 hours post-dose,OZ439 Elimination half-life,NA,NA,Up to 1008 hours post-dose (Day 43),Piperaquine area under the plasma concentration versus time curve to 168 hours post-dose,Up to 1008 hours post-dose (Day 43),Piperaquine Elimination half-life (t1/2).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DIF28,NCT00116766,Field Evaluation of Plant-based Mosquito Control,"Field Evaluation of Malaria Vector Control Using Traditional Plant-based Anti-mosquito Measures in Yunnan Province, P.R. China",Completed,July 2005,September 2006,Actual,Actual,London School of Hygiene and Tropical Medicine,"Nigel Hill, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 2,Interventional,240,Actual,Malaria; Arbovirus Infections,NA,All,6 Years,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Hong Ning Zhou, MSc",Principal Investigator,Yunnan Institute of Parasitic Diseases,NA,Reduction in vector mosquitoes entering houses,NA,Yunnan Institute,Other,NA,NA,NA,per night over 45 nights,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVG31,NCT00131794,Bacillus Calmette-Guerin (BCG) Vaccine and Morbidity From Malaria,The Effect of BCG Vaccine on Morbidity From Malaria,Completed,January 2003,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Amabelia Rodrigues, PhD",Principal Investigator,"Bandim Health Centre, Bissau.",Phase 3,Interventional,NA,NA,Malaria,Incidence of clinical malaria.,All,18 Months,24 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2003,NA,NA,NA,1200,NA,NA,Bandim Health Project,Other,"Hospital Nacional Simao Mendes, Bissau",Other,Bandim Health Project,NA,NA,NA,Statens Serum Institut,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999916033,NCT02645604,Artemether-lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali,Artemether-Lumefantrine Resistance Monitoring in Children With Uncomplicated Plasmodium Falciparum Malaria in Mali,Recruiting,"December 10, 2015","December 31, 2020",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Rick M Fairhurst, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,1700,Anticipated,Accute Falciparum Malaria,NA,All,2 Years,65 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Treatment failure up to Day 28. A subject will be defined as a treatment failure if the subject has developed P. falciparum parasitemia detected by thick blood smear (not by PCR) between the time that parasitemia becomes undetectable and Day 28,...",NA,NA,NA,NA,NA,Malaria Research and Training Center,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Treatment failure up to Day 28. A subject will be defined as a treatment failure if the subject has developed P. falciparum parasitemia detected by thick blood smear (not by PCR) between the time that parasitemia becomes undetectable and Day 28,...",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BCG-EHMI,NCT02692963,Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection,Safety and Protective Efficacy of BCG Vaccination Against Controlled Human Malaria Infection,Completed,April 2016,February 2017,Actual,Actual,Radboud University,"Robert Sauerwein, Prof.",Principal Investigator,Radboud University,Phase 2,Interventional,20,Actual,Malaria; Plasmodium Falciparum,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Mihai Netea, Prof.",Principal Investigator,Radboud University,NA,Frequency and magnitude of adverse events,Time to blood stage parasitemia detectable by qPCR,NA,NA,NA,NA,Radboud university medical center,day of BCG vaccination until day 37 after malaria challenge infection,day 1 - 21 after malaria challenge infection,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Adverse event collection and routine safety and hematology laboratory evaluations will be conducted from the day of BCG vaccination until day 37 after CHMI.,"Jona Walk, MD",Study Director,Radboud University,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The effectiveness of BCG vaccination to protect against CHMI will be evaluated by quantitative PCR.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_MMV390048_16_02,NCT02880241,MMV390048 POC in Patients With P. Vivax and P. Falciparum Malaria,"An Open Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose of MMV390048 in Adult Patients With Acute, Uncomplicated Plasmodium Vivax or Falciparum Malaria Monoinfection Over a 35 Day Period",Not yet recruiting,NA,June 2018,Anticipated,Anticipated,Medicines for Malaria Venture,"Daniel Yilma Bogale, MD",Principal Investigator,Jimma University,Phase 2,Interventional,102,Anticipated,Malaria,NA,All,18 Years,55 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Rezika Mohammed, MD",Principal Investigator,University of Gondar,NA,For P. vivax: Crude Adequate Clinical and Parasitological Response (ACPR),For P. falciparum: PCR-adjusted Crude Adequate Clinical and Parasitological Response (ACPR),University of Gondar,Other,Jimma University,Other,NA,On Day 14 post-dose,On Day 14 post-dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,July 2017,Anticipated,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
14.002,NCT02511353,Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study,Efficacy and Safety of High-dose Ivermectin for Reducing Malaria Transmission: A Dose Finding Study (IVERMAL),Completed,July 2015,NA,NA,NA,Liverpool School of Tropical Medicine,"Menno R. Smit, MD, MPH",Principal Investigator,Liverpool School of Tropical Medicine,Phase 2,Interventional,141,Actual,Malaria,NA,All,18 Years,50 Years,No,Liverpool School of Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Feiko ter Kuile, Prof.",Principal Investigator,Liverpool School of Tropical Medicine,NA,Mosquito survival,NA,Kenya Medical Research Institute,Other,Centers for Disease Control and Prevention,U.S. Fed,Jaramogi Oginga Odinga Teaching and Referral Hospital,Survival of mosquitoes at 14 days after feeding on blood taking from study participants who started the 3-day ivermectin and DP regimen 7 days earlier.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
200596,NCT02699099,"Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever (YF) Vaccines Followed by a Booster of the Malaria Vaccine.","Immunogenicity and Safety Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Given at 6, 7.5 and 9 Months of Age in Co-administration With Measles, Rubella and Yellow Fever Vaccines Followed by a Booster of the Malaria Vaccine.",Recruiting,NA,"September 25, 2020",Anticipated,Anticipated,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,700,Anticipated,Malaria,NA,All,6 Months,6 Months,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Anti-CS antibody titers,NA,NA,NA,NA,NA,NA,At one month post vaccination (Month 4),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Titers were expressed as Geometric Mean Titers (GMTs).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"May 10, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
170067,NCT03083847,Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum,Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Dose Escalation Trial to Determine Safety and Development of Protective Efficacy After Exposure to Only Pre-erythrocytic Stages of Plasmodium Falciparum,Recruiting,NA,"June 15, 2018",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,230,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"The incidence and severity of local and systemic AEs and SAEs occurring after PfSPZ CVac (Arms 1, 2, 3, 5)","P. falciparum blood stage infection defined as detection of p. falciparum parasites by qPCR (real time NIH qPCR and sensitive retrospective LMIV qPCR) following Sanaria PfSPZ Challenge (Arms 1, 2)",NA,NA,NA,NA,National Institutes of Health Clinical Center,One (1) to seven (7) Months,One (1 ) to seven (7) months,Incidence of clinical malaria diagnosis occurring after PfSPZ-CVac- chloroquine requiring treatment with additional antimalaria (Arms 3 and 5),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Seven (7) months,NA,NA,NA,"June 5, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MRT15003.2,NCT02700269,Vanderbilt-Zambia Innovations in Global Health Technologies,Vanderbilt-Zambia Innovations in Global Health Technologies,Recruiting,April 2016,July 2017,Anticipated,Anticipated,"Macha Research Trust, Zambia",NA,NA,NA,N/A,Observational,200,Anticipated,Malaria Diagnosis,NA,All,6 Months,85 Years,Accepts Healthy Volunteers,"Macha Research Trust, Zambia",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Enhancement of malaria RDT to detect low levels of P falciparum parasites,NA,Vanderbilt University,Other,National Institutes of Health (NIH),NIH,Macha Research Trust,5 years,NA,NA,John E. Fogarty International Center (FIC),NIH,NA,NA,NA,NA,NA,NA,NA,The expected outcome of this research project is to enhance the ability of standard malaria RDTs to detect low levels of Plasmodium falciparum malaria in human capillary blood.,NA,NA,NA,NA,NA,NA,NA,NA,Enhancement of malaria RDT to detect low levels of P falciparum parasites,Non-Probability Sample,"
        Inclusion Criteria:

          -  Individuals giving written informed consent for themselves

          -  Children under the age of 18 for whom a parent or guardian can give consent

          -  Individuals seeking care or treatment of suspected or possible malaria

          -  Individuals being screened as a contact of someone with recent malaria

          -  Other individuals willing to have their blood tested for malaria

        Exclusion Criteria:

          -  Anyone over 18 unwilling or unable to provide informed consent

          -  Anyone under 18 who does not have a parent or guardian to give consent

          -  Anyone between the age of 12 and 18 who does not give assent
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ORPAL,NCT02903706,Prevalence of Malaria Parasites in People Working in Illegal Gold Mining in French Guiana,Prevalence of Malaria Parasites in People Working in Illegal Gold Mining in French Guiana,Completed,October 2014,June 2015,Actual,Actual,Centre Hospitalier de Cayenne,NA,NA,NA,N/A,Observational,421,Actual,Malaria; Epidemiology,NA,All,18 Years,N/A,Accepts Healthy Volunteers,Centre Hospitalier de Cayenne,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,prevalence of malaria positive individuals (symptomatic or not symptomatic),NA,NA,NA,NA,NA,NA,1 month,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,every participant gives a capillary blood specimen which is then screened for malaria using PCR in order to obtain a prevalence of malaria positive individuals (symptomatic or not symptomatic),NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  works on a gold mining site in French Guiana

          -  has been at the resting site for less than seven days

          -  is over the age of 18

          -  accepts to take part in this study

        Exclusion Criteria:

          -  refuses to take part in the study

          -  is under the age of 18
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LVT1R01NS074409,NCT01660672,Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria,"A Dose-Escalation, Safety And Feasibility Study Of Enteral Levetiracetam For Seizure Control In Pediatric Cerebral Malaria",Completed,January 2013,July 2013,Actual,Actual,University of Rochester,"Gretchen L Birbeck, M.D.",Principal Investigator,University of Rochester,Phase 1/Phase 2,Interventional,7,Actual,Seizure; Epilepsy; Cerebral Malaria,NA,All,2 Years,6 Years,No,University of Rochester,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Freedom From Seizure,NA,National Institute of Neurological Disorders and Stroke (NINDS),NIH,NA,NA,Queen Elizabeth Central Hospital,24 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Number of subjects free of seizure at 24 hours after initiation of treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_12_005,NCT01713608,A Dose-escalation Study to Investigate Safety and Toleration of OZ439,"A Randomised, Placebo-controlled, Dose-escalation Study to Investigate Safety and Toleration of OZ439 OD for 3 Days to Healthy Male and Female Volunteers",Completed,November 2012,February 2013,Actual,Actual,Medicines for Malaria Venture,"Fiona Macintyre, PhD",Study Director,Medicines for Malaria Venture,Phase 1,Interventional,34,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 Cmax,OZ439 AUCτ,NA,NA,NA,NA,Richmond Pharmacology Ltd,"Blood for analysis of OZ439 will be collected at the following times: pre-dose, 2, 4, 6, 8, 12, and 18 hours post-dose Day 1and Day 3, pre dose Day 2 and 4 hours post dose Day 2, and 24, 48, 72, 96 and 168 hours post 3rd dose and at follow up.","pre-dose, 2, 4, 6, 8, 12, and 18 hours post-dose Day 1and Day 3, pre dose Day 2 and 4 hours post dose Day 2, and 24, 48, 72, 96 and 168 hours post 3rd dose and at follow up.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 maximum measured plasma concentration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,OZ439 Area under the plasma concentration vs time curve from time zero to the time of the last quantifiable concentration t calculated using a log-linear trapezoidal method,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
105874,NCT00307021,Double-blind Study of Safety and Immunogenicity of Two Candidate Malaria Vaccines in Gabonese Children,"Bridging Safety & Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine RTS,S/AS01E (0.5 mL Dose) to RTS,S/AS02D (0.5 mL Dose) Administered IM According to a 0, 1, 2-Month Schedule in Gabonese Children Aged 18 Months to 4 Years",Completed,"April 7, 2006","August 22, 2007",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,180,Actual,Malaria,NA,All,18 Months,48 Months,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of SAEs.,Antibody titers to the P. falciparum circumsporozoite repeat domain (anti-CS).,NA,NA,NA,NA,GSK Investigational Site,From the time of first vaccination until one month post Dose 3,One month post Dose 3.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_12_003,NCT01732588,"A Comparison of the Bioavailability of OZ439 When Delivered Directly to the Small Intestine, or Via the Oral Route",Three Way Randomised CrossOver Study in Healthy Subjects to Compare the Relative Bioavailability of Nanoparticulate OZ439 Delivered Via the Enterion™ Capsule to the Proximal Small Bowel With Orally Administered OZ439 as PIB Suspension and Orally Administered Nanoparticulate,Completed,November 2012,December 2012,Actual,Actual,Medicines for Malaria Venture,"Fiona Macintyre, PhD",Study Director,Medicines for Malaria Venture,Phase 1,Interventional,11,Actual,Healthy Volunteers,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,OZ439 AUC0-∞,OZ439 Cmax,NA,NA,NA,NA,Quotient Clinical,"pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose","pre dose, 2, 4, 6, 8, 12, 16, 24, 36 and 48 hours post dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Area under the plasma concentration-time curve from zero to infinity (AUC0-∞),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The maximum observed plasma drug concentrations (Cmax),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AMANI,NCT01782001,Evaluation of Vitamin A and Zinc Supplementation on Malarial Morbidity,Evaluation of the Impact of Vitamin A and Zinc Supplementation on Malarial Morbidity in Ghana,Completed,March 2009,November 2009,Actual,Actual,"Kintampo Health Research Centre, Ghana","Seth Owusu-Agyei, PhD",Principal Investigator,"Kintampo Health Research Centre, Ghana",Phase 3,Interventional,200,Actual,Malaria; Malnutrition,NA,All,6 Months,24 Months,No,"Kintampo Health Research Centre, Ghana",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,incidence of clinical malaria attacks,NA,International Atomic Energy Agency,Other,"University of Wisconsin, Madison",Other,Kintampo Health Research Centre,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
090213,NCT00977899,Phase 1 Study of the Safety and Immunogenicity of a Malaria Transmission-blocking Pfs25-Pfs25 Conjugate Vaccine,Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine,Withdrawn,"August 20, 2009","March 5, 2013",Actual,Actual,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),"Feng-Ying C Lin, M.D.",Principal Investigator,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),Phase 1,Interventional,0,Actual,Malaria; Malaria Vaccines; Plasmodium Falciparum Malaria,Antibody,All,18 Years,49 Years,No,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
112582,NCT01376167,Ph 2B/3 Tafenoquine (TFQ) Study in Prevention of Vivax Relapse,"A Multi-centre, Double-blind, Randomised, Parallel-group, Active Controlled Study to Evaluate the Efficacy, Safety and Tolerability of Tafenoquine (SB-252263, WR238605) in Subjects With Plasmodium Vivax Malaria.",Completed,NA,"November 18, 2016",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,851,Actual,"Malaria, Vivax",NA,All,16 Years,N/A,No,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Relapse Efficacy,Relapse-free efficacy (Part 2),Medicines for Malaria Venture,Other,NA,NA,NA,6 months post dosing (180 days),6 months post dosing (180 days),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Subjects for whom initial clearance of parasitaemia is confirmed (parasite numbers fall below the limit of detection in thick blood smear and remain undetectable at the second smear collected 6-12 hours later) and who do not present with Plasmodium vivax asexual stage parasites within six months will be considered treatment success.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Subjects for whom initial clearance of parasitaemia is confirmed (parasite numbers fall below the limit of detection in thick blood smear and remain undetectable at the second smear collected 6-12 hours later) and who do not present with Plasmodium vivax asexual stage parasites at any point in the study, and have a negative P. vivax smear within the acceptable time window for the six month assessment will be considered treatment success.",NA,NA,NA,NA,"September 19, 2011",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
110257,NCT01441167,Experimental PfSPZ Vaccine in Adults Without Malaria,"VRC 312: A Phase 1, Open-Label, Dose-Escalation Clinical Trial With Experimental Challenge to Evaluate Intravenous Administration of the PfSPZ Vaccine in Malaria-Naive Adults",Completed,"September 14, 2011","June 5, 2013",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Robert A Seder, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,64,Actual,Malaria; Prevention and Control; Acquired Immunity,The primary objectives of the study are related to the safety and tolerability of the vaccine at the 4 dosage levels when administered IV.,All,18 Years,45 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,Sanaria Incorporated,Other,U.S. Military Malaria Vaccine Program,Other,"National Institutes of Health Clinical Center, 9000 Rockville Pike",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TIP5,NCT01728701,Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis,Controlled Human Malaria Infection (CHMI) After Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chloroquine Prophylaxis,Completed,September 2012,February 2014,Actual,Actual,Sanaria Inc.,"Robert Sauerwein, MD",Principal Investigator,Radboud University,Phase 1,Interventional,30,Actual,Malaria; Plasmodium Falciparum,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Frequency and magnitude of adverse events in study groups,NA,Radboud University,Other,NA,NA,Radboud University Nijmegen Medical Centre,All study visits+as reported by volunteer upto 53 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Signs and symptoms will be recorded at all visits, and whenever a trial volunteer reports signs or symptoms to the trial physician between visits. The following signs and symptoms will be solicited: Fever, Headache, Malaise, Fatigue, Dizziness, Myalgia, Arthralgia, Nausea, Vomiting, Chills, Diarrhoea, Abdominal pain (Verhage 2005), Chest pain, Palpitations and Shortness of breath.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL 1301,NCT01814683,IMPROV (Improving the Radical Cure of Vivax Malaria),Improving the Radical Cure of Vivax Malaria: A Multicentre Randomised Comparison of Short and Long Course Primaquine Regimens,Recruiting,NA,December 2019,Anticipated,Anticipated,University of Oxford,"Ric Price, FRCP",Principal Investigator,University of Oxford,N/A,Interventional,3150,Anticipated,Uncomplicated Vivax Malaria,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence rate (per person-year) of symptomatic recurrent P. vivax,NA,Menzies School of Health Research,Other,NA,NA,NA,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The incidence rate (i.e. per person-year) of symptomatic recurrent P. vivax parasitaemia (detected by microscopy) over 12 months of follow-up in the 7 versus 14-day primaquine groups for all sites combined and stratified by site.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,July 2014,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1305,NCT01872702,Targeted Chemo-elimination (TCE) of Malaria,Targeted Chemo-elimination (TCE) to Eradicate Malaria in Areas of Suspected or Proven Artemisinin Resistance in Southeast Asia and South Asia,Recruiting,NA,December 2017,Anticipated,Anticipated,University of Oxford,"Nicholas J White, PhD",Principal Investigator,University of Oxford,N/A,Interventional,8000,Anticipated,Plasmodium Falciparum Malaria,NA,All,6 Months,N/A,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine. (1017-13 and 23-15)","prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 12 months after the first administration of targeted malaria elimination (1015-13)",Mahidol Oxford Tropical Medicine Research Unit,Other,"National Centre for Parasitology, Entomology and Malaria Control, Cambodia",Other,NA,12 months,12 months,"prevalence of falciparum malaria measured by qPCR (quantitative real time polymerase chain reaction), 4 months after the first administration of target malaria-elimination (23-15)","Family Health International, Cambodia",Other,NA,NA,NA,"Oxford University Clinical Research Unit, Vietnam",Other,"National Malaria Control Program, Vietnam",Other,"Percentage falls in asymptomatic malaria prevalence in the intervention villages vs control villages, as determined by highly sensitive qPCR, 12 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Percentage falls in asymptomatic malaria prevalence in the intervention villages vs control villages, as determined by highly sensitive qPCR, 12 months after the first administration of treatment with dihydroartemisinin-piperaquine",4 months,"Percentage falls in asymptomatic malaria prevalence in the intervention villages vs control villages, as determined by highly sensitive qPCR, 4 months after the first administration of treatment with dihydroartemisinin-piperaquine and primaquine.",NA,NA,April 2013,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Myanmar Oxford Clinical Research Unit,Other,"National Malaria Control Program, Myanmar",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Lao-Oxford-Mahosot Hospital Wellcome Trust Research Unit (LOMWRU), Laos",Other,Shoklo Malaria Research Unit,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PRIMAQUINE STUDY,NCT01906788,The Optimal Timing Of Primaquine To Prevent Malaria Transmission After Artemisinin-Combination Therapy,THE OPTIMAL TIMING OF PRIMAQUINE TO PREVENT MALARIA TRANSMISSION AFTER ARTEMISININ-COMBINATION THERAPY,Unknown status,May 2013,October 2013,Anticipated,Anticipated,Kilimanjaro Clinical Research Institute,"Seif Shekalaghe, MD, PhD",Principal Investigator,Kilimanjaro Clinical Research Institute and Ifakara Health Institute,Phase 4,Interventional,250,Anticipated,Malaria Transmission,NA,All,3 Years,17 Years,No,Kilimanjaro Clinical Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Gametocyte prevalence and density by microscopy and QT-NASBA,NA,London School of Hygiene and Tropical Medicine,Other,Ifakara Health Institute,Other,Bagamoyo Research and Training Centre,Day 14,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,By microscopy and QT-NASBA techniques we will determine and compare gametocyte prevalence and density on day 14 between the Primaquine treatment 2 and 3 arms.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UMT Evaluation,NCT01921413,Clinical Performance Evaluation of Fyodor Urine Malaria Test (UMT),Clinical Validation of Fyodor Urine Malaria Test (UMT),Completed,July 2013,February 2014,Actual,Actual,Fyodor Biotechnologies Inc,"Wellington A Oyibo, PhD",Principal Investigator,"ANDI Centre of Excellence for Malaria Diagnosis, International Malaria Microscopy Training & RDT QA Center, & WHO/TDR/FIND Malaria Specimen Bank Site, Department of Medical Microbiology & Parasitology, College of Medicine, University of Lagos, Nigeria",N/A,Observational,1893,Actual,Malaria,NA,All,2 Years,N/A,Accepts Healthy Volunteers,Fyodor Biotechnologies Inc,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"William (Bill) Brieger, DrPH",Study Director,"Johns Hopkins University, Bloomberg School of Public Health, Baltimore, Maryland, USA",NA,Accuracy of the UMT for Clinical Malaria Diagnosis,NA,"University of Lagos, Nigeria",Other,Johns Hopkins University,Other,College of Medicine of the University of Lagos,Acute (day 0) fever suspected of being malaria or recent history of fever in the past 48 hours,NA,NA,"Federal Ministry of Health, Nigeria",Other,NA,NA,NA,Duke University,Other,NA,NA,• Establish sensitivity and specificity of the UMT for malaria diagnosis in febrile patients.,"Wendy O'Meara, PhD",Study Director,"Duke University School of Medicine, Durham, North Carolina, USA","Nnenna Ezeigwe, MBBS, FMCPH",Study Director,"Coordinator, National Malaria Control Program/Federal Ministry of Health, Abuja, Nigeria",NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

        Group 1 - Febrile Patients:

          -  Age: two years or older

          -  Fever at the time of presentation (axillary temperature ≥37.5°C), or history of fever
             within the past 48 hours

          -  Subjects with concurrent illnesses not listed in the exclusion criteria will be
             evaluated and treated for these illnesses and included in the study

          -  Written informed consent obtained from the participant or parent/guardian

        Group 2 - Apparently Healthy Individuals:

          -  Children 2 years or older, as well as adults of both genders

          -  Afebrile

          -  No history of fever within the past 48 hours

          -  Negative Binax NOW test confirmed by Negative blood smear for clinical malaria

        Group 3 - Patients with unrelated medical conditions known to elicit proteinuria in
        patients:

          -  Children 2 years or older, as well as adults

          -  Afebrile

          -  No history of fever within the past 48 hours

          -  Negative Binax NOW test confirmed by Negative blood smear for clinical malaria

        Exclusion Criteria:

          -  Pregnancy

          -  Patients with respiratory distress, diffuse bleeding, recent seizures, coma, inability
             to drink, persistent vomiting, or prostration

          -  Chronic use of a medication (such as trimethoprim-sulfamethoxazole for preventing
             AIDS-associated opportunistic infections) with known antimalarial activity

          -  Any condition that in the opinion of the Principal Investigator would jeopardize the
             safety or rights of a participant in the trial or would render the participant unable
             to comply with the protocol
      ","Godwin Ntadom, MBBS, MPH",Study Director,"Head, Case Management, National Malaria Control Program/Federal Ministry of Health, Abuja, Nigeria",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
200951,NCT02184637,A Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine Co-administered With Either Artemether + Lumefantrine or Dihydroartemisinin + Piperaquine Tetraphosphate,"A Five-cohort, Randomized, Open-label, Parallel-group Study to Evaluate the Pharmacokinetics of a Single Dose of Tafenoquine (SB252263) 300mg When Co-administered With the Artemisinin-based Combination Therapies (ACT) Artemether + Lumefantrine (AL) and Dihydroartemisinin + Piperaquine Tetraphosphate (DHA+PQP)",Completed,NA,"April 8, 2015",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,120,Actual,"Malaria, Vivax",NA,All,18 Years,65 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Ratios of Geometric mean (90% [confidence interval] CI) for DHA+PQP AUC and Cmax for treatment groups: Cohort 1 (TQ + DHA+PQP) versus (vs.) cohort 3 (DHA+PQP),Ratios of geometric mean [90% CI] for A/DHA/L AUC and Cmax for treatment groups: Cohort 2 (TQ + AL) vs. cohort 4 (AL).,Medicines for Malaria Venture,Other,NA,NA,GSK Investigational Site,Up to Day 56,Up to Day 56,Ratios of geometric mean [90% CI] for TQ AUC and Cmax for treatment groups: Cohort 1 (TQ + DHA+PQP) vs. cohort 5 (TQ).,NA,NA,Ratios of geometric mean [90% CI] for TQ AUC and Cmax for treatment groups: Cohort 2 (TQ + AL) vs. cohort 5 (TQ).,NA,NA,NA,NA,NA,NA,"Blood samples will be collected on Day 1 (Pre-dose, 1, 2, 4, 6, 12 hours), Day 2 (24 hours), Day 3 (48, 48.5, 49, 49.5, 50, 51, 52, 54, 56, 60 hours), Day 4 (72 hours), Days 7, 14, 21, 28 and 56.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Blood samples will be collected on Day 1 (Pre-dose, 1, 2, 4, 6, 12 hours), Day 2 (24 hours), Day 3 (48, 60, 60.5, 61, 61.5, 62, 64 hours), Day 4 (66, 68, 72 hours), Days 7, 14, 21, 28 and 56.",Up to Day 56,"Blood samples will be collected on Day 1 (Pre-dose, 1, 2, 4, 6, 12 hours), Day 2 (24 hours), Day 3 (48, 48.5, 49, 49.5, 50, 51, 52, 54, 56, 60 hours), Day 4 (72 hours), Days 7, 14, 21, 28 and 56.",Up to Day 56,"Blood samples will be collected on Day 1 (Pre-dose, 1, 2, 4, 6, 12 hours), Day 2 (24 hours), Day 3 (48, 60, 60.5, 61, 61.5, 62, 64 hours), Day 4 (66, 68, 72 hours), Days 7, 14, 21, 28 and 56.","July 31, 2014",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999915147,NCT02471378,Laboratory Evaluation of Pregnancy Malaria Vaccine Candidates/In-vitro Testing of Pregnancy Malaria Vaccine Candidates,In-Vitro Testing of Pregnancy Malaria Vaccine Candidates,Recruiting,"June 10, 2015","December 31, 2020",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Michal Fried, Ph.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,2000,Anticipated,Malaria,NA,Female,15 Years,25 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Measure of functional activity of animal IgG against vaccine candidates to block binding of fresh pregnancy malaria isolates to the placental receptor CSA,NA,NA,NA,NA,NA,Malaria Research and Training Center,Approximately 1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IHI,NCT01930331,"Safety, Tolerability, Pharmacokinetics and Efficacy of ARCO","Safety, Tolerability, Pharmacokinetics and Efficacy, Phase Iv, Open Label Study of Fixed Arco® and Eurartesim® Therapies in Adults and Children With Uncomplicated P. Falciparum Malaria in Tanzania",Unknown status,September 2013,February 2014,Anticipated,Anticipated,Ifakara Health Institute,"Salim Abdulla, MD, PhD",Principal Investigator,Ifakara Health Institute,Phase 4,Interventional,60,Anticipated,"Plasmodium Falciparum; Malaria, Falciparum",NA,All,6 Years,60 Years,No,Ifakara Health Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of reported non serious and serious adverse events,NA,NA,NA,NA,NA,Ifakara Health Institute,Up to 6 Weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
E-22746,NCT02072629,HCU: Can VHVs Trained in ICCM Improve Care for Children,Healthy Child Uganda: Can Village Health Volunteers Trained in Integrated Community Case Management of Childhood Illness Improve Access to Care for Africa's Most Vulnerable Children?,Completed,November 2009,December 2012,Actual,Actual,University of Calgary,"Samuel Maling, MD",Principal Investigator,Mbarara University of Science and Technology,N/A,Interventional,4071,Actual,Diarrhoea; Pneumonia; Malaria,NA,Female,N/A,N/A,Accepts Healthy Volunteers,University of Calgary,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"jenn Brenner, MD",Study Director,University of Calgary,NA,Absolute change pre/post intervention (VHV ICCM training) in proportion of U5s receiving (a) antimalarial for fever (b) ORS/Zn for diarrhea (c) Abx for pneumonia,NA,Mbarara University of Science and Technology,Other,NA,NA,NA,pre- (Dec 2010) post- (Dec 2012) intervention (2 years),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absolute change pre/post intervention (VHV ICCM training) in proportion of U5s receiving (a) antimalarial for fever (b) ORS/Zn for diarrhea (c) Abx for pneumonia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
150169,NCT02511054,Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual B...,Sanaria PfSPZ Challenge With Pyrimethamine Chemoprophylaxis (PfSPZ-CVac Approach): Phase 1 Trial to Determine Safety and Protective Efficacy of Sanaria PfSPZ Challenge With Concurrent Pyrimethamine Treatment That Inhibits Development of Asexual Blood Stages of Plasmodium Falciparumc,Completed,"July 21, 2015","June 1, 2017",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,57,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence and severity of local and systemic adverse events (AEs) and serious adverse events (SAEs) occurring after each Sanaria PfSPZ Challenge (Safety),(Pilot Phase Only) P. falciparum blood stage infection defined as detection of P. falciparum parasites by sensitive research qRT-PCR following Sanaria PfSPZ Challenge during first CVac regimen (Prevention of Pf Infection),NA,NA,NA,NA,"National Institutes of Health Clinical Center, 9000 Rockville Pike",Approximately 6 months,Approximately 3 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC062,NCT02532049,A Clinical Trial to Assess the Safety and Immunogenicity of New Malaria Vaccine Candidates ChAd63 Pfs25-IMX313 and MVA Pfs25-IMX313,"A Phase Ia Clinical Trial to Assess the Safety, Immunogenicity and Ex-vivo Efficacy of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 Pfs-IMX313 Alone and With MVA Pfs25-IMX313",Completed,NA,"May 25, 2017",Actual,Actual,University of Oxford,NA,NA,NA,Phase 1,Interventional,26,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Adverse Events,NA,NA,NA,NA,NA,NA,8 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The specific endpoints for safety and reactogenicity will be actively and passively collected data on adverse events.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"October 12, 2015",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2304-493-26202,NCT02083068,Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax,Evaluation of the Protective Efficacy of a Vaccine Derived From the Synthetic CS Protein of Plasmodium Vivax,Unknown status,May 2014,August 2015,Anticipated,Anticipated,Malaria Vaccine and Drug Development Center,NA,NA,NA,Phase 2,Interventional,32,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Malaria Vaccine and Drug Development Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites,NA,"Administrative Department of Science, Technology and Innovation, Colciencias",Other,NA,NA,Malaria Vaccine and Drug Development Center,Thirty days after the last immunization,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Vaccine protective efficacy against P. vivax infection on volunteers exposed to infected mosquito bites,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
U.2012.0008,NCT02084602,Assessment of Artesunate/Mefloquine in the Peruvian Amazon,Assessment of in Vivo and in Vitro Efficacy of Combined Artesunate/Mefloquine Therapy for Treatment of Uncomplicated Plasmodium Falciparum Infection in the Peruvian Amazon,Unknown status,June 2014,February 2015,Anticipated,Anticipated,Instituto Nacional de Salud. Peru,"Salomon Durand, Master",Principal Investigator,NAMRU 6,Phase 4,Interventional,59,Anticipated,"Malaria, Falciparum",NA,All,5 Years,65 Years,No,Instituto Nacional de Salud. Peru,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Parasite clearance time,NA,Naval Medical Research Unit No 6,Other,NA,NA,NAMRU 6,up to 72 hours after administration of artesunate,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Parasite clearance time assessed by microscopy and quantitative PCR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC053,NCT02572388,"A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1","Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With and Without Matrix-M1 in Healthy UK Volunteers","Active, not recruiting",September 2015,July 2017,Anticipated,Anticipated,University of Oxford,NA,NA,NA,Phase 1,Interventional,24,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Safety and tolerability of administration of R21 with and without the adjuvant Matrix-M1. This will be done by recording the number of participants who experience adverse events and the severity of any adverse events.,NA,NA,NA,NA,NA,NA,34 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Safety and tolerability of administration of R21 with and without the adjuvant Matrix-M1. This will be done by recording the number of participants who experience adverse events and the severity of any adverse events.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999916023,NCT02612545,"Efficacy, Safety, and Tolerability of Dihydroartemisinin-piperaquine + Mefloquine Compared to Dihydroartemisinin-piperaquine or Artesunate-mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia","A Multi-Site, Open-Label, Randomized Trial to Assess the Efficacy, Safety, and Tolerability of Dihydroartemisinin-Piperaquine Plus Mefloquine Compared to Dihydroartemisinin-Piperaquine or Artesunate-Mefloquine in Patients With Uncomplicated Falciparum Malaria in Cambodia",Recruiting,"November 12, 2015","April 30, 2020",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Thomas E Wellems, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,384,Anticipated,Acute Falciparum Malaria,NA,All,2 Years,65 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Compare the efficacy of TACT versus ACT, as defined by an adequate clinical and parasitological response (ACPR), defined as: absence of parasitemia on Day 42 (detected by blood smear, not PCR), irrespective of tympanic temperature, in subjects w...",NA,NA,NA,NA,NA,"National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H",Day 42 post enrollment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MAVACHE,NCT02704533,Sequential Optimization of Dose and Schedule of PfSPZ Vaccine,"Sequential Optimization of Dose and Schedule of PfSPZ Vaccine, Verified by Randomized, Controlled, Double-blind Immunization and Controlled Human Malaria Infection in Malaria-naïve, Healthy Adult Volunteers in Germany",Recruiting,NA,April 2018,Anticipated,Anticipated,Sanaria Inc.,"Benjamin Mordmüller, MD",Principal Investigator,"Institute of Tropical Medicine, University of Tuebingen, Wilhelmstr. 27, Germany",Phase 1,Interventional,63,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number or occurrence of at least possibly related Grade 3 AEs and serious adverse events (SAEs) for PfSPZ Vaccine,PfSPZ Challenge (7G8) dose finding - Number or occurrence of at least possibly related Grade 3 AEs and SAEs,"Institute of Tropical Medicine, University of Tuebingen",Other,German Federal Ministry of Education and Research,Other,"Institute of Tropical Medicine, University of Tuebingen, Wilhelmstr. 27",Around 14 months (from day of first immunization through study completion),Around 140 days (from day of first PfSPZ Challenge (7G8) CHMI through end of follow-up),NA,German Center for Infection Research,Other,NA,NA,NA,NA,NA,NA,NA,Number or occurrence of at least possibly related Grade 3 AEs and SAEs from time of first administration of PfSPZ Vaccine to the end of the follow-up period.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Number or occurrence of at least possibly related Grade 3 AEs and SAEs from time of first administration of PfSPZ Challenge (7G8) to the end of the follow-up period.,NA,NA,NA,NA,September 2016,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UniHD008,NCT02851108,Methylene Blue Against Falciparum Malaria in Burkina Faso,Safety of Artesunate-amodiaquine Combined With Methylene Blue or Primaquine for Falciparum Malaria Treatment in African Children: A Randomised Controlled Trial,Completed,NA,February 2017,Actual,Actual,Heidelberg University,"Olaf Müller, Prof. Dr.",Principal Investigator,Heidelberg University,Phase 2,Interventional,100,Actual,"Malaria, Falciparum",NA,All,6 Months,59 Months,No,Heidelberg University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change in haemoglobin compared to the baseline,NA,"Centre de Recherche en Sante de Nouna, Burkina Faso",Other,NA,NA,CRSN,7 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,October 2016,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC065,NCT02905019,A Safety and Efficacy Study of R21 +/- ChAd63/MVA ME-TRAP,A Phase I/IIa Sporozoite Challenge Study to Assess the Safety and Protective Efficacy of Adjuvanted R21 at Two Different Doses and the Combination Malaria Vaccine Candidate Regimen of Adjuvanted R21 + ChAd63 and MVA Encoding ME-TRAP.,Recruiting,August 2016,August 2018,Anticipated,Anticipated,University of Oxford,NA,NA,NA,Phase 1/Phase 2,Interventional,70,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Efficacy of adjuvanted R21 at two different doses and adjuvanted R21 + ChAd63 and MVA encoding ME-TRAP in healthy malaria-naïve volunteers as assessed by number of completely protected individuals.,Safety of adjuvanted R21 at two different doses and adjuvanted R21 + ChAd63 and MVA encoding ME-TRAP in healthy malaria-naïve volunteers as assessed by frequency of adverse events.,NA,NA,NA,NA,NA,6 months,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Use statistical analysis to compare number of completely protected individuals (those who do not, by Day 21 following sporozoite challenge, develop blood stage infection measured by occurrence of P. falciparum parasitemia, assessed by blood slide) in the vaccine groups compared to the controls.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Solicited and unsolicited adverse event data will be collected at each clinic visit from diary cards, clinical review, clinical examination (including observations) and laboratory results. This AE data will be tabulated and frequency, duration and severity of AEs compared between groups.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
201611119,NCT03079388,Nutritional and Anti-infective Interventions for Malnutrition in Pregnancy (Beleuman Welbodi),Randomized Control Trial of the Use of Supplementary Food and Measures to Control Inflammation in Malnourished Pregnant Women to Improve Birth Outcomes,Recruiting,NA,March 2019,Anticipated,Anticipated,Washington University School of Medicine,"Mark J Manary, MD",Study Chair,Washington University School of Medicine,N/A,Interventional,1514,Anticipated,Pregnancy; Malnutrition in Pregnancy; Nutrition Disorders; Stunting,NA,Female,14 Years,N/A,No,Washington University School of Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Infant birth length,NA,The Children's Investment Fund Foundation,Other,NA,NA,1 Moriba Street,up to 40 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,mean birth length of infants born to mothers in the study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"February 27, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Yes,Must be pregnant woman,NA,NA,NA
3.0.2011,NCT02089841,Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Malaria.,Efficacy of Artemether/Lumefantrine for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Five Years After Wide Scale Use of the Drug in Tanzania.,Completed,May 2012,August 2013,Actual,Actual,Richard Mwaiswelo,"Andreas Martensson, PhD",Study Director,Karolinska Institutet,Phase 4,Interventional,140,Actual,Plasmodium Falciparum Malaria,NA,All,6 Months,120 Months,No,Richard Mwaiswelo,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of patients without parasitaemia on day 42.,NA,Karolinska Institutet,Other,NA,NA,Muhimbili University of Health and Allied Sciences,42 Days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Proportion of patients without parasitaemia or with new infection as corrected by molecular genotyping on day 42 will be used to calculate the efficacy of the trial medicine.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BMGF2a,NCT02149550,Controlled Human Malaria Infection After Bites From Mosquitoes Infected With Two Novel P. Falciparum Strains,Controlled Human Malaria Infection After Bites From Mosquitoes Infected With NF135.C10 or NF166.C8 Plasmodium Falciparum Parasites (BMGF2a),Completed,August 2014,November 2014,Actual,Actual,Radboud University,"Perry van Genderen, MD, PhD",Principal Investigator,Havenziekenhuis,N/A,Interventional,24,Actual,Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of subjects in each group who develop patent parasitaemia as assessed by QRT-PCR,NA,"Havenziekenhuis, Rotterdam",Other,NA,NA,NA,between day 5 and day 13,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Parasitaemia will be measured twice daily by QRT-PCR in venous whole blood, from day 5 post-infection until PCR-positive, or else until day 13 post-infection if subjects have not yet developed a positive PCR before then.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC045,NCT01623557,A Challenge Study to Assess the Protective Efficacy of Two Malaria Vaccine Candidates,A Phase I/IIa Sporozoite Challenge Study to Assess the Protective Efficacy of Two Prime-Boost Malaria Vaccine Candidates: ChAd63 and MVA Encoding ME-TRAP and the Same Viral Vectors Encoding CS,Completed,April 2012,November 2012,Actual,Actual,University of Oxford,"Adrian V S Hill, MD",Principal Investigator,University of Oxford,Phase 1/Phase 2,Interventional,30,Actual,Plasmodium Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The effectiveness of ChAd63-MVA CS and ChAd63-MVA ME-TRAP at preventing malaria infection,NA,NA,NA,NA,NA,NA,Up to 30 days post challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Comparison of the number of individuals who develop malaria infection between vaccinees and unvaccinated control volunteers.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SR-M-Zm,NCT02394522,Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia (SR-M-ZM),Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Zambia,Withdrawn,March 2016,April 2016,Actual,Actual,University of Notre Dame,"Neil F Lobo, PhD",Principal Investigator,"University of Notre Dame, USA",N/A,Interventional,0,Actual,Malaria,NA,All,6 Months,59 Months,Accepts Healthy Volunteers,University of Notre Dame,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Nicole L Achee, PhD",Principal Investigator,"University of Notre Dame, USa",NA,Malaria Incidence,NA,"Ministry of Health, Zambia",Other,"Macha Research Trust, Zambia",Other,Macha Research Trust,104 weeks,NA,NA,Johns Hopkins University,Other,NA,NA,NA,NA,NA,NA,NA,Incidence of malaria infections among human cohorts during the follow-up period as detected by PCR,NA,NA,NA,NA,NA,NA,NA,NA,Malaria Incidence,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC060,NCT02925403,"A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, With Matrix-M1 Adjuvant","A Phase Ib Randomised, Controlled, Single-blind Study to Assess the Safety, Immunogenicity of the Malaria Vaccine Candidate R21 With Matrix-M1 Adjuvant in West African Adult Volunteers","Active, not recruiting",August 2016,January 2018,Anticipated,Anticipated,University of Oxford,Alfred B Tiono,Principal Investigator,"Centre National de Recherche et de Formation sur la Paludisme, Ouagadougou, Burkina Faso",Phase 1/Phase 2,Interventional,24,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Safety and tolerability of administration of R21/Matrix-M1. This will be done by recording the number of participants who experience adverse events, and the severity of any adverse events.",NA,NA,NA,NA,NA,Centre National de Recherche et de Formatation sur le Paludisme (CNRFP)/Unite de Recherche Clinique de Banfora (URC-B),20 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Safety and tolerability of administration of R21/Matrix-M1. This will be done by recording the number of participants who experience adverse events, and the severity of any adverse events.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDC5972,NCT01184911,Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda,Assessment of the Efficacy of Sulphadoxine-Pyrimethamine for Intermittent Preventive Treatment of Malaria in Pregnancy in Uganda,Withdrawn,October 2010,September 2011,Anticipated,Anticipated,"University of California, San Francisco","Veronica Ades, MD, MPH",Principal Investigator,"University of California, San Francisco",Phase 4,Interventional,0,Actual,Intermittent Preventive Treatment; Placental Malaria,NA,Female,N/A,N/A,No,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Scott Filler, MD, DTM&H",Principal Investigator,Centers for Disease Control and Prevention,NA,Parasite clearance,NA,Centers for Disease Control and Prevention,U.S. Fed,Uganda Malaria Surveillance Project,Other,Infectious Disease Research Center,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Clearance of parasites in pregnant women with asymptomatic parasitemia after administration of SP,"Moses Kamya, MBChB, MMed, MPH, PhD",Principal Investigator,Uganda Malaria Surveillance Project,NA,NA,NA,NA,NA,Parasite clearance,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IPC_Pv_CQR_RTK,NCT02118090,Assessment of Plasmodium Vivax Chloroquine Resistance in Cambodia:,Assessing Chloroquine Resistance of Plasmodium Vivax in Malaria Endemic Area,Completed,May 2014,March 2015,Actual,Actual,"Institut Pasteur, Cambodia","Dysoley Lek, MD",Principal Investigator,National Centre for Parasitology Entomology and Malaria Control,Phase 4,Interventional,73,Actual,Vivax Malaria,NA,All,15 Years,N/A,No,"Institut Pasteur, Cambodia",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Didier Ménard, PharmD, PhD",Principal Investigator,Institut Pasteur in Cambodia,NA,Number of patients with P. vivax CQ resistant parasite,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,NA,NA,Provincial Hospital,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Based on parasite clearance time (slow versus fast clearers) and treatments failure (according to the CQ blood concentration),"Jean Popovici, PhD",Principal Investigator,Institut Pasteur in Cambodia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
INSP CI-624,NCT02394197,Effectiveness of Malaria Treatment in Mexico,"Comparison of the Effectiveness of Two Scheme Treatments to Treat Plasmodium Vivax Cases in Patients Living in Communities With Persistence of Transmission in Oaxaca and Chiapas, Mexico",Completed,February 2008,September 2010,Actual,Actual,LILIA GONZALEZ CERON,"LILIA GONZALEZ-CERON, PHD",Principal Investigator,NATIONAL INSTITUTE FOR PUBLIC HEALTH-MEXICO,Phase 4,Interventional,153,Actual,Malaria,NA,All,1 Year,70 Years,No,LILIA GONZALEZ CERON,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Changes in the presence and density of asexual parasites in thick blood smears by microscopy,Changes in the presence and severity of clinical symptoms,"Instituto de Diagnóstico y Referencia Epidemiológicos (InDRE), Mexico",Other,"Centro Nacional de Vigilancia Epidemiológica y control de enfermedades (CENAVECE), Mexico",Other,NA,"at days 2, 3, 7, 14, 21, 28 and monthly from month 2 to month 12, post-treatment administration","at days 2, 3, 7, 14, 21, 28 and anytime or monitor monthly during 12months, post-treatment administration",Changes in the presence of recurrent infections,"Jurisdicción Sanitaria VII, Chiapas, México",Other,NA,NA,NA,Pan American Health Organization,Other,NA,NA,"Proportion of patients at each time-point by intervention, presenting parasitemia and mean density by examining thick blood films stained with 10% Giemsa. The two thick smears were independently examined under a light microscope using oil immersion 100 × by two trained laboratory technicians. Asexual and sexual parasite densities were determined by counting the number of parasites against 200 white blood cells (WBC) (or 500 WBC, if less than 10 parasites were encountered in 200 WBC fields), assuming 7,000 WBC/μl of blood. At least 500 fields or the whole blood smear were examined before a sample was recorded as negative.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The proportion of patients at each time-point by intervension, that present any of the following symptoms; fever, headache, myalgias, arthralgias or paroxysm were indicated by patient reference or detected by field team search; by a clinical revision of the patient, using a calibrated thermometer. Othe signs were search by the clinician as jaundice (yellowish pigmentation of the skin, the conjunctival membranes over the sclerae (whites of the eyes), erythema, herpes-like small blisters on the lips and /or outer edges of the mouth and pruritus or any itching.","any time from month 1 to month 12, post T14 or during ISD treatment",Comparing the proportion of patients presenting recurrent infections at any time schedule or unschedule (symptomatic or asymptomatic) detected by any diagnosed method,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NMRR-12-89-11005,NCT01708876,P. Knowlesi Trial of Artesunate-mefloquine Versus Chloroquine,"Artesunate-mefloquine vs Chloroquine in Patients With Acute Uncomplicated P. Knowlesi and P. Vivax Malaria: a Randomized Open Label Trial in Sabah, Malaysia",Completed,October 2012,December 2014,Actual,Actual,Menzies School of Health Research,"Jayaram Menon, MBBS",Study Director,Sabah Ministry of Health,Phase 3,Interventional,250,Anticipated,Uncomplicated Plasmodium Knowlesi Malaria,NA,All,1 Year,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"D Prabhakaran, MBBS",Study Director,Sabah Ministry of Health,NA,Parasite clearance,NA,"Ministry of Health, Malaysia",Other,NA,NA,NA,24 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The primary endpoint is the therapeutic efficacy of artesunate-mefloquine versus chloroquine, as defined by the assessment of microscopic P. knowlesi and P. vivax parasite clearance 24 hours after initiation of treatment.","Matthew J Grigg, MBBS",Study Director,Menzies School of Health Research,"Tsin Yeo, MBBS",Study Director,Menzies School of Health Research,NA,NA,NA,NA,NA,"Lorenz von Seidlein, MBBS",Study Director,Menzies School of Health Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Nicholas M Anstey, MBBS",Study Director,Menzies School of Health Research,"Ric Price, MBBS",Study Director,Menzies School of Health Research,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TIP2,NCT01086917,Experimental Human Malaria Infection by PfSPZ,Experimental Human Malaria Infection by Intradermal Injection of Plasmodium Falciparum Sporozoites (PfSPZ Challenge),Completed,August 2010,July 2011,Actual,Actual,Sanaria Inc.,"Robert Sauerwein, Md PhD",Principal Investigator,UMC St Radboud,Phase 1,Interventional,18,Actual,Malaria,NA,All,19 Years,34 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of volunteers with Plasmodium falciparum Infection,NA,Radboud University,Other,NA,NA,Radboud University Nijmegen Medical Center,Upto 7 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To achieve a 100% infection rate of human volunteers by intradermal injection of aseptic, purified, cryopreserved Pf sporozoites (PfSPZ Challenge)as measured by 100% thick smear positivity (thick blood smears) of all volunteers from one group",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2010462-01H,NCT01976325,Evaluating the Ottawa Malaria Decision Aid,"Incorporation of the 'Ottawa Malaria Decision Aid' Into the Pre-travel Consultation Process: Assessment of Travelers' Knowledge, Decisional Conflict, Preparation for Decision-making and Medication Adherence Compared to Standard Care",Unknown status,January 2014,November 2015,Anticipated,Anticipated,Ottawa Hospital Research Institute,"Anne E McCarthy, MD, MSc",Principal Investigator,The Ottawa Hospital Research Institute,N/A,Interventional,100,Anticipated,Malaria,NA,All,18 Years,N/A,Accepts Healthy Volunteers,Ottawa Hospital Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Catherine Ivory, PhD",Study Chair,"University of Ottawa, Faculty of Medicine",NA,Travellers' Knowledge Score,NA,NA,NA,NA,NA,NA,One year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The traveller's knowledge score will be calculated based on participant's answers to questions from the Ottawa Malaria Knowledge Scale (2007) and the Realistic Expectations Scale (O'Connor 1996). For each multiple choice question, every possible response contains a predetermined scoring scheme. The traveller's knowledge score is calculated by adding points from each question answered. The sum of points forms the traveller's knowledge score.","Louise Balfour, PhD",Study Chair,Ottawa Hospital Research Institute,"Charde A Morgan, MScPH",Study Chair,Ottawa Hospital Research Institute,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WWARN1602,NCT02932072,Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2),Field Evaluation of a Device for Automated Malaria Microscopy (Autoscope Version 2),Not yet recruiting,October 2016,April 2017,Anticipated,Anticipated,University of Oxford,NA,NA,NA,N/A,Observational,160,Anticipated,Malaria,NA,All,6 Months,75 Years,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Diagnostic sensitivity for malaria parasite detection,Diagnostic specificity for malaria parasite detection,NA,NA,NA,NA,NA,6 months,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  Male or female subjects, age ≥ 6 months to 75 years

          -  Febrile at presentation or reported within the last 48 hours (>37.5 ºC) and no other
             obvious diagnosis cause for fever, warranting malaria investigation under routine
             clinical practice.

          -  Individual informed assent/consent obtained

        Exclusion Criteria:

          -  Signs of severe malaria as defined by WHO
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1142,NCT00292942,Study of the Safety of Intravenous Artesunate,"A Phase 1 Double-Blind, Placebo-Controlled, Randomized Multiple Dose Escalation Study to Evaluate the Safety, Tolerance, and Pharmacokinetics/Pharmacodynamics of a New GMP Formulation of Intravenous Artesunate if Healthy Subjects",Completed,NA,October 2006,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Peter J Weina, MD, PhD",Study Director,Walter Reed Army Institute of Research (WRAIR),Phase 1,Interventional,NA,NA,"Malaria; Malaria, Cerebral",NA,All,18 Years,55 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,Uniformed Services University of the HEalth Sciences,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1029,NCT00308061,"Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali","Dbl Blind Randomized Controlled Phase I Trial to Eval the Safety and Immunogenicity of WRAIR's MSP1 Candidate Malaria Vaccine (FMP1) Adjuvant in GSK Bio's AS02A vs. Rabies Vaccine in Semi-immune Adults in Bandiagara, Mali.",Completed,July 2003,NA,NA,NA,U.S. Army Medical Research and Materiel Command,"Mahamadou A Thera, MD MPH",Principal Investigator,"University of Bamako Faculty of Medicine, Mali",Phase 1,Interventional,NA,NA,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",July 2004,NA,NA,NA,40,Safety,Reactogenicity,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,Bandiagara Malaria Project,NA,NA,NA,GlaxoSmithKline,Industry,NA,NA,NA,United States Agency for International Development (USAID),U.S. Fed,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
0607M88827,NCT00850655,Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae,Genetic Association Mapping of Malaria Resistance in Anopheles Gambiae,Completed,March 2008,March 2015,Actual,Actual,University of Minnesota - Clinical and Translational Science Institute,"Kenneth D Vernick, PhD",Principal Investigator,University of Minnesota - Clinical and Translational Science Institute,N/A,Observational,20,Actual,Malaria,NA,All,5 Years,10 Years,No,University of Minnesota - Clinical and Translational Science Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,mosquito infection,NA,NA,NA,NA,NA,University of Minnesota,one week,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Protocol involves non-invasive blood draw from participant screened by finger-prick for infection with malaria. Drawn blood (0.5cc) is placed in artificial membrane feeder for feeding of mosquitoes. Primary outcome is infection of mosquitoes, detectable one week after blood feeding.",NA,NA,NA,NA,NA,NA,NA,NA,mosquito infection,Non-Probability Sample,"
        Inclusion Criteria:

          -  5-10 years old, and general good health

        Exclusion Criteria:

          -  Outside age group

          -  Specific diagnosable health problems

          -  General poor health
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2015-114,NCT02606526,Early Versus Late BCG Vaccination in HIV-1 Exposed Infants in Uganda in Uganda,A Randomised Controlled Trial in HIV-1 Exposed Ugandan Infants to Estimate Additional Benefits (Non-specific Effects) of BCG,Recruiting,July 2016,December 2020,Anticipated,Anticipated,Makerere University,"Victoria Nankabirwa, MD, MPH, PhD",Principal Investigator,"Department of Epidemiology and Biostatistics, School of Public Health, College of Health Sciences, Makerere University",Phase 3,Interventional,2200,Anticipated,Severe Illness; Septicaemia; Diarrhoea; Malaria; Lower Respiratory Infection,NA,All,N/A,1 Day,Accepts Healthy Volunteers,Makerere University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Halvor Sommerfelt, MD, PhD",Principal Investigator,"CISMAC, Center forInternational Health, University of Bergen",NA,Proportion of infants with severe illness,"Production of TNF, IL-1beta, IL-6 and IFN-γ in response to mycobacterial (from M. tuberculosis and PPD) and non-mycobacterial antigens (from E. coli, C.albicans and S. aureus)",Centre For International Health,Other,Radboud University,Other,Health Centers in Mukono and Kampala districts,The first 14 weeks of life,14 weeks post BCG vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Among children <2 months of age, severe illness (other than TB) will be defined as illness that: is associated with any of the following danger signs observed or verified by a study clinician: inability to feed or vomiting of everything and unable to keep anything down, lethargy or unconsciousness, severe lower chest in-drawing, axillary temperature of ≥37.5 deg C or <35.5 deg C, grunting, cyanosis, convulsions or a history of convulsions, and/or results in hospitalization and/or results in death. Among children ≥2 months of age, severe illness (other than TB) will be defined as illness that: is associated with at least one of the following danger signs observed by a clinician: inability to drink or breastfeed lethargy or unconsciousness, vomiting of all feeds, convulsions or a history of convulsions, and/or results in hospitalization and/or results in death. Hospitalization and death resulting from violent injury or burns will not contribute to the severe illness definition.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
LACHMI-001,NCT02237586,Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge,Effect of Plasmodium Falciparum Exposure and Sickle Cell Trait on Infection Rates and Kinetics After IV Administration of PfSPZ Challenge,Completed,July 2014,February 2015,Actual,Actual,Sanaria Inc.,"Bertrand Lell, MD",Principal Investigator,Centre de Recherche Médicale de Lambaréné,Phase 1,Interventional,25,Actual,Plasmodium Falciparum Malaria; Malaria,NA,All,18 Years,30 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Days from inoculation to start of malaria episode,"Frequency, incidence and nature of adverse events",Centre de Recherche Médicale de Lambaréné,Other,"Institute of Tropical Medicine, University of Tuebingen",Other,Centre de Recherches Médicales de Lambaréné,From day of injection until day 28,From day of injection until day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The time from parasite inoculation to first detection of malaria will be assessed by thick blood film microscopy and a clinical questionnaire. Malaria is defined as both parasitemia and clinical symptoms suggestive of malaria.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The safety of PfSPZ Challenge administered IV and the resultant P. falciparum infection will be assessed by analysing actively and passively collected data from clinical review of volunteers and laboratory measurements.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_OZ439_12_006,NCT01713621,OZ439 PhIIa Study in Plasmodium Falciparum: Extended Observation,"The Extended Observation Over a Period of 28 Days of the Effects of Single Doses of OZ439 on the Recrudescence of Plasmodium Falciparum Malaria - a PhIIa, Open Label Study in Adult Patients",Completed,March 2013,April 2015,Actual,Actual,Medicines for Malaria Venture,"Sasithon Pukrittayakamee, MD",Principal Investigator,"Faculty of Tropical Medicine, Mahidol University, Bangkok",Phase 2,Interventional,25,Actual,Malaria,NA,All,18 Years,60 Years,No,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Francois Nosten, MD",Principal Investigator,"Shoklo Malaria Research Unit, Faculty of Tropical medicine, Mahidol University",NA,Minimum Inhibitory Concentration (MIC) and Minimum Parasiticidal Concentration (MPC),NA,NA,NA,NA,NA,NA,up to 28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The estimated MIC and MPC were derived from the fitted parasitaemia concentration and PK/PD relationship.,NA,NA,NA,NA,NA,NA,NA,NA,Minimum Inhibitory Concentration (MIC) and Minimum Parasiticidal Concentration (MPC),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UGA.5.2RNA2005,NCT00259142,Acceptability and Cost Effectiveness of Home Based Management of Fever: Different Strategies,"Community Acceptability and Cost-effectiveness of Two Drug Distribution Methods for Home Based Management of Fevr in Kayunga District, Uganda",Terminated,November 2005,November 2005,Actual,Actual,DBL -Institute for Health Research and Development,"Robinah Najjembe, MD, MPH",Principal Investigator,Makerere University Institute of Public Health,N/A,Interventional,1314,Anticipated,Fever; Anaemia; Malaria,See detailed description,All,N/A,59 Months,No,DBL -Institute for Health Research and Development,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,World Health Organization,Other,"Institute for Epidemiology and Social Medicine, Aarhus University, Denmark",Other,Kayunga District,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
111315,NCT01231503,Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants,Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine 257049 When Administered on Different Schedules to Infants in Africa,Completed,January 2011,December 2014,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,480,Actual,Malaria,NA,All,N/A,7 Days,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Subjects Reported With Serious Adverse Events (SAEs),Concentrations of Antibodies Against Circumsporozoite Protein of Plasmodium Falciparum (Anti-CS Antibodies),The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,GSK Investigational Site,From study start at Month 0 up to Month 10.,"At 1 month (M) post Dose 3 of RTS,S/AS01E, e. a. M5 for RTS,S Neo-10-14, RTS,S 6-10-14 and Engerix-B Neo groups, M7 for RTS,S Neo-10-26, RTS,S 6-10-26, Engerix-B Neo/RTS,S 6-10-26, and RTS,S 10-14-26 groups), and M10 for RTS,S 14-26-9M Group",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"An SAE is any untoward medical occurrence that: results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or may evolve into one of the outcomes listed above. ""Any"" is defined an incidence of a SAE regardless of intensity/severity.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Anti-CS antibody concentrations were determined by enzyme-linked immunosorbent assay (ELISA) and presented as geometric mean concentrations (GMCs) expressed in ELISA units per milliliter (EL.U/mL). The seropositivity cut-off for the endpoint was a GMC value greater than or equal to (≥) 0.5 EL.U/mL.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDA 714703/006,NCT00371735,Chlorproguanil-Dapsone-Artesunate (CDA) Versus Chlorproguanil-Dapsone (LAPDAP) For Uncomplicated Malaria,"A Multi-centre, Randomised, Double-blind Study to Compare the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Chlorproguanil-dapsone in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children, Adolescents and Adults in Africa.",Completed,April 2006,May 2007,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,900,Actual,"Malaria, Falciparum","Parasitological cure rate, PCR-corrected, at day 28, in the per-protocol population. Parasitological cure rate is defined as the clearance of the initial malaria infection by day 7 and remaining free of this infection to the day of assessment.",All,12 Months,N/A,No,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SB-714703/003,NCT00519467,Safety and Efficacy Dose of Artesunate Used in Combination With LAPDAP Treatment of Uncomplicated Falciparum Malaria,"An Open, Randomised, Multi-centre Dose Ranging Phase II Study to Evaluate LAPDAP in Combination With Three Different Doses of Artesunate",Completed,June 2003,February 2005,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,120,Actual,Malaria,"Treatment differences between 1,2, or 4mg/kg artesunate with a fixed dose of Chlorproguanil-dapsone (LAPDAP), as measured by determination of PC90 (time to achieve reduction of parasitaemia by 90% of baseline)",All,18 Years,60 Years,No,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2011-9-56,NCT01517230,Can Mass Media Campaigns Reduce Child Mortality,Can Mass Media Campaigns Reduce Child Mortality,Completed,March 2012,April 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,"Simon N Cousens, MA",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,100000,Actual,Diarrhoea; Malaria; Pneumonia; Breastfeeding; Under-nutrition,NA,All,N/A,5 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Nicolas Meda, MD, PhD",Principal Investigator,Centre Muraz,NA,Post neonatal under-five all cause mortality,NA,Development Media International,Other,Centre Muraz,Other,Centre Muraz,1 year,NA,NA,Wellcome Trust,Other,NA,NA,NA,Planet Wheeler Foundation,Other,NA,NA,NA,"Sophie Sarrassat, PhD",Study Director,London School of Hygienne and Tropical Medicine,"Moctar Ouedraogo, MsD",Study Director,"Centre MURAZ / AfricSanté, Burkina Faso",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2000004199,NCT02450630,Assessing the Effect of Strengthening Referral of Sick Children From the Private Health Sector and Its Impact on Referral Uptake in Uganda.,Strengthening Referral of Sick Children Form the Private Health Sector,Unknown status,May 2015,May 2017,Anticipated,Anticipated,"Ministry of Health, Uganda","Anthony K Mbonye, PhD",Principal Investigator,Minstry of Health Uganda,N/A,Interventional,8910,Anticipated,Malaria,NA,All,N/A,5 Years,No,"Ministry of Health, Uganda",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The proportion of sick children referred from the private sector that complete the referral process (seen at higher level facilities).,NA,"Makerere University, College of Health Sciences Scholl of Public Health",Other,Columbia University,Other,NA,2 years,NA,NA,LSHTM,Other,NA,NA,NA,University of Copenhagen,Other,NA,NA,This will be measured as a proportion of referred sick children of the total number of sick children,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A-8340,NCT02488902,"A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum","A Randomized, Double-blind, Placebo-controlled Evaluation of Increasing Doses of Weekly Tafenoquine for Chemosuppression of Plasmodium Falciparum in Semi-immune Adults Living in the Kassena-Nankana District of Northern Ghana",Completed,August 1998,March 2003,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Braden Hale, MD",Principal Investigator,US Naval Medical Research Unit,Phase 2,Interventional,521,Actual,Malaria,NA,All,18 Years,60 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,First occurrence of malaria infection,NA,SmithKline Beecham,Industry,NA,NA,NA,16 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,First occurrence of malaria infection as documented by a positive malaria smear.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QA475,NCT02213211,School-based Programme of Malaria Diagnosis and Treatment in Southern Malawi,Impact of a School-based Programme of Malaria Diagnosis and Treatment on School Attendance in Southern Malawi,Completed,April 2014,March 2015,Actual,Actual,London School of Hygiene and Tropical Medicine,"Don P Mathanga, MBBS",Principal Investigator,"Malaria Alert Centre, College of Medicine, Malawi",N/A,Interventional,3667,Actual,Malaria,NA,All,5 Years,18 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Katherine E Halliday, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,School attendance,NA,Save the Children,Other,NA,NA,"Malaria Alert Centre, College of Medicine",1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,School attendance as assessed by class registers and independent spot-checks,"Simon J Brooker, DPhil",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVG40,NCT00115921,Evaluation of Home-Based Management of Fever in Urban Ugandan Children,Evaluation of Home-Based Management of Fever in Urban Ugandan Children,Completed,July 2005,April 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Sarah G Staedke, MD",Principal Investigator,"University of California, San Francisco",N/A,Interventional,NA,NA,Malaria; Anemia,The primary outcome measurement will be treatment incidence density (antimalarial treatments received per time at risk) for each study arm.,All,1 Year,5 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Christopher JM Whitty, FRCP",Principal Investigator,London School of Hygiene and Tropical Medicine,540,NA,NA,Makerere University,Other,"University of California, San Francisco",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVG28,NCT00121771,Malaria Candidate Vaccines FP9 Circumsporozoite (CS) and MVA CS in Adult Gambian Men,A Phase 1 Trial of the Malaria Candidate Vaccines FP9 CS and MVA CS in Adult Gambian Men Aged 18 - 45 Years,Completed,January 2004,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Adrian VS Hill, MD, Phd",Study Chair,"Centre for Human Genetics, University of Oxford",Phase 1,Interventional,NA,NA,Malaria,Safety and immunogenicity,Male,18 Years,45 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",July 2004,NA,NA,NA,32,NA,NA,Medical Research Council,Other,University of Oxford,Other,Medical Research Council Laboratories,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC-795-835,NCT00294580,Early Childhood Malaria Prevention With Maloprim in The Gambia,Comparison of Two Strategies for Control of Malaria Within A Primary Health Care Programme in the Gambia,Completed,April 1982,NA,NA,NA,Imperial College London,"Brian M Greenwood, MD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 4,Interventional,NA,NA,Malaria,NA,All,3 Months,59 Months,Accepts Healthy Volunteers,Imperial College London,Other,"ClinicalTrials.gov processed this data on July 26, 2017",September 2001,"Matthew CH Jukes, DPhil",Principal Investigator,Imperial College London,2253,Mortality,Episodes of Fever Associated with Malaria Parasitaemia,"Medical Research Council Unit, The Gambia",Other,Government of the Gambia,Other,Medical Research Council Field Station,NA,NA,Cognitive Abilities in late adolescence,London School of Hygiene and Tropical Medicine,Other,Educational Attainment (Years spent at school),NA,NA,Partnership for Child Development,Other,Wellcome Trust,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
35464-B,NCT00914225,Effect of Bednets and a Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya,Effect of Long-lasting Insecticide-treated Bednets and a Point-of-use Water Purification Device on HIV Disease Progression Among ART naïve Patients in Kenya,Completed,September 2009,December 2011,Actual,Actual,University of Washington,"Judd T Walson, MD MPH",Principal Investigator,University of Washington,N/A,Observational,500,Actual,HIV Infections; Human Immunodeficiency Virus; Malaria; Plasmodium Falciparum; Diarrhea,NA,All,18 Years,N/A,No,University of Washington,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Benson Singa, MBChB MPH",Principal Investigator,Kenya Medical Research Institute,NA,"To determine the effect of LLIN and a simple microbiological water purification system on markers of HIV progression (time to HAART eligibility and changes in CD4 counts) among antiretroviral naïve, HIV infected adults in Kenya.",NA,Kenya Medical Research Institute,Other,NA,NA,NA,"Mass screening and enrollment in July 2009, followed by two years of follow-up, and up to a year of data analysis.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"PRIMARY AIM (Aim 1): To determine the effect of the intervention, we will evaluate the effect of the provision of LLIN and water filters on markers of disease progression at 12 months. We will compare the time to eligibility for ART between the groups and the time to CD4 counts of less than 200 and 350 respectively using Cox regression analysis models. In addition, we will compare differences between the mean change in CD4 counts at month 12 of follow-up using ANCOVA controlling for baseline CD4 values.",NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Participants must be at least 18 years of age.

          -  Participants must not be or have ever been on highly active antiretroviral therapy CD4
             count at enrollment of ≥350 cells/mm3

          -  WHO Stage I or II or Stage III based on pulmonary TB only and have completed 2 months
             of first-line therapy.

          -  Participants must be able and willing to participate and give written informed consent

          -  Participants must be able and willing to return for the scheduled follow-up visits

        Exclusion Criteria:

          -  Age less than 18 years

          -  CD4 count <350 cells/mm3

          -  WHO Stage III or IV HIV Disease study (unless stage III for TB and have completed 2
             months of first-line therapy)

          -  Participants must not be pregnant at the time of enrollment (by urine HCG testing)

          -  Patients with active tuberculosis who are on second or third line therapy or have not
             completed at least 2 months of first line TB therapy (Participants who have completed
             two months of first line TB therapy will be eligible for enrolment)
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
HSR/DD/677-01/DG-CM/624-02,NCT00140517,Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance,Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance,Completed,October 2002,March 2008,Actual,Actual,London School of Hygiene and Tropical Medicine,"Sheick O Coulibaly, MD",Principal Investigator,Laboratoire National de Sante Publique,N/A,Interventional,NA,NA,Malaria in Pregnancy; Birth Weight; Anaemia,See detailed description,Female,15 Years,49 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,700,NA,NA,DBL -Institute for Health Research and Development,Other,NA,NA,Centre Medicale Paul VI,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVG04,NCT00146731,A Trial of Antimalarial Drugs Used in Pregnancy in Tanzania,Treating Malaria During Pregnancy: A Randomized Trial of Potential Options for Treatment in an Area of High Drug Resistance in Tanzania,Completed,January 2004,September 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Theonest K Mutabingwa, MD PhD",Study Director,LSHTM/NIMR,Phase 3,Interventional,310,Actual,Malaria,The primary end-point of the trial will be treatment failure. This is defined above.,Female,15 Years,38 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Christopher JM Whitty, FRCP",Principal Investigator,LSHTM,NA,NA,NA,"National Institute for Medical Research, Tanzania",Other,NA,NA,Muheza Designated District Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Daniel Chandramohan, MD",Principal Investigator,LSHTM,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
A60041,NCT01845701,Artemisinin-Based Antimalarial Combinations and Clinical Response in Cameroon,Phase III Study to Study the Clinical Response to ACT Fixed Dose Combination in 42 Days in Uncomplicated Malaria in Cameroon,Completed,March 2010,April 2015,Actual,Actual,University of Yaounde 1,"Wilfred F Mbacham, ScD",Principal Investigator,University of Yaounde 1,Phase 3,Interventional,720,Actual,Malaria,NA,All,6 Months,120 Months,No,University of Yaounde 1,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Clinical Efficacy,NA,World Health Organization,Other,Gates Malaria Partnership,Other,NA,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Patient's trial outcome will be classified according to the WHO guidelines (WHO 2003) with application as follows: Early Treatment Failure (ETF); Late Clinical Failure (LCF); Late Parasitological Failure (LPF); Adequate Clinical and Parasitological Response (ACPR) - Absence of parasitaemia on day 42 irrespective of temperature without previously meeting any of the criteria of early treatment failure or late clinical failure or late parasitological failure,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MedicalCareDev,NCT02458066,Trial to Compare Effectiveness of 2 Insecticides in Preventing Malaria,Cluster Randomised Trial to Compare Effectiveness of Bendiocarb and Deltamethrin (Long‐Lasting) in Preventing Malaria Infection,Completed,February 2014,October 2014,Actual,Actual,"Medical Care Development, Inc.",NA,NA,NA,N/A,Interventional,2800,Actual,Malaria,NA,All,2 Years,14 Years,Accepts Healthy Volunteers,"Medical Care Development, Inc.",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Prevalence of falciparum infection in 2-14 year olds,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,NA,3-5 months post receiving IRS,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Cross sectional Rapid Diagnostic Test (RDT)-based prevalence of infection of P.falciparum in children between the ages of 2 and 14 of the participating localities.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITIMVG38,NCT00146796,A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Malaria in Tanzania,A Randomised Trial of Rapid Diagnostic Tests in the Diagnosis of Non-Severe Malaria at Different Transmission Intensities of Plasmodium Falciparum in Tanzania,Completed,January 2005,November 2005,Actual,Actual,London School of Hygiene and Tropical Medicine,"Christopher Whitty, FRCP",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 4,Interventional,2400,Actual,Malaria; Febrile Illness,NA,All,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,"Kilimanjaro Christian Medical Centre, Tanzania",Other,NA,NA,Kilimanjaro Christian Medical College,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCKD45,NCT00158561,Chlorproguanil/Dapsone Compared With Chloroquine and SP for Vivax Malaria,An Open-label Three Arm Trial of the Efficacy and Safety of Chlorproguanil / Dapsone (Lapdap) Compared With Chloroquine and Sulfadoxine / Pyrimethamine for the Treatment of Vivax Malaria in Pakistan and Afghanistan,Completed,February 2004,March 2006,Actual,Actual,London School of Hygiene and Tropical Medicine,"Christopher Whitty, FRCP",Principal Investigator,LSHTM,Phase 3,Interventional,NA,NA,Malaria; Vivax Malaria,"Day 14 slide clearance rate (complete clearance of parasites), assessed by microscopists who are blind to treatment allocation.",All,3 Years,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Mark Rowland, PhD",Study Director,LSHTM,750,NA,NA,HealthNet TPO,Other,NA,NA,HealthNet International,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
7R01NS074409-02,NCT01982812,A Safety and Feasibility Study of Enteral LVT vs. Standard of Care for Seizure Control in Pediatric CM,A Safety and Feasibility Study of Enteral Levetiracetam vs. Phenobarbital for Seizure Control in Pediatric Cerebral Malaria,Completed,January 2014,June 2015,Actual,Actual,University of Rochester,"Gretchen L Birbeck, M.D.",Principal Investigator,University of Rochester,Phase 2,Interventional,44,Actual,Seizure; Epilepsy; Cerebral Malaria,NA,All,24 Months,83 Months,No,University of Rochester,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Minutes With Seizure on EEG,NA,National Institute of Neurological Disorders and Stroke (NINDS),NIH,NA,NA,Queen Elizabeth Central Hospital,72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Comparing LVT to standard AED the number of minutes spent in seizure per cEEG in the 72 hours after treatment allocation.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCR5093,NCT00169078,Impact of Insecticide-treated Curtains on Antimalarial Drug Resistance,A Study of the Impact of Insecticide-treated Curtains on the Prevalence of Antimalarial Drug Resistance in Children With Uncomplicated Malaria in Burkina Faso,Completed,July 2002,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Simon Cousens, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,NA,NA,Malaria,NA,All,6 Months,59 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2002,"Brian M Greenwood, FRCP FRS",Principal Investigator,London School of Hygiene and Tropical Medicine,1035,Clinical and parasitological failure rates by day 14,"Prevalence of pfcrt-76T, pfmdr1-86Y before treatment",NA,NA,NA,NA,Centre National de Recherche et de Formation sur le Paludisme,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Diadier Diallo, MsC",Principal Investigator,Centre National de Recherche et de Formation sur le Paludisme,"Colin Sutherland, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999904216,NCT00340431,Experimental Vaccine for Plasmodium Falciparum Malaria,"Phase 1 Study of the Safety and Immunogenicity of MSP1(42)-FVO/Alhydrogel and MSP1(42)-3D7/Alhydrogel, Asexual Blood-Stage Vaccines for Plasmodium Falciparum Malaria",Completed,"June 9, 2004",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Plasmodium Falciparum Malaria; Vaccines,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","February 6, 2008",NA,NA,NA,0,NA,NA,NA,NA,NA,NA,Quintiles Phase 1 Services,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999905117,NCT00340574,Improving the Efficacy of Experimental Malaria Vaccine AMA1-C1/Alhydrogel® (Registered Trademark),"Phase I Study of the Safety and Immunogenicity of AMA-1-C1/Alhydrogel + CPG 7909, An Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,"March 8, 2005",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Healthy Volunteer; HV,NA,All,18 Years,45 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","July 2, 2008",NA,NA,NA,0,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999905210,NCT00341003,Severe Malaria and Anti-malarial Drug Resistance in Cambodia,Multidisciplinary Studies of Severe Malaria and Antimalarial Drug Resistance in Cambodia,Completed,"July 22, 2005",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,2090,Anticipated,Severe Malaria; Malaria; Antimalarial Drug Resistance,NA,All,N/A,N/A,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","January 14, 2011",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pursat Regional Health Center,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999906081,NCT00341250,Malaria Vaccine in Children in Mali,"Randomized, Controlled, Phase 1/2 Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel Vaccine for Plasmodium Falciparum Malaria in Children in Doneguebougou and Bancoumana, Mali",Completed,"January 19, 2006",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1/Phase 2,Interventional,NA,NA,Malaria,NA,All,2 Years,3 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","December 8, 2006",NA,NA,NA,900,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MOCRU1301,NCT02020330,Optimising Operational Use of Artemether-lumefantrine Comparing 3 Day Versus 5 Day,An Open-label Randomized Controlled Trial to Evaluate the Effectiveness and Safety of a 3 Day Versus 5 Day Course of Artemether-lumefantrine for the Treatment of Uncomplicated Falciparum Malaria in Myanmar,Unknown status,January 2014,December 2015,Anticipated,Anticipated,University of Oxford,"Frank Smithuis, MD",Principal Investigator,Myanmar Oxford Clinical Research Unit,Phase 3,Interventional,150,Anticipated,Plasmodium Falciparum Infection,NA,All,6 Years,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,proportion of patients with detectable parasitaemia,NA,NA,NA,NA,NA,Medical Action Myanmar,On day 5 and day 7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Assessed by sensitive PCR on days 5 and 7 after treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_MMV390048_14_01,NCT02230579,Phase I Study of Ascending Doses of MMV390048 in Healthy Adult Volunteers,"A Single Centre, Two-part, Double-blind, Randomized, Placebo-controlled Phase I Study to Investigate the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Doses of MMV390048 in Healthy Adult Volunteers",Completed,May 2014,February 2015,Actual,Actual,Medicines for Malaria Venture,NA,NA,NA,Phase 1,Interventional,40,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of participants with adverse events,"Area under the plasma concentration versus time curve (AUC) of MMV390048, and its half life","Technology Innovation Agency, South Africa",Other,NA,NA,"Cinical Pharmacology, University of Cape Town",up to D29 or longer according to half life,"0.5, 1, 2, 3, 4, 6, 8, 12, 24, 48, 96, 144, 216, 312, 432, 600, 672 hours post-dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Subject will be in-house up to D3, and then have a follow up visit at the site on D5, 7, 10, 14, 19, 26, 29 or longer according to half life",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Pk blood collection - additional PK point may be planned final visit depending on emerging PK data, unnecessary PK points could be eliminated for the latter cohorts Investigate the effect of food on the pharmacokinetic and tolerability of the investigational drug in cohort 4 and 8",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ACTEffectiveness,NCT01017770,Artemether-lumefantrine (AL) Versus Artesunate + Amodiaquine (ASAQ) for the Treatment of Uncomplicated Falciparum Malaria in Burkina Faso,Artemether-lumefantrine Vs Co-formulated Amodiaquine + Artesunate for the Treatment of Uncomplicated Falciparum Malaria: a Randomized Open-label Trial to Evaluate the Effectiveness of the Burkina Faso New Drug Policy,Completed,September 2008,August 2010,Actual,Actual,Centre Muraz,NA,NA,NA,Phase 4,Interventional,340,Anticipated,Uncomplicated P. Falciparum Malaria in Children,NA,All,6 Months,59 Months,No,Centre Muraz,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Polymerase chain reaction (PCR) adjusted treatment failure,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,NA,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CM/CRUN0012,NCT01697787,Amodiaquine-Artesunate & Artemether-Lumefantrine Efficacy in Burkina Faso,"Efficacy of Amodiaquine-Artesunate (ASAQ) and Artemether-Lumefantrine (AL) for the Treatment of Uncomplicated Falciparum Malaria in Nanoro, Burkina Faso",Completed,October 2012,September 2014,Actual,Actual,Centre Muraz,"Halidou Tinto, PharmD, PhD",Study Director,IRSS/Centre Muraz,Phase 4,Interventional,150,Actual,Malaria,NA,All,6 Months,90 Years,No,Centre Muraz,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Rate of treatment failures,NA,"Institute of Tropical Medicine, Belgium",Other,NA,NA,Clinical Reaserch Unit,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The rate of the two ACTs treatment failures at day 28: all treatment failures, both parasitological and clinical (positive blood slide at day 28)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DIF 35,NCT00361114,IPT and Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Malaria.,Efficacy of Sulphadoxine/Pyrimethamine and Chlorproguanil/Dapsone in 6-59 Month Old Children With Uncomplicated Malaria and in 2-10 Month Old Asymptomatic Infants.,Terminated,July 2006,October 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Roly D Gosling, MD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,112,Actual,Malaria,NA,All,2 Months,59 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Samwel Gesase, MD",Principal Investigator,"National Institute of Medical Research, Tanzania",NA,Clinical /Parasitological Outcomes (WHO 2003),Early Treatment Failure (ETF),NA,NA,NA,NA,Hale Dispensary,Day 14 and 28,3 days,"§ Development of danger signs or severe malaria on Day 1, 2, or 3, in the presence of parasitemia",NA,NA,§ Parasitemia on Day 2 higher than Day 0 count irrespective of axillary temperature,§ Parasitemia on Day 3 with axillary temperature ≥37.5°C,§ Parasitemia on Day 3 ≥ 25% of count on Day 0,NA,NA,NA,NA,NA,"Jaqueline Mosha, MD",Principal Investigator,"Kilimanjaro Christian Medical College, Tanzania",NA,NA,NA,Late Clinical Failure (LCF),"§ Development of danger signs or severe malaria from Day 4 to Day 28 in the presence of parasitemia, without previously meeting any of the criteria of ETF",NA,NA,NA,NA,NA,NA,NA,3 Days,NA,2 nd day,NA,NA,NA,3 rd day,NA,3 rd Day,NA,After Day 3 to day 28,NA,Day 4 - 28,NA,"§ Presence of parasitemia and axillary temperature ≥37.5° C on any day from Day 4 to Day 28, without previously meeting any of the criteria of ETF",Day 4 to Day 28,NA,Late parasitological failure (LPF) -,Day 4 - 28,NA,"Presence of parasitemia on Day 14, 21, or 28 and axillary temperature <37.5°C without previously meeting any of the criteria of ETF or LCF (after exclusion of re-infection by PCR for failures at days 14-28)","Day 14, 21, or 28",NA,Adequate Clinical and Parasitological Response (ACPR) -,Day 28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Absence of parasitemia on Day 28 irrespective of axillary temperature, without previously meeting any of the criteria of ETF, LCF or LPF",Day 28,NA,NA,NA,NA,NA
070083,NCT00427167,Phase I Study of AMA1-C1/Alhydrogel® (Registered Trademark) + CPG 7909 Malaria Vaccine,"Phase I Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel + CPG 7909, an Asexual Blood Stage Vaccine for Plasmodium Falciparum Malaria",Completed,"January 23, 2007","November 5, 2008",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Malaria,Assessment of the safety and reactogenicity of the AMA1-C1/Alhydrogel + CPG 7909 vaccine in phosphate and saline buffers; and determine the frequency of summarized systemic and local AFs by severity and relationship to the vaccine.,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,300,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B00531,NCT01703884,ANC & Malaria Diagnostic in Pregnancy,Improved Quality of ANC and Diagnostic Services for Malaria in Pregnancy,Completed,August 2012,December 2014,Actual,Actual,Centre Muraz,"Halidou Tinto, PharmD, PhD",Principal Investigator,centre muraz - irss,Phase 4,Interventional,5254,Actual,Malaria,NA,Female,16 Years,50 Years,No,Centre Muraz,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Placental malaria at delivery,NA,World Health Organization,Other,NA,NA,Dafra & Do districts,9 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The main outcome variable of interest will be the proportion of women in each group with placental malaria at delivery (defined as placental biopsies positive for P. falciparum ),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
3245,NCT02298140,Providers' Compliance to Malaria Treatment,Responding to Efficacy Decay Analysis of Artemisinin Based Combination Therapy (ACTs) in Rural Tanzania: Intervening on Provider Compliance and Patient Adherence to Correct Malaria Treatment,Unknown status,November 2014,December 2015,Anticipated,Anticipated,Ifakara Health Institute,"Don de Savigny, PhD",Principal Investigator,Swiss Tropical & Public Health,N/A,Interventional,712,Anticipated,Malaria,NA,All,N/A,N/A,No,Ifakara Health Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Provider Compliance,NA,Swiss Tropical & Public Health Institute,Other,KEMRI-Wellcome Trust Collaborative Research Program,Other,Ifakara Health Institute,10 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Proportion of patients presenting to health provider for initial illness consultation with fever (documented fever or history of fever within 48 hours); who are tested for malaria and prescribed ACT for test positive results or not prescribed any antimalarial for test negative results.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PD 010607,NCT00494416,Different Approaches for Delivery of IPT in Pregnancy in Burkina Faso,A Comparison of Different Approaches for Delivery of Intermittent Preventive Treatment (IPT)to Pregnant Women in Burkina Faso With Regard to Coverage and Compliance,Completed,June 2007,November 2009,Actual,Actual,London School of Hygiene and Tropical Medicine,"Sheick O Coulibaly, MD, PhD",Principal Investigator,Laboratoire National de Sante Publique,N/A,Interventional,11523,Actual,Malaria Parasitaemia; Birth Weight; Anaemia,NA,Female,15 Years,45 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,compliance,coverage,DBL -Institute for Health Research and Development,Other,NA,NA,Pissy Health District,24 month after study start,24 month after study start,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DFID-R7602,NCT00857077,Intermittent Preventive Treatment for Malaria in Infants in Navrongo Ghana,Evaluation of the Safety and Effectiveness of EPI-linked Malaria Intermittent Chemotherapy and Iron Supplementation,Completed,September 2000,June 2004,Actual,Actual,London School of Hygiene and Tropical Medicine,"Daniel Chandramohan, MD; PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,2485,Actual,Anaemia; Malaria,incidence of anaemia,All,2 Months,24 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Brian Greenwood, MD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,"Navrongo Health Research Centre, Navrongo, Ghana.",Other,"Kintampo Health Research Centre, Ghana",Other,Navrongo Health Research Centre,NA,NA,NA,INDEPTH Network,Other,NA,NA,NA,"Department for International Development, United Kingdom",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999909093,NCT00863408,Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali,Estivation of Malaria Vector Mosquitoes in the Sahelian Region of Mali (Village of Thierola in the District of Banamba),Completed,"March 3, 2009",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Malaria,NA,Male,18 Years,65 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","March 10, 2010",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"National Institutes of Health Clinical Center, 9000 Rockville Pike",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMC LNS Mali,NCT03035305,Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Mali,"Seasonal Malaria Chemoprevention With or Without Lipid-based Nutrient Supplement in Children Aged 6-59 Months in Kolokani Circle, Koulikoro Region, Mali, August-November 2016: Interventional Matched-pair Clustered Cohort",Completed,NA,November 2016,Actual,Actual,Alliance for International Medical Action,"Susan Shepherd, MD",Principal Investigator,The Alliance for International Medical Action (ALIMA),N/A,Interventional,36717,Actual,Malaria,NA,All,6 Months,59 Months,No,Alliance for International Medical Action,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Renaud Becquet, PhD",Principal Investigator,"Inserm U1219 Bordeaux Population Health Center, University of Bordeaux",NA,Confirmed malaria case,NA,"Institut National de la Santé Et de la Recherche Médicale, France",Other,"Alliance médicale contre le paludisme, Mali",Other,Amcp/Alima,"From the 2nd round of SMC distribution (4 weeks after the date of inclusion) to the 4th round of SMC distribution (12 weeks after the date of inclusion), assessed up to 8 weeks",NA,NA,"Programme national de lutte contre le paludisme, Mali",Other,NA,NA,NA,United States Agency for International Development (USAID),U.S. Fed,European commission for humanitarian office,Other,Malaria case is confirmed by a positive malaria rapid diagnostic test. This outcome will be defined as the occurrence of at least one confirmed malaria case from the 2nd through the 4th round of SMC distribution.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,August 2016,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Ministry of health, Mali",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FDAAA,NCT02524444,A Comparative Study of Mefloquine and S-P as Prophylaxis Against Malaria in Pregnant HIV + Patients,A Comparative Study of Mefloquine and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant Human Immunodeficiency Virus Positive Patients,Not yet recruiting,September 2015,February 2016,Anticipated,Anticipated,ORIYOMI OMOTOYOSI AKINYOTU,"AYODELE O AROWOJOLU, MBBS IBADAN",Study Director,"UNIVERSITY COLLEGE HOSPITAL,IBADAN,OYO STATE, NIGERIA",Phase 1,Interventional,140,Anticipated,Malaria in Pregnant HIV + Patients,NA,Female,18 Years,45 Years,Accepts Healthy Volunteers,ORIYOMI OMOTOYOSI AKINYOTU,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"ORIYOMI O AKINYOTU, MBBS IBADAN",Principal Investigator,"UNIVERSITY COLLEGE HOSPITAL,IBADAN,OYO STATE,NIGERIA",NA,Level of malaria parasitemia in HIV positive women at delivery after administration of Mefloquine or sulphadoxine-pyrimethamine as prophylaxis for malaria in pregnancy,NA,University of Ibadan,Other,NA,NA,University College Hospital,6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ADENIKE F BELLO, MBBS IBADAN",Study Director,"UNIVERSITY COLLEGE HOSPITAL,IBADAN,OYO STATE, NIGERIA",NA,NA,NA,NA,NA,Level of malaria parasitemia in HIV positive women at delivery after administration of Mefloquine or sulphadoxine-pyrimethamine as prophylaxis for malaria in pregnancy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UIbadan,NCT02527005,A Comparative Study of Azithromycin and S-P as Prophylaxis in Pregnant HIV+ Patients,A Comparative Study of Azithromycin and Sulphadoxine-pyrimethamine as Prophylaxis Against Malaria in Pregnant HIV Positive Patients,Not yet recruiting,September 2015,February 2016,Anticipated,Anticipated,University of Ibadan,"AYODELE O AROWOJOLU, MBBS IBADAN",Study Director,"UNIVERSITY COLLEGE HOSPITAL,IBADAN,OYO STATE, NIGERIA",Phase 1,Interventional,140,Anticipated,Malaria; Pregnant; HIV,NA,Female,18 Years,45 Years,Accepts Healthy Volunteers,University of Ibadan,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"ORIYOMI O AKINYOTU, MBBS IBADAN",Principal Investigator,"UNIVERSITY COLLEGE HOSPITAL, IBADAN, OYO STATE, NIGERIA",NA,Level of malaria parasitemia at delivery in HIV positive women following administration of Azithromycin or Sulphadoxine- pyrimethamine as intermittent preventive therapy for malaria in pregnancy,NA,NA,NA,NA,NA,"University College Hospital,",6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"ADENIKE F BELLO, MBBS IBADAN",Study Director,"UNIVERSITY COLLEGE HOSPITAL, IBADAN, OYO STATE, NIGERIA","ADEOLA R ABDUS-SALAM, MBBS IBADAN",Study Director,"ADEOYO MATERNITY TEACHING HOSPITAL, IBADAN, OYO STATE",NA,NA,Level of malaria parasitemia at delivery in HIV positive women following administration of Azithromycin or Sulphadoxine- pyrimethamine as intermittent preventive therapy for malaria in pregnancy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMVDU-013,NCT01341704,Proof-of-Concept Study of MSP3-LSP Vaccine to Protect Against Malaria in Africa,"Phase 2B Double Blind, Randomized, Controlled Trial to Evaluate the Safety, Immunogenicity and Protective Efficacy of MSP3-LSP Vaccine Candidate Adjuvanted in Aluminium Hydroxide (AIOH) Against Plasmodium Falciparum Clinical Malaria in Healthy Children Aged 12-48 Months in Mali",Completed,May 2011,March 2013,Actual,Actual,Vac4All,"Mahamadou Sissoko, MD",Principal Investigator,"Malaria Research and Training Center Department of Epidemiology of Parasitic Diseases Faculty of Medicine, Pharmacy and Dentistry University of Bamako BP 1805, Point G Bamako, Mali, West Africa",Phase 2,Interventional,800,Actual,Malaria,NA,All,12 Months,48 Months,Accepts Healthy Volunteers,Vac4All,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Pierre L Druilhe, MD",Study Director,"CEO, Vac4All",NA,Number of episodes of clinical malaria occurring during a period beginning from 14 days after the 3rd immunization until 3 months after 3rd immunization in all subjects.,NA,University of Bamako,Other,NA,NA,"Malaria Research and Training Center Department of Epidemiology of Parasitic Diseases Faculty of Medicine, Pharmacy and Dentistry University of Bamako BP 1805, Point G Bamako, Mali, West Africa Tel/Fax 223-2022-8109",3 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,A clinical malaria episode is defined as a febrile illness with a documented axillary temperature of,"Ogobara Doumbo, MD",Study Director,"Chief, MRTC",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
EPIDZC8610,NCT02556242,Targeted Indoor Residual Spraying Against Malaria,From Malaria Control to Sustainable Elimination: Cluster Randomised Trial Comparing Targeted Versus Generalised Vector Control in South Africa,Enrolling by invitation,October 2015,July 2017,Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Maureen Coetzee, Phd",Principal Investigator,"University of Witwatersrand, South Africa",Phase 4,Interventional,500000,Anticipated,Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Immo Kleinschmidt, Phd",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,"Malaria incidence, by routine passive case detection, of clinical malaria (fever ≥37.5°C, or history of fever (48 hours), in the presence of parasitaemia confirmed by RDT or microscopy).",NA,"University of Witwatersrand, South Africa",Other,"National Department of Health, South Africa",Other,NA,Communities will be followed for up to 20 months,NA,NA,Medical Research Council,Other,NA,NA,NA,"National Institute for Communicable Diseases, South Africa",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MC-002,NCT02119312,Malaria Clinical Trials Center General Screening,"General Screening for Eligibility to Participate in Treatment, Prevention and Vaccine Trials at the Seattle Malaria Clinical Trials Center",Recruiting,June 2010,NA,NA,NA,Fred Hutchinson Cancer Research Center,"James G Kublin, MD",Principal Investigator,Fred Hutchinson Cancer Research Center,N/A,Observational [Patient Registry],3500,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Fred Hutchinson Cancer Research Center,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Participant Enrollment,NA,NA,NA,NA,NA,Fred Hutchinson Cancer Research Center,Once upon enrollment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,See inclusion/exclusion criteria.,NA,NA,NA,NA,NA,NA,NA,NA,Participant Enrollment,Probability Sample,"
        Inclusion Criteria:

          -  Good general health status as demonstrated by medical history, physical exam, and
             screening laboratory tests;

          -  No history of certain chronic medical illnesses (e.g. diabetes, epilepsy, autoimmune
             disease, hepatitis, heart disease);

          -  HIV, Hepatitis B and C negative;

          -  Low risk for coronary heart disease;

          -  Ability and willingness to provide informed consent;

          -  Reliable access to the MCTC and associated sites; and

          -  If participant is biologically female she must not be pregnant and must agree to
             consistently use an effective form of birth control 21 days prior to enrollment in an
             active clinical study and for the duration of that study.

        Exclusion Criteria:

          -  Prior receipt of an investigational malaria vaccine;

          -  Chronic use of systemic antibiotics or immunosuppressive medications with
             anti-malarial effects;

          -  Chronic medical condition, physical examination findings, other clinically significant
             abnormal laboratory results, or past medical history that may have clinically
             significant implications for current health status;

          -  History of systemic anaphylaxis;

          -  History of, or known active cardiac disease;

          -  Elevated (moderate of high) risk of coronary heart disease;

          -  Clinically significant ECG findings;

          -  Chronic or active neurological disease;

          -  History of splenectomy or functional asplenia;

          -  History of psoriasis or porphyria;

          -  History of diagnosed ocular disease;

          -  Positive history of HIV, Hepatitis B and/or C;

          -  Pregnant or lactating females or females who intend to become pregnant during study
             period;

          -  Certain psychiatric conditions that could affect study compliance; and

          -  Suspected or known current alcohol and/or drug abuse.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
R01A1050243,NCT02392832,Evaluation of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence,Impact and Cost-Effectiveness of Long-Lasting Microbial Larvicides in Reducing Malaria Transmission and Clinical Malaria Incidence: a Cluster-Randomized Controlled Trial in Western Kenya,Recruiting,April 2015,September 2019,Anticipated,Anticipated,"University of California, Irvine","Guiyun Yan, Ph.D.",Principal Investigator,University of California at Irvine,N/A,Interventional,240000,Anticipated,Malaria,NA,All,7 Months,N/A,No,"University of California, Irvine",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Changes in clinical malaria incidence rate,NA,Kenya Medical Research Institute,Other,NA,NA,Kenya Medical Research Institute,baseline and 4 months following the interventions,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Human population for each site stratified into three age groups, under 5 years, 6-15 years and >15 years, will be ascertained from our existing demographic database. Age group level aggregate morbidity data with number of clinical malaria cases without any identifiers will be obtained from local hospitals and clinics where the study residents seek treatment. This data is reported to the Ministry of Health of Kenya and hence, is publicly available.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
116441,NCT01858831,Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension,Single Oral Dose Study of Atovaquone/Proguanil Hydrochloride Combination Tablets and Atovaquone Suspension. - A Single Oral Dose Study to Investigate Pharmacokinetics of Atovaquone and Proguanil From Combination Tablets and Atovaquone From Atovaquone Suspension in Japanese Healthy Males. -,Completed,April 2012,May 2012,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 1,Interventional,30,Actual,Malaria,NA,Male,20 Years,55 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,plasma atovaquone concentration,plasma proguanil concentration,NA,NA,NA,NA,GSK Investigational Site,"pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose","pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose",plasma cycloguanil concentration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"pre, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 48, 72, 120, 168, 216, 336 post dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_DSM265_14_01,NCT02450578,DSM265 Chemoprophylaxis of Plasmodium Falciparum Malaria,Evaluation of the Prophylactic Antimalarial Activity of a Single Dose of DSM265 in Non-immune Healthy Adult Volunteers by Controlled Human Malaria Infection With PfSPZ Challenge,Completed,NA,April 2016,Actual,Actual,Medicines for Malaria Venture,"Benjamin Mordmüller, Dr. med",Principal Investigator,"Institut für Tropenmedizin, Uni. of Tübingen",Phase 1,Interventional,22,Actual,Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,time from PfSPZ IV inoculation to the first positive thick blood smear,NA,"Institute of Tropical Medicine, University of Tuebingen",Other,NA,NA,"Universitätsklinikum Tübingen, Institut für Tropenmedizin",Day 6 to Day 60 post-inoculum (daily),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Blood samples will be taken for assessment of malaria parasitemia by thick blood smear (TBS) daily on Days: D6 to D28 or early termination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,October 2015,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Epicentre/Nig/2012/Palu3ACT,NCT01755559,Efficacy of Three ACTs for the Treatment of Falciparum Malaria in Maradi Niger,"Efficacy of Artesunate-amodiaquine, Dihydroartemisinin-piperaquine and Artemether-lumefantrine Combination Therapies for the Treatment of Uncomplicated Plasmodium Falciparum Malaria in Children Aged 6 to 59 Months in Maradi, Niger 2012-13",Completed,June 2013,November 2014,Actual,Actual,Epicentre,"Francesco Grandesso, MSc",Principal Investigator,Epicentre,Phase 4,Interventional,663,Actual,Malaria,NA,All,6 Months,59 Months,No,Epicentre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Lynda Woi Messe, MD",Study Chair,Epicentre,NA,Adequate clinical and parasitological response,NA,"Centre de Recherche Médicale et Sanitaire (Cermes), Niamey",Other,NA,NA,Andoumé Health Centre,42 days after treatement start,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Absence of parasitaemia on day 42, irrespective of axillary temperature, in patients who did not previously meet any of the criteria of early treatment failure, late clinical failure or late parasitological failure.","Ibrahim M Laminou, PhD",Study Chair,Cermes,"Jean-François Etard, PhD",Study Chair,Epicentre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SSC 1512,NCT00872963,"An Extended Follow up of a RTS,S/AS01E Malaria Vaccine Trial","An Extended Follow up of a Phase 2b Vaccine Trial With RTS,S/AS01E in Kilifi District, Kenya.","Active, not recruiting",February 2009,August 2016,Anticipated,Anticipated,KEMRI-Wellcome Trust Collaborative Research Program,Ally Olotu,Principal Investigator,KEMRI-Wellcome Trust Collaborative Research Program,Phase 2/Phase 3,Observational,450,Anticipated,Malaria,NA,All,19 Months,35 Months,Accepts Healthy Volunteers,KEMRI-Wellcome Trust Collaborative Research Program,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Long term febrile malaria episodes,NA,GlaxoSmithKline,Industry,NA,NA,Kemri Wellcome Trust Research Programme,4 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Enrollment and vaccination in the RTS,S/AS01E clinical trial (NCT00380393)

          -  Written or oral, signed or thumb-printed and witnessed informed consent obtained from
             the parent(s)/guardian(s) of the child.

        Exclusion Criteria:

          -  Moving out of the study area, so that follow up is impractical.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pro00063384,NCT02461628,Innovative Public-private Partnership to Target Subsidized Antimalarials in the Retail Sector (Aim 2),Innovative Partnership to Target Antimalarial Subsidies in the Retail Sector,Recruiting,July 2015,July 2017,Anticipated,Anticipated,Duke University,"Wendy O'Meara, PhD",Principal Investigator,Duke University,N/A,Interventional,95220,Anticipated,Fever; Malaria,NA,All,1 Year,N/A,Accepts Healthy Volunteers,Duke University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Comparison of percent of fevers that receive a malaria test from any source between arms.,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Moi University,Other,Moi University,12 months post-baseline,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The primary outcome of this study is to compare the percent of fevers that receive a malaria test from any source between the intervention and control arms. While the outcome will be measured in three population-based cross-sectional surveys (6, 12, and 18 months post-baseline), the primary endpoint will be evaluated at 12 months post-baseline. Additional information will be provided by the 6-month and 18-month timepoints.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KEMRI_CT_2010/0013,NCT01190371,Have Malaria Infections in Kenya Become Less Responsive to Artemisinin Treatment?,Confirmation of Artemisinin Tolerance in Malaria Parasites Trial in Kilifi,"Active, not recruiting",April 2011,December 2017,Anticipated,Anticipated,KEMRI-Wellcome Trust Collaborative Research Program,Roma Chilengi,Principal Investigator,"KEMRI Centre for Geographic Medicine Research (Coast), University of Oxford, England",Phase 4,Interventional,175,Actual,Malaria,NA,All,6 Months,10 Years,No,KEMRI-Wellcome Trust Collaborative Research Program,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,Steffen Borrmann,Principal Investigator,"KEMRI Centre for Geographic Medicine Research (Coast), Heidelberg University of Medicine, Germany",NA,The primary endpoint of this study will be the re-infection-adjusted day 28 failure rate,NA,University of Oxford,Other,Heidelberg University,Other,NA,Day 0-28,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Cure is defined as clearance of asexual P. falciparum parasitemia until day 7 and no recrudescence of asexual P. falciparum parasitemia until day 28. Re-infections are defined by genetic fingerprinting methods as newly emerging parasite clones during follow-up.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC057,NCT02181088,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5,A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5,Completed,August 2014,October 2015,Actual,Actual,University of Oxford,NA,NA,NA,Phase 1,Interventional,26,Actual,Malaria; Plasmodium Falciparum,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To assess the safety of ChAd63 RH5 when administered alone and in heterologous prime-boost with MVA RH5,NA,European Commission,Other,NA,NA,NA,240 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Occurrence of solicited and unsolicited adverse events will be monitored at each clinic visit from diary cards, clinical review, clinical examination (including observations) and laboratory results.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NMRC.2006.0001,NCT00392015,NMRC-M3V-Ad-PfCA Vaccine - Clinical Trial 1,"A Two Part Clinical Trial Assessing the Safety, Tolerability, Immunogenicity and Protective Efficacy of NMRC-M3V-Ad-PfCA, a Multivalent, Adenovirus-Vectored Plasmodium Falciparum Malaria Vaccine, in Healthy, Malaria-Naïve Adults","Active, not recruiting",October 2006,June 2017,Anticipated,Anticipated,U.S. Army Medical Research and Materiel Command,"Cindy Tamminga, MD, MPH",Principal Investigator,Naval Medical Research Center,Phase 1/Phase 2,Interventional,70,Anticipated,Plasmodium Falciparum,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Part A Dose-escalation: Assess the safety and tolerability of NMRC-M3V-Ad-PfCA, in a dose-escalation design, in healthy, malaria-naïve adults.","Part B Regimen-comparison: Assess the safety and tolerability of the two components individually (NMRC-MV-Ad-PfC, NMRC-MV-Ad-PfA) and when combined (NMRC-M3V-Ad-PfCA).",United States Agency for International Development (USAID),U.S. Fed,Congressionally Directed Medical Research Programs,U.S. Fed,Naval Medical Research Center (NMRC) Clinical Trials Center,study duration,study duration,"Part B Regimen Comparison: Assess the protective efficacy against sporozoite challenge (Pf, 3D7 strain) of the two components individually (NMRC-MV-Ad-PfC, NMRC-MV-Ad-PfA) and when combined (NMRC-M3V-Ad-PfCA).",Military Infectious Diseases Research Program (MIDRP),Other,NA,NA,NA,Naval Medical Research Center,U.S. Fed,NA,NA,NMRC-M3V-Ad-PfCA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"NMRC-MV-Ad-PfC, NMRC-MV-Ad-PfA",study duration,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DL Project in Tanzania,NCT02533336,The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania,The Effectiveness of Non-Pyrethroid Insecticide-Treated Durable Wall Liners as a Method for Malaria Control in Endemic Rural Tanzania: Cluster Randomized Trial,Terminated,NA,"March 31, 2017",Anticipated,Anticipated,"National Institute for Medical Research, Tanzania","William N Kisinza, PhD",Principal Investigator,National Institute for Medical Research,Phase 3,Interventional,4917,Actual,Malaria,NA,All,6 Months,11 Years,No,"National Institute for Medical Research, Tanzania",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Joseph P Mugasa, PhD",Study Director,National Institute for Medical Research,NA,Incidence of malaria parasitemia,NA,"Kilimanjaro Christian Medical Centre, Tanzania",Other,London School of Hygiene and Tropical Medicine,Other,Muheza,1 year,NA,NA,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,NA,Brandeis University,Other,United States Agency for International Development (USAID),U.S. Fed,The primary end point of the study is the cumulative incidence of malaria parasitaemia (asymptomatic or symptomatic) defined as the number of mRDT-confirmed episodes of parasitaemia per person-year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"November 9, 2015",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
824338,NCT01958905,Efficacy and Bio-availability of Artemether-Lumefantrine in Severely Malnourished Children,Efficacy and Bio-availability of Artemether-Lumefantrine Fixed Combination in Severely Malnourished Children Compared to Non-severely Malnourished Children,Completed,November 2013,May 2015,Actual,Actual,Epicentre,"Jean-Francois Etard, MD, PHD",Study Director,Epicentre,N/A,Interventional,399,Actual,Malaria; Severe Acute Malnutrition,NA,All,6 Months,5 Years,No,Epicentre,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of adequate clinical and parasitological response after PCR correction,NA,"Malaria Research and Training Center, Bamako, Mali",Other,University of Cape Town,Other,NA,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Standard primary outcome as defined wy the WHO guidelines for assessing antimalarial efficacy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU1409,NCT02427360,Evaluating the Efficacy of Artesunate-mefloquine and the Relative Roles of Resistance Genetic Markers,Evaluating the Efficacy of Artesunate-mefloquine on the Thai-Myanmar Border and the Relative Roles of Resistance Genetic Markers: A Retrospective Cohort Study,Completed,May 2015,December 2015,Actual,Actual,University of Oxford,NA,NA,NA,N/A,Observational,1022,Actual,P. Falciparum Malaria; P. Falciparum Malaria Mixed Infection,NA,All,N/A,N/A,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,proportion of patients with clearance of asexual parasitaemia within 7 days of initiation of trial treatment,NA,NA,NA,NA,NA,Shoklo Malaria Research Unit,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Patients of any age and sex who received treatment for uncomplicated malaria and
             followed up between January 2003 to December 2013

          -  Symptomatic of malaria infection, i.e. history of fever or tympanic temperature
             ≥37.5°c

          -  Microscopically confirmed asexual stages of P. falciparum ≥ 5/500 WBC (alone or mixed
             with non- P. falciparum species)

          -  Received fully supervised treatment of mefloquine-artesunate

        Exclusion Criteria:

          -  Pregnant woman

          -  P. falciparum asexual stage parasitaemia greater than or equal to 4% red blood cells
             Signs or symptoms indicative of severe malaria29

          -  Mefloquine treatment within the 60 days preceding the current episode of malaria

          -  Splenectomy

        Patients will be excluded from the efficacy analysis if they didn't finish the 3 days
        treatment of mefloquine artesunate but still kept in intention-to-treat population.
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MALACHITE,NCT02858817,Safety and Protective Efficacy of IV Immunization With Cryopreserved PfSPZ Under A/P Chemoprophylaxis,Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Atovaquone/Proguanil Chemoprophylaxis,"Active, not recruiting",NA,March 2018,Anticipated,Anticipated,University Hospital Tuebingen,"Peter G Kremsner, Prof",Principal Investigator,"University Hospital Tübingen, Tübingen, Germany",Phase 1,Interventional,30,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,University Hospital Tuebingen,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number or occurrence of related Grade 3 and 4 adverse events (AEs) and serious adverse events (SAEs),NA,Sanaria Inc.,Industry,NA,NA,NA,"from time of first administration of A/P until the last follow up visit, 414 days after first administration",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"November 28, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
113398,NCT01323972,Consistency of Immunogenicity and Non Inferiority of GSK Biologicals' Candidate Malaria Vaccine Lots in Children,Consistency of Immunogenicity and Non Inferiority of Three Production Lots of GSK Biologicals' Candidate Malaria Vaccine in Children,Completed,"May 16, 2011","May 4, 2012",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,327,Actual,Malaria,NA,All,5 Months,17 Months,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Lot-to lot consistency for immunogenicity of the investigational vaccine in terms of circumsporozoite protein (CS) antibody titers,Non-inferiority of pooled commercial scale lots versus the pilot scale in terms of CS antibody titers,The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,NA,1 month post-dose 3 (Day 90),1 month post-dose 3 (Day 90),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1504,NCT02640495,Artemisinin Resistance In Malaria Treated With IV Artesunate,"A Multicenter, Prospective, Observational Study to Assess the Effi-cacy of Artesunate in Malaria Treated With Parenteral Artesunate in Areas With Artemisinin Resistance A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC)",Not yet recruiting,April 2016,June 2018,Anticipated,Anticipated,University of Oxford,"Prof. Arjen M Dondorp, MD",Principal Investigator,Mahidol Oxford Research Unit (MORU),N/A,Observational,132,Anticipated,Malaria,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Absolute reduction of lactate,NA,Mahidol Oxford Tropical Medicine Research Unit,Other,"Oxford University Clinical Research Unit, Vietnam",Other,NA,12 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Absolute reduction of lactate at 12 hours after the first artesunate treat-ment compared to baseline.,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Male or female, aged over 6 months old

          -  Acute severe P. falciparum malaria or another indication to treat with IV artesunate.
             Defined as one or more of the following, occurring in the absence of an identified
             alternative cause, and in the presence of P. falciparum asexual parasitaemia:

               -  Prostration OR obtundation

               -  BCS<3 (preverbal children) or GCS<11 (adults)

               -  Convulsion in last 24 hours

               -  Suspected acidosis, manifesting as acidotic breathing

               -  Respiratory distress manifesting clinically (nasal flaring/indrawing) or oxygen
                  saturation <92% or respiratory rate >30/min

               -  History of anuria

               -  Jaundice and/or hemoglobinuria

               -  Hemoglobin <7 g/dl or hematocrit <20%

               -  Significant bleeding including recurrent or prolonged bleeding from nose gums or
                  venipuncture sites; hematemesis or melena

               -  Shock defined as systolic blood pressure <70 mm Hg (children) OR <80 mm Hg
                  (adults)

               -  P. falciparum parasitaemia >10%

               -  Indication for parenteral antimalarial treatment (as assessed by clinician) other
                  than nausea and vomiting. These may include laboratory findings such as:

                    -  Creatinine >2.5 mg/dL (>220uM/L) or blood urea >56mg/dL (>20 mM/L)

                    -  Glucose <4.0 mmol/L (<72mg/dL)

                    -  Bilirubin > 3 mg/dL (>50uM/L)

                    -  Hemoglobin <7g/dL or Hematocrit <20%

                    -  P. falciparum parasitaemia >4%

                    -  Venous plasma lactate >5 mM, Base deficit of >8meq/L or bicarbonate <15mM

               -  Written informed consent or consent by locally accepted representative in the
                  case of patients rendered incapable of providing consent due to illness

        Exclusion Criteria:

          -  History of 2 or more doses of parenteral antimalarial treatment in the previous 24
             hours

          -  History of allergy or known contraindication to artemisinins
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2014-61,NCT02646410,Optimization of Seasonal Malaria Chemoprevention (SMC) Delivery,Optimal Delivery of Seasonal Malaria Chemoprevention and Its Effects on the Acquisition of Malaria Immunity,Recruiting,August 2014,December 2016,Anticipated,Anticipated,University of Bamako,NA,NA,NA,Phase 4,Interventional,10000,Anticipated,Malaria; Anemia,NA,All,3 Months,59 Months,Accepts Healthy Volunteers,University of Bamako,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Coverage of SMC,Incidence of clinical malaria in Year 2,NA,NA,NA,NA,Malaria Research and Training Center,1-5 weeks after last round of SMC in Year1,up to 4 weeks after the last round of SMC,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,SMC coverage will be defined as proportion of the children who have received the three treatments doses at each of the three rounds of SMC.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Clinical malaria defined as signs and symptoms suggestive of malaria with positive RDT and/or positive blood smear.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PALUBAC,NCT02669823,Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region,Optimizing Sysmex Technology as an Innovative Tool to Differentiate Between Malaria (PALUdism) and BACterial Infections in a Malaria Endemic Region,Completed,NA,"June 30, 2017",Actual,Actual,Sysmex Europe GmbH,Andre van der Ven,Principal Investigator,Radboud University,N/A,Observational,930,Actual,Tropical Infectious Diseases,NA,All,3 Months,N/A,No,Sysmex Europe GmbH,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,Halidou Tinto,Principal Investigator,CRUN,NA,• Diagnostic sensitivity and specificity of Sysmex XN blue laser for malaria parasite detection in a malaria endemic area,• Diagnostic sensitivity and specificity of Sysmex XN infection manager for diagnosing bacterial bloodstream infection (bBSI) and mixed malaria/bBSI in a malaria endemic area in participants of 5 years and older,"Clinical Research Unit of Nanaro (CRUN), Burkina Faso",Other,"Instituut voor Tropische Geneeskunde (ITG), Belgium",Other,Clinical Research Unit Nanaro,1 year based on frozen specimens,1 year based on frozen specimens,NA,"Radboudumc, Algemeen Interne Geneeskunde, The Netherlands",Other,NA,NA,NA,NA,NA,NA,NA,"based on microscopy of a blood smear or PCR in case of a negative smear or incongruent results. Diagnostic performance will be evaluated before and after training of the algorithm.
Malaria parasitemia is defined as the presence of one or more parasites in malaria microscopy or a malaria qPCR 18S result over 50 p/ml.",Jan Jacobs,Principal Investigator,ITG,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          1. Children between ages >3 months and < 15 years old OR adults of 15 years and above

          2. AND willing and able to provide written informed consent (parent`s or guardian`s
             consent for minors). In case of very sick adults not able to give consent, sampling
             will be done and ICF will be asked upon his/her recovery or from his/her
             representative in case of death.

          3. AND presenting with one of the following:

             Recorded temperature of > 38.0°C or temperature < 35.5°C (tympanic). OR episode of
             fever within 48 hours prior to admission

             OR signs of severe clinical illness including one or more of the following:

               -  Respiratory distress

               -  Prostration

               -  Altered consciousness

               -  Convulsions (one or more episodes)

               -  Clinical jaundice

               -  Signs of shock

               -  Severe malnutrition with severe anemia (hemoglobin < 5 g/dl)

          4. AND Having one of the following clinically suspected infections

               -  Severe malaria

               -  Invasive bacterial infection (including pneumonia, arthritis, peritonitis,
                  meningitis or complicated urinary tract infection, typhoid fever)

               -  Severe viral infection such as influenza

        Exclusion Criteria:

        • Fever episode for more than 7 days or no informed consent was given
      ",NA,NA,NA,"Diagnostic performance will be evaluated before and after training of the algorithm.
Malaria parasitemia is defined as the presence of one or more parasites in malaria microscopy or a malaria qPCR 18S result over 50 p/ml Bacterial bloodstream infection is defined as growth of a clinically significant bacterial organism from blood culture within 5 days of incubation or a (16s) PCR result positive for a clinically significant organism.",NA,NA,NA,NA,"April 1, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITMP0108,NCT00711906,Daily Co-trimoxazole Prophylaxis to Prevent Malaria in Pregnancy,The Role of Daily Co-trimoxazole Prophylaxis For Prevention of Malaria And Its Effects in Pregnancy,Terminated,February 2009,September 2010,Actual,Actual,"Institute of Tropical Medicine, Belgium","Christine Manyando, MD",Principal Investigator,Tropical Diseases Research Centre,Phase 3,Interventional,352,Actual,Malaria in Pregnancy,NA,Female,N/A,N/A,No,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Jean-Pierre Van geertruyden, MD PhD",Study Director,Institute of Tropical Medicine,NA,To test the hypothesis that co-trimoxazole prophylaxis is not inferior to SP intermittent preventive treatment in preventing placental malaria.,NA,"Tropical Diseases Research Centre, Zambia",Other,NA,NA,NA,Pregnancy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CKAE609A2201,NCT01836458,A Study to Find the Minimum Inhibitory Concentration of KAE609 in Adult Male Patients With P. Falciparum Monoinfection,"An Open-label Study to Find the Minimum Inhibitory Concentration(MIC) of KAE609 in Adult Male Patients With Acute, Uncomplicated Malaria Due to Plasmodium Falciparum Monoinfection",Completed,January 2014,March 2015,Actual,Actual,Novartis Pharmaceuticals,Novartis Pharmaceuticals,Study Director,Novartis Pharmaceuticals,Phase 2,Interventional,25,Actual,Malaria,NA,All,20 Years,60 Years,No,Novartis Pharmaceuticals,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Minimum Inhibitory Concentration (MIC) of KAE609,NA,NA,NA,NA,NA,Novartis Investigative Site,Up to Day 8 after a single dose of KAE609,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"To observe the exposure-response (PK/PD) relationship for a single dose of KAE609. The key parameter is MIC, defined as the concentration at which the relative rate of change in parasitemia is equal to zero. Approximation of MIC will assist in identifying the optimal dose of KAE609, which will be one component of a future combination antimalarial. MIC could not be determined due to small sample size no data was collected from any participants.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU0801,NCT00840502,Ultrasound Study in Pregnant Women With Malaria,Impact of Malaria Infection in Pregnancy on Fetal and Newborn Growth,Recruiting,February 2009,September 2018,Anticipated,Anticipated,University of Oxford,"Francois Nosten, MD",Principal Investigator,Shoklo Malaria Research Unit,N/A,Observational,400,Anticipated,Pregnant Women; Malaria,NA,Female,18 Years,N/A,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Ultrasound measurements,NA,NA,NA,NA,NA,Shoklo Malaria Research Unit,Up to birth,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Singleton viable pregnancy. If not detected at enrolment, multiple pregnancies will be
             excluded from the analysis.

          -  Age ≥18 years old.

          -  Willing and able to participate and comply with the study protocol and attend the SMRU
             ANCs regularly.

          -  EGA between 9+0 and 13+6 weeks by Ultrasound (CRL)

          -  Able to communicate in Burmese, Karen or English language

          -  written informed consent to participate in trial and follow consultation

        Exclusion Criteria:

          -  Evidence of major congenital abnormality in the present pregnancy (e.g. anencephaly,
             omphalocele, hydrocephalus).

          -  Known chronic maternal illness.

          -  Thai national whose primary language is Thai
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU1203,NCT01780753,Primaquine Pharmacokinetics in Lactating Women and Their Infants,A Study of the Pharmacokinetics of Primaquine in Lactating Women and Breastfed Infants for the Radical Treatment of Uncomplicated Maternal P. Vivax,Completed,December 2012,December 2014,Actual,Actual,University of Oxford,"Rose McGready, MD",Principal Investigator,University of Oxford,Phase 1,Interventional,20,Actual,Vivax Malaria,NA,All,18 Years,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Pharmacokinetic Parameters of Primaquine and Carboxyprimaquine in breast milk. Area Under Curve (AUC),NA,NA,NA,NA,NA,Shoklo Malaria Research Unit,"13 Days. Time Frame: predose, 0,1,2,3,4,6,8,12,24,72 hours; Day 7, Day 13 post-dose",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Primaquine and carboxyprimaquine pharmacokinetic parameters to day 13 in breast milk of lactating women treated with primaquine for radical treatment of P.vivax.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
version 8/DHAPPQ/MIP,NCT01231113,"Efficacy,Safety and Tolerability of Dihydroartemisinin-Piperaquine for Uncomplicated Malaria in Pregnancy in Ghana","Efficacy, Safety and Tolerability of Dihydroartemisinin-Piperaquine for Treatment of Uncomplicated Falciparum Malaria in Pregnancy: an Open-label, Randomised Controlled, Non-inferiority Trial",Completed,July 2011,February 2013,Actual,Actual,Kwame Nkrumah University of Science and Technology,"Joseph Osarfo, MBCHB, MPH",Principal Investigator,"Malaria Capacity Development Consortium-Ghana, Department of Community Health, School of Medical Science, Kwame Nkrumah University of Science and Technology",Phase 3,Interventional,417,Actual,Pregnancy Complicated by Malaria as Antepartum Condition,NA,Female,15 Years,45 Years,No,Kwame Nkrumah University of Science and Technology,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Harry Tagbor, PhD",Study Director,Kwame Nkrumah University of Science and Technology,NA,PCR-corrected parasitological cure rates at days 28 and 42,NA,Malaria Capacity Development Consortium,Other,NA,NA,"St.Michael's Hospital, Pramso",42-day follow-up,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Only eligible subjects with positive falciparum rapid diagnostic test results and positive blood films on microscopy will be recruited. Filter paper blots will be prepared at recruitment as well.
Blood films and filter paper blots will be repeated on days 3,7,14,28 and 42 post-first dose of treatment.
PCR analysis will be conducted on only those follow-ups with positive blood films",Pascal Magnussen,Study Director,DBL-University of Copenhagen,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CNBS (173/CNBS/13),NCT02698748,Evaluating the Role of Chloroquine for Malaria Elimination,"Evaluating the Potential Role of Chloroquine in Preventing Infections During Elimination Campaigns: A Randomized, Single-blind, Placebo-controlled Trial in Asymptomatic Mozambican Adults",Completed,January 2015,June 2015,Actual,Actual,Centro de Investigacao em Saude de Manhica,"Pedro Aide, MD, MSc, PhD",Principal Investigator,Centro de Investigação em Saude de Manhiça,Phase 2/Phase 3,Interventional,75,Actual,Malaria,NA,Male,18 Years,N/A,No,Centro de Investigacao em Saude de Manhica,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adequate parasitologic response (APR) to therapy,NA,NA,NA,NA,NA,Centro de Investigaçao em Saude de Manhiça,28 days after first day of drug intake,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FeGOS_KP,NCT02666417,Iron Absorption From a Micronutrient Powder Containing Galacto-oligosaccharides (GOS),Testing Iron Absorption From a New Micronutrient Powder Containing Galacto-oligosaccharides (GOS) for Fortification of Infant Foods in Sub-Saharan Africa,Completed,January 2016,April 2016,Actual,Actual,Swiss Federal Institute of Technology,"Michael Zimmermann, MD",Principal Investigator,"Swiss Federal Institute of Technology (ETH), Zurich",N/A,Interventional,64,Actual,"Anemia, Iron-Deficiency",NA,All,6 Months,14 Months,Accepts Healthy Volunteers,Swiss Federal Institute of Technology,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Change from baseline in the isotopic ratio of iron in blood at week 5,NA,Jomo Kenyatta University of Agriculture and Technology,Other,International Centre for Behavioural Studies,Other,Msambweni District Hopsital,Baseline and Week 5,NA,NA,Msambweni District Hospital,Other,NA,NA,NA,NA,NA,NA,NA,The change in the isotopic ratio of iron will be measured after the administration of test meals including iron isotopes.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TUCHMI-001,NCT01624961,Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults,Controlled Human Malarial Infection by Intravenous Injection of Plasmodium Falciparum Sporozoites in Non-Immune Adults,Completed,June 2012,February 2013,Actual,Actual,Sanaria Inc.,"Benjamin G Mordmüller, MD",Principal Investigator,"Eberhard Karls University of Tübingen, Germany",Phase 1,Interventional,30,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The infectivity of the administration regimens will be assessed by thick film microscopy and PCR for P. falciparum DNA.,NA,"Institute of Tropical Medicine, University of Tuebingen",Other,NA,NA,"Eberhard Karls University of Tübingen, Germany",Day 5 until day 21 or until treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Parasitology and parasite molecular biology tests: These tests are used to determine malaria parasites (thick blood smear and PCR). Both tests are performed at screening and then approximately every 12 hours during the period of intense observation from day 5 until day 21 or until treatment. Thereafter, these tests are performed during safety follow-ups at Days 28, 84, and 168. Turn over time for thick blood smear microscopy is < 2 hours to ensure timely treatment in case of a positive result. PCR results are available only after study completion.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC 1321,NCT01838902,Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers,Primaquine's Gametocytocidal Efficacy in Malaria Asymptomatic Carriers Treated With Dihydroartemisinin-piperaquine in The Gambia,Completed,August 2013,October 2015,Actual,Actual,"Medical Research Council Unit, The Gambia","Umberto D'Alessandro, MD, PhD",Principal Investigator,"MRC Unit, Fajara The Gambia",Phase 3,Interventional,467,Actual,Malaria,NA,All,12 Months,N/A,Accepts Healthy Volunteers,"Medical Research Council Unit, The Gambia",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Prevalence of P. falciparum gametocyte carriers (QT-NASBA),NA,NA,NA,NA,NA,"Medical Research Council Unit (MRC), The Gambia",Day 7,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Proportion of study participants in each arm with P. falciparum gametocyte carriers as determined by quantitative nucleic acid sequence based amplification assay (QT-NASBA),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DMED-1712-14,NCT02561624,Hati Salama (Secure Voucher),Expanding the Successful E-voucher System to Improve Malaria Prevention and Fight New Global Health Threats Through Innovative Health Partnerships and Mobile Phone Technology in Tanzania,Completed,July 2015,January 2016,Actual,Actual,Queen's University,"Karen Yeates, MD",Principal Investigator,Queen's University,N/A,Interventional,5219,Actual,Malaria,NA,Female,18 Years,50 Years,Accepts Healthy Volunteers,Queen's University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Increased uptake of long-lasting insecticide treated nets from retailers using an electronic voucher through text messaging.,NA,Mennonite Economic Development Associates,Other,NA,NA,Pamoja Tunawez,12 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The outcome measure will be assessed by LLIN evoucher redemption.,NA,NA,NA,NA,NA,NA,NA,NA,Increased uptake of long-lasting insecticide treated nets from retailers using an electronic voucher through text messaging.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_ MMV390048_15_01,NCT02554799,A Study to Evaluate the Pharmacokinetics of Oral Formulations of MMV390048 Administered Fasted to Healthy Volunteers,A Phase 1 Exploratory Study to Evaluate the Pharmacokinetics of Selected Oral Formulations of MMV390048 Administered in the Fasted State to Healthy Volunteers,Completed,September 2015,October 2015,Actual,Actual,Medicines for Malaria Venture,NA,NA,NA,Phase 1,Interventional,18,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Maximum concentration (Cmax) of two MMV390048 prototype formulations administered in the fasted state,Time to reach maximum plasma concentration (Tmax) of two MMV390048 prototype formulations administered in the fasted state,Richmond Pharmacology Limited,Industry,NA,NA,Richmond Pharmacology Ltd.,Up to 672 hours post-dose,Up to 672 hours post-dose,Area under the plasma concentration-time curve (AUC) of two MMV390048 prototype formulations administered in the fasted state,NA,NA,Terminal elimination half-life of two MMV390048 prototype formulations administered in the fasted state,Terminal elimination rate constant of two MMV390048 prototype formulations administered in the fasted state,Oral plasma clearance of two MMV390048 prototype formulations administered in the fasted state,NA,NA,NA,NA,Peak plasma concentration,NA,NA,NA,NA,NA,NA,Apparent volume of distribution of two MMV390048 prototype formulations administered in the fasted state,NA,NA,NA,NA,NA,NA,NA,Time to reach peak plasma concentration,From Pre-dose to 672 hours post-dose,Area under the plasma concentration-time curve from zero to infinity,Up to 672 hours post-dose,Terminal elimination half-life,NA,NA,Up to 672 hours post-dose,Terminal elimination rate constant,Up to 672 hours post-dose,Oral plasma clearance,Up to 672 hours post-dose,Apparent volume of distribution,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999907141,NCT00471302,"Normal Immunological Parameters Among Healthy Volunteers in Kambila, Mali","Establishment of Normal Immunological Parameters Among Healthy Volunteers in Kambila, Tieneguebougou and Kalifabougou, Mali",Recruiting,"May 3, 2007",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Peter D Crompton, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,280,Anticipated,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Obtain blood samples from healthy Malian adults in order to establish normal immunologic parameters for this population and to optimize research assays performed at the MRTC.,NA,University of Bamako,Other,NA,NA,NA,"After enrollment, all volunteers will undergo a baseline medical history and physical examination, and will provide a blood sample for a malaria blood smear, and for a filter paper sample for P. falciparum polymerase chain reaction (PCR) analysis.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Obtain blood samples from healthy Malian adults in order to establish normal immunologic parameters for this population and to optimize research assays performed at the MRTC.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999909115,NCT00878098,Study of DDT and Loss of Clinically-Recognized Pregnancies in South Africa,Study of DDT and Loss of Clinically Recognized Pregnancies in South Africa,Completed,"April 2, 2009",NA,NA,NA,National Institute of Environmental Health Sciences (NIEHS),"Gitanjali Taneja, Ph.D.",Principal Investigator,National Institute of Environmental Health Sciences (NIEHS),N/A,Observational,2805,Anticipated,Spontaneous Abortion; Malaria; Pregnancy Outcome; Stillbirth; HIV Infections,NA,Female,20 Years,34 Years,Accepts Healthy Volunteers,National Institute of Environmental Health Sciences (NIEHS),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Pretoria Academic Hospital,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999913107,NCT01829737,Malaria Transmission Studies in Mali,"Epidemiologic Studies of Plasmodium Falciparum Gametocytemia and Transmission-blocking Immunity in Kenieroba, Mali",Completed,"March 20, 2013","January 20, 2015",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Rick M Fairhurst, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,650,Anticipated,"Malaria, Falciparum",NA,All,6 Months,65 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Determine gametocytemia prevalence at each time point relative to age group, asexual parasitemia prevalence, season, and red blood cell polymorphisms, for all cohort enrollees residing in Kenieroba and not treated for malaria during the previous...",NA,"Faculte de Pharmacie, USTTB, Mali",Other,NA,NA,"National Institutes of Health Clinical Center, 9000 Rockville Pike",1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Determine gametocytemia prevalence at each time point relative to age group, asexual parasitemia prevalence, season, and red blood cell polymorphisms, for all cohort enrollees residing in Kenieroba and not treated for malaria during the previous...",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999913074,NCT01862783,Collection of Biological Material From Pregnant Women in a Malarial Region,In-Vitro Evaluation of Anti-Adhesion Activity by Antibodies to Pregnancy Malaria Vaccine Candidates,Terminated,"February 10, 2013","March 15, 2016",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Michal Fried, Ph.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,2500,Anticipated,Malaria,NA,Female,14 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Samples collected from the women will be used in in-vitro assays to assess the functional activity of antisera raised against pregnancy malaria vaccine candidates as the primary outcome of this study.,NA,NA,NA,NA,NA,Kalisizo Hospital,ongoing,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Samples collected from the women will be used in in-vitro assays to assess the functional activity of antisera raised against pregnancy malaria vaccine candidates as the primary outcome of this study.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU1102,NCT01640574,Comparison Between 7 and 14 Day Primaquine Combined With Dihydroartemisinin-piperaquine or 3 Day Chloroquine Radical Cure of P. Vivax (BPD),Randomised Parallel Open Label Comparison Between 7 and 14 Day Primaquine Combined With 3-day Dihydroartemisinin-piperaquine or 3-day Chloroquine Regimens for Radical Cure of Plasmodium Vivax,Completed,February 2012,December 2015,Actual,Actual,University of Oxford,"Francois Nosten, MD",Principal Investigator,University of Oxford,Phase 3,Interventional,680,Actual,Vivax Malaria,NA,All,6 Months,N/A,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Cindy Chu, MD",Principal Investigator,Shoklo Malaria Research Unit,NA,Recurrence of P. vivax,NA,NA,NA,NA,NA,Shoklo Malaria Research Unit,52 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Recurrence with Plasmodium vivax malaria within 52 weeks of first treatment dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
JSI-MIPP-NG #1,NCT02758353,The Impact of Sulphadoxine-Pyrimethamine Use At Scale on Newborn Outcomes in Nigeria,"Scaling up the Use of Sulphadoxine-Pyrimethamine for the Preventive Treatment of Malaria in Pregnancy: Results and Lessons on Scalability, Costs and Program From Three Local Government Areas in Sokoto State, Nigeria",Completed,April 2015,November 2015,Actual,Actual,"JSI Research & Training Institute, Inc.","Nosa G Orobaton, MD, DrPH",Principal Investigator,"John Snow, Inc.",N/A,Interventional,31493,Actual,Malaria; Stillbirths,NA,Female,N/A,N/A,Accepts Healthy Volunteers,"JSI Research & Training Institute, Inc.",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percentage of participants that got SP coverage among all pregnant women,NA,Bill and Melinda Gates Foundation,Other,"Federal Ministry of Health, Nigeria",Other,NA,Up to 7 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The percentage SP coverage among all pregnant participants and by number of SP doses ingested. The outcome form will be used to obtain an aggregate number of women that received SP. The total number of eligible women will be obtained from either an enumeration of eligible women in the intervention LGA, or by population estimation in the counterfactual LGA.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
FhCMB Pfs25-001,NCT02013687,Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults,A Phase 1 Study of the Safety and Immunogenicity of Plant-Derived Pfs25 VLP-FhCMB Malaria Transmission Blocking Vaccine in Healthy Adults,Completed,October 2013,January 2015,Actual,Actual,"Fraunhofer, Center for Molecular Biotechnology",NA,NA,NA,Phase 1,Interventional,44,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,"Fraunhofer, Center for Molecular Biotechnology",Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Subjects With at Least One Adverse Event,Subjects With Solicited Systemic Adverse Events,NA,NA,NA,NA,Accelovance,336 days,336 days,Subjects With Solicited Local Adverse Events,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,336 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Pro00063521,NCT02504593,Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis,Novel mHealth Platform to Ensure Quality of Community-based Malaria Diagnosis,Completed,July 2015,April 2016,Actual,Actual,Duke University,"Wendy O'Meara, PhD",Principal Investigator,Duke University,N/A,Interventional,100,Actual,Quality Assurance of Malaria Diagnosis,NA,All,18 Years,N/A,Accepts Healthy Volunteers,Duke University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Percent of RDTs with correct administration and interpretation by CHVs compared across the first and tenth tests,NA,NA,NA,NA,NA,Duke University,6 months (during which each consenting CHV of the 200 eligible will conduct 10 tests),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The percent of RDTs that were properly conducted and interpreted by CHVs, according to Deki Reader results, comparing across the first and tenth RDTs read with the Deki Reader for each CHV.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999913109,NCT01867463,Testing Pfs25-EPA/Alhydrogel as a Potential Malaria Transmission Blocking Vaccine,"Double Blind Dose-Escalating Randomized Controlled Phase 1 Study in Malaria Exposed Adults of the Safety and Immunogenicity of Pfs25-EPA/ Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum in Bancoumana, Mali",Completed,"March 27, 2013","December 19, 2016",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,350,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of local and systemic adverse events and serious adverse events.,NA,"Malaria Research and Training Center, Bamako, Mali",Other,NA,NA,Malaria Research and Training Center,12 months following the last vaccination; and for 6 months following the fourth vaccination.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999914073,NCT02094508,Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda,Impact of Trimethoprim-sulfamethoxazole Prophylaxis on Malaria Infection and Immunity in Children in Uganda,Completed,"March 7, 2014","December 14, 2016",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Steven J Reynolds, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,400,Anticipated,Malaria,NA,All,2 Months,6 Months,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Malaria incidence rate (number of new malaria parasitemia episodes per time at risk) in HUE children on TMP-SMX prophylaxis compared to HUU children (not on TMP-SMX prophylaxis) between enrollment and study end. A malaria parasitemia episode is ...,NA,NA,NA,NA,NA,Rakai Health Sciences Program Uganda Virus Research Institute,At end of the study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Malaria incidence rate (number of new malaria parasitemia episodes per time at risk) in HUE children on TMP-SMX prophylaxis compared to HUU children (not on TMP-SMX prophylaxis) between enrollment and study end. A malaria parasitemia episode is ...,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2149,NCT01614964,Studies of a Candidate Aminoquinoline Antimalarial (AQ-13),Phase 2 Proof of Concept Study of a Candidate Aminoquinoline Antimalarial (AQ-13),"Active, not recruiting",August 2013,December 2016,Anticipated,Anticipated,Donald Krogstad,"Donald J. Krogstad, MD",Principal Investigator,Tulane School of Public Health and Tropical Medicine,Phase 2,Interventional,66,Anticipated,Malaria,NA,Male,18 Years,N/A,No,Donald Krogstad,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The primary outcome of this study is a comparison of the cure rates of AQ-13 and Coartem for uncomplicated Plasmodium falciparum malaria in adult Malian males.,NA,"University of the Sciences, Techniques and Technologies of Bamako",Other,NA,NA,"Clinical Research Center (Hopital Point G, University of the Sciences, Techniques and Technologies of Bamako)",Subjects are followed for 42 days after beginning treatment with either AQ-13 or Coartem..,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Cure is defined as a lack of recrudescence within 42 days (PCR-corrected) - no evidence of recurrent infection with the same parasite genotype after reduction of the asexual parasitemia to less than 25% of the admission value by day 3 and clearance of asexual parasites and fever by day 7. Failure is defined as lack of cure.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KMRL_2016_02,NCT02792816,Molecular Surveillance of Artemisinin Resistance Malaria in Myanmar,A Multi-site Cohort Observational Study for Molecular Assessment of Artemisinin Resistance Falciparum Malaria in Myanmar,Completed,June 2009,May 2016,Actual,Actual,"Department of Medical Research, Lower Myanmar",NA,NA,NA,N/A,Observational,550,Actual,Drug Resistance; Plasmodium Falciparum Malaria,NA,All,3 Months,69 Years,No,"Department of Medical Research, Lower Myanmar",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of adequate clinical and parasitological response (ACPR),NA,Kangwon National University,Other,NA,NA,Dr. Myat Phone Kyaw,day 28 or day 42 after initial dose of ACT,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"For artesunate-mefloquine or dihydroartemisinin-piperaquine, 42 days follow-ups and for artemether-lumefrantrine combinations, 28 days followe-ups",NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          -  Plasmodium falciparum mono infection by microscopy

          -  Presence of axillary equal to or more than 37.5 degrees centigrade or history of fever
             during the past 24 hours

          -  Ability to swallow oral medication

          -  Ability and willingness to comply with the study protocol for the duration of the
             study and to comply with the study visit schedule

          -  Informed consent from the patient or from a parent or guardian in the case of children

        Exclusion Criteria:

          -  Presence of signs of severe falciparum malaria according to the definitions of World
             Health Organisation (WHO)

          -  Mixed or mono-infection with another Plasmodium species detected by microscopy

          -  Presence of severe malnutrition (defined as a child whose growth standard is below 3
             z-score, has symmetrical oedema involving at least the feet or has a mid-upper arm
             circumference below 110 mm)

          -  Presence of febrile conditions due to diseases other than malaria (e.g. measles, acute
             lower respiratory tract infection, severe diarrhoea with dehydration) or other known
             underlying chronic or severe diseases (e.g. cardiac, renal and hepatic diseases, Human
             Immune Deficiency Virus (HIV)/Acquired Immune Deficiency Syndrom (AIDS)

          -  Regular medication, which may interfere with antimalarial pharmacokinetics

          -  History of hypersensitivity reactions or contraindications to any of the medicine(s)
             being tested or used as alternative treatment(s)

          -  A positive pregnancy test or breastfeeding

          -  Unable to or unwilling to take a pregnancy test or contraceptives
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
116564,NCT02216123,"Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria","A Randomized, Double-Blind, Double Dummy, Comparative, Multicenter Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in the Treatment of Subjects With Plasmodium Vivax Malaria",Completed,"April 30, 2015","November 4, 2016",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,251,Actual,"Malaria, Vivax",NA,All,16 Years,N/A,No,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of all subjects with Plasmodium vivax (P. vivax) experiencing clinically relevant hemolysis,Proportion of female subjects with P. vivax who are moderately (40-70 percent) G6PD deficient experiencing clinically relevant hemolysis,Medicines for Malaria Venture,Other,NA,NA,NA,Up to Day 180,Up to Day 180,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Clinically relevant hemolysis in all subjects is defined as, a decrease in haemoglobin (Hb) of >=30% or >3 gram per decilitre (g/dL) from baseline; or, an overall drop in Hb below 6.0 g/dL.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Clinically relevant hemolysis in all subjects is defined as, a decrease in haemoglobin (Hb) of >=30% or >3 g/dL from baseline; or, an overall drop in Hb below 6.0 g/dL.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
150044,NCT02334462,"Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel , a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria, in Adults in the U.S. and Mali","Phase 1 Study of the Safety and Immunogenicity of Pfs230D1M-EPA/Alhydrogel and Pfs25M-EPA/Alhydrogel, a Transmission Blocking Vaccine Against Plasmodium Falciparum Malaria in Adults in the US and Mali","Active, not recruiting","December 10, 2014","September 30, 2017",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,54,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of local and systemic adverse events and serious advents in U.S. adults and in exposed Malian adults.,NA,"Rodolphe Merieux Laboratory@@@Bamako, Mali",Other,NA,NA,NA,"U.S. Study: Days 1,3,7,14,28,29,31,35,42,56,84,112,140,168 and 196. Same as U.S. plus Days 169,171,175,182,189,196,203,210,217,240,2 70,300,330,360,390,420,450,480,510,540,541,543,547,554,561,568,575,582,589,610,640,670,700,730",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP15C20,NCT02867059,SJ733 Induced Blood Stage Malaria Challenge Study,A Proof-of-concept Study to Assess the Effect of (+)-SJ000557733 (SJ733) Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants,Recruiting,August 2016,July 2017,Anticipated,Anticipated,Medicines for Malaria Venture,NA,NA,NA,Phase 1,Interventional,16,Anticipated,Plasmodium Falciparum Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Activity of SJ733 treatment on clearance of malaria parasites will be monitored by PCR.,"The safety and tolerability of SJ733 in healthy subjects (men and WNCBP) following infection with blood stage P. falciparum during the IBSM challenge study will be evaluated by observation of occurrence of adverse events, blood samples (incl. LFT, etc.).",QIMR Berghofer Medical Research Institute,Other,Q-Pharm Pty Limited,Industry,NA,Up to 16 days post dose or less if rescue medication is require earlier due to insufficient clearance of parasites by SJ733,for up to 25th day post SJ733 treatment or longer as determind by the principal investigator,NA,Clinical Network Services (CNS) Pty Ltd,Industry,NA,NA,NA,NA,NA,NA,NA,"PCR monitoring of parasitaemia will occur AM/PM or AM at 84 h, 96 h, 120 h, and 144 h post initial SJ733 dose. Participants will return morning and evening until parasite counts are <~500 parasites(p)/ml which is when sampling may revert to daily visits at the investigator's discretion.
When parasite counts are <~200p/ml sampling may revert to alternate day visits at the investigator's discretion. Once the qPCR results are negative, or low and stable, the participants will be reviewed 3 times per week, coinciding with PK time-points where possible until rescue medication treatment.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAZ20016,NCT02878265,The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children,The Effect of Vitamin A With and Without Zinc and Multivitamin Supplementation on Malaria Morbidity in Ghanaian Children,Completed,November 2011,December 2012,Actual,Actual,University of Ghana,"Patricia k Brown, PhD",Study Chair,Kwame Nkrumah Univeristy of Science and Technolgy,Phase 3,Interventional,547,Actual,Malaria,NA,Female,N/A,N/A,No,University of Ghana,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Wilhelmina A Mensah, Mphil",Principal Investigator,University of Ghana,NA,Incidence of clinical malaria attacks,NA,Kwame Nkrumah University of Science and Technology,Other,NA,NA,Amoako,Baseline and every month up to six months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"While taking the supplement, malaria incidence will be measured",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
KIT601714,NCT02411994,Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Malaria,Pyronaridine-artesunate and Artemether-lumefantrine for the Treatment of Paediatric Uncomplicated Falciparum Malaria in Western Kenya,Recruiting,October 2015,July 2017,Anticipated,Anticipated,Royal Tropical Institute,"Patrick Sawa, MD, PhD",Principal Investigator,"International Centre of Insect Physiology and Ecology, Mbita, Kenya",Phase 3,Interventional,450,Anticipated,Malaria,NA,All,6 Months,12 Years,No,Royal Tropical Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR-corrected adequate clinical and parasitological response (ACPR),NA,NA,NA,NA,NA,"St. Jude's Clinic, ICIPE",day 28 after initial dose,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999915163,NCT02504918,Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment in Malian Children,Markers of T Cell Suppression: Associations With Malaria Infection and Antimalarial Treatment,Completed,"July 6, 2015","June 14, 2017",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Michal Fried, Ph.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,400,Anticipated,Malaria,NA,All,12 Months,59 Months,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,To investigate the association of recent malaria infection and percentage of PD1+ CD4 T cells in children that have not received SMC during the rainy season.,"To compare the percentage of PD1 +CD4 T cells in children who do or do not receive antimalarial treatment, in both rainy season and drythedry season.",NA,NA,NA,NA,Ouelessebougou Clinical Research Center MRTC/ FMPOS,Approximately 3-6 months,Approximately 3-6 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ASAQ-LA-DHAPQP 2015 DRC,NCT02940756,Efficacy and Safety of Artemisinin-based Combination Treatments in the Democratic Republic of the Congo,"Efficacy and Safety of Artesunate-amodiaquine, Artemether-lumefantrine and Dihydroartemisinine-piperaquine in the Treatment of Uncomplicated Plasmodium Falciparum Malaria in the Democratic Republic of Congo: a Randomized Controlled Trial",Recruiting,NA,"December 31, 2017",Anticipated,Anticipated,"Ministry of Public Health, Democratic Republic of the Congo","Gauthier Mesia Kahunu, PhD",Principal Investigator,University of Kinshasa,Phase 4,Interventional,1584,Anticipated,Malaria,NA,All,6 Months,59 Months,No,"Ministry of Public Health, Democratic Republic of the Congo",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR-adjusted efficacy,NA,NA,NA,NA,NA,NA,day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,the proportion of children with PCR adequate clinical and parasitological response,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"March 15, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
106369,NCT00436007,"Safety and Immunogenicity Study of GSK Biologicals' Malaria Vaccine 257049, When Incorporated Into an EPI Regimen","Safety and Immunogenicity Study of GSK Biologicals' Investigational Vaccination Regimen Malaria Vaccine 257049, When Incorporated Into an Expanded Program on Immunization (EPI) Regimen That Includes Tritanrix HepB/Hib, OPV, Measles and Yellow Fever Vaccination in Infants",Completed,"April 30, 2007","October 7, 2009",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,511,Actual,Malaria,NA,All,6 Weeks,10 Weeks,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Subjects With Serious Adverse Events (SAEs).,NA,NA,NA,NA,NA,NA,From Month 0 to Month 8,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"SAEs were defined as medical occurrences that resulted in death, were life threatening, required hospitalization or prolongation of hospitalization or resulted in disability/incapacity.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
107731,NCT00443131,Characterisation of the Immune Responses of 2 Experimental Malaria Vaccines,"Adjuvant Justification Study of Candidate Malaria Vaccines (257049), Administered According to a 0, 1, 2 Months Schedule .",Completed,"March 26, 2007","July 13, 2007",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,36,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Anti-CS antibody titers.,NA,NA,NA,NA,NA,GSK Investigational Site,One month post Dose 3.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
TUCHMI-002,NCT02115516,Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis,Safety and Protective Efficacy of Intravenous Immunization With Cryopreserved Plasmodium Falciparum Sporozoites Under Chemoprophylaxis,Completed,April 2014,April 2016,Actual,Actual,Sanaria Inc.,"Benjamin Mordmüller, MD",Principal Investigator,"Institute of Tropical Medicine, University of Tuebingen",Phase 1,Interventional,67,Actual,Malaria; Plasmodium Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Proportion of volunteers who become parasitemic, detected by thick blood film microscopy, within 21 days following CHMI after immunization using PfSPZ Challenge or placebo under chemoprophylaxis [PfSPZ Challenge Vaccine (PfSPZ-CVac) approach].",Occurrence of related Grade 3 adverse events (AEs) and SAEs from time of first administration of an immunizing regimen (chemoprophylactic antimalarial and PfSPZ Challenge) until the end of the study.,"Institute of Tropical Medicine, University of Tuebingen",Other,German Federal Ministry of Education and Research,Other,"Institute of Tropical Medicine, University of Tuebingen, Wilhelmstr. 27",Within 21 days following CHMI,19 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
1506994146,NCT02557425,Prophylaxis Against Malaria to Enhance Child Development (PROTECT Study),Prophylaxis Against Malaria to Enhance Child Development,"Active, not recruiting",October 2015,December 2021,Anticipated,Anticipated,Indiana University,"Chandy C John, MD",Principal Investigator,Indiana University,N/A,Observational,272,Actual,Neurobehavioral Manifestations,NA,All,10 Months,38 Months,No,Indiana University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Z-scores for Overall cognitive ability,Z-scores for Overall cognitive ability,Makerere University,Other,NA,NA,Tororo District Hospital,12 months of age,24 months of age,Z-scores for Overall cognitive ability,NA,NA,Z scores for Elicited Imitation,Z scores for Elicited Imitation,Z scores for Elicited Imitation,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Non-Probability Sample,"
        Inclusion Criteria:

          1. Enrolled in Makerere University-UCSF PROMOTE II study

          2. HIV-uninfected

          3. 12 months of age at the time of enrollment

          4. Within 30 km of the clinic

        Exclusion Criteria:

          1. Serious adverse event to the study drugs requiring cessation of study drug

          2. Active illness at enrollment (child can be enrolled once active illness has been
             treated and they are back to baseline health)

          3. Previous history of head trauma or coma in the child

          4. Cerebral palsy or other severe neurologic disease

          5. Known chronic illness requiring medical care

          6. Major medical abnormalities on screening history of past health

          7. Known developmental delay
      ",NA,NA,NA,NA,36 months of age,NA,12 months of age,NA,NA,NA,24 months of age,NA,36 months of age,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
5375011,NCT02509481,Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study,Repeat Ivermectin Mass Drug Administrations for Control of Malaria: a Pilot Safety and Efficacy Study,Completed,June 2015,December 2015,Actual,Actual,Colorado State University,"Brian D. Foy, PhD",Principal Investigator,Colorado State University,Phase 2/Phase 3,Interventional,2712,Actual,Malaria; Lymphatic Filariasis,NA,All,N/A,N/A,Accepts Healthy Volunteers,Colorado State University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Roch K Dabire, PhD",Principal Investigator,Institute de Recherche en Sciences de la Santé,NA,Incidence of clinical malaria episodes,NA,"Institut de Recherche en Sciences de la Sante, Burkina Faso",Other,Centre Muraz,Other,NA,"Approximately 18 weeks, from the start of the first MDA to 3 weeks following the last MDA in the Experimental arm",NA,NA,Ministère de la Santé du Burkina Faso,Other,NA,NA,NA,NA,NA,NA,NA,Cumulative incidence of malaria episodes in children ≤ 5 years of age (as assessed by active case surveillance in study villages - malaria episode defined as ≥38.0°C fever or history of fever in the last 24 hours + positive rapid diagnostic test for Plasmodium falciparum).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_P218_15_01,NCT02885506,"A FIH Study to Investigate the Safety, Tolerability and PK of P218","A Phase I Study to Investigate the Safety, Tolerability and Pharmacokinetic Profile and Food Effect of P218 in Healthy Adult Volunteers",Recruiting,August 2016,April 2017,Anticipated,Anticipated,Medicines for Malaria Venture,"Emilie Rossignol, PhD",Study Director,Medicines for Malaria Venture,Phase 1,Interventional,72,Anticipated,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Safety and tolerability of P218: Incidence, severity and relationship to the investigational product of observed and self-reported adverse events",NA,Richmond Pharmacology Limited,Industry,NA,NA,Richmond Pharmacology Ltd,During 11 days post administration of a single oral dose of P218 to healthy volunteers,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
15-0052,NCT02996695,PfSPZ Challenge With Prophylaxis in Mali,"Safety, Tolerability, Immunogenicity and Protective Efficacy Against Naturally-Transmitted Malaria of Infectious, Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) Administered by Direct Venous Inoculation Under Chloroquine Chemoprophylaxis (PfSPZ-CVac), in Malian Adults: A Randomized, Double Blind, Placebo-Controlled Trial",Recruiting,NA,"December 1, 2018",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,62,Anticipated,Plasmodium Falciparum Infection,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The number of serious adverse events (SAEs),The number of solicited local and systemic adverse events (AE),NA,NA,NA,NA,University of Bamako - Epidemiology of Parasitic Diseases - Malaria Research and Training Center,45 days,Day 12 after vaccination,The number of unsolicited AEs related to study product,NA,NA,The severity of solicited local and systemic adverse events (AE),The severity of unsolicited AEs related to study product,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Day 12 after vaccination,NA,Day 12 after vaccination,NA,"April 6, 2017",Actual,Day 12 after vaccination,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
PbVac,NCT03138096,Safety and Protective Efficacy of Pb(PfCS@UIS4),Safety and Protective Efficacy of Genetically Modified Plasmodium Berghei (Pb(PfCS@UIS4)) Malaria Parasites in Healthy Volunteers,Recruiting,NA,July 2018,Anticipated,Anticipated,Radboud University,NA,NA,NA,Phase 1/Phase 2,Interventional,30,Anticipated,"Malaria,Falciparum; Plasmodium Falciparum; Plasmodium Berghei; Controlled Human Malaria Infection (CHMI)",NA,All,18 Years,35 Years,Accepts Healthy Volunteers,Radboud University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Frequency and magnitude of adverse events in study groups [Safety],Presence of parasitemia after exposure to Pb(PfCS@UIS4) [Safety],Havenziekenhuis,Other,Erasmus Medical Center,Other,Havenziekenhuis,"through study completion, up to 8 months","through study completion, up to 8 months",Time to parasitemia after CHMI with the wild-type NF54 P. falciparum strain [Efficacy],The PATH Malaria Vaccine Initiative (MVI),Other,NA,NA,NA,NA,NA,NA,NA,Frequency and magnitude of adverse events in study groups.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Presence of parasitemia after exposure to Pb(PfCS@UIS4), as assessed by thick smear.","through study completion, up to 8 months","Time to parasitemia after CHMI with the wild-type NF54 P. falciparum strain, as detected by qPCR.",NA,NA,May 2017,Anticipated,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SL-ACT-01,NCT01967472,Adherence to Antimalarial Drugs in Sierra Leone,Adherence to Artemisinin-Based Combination Therapy (ACT) for the Treatment of Malaria in Sierra Leone,Completed,September 2013,January 2014,Actual,Actual,London School of Hygiene and Tropical Medicine,Kristin Banek,Principal Investigator,London School of Hygiene and Tropical Medicine,N/A,Interventional,792,Anticipated,Malaria,NA,All,6 Months,59 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Adherence,NA,"National Malaria Control Program, Ministry of Health and Sanitation",Other,"Pharmacy Board of Sierra Leone, Ministry of Health and Sanitation",Other,NA,Day 4,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Adherence is measured on the day following the last day of treatment. Adherence is defined as taking all of the prescribed dose at the correct time.,NA,NA,NA,NA,NA,NA,NA,NA,Adherence,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
B300201627244,NCT02900079,Use of Malaria Rapid Diagnostic Tests as a Decision Aid for the Management of Fever by International Travelers,New Tools for Diagnosis and Management of Febrile Illness in Travelers to the Tropics: a Cohort Study- JOKA I,Not yet recruiting,February 2017,August 2019,Anticipated,Anticipated,"Institute of Tropical Medicine, Belgium","Jan Jacobs, MD PhD",Study Chair,"Institute of Tropical Medicine, Antwerp, Belgium",N/A,Observational [Patient Registry],4500,Anticipated,Fever; Malaria,NA,All,18 Years,N/A,Accepts Healthy Volunteers,"Institute of Tropical Medicine, Belgium",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,negative predictive value of a malaria RDT when used by travelers with febrile illness,NA,NA,NA,NA,NA,ITM,up to 12 weeks followup,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"malaria RDT results will be compared to post hoc PCR diagnosis of malaria on the original test strip; the negative predictive value (NPV) will be calculated in a travelers' cohort. A NPV > 99,0 % will be considered as safe to rule out malaria.",NA,NA,NA,NA,NA,NA,NA,NA,NA,Probability Sample,"
        Inclusion Criteria:

          -  residing in Belgium

          -  Attend a briefing session on the topic ""Fever in The Tropics"" by an ITM physician

          -  able to comply with study procedures:

          -  carry and complete a study diary in case of illness

          -  be trained to use RDT

          -  Willing and able to provide written informed consent

          -  Adults fulfilling all criteria and volunteer to have their RDT collected by their
             trained peers during travel, may be included for analysis after obtaining informed
             consent upon post-travel evaluation.

        Exclusion Criteria:

          -  known intolerance or hypersensitivity to artemisinine based combination therapy

          -  known pregnancy at time of travel
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCZJ29 - Greenwood,NCT03143218,"Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)","A Phase IIIB Comparative Trial of Seasonal Vaccination With the Malaria Vaccine RTS,S/AS01, Seasonal Malaria Chemoprevention and of the Two Interventions Combined",Recruiting,NA,"June 30, 2020",Anticipated,Anticipated,London School of Hygiene and Tropical Medicine,"Alassane Dicko, Professor",Principal Investigator,"Malaria Research & Training Center, Bamako",Phase 3,Interventional,6000,Anticipated,"Malaria,Falciparum; Children, Only",NA,All,5 Months,17 Months,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Ogobara Doumbo, Professor",Study Director,"Malaria Research & Training Center, Bamako",NA,Incidence of clinical episodes of malaria,NA,"Malaria Research and Training Center, Bamako, Mali",Other,"Institut de Recherche en Sciences de la Sante, Burkina Faso",Other,NA,Passive surveillance of clinical episodes of malaria within the study area starting 4 weeks post primary vaccination dose 3 (1 August 2017) till end of malaria transmission season in December 2019 (29 months),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Passive surveillance to detect episode of fever (temperature > 37.5 C), or a history of fever within the past 48 hours, that is severe enough to require treatment at a health centre and which is accompanied by a positive blood film with a parasite density of 5,000 per µl or more","Jean Bosco Ouedraogo, Professor",Study Director,"Institut de Recherche en Sciences de la Santé, Direction Régionale de l'Ouest (IRSS-DRO)",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"April 17, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
IMPAACT P1068s,NCT00719602,Differences in Malaria Infection Levels in HIV-infected Infants and Children Receiving PI- and NNRTI-based HAART,P1060 Substudy Comparing Differences in Malaria Parasitemia by Real Time Quantitative PCR in HIV-Infected Infants and Children on PI-Based HAART Versus NNRTI-Based HAART,Completed,August 2009,August 2013,Actual,Actual,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,"Charlotte Hobbs, MD",Study Chair,New York University School of Medicine,Early Phase 1,Interventional,105,Actual,HIV Infections; Malaria,NA,All,6 Months,35 Months,No,International Maternal Pediatric Adolescent AIDS Clinical Trials Group,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"William Borkowsky, MD",Study Chair,New York University School of Medicine,NA,Parasitemia in blood samples,NA,National Institute of Allergy and Infectious Diseases (NIAID),NIH,Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD),NIH,NA,Throughout study,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU0905,NCT01054248,Randomised Trial of 3 Artemisinin Combination Therapy for Malaria in Pregnancy,"A Randomised Open Label Trial Comparing Standard Dose of Dihydroartemisinin-piperaquine, Standard Fixed Artesunate-mefloquine Regimen and a Longer Regimen of Artemether-lumefantrine in the Treatment of Uncomplicated Malaria in Pregnancy",Completed,February 2016,September 2016,Actual,Actual,University of Oxford,"Rose McGready, MBBS",Principal Investigator,Shoklo Malaria Research Unit,Phase 3,Interventional,499,Actual,Malaria,NA,All,18 Years,45 Years,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Cure rate defined as clearance of asexual parasites without recurrence within the period between treatment and delivery or a 63 day period,NA,NA,NA,NA,NA,Shoklo Malaria Research Unit,"Day 63 or until delivery, whichever occurs later",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CHANGE BF,NCT02236468,Creating Homestead Agriculture for Nutrition and Gender Equity (CHANGE) in Burkina Faso,Creating Homestead Agriculture for Nutrition and Gender Equity in Burkina Faso,Completed,March 2014,June 2016,Actual,Actual,International Food Policy Research Institute,"Deanna Olney, PhD",Principal Investigator,International Food Policy Research Institute,N/A,Interventional,2747,Actual,Anemia; Growth Retardation,NA,All,N/A,12 Months,Accepts Healthy Volunteers,International Food Policy Research Institute,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Hemoglobin (g/dl),NA,Helen Keller International,Other,"Foreign Affairs, Trade and Development, Canada",Other,Hellen Keller International,"Measurements will be made for children between the ages of 0 and 12 months of age at baseline and 2 years later, at endline, when the children are between the ages of 24 and 36 months.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Changes in hemoglobin (g/dl) and in prevalence of anemia (<11g/dl) will be measured over the course of the two year program period.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
762488-1,NCT02536222,"Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts","Accelerating the Reduction of Malaria Transmission in Kanel, Ranérou and Linguère Districts",Completed,September 2015,July 2016,Actual,Actual,PATH,NA,NA,NA,Phase 4,Interventional,20379,Actual,Malaria,NA,All,2 Months,N/A,Accepts Healthy Volunteers,PATH,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of passively detected malaria cases,NA,National malaria Control Program of Senegal,Other,Regional and district health authorities of Matam and Louga regions and Kanel Ranerou and Linguere districts of Senegal,Other,"six health posts in Kanel, Linguère and Ranérou districts",one malaria transmission season (up to 5 months),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Incidence of passively detected RDT-confirmed malaria cases among individuals older than 2 months (at the health posts or by community health workers), collected through the rapid reporting system already in place. Every week, health facility workers submit basic information on malaria burden, that is entered into DHIS2 (district health information system) at the district level. The quality of the rapid reporting system will be monitored through routine data quality audits (comparing health post registers with submitted data) and continuous monitoring of the data submitted to DHIS2. The estimated enrollment is 30 000 individuals. A comparison before and after the intervention and between interventions and control villages will be done using a difference-in-difference analysis.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
mixmalaria,NCT02903758,Frequency and Distribution of Mixed Falciparum-vivax Infections in French Guiana,NA,Completed,January 2000,December 2008,Actual,Actual,Centre Hospitalier de Cayenne,NA,NA,NA,N/A,Observational,400,Actual,Malaria,NA,All,N/A,N/A,No,Centre Hospitalier de Cayenne,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,malaria,NA,universite de guyane,Other,NA,NA,Centre Hospitalier de Cayenne,At the time of diagnosis of malaria,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,PCR positive for malaria parasites,NA,NA,NA,NA,NA,NA,NA,NA,malaria,Non-Probability Sample,"
        Inclusion Criteria:

          -  malaria diagnosis

        Exclusion Criteria:

          -  no malaria
      ",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SR-M-IDR,NCT02294188,Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia,Spatial Repellent Products for Control of Vector Borne Diseases - Malaria - Indonesia,"Active, not recruiting",May 2015,March 2018,Anticipated,Anticipated,University of Notre Dame,"Neil F Lobo, PhD",Principal Investigator,"University of Notre Dame, USA",N/A,Interventional,2000,Anticipated,Malaria,NA,All,6 Months,59 Months,Accepts Healthy Volunteers,University of Notre Dame,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Nicole L Achee, PhD",Principal Investigator,"University of Notre Dame, USa",NA,Malaria Incidence,NA,"Ministry of Health, Indonesia",Other,NA,NA,Eijkman Institute for Molecular Biology,104 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Incidence of malaria infections among human cohorts during the follow-up period as detected by PCR,NA,NA,NA,NA,NA,NA,NA,NA,Malaria Incidence,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SR-M-KEN,NCT02294201,Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya,Spatial Repellent Products for the Control of Vector Borne Diseases - Malaria - Kenya,Withdrawn,June 2016,July 2016,Actual,Actual,University of Notre Dame,"Neil Lobo, PhD",Principal Investigator,University of Notre Dame,N/A,Interventional,0,Actual,Malaria,NA,All,6 Months,59 Months,Accepts Healthy Volunteers,University of Notre Dame,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Nicole Achee, PhD",Principal Investigator,University of Notre Dame,NA,Malaria Incidence,NA,Centers for Disease Control and Prevention,U.S. Fed,Kenya Medical Research Institute,Other,Kemri-Crc,104 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Incidence of malaria infections among human cohorts during the follow-up period as detected by PCR,NA,NA,NA,NA,NA,NA,NA,NA,Malaria Incidence,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1128,NCT00292929,Study of the Safety of Intravenous Artesunate,"A Phase 1 Randomized, Double-Blind, Placebo-Controlled Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Single Intravenous Doses of Artesunate Administered to Healthy Subjects",Completed,NA,October 2006,Actual,Actual,U.S. Army Medical Research and Materiel Command,"Peter J Weina, MD, PhD",Study Director,Walter Reed Army Institute of Research (WRAIR),Phase 1,Interventional,NA,NA,"Malaria; Malaria, Cerebral",NA,All,18 Years,55 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,40,NA,NA,NA,NA,NA,NA,Uniformed Services University of the Health Sciences,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP14C21,NCT02431637,Experimental Falciparum Transmission to Anopheles,Blood Stage Challenge Study to Asses Mosquito Transmissibility in Participants Inoculated With Plasmodium Falciparum,Completed,NA,September 2016,Actual,Actual,Medicines for Malaria Venture,"James McCarthy, Prof",Principal Investigator,QIMR Berghofer Medical Research Institute,Phase 1,Interventional,6,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Successful infection of vector mosquitoes following both direct and indirect feeding on the blood of infected participants,NA,Q-Pharm Pty Limited,Industry,Clinical Network Services (CNS) Pty Ltd,Industry,Q-Pharm Clinics,7-10 days after blood feeding,NA,NA,Sullivan Nicolaides Pathology,Other,NA,NA,NA,QIMR Berghofer Medical Research Institute,Other,"Army Malaria Institute, Australia",Other,"Seven to ten days after blood feeding, mosquitoes will be dissected to check for oocysts in midgut preparations. For permanent preparations, oocysts will be stained with 0.1% mercurochrome in PBS for 5 to 60 mins then fixed in 1%glutaraldehyde or formaldehyde. Oocysts will be counted per mosquito dissected and recorded. Relationship between parasitemia, gametocytemia and mosquito infection (both oocyst prevalence and intensity) will be determined using generalized-linear mixed models. The number of mosquitoes dying prior to dissection will be recorded.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,April 2015,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP15C05,NCT02431650,Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent,A Proof-Of-Concept Study to Assess the Effectiveness of OZ439 as a Gametocytocidal and Transmission Blocking Agent in Experimental P. Falciparum Infection,Completed,NA,September 2016,Actual,Actual,Medicines for Malaria Venture,"James McCarthy, Prof",Principal Investigator,QIMR Berghofer Medical Research Institute,Phase 1/Phase 2,Interventional,12,Actual,Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Infection success of vector mosquitoes,NA,Q-Pharm Pty Limited,Industry,Clinical Network Services (CNS) Pty Ltd,Industry,Q-Pharm Clinics,From day 10 to 21 post Piperaquine dosing,NA,NA,Sullivan Nicolaides Pathology,Other,NA,NA,NA,QIMR Berghofer Medical Research Institute,Other,"Army Malaria Institute, Australia",Other,Assessing the transmissibility by oocyst detection in mosquito midgut preparations following direct and membrane (indirect) feeding,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,April 2015,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BAKMAL1502,NCT02453308,A Study by the Tracking Resistance to Artemisinin Collaboration (TRAC),"A Multi-centre, Open-label Randomised Trial to Assess the Efficacy, Safety and Tolerability of Triple Artemisinin-based Combination Therapies (TACTs) Com-pared to Artemisinin-based Combination Therapies (ACTs) in Uncomplicated Falciparum Malaria and to Map the Geographical Spread of Artemisinin and Partner Drug Resistance",Recruiting,August 2015,April 2018,Anticipated,Anticipated,University of Oxford,NA,NA,NA,Phase 2/Phase 3,Interventional,2040,Anticipated,"Malaria, Falciparum",NA,All,6 Months,65 Years,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,PCR corrected efficacy defined as adequate clinical and parasitological response (ACPR),NA,NA,NA,NA,NA,NA,42 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
CDA 714703/005,NCT00344006,Chlorproguanil-Dapsone-Artesunate Versus COARTEM For Uncomplicated Malaria,"A Multi-centre, Randomised, Double-blind, Double Dummy Study Comparing the Efficacy and Safety of Chlorproguanil-dapsone-artesunate Versus Artemether-lumefantrine in the Treatment of Acute Uncomplicated Plasmodium Falciparum Malaria in Children and Adolescents in Africa.",Completed,June 2006,August 2007,Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,1395,Actual,"Malaria, Falciparum","Parasitological cure rate, PCR corrected, at day 28 in the PP population The ITT population is a key supportive analysis.",All,12 Months,14 Years,No,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
2380,NCT02987270,Evaluation of Community-based Mass Screening and Treatment for Malaria in Western Kenya,Evaluation of Community-based Screening and Treatment for Malaria in the KEMRI/CDC Health and Demographic Surveillance System (HDSS) in Western Kenya,Completed,April 2013,August 2015,Actual,Actual,Simon Kariuki,"Meghna R Desai, PhD",Principal Investigator,Centers for Disease Control and Prevention,Phase 3,Interventional,90000,Actual,"Malaria,Falciparum",NA,All,N/A,N/A,Accepts Healthy Volunteers,Simon Kariuki,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Simon K Kariuki, PhD",Principal Investigator,Kenya Medical Research Institute,NA,Incidence of malaria infection,NA,Centers for Disease Control and Prevention,U.S. Fed,NA,NA,NA,After year 1 and after year 2,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Incidence of malaria infection as determined by malaria blood smear microscopy in members of the cohort after year 1 and year 2 of mass screening and treatment,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SMRU1003,NCT01546961,Chloroquine Population Pharmacokinetics in Pre and Post-partum Women,The Population Pharmacokinetics of Chloroquine for the Treatment of Uncomplicated P.Vivax Malaria in Pre- and Post-partum Women.,Recruiting,June 2011,December 2017,Anticipated,Anticipated,University of Oxford,"Rose McGready, MD",Principal Investigator,University of Oxford,N/A,Interventional,160,Anticipated,Vivax Malaria,NA,All,18 Years,50 Years,No,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Population Pharmacokinetics of Chloroquine,NA,NA,NA,NA,NA,Shoklo Malaria Research Unit,63 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Population pharmacokinetic parameters up to day 63 in pregnant women with uncomplicated P.vivax malaria, and in the same women post-partum with P.vivax or without P.vivax.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MV-713-624-02-0033,NCT00118027,A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda,A New Approach to Deliver Malaria Preventions to Pregnant Women at a Community Level in Uganda,Completed,May 2003,June 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Anthony K Mbonye, MpH",Principal Investigator,"Ministry of Health, Uganda",N/A,Interventional,NA,NA,Malaria; Pregnancy; Anemia,NA,Female,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,2150,Timing of the first dose of SP.,Proportion of women who complete two doses of SP.,DBL -Institute for Health Research and Development,Other,"Ministry of Health, Uganda",Other,Mukono District,NA,NA,Birth weight of babies.,NA,NA,Proportion of low birth-weight babies.,Maternal haemoglobin and malaria parasite counts.,Proportion of adolescent pregnancies participating in the study.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Proportion of pregnant women who agree to take part in the study.,Proportion of scheduled visits completed by each delivery approach.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,The costs per low birth weight of babies avoided.,NA,NA,The costs per anaemic pregnant woman avoided.,NA,NA,Mothers' perceptions on the four different SP delivery outlets,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCR5098,NCT00119132,Effectiveness of Intermittent Preventive Treatment for Malaria in Children,A Study Of Impact Of Intermittent Preventive Treatment In Children With Amodiaquine Plus Artesunate Versus Sulphadoxine-Pyrimethamine On Hemoglobin Levels And Malaria Morbidity In Hohoe District Of Ghana,Completed,June 2005,December 2006,Actual,Actual,London School of Hygiene and Tropical Medicine,"Margaret Kweku, MBChB, MPH",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 2/Phase 3,Interventional,2602,Actual,Malaria,Mean Hb at the end of the high transmission season.,All,3 Months,59 Months,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Daniel Chandramohan, MBBS, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,INDEPTH Network,Other,NA,NA,"Ministry of Health, Hohoe district hospital",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Brian Greenwood, FRCP, FRS",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVG44,NCT00119145,Kintampo Trial of Combination Therapy for Malaria,"A Non-Inferiority, Open-Labelled, Randomised Trial Of The Efficacy And Safety Of Artesunate-Amodiaquine, Artemether-Lumefantrine, And Artesunate-Lapdap For Treatment Of Uncomplicated P. Falciparum Malaria Among Children In Ghana",Completed,June 2005,May 2006,Actual,Actual,London School of Hygiene and Tropical Medicine,"Seth Owusu-Agyei, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 4,Interventional,510,Anticipated,Malaria,adequate clinical and Parasitological response (ACPR)by day 28.,All,6 Months,10 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Daniel Chandramohan, MBBS, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,"Kintampo Health Research Centre, Ghana",Other,NA,NA,Kintampo Health Research Centre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Brian M Greenwood, FRCP, FRS",Principal Investigator,London School of Hygiene and Tropical Medicine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVG27b,NCT00120809,Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae,"A Randomised, Placebo Controlled Trial of Intermittent Preventative Treatment With Sulfadoxine-pyrimethamine in Gambian Multigravidae.",Completed,July 2002,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Brian Greenwood, MD",Study Chair,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,NA,NA,Malaria,NA,Female,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",September 2004,NA,NA,NA,3000,Hemoglobin concentration at delivery.,Birthweight.,"Medical Research Council Unit, The Gambia",Other,"Department of State for Health and Social Welfare, The Gambia",Other,Medical Research Council Laboratories,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVG27a,NCT00120822,Folic Acid Supplementation in Gambian Primigravidae,A Study of the Effect of Folic Acid Supplementation on the Anti-malarial Action of Sulfadoxine-pyrimethamine When Used for Intermittent Preventive Treatment in Gambian Primigravidae.,Completed,July 2002,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Brian Greenwood, MD",Study Chair,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,NA,NA,Malaria,Clearance of malaria parasitemia in parasitemic pregnant women 14 days after treatment with sulfadoxine-pyrimethamine.,Female,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",January 2004,NA,NA,NA,1000,NA,NA,"Medical Research Council Unit, The Gambia",Other,"Department of State for Health and Social Welfare, The Gambia",Other,"Medical Research Council, Laboratories",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCR5092,NCT00131703,Efficacy and Safety of Sulphadoxine-pyrimethamine and Amodiaquine in Ghanaian Pregnant Women,A Randomised Double Blind Clinical Trial of Amodiaquine (AQ) and Sulphadoxine-pyrimethamine (SP) Used Singly and in Combination (AQ+SP) Compared With Chloroquine (CQ) in the Treatment of Falciparum Malaria Infection in Pregnancy,Completed,March 2003,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Harry K Tagbor, MD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,NA,NA,Malaria; Pregnancy,NA,Female,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",March 2005,NA,NA,NA,900,Prevalence of parasitaemia on day 28 post treatment.,Prevalence of parasitaemia on day 14 post treatment.,"Ministry of Health, Ghana",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MV-714-624-03-0001,NCT00132535,Influence of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda,"Influence of HIV Infection on the Effectiveness of Malaria Prevention During Pregnancy, With Emphasis on the Effect of Chloroquine on HIV Viral Load Among Pregnant Women in Uganda",Completed,August 2003,June 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Lucy N Korukiiko, MPH",Principal Investigator,Uganda AIDS Commission,N/A,Interventional,NA,NA,Malaria in Pregnancy; HIV Infections,NA,Female,15 Years,49 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,2548,maternal peripheral parasitaemia,placental parasitaemia,DBL -Institute for Health Research and Development,Other,Uganda AIDS Commission,Other,Uganda AIDS Commission,NA,NA,clinical malaria,NA,NA,maternal and infant Hb,birth weight,congenital parasitaemia,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,maternal HIV viral load at inclusion and before delivery,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITCRVF02,NCT00132548,A Trial of Four Drug Regimens for the Prevention of Malaria in Senegalese Children,A Randomised Trial of the Efficacy and Safety of Four Drug Regimens When Used for Intermittent Preventive Treatment of Malaria in Senegalese Children,Completed,June 2004,NA,NA,NA,London School of Hygiene and Tropical Medicine,"Cheick Sokhna, PhD",Principal Investigator,"Institut de Recherche pour le Developpement, Senegal",Phase 3,Interventional,NA,NA,Malaria,Prevalence of drug resistance,All,1 Year,5 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",December 2004,NA,NA,NA,2200,NA,NA,"Institut de Recherche pour le Developpement, Senegal",Other,"Cheikh Anta Diop University, Senegal",Other,Institut de recherche pour le developpement,NA,NA,NA,"Ministry of Health, Senegal",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVG32,NCT00142207,Preventing Malaria During Pregnancy in Epidemic-prone Areas.,"The Efficacy and Cost-effectiveness of Malaria Prevention in Pregnancy in an Area of Low and Unstable Transmission in Kabale, Uganda: Use of Intermittent Preventive Treatment and Insecticide-treated Nets.",Completed,January 2004,January 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Richard H Ndyomugyenyi, MBChB, PhD",Principal Investigator,"Vector Control Division, Ministry of Health, Uganda",Phase 3,Interventional,4775,Actual,"Malaria, Falciparum",NA,Female,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Sian E Clarke, PhD",Principal Investigator,"London School of Hygiene and Tropical Medicine, University of London, UK",NA,mean birthweight,prevalence of low birthweight,"Ministry of Health, Uganda",Other,NA,NA,Kabale District Health Services (antenatal clinics at selected sites),April 2004-Jan 2007,April 2004 - Jan 2007,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Pascal Magnussen, MD",Principal Investigator,"DBL - Institute for Health Research and Development, Denmark","Kristian Schultz Hansen, PhD",Principal Investigator,"DBL - Institute for Health Research and Development, Denmark",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
DIF23,NCT00158587,Eight Week Primaquine Regimen for the Treatment of Vivax Malaria,"A Placebo Controlled, Randomised Evaluation of an Eight Week Primaquine Regimen for the Treatment of Vivax Malaria.",Completed,April 2004,March 2007,Actual,Actual,London School of Hygiene and Tropical Medicine,"Mark Rowland, PhD",Principal Investigator,LSHTM,Phase 3,Interventional,150,Actual,Malaria; Vivax Malaria,NA,All,3 Years,70 Years,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Primary Efficacy Variable: Proportion with relapse(s) of P. vivax in 12 months of follow-up.,NA,HealthNet TPO,Other,NA,NA,NA,2004-March 2007,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
UCSF CHR # 15-16839,NCT02831023,Phase 2 Efficacy Study of Primaquine and Methylene Blue,"Efficacy, Safety, and Pharmacokinetics of Sulphadoxine-pyrimethamine-amodiaquine (SP-AQ), SP-AQ Plus Primaquine, Dihydroartemisinin-piperaquine (DP), DP Plus Methylene Blue for Preventing Transmission of P. Falciparum Gametocytes in Mali",Completed,July 2016,January 2017,Actual,Actual,"University of California, San Francisco","Roland Gosling, MD, PhD",Principal Investigator,"University of California, San Francisco",Phase 2,Interventional,80,Actual,Malaria,NA,Male,5 Years,50 Years,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Alassane Dicko, MD",Principal Investigator,Malaria Research and Training Centre,NA,Mosquito infectivity assessed through membrane feeding assays,NA,"Malaria Research and Training Center, Bamako, Mali",Other,Radboud University,Other,Malaria Research and Training Centre,7 day,NA,NA,London School of Hygiene and Tropical Medicine,Other,NA,NA,NA,Heidelberg University,Other,Bill and Melinda Gates Foundation,Other,Infectivity will be measured by oocyst prevalence in dissected mosquitoes. Primary endpoint will be a comparison between mean of pretreatment infectivity (day 0) and infectivity at days 2 and 7 post first dose.,"Teun Bousema, PhD",Principal Investigator,Radboud University,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
050133,NCT00114010,Experimental Vaccine for Malaria,"Phase 1 Study of the Safety of Immunization of Naive Individuals With AMA1-C1/Alhydrogel [R], an Asexual Blood-Stage Vaccine for Plasmodium Falciparum Malaria, and the Effect of Immunization on Antigen-specific Memory and Plasma B Cells and T Cells",Completed,"April 1, 2005","December 22, 2006",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,13,Actual,Malaria,NA,All,18 Years,50 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"National Institutes of Health Clinical Center, 9000 Rockville Pike",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
ITDCVG41,NCT00142246,"Study of the Impact of Intermittent Preventive Treatment in Schools on Malaria, Anaemia and Education.","Intermittent Preventive Treatment in Schools: a Randomised Controlled Trial of the Impact of IPT on Malaria, Anaemia and Education Amongst Schoolchildren in Western Kenya",Completed,January 2005,April 2006,Actual,Actual,London School of Hygiene and Tropical Medicine,"Sian E Clarke, PhD",Principal Investigator,"London School of Hygiene and Tropical Medicine, University of London, UK",Phase 3,Interventional,6758,Actual,"Malaria, Falciparum",NA,All,N/A,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Simon J Brooker, PhD",Principal Investigator,"London School of Hygiene and Tropical Medicine, University of London, UK",NA,Prevalence of anaemia (Hb <112g/L),NA,University of Nairobi,Other,NA,NA,Primary schools within Bondo district / Bondo District Hospital,March 2006,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Benson BA Estambale, MBChB, PhD",Principal Investigator,University of Nairobi,"Matthew CH Jukes, PhD",Principal Investigator,"Partnership for Child Development, Imperial College, University of London, UK",NA,NA,NA,NA,NA,"Pascal Magnussen, MD",Principal Investigator,"DBL - Institute for Health Research and Development, Denmark",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
060074,NCT00277849,Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research,Collection of Blood From Persons With Hemoglobin and Erythrocyte Polymorphisms for Laboratory Malaria Research,Completed,"January 11, 2006",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,130,Anticipated,Hemoglobin Mutations; Erythrocyte Variants,NA,All,18 Years,65 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","July 20, 2010",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"National Institutes of Health Clinical Center, 9000 Rockville Pike",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999905214,NCT00342043,Examination of Protective Factors Against Severe Malaria,Multidisciplinary Studies of Malaria Protection by Hemoglobinopathies and G6PD Deficiency in Mali,Completed,"August 2, 2005",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Malaria; Severe Malaria,NA,All,N/A,10 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","April 16, 2009",NA,NA,NA,4850,NA,NA,NA,NA,NA,NA,Malaria Research and Training Center,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999904175,NCT00343005,Experimental Vaccine for Malaria in Adults in Mali,"Double-Blind, Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of AMA1-C1/Alhydrogel Vaccine for Plasmodium Falciparum Malaria, in Semi-Immune Adults in Doneguebougou, Mali",Completed,"April 23, 2004",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Plasmodium Falciparum Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","January 22, 2008",NA,NA,NA,54,NA,NA,NA,NA,NA,NA,Malaria Research and Training Center (MRTC),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999906104,NCT00368810,Study of Factors Involved in Resistance to Severe Malaria,Response to Plasmodium Falciparum-Derived TLR Ligands in Severe and Uncomplicated Malaria in Mali,Completed,"February 21, 2006",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,N/A,Observational,NA,NA,Malaria,NA,All,2 Years,10 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","November 30, 2006",NA,NA,NA,120,NA,NA,NA,NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999907051,NCT00414336,Phase I Study of Safety and Immunogenicity of AMA1-C1Alhydrogel + CPG 7909 Vaccine for Malaria,"Randomized, Controlled, Phase 1 Study of the Safety and Immunogenicity of the AMA1-C1/Alhydrogel + CPG 7909 Vaccine for Plasmodium Falciparum Malaria in Semi-Immune Malian Adults",Completed,"December 15, 2006","December 15, 2006",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Malaria,Safety and reactogenicity.,All,18 Years,45 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,150,NA,NA,National Institute of Allergy and Infectious Diseases@@@Coley Pharmaceutical Group,Other,NA,NA,Doneguebougou Malaria Vaccine Center,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999907170,NCT00487916,"Phase 1 Study of the Safety, Reactogenicity, and Immunogenicity of AMA1-C1/ISA 720: Blood Stage Vaccine for Plasmodium Falciparum","Phase 1 Study of the Safety, Reactogenicity and Immunogenicity of AMA1-C1/ISA 720: A Blood Stage Vaccine for Plasmodium Falciparum",Completed,"June 13, 2007","February 5, 2009",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,NA,NA,Malaria,Assessment of the safety and reactogenicity of the AMA1-C1/ISA 720 vaccine; and to determine the frequency of systemic and local AEs as recorded for 28 days following each vaccination.,All,18 Years,45 Years,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,150,NA,NA,NA,NA,NA,NA,QIMR - CLive Berghofer Cancer Research Centre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
REG_9,NCT00499876,The Effect of Malaria on Disease Progression of HIV/AIDS,"The Effect of Malaria on Disease Progression of HIV/AIDS in Kumasi, Ghana",Completed,October 2007,December 2009,Actual,Actual,London School of Hygiene and Tropical Medicine,"Ruby Martin-Peprah, MBChB, PhD",Principal Investigator,Komfo Anokye Teaching Hospital,N/A,Interventional,197,Actual,HIV Infections; Malaria,NA,All,19 Years,N/A,No,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Measure the effects of antimalarials on CD4 cell count decline and HIV viral load increase in study patients,NA,Noguchi Memorial Institute for Medical Research,Other,NA,NA,Komfo Anokye Teaching Hospital,12 months,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC1089,NCT00561899,Comparison of Three Drug Combinations for Intermittent Treatment of Malaria in Children,"Comparison of Safety, Tolerability and Efficacy of Three Drug Combinations for Intermittent Preventive Treatment in Children Aged 1-5 Years in an Area of Seasonal Malaria Transmission in Upper River Division, The Gambia",Completed,August 2007,June 2008,Actual,Actual,London School of Hygiene and Tropical Medicine,"Kalifa Bojang, MD",Principal Investigator,"Medical Research Council Unit, The Gambia",Phase 2/Phase 3,Interventional,1295,Actual,Malaria,NA,All,1 Year,5 Years,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Kalifa Bojang, MD",Principal Investigator,Medical Research Council,NA,"The safety and tolerability of AQ plus SP, PQP plus SP, and PQP plus DHA when used for seasonal IPT in children",NA,"Department of State for Health and Social Welfare, The Gambia",Other,NA,NA,"Medical Research Council Laboratories,",Onset of IPT to end of malaria season,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
15-0001,NCT02663700,Safety and Immunogenicity of Sanaria's Irradiated Sporozoite Vaccine (PfSPZ Vaccine) in Malaria-Experienced Adults in Burkina Faso,"Dose Escalation Study of Sanaria's Irradiated Sporozoite Vaccine (PFSPZ Vaccine), Followed by a Randomized, Double-Blind, Placebo-Controlled Phase 1 Clinical Trial to Evaluate the Safety and Immunogenicity of PfSPZ Vaccine in Malaria-Experienced Adults in Burkina Faso.","Active, not recruiting",NA,"April 20, 2019",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,112,Actual,Plasmodium Falciparum Infection,NA,All,21 Years,40 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Occurrence of serious adverse events (SAEs) at any point during the study period, according to the MedDRA classification","Occurrence of serious adverse events (SAEs) considered related to vaccination within 28 days following vaccination (day of vaccination and 27 subsequent days), according to the MedDRA classification",NA,NA,NA,NA,Centre National de Recherche et de Formation sur le Paludisme - Research and Training,26 months,28 days,Occurrence of solicited reactions within 7 days following vaccination (day of vaccination and 7 subsequent days),NA,NA,"Occurrence of unsolicited adverse events (AEs) considered related to vaccination and that are severe (Grade 3) in severity within 28 days following vaccination (day of vaccination and 27 subsequent days), according to the MedDRA",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,8 days,NA,28 days,NA,"April 7, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Swaziland fMDA,NCT02315690,Evaluation of Reactive Focal Mass Drug Administration for Malaria Elimination in Swaziland,Evaluating the Effectiveness and Feasibility of Reactive Focal Mass Drug Administration vs. Reactive Case Detection as a Community Level Intervention in Response to a Passively Identified Index Malaria Case in Swaziland,Recruiting,NA,February 2018,Anticipated,Anticipated,"University of California, San Francisco","Michelle S Hsiang, MD",Principal Investigator,"UTSW, UCSF",Phase 3,Interventional,6000,Anticipated,Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence of malaria cases,NA,"Ministry of Health, Swaziland",Other,"Clinton Health Access Initiative, Nigeria",Other,Swaziland Ministry of Health,2 years,NA,NA,University of Texas,Other,NA,NA,NA,NA,NA,NA,NA,Cumulative incidence of malaria cases by locality,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,September 2015,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
VAC056,NCT02600975,"A Study to Assess the Safety and Immunogenicity of a Malaria Vaccine Candidate, R21, Administered With AS01B","A Phase I Study to Assess the Safety and Immunogenicity of a Protein Particle Malaria Vaccine Candidate, R21, Administered With AS01B in Healthy UK Volunteers",Completed,NA,"January 19, 2017",Actual,Actual,University of Oxford,NA,NA,NA,Phase 1,Interventional,20,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,University of Oxford,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Safety and tolerability of administration of R21 with adjuvant AS01B. This will be done by recording the number of participants who experience adverse events, and the severity of any adverse events.",NA,NA,NA,NA,NA,NA,34 weeks,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Safety and tolerability of administration of R21 with adjuvant AS01B. This will be done by recording the number of participants who experience adverse events, and the severity of any adverse events.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"December 8, 2015",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NMRR-16-356-29088,NCT03056391,Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria,Effect of Paracetamol on Renal Function in Plasmodium Knowlesi Malaria: A Randomised Controlled Clinical Trial,Recruiting,October 2016,August 2018,Anticipated,Anticipated,Menzies School of Health Research,"Giri M Rajahram, MD",Principal Investigator,"Clinical Research Center, Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia",Phase 3,Interventional,200,Anticipated,Malaria,NA,All,12 Years,N/A,No,Menzies School of Health Research,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Bridget Barber, MBBS",Study Director,Menzies School of Health Research,NA,Effect of Paracetamol on kidney function,NA,NA,NA,NA,NA,NA,72 hours,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Change in creatinine concentration (umol/L) at 72 hours from enrolment in patients receiving regularly-dosed paracetamol compared to those not receiving regular paracetamol, stratified by the level of intravascular haemolysis (cell-free haemoglobin).","Nicholas Anstey, PhD",Study Director,Menzies School of Health Research,"Matthew Grigg, MBBS",Study Director,Menzies School of Health Research,NA,NA,NA,NA,NA,"Timothy William, MBBS",Study Director,Jesselton Medical Centre,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Jayaram Menon, MBBS",Study Director,"Ministry of Health, Malaysia","Tsin Yeo, MBBS",Study Director,Menzies School of Health Research,"Katherine Plewes, MD",Study Director,"Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand","Arjen Dondorp, MD",Study Director,"Mahidol Oxford Tropical Medicine Research Unit, Bangkok, Thailand",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Daniel Cooper, MBChB",Study Director,Menzies School of Health Research
MaDrAZ-001,NCT02721186,Effectiveness of Mass Drug Administration for Reducing Seasonal Malaria Transmission in Zanzibar,Effectiveness of Mass Drug Administration (MDA) for Reducing Seasonal Malaria Transmission Towards Its Elimination in Hotspot Areas in Zanzibar - a Cluster-randomised Controlled Trial,"Active, not recruiting",NA,September 2017,Anticipated,Anticipated,Ulrika Morris,"Anders Björkman, MD, PhD",Principal Investigator,Karolinska Institutet,N/A,Interventional,22500,Actual,Malaria; Plasmodium Infections,NA,All,6 Months,N/A,Accepts Healthy Volunteers,Ulrika Morris,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,"Abdullah S Ali, Programme Manager",Principal Investigator,Zanzibar Malaria Elimination Programme,NA,Cumulative notified malaria incidence in the MDA and control Shehias,NA,Mahidol Oxford Tropical Medicine Research Unit,Other,RTI International,Other,Zanzibar Malaria Elimination Programme,6 months after second round of MDA,NA,NA,The President’s Malaria Initiative,Other,NA,NA,NA,"University of California, San Francisco",Other,Uppsala University,Other,Cumulative notified malaria incidence determined as the number of confirmed malaria cases notified at health facilities (monitored through the malaria case notification system during the period of six months) over the Shehia population size determined by population enumeration at the time of the intervention.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"April 30, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Zanzibar Malaria Elimination Programme,Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
15-0058,NCT03014258,A Systems Biology Approach to Malaria Immunity,A Systems Biology Approach to Malaria Immunity Repetitive Controlled Human Malaria Infection (CHMI) Study in Malaria-Naïve Adults Using NF54 Strain Plasmodium Falciparum (Pf),Recruiting,NA,"November 1, 2020",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,28,Anticipated,Plasmodium Falciparum Infection,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of a positive malaria smear,Occurrence of parasites using real-time quantitative PCR,NA,NA,NA,NA,University of Maryland School of Medicine - Center for Vaccine Development - Baltimore,Study Days 6-29 post-CHMI,Study Days 6-29 post-CHMI,Quantification of parasites using real-time quantitative PCR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Study Days 6-29 post-CHMI,NA,NA,NA,"June 7, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
SCC L2002.69,NCT00269178,Cluster Randomized Trial of Peer Health Education in Malaria in The Gambia,Cluster Randomized Trial of the Impact of a Peer-health Education Programme on Malaria Knowledge Attitudes and Practice in Students and Their Families,Completed,August 2003,October 2004,Actual,Actual,London School of Hygiene and Tropical Medicine,"Paul JM Milligan, PhD",Principal Investigator,London School of Hygiene and Tropical Medicine,Phase 3,Interventional,NA,NA,Malaria,NA,All,N/A,N/A,Accepts Healthy Volunteers,London School of Hygiene and Tropical Medicine,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,960,1. Bednet use among children under 5yrs of age living in the household of peer health educators 10 wweks and 6 months after the start of the intervention,2. Malaria knowledge attitudes and practice among women in the family of peer health educators 10 week and 6 months after the start of the intervention,"Medical Research Council Unit, The Gambia",Other,"Nova Scotia Gambia Association, The Gambia",Other,Medical Research Council Laboratories,NA,NA,3. Malaria knowledge attitudes and practice among school students 10 weeks and 6 months after the start of the intervention,"Centre for Innovation Against Malaria, The Gambia",Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
114460,NCT01366534,"Safety, Immunogenicity and Efficacy Against of a Combined Malaria Vaccine in Healthy Malaria-naïve Adults","Safety, Immunogenicity and Efficacy Against Malaria in the Sporozoite Challenge Model of One Dose of Ad35.CS.01 Malaria Vaccine Followed by Two Doses of Malaria 257049 Vaccine in Healthy Malaria-naïve Adults",Completed,NA,"July 3, 2012",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,68,Actual,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of Subjects With Plasmodium Falciparum Parasitemia Following Sporozoite Challenge,Number of Subjects With Any and Grade 3 Solicited Local Symptoms,The PATH Malaria Vaccine Initiative (MVI),Other,Crucell Holland BV,Industry,GSK Investigational Site,28 days following sporozoite challenge (Day 105),Within the 7-day (Day 0 - Day 6) follow-up period post-vaccination,"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms",NA,NA,Number of Subjects With Any Unsolicited Adverse Events (AEs),Number of Subjects With Any Unsolicited Adverse Events (AEs),Number of Subjects With Serious Adverse Events (SAEs),NA,NA,NA,NA,P. falciparum parasitemia was defined as a positive blood slide.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest, pain that prevented normal every day activities. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.",Within the 7-day (Day 0 - Day 6) follow-up period post-vaccination,"Assessed solicited general symptoms were chills, fatigue, gastrointestinal symptoms, headache and temperature [defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)]. Any = occurrence of the symptom regardless of intensity grade.Grade 3 Chills = rigors [uncontrollable shivering more than (>) 15 seconds]. Grade 3 Fatigue, Gastrointestinal symptoms and Headache = symptoms that prevented normal activity. Grade 3 fever = fever higher than (>) 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.",Within the 30-day (Day 0 - Day 29) follow-up period post-vaccination,"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","August 10, 2011",Actual,Within the 30-day (Day 0 - Day 29) follow-up period post-challenge,"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.",Throughout the study period (Day 0 - Day 236),"Serious adverse events (SAEs) assessed include medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
116682,NCT02251704,An Epidemiology Study of Malaria Transmission Intensity in Children in Sub-Saharan Africa,Epidemiology Study of Malaria Transmission Intensity in Sub-Saharan Africa,Recruiting,"October 22, 2014","August 31, 2023",Anticipated,Anticipated,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,N/A,Interventional,56000,Anticipated,Malaria,NA,All,6 Months,10 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of P. falciparum parasitaemia (using microscopy),Occurrence of malaria control interventions,NA,NA,NA,NA,NA,Day 0 to Year 5,Day 0 to Year 5,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Infection with P. falciparum determined using a blood smear slide and determined using microscopy,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Malaria control interventions are mosquito net usage, residual spraying, seasonal malaria chemoprevention (SMC), intermittent preventative treatment in infants (IPTi), and artemisinin-based combination therapy (ACT) therapy received within the last 14 days",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
17MA,NCT02788864,Prevention of Malaria With Dihydroartemisinine + Piperaquine for Forest Rangers,"A Randomized, Placebo-controlled, Double-blind Trial Using Dihydroartemisinine+Piperaquine (DP) to Protect Forest Workers From Malaria in Bu Gia Map National Park",Completed,NA,"November 30, 2016",Actual,Actual,"Oxford University Clinical Research Unit, Vietnam","Hung Son Do, Dr",Principal Investigator,Oxford University Clinical Research Unit,Phase 4,Interventional,150,Actual,Malaria,NA,Male,18 Years,N/A,Accepts Healthy Volunteers,"Oxford University Clinical Research Unit, Vietnam",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"the proportion of study subjects with any malaria parasitaemia (P.falciparum, mixed parasitaemia of P.falciparum and P.vivax) and the incidence rate of symptomatic malaria",NA,Binh Phuoc Malaria Control Centre,Other,"Bu Gia Map National Park, Binh Phuoc Province, Vietnam",Other,Bu Gia Map Commune Health Station,at 2 weeks after coming back from the forest,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The primary endpoints are the proportion of study subjects with any malaria parasitaemia (P.falciparum, mixed parasitaemia of P.falciparum and P.vivax) at 2 weeks after coming back from the forest assessed by high volume, ultrasensitive PCR (HVUSqPCR) and the incidence rate of symptomatic malaria (P.falciparum, mixed P.falciparum + P.vivax) during the two week follow-up period as assessed by the study doctor.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"May 20, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
200599,NCT02207816,"An Extension to Study MALARIA-055 PRI (NCT00866619) to Evaluate the Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine in Infants and Children in Africa","Extension to Study MALARIA-055 PRI (NCT00866619) for Evaluation of Long-term Efficacy, Safety and Immunogenicity of GSK Biologicals' Candidate Malaria Vaccine (SB257049) in Infants and Children in Africa",Completed,NA,"January 31, 2017",Actual,Actual,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,3084,Actual,Malaria,NA,All,42 Months,9 Years,Accepts Healthy Volunteers,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Occurrence of severe malaria meeting the primary case definition.,NA,NA,NA,NA,NA,NA,Starting January 2014 until the end of the 3-year follow-up period (Year 3).,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"September 18, 2014",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
MMV_DSM265_14_03,NCT02562872,DSM265 Prophylaxis of Plasmodium Falciparum Malaria,"Proof-of-concept, Single Center Study in Healthy Adult Volunteers to Investigate Safety, Tolerability, Pharmacokinetics and Prophylactic Activity of Single Dose DSM265 in a Controlled Human Malarial Infection Challenge Either by Direct Venous Inoculation of Plasmodium Falciparum Sporozoites or Mosquito-borne Plasmodium Falciparum",Completed,NA,May 2017,Actual,Actual,Medicines for Malaria Venture,"James G Kublin, MD/MPH",Principal Investigator,Fred Hutchinson Cancer Research Centre,Phase 1,Interventional,24,Actual,Healthy,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of subjects with positive parasitemia,Time interval between challenge and the first positive parasitemia,Fred Hutchinson Cancer Research Center,Other,United States Department of Defense,U.S. Fed,Fred Hutchinson Cancer Research Center - Prevention Center,28 days,28 days,NA,Center for Infectious Disease Research,Other,NA,NA,NA,NA,NA,NA,NA,positive parasitemia detected by qRT-PCR,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Time from infection to peripheral parasitemia (qRT-PCR) in DSM265 / placebo treated subjects in each cohort given as a geometric mean [days],NA,NA,NA,NA,March 2016,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
QP15C20,NCT02867059,SJ733 Induced Blood Stage Malaria Challenge Study,A Proof-of-concept Study to Assess the Effect of (+)-SJ000557733 (SJ733) Against Early Plasmodium Falciparum Blood Stage Infection in Healthy Participants,Recruiting,August 2016,July 2017,Anticipated,Anticipated,Medicines for Malaria Venture,NA,NA,NA,Phase 1,Interventional,16,Anticipated,Plasmodium Falciparum Malaria,NA,All,18 Years,55 Years,Accepts Healthy Volunteers,Medicines for Malaria Venture,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Activity of SJ733 treatment on clearance of malaria parasites will be monitored by PCR.,"The safety and tolerability of SJ733 in healthy subjects (men and WNCBP) following infection with blood stage P. falciparum during the IBSM challenge study will be evaluated by observation of occurrence of adverse events, blood samples (incl. LFT, etc.).",QIMR Berghofer Medical Research Institute,Other,Q-Pharm Pty Limited,Industry,NA,Up to 16 days post dose or less if rescue medication is require earlier due to insufficient clearance of parasites by SJ733,for up to 25th day post SJ733 treatment or longer as determind by the principal investigator,NA,Clinical Network Services (CNS) Pty Ltd,Industry,NA,NA,NA,NA,NA,NA,NA,"PCR monitoring of parasitaemia will occur AM/PM or AM at 84 h, 96 h, 120 h, and 144 h post initial SJ733 dose. Participants will return morning and evening until parasite counts are <~500 parasites(p)/ml which is when sampling may revert to daily visits at the investigator's discretion.
When parasite counts are <~200p/ml sampling may revert to alternate day visits at the investigator's discretion. Once the qPCR results are negative, or low and stable, the participants will be reviewed 3 times per week, coinciding with PK time-points where possible until rescue medication treatment.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
11-0042,NCT02773979,PfSPZ Challenge in Healthy Malaria-Naïve Adults in the United States,"A Phase 1, Blinded, Randomized, Dose Escalation Trial to Assess the Safety and Efficacy of Infectious (Replication-intact), Cryopreserved Plasmodium Falciparum Sporozoites (PfSPZ Challenge) Administered by Direct Venous Inoculation Under Chloroquine Cover (PfSPZ-CVac) in Healthy Malaria-Naïve Adults in the United States",Recruiting,NA,"September 30, 2017",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),NA,NA,NA,Phase 1,Interventional,36,Anticipated,Plasmodium Falciparum Infection,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The number of serious adverse events (SAEs) related to study product.,The number of solicited local and systemic adverse events (AEs) following PfSPZ-CVac.,NA,NA,NA,NA,Kaiser Permanente Washington Health Research Institute - Vaccines and Infectious Diseases,Days 1-143,Days 1-115,The number of unsolicited adverse events (AEs) related to study product following PfSPZ-CVac.,NA,NA,The severity of unsolicited AEs related to study product following PfSPZ-CVac.,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Days 0-129,NA,Days 0-129,NA,"September 12, 2016",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999912163,NCT01736319,Artemisinin-resistant Malaria in Cambodia,Artemisinin-resistant Plasmodium Falciparum Malaria in Cambodia,Completed,"June 26, 2012",NA,NA,NA,National Institute of Allergy and Infectious Diseases (NIAID),"Rick M Fairhurst, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,860,Anticipated,Plasmodium Falciparum Malaria,NA,All,2 Years,65 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017","April 6, 2016",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"National Center for Parasitology, Entomology, and Malaria Controk, Ministry of H",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999914010,NCT01988636,Study of Safety and Effectiveness of Intravenous Immunization With PfSPZ Vaccine in Healthy African Adults,Assessment of Safety and Immunogenicity of Intravenous Immunization With Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) in Healthy African Adults,Completed,"October 29, 2013","August 20, 2015",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),Phase 1,Interventional,450,Anticipated,Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Assess the safety of repeated IV immunizations with PfSPZ Vaccine,NA,"Malaria Research and Training Center, Bamako, Mali",Other,Sanaria Inc.,Industry,University of Bamako,28 days,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Assess the safety of repeated IV immunizations with PfSPZ Vaccine,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999914159,NCT02206451,Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Mali,Assessing Human-to-Mosquito Transmission in Volunteers Participating in Malaria Vaccine Candidate Trials in Don(SqrRoot)(Copyright)gu(SqrRoot)(Copyright)Bougou Mali,Completed,"July 16, 2014","July 16, 2014",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,110,Anticipated,Malaria,NA,All,18 Years,35 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Measurement of infection/infectivity incidences,NA,NA,NA,NA,NA,Malaria Research and Training Center,1 year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999915197,NCT02544048,Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults,Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults,Completed,"September 4, 2015","August 24, 2016",Actual,Actual,National Institute of Allergy and Infectious Diseases (NIAID),"Sara A Healy, M.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,75,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of T cells expressing PD-1 among all T cells on Study Day 42,NA,NA,NA,NA,NA,Malaria Research and Training Center,Study Day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Proportion of T cells expressing PD-1 among all T cells on Study Day 42,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
OPP1089413_Namibia_TPE,NCT02610400,Evaluation of Targeted Parasite Elimination (TPE) in Namibia,"Effectiveness and Feasibility of Targeted Parasite Elimination vs. Reactive Case Detection, With/Without Reactive Vector Control, as a Community Intervention in Response to Confirmed Passively Identified Index Cases, Zambezi Region, Namibia",Recruiting,February 2016,August 2017,Anticipated,Anticipated,"University of California, San Francisco","Michelle Hsiang, MD",Principal Investigator,"University of California, San Francisco",Phase 3,Interventional,6579,Anticipated,Malaria,NA,All,6 Months,N/A,Accepts Healthy Volunteers,"University of California, San Francisco",Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence,NA,University of Texas,Other,London School of Hygiene and Tropical Medicine,Other,University of Namibia Multidisciplinary Research Centre,Up to 24 months,NA,NA,University of Southampton,Other,NA,NA,NA,The Novartis Foundation,Other,"Clinton Health Access Initiative, Nigeria",Other,"Incidence of confirmed, passively identified malaria cases",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
999917018,NCT02974608,"Impact of Malaria on Pregnant Women in Ouelessebougou, Mali","Demographic Surveillance to Monitor Impact of Malaria on Pregnant Women in Ouelessebougou, Mali",Recruiting,"November 17, 2016","January 31, 2020",Anticipated,Anticipated,National Institute of Allergy and Infectious Diseases (NIAID),"Michal Fried, Ph.D.",Principal Investigator,National Institute of Allergy and Infectious Diseases (NIAID),N/A,Observational,6525,Anticipated,Malaria,NA,All,N/A,N/A,No,National Institute of Allergy and Infectious Diseases (NIAID),NIH,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,The rate of second and third trimester miscarriages/stillbirths,The prevalence of malaria infection in children and pregnant women,NA,NA,NA,NA,Malaria Research and Training Center,Once a year,Twice a year,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR 1550,NCT00870987,"Clinical Trial for Malaria Vaccines to Test for Safety, Immune Response and Protection Against Malaria","Clinical Trial on Safety, Immunogenicity, and Efficacy of a Prime Boost Regimen of DNA- and Adenovirus-vectored Malaria Vaccines Encoding Plasmodium Falciparum Circumsporozoite Protein and Apical Membrane Antigen 1 in Healthy Malaria-Naïve Adults in the US","Active, not recruiting",May 2009,November 2018,Anticipated,Anticipated,U.S. Army Medical Research and Materiel Command,"Judith Epstein, MD",Principal Investigator,"US Military Vaccine Program, NMRC PI, Naval Officer",Phase 1/Phase 2,Interventional,26,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Number of adverse events,NA,United States Agency for International Development (USAID),U.S. Fed,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,"Clinical Trials Center, WRAIR",5 years,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"The vaccine will be considered safe and well-tolerated if there are no severe or serious adverse events (AE) related to vaccine administration or if any severe events are relatively benign (e.g.
erythema meeting criteria for severe due to its dimensions but not significantly affecting the activities of daily living for the subject) or brief in duration (e.g. less than 48 hours). The AEs will be assessed according to the method below.
Occurrence, severity, and duration of any solicited symptoms starting on the day of immunization through day 7 after each immunization
Occurrence of any unsolicited symptoms, abnormal physical findings, and laboratory values starting from the day of immunization through day 28 after each immunization
Occurrence of any serious adverse events, as defined in 21 CFR 312.32, during the five-year study period",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
S-12-22,NCT01994525,Immunization Via Mosquito Bite With Radiation-attenuated Sporozoites,Phase 1 Trial With Challenge to Assess the Safety and Biomarkers of Protection in Malaria-naïve Adults of Immunization Via Mosquito Bite With Radiation-Attenuated Plasmodium Falciparum Sporozoites (IMRAS),Recruiting,December 2013,November 2018,Anticipated,Anticipated,U.S. Army Medical Research and Materiel Command,"Nimfa Teneza-Mora, MD",Principal Investigator,Naval Medical Research Center,Phase 1,Interventional,60,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,U.S. Army Medical Research and Materiel Command,U.S. Fed,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Solicited adverse events,Unsolicited adverse events,Seattle Biomedical Research Institute,Other,Bill and Melinda Gates Foundation,Other,Naval Medical Research Center Clinical Trials Center (CTC),7 days,14 days,Laboratory adverse events,NA,NA,Serious adverse events,Signs and symptoms related to malaria infection,Parasitemia,NA,NA,NA,NA,Occurrence of solicited adverse events (AE) from administration of study immunization (PfRAS),NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Occurrence of unsolicited adverse events (AEs) from administration of immunization (PfRAS),7 days,Occurrence of laboratory AEs from administration of study immunization (PfRAS),52 weeks,Occurrence of serious adverse events (SAEs) from administration of immunization (PfRAS),NA,NA,7 days,Occurrence of signs and symptoms related to malaria infection starting 7 days post-Controlled Human Malaria Infection (CHMI) (these will not be recorded as adverse events because they are expected as a result of malaria infection),52 weeks,Development of parasitemia and time to parasitemia after malaria challenge,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
WRAIR #2080,NCT02215707,A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses,A Clinical Trial of the PfSPZ Vaccine Administered by Direct Venous Inoculation in Healthy Malaria-Naïve Adults: Heterologous vs. Homologous Controlled Human Malaria Infection and Reduction in Number of Doses,Completed,June 2014,June 2015,Actual,Actual,Sanaria Inc.,"Judith Epstein, MD",Principal Investigator,Naval Medical Research Center,Phase 1,Interventional,67,Actual,Malaria,NA,All,18 Years,45 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,"Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings.","Evidence of vaccine-mediated protection against CHMI 2-3 weeks and 24 weeks after last immunization in Groups 1, 2, and 3, preventing blood stage infection for 28 days (as detected by blood smear analysis) following CHMI.",Naval Medical Research Center,U.S. Fed,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,Walter Reed Army Institute of Research (WRAIR) Clinical Trials Center,Day of immunization through week 52,28 days post each CHMI,NA,Military Infectious Diseases Research Program (MIDRP),Other,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
113577,NCT02563496,"A Pharmacokinetics, Safety and Efficacy Study of Tafenoquine (TQ) in Pediatric Subjects With Plasmodium Vivax (P. Vivax) Malaria","An Open Label, Non-comparative, Multicenter Study to Assess the Pharmacokinetics, Safety and Efficacy of Tafenoquine (SB-252263, WR238605) in the Treatment of Pediatric Subjects With Plasmodium Vivax Malaria",Recruiting,NA,"November 22, 2018",Anticipated,Anticipated,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 2,Interventional,60,Anticipated,"Malaria, Vivax",NA,All,6 Months,15 Years,No,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Area under the curve from time 0 extrapolated to infinite time (AUC [0-infinity]) of TQ,NA,Medicines for Malaria Venture,Other,NA,NA,NA,Up to Day 120,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"AUC (0-infinity) will be calculated as dose divided by clearance estimate (CL). AUC (0-infinity) of TQ will be calculated by weight band in pediatric subjects aged >=2 years to <16 years (weighing >=5 kg). PK assessment of AUC (0-infinity) will be assessed at Days 3, 15, 29, 60 and at the time of recurrence. Recurrence is defined by a positive blood smear with or without vivax malaria symptoms.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"February 6, 2017",Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
NMRC.2015.0009,NCT02601716,PfSPZ Vaccine: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults,Clinical Trial of PfSPZ Vaccine Administered by Direct Venous Inoculation: Dose Optimization With Heterologous Challenge in Healthy Malaria-Naïve Adults,Recruiting,NA,October 2017,Anticipated,Anticipated,Sanaria Inc.,"Alexandra Singer, MD",Principal Investigator,Naval Medical Research Center,Phase 2,Interventional,84,Anticipated,Malaria,NA,All,18 Years,50 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence and type of Adverse Events,Efficacy,Naval Medical Research Center,U.S. Fed,University of Maryland,Other,NA,52 weeks,28 days post-CHMI,Immunological response,Walter Reed Army Institute of Research (WRAIR),U.S. Fed,NA,NA,NA,Joint Warfighter Medical Research Program,Other,NA,NA,"Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings post first immunization onwards.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Evidence of vaccine-mediated protection against CHMI 24 weeks after last immunization in Groups 1, 2, 3, and 4 by preventing blood stage infection for 28 days (as detected by blood smear analysis) following CHMI.
Evidence of vaccine-mediated protection against CHMI 12 weeks after last immunization in Groups 1 and 2 by preventing blood stage infection for 28 days (as detected by blood smear analysis) following CHMI.",2 weeks post-immunization and 28 days post-CHMI,"Antibody responses by PfCSP ELISA two weeks after the second and third immunizations (Groups 2-4) or after the fourth and fifth immunizations (Group 1) (serum dilution at which the optical density is 1.0 referred to as the OD 1.0)
Positive predictive values for anti-PfCSP antibody responses at or above a threshold for predicting sterile protection following CHMI (threshold = OD 1.0 of 2,000)",NA,NA,January 2016,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
BSPZV2,NCT02613520,"Safety and Immunogenicity in Age De-Escalation of PfSPZ Vaccine in Tanzanian Adults, Children, and Infants","Clinical Trial to Evaluate the Safety and Immunogenicity in Age De-Escalation of Direct Venous Inoculation of a Plasmodium Falciparum Sporozoite Vaccine in Tanzanian Adults, Children, and Infants","Active, not recruiting",NA,June 2017,Anticipated,Anticipated,Sanaria Inc.,"Said Jongo, MD, MMED",Principal Investigator,"Ifakara Health Institute (IHI), Bagamoyo, Tanzania",Phase 1,Interventional,99,Anticipated,Malaria,NA,All,6 Months,45 Years,Accepts Healthy Volunteers,Sanaria Inc.,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Incidence and type of Adverse Events,NA,Ifakara Health Institute,Other,Swiss Tropical & Public Health Institute,Other,Bagamoyo Research and Training center of the Ifakara Health Institute,Post first immunization uptil 56 days post-CHMI or 56 days post-3rd immunization,NA,NA,"Medical Care Development, Inc.",Other,NA,NA,NA,Tanzania Commission for Science and Technology,Other,Government of Equatorial Guinea,Other,"Incidence and type of adverse events (including breakthrough infections), vital signs, clinical laboratory assessments, physical examination findings post first immunization onwards.
Occurrence of solicited symptoms during a 7-day surveillance period after vaccination (day of vaccination (Vx) and +7 days post vaccination)
Occurrence of unsolicited symptoms during a 28-day surveillance period after each vaccination.
Occurrence of serious adverse events during the study period.
Occurrence of Pf infection of vaccine type detected at any point after the first vaccination (retrospectively determined).",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,December 2015,Actual,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,Marathon Oil Corporation,Industry,Noble Oil Services,Industry,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
200894,NCT02802501,Efficacy and Safety Study of Tafenoquine (TQ) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax (P. Vivax) Malaria,"Study 200894: A Double-blind, Double-dummy, Randomized, Parallel Group, Placebo-controlled Superiority Study to Evaluate the Efficacy and Safety of Tafenoquine (SB-252263, WR238605) Co-administered With Dihydroartemisinin-piperaquine (DHA-PQP) for the Radical Cure of Plasmodium Vivax Malaria",Not yet recruiting,NA,"February 1, 2019",Anticipated,Anticipated,GlaxoSmithKline,GSK Clinical Trials,Study Director,GlaxoSmithKline,Phase 3,Interventional,150,Anticipated,"Malaria, Vivax",NA,Male,18 Years,N/A,No,GlaxoSmithKline,Industry,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Subjects with relapse-free efficacy six months post-dosing (that is clearance of initial infection without subsequent microscopically confirmed recurrence during the 6 month follow up),NA,Medicines for Malaria Venture,Other,NA,NA,NA,Up to Day 180,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"Subjects for whom initial clearance of parasitemia is confirmed, who do not present with Plasmodium vivax asexual stage parasites within six months, who did not take concomitant medication with anti-malarial activity (excluding study treatment) during the study will be considered as treatment success.",NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,"January 15, 2018",Anticipated,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
00456728,NCT03128515,Optimizing Hydroxyurea Therapy in Children With SCA In Malaria Endemic Areas,Optimizing Hydroxyurea Therapy in Children With Sickle Cell Anemia In Malaria Endemic Areas: The NOHARM Maximum Tolerated Dose (MTD) Study,Not yet recruiting,NA,December 2020,Anticipated,Anticipated,Indiana University,"Chandy C John, M.D.",Principal Investigator,Indiana University,Phase 3,Interventional,180,Anticipated,Sickle Cell Anemia; Sickle Cell Disease; Malaria,NA,All,24 Months,72 Months,No,Indiana University,Other,"ClinicalTrials.gov processed this data on July 26, 2017",NA,NA,NA,NA,NA,Proportion of children with average hemoglobin ≥9.0 g/dL or average HbF ≥20%,NA,Doris Duke Charitable Foundation,Other,Makerere University,Other,Mulago Hospital Sickle Cell Clinic,Over 24 month period on study drug,NA,NA,"Mulago Hospital, Uganda",Other,NA,NA,NA,"Children's Hospital Medical Center, Cincinnati",Other,NA,NA,Proportion of children who achieve either an average hemoglobin ≥9.0 g/dL or an average HbF ≥20% after 24 months on study drug,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,July 2017,Anticipated,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
